userSet	dbSet	collection	pValueLog	oddsRatio	support	rnkPV	rnkOR	rnkSup	maxRnk	meanRnk	b	c	d	description	cellType	tissue	antibody	treatment	dataSource	filename	size
1	3963	TP53	3.10148871451885	2.97819050378295	68	1	344	703	703	349	8	6313	2212	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 7.5h	GTRD	EXP036829_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3579
1	3970	TP53	2.87784896227276	1.91777870593751	131	2	430	328	430	253	24	6250	2196	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	Nutlin	GTRD	EXP037747_HCT-116--colon-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	8401
1	4020	TP53	2.51883251579435	3.03163499021057	52	3	343	921	921	422	6	6329	2214	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	5FU	GEO	GSE58506_tp53_hct166-5fu_MACS_TP53_MA0106.3.damo.pwm.bed	2600
1	4039	TP63	2.37266310097239	1.33280233473221	422	4	748	33	748	262	112	5959	2108	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	Treatment: DMSO for 6 hrs;	GTRD	EXP057961_MCF10A--breast-epithelial-cells-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	26768
1	1435	ESR1	2.16418043444388	1.75308483526301	115	5	454	388	454	282	23	6266	2197	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	E2	GEO	GSE72249_esr1_zr751-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	22135
1	3978	TP53	2.10112680730694	3.31875430082409	38	6	334	1238	1238	526	4	6343	2216	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #45	GTRD	EXP048267_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4710
1	3951	TP53	2.0766742763202	Inf	16	7	1	2127	2127	712	0	6365	2220	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	UV_16H	Array Express	ERP004176_tp53_u2os-uv-16h_MACS_TP53_MA0106.3.damo.pwm.bed	1275
1	3213	PAX5	1.98425122425395	4.71202789533305	27	8	324	1564	1564	632	2	6354	2218	PAX5 GM12878 (female B-cells lymphoblastoid cell line) PAX5	GM12878 (female B-cells lymphoblastoid cell line)	NULL	PAX5		ENCODE	ENCSR000BHD_GM12878_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	41397
1	4051	TP63	1.96266139038884	1.2270626197168	620	9	863	5	863	292	179	5761	2041	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D2	GEO	GSE59824_tp63_keratinocyte-d2_MACS_TP63_MA0525.2.damo.pwm.bed	44767
1	3997	TP53	1.89331520747024	2.13300402139844	61	10	392	785	785	396	10	6320	2210	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	Treatment: nutlin3a (5uM final) for 6hrs; Passage: 30-35;	GTRD	EXP054820_IMR90--lung-fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4223
1	3957	TP53	1.89078699332948	3.60748174912832	31	11	329	1439	1439	593	3	6350	2217	TP53 BJ (fibroblasts) TP53	BJ (fibroblasts)	NULL	TP53	ionizing radiation	GTRD	EXP032954_BJ--fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1723
1	4002	TP53	1.87488734390658	1.50758890356543	159	12	575	256	575	281	37	6222	2183	TP53 SaOS2 (osteosarcoma) TP53	SaOS2 (osteosarcoma)	BTO:0000971	TP53		GEO	GSE15780_tp53_saos_MACS_TP53_MA0106.3.damo.pwm.bed	20246
1	4040	TP63	1.69869768462926	1.21867858704772	528	13	872	12	872	299	153	5853	2067	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	Treatment: 5 uM Nutlin3A for 6 hrs;	GTRD	EXP057962_MCF10A--breast-epithelial-cells-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	35495
1	1057	EGR1	1.68695443239229	Inf	13	14	1	2306	2306	774	0	6368	2220	EGR1 GM12878 (female B-cells lymphoblastoid cell line) EGR1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EGR1		ENCODE	ENCSR000BMQ_GM12878_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	18885
1	3987	TP53	1.68531115760139	2.29551973989593	46	15	385	1028	1028	476	7	6335	2213	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	Treatment: etoposide (100uM, 6hrs) Source: IMR90 fetal lung fibroblasts Passage: #30-35	GTRD	EXP048593_IMR90--lung-fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4613
1	4015	TP53	1.6727308012779	1.82348269074203	73	16	450	644	644	370	14	6308	2206	TP53 GM00011 (fetal skin fibroblasts) TP53	GM00011 (fetal skin fibroblasts)	NULL	TP53		GEO	GSE55727_tp53_gm00011_MACS_TP53_MA0106.3.damo.pwm.bed	4818
1	1559	FOS	1.66671488267715	1.18882302719695	672	17	943	1	943	320	200	5709	2020	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	95991
1	3965	TP53	1.63221829999284	2.58364752669804	37	18	364	1264	1264	549	5	6344	2215	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	400 ng/mL neocarzinostatin for 3 h	GTRD	EXP036872_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2402
1	4071	USF1	1.62239845076735	1.99188693639634	57	19	422	839	839	427	10	6324	2210	USF1 WA01 (H1, human embryonic stem cells) USF1	WA01 (H1, human embryonic stem cells)	NULL	USF1		ENCODE	ENCSR000BIU_H1-hESC_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	49138
1	1211	ESR1	1.61226536424675	3.25687184288164	28	20	336	1531	1531	629	3	6353	2217	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Vehicle treatment	GTRD	EXP036167_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3556
1	3223	PBX2	1.61042033766454	1.54857635182014	115	21	556	388	556	322	26	6266	2194	PBX2 PBX2	NA	NA	PBX2	NA	NA	ENCSR979UVS_K562_PBX2_MACS_PBX2_MA1113.2.damo.pwm.bed	110496
1	1436	ESR1	1.56424797010493	1.59050637046859	100	22	531	446	531	333	22	6281	2198	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1		GEO	GSE72249_esr1_zr751_MACS_ESR1_MA0112.3.damo.pwm.bed	13406
1	4037	TP63	1.5348630481135	1.19423190930875	555	23	933	10	933	322	164	5826	2056	TP63 human keratinocytes TP63	human keratinocytes	NULL	TP63	Treatment: Day 0 of epidermal differentiation Genotype: wildtype Source: background cell line WA 09	GTRD	EXP053351_human-keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	35404
1	795	CTCF	1.52484355177169	1.65157433352454	85	24	514	545	545	361	18	6296	2202	CTCF foreskin keratinocyte CTCF	foreskin keratinocyte	NULL	CTCF	1mM calcium (CHEBI:86158) for 2 day	GTRD	EXP040256_foreskin-keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46661
1	1026	E2F1	1.52163497072723	3.14007512171072	27	25	337	1564	1564	642	3	6354	2217	E2F1 U87 (glioblastoma) E2F1	U87 (glioblastoma)	NULL	E2F1	Treatment: Mock	GTRD	EXP049850_U87--glioblastoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	32575
1	4062	TP73	1.51060212451027	1.33947977729457	210	26	742	172	742	313	55	6171	2165	TP73 TP73	NA	NA	TP73	NA	GEO	GSE15780_tp73_saos-rep1_MACS_TP73_MA0861.1.damo.pwm.bed	15365
1	559	CTCF	1.47088277460651	1.42048942727014	146	27	620	295	620	314	36	6235	2184	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	E2_SHCTR	Array Express	ERP000209_ctcf_mcf7-e2-shctr_MACS_CTCF_MA0139.1.damo.pwm.bed	77780
1	3964	TP53	1.46911572636806	1.3849994204244	166	28	707	241	707	325	42	6215	2178	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 7.5h + Nutlin	GTRD	EXP036830_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	17025
1	3959	TP53	1.46071501756703	1.80532493566226	62	29	452	769	769	417	12	6319	2208	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 1h	GTRD	EXP036825_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4156
1	1367	ESR1	1.4272293470408	Inf	11	30	1	2426	2426	819	0	6370	2220	ESR1 primary breast cancer ESR1	primary breast cancer	NULL	ESR1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053237_primary-breast-cancer_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3800
1	528	CTCF	1.42071796351143	1.61204993412923	83	31	522	565	565	373	18	6298	2202	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUS_mammary_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46934
1	3983	TP53	1.40630319488931	2.6168493563645	30	32	361	1473	1473	622	4	6351	2216	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #104	GTRD	EXP048274_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2996
1	1976	GATA3	1.36592674940328	5.57741304111334	16	33	317	2127	2127	826	1	6365	2219	GATA3 A1A3(breast cancer cells) GATA3	A1A3(breast cancer cells)	NULL	GATA3	Treatment: 1hr EtOH, Doxycycline 72 hr CellLine: A1A3 from T47D cell line Genotype: Brg1 knockdown	GTRD	EXP048406_A1A3-breast-cancer-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	6284
1	3389	RELB	1.36592674940328	5.57741304111334	16	33	317	2127	2127	826	1	6365	2219	RELB L1236 (Hodgkin lymphoma) RELB	L1236 (Hodgkin lymphoma)	NULL	RELB	NA	GEO	GSE63736_relb_l1236_MACS_RELB_MA1117.1.damo.pwm.bed	10169
1	4024	TP53	1.35074546769869	1.90104994288752	49	35	438	967	967	480	9	6332	2211	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	NUT3A	GEO	GSE58740_tp53_imr90-nut3a_MACS_TP53_MA0106.3.damo.pwm.bed	3591
1	1558	FOS	1.34170378652275	1.16431052413996	601	36	980	8	980	341	182	5780	2038	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	86734
1	4052	TP63	1.34067054925746	1.16376138507174	604	37	981	7	981	342	183	5777	2037	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D4	GEO	GSE59824_tp63_keratinocyte-d4_MACS_TP63_MA0525.2.damo.pwm.bed	41698
1	3206	OTX2	1.32461736166611	2.52923406669049	29	38	366	1504	1504	636	4	6352	2216	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.OTX2.4	GTRD	EXP038205_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	43257
1	790	CTCF	1.32092566389216	1.45098983724663	112	39	608	399	608	349	27	6269	2193	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP040241_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	63245
1	810	CTCF	1.30701792046926	1.69284903181151	63	40	504	753	753	432	13	6318	2207	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Wapl-depletion	GTRD	EXP040504_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47767
1	605	CTCF	1.30301795741013	1.37179568949917	145	41	716	300	716	352	37	6236	2183	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	oestrogen	GTRD	EXP030932_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	81857
1	3174	NRF1	1.29739323308732	Inf	10	42	1	2487	2487	843	0	6371	2220	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR837EYC_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	17713
1	3179	NRF1	1.29739323308732	Inf	10	42	1	2487	2487	843	0	6371	2220	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		GTRD	EXP038538_K562--myelogenous-leukemia-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	14312
1	3316	RARG	1.29739323308732	Inf	10	42	1	2487	2487	843	0	6371	2220	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM DMSO for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048631_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA1553.1.damo.pwm.bed	1173
1	2685	MAFK	1.29065642216601	3.48665700094229	20	45	330	1901	1901	759	2	6361	2218	MAFK MCF7 (Invasive ductal breast carcinoma) MAFK	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MAFK	NA	ENCODE	ENCSR555PBN_MCF-7_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	8728
1	3744	STAT3	1.29065642216601	3.48665700094229	20	45	330	1901	1901	759	2	6361	2218	STAT3 SU-DHL-1 (Anaplastic large cell lymphoma) STAT3	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	STAT3	Treatment: DMSO for 3 hrs	GTRD	EXP053281_SU-DHL-1--Anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	13426
1	4028	TP63	1.28095410819955	1.16538446447994	546	47	979	11	979	346	165	5835	2055	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	NULL	GTRD	EXP000293_keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	35453
1	2071	GRHL2	1.26209691587848	1.24660465882043	263	48	843	115	843	335	74	6118	2146	GRHL2 HBE GRHL2	HBE	NA	GRHL2		GEO	GSE46194_grhl2_hbe_MACS_GRHL2_MA1105.2.damo.pwm.bed	40252
1	270	BACH1	1.25847202221515	5.22802730190654	15	49	319	2200	2200	856	1	6366	2219	BACH1 BACH1	NA	NA	BACH1	NA	NA	ENCSR699TNT_HepG2_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	6555
1	3331	RELA	1.25847202221515	5.22802730190654	15	49	319	2200	2200	856	1	6366	2219	RELA GM12891 (male B- cells lymphoblastoid cell line) RELA	GM12891 (male B- cells lymphoblastoid cell line)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAI_GM12891_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	14885
1	3969	TP53	1.25730945798068	2.78990348959765	24	51	346	1691	1691	696	3	6357	2217	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	DMSO	GTRD	EXP037746_HCT-116--colon-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1588
1	3992	TP53	1.25730945798068	2.78990348959765	24	51	346	1691	1691	696	3	6357	2217	TP53 A549 (lung carcinoma) TP53	A549 (lung carcinoma)	BTO:0000018	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051021_A549--lung-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3125
1	160	AR	1.25514379705695	1.35393757860917	147	53	728	290	728	357	38	6234	2182	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SHPIAS1_R1881	GEO	GSE56086_AR_vcap-shpias1-r1881_MACS_AR_MA0007.3.damo.pwm.bed	83992
1	1837	FOXA2	1.25416467073753	1.27708587824024	215	54	801	166	801	340	59	6166	2161	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: FOXA2 mimo	GTRD	EXP049299_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	117553
1	1288	ESR1	1.25218994458368	1.43904162955047	107	55	613	416	613	361	26	6274	2194	ESR1 BT-474 (breast invasive ductal carcinoma) ESR1	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	ESR1	Tam-Resist	GTRD	EXP038791_BT-474--breast-invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19237
1	3209	OTX2	1.25168616164365	1.66571918637968	62	56	510	769	769	445	13	6319	2207	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	shGFP	GTRD	EXP038214_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	92034
1	636	CTCF	1.24267534194933	2.23273075224307	32	57	388	1410	1410	618	5	6349	2215	CTCF IPSC-derived bipolar neuron CTCF	IPSC-derived bipolar neuron	NULL	CTCF		GTRD	EXP036844_IPSC-derived-bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46772
1	3726	STAT1	1.24267534194933	2.23273075224307	32	57	388	1410	1410	618	5	6349	2215	STAT1 HeLa S3 (cervical adenocarcinoma) STAT1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT1	IFNgamma	GTRD	EXP000505_HeLa-S3--cervical-adenocarcinoma-_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	15253
1	1560	FOS	1.24222300649573	1.15167647024854	608	59	1020	6	1020	362	186	5773	2034	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	88249
1	484	CTCF	1.23517891721236	1.39905297384477	120	60	621	367	621	349	30	6261	2190	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DMR_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	63664
1	811	CTCF	1.22883359269635	1.68780154388953	58	61	505	824	824	463	12	6323	2208	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Pds5SA/B depletion	GTRD	EXP040505_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44523
1	666	CTCF	1.2215260460797	1.62146271262752	65	62	520	738	738	440	14	6316	2206	CTCF MCF10A (breast epithelial cells) CTCF	MCF10A (breast epithelial cells)	BTO:0001939	CTCF		GTRD	EXP038623_MCF10A--breast-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42899
1	1561	FOS	1.21975573992886	1.14687679145973	625	63	1029	3	1029	365	192	5756	2028	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: transformed	GTRD	EXP048568_MCF10A-ER-Src_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	90835
1	3348	RELA	1.19646357111985	3.31182395038901	19	64	335	1956	1956	785	2	6362	2218	RELA GM12891 (male B- cells lymphoblastoid cell line) RELA	GM12891 (male B- cells lymphoblastoid cell line)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000774_GM12891--male-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	19931
1	981	CTCF	1.18048327799527	1.48495959569471	85	65	581	545	581	397	20	6296	2200	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GEO	GSE70764_ctcf_mcf7_MACS_CTCF_MA0139.1.damo.pwm.bed	51481
1	4011	TP53	1.17790094118042	2.03509391620298	35	66	419	1318	1318	601	6	6346	2214	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	DMSO	GEO	GSE46641_tp53_u2os-dmso_MACS_TP53_MA0106.3.damo.pwm.bed	2016
1	3824	TEAD1	1.17198642781363	2.67325204935461	23	67	360	1739	1739	722	3	6358	2217	TEAD1 SF268 (astrocytoma ) TEAD1	SF268 (astrocytoma )	BTO:0003772	TEAD1		GTRD	EXP034063_SF268--astrocytoma--_TEAD1_MACS_TEAD1_MA0090.3.damo.pwm.bed	23693
1	4082	USF2	1.16757473186093	Inf	9	68	1	2585	2585	885	0	6372	2220	USF2 HepG2 (hepatoblastoma) USF2	HepG2 (hepatoblastoma)	BTO:0000599	USF2		ENCODE	ENCSR000EEF_HepG2_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	7970
1	784	CTCF	1.16360616306633	1.78382908722015	46	69	453	1028	1028	517	9	6335	2211	CTCF LNCaP C4-2B (prostate carcinoma) CTCF	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	CTCF		GTRD	EXP040145_LNCaP-C4-2B--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37006
1	3400	REST	1.15225552013461	4.878751890122	14	70	321	2252	2252	881	1	6367	2219	REST PFSK1 (primitive neuroectodermal tumor) REST	PFSK1 (primitive neuroectodermal tumor)	NULL	REST		ENCODE	ENCSR000BOX_PFSK-1_REST_MACS_REST_MA0138.2.damo.pwm.bed	13730
1	3428	REST	1.15225552013461	4.878751890122	14	70	321	2252	2252	881	1	6367	2219	REST CRC107 (colorectal cancer metastatic stem cells) REST	CRC107 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid integrity;	GTRD	EXP058086_CRC107--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	11191
1	3471	RUNX1	1.15225552013461	4.878751890122	14	70	321	2252	2252	881	1	6367	2219	RUNX1 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) RUNX1	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	RUNX1		GTRD	EXP037836_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	22588
1	3508	RUNX3	1.13524809260499	1.46726113807607	84	73	589	557	589	406	20	6297	2200	RUNX3 GM12878 (female B-cells lymphoblastoid cell line) RUNX3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RUNX3	NA	ENCODE	ENCSR000BRI_GM12878_RUNX3_MACS_RUNX3_MA0684.2.damo.pwm.bed	82726
1	800	CTCF	1.12626119027991	1.7101953547652	49	74	501	967	967	514	10	6332	2210	CTCF neural progenitors CTCF	neural progenitors	NULL	CTCF		GTRD	EXP040290_neural-progenitors_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	64099
1	635	CTCF	1.12525700764162	1.89393572288638	38	75	439	1238	1238	584	7	6343	2213	CTCF IPSC-derived bipolar neuron CTCF	IPSC-derived bipolar neuron	NULL	CTCF		GTRD	EXP036843_IPSC-derived-bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49668
1	4010	TP53	1.11759762973241	1.57108736627079	63	76	533	753	753	454	14	6318	2206	TP53 hESC-1 (Embryonic stem cells) TP53	hESC-1 (Embryonic stem cells)	NULL	TP53	DAMAGED	GEO	GSE39912_tp53_esc-damaged_MACS_TP53_MA0106.3.damo.pwm.bed	10320
1	3981	TP53	1.10900115423467	1.97664228410807	34	77	423	1349	1349	616	6	6347	2214	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #90	GTRD	EXP048271_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3055
1	3185	NRF1	1.10378697914867	3.13704549233148	18	78	338	1996	1996	804	2	6363	2218	NRF1 HCC1954 (ductal breast carcinoma) NRF1	HCC1954 (ductal breast carcinoma)	BTO:0005368	NRF1		GEO	GSE67867_nrf1_hcc1954_MACS_NRF1_MA0506.1.damo.pwm.bed	14946
1	587	CTCF	1.10325311906032	1.37313867871064	110	79	715	404	715	399	28	6271	2192	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	NULL	GTRD	EXP001021_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	82047
1	4001	TP53	1.09348435580504	1.23699442195957	219	80	853	160	853	364	62	6162	2158	TP53 MCF10A (breast epithelial cells) TP53	MCF10A (breast epithelial cells)	BTO:0001939	TP53	Treatment: 5 uM Nutlin3A for 6 hrs;	GTRD	EXP057964_MCF10A--breast-epithelial-cells-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	16776
1	966	CTCF	1.08823905996462	1.38437713249244	103	81	708	434	708	408	26	6278	2194	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	EMB	GEO	GSE52457_ctcf_h1-emb_MACS_CTCF_MA0139.1.damo.pwm.bed	96285
1	2210	IRF4	1.08820656650595	2.5566365612353	22	82	365	1797	1797	748	3	6359	2217	IRF4 GM12878 (female B-cells lymphoblastoid cell line) IRF4	GM12878 (female B-cells lymphoblastoid cell line)	NULL	IRF4		ENCODE	ENCSR000BGY_GM12878_IRF4_MACS_IRF4_MA1419.1.damo.pwm.bed	32606
1	1884	GABPA	1.08791711709116	2.26650054602961	26	83	386	1602	1602	690	4	6355	2216	GABPA GM12878 (female B-cells lymphoblastoid cell line) GABPA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	GABPA		GTRD	EXP054616_GM12878--female-B-cells-lymphoblastoid-cell-line-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	34360
1	2723	MEF2A	1.08791711709116	2.26650054602961	26	83	386	1602	1602	690	4	6355	2216	MEF2A GM12878 (female B-cells lymphoblastoid cell line) MEF2A	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MEF2A	NA	ENCODE	ENCSR000BKB_GM12878_MEF2A_MACS_MEF2A_MA0052.4.damo.pwm.bed	24947
1	4047	TP63	1.08073603387556	1.4744908659811	76	85	588	619	619	431	18	6305	2202	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	ADRIA	GEO	GSE56674_tp63_keratinocyte-adria_MACS_TP63_MA0525.2.damo.pwm.bed	4088
1	4013	TP53	1.07861407427447	1.32654315451921	129	86	752	338	752	392	34	6252	2186	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	NUT	GEO	GSE46641_tp53_u2os-nut_MACS_TP53_MA0106.3.damo.pwm.bed	12520
1	3739	STAT3	1.0703118888729	1.26400566061534	177	87	822	225	822	378	49	6204	2171	STAT3 MCF10A-ER-Src STAT3	MCF10A-ER-Src	NULL	STAT3	Genotype: transformed	GTRD	EXP048576_MCF10A-ER-Src_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	31673
1	4016	TP53	1.06092733662244	1.38358911342341	99	88	709	455	709	417	25	6282	2195	TP53 GM06170 (fetal skin fibroblasts) TP53	GM06170 (fetal skin fibroblasts)	NULL	TP53		GEO	GSE55727_tp53_gm06170_MACS_TP53_MA0106.3.damo.pwm.bed	12436
1	3967	TP53	1.06069551103824	1.84381072023674	37	89	447	1264	1264	600	7	6344	2213	TP53 MCF-7 C4-12 (invasive breast ductal carcinoma) TP53	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	TP53	400 ng/mL neocarzinostatin for 3 h	GTRD	EXP036874_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2695
1	3973	TP53	1.06069551103824	1.84381072023674	37	89	447	1264	1264	600	7	6344	2213	TP53 SJSA-1(osteosarcoma) TP53	SJSA-1(osteosarcoma)	BTO:0004216	TP53	DMSO	GTRD	EXP037750_SJSA-1-osteosarcoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2229
1	2632	KLF4	1.04741784003712	4.52958675518623	13	91	325	2306	2306	907	1	6368	2219	KLF4 MCF7 (Invasive ductal breast carcinoma) KLF4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	KLF4		ENCODE	ENCSR265WJC_MCF-7_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	1950
1	3138	NR3C1	1.04712136942358	1.43188073570888	82	92	615	570	615	426	20	6299	2200	NR3C1 A1-2 (breast cancer cells) NR3C1	A1-2 (breast cancer cells)	NULL	NR3C1	Treatment: 1hr Dex	GTRD	EXP048394_A1-2--breast-cancer-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	28085
1	4018	TP53	1.04259434381921	1.22814293362893	214	93	861	167	861	374	61	6167	2159	TP53 keratinocytes TP53	keratinocytes	NULL	TP53	CISP	GEO	GSE56674_tp53_keratinocyte-cisp_MACS_TP53_MA0106.3.damo.pwm.bed	12610
1	3236	PKNOX1	1.04149553601803	1.9182095982118	33	94	429	1379	1379	634	6	6348	2214	PKNOX1 GM12878 (female B-cells lymphoblastoid cell line) PKNOX1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	PKNOX1	NA	GTRD	EXP039329_GM12878--female-B-cells-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	32796
1	899	CTCF	1.04002217480457	1.55713728074211	58	95	553	824	824	491	13	6323	2207	CTCF HMEC (human mammary epithelial cells) CTCF	HMEC (human mammary epithelial cells)	NULL	CTCF	Treatment: None;	GTRD	EXP054036_HMEC--human-mammary-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44084
1	2057	GRHL2	1.04002217480457	1.55713728074211	58	95	553	824	824	491	13	6323	2207	GRHL2 LNCaP (prostate carcinoma) GRHL2	LNCaP (prostate carcinoma)	BTO:0001321	GRHL2		GTRD	EXP037342_LNCaP--prostate-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	10213
1	3285	PPARG	1.04002217480457	1.55713728074211	58	95	553	824	824	491	13	6323	2207	PPARG hMADS-3 (adipose-derived stem cells) PPARG	hMADS-3 (adipose-derived stem cells)	NULL	PPARG	differentiaiton inductors	GTRD	EXP033781_hMADS-3--adipose-derived-stem-cells-_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	63954
1	2185	HSF1	1.03777383854832	Inf	8	98	1	2675	2675	925	0	6373	2220	HSF1 HME1 HSF1	HME1	NA	HSF1	HEAT	GEO	GSE38901_hsf1_hme1-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	2679
1	2212	IRF4	1.03777383854832	Inf	8	98	1	2675	2675	925	0	6373	2220	IRF4 IRF4	NA	NA	IRF4	NA	GEO	GSE56857_irf4_ocily10_MACS_IRF4_MA1419.1.damo.pwm.bed	10104
1	2676	MAFF	1.03777383854832	Inf	8	98	1	2675	2675	925	0	6373	2220	MAFF MAFF	NA	NA	MAFF	NA	NA	ENCSR237YZZ_GM12878_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	4387
1	3177	NRF1	1.03777383854832	Inf	8	98	1	2675	2675	925	0	6373	2220	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		GTRD	EXP038536_K562--myelogenous-leukemia-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	15661
1	3838	TEAD4	1.03777383854832	Inf	8	98	1	2675	2675	925	0	6373	2220	TEAD4 HCT-116 (colon carcinoma) TEAD4	HCT-116 (colon carcinoma)	BTO:0001109	TEAD4		ENCODE	ENCSR000BVJ_HCT116_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	4173
1	3106	NR3C1	1.02144531248451	1.36939902103935	98	103	717	460	717	427	25	6283	2195	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	E2, DEX	GTRD	EXP037450_MCF7--Invasive-ductal-breast-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	29455
1	3961	TP53	1.01284159839681	1.57027616523958	54	104	534	886	886	508	12	6327	2208	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 4h	GTRD	EXP036827_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3393
1	1043	E2F6	1.01275481280817	2.96232138573553	17	105	345	2066	2066	839	2	6364	2218	E2F6 K562 (myelogenous leukemia) E2F6	K562 (myelogenous leukemia)	NULL	E2F6		ENCODE	ENCSR000BLI_K562_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	36905
1	1674	FOXA1	1.0120584895208	2.17898802650624	25	106	391	1657	1657	718	4	6356	2216	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	control; 100 nM 17-beta-estradiol for 0h	GTRD	EXP037652_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	3552
1	2997	NFE2L2	1.00607321367493	2.44005681588628	21	107	367	1852	1852	775	3	6360	2217	NFE2L2 A549 (lung carcinoma) NFE2L2	A549 (lung carcinoma)	BTO:0000018	NFE2L2		ENCODE	ENCSR584GHV_A549_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	9049
1	3186	NRF1	1.00607321367493	2.44005681588628	21	107	367	1852	1852	775	3	6360	2217	NRF1 HMEC-1 NRF1	HMEC-1	NA	NRF1		GEO	GSE67867_nrf1_hmec_MACS_NRF1_MA0506.1.damo.pwm.bed	16502
1	1259	ESR1	0.998774179425861	1.31885887599981	117	109	759	378	759	415	31	6264	2189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038371_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29876
1	1515	FOS	0.985546001674131	1.14707879326535	412	110	1027	41	1027	393	126	5969	2094	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DON_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	64757
1	4053	TP63	0.979635868430495	1.12169259515771	581	111	1075	9	1075	398	182	5800	2038	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D7	GEO	GSE59824_tp63_keratinocyte-d7_MACS_TP63_MA0525.2.damo.pwm.bed	39977
1	555	CTCF	0.979048639634623	1.46161099576714	67	112	601	710	710	474	16	6314	2204	CTCF Loucy (adult T acute lymphoblastic leukemia) CTCF	Loucy (adult T acute lymphoblastic leukemia)	NULL	CTCF		ENCODE	ENCSR464DKE_Loucy_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	61498
1	4027	TP63	0.978686106470436	1.11615034329625	635	113	1082	2	1082	399	200	5746	2020	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	NULL	GTRD	EXP000292_keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	43062
1	418	CREB1	0.975441703856743	1.85979578615319	32	114	440	1410	1410	655	6	6349	2214	CREB1 GM12878 (female B-cells lymphoblastoid cell line) CREB1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CREB1		ENCODE	ENCSR000BUF_GM12878_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	31548
1	3225	PBX3	0.975441703856743	1.85979578615319	32	114	440	1410	1410	655	6	6349	2214	PBX3 GM12878 (female B-cells lymphoblastoid cell line) PBX3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	PBX3	NA	ENCODE	ENCSR000BGR_GM12878_PBX3_MACS_PBX3_MA1114.1.damo.pwm.bed	29964
1	893	CTCF	0.962499041698398	1.43726612066424	70	116	614	666	666	465	17	6311	2203	CTCF HNEK (epidermal keratinocytes) CTCF	HNEK (epidermal keratinocytes)	NULL	CTCF	Treatment: None;	GTRD	EXP054030_HNEK--epidermal-keratinocytes-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48232
1	970	CTCF	0.96219157354985	1.39652229409698	80	117	622	585	622	441	20	6301	2200	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	TROP	GEO	GSE52457_ctcf_h1-trop_MACS_CTCF_MA0139.1.damo.pwm.bed	77854
1	1203	ESR1	0.961128997178857	1.7003275739706	39	118	502	1206	1206	609	8	6342	2212	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP034901_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10873
1	3962	TP53	0.961128997178857	1.7003275739706	39	118	502	1206	1206	609	8	6342	2212	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 5h	GTRD	EXP036828_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1991
1	3972	TP53	0.959366354975164	1.19312112501306	242	120	939	138	939	399	71	6139	2149	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Nutlin	GTRD	EXP037749_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	29663
1	1574	FOSL2	0.958082597104991	1.60458831291669	46	121	523	1028	1028	557	10	6335	2210	FOSL2 SK-N-SH (neuroblastoma) FOSL2	SK-N-SH (neuroblastoma)	BTO:0001620	FOSL2		ENCODE	ENCSR000BVB_SK-N-SH_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	42468
1	431	CREM	0.955181967220965	1.95242833251892	28	122	427	1531	1531	693	5	6353	2215	CREM GM12878 (female B-cells lymphoblastoid cell line) CREM	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CREM	NA	ENCODE	ENCSR839XZU_GM12878_CREM_MACS_CREM_MA0609.2.damo.pwm.bed	27018
1	3205	OTX2	0.955181967220965	1.95242833251892	28	122	427	1531	1531	693	5	6353	2215	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.OTX2.2	GTRD	EXP038204_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	44120
1	887	CTCF	0.95485446382742	1.35322282899559	93	124	729	489	729	447	24	6288	2196	CTCF EOL-1 (Acute myeloid leukemia) CTCF	EOL-1 (Acute myeloid leukemia)	BTO:0002405	CTCF	Treatment: untreated	GTRD	EXP053093_EOL-1--Acute-myeloid-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	76394
1	2756	MITF	0.944125365676776	4.18053178853519	12	125	326	2359	2359	937	1	6369	2219	MITF melanocytes MITF	melanocytes	NULL	MITF	BRAFV600E	GEO	GSE50681_mitf_melanocyte-brafv600e_MACS_MITF_MA0620.3.damo.pwm.bed	14307
1	3465	RUNX1	0.944125365676776	4.18053178853519	12	125	326	2359	2359	937	1	6369	2219	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1	MEIS2 KD	GTRD	EXP036424_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	15154
1	620	CTCF	0.926806521880009	1.35108147617478	89	127	730	515	730	457	23	6292	2197	CTCF erythroid progenitors CTCF	erythroid progenitors	BTO:0002731	CTCF	none	GTRD	EXP033119_erythroid-progenitors_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73102
1	963	CTCF	0.926806521880009	1.35108147617478	89	127	730	515	730	457	23	6292	2197	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_snyder_MACS_CTCF_MA0139.1.damo.pwm.bed	79374
1	433	CTCF	0.925997600892796	1.31936463272485	102	129	758	438	758	442	27	6279	2193	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000AHD_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	53329
1	399	CEBPB	0.925699927540515	2.32347288973441	20	130	381	1901	1901	804	3	6361	2217	CEBPB monocyte CEBPB	monocyte	NA	CEBPB	MACROPHAGE	GEO	GSE31621_cebpb_monocyte-macro_MACS_CEBPB_MA0466.2.damo.pwm.bed	14991
1	1485	ETV6	0.925699927540515	2.32347288973441	20	130	381	1901	1901	804	3	6361	2217	ETV6 GM12878 (female B-cells lymphoblastoid cell line) ETV6	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETV6		GTRD	EXP038555_GM12878--female-B-cells-_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	22987
1	2686	MAFK	0.925699927540515	2.32347288973441	20	130	381	1901	1901	804	3	6361	2217	MAFK OCI-LY7 (diffuse large B-cell lymphoma) MAFK	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	MAFK	NA	GEO	GSE47784_mafk_ocily7_MACS_MAFK_MA0496.3.damo.pwm.bed	14919
1	3979	TP53	0.925699927540515	2.32347288973441	20	130	381	1901	1901	804	3	6361	2217	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #45	GTRD	EXP048268_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2351
1	1002	DUX4	0.923511909554804	2.78765130816496	16	134	348	2127	2127	870	2	6365	2218	DUX4 LHCN-M2 (myoblasts) DUX4	LHCN-M2 (myoblasts)	BTO:0005046	DUX4	250 ng/ml doxycycline 6hrs	GTRD	EXP036164_LHCN-M2--myoblasts-_DUX4_MACS_DUX4_MA0468.1.damo.pwm.bed	9681
1	3977	TP53	0.923511909554804	2.78765130816496	16	134	348	2127	2127	870	2	6365	2218	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Treatment: Decitabine;	GTRD	EXP047474_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	922
1	1555	FOS	0.922636589232589	1.13154065323342	442	136	1053	29	1053	406	137	5939	2083	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	70735
1	3960	TP53	0.920952724240824	1.37885128737028	79	137	710	599	710	482	20	6302	2200	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 2.5h	GTRD	EXP036826_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	5089
1	812	CTCF	0.911265541726422	1.5116549782855	52	138	563	921	921	541	12	6329	2208	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Wapl/Pds5A/B depletion	GTRD	EXP040506_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43723
1	775	CTCF	0.909643776833516	1.30069203022715	108	139	778	412	778	443	29	6273	2191	CTCF GM23338 CTCF	GM23338	NULL	CTCF		GTRD	EXP040082_GM23338_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	96946
1	573	CTCF	0.908596696438725	1.27411975137215	124	140	815	349	815	435	34	6257	2186	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	NULL	GTRD	EXP000597_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	80090
1	268	BACH1	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	BACH1 BACH1	NA	NA	BACH1	NA	NA	ENCSR043EHG_A549_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	4232
1	275	BACH2	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	BACH2 OCI-LY7 (diffuse large B-cell lymphoma) BACH2	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	BACH2		GEO	GSE44420_bach2_ocily7_MACS_BACH2_MA1101.2.damo.pwm.bed	7273
1	1941	GATA2	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	GATA2 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) GATA2	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	GATA2	RUNX1-EVI1 KD	GTRD	EXP037841_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	17930
1	2179	HSF1	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	HSF1 BPE (mammary epithelial cells) HSF1	BPE (mammary epithelial cells)	NULL	HSF1	HEAT	GEO	GSE38901_hsf1_bpe-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	2886
1	2213	IRF4	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	IRF4 OCI-LY3 (diffuse large B-cell lymphoma) IRF4	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	IRF4	SHCTR	GEO	GSE56857_irf4_ocily3-shctr_MACS_IRF4_MA1419.1.damo.pwm.bed	5190
1	2634	KLF4	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	KLF4 WA09 (embryonic stem cells) KLF4	WA09 (embryonic stem cells)	NULL	KLF4	Treatment: under normal conditions	GTRD	EXP047912_WA09--embryonic-stem-cells-_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	4322
1	2742	MEF2C	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	MEF2C GM12878 (female B-cells lymphoblastoid cell line) MEF2C	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MEF2C		ENCODE	ENCSR000BNG_GM12878_MEF2C_MACS_MEF2C_MA0497.1.damo.pwm.bed	7953
1	2956	MYF5	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	MYF5 RH18 (alveolar rhabdomyosarcoma) MYF5	RH18 (alveolar rhabdomyosarcoma)	BTO:0005380	MYF5	NA	GTRD	EXP037595_RH18--alveolar-rhabdomyosarcoma-_MYF5_MACS_MYF5_MA1641.1.damo.pwm.bed	19988
1	3173	NRF1	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR494TDU_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	13310
1	3275	POU5F1	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	POU5F1 HUES8 (Embryonic stem cell, blastocyst stage) POU5F1	HUES8 (Embryonic stem cell, blastocyst stage)	NULL	POU5F1	Genotype: SOX17-GFP knockout;	GTRD	EXP057925_HUES8--Embryonic-stem-cell--blastocyst-stage-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	33539
1	3603	SOX2	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048955_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	5225
1	3988	TP53	0.907990548338146	Inf	7	141	1	2768	2768	970	0	6374	2220	TP53 LOXIMVI TP53	LOXIMVI	NULL	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051014_LOXIMVI_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1322
1	3024	NFKB1	0.904426656752906	1.56946725007603	45	153	535	1054	1054	581	10	6336	2210	NFKB1 L1236 (Hodgkin lymphoma) NFKB1	L1236 (Hodgkin lymphoma)	NULL	NFKB1		GEO	GSE63736_nfkb1_l1236_MACS_NFKB1_MA0105.4.damo.pwm.bed	39102
1	3985	TP53	0.90293746097494	1.6563074127987	38	154	511	1238	1238	634	8	6343	2212	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #116	GTRD	EXP048276_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3168
1	4063	TP73	0.90131356634003	1.24444377700671	146	155	844	295	844	431	41	6235	2179	TP73 TP73	NA	NA	TP73	NA	GEO	GSE15780_tp73_saos-rep2_MACS_TP73_MA0861.1.damo.pwm.bed	13096
1	891	CTCF	0.89211484630081	1.37768503850819	75	156	711	632	711	500	19	6306	2201	CTCF TTC-1240 (Rhabdoid tumor of the kidney) CTCF	TTC-1240 (Rhabdoid tumor of the kidney)	NULL	CTCF	Treatment: lentivirally infected with empty vector control	GTRD	EXP053111_TTC-1240--Rhabdoid-tumor-of-the-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69124
1	613	CTCF	0.892003422147494	1.47591605761118	55	157	587	875	875	540	13	6326	2207	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	No special treatment	GTRD	EXP032761_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54018
1	1557	FOS	0.889128481403431	1.12927294576207	422	158	1067	33	1067	419	131	5959	2089	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	67959
1	4088	USF2	0.875445383487935	1.58855501390123	41	159	532	1155	1155	615	9	6340	2211	USF2 GM12878 (female B-cells lymphoblastoid cell line) USF2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	USF2		GTRD	EXP038558_GM12878--female-B-cells-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	36541
1	263	ATF7	0.86542843326087	2.00405006020275	23	160	420	1739	1739	773	4	6358	2216	ATF7 GM12878 (female B-cells lymphoblastoid cell line) ATF7	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ATF7	NA	GTRD	EXP039442_GM12878--female-B-cells-_ATF7_MACS_ATF7_MA0834.1.damo.pwm.bed	32534
1	3724	STAT1	0.86542843326087	2.00405006020275	23	160	420	1739	1739	773	4	6358	2216	STAT1 HeLa S3 (cervical adenocarcinoma) STAT1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT1	IFN gamma	GTRD	EXP000489_HeLa-S3--cervical-adenocarcinoma-_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	10049
1	1205	ESR1	0.852026618655806	1.53435701142603	44	162	558	1072	1072	597	10	6337	2210	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GTRD	EXP035621_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9594
1	1697	FOXA1	0.852026618655806	1.53435701142603	44	162	558	1072	1072	597	10	6337	2210	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr Dex, PBS 72 hr CellLine: A1A3 from T47D cell line	GTRD	EXP048403_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	6924
1	2673	MAFF	0.851476061740269	1.359104832455	74	164	723	640	723	509	19	6307	2201	MAFF HepG2 (hepatoblastoma) MAFF	HepG2 (hepatoblastoma)	BTO:0000599	MAFF	NA	ENCODE	ENCSR000EEC_HepG2_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	70406
1	294	BHLHE40	0.847211749894892	2.20695547144406	19	165	390	1956	1956	837	3	6362	2217	BHLHE40 K562 (myelogenous leukemia) BHLHE40	K562 (myelogenous leukemia)	NULL	BHLHE40	NA	ENCODE	ENCSR000EGV_K562_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	24254
1	798	CTCF	0.846148043631941	1.61247726295191	37	166	521	1264	1264	650	8	6344	2212	CTCF H929 (plasma cell myeloma) CTCF	H929 (plasma cell myeloma)	BTO:0002416	CTCF		GTRD	EXP040275_H929--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39497
1	980	CTCF	0.844823195400343	1.44885899609878	54	167	609	886	886	554	13	6327	2207	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GEO	GSE70764_ctcf_k562_MACS_CTCF_MA0139.1.damo.pwm.bed	58776
1	3238	PKNOX1	0.844823195400343	1.44885899609878	54	167	609	886	886	554	13	6327	2207	PKNOX1 MCF7 (Invasive ductal breast carcinoma) PKNOX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	PKNOX1	NA	GTRD	EXP040011_MCF7--Invasive-ductal-breast-carcinoma-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	15582
1	4026	TP53	0.84257698654173	3.8315867703329	11	169	328	2426	2426	974	1	6370	2219	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	DMSO_KOATF3	GEO	GSE74355_tp53_htc116-dmso-koatf3_MACS_TP53_MA0106.3.damo.pwm.bed	821
1	606	CTCF	0.8425153547623	1.30895620616106	90	170	766	511	766	482	24	6291	2196	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	oestrogen	GTRD	EXP030933_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62227
1	671	CTCF	0.8425153547623	1.30895620616106	90	170	766	511	766	482	24	6291	2196	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP038774_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62133
1	4050	TP63	0.841504303049467	1.09881376586048	623	172	1121	4	1121	432	199	5758	2021	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	D0	GEO	GSE59824_tp63_keratinocyte-d0_MACS_TP63_MA0525.2.damo.pwm.bed	42276
1	910	CTCF	0.841273084082217	1.27620367240227	106	173	808	420	808	467	29	6275	2191	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	Treatment: 1 h with 0.02% Ethanol;	GTRD	EXP054083_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	81438
1	3828	TEAD1	0.836222682654742	2.61303482666693	15	174	362	2200	2200	912	2	6366	2218	TEAD1 MSTO TEAD1	MSTO	NA	TEAD1		GEO	GSE68170_tead1_msto_MACS_TEAD1_MA0090.3.damo.pwm.bed	17117
1	3984	TP53	0.836222682654742	2.61303482666693	15	174	362	2200	2200	912	2	6366	2218	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.1% DMSO for 24 hrs Source: healthy volunteer#116	GTRD	EXP048275_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1899
1	618	CTCF	0.833348882485514	1.37503049313841	67	176	712	710	712	533	17	6314	2203	CTCF PC3(bone mets prostate adenocarcinoma) CTCF	PC3(bone mets prostate adenocarcinoma)	NULL	CTCF		GTRD	EXP033039_PC3-bone-mets-prostate-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46343
1	850	CTCF	0.83183043278588	1.49001676896518	47	177	579	1002	1002	586	11	6334	2209	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-SHB_1-gRNA-GFP	GTRD	EXP048002_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44708
1	3986	TP53	0.83183043278588	1.49001676896518	47	177	579	1002	1002	586	11	6334	2209	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 10 uM Nutlin-3 for 24 hrs Source: healthy volunteer #116	GTRD	EXP048277_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	8297
1	301	CDX2	0.822035753323737	1.35682089693175	70	179	725	666	725	523	18	6311	2202	CDX2 naive endoderm CDX2	naive endoderm	NULL	CDX2	Treatment: Doxycycline; Genotype: wildtype; Source: induced CDX2 culture cells;	GTRD	EXP058138_naive-endoderm_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	130730
1	1231	ESR1	0.82093525407377	1.81241418201556	26	180	451	1602	1602	744	5	6355	2215	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	ICI	GTRD	EXP037443_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4251
1	397	CEBPB	0.816387412179775	1.17900793308386	199	181	955	192	955	443	59	6182	2161	CEBPB SU-DHL-1 (Anaplastic large cell lymphoma) CEBPB	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	CEBPB	Treatment: DMSO for 3 hrs	GTRD	EXP053283_SU-DHL-1--Anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	100244
1	696	CTCF	0.803335370608571	1.37350182068324	63	182	713	753	753	549	16	6318	2204	CTCF epithelial cell of prostate CTCF	epithelial cell of prostate	NULL	CTCF		GTRD	EXP039487_epithelial-cell-of-prostate_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44953
1	3202	OTX2	0.803335370608571	1.37350182068324	63	182	713	753	753	549	16	6318	2204	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038200_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	86791
1	801	CTCF	0.799473718746919	1.2843510536755	92	184	796	498	796	493	25	6289	2195	CTCF PC3(bone mets prostate adenocarcinoma) CTCF	PC3(bone mets prostate adenocarcinoma)	NULL	CTCF		GTRD	EXP040291_PC3-bone-mets-prostate-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57582
1	489	CTCF	0.792867610171564	1.27525237264934	95	185	814	478	814	492	26	6286	2194	CTCF keratinocytes CTCF	keratinocytes	NULL	CTCF		ENCODE	ENCSR000DNC_keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56512
1	168	AR	0.792182826557026	1.35429805468752	66	186	727	727	727	547	17	6315	2203	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT24H	GEO	GSE58428_AR_lncap-dht24h_MACS_AR_MA0007.3.damo.pwm.bed	13725
1	2646	KLF5	0.790807146634108	1.56866061134639	36	187	536	1288	1288	670	8	6345	2212	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 D418N	GTRD	EXP049098_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	12160
1	924	CTCF	0.786703147684388	1.26682932197838	98	188	819	460	819	489	27	6283	2193	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 24 hrs;	GTRD	EXP057866_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60686
1	2674	MAFF	0.786614224868276	1.68449345666161	29	189	506	1504	1504	733	6	6352	2214	MAFF K562 (myelogenous leukemia) MAFF	K562 (myelogenous leukemia)	NULL	MAFF	NA	ENCODE	ENCSR000EGI_K562_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	24504
1	852	CTCF	0.785054131840654	1.39501916474738	56	190	623	859	859	557	14	6325	2206	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-CCDC85C_3-gRNA-GFP	GTRD	EXP048004_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46456
1	563	CTCF	0.783033466074655	1.45809206197745	46	191	602	1028	1028	607	11	6335	2209	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		Array Express	ERP000395_ctcf_hepatocytes_MACS_CTCF_MA0139.1.damo.pwm.bed	50690
1	595	CTCF	0.783033466074655	1.45809206197745	46	191	602	1028	1028	607	11	6335	2209	CTCF mammary epithelial cells CTCF	mammary epithelial cells	NULL	CTCF		GTRD	EXP030401_mammary-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36660
1	3854	TFAP2A	0.783033466074655	1.45809206197745	46	191	602	1028	1028	607	11	6335	2209	TFAP2A cranial neural crest cells TFAP2A	cranial neural crest cells	NULL	TFAP2A		GTRD	EXP035244_cranial-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	45710
1	1959	GATA3	0.780940420520615	1.25900951820151	101	194	826	440	826	487	28	6280	2192	GATA3 SK-N-SH (neuroblastoma) GATA3	SK-N-SH (neuroblastoma)	BTO:0001620	GATA3		ENCODE	ENCSR000BTH_SK-N-SH_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	95522
1	318	CEBPA	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	RUNX1-EVI1 KD after 10 days	GTRD	EXP037839_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	14374
1	324	CEBPA	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047669_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	8978
1	2126	HNF4A	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000307_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	12759
1	3176	NRF1	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR998AJK_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	13918
1	3337	RELA	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	RELA GM19099 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19099 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBI_GM19099_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	12021
1	3520	RXRA	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	RXRA monocyte-derived macrophages RXRA	monocyte-derived macrophages	NULL	RXRA	untreated	GTRD	EXP036837_monocyte-derived-macrophages_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	11929
1	3939	TFAP4	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	TFAP4 Kasumi-1 (acute myeloblastic leukemia) TFAP4	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TFAP4	NA	GEO	GSE45738_tfap4_kasumi1_MACS_TFAP4_MA0691.1.damo.pwm.bed	12054
1	4106	VDR	0.778224856421068	Inf	6	195	1	2870	2870	1020	0	6375	2220	VDR LS180 (colon cancer) VDR	LS180 (colon cancer)	NULL	VDR	125	GEO	GSE31939_vdr_ls180-125_MACS_VDR_MA0693.2.damo.pwm.bed	3074
1	982	CTCF	0.778218643855303	1.28955273598709	85	203	788	545	788	512	23	6296	2197	CTCF OVCAR8 (high grade ovarian serous adenocarcinoma) CTCF	OVCAR8 (high grade ovarian serous adenocarcinoma)	BTO:0003054	CTCF		GEO	GSE70764_ctcf_ovcar8_MACS_CTCF_MA0139.1.damo.pwm.bed	61455
1	1519	FOS	0.778218643855303	1.28955273598709	85	203	788	545	788	512	23	6296	2197	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000EVU_endothelial_cell_of_umbilical_vein_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	49094
1	4000	TP53	0.772850337765386	1.32196159602501	72	205	755	651	755	537	19	6309	2201	TP53 MCF10A (breast epithelial cells) TP53	MCF10A (breast epithelial cells)	BTO:0001939	TP53	Treatment: DMSO for 6 hrs;	GTRD	EXP057963_MCF10A--breast-epithelial-cells-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4006
1	1018	E2F1	0.770746638492736	2.09047745460198	18	206	393	1996	1996	865	3	6363	2217	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032868_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	20592
1	789	CTCF	0.767482123258397	1.42379079516393	49	207	618	967	967	597	12	6332	2208	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		GTRD	EXP040228_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48187
1	2991	NFE2	0.767482123258397	1.42379079516393	49	207	618	967	967	597	12	6332	2208	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		ENCODE	ENCSR000FCC_K562_NFE2_MACS_NFE2_MA0841.1.damo.pwm.bed	32173
1	3026	NFKB2	0.759276767919735	1.59327018247152	32	209	529	1410	1410	716	7	6349	2213	NFKB2 L1236 (Hodgkin lymphoma) NFKB2	L1236 (Hodgkin lymphoma)	NULL	NFKB2	NA	GEO	GSE63736_nfkb2_l1236_MACS_NFKB2_MA0778.1.damo.pwm.bed	20202
1	4012	TP53	0.759276767919735	1.59327018247152	32	209	529	1410	1410	716	7	6349	2213	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	DXR	GEO	GSE46641_tp53_u2os-dxr_MACS_TP53_MA0106.3.damo.pwm.bed	1938
1	1006	E2F1	0.756464356156241	1.74244093186702	25	211	455	1657	1657	774	5	6356	2215	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000658_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	19120
1	612	CTCF	0.753836871208912	1.39476974551844	52	212	624	921	921	586	13	6329	2207	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	DNMT3BKO	GTRD	EXP032760_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51001
1	435	CTCF	0.751129831701519	1.4641688242092	42	213	590	1124	1124	642	10	6339	2210	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000AKO_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48698
1	609	CTCF	0.751129831701519	1.4641688242092	42	213	590	1124	1124	642	10	6339	2210	CTCF PrEC (prostate cells) CTCF	PrEC (prostate cells)	BTO:0003160	CTCF		GTRD	EXP031555_PrEC--prostate-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37891
1	1675	FOXA1	0.751129831701519	1.4641688242092	42	213	590	1124	1124	642	10	6339	2210	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	100 nM 17-beta-estradiol for 3h	GTRD	EXP037654_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	6237
1	370	CEBPB	0.751074650661865	2.43847135949427	14	216	369	2252	2252	946	2	6367	2218	CEBPB monocyte-derived macrophages CEBPB	monocyte-derived macrophages	NULL	CEBPB	none	GTRD	EXP038589_monocyte-derived-macrophages_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	23918
1	968	CTCF	0.749587917524347	1.28449542000308	81	217	794	579	794	530	22	6300	2198	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	MESEN	GEO	GSE52457_ctcf_h1-mesen_MACS_CTCF_MA0139.1.damo.pwm.bed	85879
1	1564	FOSL1	0.749587917524347	1.28449542000308	81	217	794	579	794	530	22	6300	2198	FOSL1 HCT-116 (colon carcinoma) FOSL1	HCT-116 (colon carcinoma)	BTO:0001109	FOSL1	NA	ENCODE	ENCSR000BTE_HCT116_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	24568
1	1835	FOXA2	0.747163013274513	1.1873508512385	153	219	944	272	944	478	45	6228	2175	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: cTermCDT1	GTRD	EXP049294_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	73106
1	1224	ESR1	0.743013158398936	3.48275127149086	10	220	332	2487	2487	1010	1	6371	2219	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor B	GTRD	EXP036415_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4921
1	2729	MEF2B	0.743013158398936	3.48275127149086	10	220	332	2487	2487	1010	1	6371	2219	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: MEF2B- D83V mutant	GTRD	EXP048301_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	16222
1	3730	STAT3	0.73988180428597	1.15363443668074	208	222	1017	177	1017	472	63	6173	2157	STAT3 STAT3	NA	NA	STAT3	NA	NA	ENCSR000DOQ_MCF_10A_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	38533
1	438	CTCF	0.736962750774853	1.52485737987271	35	223	562	1318	1318	701	8	6346	2212	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ALV_mammary_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35153
1	799	CTCF	0.734963417141755	1.22713257375086	109	224	862	409	862	498	31	6272	2189	CTCF foreskin keratinocyte CTCF	foreskin keratinocyte	NULL	CTCF		GTRD	EXP040282_foreskin-keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60376
1	614	CTCF	0.73103226841509	1.34834426796534	58	225	735	824	824	595	15	6323	2205	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	DNMT1KO, DNMT3BKO	GTRD	EXP032762_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60838
1	343	CEBPA	0.727454797959536	1.29057806254242	74	226	787	640	787	551	20	6307	2200	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 24 hrs	GTRD	EXP053365_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	52528
1	2698	MAX	0.727007420924146	1.6261659166557	28	227	515	1531	1531	758	6	6353	2214	MAX K562 (myelogenous leukemia) MAX	K562 (myelogenous leukemia)	NULL	MAX		ENCODE	ENCSR000EFV_K562_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	42500
1	3372	RELA	0.726260742436515	1.82922719294863	21	228	449	1852	1852	843	4	6360	2216	RELA HeLa-B2 RELA	HeLa-B2	NA	RELA	TA_TNFA	GEO	GSE24518_rela_helab2-ta-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	8311
1	2622	JUND	0.722385355496054	1.09643153858053	451	229	1127	27	1127	461	144	5930	2076	JUND JUND	NA	NA	JUND	NA	GEO	GSE61369_jund_artery-smooth-muscle_MACS_JUND_MA0491.2.damo.pwm.bed	118029
1	451	CTCF	0.720648385948264	1.27898063936685	77	230	797	609	797	545	21	6304	2199	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000AUF_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60800
1	923	CTCF	0.714396631949737	1.26843950699188	80	231	818	585	818	545	22	6301	2198	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 16 hrs;	GTRD	EXP057864_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	53000
1	1517	FOS	0.712973143029544	1.08964757717892	501	232	1149	16	1149	466	161	5880	2059	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DOP_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	78030
1	440	CTCF	0.712763570174543	1.31285226010762	64	233	765	747	765	582	17	6317	2203	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		ENCODE	ENCSR000AMF_H1-hESC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69374
1	333	CEBPA	0.711625356030028	1.19413692232896	130	234	934	333	934	500	38	6251	2182	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA		GTRD	EXP053324_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	103731
1	1556	FOS	0.707462169149826	1.09354106283676	453	235	1141	26	1141	467	145	5928	2075	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	72511
1	1554	FOS	0.705986619405053	1.09496086129853	438	236	1128	30	1128	465	140	5943	2080	FOS MCF10A-ER-Src FOS	MCF10A-ER-Src	NULL	FOS	Genotype: non-transformed	GTRD	EXP048567_MCF10A-ER-Src_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	70464
1	931	CTCF	0.704840803351414	1.21568287005518	108	237	904	412	904	518	31	6273	2189	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: none;	GTRD	EXP058383_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	81070
1	3620	SOX2	0.703651169763964	1.54324991773791	31	238	557	1439	1439	745	7	6350	2213	SOX2 hNSC (neural stem cells) SOX2	hNSC (neural stem cells)	NULL	SOX2		GEO	GSE69479_sox2_hnsc_MACS_SOX2_MA0143.4.damo.pwm.bed	62508
1	898	CTCF	0.702702737296854	1.42909077907391	41	239	616	1155	1155	670	10	6340	2210	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	Treatment: None;	GTRD	EXP054035_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55566
1	985	CTCF	0.702702737296854	1.42909077907391	41	239	616	1155	1155	670	10	6340	2210	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	HYPOXIA	GEO	GSE78113_ctcf_mcf7-hypoxia_MACS_CTCF_MA0139.1.damo.pwm.bed	42817
1	201	AR	0.699605656984025	1.34478345714798	54	241	736	886	886	621	14	6327	2206	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	MPA	GEO	GSE74069_AR_mdamb45-mpa_MACS_AR_MA0007.3.damo.pwm.bed	6213
1	553	CTCF	0.699605656984025	1.34478345714798	54	241	736	886	886	621	14	6327	2206	CTCF KARPAS-422 (diffuse large B-cell lymphoma) CTCF	KARPAS-422 (diffuse large B-cell lymphoma)	BTO:0004981	CTCF		ENCODE	ENCSR113REG_Karpas-422_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52837
1	1676	FOXA1	0.698111132488524	1.20550335837574	114	243	918	392	918	518	33	6267	2187	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP038333_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	17608
1	575	CTCF	0.697839319363039	1.28484120081285	70	244	793	666	793	568	19	6311	2201	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	NULL	GTRD	EXP000599_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73652
1	1279	ESR1	0.696457081412168	1.97403859649176	17	245	424	2066	2066	912	3	6364	2217	ESR1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) ESR1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	ESR1	vehicle	GTRD	EXP038761_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4048
1	1570	FOSL1	0.696457081412168	1.97403859649176	17	245	424	2066	2066	912	3	6364	2217	FOSL1 BT-549 (breast invasive ductal carcinoma) FOSL1	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	FOSL1	NA	GEO	GSE46166_fosl1_bt549_MACS_FOSL1_MA0477.2.damo.pwm.bed	16372
1	3297	PPARG	0.696457081412168	1.97403859649176	17	245	424	2066	2066	912	3	6364	2217	PPARG hASC (preadipocytes) PPARG	hASC (preadipocytes)	NULL	PPARG		GEO	GSE21366_pparg_asc_MACS_PPARG_MA0066.1.damo.pwm.bed	16549
1	1627	FOSL2	0.695050209661479	1.20086469657944	117	248	925	378	925	517	34	6264	2186	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	52654
1	449	CTCF	0.693881163654316	1.67231927465451	24	249	507	1691	1691	816	5	6357	2215	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ATN_CD14-positive_monocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35404
1	1058	EGR1	0.693881163654316	1.67231927465451	24	249	507	1691	1691	816	5	6357	2215	EGR1 K562 (myelogenous leukemia) EGR1	K562 (myelogenous leukemia)	NULL	EGR1		ENCODE	ENCSR000BNE_K562_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	42133
1	1239	ESR1	0.693881163654316	1.67231927465451	24	249	507	1691	1691	816	5	6357	2215	ESR1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) ESR1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	ESR1	White Medium	GTRD	EXP037776_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7077
1	332	CEBPA	0.692171828983192	1.19649239887716	120	252	931	367	931	517	35	6261	2185	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA		GTRD	EXP053324_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	96696
1	848	CTCF	0.691370030706335	1.272939724264	73	253	816	644	816	571	20	6308	2200	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under normal conditions	GTRD	EXP047929_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	72780
1	1213	ESR1	0.689270148986194	1.39427184665288	44	254	625	1072	1072	650	11	6337	2209	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Vehicle treatment	GTRD	EXP036169_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9086
1	543	CTCF	0.685457248185225	1.26217378377281	76	255	824	619	824	566	21	6305	2199	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DXI_bronchial_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55364
1	159	AR	0.684664371150065	1.48106748436137	34	256	582	1349	1349	729	8	6347	2212	AR AR	NA	NA	AR	NA	GEO	GSE55062_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	8080
1	1226	ESR1	0.684664371150065	1.48106748436137	34	256	582	1349	1349	729	8	6347	2212	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2+ICI	GTRD	EXP036976_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9899
1	3001	NFE2L2	0.684664371150065	1.48106748436137	34	256	582	1349	1349	729	8	6347	2212	NFE2L2 HeLa S3 (cervical adenocarcinoma) NFE2L2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NFE2L2		GTRD	EXP039984_HeLa-S3--cervical-adenocarcinoma-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	18623
1	3742	STAT3	0.684664371150065	1.48106748436137	34	256	582	1349	1349	729	8	6347	2212	STAT3 JB6 (Human anaplastic large cell lymphoma) STAT3	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	STAT3	Treatment: DMSO for 3 hrs	GTRD	EXP053277_JB6--Human-anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	17784
1	425	CREB1	0.67764852473464	1.36525938533994	47	260	718	1002	1002	660	12	6334	2208	CREB1 MDA-MB-134 (invasive lobular breast carcinoma) CREB1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	CREB1	Treatment:a cocktail of 10 µM forskolin plus 100 µM 3-isobutyl-1-methylxanthine (FI) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048182_MDA-MB-134--invasive-lobular-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	9841
1	448	CTCF	0.67764852473464	1.36525938533994	47	260	718	1002	1002	660	12	6334	2208	CTCF DND41 (acute lymphoblastic leukemia) CTCF	DND41 (acute lymphoblastic leukemia)	NULL	CTCF		ENCODE	ENCSR000AQU_DND-41_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56279
1	712	CTCF	0.67764852473464	1.36525938533994	47	260	718	1002	1002	660	12	6334	2208	CTCF bipolar neuron CTCF	bipolar neuron	NULL	CTCF	0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day	GTRD	EXP039610_bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62864
1	2992	NFE2	0.67764852473464	1.36525938533994	47	260	718	1002	1002	660	12	6334	2208	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		GTRD	EXP040018_K562--myelogenous-leukemia-_NFE2_MACS_NFE2_MA0501.1.damo.pwm.bed	31106
1	3853	TFAP2A	0.67764852473464	1.36525938533994	47	260	718	1002	1002	660	12	6334	2208	TFAP2A cranial neural crest cells TFAP2A	cranial neural crest cells	NULL	TFAP2A		GTRD	EXP035244_cranial-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	47663
1	906	CTCF	0.674539167423116	1.29213888055027	63	265	786	753	786	601	17	6318	2203	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	Treatment: None;	GTRD	EXP054043_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54354
1	2689	MAX	0.669189273057542	1.56785623966609	27	266	537	1564	1564	789	6	6354	2214	MAX WA01 (H1, human embryonic stem cells) MAX	WA01 (H1, human embryonic stem cells)	NULL	MAX		ENCODE	ENCSR000BSJ_H1-hESC_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	48378
1	1258	ESR1	0.661718527929494	1.26628954772066	69	267	821	687	821	592	19	6312	2201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038370_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16403
1	886	CTCF	0.659761417509715	1.74185834501242	20	268	456	1901	1901	875	4	6361	2216	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	110 mM NaCl	GTRD	EXP053053_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32606
1	1222	ESR1	0.659761417509715	1.74185834501242	20	268	456	1901	1901	875	4	6361	2216	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor C	GTRD	EXP036410_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8146
1	2663	LHX9	0.659761417509715	1.74185834501242	20	268	456	1901	1901	875	4	6361	2216	LHX9 HCT-116 (colon carcinoma) LHX9	HCT-116 (colon carcinoma)	BTO:0001109	LHX9	Genotype:Expressing LHX9-V5 open reading frame and shKRAS Tissue: colon	GTRD	EXP053274_HCT-116--colon-carcinoma-_LHX9_MACS_LHX9_MA0701.2.damo.pwm.bed	14265
1	537	CTCF	0.658680088613424	1.21435922794502	94	271	905	482	905	553	27	6287	2193	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DWH_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55196
1	572	CTCF	0.6585763189443	1.3196770836932	53	272	756	905	905	644	14	6328	2206	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	NULL	GTRD	EXP000596_WA01--H1--human-embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	78373
1	1270	ESR1	0.6585763189443	1.3196770836932	53	272	756	905	905	644	14	6328	2206	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Doxycycline + E2	GTRD	EXP038383_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15711
1	652	CTCF	0.656181568538232	1.25530680476851	72	274	828	651	828	584	20	6309	2200	CTCF epidermal keratinocytes CTCF	epidermal keratinocytes	NULL	CTCF	undifferentiated	GTRD	EXP037596_epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51004
1	1997	GATA3	0.655670713224814	1.39402336585404	40	275	626	1189	1189	697	10	6341	2210	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GEO	GSE60270_gata3_mcf7-e2_MACS_GATA3_MA0037.3.damo.pwm.bed	12027
1	1007	E2F1	0.649715771957844	1.49324485103873	30	276	576	1473	1473	775	7	6351	2213	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000659_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	19822
1	1299	ESR1	0.649715771957844	1.49324485103873	30	276	576	1473	1473	775	7	6351	2213	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	ICI for 3h	GTRD	EXP040894_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5952
1	2995	NFE2L2	0.649715771957844	1.49324485103873	30	276	576	1473	1473	775	7	6351	2213	NFE2L2 NFE2L2	NA	NA	NFE2L2	NA	NA	ENCSR485GKE_K562_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	37495
1	920	CTCF	0.649262148434369	1.19764406622676	103	279	930	434	930	548	30	6278	2190	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: untreated;	GTRD	EXP057858_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	102321
1	1839	FOXA2	0.648681012149845	1.1168230646864	243	280	1081	137	1081	499	76	6138	2144	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049303_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	104199
1	195	AR	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	R1881	GEO	GSE70161_AR_mdamb453-r1881_MACS_AR_MA0007.3.damo.pwm.bed	283
1	285	BCL6	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6	UV	GTRD	EXP040596_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	8139
1	317	CEBPA	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	RUNX1-EVI1 KD after 10 days	GTRD	EXP037839_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	9655
1	1823	FOXA2	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	FOXA2 endometrioid adenocarcinoma FOXA2	endometrioid adenocarcinoma	NULL	FOXA2	tumor A	GTRD	EXP036409_endometrioid-adenocarcinoma_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	1480
1	1858	FOXP1	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	FOXP1 SU-DHL-6 (diffuse large B-cell lymphoma) FOXP1	SU-DHL-6 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	Array Express	ERP010999_foxp1_sudhl6_MACS_FOXP1_MA0481.3.damo.pwm.bed	13126
1	1859	FOXP1	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	FOXP1 U2932 (diffuse large B-cell lymphoma) FOXP1	U2932 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	Array Express	ERP010999_foxp1_u2932_MACS_FOXP1_MA0481.3.damo.pwm.bed	6774
1	2127	HNF4A	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000307_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	13234
1	2594	JUND	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND		ENCODE	ENCSR000DYS_GM12878_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	3719
1	3031	NFYB	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	NFYB HeLa S3 (cervical adenocarcinoma) NFYB	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NFYB	NA	ENCODE	ENCSR000DNR_HeLa-S3_NFYB_MACS_NFYB_MA0502.2.damo.pwm.bed	6481
1	3033	NFYB	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	NFYB K562 (myelogenous leukemia) NFYB	K562 (myelogenous leukemia)	NULL	NFYB	NA	GEO	GSE26439_nfyb_k562_MACS_NFYB_MA0502.2.damo.pwm.bed	8302
1	3178	NRF1	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		GTRD	EXP038537_K562--myelogenous-leukemia-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	9337
1	3216	PAX5	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	PAX5 Raji (Burkitt lymphoma) PAX5	Raji (Burkitt lymphoma)	BTO:0001154	PAX5	none	GTRD	EXP031938_Raji--Burkitt-lymphoma-_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	7144
1	3276	POU5F1	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	POU5F1 HUES8 (Embryonic stem cell, blastocyst stage) POU5F1	HUES8 (Embryonic stem cell, blastocyst stage)	NULL	POU5F1	Genotype: SOX17-GFP knockout;	GTRD	EXP057925_HUES8--Embryonic-stem-cell--blastocyst-stage-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	24234
1	3290	PPARG	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034425_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	9105
1	3505	RUNX2	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	RUNX2 SaOS2 (osteosarcoma) RUNX2	SaOS2 (osteosarcoma)	BTO:0000971	RUNX2		GTRD	EXP037204_SaOS2--osteosarcoma-_RUNX2_MACS_RUNX2_MA0511.2.damo.pwm.bed	10625
1	3781	TCF12	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	TCF12 GM12878 (female B-cells lymphoblastoid cell line) TCF12	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF12	NA	GTRD	EXP039314_GM12878--female-B-cells-_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	3302
1	3782	TCF12	0.648476757989718	Inf	5	281	1	2973	2973	1080	0	6376	2220	TCF12 GM12878 (female B-cells lymphoblastoid cell line) TCF12	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF12	NA	GTRD	EXP039314_GM12878--female-B-cells-_TCF12_MACS_TCF12_MA1648.1.damo.pwm.bed	3332
1	1014	E2F1	0.645728358763904	3.13402447200112	9	298	339	2585	2585	1070	1	6372	2219	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032860_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	14525
1	3485	RUNX1	0.645728358763904	3.13402447200112	9	298	339	2585	2585	1070	1	6372	2219	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: no dox; Genotype: CBFB-MYH11 knockdown construct, RUNX1 wildtype;	GTRD	EXP058216_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	24172
1	3701	SREBF1	0.645728358763904	3.13402447200112	9	298	339	2585	2585	1070	1	6372	2219	SREBF1 MCF7 (Invasive ductal breast carcinoma) SREBF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	SREBF1		ENCODE	ENCSR197DJH_MCF-7_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	3673
1	4008	TP53	0.645728358763904	3.13402447200112	9	298	339	2585	2585	1070	1	6372	2219	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_u2os-eto_MACS_TP53_MA0106.3.damo.pwm.bed	840
1	1250	ESR1	0.64420470891632	1.15100257075472	155	302	1021	267	1021	530	47	6226	2173	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	80min E2	GTRD	EXP038340_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	37461
1	921	CTCF	0.638402273313144	1.22054623010284	84	303	864	557	864	575	24	6297	2196	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 1 hr;	GTRD	EXP057860_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55950
1	889	CTCF	0.634825010386608	1.21359849571903	87	304	906	530	906	580	25	6294	2195	CTCF SYO-1(Biphasic synovial sarcoma) CTCF	SYO-1(Biphasic synovial sarcoma)	NULL	CTCF	Treatment: lentivirally infected with shControl	GTRD	EXP053102_SYO-1-Biphasic-synovial-sarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	79791
1	929	CTCF	0.634825010386608	1.21359849571903	87	304	906	530	906	580	25	6294	2195	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: none;	GTRD	EXP058381_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	72872
1	521	CTCF	0.634617650924569	1.33600700128842	46	306	743	1028	1028	692	12	6335	2208	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTR_epithelial_cell_of_esophagus_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36760
1	3855	TFAP2A	0.634617650924569	1.33600700128842	46	306	743	1028	1028	692	12	6335	2208	TFAP2A cranial neural crest cells TFAP2A	cranial neural crest cells	NULL	TFAP2A		GTRD	EXP035244_cranial-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	47331
1	1255	ESR1	0.633282230822108	1.60240437930863	23	308	524	1739	1739	857	5	6358	2215	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	Tamoxifen-associated	GTRD	EXP038345_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11177
1	1294	ESR1	0.633282230822108	1.60240437930863	23	308	524	1739	1739	857	5	6358	2215	ESR1 breast tumor ESR1	breast tumor	NULL	ESR1	Female	GTRD	EXP040663_breast-tumor_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5992
1	2662	LHX9	0.633282230822108	1.60240437930863	23	308	524	1739	1739	857	5	6358	2215	LHX9 HCT-116 (colon carcinoma) LHX9	HCT-116 (colon carcinoma)	BTO:0001109	LHX9	Genotype: Expressing LHX9-V5 open reading frame Tissue: colon	GTRD	EXP053273_HCT-116--colon-carcinoma-_LHX9_MACS_LHX9_MA0701.2.damo.pwm.bed	10590
1	2679	MAFK	0.633282230822108	1.60240437930863	23	308	524	1739	1739	857	5	6358	2215	MAFK HeLa S3 (cervical adenocarcinoma) MAFK	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MAFK	NA	ENCODE	ENCSR000ECK_HeLa-S3_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	13597
1	3277	POU5F1	0.633282230822108	1.60240437930863	23	308	524	1739	1739	857	5	6358	2215	POU5F1 HUES8 (Embryonic stem cell, blastocyst stage) POU5F1	HUES8 (Embryonic stem cell, blastocyst stage)	NULL	POU5F1	Genotype: SOX17-GFP knockout;	GTRD	EXP057927_HUES8--Embryonic-stem-cell--blastocyst-stage-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	49407
1	3199	OTX2	0.631654382650007	1.25892850957849	65	313	827	738	827	626	18	6316	2202	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038196_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	93215
1	3731	STAT3	0.629713371923984	1.11204664391783	242	314	1093	138	1093	515	76	6139	2144	STAT3 STAT3	NA	NA	STAT3	NA	NA	ENCSR000DPB_MCF_10A_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	47234
1	907	CTCF	0.626536137174878	1.24774358089754	68	315	842	703	842	620	19	6313	2201	CTCF DND41 (acute lymphoblastic leukemia) CTCF	DND41 (acute lymphoblastic leukemia)	NULL	CTCF	Treatment: None;	GTRD	EXP054054_DND41--acute-lymphoblastic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	72222
1	654	CTCF	0.626137822926744	1.31369767616207	49	316	763	967	967	682	13	6332	2207	CTCF epidermal keratinocytes CTCF	epidermal keratinocytes	NULL	CTCF	day6 of differentiation	GTRD	EXP037598_epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40305
1	834	CTCF	0.626137822926744	1.31369767616207	49	316	763	967	967	682	13	6332	2207	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 60min	GTRD	EXP047801_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52712
1	1694	FOXA1	0.625660095267366	1.19574235942758	96	318	932	475	932	575	28	6285	2192	FOXA1 breast tumor FOXA1	breast tumor	NULL	FOXA1	Female	GTRD	EXP040664_breast-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	13725
1	2469	JUN	0.62451190254132	1.85763851946442	16	319	442	2127	2127	963	3	6365	2217	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE46166_jun_bt549_MACS_JUN_MA0488.1.damo.pwm.bed	12667
1	3952	TP53	0.62451190254132	1.85763851946442	16	319	442	2127	2127	963	3	6365	2217	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	UV_8H	Array Express	ERP004176_tp53_u2os-uv-8h_MACS_TP53_MA0106.3.damo.pwm.bed	1505
1	3993	TP53	0.62451190254132	1.85763851946442	16	319	442	2127	2127	963	3	6365	2217	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051022_HCT-116--colon-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1307
1	3999	TP53	0.62451190254132	1.85763851946442	16	319	442	2127	2127	963	3	6365	2217	TP53 foreskin fibroblast TP53	foreskin fibroblast	NULL	TP53	Treatment: 5 uM Nutlin3A for 6 hrs;	GTRD	EXP057960_foreskin-fibroblast_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2943
1	4038	TP63	0.62451190254132	1.85763851946442	16	319	442	2127	2127	963	3	6365	2217	TP63 tongue TP63	tongue	BTO:0001385	TP63	Source: Head and neck squamous cell carcinoma;	GTRD	EXP057764_tongue_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	994
1	3868	TFAP2A	0.623049400925125	1.1906143460213	99	324	941	455	941	573	29	6282	2191	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A	E2	GEO	GSE60270_tfap2a_mcf7-e2_MACS_TFAP2A_MA0810.1.damo.pwm.bed	29396
1	4058	TP63	0.620965338742079	1.39377519670535	36	325	627	1288	1288	747	9	6345	2211	TP63 TP63	NA	NA	TP63	NA	GEO	GSE64298_tp63_dk_MACS_TP63_MA0525.2.damo.pwm.bed	1822
1	3284	PPARG	0.618704019645263	1.29457833787288	52	326	781	921	921	676	14	6329	2206	PPARG hMADS-3 (adipose-derived stem cells) PPARG	hMADS-3 (adipose-derived stem cells)	NULL	PPARG	differentiaiton inductors	GTRD	EXP033780_hMADS-3--adipose-derived-stem-cells-_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	60933
1	4057	TP63	0.615780311602754	1.13105572266192	175	327	1061	226	1061	538	54	6206	2166	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	LacZ_TGFB	GEO	GSE60814_tp63_hacat-lacz-tgfb_MACS_TP63_MA0525.2.damo.pwm.bed	12030
1	1054	EBF1	0.613237565903064	1.5095642516538	26	328	564	1602	1602	831	6	6355	2214	EBF1 MUTUL EBF1	MUTUL	NA	EBF1	NA	GEO	GSE75503_ebf1_mutul_MACS_EBF1_MA0154.4.damo.pwm.bed	47046
1	1055	EBF3	0.613237565903064	1.5095642516538	26	328	564	1602	1602	831	6	6355	2214	EBF3 SK-N-SH (neuroblastoma) EBF3	SK-N-SH (neuroblastoma)	BTO:0001620	EBF3	NA	GTRD	EXP038092_SK-N-SH--neuroblastoma-_EBF3_MACS_EBF3_MA1637.1.damo.pwm.bed	43729
1	1204	ESR1	0.613237565903064	1.5095642516538	26	328	564	1602	1602	831	6	6355	2214	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2+PG	GTRD	EXP034903_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7125
1	1720	FOXA1	0.610872551285274	1.16602671074562	117	331	978	378	978	562	35	6264	2185	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: ethanol	GTRD	EXP048914_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	21482
1	485	CTCF	0.610343400983125	1.21274869426744	80	332	908	585	908	608	23	6301	2197	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	45 min with 100 nM Estradiol (Crawford)	ENCODE	ENCSR000DMS_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47846
1	670	CTCF	0.610343400983125	1.21274869426744	80	332	908	585	908	608	23	6301	2197	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP038773_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56808
1	639	CTCF	0.610070095764195	1.35896653326725	39	334	724	1206	1206	755	10	6342	2210	CTCF PC9 (lung adenocarcinoma) CTCF	PC9 (lung adenocarcinoma)	NULL	CTCF		GTRD	EXP036849_PC9--lung-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40068
1	2581	JUNB	0.610018912668941	1.08209142540462	387	335	1163	47	1163	515	125	5994	2095	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	63850
1	3107	NR3C1	0.607855770373164	1.15961264133912	123	336	1013	351	1013	567	37	6258	2183	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	ICI, DEX, pBox mutant	GTRD	EXP037452_MCF7--Invasive-ductal-breast-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17964
1	1269	ESR1	0.601131835829105	1.25073110299393	61	337	839	785	839	654	17	6320	2203	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Doxycycline	GTRD	EXP038382_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17182
1	610	CTCF	0.600818891257151	1.33049030130094	42	338	749	1124	1124	737	11	6339	2209	CTCF LNCaP (prostate carcinoma) CTCF	LNCaP (prostate carcinoma)	BTO:0001321	CTCF		GTRD	EXP031556_LNCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38157
1	2750	MEIS2	0.600818891257151	1.33049030130094	42	338	749	1124	1124	737	11	6339	2209	MEIS2 K562 (myelogenous leukemia) MEIS2	K562 (myelogenous leukemia)	NULL	MEIS2	NA	ENCODE	ENCSR851BNE_K562_MEIS2_MACS_MEIS2_MA0774.1.damo.pwm.bed	41488
1	2993	NFE2	0.600818891257151	1.33049030130094	42	338	749	1124	1124	737	11	6339	2209	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		GTRD	EXP040018_K562--myelogenous-leukemia-_NFE2_MACS_NFE2_MA0841.1.damo.pwm.bed	23710
1	611	CTCF	0.597533996839249	1.44325485418687	29	341	611	1504	1504	819	7	6352	2213	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF	DNMT1KO	GTRD	EXP032759_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39216
1	2755	MITF	0.597533996839249	1.44325485418687	29	341	611	1504	1504	819	7	6352	2213	MITF K562 (myelogenous leukemia) MITF	K562 (myelogenous leukemia)	NULL	MITF		GTRD	EXP040317_K562--myelogenous-leukemia-_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	28681
1	1729	FOXA1	0.596639628990564	1.13220181721751	159	343	1050	256	1050	550	49	6222	2171	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10	GTRD	EXP049900_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	21773
1	1805	FOXA1	0.596639628990564	1.13220181721751	159	343	1050	256	1050	550	49	6222	2171	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	E2	GEO	GSE72249_foxa1_t47d-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	17954
1	1535	FOS	0.596482595436284	1.23936801365749	64	345	847	747	847	646	18	6317	2202	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	42988
1	2603	JUND	0.595489666059426	1.65435037506881	19	346	512	1956	1956	938	4	6362	2216	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	8264
1	4061	TP73	0.595489666059426	1.65435037506881	19	346	512	1956	1956	938	4	6362	2216	TP73 GM12878 (female B-cells lymphoblastoid cell line) TP73	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TP73	NA	GTRD	EXP038553_GM12878--female-B-cells-_TP73_MACS_TP73_MA0861.1.damo.pwm.bed	1828
1	3867	TFAP2A	0.59087831876956	1.16991970673731	104	348	969	429	969	582	31	6277	2189	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A	E2	GEO	GSE60270_tfap2a_mcf7-e2_MACS_TFAP2A_MA0003.4.damo.pwm.bed	29544
1	895	CTCF	0.588534314940546	1.22005719816641	70	349	865	666	865	627	20	6311	2200	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	Treatment: None;	GTRD	EXP054032_WA01--H1--human-embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	79602
1	2681	MAFK	0.588534314940546	1.22005719816641	70	349	865	666	865	627	20	6311	2200	MAFK HepG2 (hepatoblastoma) MAFK	HepG2 (hepatoblastoma)	BTO:0000599	MAFK	NA	ENCODE	ENCSR000EEB_HepG2_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	79576
1	266	BACH1	0.588094581168355	2.08945225072476	12	351	394	2359	2359	1030	2	6369	2218	BACH1 WA01 (H1, human embryonic stem cells) BACH1	WA01 (H1, human embryonic stem cells)	NULL	BACH1	NA	ENCODE	ENCSR000EBQ_H1-hESC_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	14931
1	3218	PAX5	0.588094581168355	2.08945225072476	12	351	394	2359	2359	1030	2	6369	2218	PAX5 L428 (Hodgkin lymphoma) PAX5	L428 (Hodgkin lymphoma)	BTO:0000406	PAX5	Mifepristone	GTRD	EXP031940_L428--Hodgkin-lymphoma-_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	13274
1	3379	RELA	0.588094581168355	2.08945225072476	12	351	394	2359	2359	1030	2	6369	2218	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	TNF_JQ1	GEO	GSE53998_rela_huvec-tnf-jq1_MACS_RELA_MA0107.1.damo.pwm.bed	14471
1	3644	SPDEF	0.588094581168355	2.08945225072476	12	351	394	2359	2359	1030	2	6369	2218	SPDEF A549 (lung carcinoma) SPDEF	A549 (lung carcinoma)	BTO:0000018	SPDEF	NA	GTRD	EXP037793_A549--lung-carcinoma-_SPDEF_MACS_SPDEF_MA0686.1.damo.pwm.bed	6933
1	988	CTCF	0.586005582512936	1.28669003767895	48	355	792	982	982	710	13	6333	2207	CTCF VCaP (prostate carcinoma) CTCF	VCaP (prostate carcinoma)	BTO:0003215	CTCF	R1881	GEO	GSE84432_ctcf_vcap-r1881_MACS_CTCF_MA0139.1.damo.pwm.bed	40435
1	342	CEBPA	0.585125776123719	1.2117842179497	73	356	910	644	910	637	21	6308	2199	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 24 hrs	GTRD	EXP053365_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	50732
1	1625	FOSL2	0.58497232719095	1.15587783266374	116	357	1015	383	1015	585	35	6265	2185	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	52720
1	919	CTCF	0.584910901636882	1.39352733862917	32	358	628	1410	1410	799	8	6349	2212	CTCF HAP1 (chronic myelogenous leukemia) CTCF	HAP1 (chronic myelogenous leukemia)	NULL	CTCF	Genotype: Wapl and SCC4 knockout;	GTRD	EXP055798_HAP1--chronic-myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42615
1	3813	TCF7L2	0.584910901636882	1.39352733862917	32	358	628	1410	1410	799	8	6349	2212	TCF7L2 MCF7 (Invasive ductal breast carcinoma) TCF7L2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TCF7L2		ENCODE	ENCSR000EWT_MCF-7_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	7575
1	41	AR	0.583766341229374	1.15285804598531	119	360	1018	373	1018	584	36	6262	2184	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR	DHT+Bicalutamide	GTRD	EXP034148_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	40211
1	1624	FOSL2	0.582652948928022	1.15000270841855	122	361	1022	356	1022	580	37	6259	2183	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	56002
1	2579	JUNB	0.581479215876969	1.07594393982367	388	362	1178	46	1178	529	126	5993	2094	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	63920
1	851	CTCF	0.58000894491875	1.26948720165478	51	363	817	932	932	704	14	6330	2206	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: GK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-MIR152_3-gRNA-GFP	GTRD	EXP048003_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45853
1	3571	SMAD3	0.579806102429573	1.14230007300171	131	364	1041	328	1041	578	40	6250	2180	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047901_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	47849
1	1995	GATA3	0.576407811546714	1.13176478709963	146	365	1052	295	1052	571	45	6235	2175	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GEO	GSE51274_gata3_mcf7_MACS_GATA3_MA0037.3.damo.pwm.bed	38880
1	1730	FOXA1	0.575428571925064	1.1281851047723	152	366	1068	277	1068	570	47	6229	2173	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10	GTRD	EXP049901_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	25735
1	1011	E2F1	0.574769952082567	1.53251068634045	22	367	560	1797	1797	908	5	6359	2215	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032856_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	21655
1	3489	RUNX1	0.574769952082567	1.53251068634045	22	367	560	1797	1797	908	5	6359	2215	RUNX1 RUNX1	NA	NA	RUNX1	NA	GEO	GSE42075_runx1_sem_MACS_RUNX1_MA0002.2.damo.pwm.bed	33164
1	3787	TCF3	0.574560081788491	1.3548545661366	35	369	726	1318	1318	804	9	6346	2211	TCF3 GM12878 (female B-cells lymphoblastoid cell line) TCF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF3		ENCODE	ENCSR000BQT_GM12878_TCF3_MACS_TCF3_MA0522.3.damo.pwm.bed	46865
1	1713	FOXA1	0.573992918220218	1.12187881978628	164	370	1074	246	1074	563	51	6217	2169	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048452_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	32606
1	3577	SMAD3	0.57275260580402	1.1118691332683	188	371	1094	204	1094	556	59	6193	2161	SMAD3 PC3(bone mets prostate adenocarcinoma) SMAD3	PC3(bone mets prostate adenocarcinoma)	NULL	SMAD3	Treatment: hypoxia (0.2% O2);	GTRD	EXP057828_PC3-bone-mets-prostate-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	45736
1	4060	TP63	0.57275260580402	1.1118691332683	188	371	1094	204	1094	556	59	6193	2161	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	DCIS	GEO	GSE72009_tp63_mcf10dcis_MACS_TP63_MA0525.2.damo.pwm.bed	12720
1	3770	TBX21	0.56593761707845	1.32392023049751	38	373	753	1238	1238	788	10	6343	2210	TBX21 GM12878 (female B-cells lymphoblastoid cell line) TBX21	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TBX21		ENCODE	ENCSR739IHN_GM12878_TBX21_MACS_TBX21_MA0690.1.damo.pwm.bed	44000
1	3227	PDX1	0.565396780693827	1.16221194726313	100	374	982	446	982	601	30	6281	2190	PDX1 pancreatic islets PDX1	pancreatic islets	NULL	PDX1		Array Express	ERP001456_pdx1_islet_MACS_PDX1_MA0132.2.damo.pwm.bed	47872
1	2680	MAFK	0.562308029077852	1.21981349298366	63	375	867	753	867	665	18	6318	2202	MAFK HepG2 (hepatoblastoma) MAFK	HepG2 (hepatoblastoma)	BTO:0000599	MAFK	NA	ENCODE	ENCSR000EDZ_HepG2_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	55847
1	823	CTCF	0.559233598048201	1.45128975937287	25	376	605	1657	1657	879	6	6356	2214	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siNIPBL(siRNA)	GTRD	EXP047779_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36084
1	1298	ESR1	0.559233598048201	1.45128975937287	25	376	605	1657	1657	879	6	6356	2214	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	vehicle for 3h	GTRD	EXP040893_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4250
1	3370	RELA	0.559233598048201	1.45128975937287	25	376	605	1657	1657	879	6	6356	2214	RELA GM12878 (female B-cells lymphoblastoid cell line) RELA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELA		GTRD	EXP054685_GM12878--female-B-cells-lymphoblastoid-cell-line-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	31878
1	599	CTCF	0.559030914528825	1.21066868054166	66	379	911	727	911	672	19	6315	2201	CTCF normal epidermal keratinocytes CTCF	normal epidermal keratinocytes	NULL	CTCF		GTRD	EXP030405_normal-epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47278
1	1268	ESR1	0.559030914528825	1.21066868054166	66	379	911	727	911	672	19	6315	2201	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2	GTRD	EXP038381_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14884
1	26	AR	0.558662967990732	1.29861393330986	41	381	779	1155	1155	772	11	6340	2209	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032855_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	7677
1	593	CTCF	0.558662967990732	1.29861393330986	41	381	779	1155	1155	772	11	6340	2209	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		GTRD	EXP030399_WA01--H1--human-embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	60874
1	474	CTCF	0.55609524418537	1.20244050104781	69	383	923	687	923	664	20	6312	2200	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF		ENCODE	ENCSR000DLO_HeLa-S3_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49889
1	1422	ESR1	0.55609524418537	1.20244050104781	69	383	923	687	923	664	20	6312	2200	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	PROG	GEO	GSE68355_ESR1_t47d-prog_MACS_ESR1_MA0112.3.damo.pwm.bed	18511
1	1903	GATA1	0.555098256095456	1.7412766643768	15	385	459	2200	2200	1010	3	6366	2217	GATA1 primary erythroblasts GATA1	primary erythroblasts	NULL	GATA1	NULL	GTRD	EXP000701_primary-erythroblasts_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	25824
1	2216	ISL1	0.555098256095456	1.7412766643768	15	385	459	2200	2200	1010	3	6366	2217	ISL1 BE2C ISL1	BE2C	NULL	ISL1	Treatment: untreated	GTRD	EXP049483_BE2C_ISL1_MACS_ISL1_MA1608.1.damo.pwm.bed	33509
1	1842	FOXA2	0.554389805903022	1.09890813911177	211	387	1120	170	1120	559	67	6170	2153	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: FOXA2 mimo released	GTRD	EXP049307_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	79019
1	1388	ESR1	0.55415668461618	1.09967322768108	208	388	1115	177	1115	560	66	6173	2154	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SIGATA_E2	GEO	GSE40129_esr1_mcf7-sigata-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	48903
1	1287	ESR1	0.552703075933575	1.11113208197118	172	389	1096	234	1096	573	54	6209	2166	ESR1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) ESR1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	ESR1	Tam-Resist	GTRD	EXP038790_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	36346
1	480	CTCF	0.552461313857933	1.27752872574964	44	390	798	1072	1072	753	12	6337	2208	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DMF_LNCaP_clone_FGC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35290
1	653	CTCF	0.552461313857933	1.27752872574964	44	390	798	1072	1072	753	12	6337	2208	CTCF epidermal keratinocytes CTCF	epidermal keratinocytes	NULL	CTCF	day3 of differentiation	GTRD	EXP037597_epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36232
1	745	CTCF	0.552461313857933	1.27752872574964	44	390	798	1072	1072	753	12	6337	2208	CTCF LNCaP (prostate carcinoma) CTCF	LNCaP (prostate carcinoma)	BTO:0001321	CTCF		GTRD	EXP039840_LNCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37017
1	1168	ESR1	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TAMR	Array Express	ERP000380_esr1_mcf7tamr_MACS_ESR1_MA0112.3.damo.pwm.bed	1682
1	1359	ESR1	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10nM Estradiol + 10 nM Aldosterone for 45 mins Genotype: ER+/PR+	GTRD	EXP049943_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6551
1	1405	ESR1	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_5M	GEO	GSE54855_esr1_mcf7-e2-5m_MACS_ESR1_MA0112.3.damo.pwm.bed	1208
1	2786	MYC	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	MYC MYC	NA	NA	MYC	NA	NA	ENCSR000DLU_endothelial_cell_of_umbilical_vein_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	22424
1	3032	NFYB	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	NFYB K562 (myelogenous leukemia) NFYB	K562 (myelogenous leukemia)	NULL	NFYB	NA	ENCODE	ENCSR000EGQ_K562_NFYB_MACS_NFYB_MA0502.2.damo.pwm.bed	11601
1	3181	NRF1	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	NRF1 MCF7 (Invasive ductal breast carcinoma) NRF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NRF1		GTRD	EXP038568_MCF7--Invasive-ductal-breast-carcinoma-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	10163
1	3641	SP2	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	SP2 HEK293 (embryonic kidney) SP2	HEK293 (embryonic kidney)	NULL	SP2	NA	GTRD	EXP039876_HEK293--embryonic-kidney-_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	14615
1	3772	TBX21	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	TBX21 CD4 TBX21	CD4	NA	TBX21	TH1	GEO	GSE62482_tbx21_cd4-th1_MACS_TBX21_MA0690.1.damo.pwm.bed	11790
1	3776	TBX5	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	G296S mutant	GTRD	EXP037723_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	17357
1	3995	TP53	0.551088588314681	2.78540482222819	8	393	350	2675	2675	1140	1	6373	2219	TP53 UACC257 TP53	UACC257	BTO:0004233	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051025_UACC257_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1484
1	1659	FOXA1	0.548637425208379	1.06161839189777	477	403	1216	21	1216	547	157	5904	2063	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	10 nm DHT	GTRD	EXP033301_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	187434
1	2813	MYC	0.547128859247014	1.25969055447205	47	404	825	1002	1002	744	13	6334	2207	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC	NULL	GTRD	EXP001022_MCF7--Invasive-ductal-breast-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	23343
1	1263	ESR1	0.545282342811752	1.17119944846829	84	405	968	557	968	643	25	6297	2195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038376_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	26670
1	4059	TP63	0.53924339734776	1.08871474785477	234	406	1151	150	1151	569	75	6147	2145	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	epidermal_KDPAF	GEO	GSE67382_tp63_epidermal-keratinocyte-kdpaf_MACS_TP63_MA0525.2.damo.pwm.bed	13674
1	2582	JUNB	0.538814678544581	1.06722272663177	382	407	1200	50	1200	552	125	5999	2095	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	63227
1	1739	FOXA1	0.537865836283014	1.14705949777327	102	408	1028	438	1028	625	31	6279	2189	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: FA (control)	GTRD	EXP053230_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	12622
1	736	CTCF	0.537561634717065	1.34977689859241	31	409	732	1439	1439	860	8	6350	2212	CTCF 22RV1 (prostate carcinoma) CTCF	22RV1 (prostate carcinoma)	BTO:0002999	CTCF		GTRD	EXP039762_22RV1--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37949
1	1379	ESR1	0.537561634717065	1.34977689859241	31	409	732	1439	1439	860	8	6350	2212	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 24 hrs;	GTRD	EXP057865_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6601
1	3493	RUNX1	0.537561634717065	1.34977689859241	31	409	732	1439	1439	860	8	6350	2212	RUNX1 TSU-1621-MT (adult acute myeloid leukemia) RUNX1	TSU-1621-MT (adult acute myeloid leukemia)	NULL	RUNX1		GEO	GSE60477_runx1_tsu1621mt_MACS_RUNX1_MA0002.2.damo.pwm.bed	53838
1	4048	TP63	0.53693709896289	1.0627387756242	429	412	1213	31	1213	552	141	5952	2079	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	CISP	GEO	GSE56674_tp63_keratinocyte-cisp_MACS_TP63_MA0525.2.damo.pwm.bed	26510
1	3162	NR3C1	0.533983397639004	1.13079187779503	120	413	1066	367	1066	615	37	6261	2183	NR3C1 ZR-75-1 (invasive ductal carcinoma) NR3C1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	NR3C1	DEX	GEO	GSE72249_nr3c1_zr751-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	15313
1	567	CTCF	0.533586717799326	1.56705412569941	18	414	538	1996	1996	983	4	6363	2216	CTCF 81-3 CTCF	81-3	NA	CTCF		Array Express	ERP002246_ctcf_813_MACS_CTCF_MA0139.1.damo.pwm.bed	29631
1	844	CTCF	0.533586717799326	1.56705412569941	18	414	538	1996	1996	983	4	6363	2216	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: H5N1-dNS1 IAV infected 6hr	GTRD	EXP047827_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30621
1	1356	ESR1	0.533586717799326	1.56705412569941	18	414	538	1996	1996	983	4	6363	2216	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: Vehicle for 60 mins Genotype: ER+/PR+	GTRD	EXP049938_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2998
1	3990	TP53	0.533586717799326	1.56705412569941	18	414	538	1996	1996	983	4	6363	2216	TP53 A498 TP53	A498	BTO:0003769	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051016_A498_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3142
1	1249	ESR1	0.532701821437683	1.10346193649511	174	418	1106	229	1106	584	55	6207	2165	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	40min E2	GTRD	EXP038339_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	48248
1	542	CTCF	0.531871890918804	1.20934857369471	59	419	913	805	913	712	17	6322	2203	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DXD_epithelial_cell_of_proximal_tubule_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54704
1	637	CTCF	0.529753319858741	1.31594555486421	34	420	760	1349	1349	843	9	6347	2211	CTCF DOHH2 (diffuse large B-cell lymphoma) CTCF	DOHH2 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036845_DOHH2--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46511
1	820	CTCF	0.529753319858741	1.31594555486421	34	420	760	1349	1349	843	9	6347	2211	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 0hr, IAV NS1(EP mRNA), siCtrl(siRNA)	GTRD	EXP047776_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41322
1	2759	MITF	0.529753319858741	1.31594555486421	34	420	760	1349	1349	843	9	6347	2211	MITF 501Mel (melanoma) MITF	501Mel (melanoma)	BTO:0002956	MITF		GEO	GSE61965_mitf_501mel_MACS_MITF_MA0620.3.damo.pwm.bed	24233
1	330	CEBPA	0.529142549750006	1.20026494179333	62	423	926	769	926	706	18	6319	2202	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047678_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	47021
1	957	CTCF	0.529142549750006	1.20026494179333	62	423	926	769	926	706	18	6319	2202	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19239_MACS_CTCF_MA0139.1.damo.pwm.bed	66075
1	2589	JUND	0.529142549750006	1.20026494179333	62	423	926	769	926	706	18	6319	2202	JUND HCT-116 (colon carcinoma) JUND	HCT-116 (colon carcinoma)	BTO:0001109	JUND		ENCODE	ENCSR000BSA_HCT116_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	20402
1	1534	FOS	0.526729482027058	1.19213973685489	65	426	940	738	940	701	19	6316	2201	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	45945
1	2580	JUNB	0.525204972671786	1.06425194231522	381	427	1210	51	1210	563	125	6000	2095	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	62952
1	2583	JUNB	0.523736953545566	1.06447621124423	375	428	1209	54	1209	564	123	6006	2097	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	62781
1	502	CTCF	0.523310243308255	1.28888440872216	37	429	790	1264	1264	828	10	6344	2210	CTCF GM06990 (female B-cells) CTCF	GM06990 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DQW_GM06990_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44667
1	3936	TFAP4	0.523310243308255	1.28888440872216	37	429	790	1264	1264	828	10	6344	2210	TFAP4 COLO-320 (colon adenocarcinoma) TFAP4	COLO-320 (colon adenocarcinoma)	BTO:0002047	TFAP4	NA	GTRD	EXP037553_COLO-320--colon-adenocarcinoma-_TFAP4_MACS_TFAP4_MA0691.1.damo.pwm.bed	56917
1	1684	FOXA1	0.518925523946259	1.07243170031537	295	431	1186	96	1186	571	96	6086	2124	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1		GTRD	EXP038766_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	39508
1	63	AR	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Control	GTRD	EXP038191_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	175
1	288	BCL6	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	BCL6 BCL6	NA	NA	BCL6	NA	GEO	GSE59538_bcl6_icn12_MACS_BCL6_MA0463.2.damo.pwm.bed	14838
1	1019	E2F1	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	E2F1 Raji (Burkitt lymphoma) E2F1	Raji (Burkitt lymphoma)	BTO:0001154	E2F1		GTRD	EXP035849_Raji--Burkitt-lymphoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	3952
1	1022	E2F1	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	E2F1 K562 (myelogenous leukemia) E2F1	K562 (myelogenous leukemia)	NULL	E2F1		GTRD	EXP039542_K562--myelogenous-leukemia-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	2705
1	1037	E2F4	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	Treatment:  treated with 100nm Tamoxifen for 48hrs;	GTRD	EXP054360_MCF7--Invasive-ductal-breast-carcinoma-_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	4173
1	1081	ELF1	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	ELF1 SK-N-SH (neuroblastoma) ELF1	SK-N-SH (neuroblastoma)	BTO:0001620	ELF1		ENCODE	ENCSR000BTA_SK-N-SH_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	8683
1	1503	FLI1	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049962_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	6792
1	1944	GATA2	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048217_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	6980
1	2724	MEF2A	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	MEF2A K562 (myelogenous leukemia) MEF2A	K562 (myelogenous leukemia)	NULL	MEF2A	NA	ENCODE	ENCSR000BNV_K562_MEF2A_MACS_MEF2A_MA0052.4.damo.pwm.bed	3534
1	2727	MEF2B	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: wiltype MEF2B	GTRD	EXP048299_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	9686
1	3030	NFYB	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	NFYB GM12878 (female B-cells lymphoblastoid cell line) NFYB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFYB	NA	ENCODE	ENCSR000DNM_GM12878_NFYB_MACS_NFYB_MA0502.2.damo.pwm.bed	7167
1	3340	RELA	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	RELA GM18505 (female B-cells Lymphoblastoid Cell Lines) RELA	GM18505 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000758_GM18505--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	7045
1	3344	RELA	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	RELA GM10847 (female B-cells Lymphoblastoid Cell Lines) RELA	GM10847 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000766_GM10847--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	7285
1	3346	RELA	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	RELA GM18526 (B – cells Lymphoblastoid Cell Lines) RELA	GM18526 (B – cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000770_GM18526--B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5127
1	3556	SIX1	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	SIX1 SIX1	NA	NA	SIX1	NA	GEO	GSE73865_six1_hek_MACS_SIX1_MA1118.1.damo.pwm.bed	5251
1	3804	TCF7	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	TCF7 DLD-1 (colon adenocarcinoma) TCF7	DLD-1 (colon adenocarcinoma)	BTO:0000391	TCF7	1 ug/mL Doxycycline	GTRD	EXP033180_DLD-1--colon-adenocarcinoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	1881
1	3895	TFAP2C	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047539_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	8438
1	3896	TFAP2C	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047539_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	8933
1	4005	TP53	0.518746248238718	Inf	4	432	1	3105	3105	1180	0	6377	2220	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ACTD	GEO	GSE21939_tp53_u2os-actd_MACS_TP53_MA0106.3.damo.pwm.bed	381
1	1062	EGR1	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	EGR1 MCF7 (Invasive ductal breast carcinoma) EGR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	EGR1		ENCODE	ENCSR000BUX_MCF-7_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	9340
1	1365	ESR1	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: FA (control)	GTRD	EXP053228_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3431
1	2648	KLF5	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049100_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	7498
1	2694	MAX	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	MAX SK-N-SH (neuroblastoma) MAX	SK-N-SH (neuroblastoma)	BTO:0001620	MAX		ENCODE	ENCSR000BVD_SK-N-SH_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	33922
1	2963	NEUROD1	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	NEUROD1 D341 Med (medulloblastoma) NEUROD1	D341 Med (medulloblastoma)	NULL	NEUROD1	shGFP	GTRD	EXP038206_D341-Med--medulloblastoma-_NEUROD1_MACS_NEUROD1_MA1109.1.damo.pwm.bed	37855
1	3426	REST	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	REST Jurkat (T-cells) REST	Jurkat (T-cells)	BTO:0000661	REST		GTRD	EXP054615_Jurkat--T-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	24996
1	3771	TBX21	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	TBX21 Th1-cells TBX21	Th1-cells	BTO:0001678	TBX21		GTRD	EXP031082_Th1-cells_TBX21_MACS_TBX21_MA0690.1.damo.pwm.bed	13777
1	3976	TP53	0.518452670076976	1.46263788429166	21	451	593	1852	1852	965	5	6360	2215	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP047468_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	2080
1	459	CTCF	0.517928433694309	1.26674712057032	40	459	820	1189	1189	823	11	6341	2209	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000BPJ_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47386
1	3207	OTX2	0.517011795650465	1.15707516762479	83	460	1014	565	1014	680	25	6298	2195	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2	shGFP	GTRD	EXP038209_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	113190
1	1387	ESR1	0.515398841107513	1.09209593817199	191	461	1144	200	1144	602	61	6190	2159	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SICTR_E2	GEO	GSE40129_esr1_mcf7-sictr-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	45216
1	2600	JUND	0.513389083553931	1.24830278023934	43	462	840	1101	1101	801	12	6338	2208	JUND SK-N-SH (neuroblastoma) JUND	SK-N-SH (neuroblastoma)	BTO:0001620	JUND		ENCODE	ENCSR000EIB_SK-N-SH_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	28134
1	3362	RELA	0.513389083553931	1.24830278023934	43	462	840	1101	1101	801	12	6338	2208	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	Treatment: confluent, treated with Scr siRNA and stimulated with IL-1beta Passage: 4	GTRD	EXP049055_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	44703
1	1322	ESR1	0.511900006395762	1.13284783338936	104	464	1048	429	1048	647	32	6277	2188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p21;	GTRD	EXP047705_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24114
1	464	CTCF	0.510796937836935	1.91504449213178	11	465	431	2426	2426	1110	2	6370	2218	CTCF GM10266 (male B-cells) CTCF	GM10266 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DKR_GM10266_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24911
1	1024	E2F1	0.510796937836935	1.91504449213178	11	465	431	2426	2426	1110	2	6370	2218	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Treatment: CDT for 72 hrs Genotype: knockdown with shRB of RB	GTRD	EXP049491_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	23883
1	1370	ESR1	0.510796937836935	1.91504449213178	11	465	431	2426	2426	1110	2	6370	2218	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM 17-beta-estradiol for 30 mins Genotype: pS118-ER	GTRD	EXP053336_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2817
1	1940	GATA2	0.510796937836935	1.91504449213178	11	465	431	2426	2426	1110	2	6370	2218	GATA2 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) GATA2	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	GATA2		GTRD	EXP037840_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	23536
1	2653	KLF9	0.510796937836935	1.91504449213178	11	465	431	2426	2426	1110	2	6370	2218	KLF9 HEK293 (embryonic kidney) KLF9	HEK293 (embryonic kidney)	NULL	KLF9	NA	GTRD	EXP039681_HEK293--embryonic-kidney-_KLF9_MACS_KLF9_MA1107.2.damo.pwm.bed	11770
1	2703	MAX	0.510796937836935	1.91504449213178	11	465	431	2426	2426	1110	2	6370	2218	MAX GM12878 (female B-cells lymphoblastoid cell line) MAX	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MAX	NULL	GTRD	EXP000438_GM12878--female-B-cells-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	19681
1	3330	RELA	0.510796937836935	1.91504449213178	11	465	431	2426	2426	1110	2	6370	2218	RELA GM12878 (female B-cells lymphoblastoid cell line) RELA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAG_GM12878_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13302
1	1626	FOSL2	0.510520233148255	1.12119097958309	119	472	1078	373	1078	641	37	6262	2183	FOSL2 LPS141 (Dedifferentiated liposarcoma) FOSL2	LPS141 (Dedifferentiated liposarcoma)	NULL	FOSL2		GTRD	EXP057976_LPS141--Dedifferentiated-liposarcoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	55989
1	1267	ESR1	0.510319989840491	1.11233615301401	134	473	1092	322	1092	629	42	6247	2178	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038380_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	39448
1	1209	ESR1	0.509530391590578	1.23269920771388	46	474	860	1028	1028	787	13	6335	2207	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	sgRNA_enh588	GTRD	EXP035791_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9491
1	2577	JUNB	0.508718013850611	1.06164798299375	368	475	1215	57	1215	582	121	6013	2099	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	61309
1	1352	ESR1	0.506229956206269	1.21932769530264	49	476	868	967	967	770	14	6332	2206	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10	GTRD	EXP049892_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11209
1	566	CTCF	0.503393357798166	1.20774185214735	52	477	914	921	921	771	15	6329	2205	CTCF ZR-75-1 (invasive ductal carcinoma) CTCF	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	CTCF		Array Express	ERP000783_ctcf_zr751_MACS_CTCF_MA0139.1.damo.pwm.bed	38750
1	836	CTCF	0.503393357798166	1.20774185214735	52	477	914	921	921	771	15	6329	2205	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 150min + Flavopiridol 30min	GTRD	EXP047803_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49692
1	1693	FOXA1	0.501045026548178	1.08224712711021	211	479	1162	170	1162	604	68	6170	2152	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP040141_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	37981
1	1841	FOXA2	0.500458360549536	1.08275962918553	208	480	1158	177	1158	605	67	6173	2153	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: Mimo FOXA2	GTRD	EXP049306_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	78132
1	3922	TFAP2C	0.498847339654206	1.07017176082482	273	481	1193	105	1193	593	89	6108	2131	TFAP2C BT-474 (breast invasive ductal carcinoma) TFAP2C	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	TFAP2C		GEO	GSE36351_tfap2c_bt474_MACS_TFAP2C_MA0814.2.damo.pwm.bed	97552
1	308	CEBPA	0.498695226812451	1.34331952110551	27	482	738	1564	1564	928	7	6354	2213	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA		Array Express	ERP008568_cebpa_u937_MACS_CEBPA_MA0102.4.damo.pwm.bed	26296
1	641	CTCF	0.498695226812451	1.34331952110551	27	482	738	1564	1564	928	7	6354	2213	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GTRD	EXP036853_MM1.S--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38961
1	691	CTCF	0.498695226812451	1.34331952110551	27	482	738	1564	1564	928	7	6354	2213	CTCF LNCaP (prostate carcinoma) CTCF	LNCaP (prostate carcinoma)	BTO:0001321	CTCF	10 nM 17β-hydroxy-5α-androstan-3-one (CHEBI:16330) for 4 hour	GTRD	EXP039468_LNCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31277
1	1008	E2F1	0.498695226812451	1.34331952110551	27	482	738	1564	1564	928	7	6354	2213	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000660_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	18978
1	839	CTCF	0.496997607408927	1.18072235590275	61	486	952	785	952	741	18	6320	2202	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment:  Flavopiridol 240min	GTRD	EXP047806_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54699
1	1536	FOS	0.496997607408927	1.18072235590275	61	486	952	785	952	741	18	6320	2202	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	40074
1	1537	FOS	0.496997607408927	1.18072235590275	61	486	952	785	952	741	18	6320	2202	FOS HUVEC-C (HUVEC, umbilical vein endothelial cells) FOS	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FOS	NULL	GTRD	EXP000672_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	40332
1	960	CTCF	0.494032995348519	1.16722330180056	67	489	977	710	977	725	20	6314	2200	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2588_MACS_CTCF_MA0139.1.damo.pwm.bed	65600
1	806	CTCF	0.492842571321568	1.16144106883416	70	490	983	666	983	713	21	6311	2199	CTCF NB69 (neuroblastoma) CTCF	NB69 (neuroblastoma)	BTO:0005426	CTCF		GTRD	EXP040385_NB69--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62006
1	3567	SMAD3	0.492842571321568	1.16144106883416	70	490	983	666	983	713	21	6311	2199	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	CellType: immortalized human mammary epithelial cells Treatment:TGF--beta	GTRD	EXP047899_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	13957
1	1234	ESR1	0.491969650067754	1.30603942010433	30	492	768	1473	1473	911	8	6351	2212	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	DMSO	GTRD	EXP037590_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5246
1	1698	FOXA1	0.491969650067754	1.30603942010433	30	492	768	1473	1473	911	8	6351	2212	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr EtOH, Doxycycline 72 hr CellLine: A1A3 from T47D cell line Genotype: Brg1 knockdown	GTRD	EXP048405_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4671
1	1243	ESR1	0.488423786819072	1.6247910910086	14	494	516	2252	2252	1090	3	6367	2217	ESR1 breast tumor xenograft ESR1	breast tumor xenograft	NULL	ESR1	estrogen	GTRD	EXP038284_breast-tumor-xenograft_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4681
1	1244	ESR1	0.488423786819072	1.6247910910086	14	494	516	2252	2252	1090	3	6367	2217	ESR1 breast tumor xenograft ESR1	breast tumor xenograft	NULL	ESR1	estrogen plus progesterone	GTRD	EXP038286_breast-tumor-xenograft_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4210
1	3450	RFX5	0.488423786819072	1.6247910910086	14	494	516	2252	2252	1090	3	6367	2217	RFX5 MCF7 (Invasive ductal breast carcinoma) RFX5	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RFX5	NA	ENCODE	ENCSR924TVL_MCF-7_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	6720
1	3640	SP2	0.488423786819072	1.6247910910086	14	494	516	2252	2252	1090	3	6367	2217	SP2 HEK293 (embryonic kidney) SP2	HEK293 (embryonic kidney)	NULL	SP2	NA	GTRD	EXP035889_HEK293--embryonic-kidney-_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	22049
1	1770	FOXA1	0.488194169163522	1.13257332290965	91	498	1049	506	1049	684	28	6290	2192	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1	FOXA1_ARC562S	GEO	GSE47987_foxa1_du145-foxa1-arc562s_MACS_FOXA1_MA0148.4.damo.pwm.bed	62786
1	1660	FOXA1	0.487648412231742	1.06515189148899	287	499	1204	101	1204	601	94	6094	2126	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GTRD	EXP035474_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	81709
1	200	AR	0.487533592669687	1.12421353064199	100	500	1072	446	1072	673	31	6281	2189	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	DHT	GEO	GSE74069_AR_mdamb45-dht_MACS_AR_MA0007.3.damo.pwm.bed	15412
1	3105	NR3C1	0.487533592669687	1.12421353064199	100	500	1072	446	1072	673	31	6281	2189	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	ICI, DEX	GTRD	EXP037448_MCF7--Invasive-ductal-breast-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	28242
1	473	CTCF	0.486589680986708	1.27704809800751	33	502	802	1379	1379	894	9	6348	2211	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		ENCODE	ENCSR000DLK_H1-hESC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43288
1	1433	ESR1	0.482224975217917	1.25385902320204	36	503	829	1288	1288	873	10	6345	2210	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2	GEO	GSE72249_esr1_t47d-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	5326
1	569	CTCF	0.478646283331726	1.23488983198567	39	504	854	1206	1206	855	11	6342	2209	CTCF pancreatic islets CTCF	pancreatic islets	NULL	CTCF		Array Express	ERP004003_ctcf_islet_MACS_CTCF_MA0139.1.damo.pwm.bed	48736
1	667	CTCF	0.478646283331726	1.23488983198567	39	504	854	1206	1206	855	11	6342	2209	CTCF MCF10AT1 (breast premetastatic epithelial cells) CTCF	MCF10AT1 (breast premetastatic epithelial cells)	NULL	CTCF		GTRD	EXP038624_MCF10AT1--breast-premetastatic-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34671
1	1207	ESR1	0.478646283331726	1.23488983198567	39	504	854	1206	1206	855	11	6342	2209	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GTRD	EXP035789_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7588
1	1696	FOXA1	0.478646283331726	1.23488983198567	39	504	854	1206	1206	855	11	6342	2209	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr EtOH, PBS 72 hr CellLine: A1A3 from T47D cell line	GTRD	EXP048401_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4867
1	3204	OTX2	0.478646283331726	1.23488983198567	39	504	854	1206	1206	855	11	6342	2209	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.GFP2	GTRD	EXP038203_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	66447
1	3360	RELA	0.478646283331726	1.23488983198567	39	504	854	1206	1206	855	11	6342	2209	RELA HAEC (human aortic endothelial cells) RELA	HAEC (human aortic endothelial cells)	NULL	RELA	TNFa, 4h	GTRD	EXP038050_HAEC--human-aortic-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	46162
1	1748	FOXA1	0.477374812946429	1.0678273488578	248	510	1196	128	1196	611	81	6133	2139	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058103_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	36354
1	520	CTCF	0.475689187854984	1.21908559927282	42	511	869	1124	1124	835	12	6339	2208	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		ENCODE	ENCSR000DTO_HCT116_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45066
1	4074	USF1	0.475689187854984	1.21908559927282	42	511	869	1124	1124	835	12	6339	2208	USF1 SK-N-SH (neuroblastoma) USF1	SK-N-SH (neuroblastoma)	BTO:0001620	USF1	6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour	ENCODE	ENCSR000BMF_SK-N-SH_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	45840
1	1090	ELF1	0.47420475807979	1.47978388378393	17	513	586	2066	2066	1060	4	6364	2216	ELF1 SK-N-MC (Askin tumor) ELF1	SK-N-MC (Askin tumor)	BTO:0002914	ELF1	SHFLI_96H	GEO	GSE61944_elf1_skmnc-shfli-96h_MACS_ELF1_MA0473.3.damo.pwm.bed	33490
1	461	CTCF	0.473232499624027	1.20571598217306	45	514	916	1054	1054	828	13	6336	2207	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		ENCODE	ENCSR000BSE_HCT116_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37233
1	1353	ESR1	0.473232499624027	1.20571598217306	45	514	916	1054	1054	828	13	6336	2207	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10	GTRD	EXP049893_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10420
1	1836	FOXA2	0.470920626884916	1.08930007590342	150	516	1150	284	1150	650	48	6231	2172	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: CDT1 mimo FOXA2	GTRD	EXP049298_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	61484
1	3917	TFAP2C	0.469780831220484	1.09114835288769	144	517	1146	302	1146	655	46	6237	2174	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	E2	GEO	GSE23852_tfap2c_mcf7-e2_MACS_TFAP2C_MA0815.1.damo.pwm.bed	41093
1	1421	ESR1	0.469227931606376	1.09213559955388	141	518	1143	310	1143	657	45	6240	2175	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE68355_ESR1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	34340
1	1292	ESR1	0.468050389929706	1.17565010483949	54	519	960	886	960	788	16	6327	2204	ESR1 breast tumor ESR1	breast tumor	NULL	ESR1	Responder	GTRD	EXP038798_breast-tumor_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23683
1	450	CTCF	0.466864910543595	1.16799124115185	57	520	972	839	972	777	17	6324	2203	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000AUE_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50435
1	697	CTCF	0.466864910543595	1.16799124115185	57	520	972	839	972	777	17	6324	2203	CTCF RWPE2 CTCF	RWPE2	NULL	CTCF		GTRD	EXP039498_RWPE2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45527
1	805	CTCF	0.466864910543595	1.16799124115185	57	520	972	839	972	777	17	6324	2203	CTCF SK-N-AS (neuroblastoma) CTCF	SK-N-AS (neuroblastoma)	BTO:0002827	CTCF		GTRD	EXP040384_SK-N-AS--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55545
1	959	CTCF	0.466864910543595	1.16799124115185	57	520	972	839	972	777	17	6324	2203	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2255_MACS_CTCF_MA0139.1.damo.pwm.bed	66228
1	2224	JUN	0.466864910543595	1.16799124115185	57	520	972	839	972	777	17	6324	2203	JUN JUN	NA	NA	JUN	NA	NA	ENCSR000EFA_endothelial_cell_of_umbilical_vein_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	29202
1	1843	FOXA2	0.466280185497247	1.07200258871892	206	525	1190	181	1190	632	67	6175	2153	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: addition of 200 uM mimosine over night Genotype: Clonal FOXA2 doxycycline inducible cells	GTRD	EXP049378_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	77665
1	462	CTCF	0.465884155506239	1.16118573304716	60	526	985	797	985	769	18	6321	2202	CTCF D54 (H54, Human glioblastoma) CTCF	D54 (H54, Human glioblastoma)	NULL	CTCF		ENCODE	ENCSR000DKN_H54_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56715
1	1749	FOXA1	0.465422877707147	1.06263036622895	259	527	1214	118	1214	620	85	6122	2135	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058104_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	38746
1	2065	GRHL2	0.46469997433404	1.07275730432057	200	528	1185	190	1185	634	65	6181	2155	GRHL2 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) GRHL2	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048442_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	41775
1	212	AR	0.464573008536918	1.10518105384639	111	529	1105	401	1105	678	35	6270	2185	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_30M	GEO	GSE84432_AR_vcap-r1881-30m_MACS_AR_MA0007.3.damo.pwm.bed	53687
1	1233	ESR1	0.464444662230597	1.39278562508003	20	530	630	1901	1901	1020	5	6361	2215	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2, DEX	GTRD	EXP037446_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7711
1	3398	REST	0.464444662230597	1.39278562508003	20	530	630	1901	1901	1020	5	6361	2215	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		ENCODE	ENCSR000BMW_K562_REST_MACS_REST_MA0138.2.damo.pwm.bed	28812
1	3901	TFAP2C	0.464444662230597	1.39278562508003	20	530	630	1901	1901	1020	5	6361	2215	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047542_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	35163
1	3208	OTX2	0.464427272385208	1.14962279662733	66	533	1023	727	1023	761	20	6315	2200	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2	shOTX2.1393	GTRD	EXP038210_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	85490
1	1158	ESR1	0.463907977712107	1.14467032409812	69	534	1030	687	1030	750	21	6312	2199	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	100nM bisphenol A (CHEBI:33216) for 30 minute	ENCODE	ENCSR000BQD_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12585
1	2682	MAFK	0.463505177359591	1.1401700373035	72	535	1044	651	1044	743	22	6309	2198	MAFK IMR90 (lung fibroblasts) MAFK	IMR90 (lung fibroblasts)	NULL	MAFK	NA	ENCODE	ENCSR000EFH_IMR-90_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	77567
1	1167	ESR1	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TAMR_TAM	Array Express	ERP000380_esr1_mcf7tamr-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	1838
1	2116	HNF1A	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	HNF1A HEE (human epididymis epithelial cells) HNF1A	HEE (human epididymis epithelial cells)	NULL	HNF1A	Treatment: untreated	GTRD	EXP048857_HEE--human-epididymis-epithelial-cells-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	11809
1	2787	MYC	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC	45 min with 100 nM Estradiol (Crawford)	ENCODE	ENCSR000DMP_MCF-7_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	4260
1	3180	NRF1	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	NRF1 HepG2 (hepatoblastoma) NRF1	HepG2 (hepatoblastoma)	BTO:0000599	NRF1		GTRD	EXP038544_HepG2--hepatoblastoma-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	8596
1	3387	RELA	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	RELA LNCaP (prostate carcinoma) RELA	LNCaP (prostate carcinoma)	BTO:0001321	RELA	TNFA	GEO	GSE83860_rela_lncap-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	2124
1	3458	RUNX1	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP031175_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	16552
1	3480	RUNX1	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	RUNX1 pre-B-lymphoblast cells with BCP-ALL RUNX1	pre-B-lymphoblast cells with BCP-ALL	NULL	RUNX1	DIsease: human precursor leukemia (BCP-ALL) Tissue: bone marrow	GTRD	EXP048191_pre-B-lymphoblast-cells-with-BCP-ALL_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	13339
1	4003	TP53	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_ps15-u2os-eto_MACS_TP53_MA0106.3.damo.pwm.bed	480
1	4004	TP53	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ACTD	GEO	GSE21939_tp53_u2os-actd-ps15_MACS_TP53_MA0106.3.damo.pwm.bed	411
1	4006	TP53	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_u2os-eto-ps15_MACS_TP53_MA0106.3.damo.pwm.bed	435
1	4084	USF2	0.459556589289114	2.43688941659574	7	536	370	2768	2768	1220	1	6374	2219	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2		ENCODE	ENCSR359NFW_K562_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	7357
1	1712	FOXA1	0.459199961839417	1.07583363743041	179	547	1179	221	1179	649	58	6202	2162	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048451_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	36083
1	4049	TP63	0.458068091444881	1.04447272364966	446	548	1240	28	1240	605	149	5935	2071	TP63 keratinocytes TP63	keratinocytes	NULL	TP63		GEO	GSE56674_tp63_keratinocyte_MACS_TP63_MA0525.2.damo.pwm.bed	26690
1	793	CTCF	0.457410846938612	1.33479241478016	23	549	745	1739	1739	1010	6	6358	2214	CTCF human cardiac myocytes CTCF	human cardiac myocytes	NULL	CTCF		GTRD	EXP040253_human-cardiac-myocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40422
1	1296	ESR1	0.457410846938612	1.33479241478016	23	549	745	1739	1739	1010	6	6358	2214	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100 nM ICI for 30 min	GTRD	EXP040889_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4537
1	3836	TEAD4	0.457410846938612	1.33479241478016	23	549	745	1739	1739	1010	6	6358	2214	TEAD4 MCF7 (Invasive ductal breast carcinoma) TEAD4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TEAD4		ENCODE	ENCSR000BUO_MCF-7_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	6589
1	1804	FOXA1	0.455321202762593	1.07855435507657	164	552	1175	246	1175	658	53	6217	2167	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	DEX	GEO	GSE72249_foxa1_t47d-dex_MACS_FOXA1_MA0148.4.damo.pwm.bed	18760
1	1171	ESR1	0.455162461330067	1.05778418781001	273	553	1225	105	1225	628	90	6108	2130	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		Array Express	ERP000783_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	67491
1	882	CTCF	0.452174617043518	1.293373905485	26	554	782	1602	1602	979	7	6355	2213	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: triploide, no stress  Source: T47D whole cell	GTRD	EXP053049_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34971
1	1434	ESR1	0.452174617043518	1.293373905485	26	554	782	1602	1602	979	7	6355	2213	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GEO	GSE72249_esr1_t47d_MACS_ESR1_MA0112.3.damo.pwm.bed	3248
1	3373	RELA	0.452174617043518	1.293373905485	26	554	782	1602	1602	979	7	6355	2213	RELA HeLa-B2 RELA	HeLa-B2	NA	RELA	TNFA	GEO	GSE24518_rela_helab2-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	8991
1	4069	USF1	0.452174617043518	1.293373905485	26	554	782	1602	1602	979	7	6355	2213	USF1 HepG2 (hepatoblastoma) USF1	HepG2 (hepatoblastoma)	BTO:0000599	USF1		ENCODE	ENCSR000BGM_HepG2_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	21469
1	1418	ESR1	0.448190091660508	1.26231481399445	29	558	823	1504	1504	962	8	6352	2212	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE60270_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	4935
1	443	CTCF	0.445113916340004	1.23816213769112	32	559	848	1410	1410	939	9	6349	2211	CTCF myotube CTCF	myotube	BTO:0001760	CTCF		ENCODE	ENCSR000ANS_myotube_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46072
1	821	CTCF	0.445113916340004	1.23816213769112	32	559	848	1410	1410	939	9	6349	2211	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siCtrl(siRNA)	GTRD	EXP047777_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39467
1	1253	ESR1	0.445113916340004	1.23816213769112	32	559	848	1410	1410	939	9	6349	2211	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	640min E2	GTRD	EXP038343_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7280
1	1699	FOXA1	0.445113916340004	1.23816213769112	32	559	848	1410	1410	939	9	6349	2211	FOXA1 A1A3(breast cancer cells) FOXA1	A1A3(breast cancer cells)	NULL	FOXA1	Treatment: 1hr Dex, Doxycycline 72 hr CellLine: A1A3 from T47D cell line Genotype: Brg1 knockdown	GTRD	EXP048407_A1A3-breast-cancer-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	5294
1	1919	GATA1	0.445113916340004	1.23816213769112	32	559	848	1410	1410	939	9	6349	2211	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		GTRD	EXP040807_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	55620
1	21	AR	0.444307108859582	1.09119006782733	119	564	1145	373	1145	694	38	6262	2182	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	100 nM DHT	GTRD	EXP030507_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	59512
1	1156	ESR1	0.44363407472763	1.09240635506863	116	565	1142	383	1142	697	37	6265	2183	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	1 h with 10 nM Estradiol (Myers)	ENCODE	ENCSR000BKN_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	25282
1	668	CTCF	0.442718605142929	1.21884403610848	35	566	871	1318	1318	918	10	6346	2210	CTCF MCF10CA1a (breast metastatic epithelial cells) CTCF	MCF10CA1a (breast metastatic epithelial cells)	NULL	CTCF		GTRD	EXP038625_MCF10CA1a--breast-metastatic-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31583
1	1235	ESR1	0.440847105564503	1.20304204278387	38	567	919	1238	1238	908	11	6343	2209	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	BYL719	GTRD	EXP037592_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8846
1	3211	OTX2	0.440847105564503	1.20304204278387	38	567	919	1238	1238	908	11	6343	2209	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP053393_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	63701
1	3388	RELB	0.440847105564503	1.20304204278387	38	567	919	1238	1238	908	11	6343	2209	RELB GM12878 (female B-cells lymphoblastoid cell line) RELB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELB	NA	GTRD	EXP054686_GM12878--female-B-cells-lymphoblastoid-cell-line-_RELB_MACS_RELB_MA1117.1.damo.pwm.bed	43442
1	3937	TFAP4	0.440847105564503	1.20304204278387	38	567	919	1238	1238	908	11	6343	2209	TFAP4 COLO-320 (colon adenocarcinoma) TFAP4	COLO-320 (colon adenocarcinoma)	BTO:0002047	TFAP4	NA	GTRD	EXP037553_COLO-320--colon-adenocarcinoma-_TFAP4_MACS_TFAP4_MA1570.1.damo.pwm.bed	57111
1	213	AR	0.44047987502857	1.09964873043808	101	571	1116	440	1116	709	32	6280	2188	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_4H	GEO	GSE84432_AR_vcap-r1881-4h_MACS_AR_MA0007.3.damo.pwm.bed	55427
1	1723	FOXA1	0.440376628638218	1.04624212614722	351	572	1235	65	1235	624	117	6030	2103	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression	GTRD	EXP048989_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	104307
1	723	CTCF	0.439387304239475	1.18987716670806	41	573	942	1155	1155	890	12	6340	2208	CTCF PC9 (lung adenocarcinoma) CTCF	PC9 (lung adenocarcinoma)	NULL	CTCF		GTRD	EXP039683_PC9--lung-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38535
1	278	BATF	0.438815819494954	1.10521105759276	92	574	1104	498	1104	725	29	6289	2191	BATF GM12878 (female B-cells lymphoblastoid cell line) BATF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	BATF	NA	ENCODE	ENCSR000BGT_GM12878_BATF_MACS_BATF_MA0462.2.damo.pwm.bed	51722
1	986	CTCF	0.438256919385871	1.17874086748186	44	575	956	1072	1072	868	13	6337	2207	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	NORMOXIA	GEO	GSE78113_ctcf_mcf7-normoxia_MACS_CTCF_MA0139.1.damo.pwm.bed	43891
1	1257	ESR1	0.438256919385871	1.17874086748186	44	575	956	1072	1072	868	13	6337	2207	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1		GTRD	EXP038352_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	21233
1	1820	FOXA2	0.438256919385871	1.17874086748186	44	575	956	1072	1072	868	13	6337	2207	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2	CARN1618	Array Express	ERP008682_foxa2_liver-carn1618_MACS_FOXA2_MA0047.3.damo.pwm.bed	31178
1	3210	OTX2	0.438256919385871	1.17874086748186	44	575	956	1072	1072	868	13	6337	2207	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	shOTX2.1393	GTRD	EXP038215_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	72796
1	552	CTCF	0.437394137136644	1.16919846826358	47	579	970	1002	1002	850	14	6334	2206	CTCF DOHH2 (diffuse large B-cell lymphoma) CTCF	DOHH2 (diffuse large B-cell lymphoma)	NULL	CTCF		ENCODE	ENCSR084RDK_DOHH2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56288
1	1382	ESR1	0.437394137136644	1.16919846826358	47	579	970	1002	1002	850	14	6334	2206	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058226_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12955
1	49	AR	0.436751585392049	1.16093120272642	50	581	986	945	986	837	15	6331	2205	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	siControl	GTRD	EXP036106_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	11234
1	351	CEBPB	0.436751585392049	1.16093120272642	50	581	986	945	986	837	15	6331	2205	CEBPB K562 (myelogenous leukemia) CEBPB	K562 (myelogenous leukemia)	NULL	CEBPB		ENCODE	ENCSR000BRQ_K562_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	38939
1	830	CTCF	0.436751585392049	1.16093120272642	50	581	986	945	986	837	15	6331	2205	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 20min	GTRD	EXP047797_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49408
1	1227	ESR1	0.436751585392049	1.16093120272642	50	581	986	945	986	837	15	6331	2205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	IL1b+ICI	GTRD	EXP036977_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13876
1	239	ATF2	0.436723692022692	1.74051096967578	10	585	461	2487	2487	1180	2	6371	2218	ATF2 GM12878 (female B-cells lymphoblastoid cell line) ATF2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ATF2	NA	GTRD	EXP039489_GM12878--female-B-cells-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	12052
1	1473	ETV1	0.436723692022692	1.74051096967578	10	585	461	2487	2487	1180	2	6371	2218	ETV1 GIST-T1 (Gastrointestinal stromal tumor) ETV1	GIST-T1 (Gastrointestinal stromal tumor)	NULL	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048909_GIST-T1--Gastrointestinal-stromal-tumor-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	18363
1	1936	GATA2	0.436723692022692	1.74051096967578	10	585	461	2487	2487	1180	2	6371	2218	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2	bio	GTRD	EXP000941_K562--myelogenous-leukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	21473
1	2601	JUND	0.436723692022692	1.74051096967578	10	585	461	2487	2487	1180	2	6371	2218	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND		ENCODE	ENCSR000EYV_GM12878_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	3410
1	2717	MAX	0.436723692022692	1.74051096967578	10	585	461	2487	2487	1180	2	6371	2218	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX		GEO	GSE36354_max_p493_MACS_MAX_MA0058.3.damo.pwm.bed	26087
1	2757	MITF	0.436723692022692	1.74051096967578	10	585	461	2487	2487	1180	2	6371	2218	MITF melanocytes MITF	melanocytes	NULL	MITF	CTR	GEO	GSE50681_mitf_melanocyte-ctr_MACS_MITF_MA0620.3.damo.pwm.bed	24347
1	3347	RELA	0.436723692022692	1.74051096967578	10	585	461	2487	2487	1180	2	6371	2218	RELA GM12878 (female B-cells lymphoblastoid cell line) RELA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000772_GM12878--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11260
1	319	CEBPA	0.436292329436886	1.15369999393586	53	592	1016	905	1016	838	16	6328	2204	CEBPA MV-4-11 (Childhood acute monocytic leukemia) CEBPA	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	CEBPA		GTRD	EXP037965_MV4-11--childhood-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	46332
1	562	CTCF	0.435987136625096	1.1473220168725	56	593	1026	859	1026	826	17	6325	2203	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		Array Express	ERP000380_ctcf_mcf7_MACS_CTCF_MA0139.1.damo.pwm.bed	43674
1	962	CTCF	0.4358987013058	1.1279047325916	68	594	1069	703	1069	789	21	6313	2199	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2630_MACS_CTCF_MA0139.1.damo.pwm.bed	66301
1	911	CTCF	0.435812562534395	1.14165507327623	59	595	1042	805	1042	814	18	6322	2202	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	Treatment: 1 h with 100 nM Dexamethasone;	GTRD	EXP054084_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54719
1	2872	MYC	0.435812562534395	1.14165507327623	59	595	1042	805	1042	814	18	6322	2202	MYC NCI-H2171 (small cell lung carcinoma) MYC	NCI-H2171 (small cell lung carcinoma)	NULL	MYC	Treatment: Treatment withKL-1 or KL-2 inhibitors was administrated only once; Genotype: mutation by amplification of MYC;	GTRD	EXP047290_NCI-H2171--small-cell-lung-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	56690
1	314	CEBPA	0.435749583333071	1.13658690064348	62	597	1045	769	1045	804	19	6319	2201	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	dmso	GTRD	EXP000947_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	43146
1	1753	FOXA1	0.435749583333071	1.13658690064348	62	597	1045	769	1045	804	19	6319	2201	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: ethanol (Vehicle) treatment for 24 hrs;	GTRD	EXP058394_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	27821
1	2871	MYC	0.435749583333071	1.13658690064348	62	597	1045	769	1045	804	19	6319	2201	MYC NCI-H2171 (small cell lung carcinoma) MYC	NCI-H2171 (small cell lung carcinoma)	NULL	MYC	Treatment: Treatment withKL-1 or KL-2 inhibitors was administrated only once; Genotype: mutation by amplification of MYC;	GTRD	EXP047290_NCI-H2171--small-cell-lung-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	58030
1	398	CEBPB	0.433519157120382	1.06125245274012	204	600	1217	184	1217	667	67	6177	2153	CEBPB SU-DHL-1 (Anaplastic large cell lymphoma) CEBPB	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	CEBPB	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053284_SU-DHL-1--Anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	110571
1	1373	ESR1	0.432578521616063	1.07443317727116	148	601	1183	287	1183	690	48	6233	2172	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM 17-beta-estradiol for 30 mins Genotype: wildtype ER	GTRD	EXP053340_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	53628
1	1247	ESR1	0.426165467384906	1.07923298338452	127	602	1168	342	1168	704	41	6254	2179	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	10min E2	GTRD	EXP038337_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	40458
1	303	CDX2	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	CDX2 COLO-320 (colon adenocarcinoma) CDX2	COLO-320 (colon adenocarcinoma)	BTO:0002047	CDX2		GEO	GSE30026_cdx2_colo320_MACS_CDX2_MA0465.2.damo.pwm.bed	16302
1	434	CTCF	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000AKB_GM12878_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30236
1	570	CTCF	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	CTCF CHRF28811 CTCF	CHRF28811	NA	CTCF		Array Express	ERP008568_ctcf_chrf28811_MACS_CTCF_MA0139.1.damo.pwm.bed	21169
1	1343	ESR1	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	CellSubtype: stable ESR1-PCDH11X fusion expressing model Treatment: Hormone-deprived media using RPMI1640 without phenol red and 10% charcoal-stripped FBS) for 5-7 days	GTRD	EXP048599_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2300
1	1821	FOXA2	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	FOXA2 pancreas FOXA2	pancreas	BTO:0000988	FOXA2	CARN1618	Array Express	ERP008682_foxa2_pancreas-carn1618_MACS_FOXA2_MA0047.3.damo.pwm.bed	4840
1	2470	JUN	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE46166_jun_bt549_MACS_JUN_MA0489.1.damo.pwm.bed	12167
1	2746	MEIS1	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	MEIS1 CHRF28811 MEIS1	CHRF28811	NA	MEIS1	NA	Array Express	ERR063469_meis1_chrf28811_MACS_MEIS1_MA0498.2.damo.pwm.bed	19457
1	3823	TEAD1	0.424718894377929	1.50852524577754	13	603	567	2306	2306	1160	3	6368	2217	TEAD1 pancreas TEAD1	pancreas	BTO:0000988	TEAD1	12D	Array Express	ERP008682_tead1_pancreas-12d_MACS_TEAD1_MA0090.3.damo.pwm.bed	19019
1	2070	GRHL2	0.42250976295497	1.08281750558928	115	611	1156	388	1156	718	37	6266	2183	GRHL2 MCF7 WS8 cells GRHL2	MCF7 WS8 cells	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048456_MCF7-WS8-cells_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	25795
1	3825	TEAD1	0.42250976295497	1.08281750558928	115	611	1156	388	1156	718	37	6266	2183	TEAD1 MCF-7 C4-12 (invasive breast ductal carcinoma) TEAD1	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	TEAD1	Genotype: wildtype	GTRD	EXP047969_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_TEAD1_MACS_TEAD1_MA0090.3.damo.pwm.bed	48184
1	1638	FOXA1	0.42075335232498	1.04981725553444	253	613	1234	123	1234	657	84	6128	2136	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	TAMR_E2_TAM	Array Express	ERP000380_foxa1_mcf7tamr-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	35675
1	1784	FOXA1	0.420429319722932	1.06471745232268	165	614	1205	244	1205	688	54	6216	2166	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2_TNF	GEO	GSE59530_foxa1_mcf7-e2-tnf_MACS_FOXA1_MA0148.4.damo.pwm.bed	28399
1	689	CTCF	0.417507346154616	1.39253900554511	16	615	633	2127	2127	1120	4	6365	2216	CTCF breast epithelial cells CTCF	breast epithelial cells	NULL	CTCF		GTRD	EXP039457_breast-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27302
1	975	CTCF	0.417507346154616	1.39253900554511	16	615	633	2127	2127	1120	4	6365	2216	CTCF hESC-1 (Embryonic stem cells) CTCF	hESC-1 (Embryonic stem cells)	NULL	CTCF	PRIMED	GEO	GSE69646_ctcf_esc-primed_MACS_CTCF_MA0139.1.damo.pwm.bed	26931
1	2056	GLIS3	0.417507346154616	1.39253900554511	16	615	633	2127	2127	1120	4	6365	2216	GLIS3 H9 GLIS3	H9	NULL	GLIS3	Genotype: inducible Glis3 expression Treatment: with Doxycycline , 12 hrs Source: G3- human embryonic stem cells	GTRD	EXP052996_H9_GLIS3_MACS_GLIS3_MA0737.1.damo.pwm.bed	37175
1	2641	KLF5	0.417507346154616	1.39253900554511	16	615	633	2127	2127	1120	4	6365	2216	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 E419Q	GTRD	EXP049093_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	19582
1	1261	ESR1	0.417104194759754	1.08997129094426	97	619	1148	468	1148	745	31	6284	2189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038374_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	30537
1	1651	FOXA1	0.415469383599052	1.04996751826963	238	620	1233	145	1233	666	79	6143	2141	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	NULL	GTRD	EXP000624_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	37716
1	1740	FOXA1	0.415179432795263	1.06658113972599	150	621	1201	284	1201	702	49	6231	2171	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053231_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	19565
1	1320	ESR1	0.413621804128731	1.09653919687555	85	622	1126	545	1126	764	27	6296	2193	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p20;	GTRD	EXP047703_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	18219
1	786	CTCF	0.412865949924166	1.32295353768277	19	623	754	1956	1956	1110	5	6362	2215	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP040169_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30274
1	1272	ESR1	0.412777454505542	1.09850111399529	82	624	1122	570	1122	772	26	6299	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038385_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19528
1	67	AR	0.409770609263	1.27656912771098	22	625	803	1797	1797	1080	6	6359	2214	AR breast tumor AR	breast tumor	NULL	AR	Female	GTRD	EXP040660_breast-tumor_AR_MACS_AR_MA0007.3.damo.pwm.bed	6126
1	842	CTCF	0.409770609263	1.27656912771098	22	625	803	1797	1797	1080	6	6359	2214	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: mock infected 6hr	GTRD	EXP047825_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30753
1	2073	GRHL2	0.409770609263	1.27656912771098	22	625	803	1797	1797	1080	6	6359	2214	GRHL2 OVCAR3 (high grade ovarian serous adenocarcinoma) GRHL2	OVCAR3 (high grade ovarian serous adenocarcinoma)	BTO:0000812	GRHL2		GEO	GSE71018_grhl2_ovcar3_MACS_GRHL2_MA1105.2.damo.pwm.bed	10555
1	3725	STAT1	0.409770609263	1.27656912771098	22	625	803	1797	1797	1080	6	6359	2214	STAT1 HeLa S3 (cervical adenocarcinoma) STAT1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT1	IFN gamma	GTRD	EXP000489_HeLa-S3--cervical-adenocarcinoma-_STAT1_MACS_STAT1_MA0517.1.damo.pwm.bed	11729
1	3989	TP53	0.409770609263	1.27656912771098	22	625	803	1797	1797	1080	6	6359	2214	TP53 UO31 TP53	UO31	BTO:0004234	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051015_UO31_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	3050
1	437	CTCF	0.4095668938157	1.10815199168645	70	630	1097	666	1097	798	22	6311	2198	CTCF keratinocytes CTCF	keratinocytes	NULL	CTCF		ENCODE	ENCSR000ALJ_keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51999
1	1671	FOXA1	0.408504463526854	1.04207202668742	293	631	1377	97	1377	702	98	6088	2122	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Nonspecific siRNA	GTRD	EXP037434_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	43842
1	554	CTCF	0.407679710074807	1.24344281667863	25	632	845	1657	1657	1040	7	6356	2213	CTCF SU-DHL-6 (diffuse large B-cell lymphoma) CTCF	SU-DHL-6 (diffuse large B-cell lymphoma)	NULL	CTCF		ENCODE	ENCSR125DKL_SUDHL6_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38826
1	840	CTCF	0.407679710074807	1.24344281667863	25	632	845	1657	1657	1040	7	6356	2213	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: untreated	GTRD	EXP047811_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30718
1	329	CEBPA	0.407427881522117	1.11808062257217	61	634	1080	785	1080	833	19	6320	2201	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047678_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	45915
1	1705	FOXA1	0.406711298919819	1.05028600408732	214	635	1232	167	1232	678	71	6167	2149	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048441_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	38637
1	4017	TP53	0.406479363116352	1.0705650273911	126	636	1192	344	1192	724	41	6255	2179	TP53 keratinocytes TP53	keratinocytes	NULL	TP53	ADRIA	GEO	GSE56674_tp53_keratinocyte-adria_MACS_TP53_MA0106.3.damo.pwm.bed	6971
1	897	CTCF	0.406278400722558	1.21860300406282	28	637	873	1531	1531	1010	8	6353	2212	CTCF HUVEC-C (HUVEC, umbilical vein endothelial cells) CTCF	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	CTCF	Treatment: None;	GTRD	EXP054034_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45374
1	1423	ESR1	0.406208332049391	1.12665908946826	55	638	1070	875	1070	861	17	6326	2203	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	R5020	GEO	GSE68355_ESR1_t47d-r5020_MACS_ESR1_MA0112.3.damo.pwm.bed	15334
1	885	CTCF	0.405370563615466	1.19928762823685	31	639	929	1439	1439	1000	9	6350	2211	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: pre treatment with 500 nM triptolide for 2 hrs, 110 mM NaCl for 60 min  + triptolide Source: T47D whole cell	GTRD	EXP053052_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37158
1	3954	TP53	0.40536301943759	1.07118003870732	123	640	1191	351	1191	727	40	6258	2180	TP53 lymphoblastoid cells TP53	lymphoblastoid cells	NULL	TP53	Doxo	GTRD	EXP030850_lymphoblastoid-cells_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	22844
1	1889	GABPA	0.404875703987842	1.14414519714476	46	641	1031	1028	1031	900	14	6335	2206	GABPA VCaP (prostate carcinoma) GABPA	VCaP (prostate carcinoma)	BTO:0003215	GABPA		GEO	GSE49091_gabpa_vcap_MACS_GABPA_MA0062.3.damo.pwm.bed	32492
1	615	CTCF	0.40482742324198	1.18383942031433	34	642	945	1349	1349	979	10	6347	2210	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GTRD	EXP032763_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47995
1	4073	USF1	0.40482742324198	1.18383942031433	34	642	945	1349	1349	979	10	6347	2210	USF1 K562 (myelogenous leukemia) USF1	K562 (myelogenous leukemia)	NULL	USF1		ENCODE	ENCSR000BKT_K562_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	31535
1	743	CTCF	0.404624612954214	1.15177385971113	43	644	1019	1101	1101	921	13	6338	2207	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039808_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42477
1	465	CTCF	0.404560828517768	1.17120373731239	37	645	965	1264	1264	958	11	6344	2209	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DKV_GM12878_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45729
1	809	CTCF	0.404560828517768	1.17120373731239	37	645	965	1264	1264	958	11	6344	2209	CTCF HeLa Kyoto (cervical adenocarcinoma) CTCF	HeLa Kyoto (cervical adenocarcinoma)	NULL	CTCF	Wild type	GTRD	EXP040503_HeLa-Kyoto--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39051
1	1440	ESR2	0.404560828517768	1.17120373731239	37	645	965	1264	1264	958	11	6344	2209	ESR2 MDA-MB-231ERb(triple negative breast cancer) ESR2	MDA-MB-231ERb(triple negative breast cancer)	NULL	ESR2	Treatment: 1 nM estradiol for 3 hr Passage: 20-25	GTRD	EXP048149_MDA-MB-231ERb-triple-negative-breast-cancer-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	24135
1	792	CTCF	0.40450836931387	1.16067747408065	40	648	990	1189	1189	942	12	6341	2208	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		GTRD	EXP040246_SK-N-SH--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48218
1	1728	FOXA1	0.401999849307717	1.04170491733641	275	649	1378	103	1378	710	92	6106	2128	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049579_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	83834
1	3974	TP53	0.394896653480235	1.05985823689264	143	650	1222	304	1222	725	47	6238	2173	TP53 SJSA-1(osteosarcoma) TP53	SJSA-1(osteosarcoma)	BTO:0004216	TP53	Nutlin	GTRD	EXP037751_SJSA-1-osteosarcoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	10647
1	1744	FOXA1	0.394255430909699	1.03588650802875	321	651	1383	82	1383	705	108	6060	2112	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058099_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	52782
1	2940	MYCN	0.393794505376315	1.07966558280114	93	652	1166	489	1166	769	30	6288	2190	MYCN NGP (neuroblastoma) MYCN	NGP (neuroblastoma)	NULL	MYCN		GTRD	EXP038397_NGP--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	185849
1	1658	FOXA1	0.391920036389873	1.02648827365408	527	653	1399	13	1399	688	179	5854	2041	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	vehicle, control	GTRD	EXP033300_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	209675
1	1672	FOXA1	0.391839300947567	1.04109295458083	248	654	1379	128	1379	720	83	6133	2137	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	DMSO	GTRD	EXP037591_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45597
1	138	AR	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	DHT	GEO	GSE40050_AR_22rv1-dht_MACS_AR_MA0007.3.damo.pwm.bed	160
1	220	ARNT	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	ARNT GM12878 (female B-cells lymphoblastoid cell line) ARNT	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ARNT		GTRD	EXP040302_GM12878--female-B-cells-_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	3902
1	221	ARNT	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	ARNT GM12878 (female B-cells lymphoblastoid cell line) ARNT	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ARNT		GTRD	EXP040302_GM12878--female-B-cells-_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	3751
1	222	ARNT	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	ARNT GM12878 (female B-cells lymphoblastoid cell line) ARNT	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ARNT		GTRD	EXP040302_GM12878--female-B-cells-_ARNT_MACS_ARNT_MA0259.1.damo.pwm.bed	3445
1	267	BACH1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	BACH1 K562 (myelogenous leukemia) BACH1	K562 (myelogenous leukemia)	NULL	BACH1	NA	ENCODE	ENCSR000EGD_K562_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	2796
1	298	CDX2	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	CDX2 HUES64 (embryonic stem cells) CDX2	HUES64 (embryonic stem cells)	NULL	CDX2		GTRD	EXP036697_HUES64--embryonic-stem-cells-_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	5046
1	419	CREB1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	CREB1 Ishikawa (endometrial adenocarcinoma) CREB1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	CREB1		ENCODE	ENCSR000BUR_Ishikawa_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	4302
1	1056	EGR1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	EGR1 WA01 (H1, human embryonic stem cells) EGR1	WA01 (H1, human embryonic stem cells)	NULL	EGR1		ENCODE	ENCSR000BJA_H1-hESC_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	7099
1	1176	ESR1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	MRNAHIST	Array Express	ERP002305_esr1_mcf7-mrnahist_MACS_ESR1_MA0112.3.damo.pwm.bed	988
1	1412	ESR1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE59530_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	765
1	1920	GATA1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Non-hub KO	GTRD	EXP040809_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	6940
1	1921	GATA1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Non-hub KO	GTRD	EXP040809_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	7411
1	2078	HIC1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	HIC1 HEK293 (embryonic kidney) HIC1	HEK293 (embryonic kidney)	NULL	HIC1	NA	GTRD	EXP039956_HEK293--embryonic-kidney-_HIC1_MACS_HIC1_MA0739.1.damo.pwm.bed	956
1	2215	IRF4	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	IRF4 OCI-LY3 (diffuse large B-cell lymphoma) IRF4	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	IRF4		GEO	GSE56857_irf4_ocily3_MACS_IRF4_MA1419.1.damo.pwm.bed	6603
1	2217	ISL1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	ISL1 Kelly (neuroblastoma) ISL1	Kelly (neuroblastoma)	NULL	ISL1	Treatment: untreated	GTRD	EXP049485_Kelly--neuroblastoma-_ISL1_MACS_ISL1_MA1608.1.damo.pwm.bed	8286
1	2677	MAFK	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	MAFK GM12878 (female B-cells lymphoblastoid cell line) MAFK	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MAFK	NA	ENCODE	ENCSR000DYV_GM12878_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	1410
1	2728	MEF2B	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: wiltype MEF2B with Flag and HA	GTRD	EXP048300_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	3984
1	2908	MYC	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	MYC Blue1 (sporadic Burkitt lymphoma) MYC	Blue1 (sporadic Burkitt lymphoma)	NULL	MYC		GEO	GSE30726_myc_blue1_MACS_MYC_MA0147.3.damo.pwm.bed	4174
1	2913	MYC	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	CMYC_1H	GEO	GSE36354_myc_p493-cmyc-1h_MACS_MYC_MA0147.3.damo.pwm.bed	5889
1	3005	NFE2L2	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	NFE2L2 A375 (malignant melanoma) NFE2L2	A375 (malignant melanoma)	BTO:0002806	NFE2L2	A771726	GEO	GSE57431_NFE2L2_a375-a771726_MACS_NFE2L2_MA0150.2.damo.pwm.bed	3322
1	3049	NR2C2	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	NR2C2 HeLa S3 (cervical adenocarcinoma) NR2C2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NR2C2		ENCODE	ENCSR000EVN_HeLa-S3_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	963
1	3060	NR2F1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	NR2F1 H9-derived neural crest cells NR2F1	H9-derived neural crest cells	NULL	NR2F1	NA	GTRD	EXP030994_H9-derived-neural-crest-cells_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	4108
1	3148	NR3C1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	NR3C1 macrophages NR3C1	macrophages	NULL	NR3C1	Treatment: treated with 1 micromolar (1uM) TA for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 11;	GTRD	EXP057902_macrophages_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1977
1	3196	OTX2	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036799_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	20866
1	3220	PAX5	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	PAX5 OCI-LY7 (diffuse large B-cell lymphoma) PAX5	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	PAX5		GEO	GSE69558_pax5_ocily7_MACS_PAX5_MA0014.3.damo.pwm.bed	3918
1	3271	POU5F1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048952_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	2979
1	3272	POU5F1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048952_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	2519
1	3329	RELA	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	RELA GM10847 (female B-cells Lymphoblastoid Cell Lines) RELA	GM10847 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000DYM_GM10847_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5056
1	3333	RELA	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	RELA GM15510 (B-cells) RELA	GM15510 (B-cells)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAQ_GM15510_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4853
1	3334	RELA	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	RELA GM18505 (female B-cells Lymphoblastoid Cell Lines) RELA	GM18505 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAW_GM18505_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4422
1	3336	RELA	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	RELA GM18951 (B-cells Lymphoblastoid Cell Lines) RELA	GM18951 (B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBD_GM18951_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4798
1	3380	RELA	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	TNF	GEO	GSE59530_rela_mcf7-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	844
1	3634	SP1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	SP1 HUES64 (embryonic stem cells) SP1	HUES64 (embryonic stem cells)	NULL	SP1		GTRD	EXP036810_HUES64--embryonic-stem-cells-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	12324
1	3635	SP1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	SP1 A375 (malignant melanoma) SP1	A375 (malignant melanoma)	BTO:0002806	SP1	DMSO	GTRD	EXP036992_A375--malignant-melanoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	10372
1	3667	SPI1	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1		GTRD	EXP054612_GM12878--female-B-cells-lymphoblastoid-cell-line-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	11583
1	3706	SRF	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	SRF K562 (myelogenous leukemia) SRF	K562 (myelogenous leukemia)	NULL	SRF		ENCODE	ENCSR000BLK_K562_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	4911
1	3802	TCF7	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	TCF7 K562 (myelogenous leukemia) TCF7	K562 (myelogenous leukemia)	NULL	TCF7		ENCODE	ENCSR863KUB_K562_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	3359
1	3803	TCF7	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	TCF7 DLD-1 (colon adenocarcinoma) TCF7	DLD-1 (colon adenocarcinoma)	BTO:0000391	TCF7	1 ug/mL Doxycycline	GTRD	EXP033179_DLD-1--colon-adenocarcinoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	1959
1	3815	TCF7L2	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	TCF7L2 K562 (myelogenous leukemia) TCF7L2	K562 (myelogenous leukemia)	NULL	TCF7L2	bio	GTRD	EXP000958_K562--myelogenous-leukemia-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	9730
1	3947	THAP11	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036773_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	2021
1	3975	TP53	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP047456_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	383
1	3996	TP53	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	Treatment: DMSO for 6hrs; Passage: 30-35;	GTRD	EXP054819_IMR90--lung-fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	385
1	4099	VDR	0.38903332236467	Inf	3	655	1	3252	3252	1300	0	6378	2220	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	EtOH for 24h	GTRD	EXP037994_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	5318
1	4041	TP63	0.388247657694207	1.04513443015306	204	698	1236	184	1236	706	68	6177	2152	TP63 MCF10A (breast epithelial cells) TP63	MCF10A (breast epithelial cells)	BTO:0001939	TP63	Treatment: DMSO for 6 hrs;	GTRD	EXP057966_MCF10A--breast-epithelial-cells-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	13671
1	1516	FOS	0.385260489915691	1.02845593436722	419	699	1391	38	1391	709	142	5962	2078	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DOO_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	67229
1	948	CTCF	0.382681083624938	1.09438902314697	66	700	1129	727	1129	852	21	6315	2199	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12891_MACS_CTCF_MA0139.1.damo.pwm.bed	66327
1	1927	GATA1	0.382681083624938	1.09438902314697	66	700	1129	727	1129	852	21	6315	2199	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		GEO	GSE70482_gata1_k562_MACS_GATA1_MA0035.4.damo.pwm.bed	96140
1	874	CTCF	0.381405048119158	1.09685367755745	63	702	1125	753	1125	860	20	6318	2200	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: no stress  Source: T47D whole cell	GTRD	EXP053041_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47893
1	444	CTCF	0.380122036759453	1.09958001887862	60	703	1117	797	1117	872	19	6321	2201	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF		ENCODE	ENCSR000AOA_HeLa-S3_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55060
1	791	CTCF	0.380122036759453	1.09958001887862	60	703	1117	797	1117	872	19	6321	2201	CTCF foreskin keratinocyte CTCF	foreskin keratinocyte	NULL	CTCF	1mM calcium (CHEBI:86158) for 5 day	GTRD	EXP040244_foreskin-keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41490
1	958	CTCF	0.380122036759453	1.09958001887862	60	703	1117	797	1117	872	19	6321	2201	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19240_MACS_CTCF_MA0139.1.damo.pwm.bed	61208
1	1655	FOXA1	0.378832910691046	1.10261165759963	57	706	1107	839	1107	884	18	6324	2202	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033207_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	24003
1	2225	JUN	0.378832910691046	1.10261165759963	57	706	1107	839	1107	884	18	6324	2202	JUN JUN	NA	NA	JUN	NA	NA	ENCSR000EFA_endothelial_cell_of_umbilical_vein_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	29452
1	1782	FOXA1	0.378590939291252	1.05213221111494	145	708	1231	300	1231	746	48	6236	2172	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	DHT24H	GEO	GSE58428_foxa1_vcap-dht24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	47458
1	590	CTCF	0.377538852388953	1.10600246534694	54	709	1101	886	1101	899	17	6327	2203	CTCF D54 (H54, Human glioblastoma) CTCF	D54 (H54, Human glioblastoma)	NULL	CTCF	NULL	GTRD	EXP001027_D54--glioblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50994
1	984	CTCF	0.377538852388953	1.10600246534694	54	709	1101	886	1101	899	17	6327	2203	CTCF RCC 7860 (Renal cell carcinoma) CTCF	RCC 7860 (Renal cell carcinoma)	BTO:0003781	CTCF	NORMOXIA	GEO	GSE78113_ctcf_786o-normoxia_MACS_CTCF_MA0139.1.damo.pwm.bed	63941
1	1917	GATA1	0.377538852388953	1.10600246534694	54	709	1101	886	1101	899	17	6327	2203	GATA1 CD34+ bone marrow cell-derived erythroid progenitors GATA1	CD34+ bone marrow cell-derived erythroid progenitors	NULL	GATA1		GTRD	EXP038306_CD34--bone-marrow-cell-derived-erythroid-progenitors_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	75764
1	1274	ESR1	0.3750110978105	1.06648075023462	98	712	1202	460	1202	791	32	6283	2188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038387_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	21980
1	549	CTCF	0.374942962608183	1.11414890200834	48	713	1083	982	1083	926	15	6333	2205	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000EGM_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51514
1	551	CTCF	0.374942962608183	1.11414890200834	48	713	1083	982	1083	926	15	6333	2205	CTCF OCI-LY7 (diffuse large B-cell lymphoma) CTCF	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	CTCF		ENCODE	ENCSR027HML_OCI-LY7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49918
1	522	CTCF	0.373646298969816	1.11909949307566	45	715	1079	1054	1079	949	14	6336	2206	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		ENCODE	ENCSR000DTW_HEK293_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54149
1	788	CTCF	0.372355551815391	1.12481496332313	42	716	1071	1124	1124	970	13	6339	2207	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP040193_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44167
1	273	BACH2	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	BACH2 B-cells BACH2	B-cells	NULL	BACH2	siBACH2	GTRD	EXP040450_B-cells_BACH2_MACS_BACH2_MA1101.2.damo.pwm.bed	3391
1	323	CEBPA	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047669_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	10812
1	1502	FLI1	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049961_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	13458
1	1506	FLI1	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	FLI1 NB4 (acute promyelocytic leukemia ) FLI1	NB4 (acute promyelocytic leukemia )	NULL	FLI1		GEO	GSE23730_fli1_nb4_MACS_FLI1_MA0475.2.damo.pwm.bed	15455
1	1951	GATA2	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	GATA2 TSU-1621-MT (adult acute myeloid leukemia) GATA2	TSU-1621-MT (adult acute myeloid leukemia)	NULL	GATA2		GEO	GSE60477_gata2_tsu1621mt_MACS_GATA2_MA0036.3.damo.pwm.bed	5886
1	2125	HNF4A	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000306_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	17270
1	2295	JUN	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	10467
1	2297	JUN	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	10992
1	2848	MYC	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036778_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15960
1	2966	NEUROG2	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037146_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	15009
1	2990	NFE2	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	NFE2 K562 (myelogenous leukemia) NFE2	K562 (myelogenous leukemia)	NULL	NFE2		ENCODE	ENCSR000FAF_K562_NFE2_MACS_NFE2_MA0841.1.damo.pwm.bed	4041
1	3339	RELA	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	RELA GM19193 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19193 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000756_GM19193--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	10237
1	3341	RELA	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	RELA GM19099 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19099 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000760_GM19099--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13582
1	3375	RELA	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	TNF	GEO	GSE43070_rela_huvec-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	6568
1	3420	REST	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	REST HEK293 (embryonic kidney) REST	HEK293 (embryonic kidney)	NULL	REST		GTRD	EXP039673_HEK293--embryonic-kidney-_REST_MACS_REST_MA0138.2.damo.pwm.bed	9695
1	3498	RUNX1	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GEO	GSE65427_runx1_kasumi1_MACS_RUNX1_MA0002.2.damo.pwm.bed	13541
1	3591	SOX17	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	SOX17 HUES64 (embryonic stem cells) SOX17	HUES64 (embryonic stem cells)	NULL	SOX17	NA	GTRD	EXP036748_HUES64--embryonic-stem-cells-_SOX17_MACS_SOX17_MA0078.1.damo.pwm.bed	10689
1	3609	SOX2	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	SOX2 hESC-1 (Embryonic stem cells) SOX2	hESC-1 (Embryonic stem cells)	NULL	SOX2		GEO	GSE18292_sox2_esc_MACS_SOX2_MA0143.4.damo.pwm.bed	12842
1	3811	TCF7L2	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	TCF7L2 HeLa S3 (cervical adenocarcinoma) TCF7L2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TCF7L2		ENCODE	ENCSR000EVF_HeLa-S3_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	2205
1	3955	TP53	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	TP53 lymphoblastoid cells TP53	lymphoblastoid cells	NULL	TP53	ionizing radiation	GTRD	EXP030855_lymphoblastoid-cells_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	509
1	4159	ZNF143	0.371729262454162	2.08842895313854	6	717	398	2870	2870	1330	1	6375	2219	ZNF143 CUTLL1 (T-cell lymphoblastic lymphoma 1) ZNF143	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	ZNF143		GEO	GSE29600_znf143_cutll_MACS_ZNF143_MA0088.2.damo.pwm.bed	5324
1	594	CTCF	0.371076324994543	1.13148652323972	39	738	1054	1206	1206	999	12	6342	2208	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		GTRD	EXP030400_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50764
1	598	CTCF	0.371076324994543	1.13148652323972	39	738	1054	1206	1206	999	12	6342	2208	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GTRD	EXP030404_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46962
1	3355	RELA	0.371076324994543	1.13148652323972	39	738	1054	1206	1206	999	12	6342	2208	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	TNFa for 45m	GTRD	EXP036987_MCF7--Invasive-ductal-breast-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11030
1	476	CTCF	0.368586865335414	1.14884516444503	33	741	1024	1379	1379	1050	10	6348	2210	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DLW_endothelial_cell_of_umbilical_vein_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39265
1	4076	USF1	0.368586865335414	1.14884516444503	33	741	1024	1379	1379	1050	10	6348	2210	USF1 Ishikawa (endometrial adenocarcinoma) USF1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	USF1		ENCODE	ENCSR000BSX_Ishikawa_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	25706
1	186	AR	0.367403532531513	1.16042454334215	30	743	991	1473	1473	1070	9	6351	2211	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GEO	GSE63202_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	9786
1	3000	NFE2L2	0.367403532531513	1.16042454334215	30	743	991	1473	1473	1070	9	6351	2211	NFE2L2 IMR90 (lung fibroblasts) NFE2L2	IMR90 (lung fibroblasts)	NULL	NFE2L2		GTRD	EXP039771_IMR90--lung-fibroblasts-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	29082
1	387	CEBPB	0.366289832943736	1.17490393744796	27	745	961	1564	1564	1090	8	6354	2212	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047813_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	24461
1	753	CTCF	0.366289832943736	1.17490393744796	27	745	961	1564	1564	1090	8	6354	2212	CTCF 22RV1 (prostate carcinoma) CTCF	22RV1 (prostate carcinoma)	BTO:0002999	CTCF	10 nM 17β-hydroxy-5α-androstan-3-one (CHEBI:16330) for 4 hour	GTRD	EXP039943_22RV1--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34792
1	2129	HNF4A	0.366289832943736	1.17490393744796	27	745	961	1564	1564	1090	8	6354	2212	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	none	GTRD	EXP030930_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	40673
1	3647	SPI1	0.366289832943736	1.17490393744796	27	745	961	1564	1564	1090	8	6354	2212	SPI1 GM12891 (male B- cells lymphoblastoid cell line) SPI1	GM12891 (male B- cells lymphoblastoid cell line)	NULL	SPI1		ENCODE	ENCSR000BIJ_GM12891_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	50900
1	568	CTCF	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		Array Express	ERP002246_ctcf_gm12878_MACS_CTCF_MA0139.1.damo.pwm.bed	23352
1	656	CTCF	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	100 nM 17-beta-estradiol for 45 min	GTRD	EXP037647_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	12741
1	939	CTCF	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	CTCF VA13 (transformed lung fibroblasts) CTCF	VA13 (transformed lung fibroblasts)	NULL	CTCF		GEO	GSE41048_ctcf_wi38va13_MACS_CTCF_MA0139.1.damo.pwm.bed	19330
1	1417	ESR1	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHGATA3_E2	GEO	GSE60270_esr1_mcf7-shgata3-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	2489
1	3039	NKX3-1	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	NKX3-1 LNCaP (prostate carcinoma) NKX3-1	LNCaP (prostate carcinoma)	BTO:0001321	NKX3-1	ETOH	GEO	GSE28264_nkx3-1_lncap-etoh_MACS_NKX3-1_MA0124.2.damo.pwm.bed	1728
1	3184	NRF1	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	NRF1 T47D (invasive ductal carcinoma) NRF1	T47D (invasive ductal carcinoma)	BTO:0001248	NRF1	HAEGIN2	GEO	GSE59935_nrf1_t47d-haegin2_MACS_NRF1_MA0506.1.damo.pwm.bed	10336
1	3281	POU5F1	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	POU5F1 hESC-1 (Embryonic stem cells) POU5F1	hESC-1 (Embryonic stem cells)	NULL	POU5F1	PRIMED	GEO	GSE69646_pou5f1_esc-primed_MACS_POU5F1_MA1115.1.damo.pwm.bed	17960
1	3371	RELA	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	RELA HeLa-B2 RELA	HeLa-B2	NA	RELA	GRKD_TA_TNFA	GEO	GSE24518_rela_helab2-grkd-ta-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	3979
1	3700	SREBF1	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	SREBF1 MCF7 (Invasive ductal breast carcinoma) SREBF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	SREBF1		ENCODE	ENCSR197DJH_MCF-7_SREBF1_MACS_SREBF1_MA0595.1.damo.pwm.bed	4411
1	3718	SRF	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox & 15nM TPA for 24 horus Genotype: mkl overexpressed	GTRD	EXP053077_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	9304
1	3801	TCF7	0.366265521536829	1.56625426015919	9	749	542	2585	2585	1290	2	6372	2218	TCF7 GM12878 (female B-cells lymphoblastoid cell line) TCF7	GM12878 (female B-cells lymphoblastoid cell line)	NULL	TCF7		ENCODE	ENCSR501DKS_GM12878_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	7268
1	1392	ESR1	0.36556489208662	1.03927458317401	185	760	1380	212	1380	784	62	6196	2158	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE41561_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	42520
1	908	CTCF	0.365281345565928	1.19352615367104	24	761	935	1691	1691	1130	7	6357	2213	CTCF CD20+ CTCF	CD20+	NULL	CTCF	Treatment: None;	GTRD	EXP054057_CD20-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47818
1	1826	FOXA2	0.365281345565928	1.19352615367104	24	761	935	1691	1691	1130	7	6357	2213	FOXA2 HUES64 (embryonic stem cells) FOXA2	HUES64 (embryonic stem cells)	NULL	FOXA2		GTRD	EXP036705_HUES64--embryonic-stem-cells-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	22449
1	3615	SOX2	0.365281345565928	1.19352615367104	24	761	935	1691	1691	1130	7	6357	2213	SOX2 hiPSC SOX2	hiPSC	NULL	SOX2		GEO	GSE56567_sox2_ipsc_MACS_SOX2_MA0143.4.damo.pwm.bed	44530
1	3900	TFAP2C	0.365281345565928	1.19352615367104	24	761	935	1691	1691	1130	7	6357	2213	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047542_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	36939
1	161	AR	0.364461866742348	1.04474085966515	150	765	1237	284	1237	762	50	6231	2170	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GEO	GSE56086_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	88405
1	1377	ESR1	0.364434261427717	1.21836250139662	21	766	874	1852	1852	1160	6	6360	2214	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 4 hrs;	GTRD	EXP057861_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4050
1	2602	JUND	0.364434261427717	1.21836250139662	21	766	874	1852	1852	1160	6	6360	2214	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	10418
1	2996	NFE2L2	0.364434261427717	1.21836250139662	21	766	874	1852	1852	1160	6	6360	2214	NFE2L2 HepG2 (hepatoblastoma) NFE2L2	HepG2 (hepatoblastoma)	BTO:0000599	NFE2L2		ENCODE	ENCSR488EES_HepG2_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	10584
1	3224	PBX2	0.364434261427717	1.21836250139662	21	766	874	1852	1852	1160	6	6360	2214	PBX2 K562 (myelogenous leukemia) PBX2	K562 (myelogenous leukemia)	NULL	PBX2	NA	GTRD	EXP039437_K562--myelogenous-leukemia-_PBX2_MACS_PBX2_MA1113.2.damo.pwm.bed	24496
1	4124	YY1	0.364434261427717	1.21836250139662	21	766	874	1852	1852	1160	6	6360	2214	YY1 HCT-116 (colon carcinoma) YY1	HCT-116 (colon carcinoma)	BTO:0001109	YY1		ENCODE	ENCSR000BNX_HCT116_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	31954
1	1303	ESR1	0.364280089646086	1.07242122499546	77	771	1187	609	1187	856	25	6304	2195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040952_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20150
1	1650	FOXA1	0.364280089646086	1.07242122499546	77	771	1187	609	1187	856	25	6304	2195	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	E2	GTRD	EXP000623_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	9600
1	3888	TFAP2C	0.364280089646086	1.07242122499546	77	771	1187	609	1187	856	25	6304	2195	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p33; Treatment: 5 days in 5iLAF;	GTRD	EXP047537_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	71372
1	416	CREB1	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	CREB1 WA01 (H1, human embryonic stem cells) CREB1	WA01 (H1, human embryonic stem cells)	NULL	CREB1		ENCODE	ENCSR000BSN_H1-hESC_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	28600
1	879	CTCF	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 30 min  Source: T47D whole cell	GTRD	EXP053046_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21116
1	1015	E2F1	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032862_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	17348
1	1157	ESR1	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BLL_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2757
1	1384	ESR1	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TLED	GEO	GSE27300_esr1_mcf7-tled_MACS_ESR1_MA0112.3.damo.pwm.bed	1564
1	1906	GATA1	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 KD shLuc control	GTRD	EXP000914_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	22864
1	1907	GATA1	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 KD shLuc control	GTRD	EXP000914_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	23405
1	1929	GATA2	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2		ENCODE	ENCSR000DKA_K562_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	26344
1	2799	MYC	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000439_GM12878--female-B-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	21677
1	2955	MYCN	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	MYCN SHEP-21N MYCN	SHEP-21N	NA	MYCN		GEO	GSE80151_mycn_shep21_MACS_MYCN_MA0104.4.damo.pwm.bed	24321
1	3326	RBPJ	0.364238973937816	1.39229269421517	12	774	637	2359	2359	1260	3	6369	2217	RBPJ NHEK RBPJ	NHEK	NA	RBPJ		GEO	GSE29498_rbpj_NHEK_MACS_RBPJ_MA1116.1.damo.pwm.bed	19869
1	241	ATF2	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	ATF2 HEK293 (embryonic kidney) ATF2	HEK293 (embryonic kidney)	NULL	ATF2	NA	GTRD	EXP039894_HEK293--embryonic-kidney-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	16137
1	282	BATF3	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	BATF3 ST-1 (Adult T acute lymphoblastic leukemia) BATF3	ST-1 (Adult T acute lymphoblastic leukemia)	NULL	BATF3	Treatment: BirA enzyme were transduced with N-terminally tagged BATF3 (pRCMV/TO-flag-BIOTIN-BATF3-puro)	GTRD	EXP049467_ST-1--Adult-T-acute-lymphoblastic-leukemia-_BATF3_MACS_BATF3_MA0835.2.damo.pwm.bed	5818
1	458	CTCF	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BNO_T47D_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26379
1	510	CTCF	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	CTCF GM12870 (male B-cells) CTCF	GM12870 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRK_GM12870_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38893
1	571	CTCF	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	CTCF HL-60 (acute myeloid leukemia) CTCF	HL-60 (acute myeloid leukemia)	BTO:0000738	CTCF		Array Express	ERP008568_ctcf_hl60_MACS_CTCF_MA0139.1.damo.pwm.bed	28129
1	843	CTCF	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: H5N1 IAV infected 6hr	GTRD	EXP047826_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29557
1	1364	ESR1	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM Estradiol for 45 mins Genotype: ER+/PR+	GTRD	EXP049950_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7185
1	2683	MAFK	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	MAFK K562 (myelogenous leukemia) MAFK	K562 (myelogenous leukemia)	NULL	MAFK	NA	ENCODE	ENCSR000EGX_K562_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	21126
1	3504	RUNX1	0.363841854472073	1.25314125814906	18	785	830	1996	1996	1200	5	6363	2215	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE76181_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	26249
1	617	CTCF	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF		GTRD	EXP032934_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29314
1	845	CTCF	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: IFNb treated 6hr	GTRD	EXP047828_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28851
1	935	CTCF	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	CTCF pancreatic islets CTCF	pancreatic islets	NULL	CTCF		GEO	GSE23784_ctcf_islet_MACS_CTCF_MA0139.1.damo.pwm.bed	26632
1	1064	EGR1	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	EGR1 K562 (myelogenous leukemia) EGR1	K562 (myelogenous leukemia)	NULL	EGR1		GTRD	EXP039497_K562--myelogenous-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	19343
1	1902	GATA1	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	GATA1 primary erythroblasts GATA1	primary erythroblasts	NULL	GATA1	NULL	GTRD	EXP000701_primary-erythroblasts_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	25151
1	2985	NEUROG2	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037155_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	28138
1	3461	RUNX1	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	RUNX1 CUTLL1 (T-cell lymphoblastic lymphoma 1) RUNX1	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	RUNX1	vehicle	GTRD	EXP032406_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	37352
1	3792	TCF3	0.363669558213157	1.30531878209663	15	794	770	2200	2200	1250	4	6366	2216	TCF3 TCF3	NA	NA	TCF3	NA	GEO	GSE59538_TCF3_icn12_MACS_TCF3_MA0522.3.damo.pwm.bed	33348
1	1714	FOXA1	0.363006318913955	1.04471919768364	147	802	1238	290	1238	777	49	6234	2171	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048453_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	30531
1	124	AR	0.360955417349203	1.07479949347756	71	803	1181	659	1181	881	23	6310	2197	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHAT_18H	GEO	GSE28950_AR_vcap-dhat-18h_MACS_AR_MA0007.3.damo.pwm.bed	28279
1	3740	STAT3	0.360955417349203	1.07479949347756	71	803	1181	659	1181	881	23	6310	2197	STAT3 NCI-H358 (human nnon small cell lung cancer cell line) STAT3	NCI-H358 (human nnon small cell lung cancer cell line)	BTO:0002835	STAT3		GTRD	EXP048895_NCI-H358--human-nnon-small-cell-lung-cancer-cell-line-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	18073
1	961	CTCF	0.359239306911372	1.07615370191574	68	805	1177	703	1177	895	22	6313	2198	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm2610_MACS_CTCF_MA0139.1.damo.pwm.bed	66631
1	1374	ESR1	0.357483507980512	1.07763891759886	65	806	1176	738	1176	907	21	6316	2199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle (0.01% EtOH) for 30 mins Genotype: wildtype-ER	GTRD	EXP053341_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15436
1	1003	DUX4	0.355684650307792	1.07927478842216	62	807	1167	769	1167	914	20	6319	2200	DUX4 induced pluripotent stem cells DUX4	induced pluripotent stem cells	NULL	DUX4	18hr dox-induction	GTRD	EXP038408_induced-pluripotent-stem-cells_DUX4_MACS_DUX4_MA0468.1.damo.pwm.bed	129116
1	27	AR	0.353838877300869	1.08108509865131	59	808	1164	805	1164	926	19	6322	2201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032859_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12995
1	336	CEBPA	0.353838877300869	1.08108509865131	59	808	1164	805	1164	926	19	6322	2201	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 2 hrs	GTRD	EXP053362_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	42489
1	482	CTCF	0.35279700536567	1.05574702862481	94	810	1230	482	1230	841	31	6287	2189	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DML_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69084
1	335	CEBPA	0.35194174387398	1.08309891790339	56	811	1153	859	1153	941	18	6325	2202	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 2 hrs	GTRD	EXP053361_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	43181
1	651	CTCF	0.35194174387398	1.08309891790339	56	811	1153	859	1153	941	18	6325	2202	CTCF RH4 (alveolar rhabdomyosarcoma) CTCF	RH4 (alveolar rhabdomyosarcoma)	NULL	CTCF		GTRD	EXP037532_RH4--alveolar-rhabdomyosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58842
1	2718	MAX	0.35194174387398	1.08309891790339	56	811	1153	859	1153	941	18	6325	2202	MAX U-87MG MAX	U-87MG	NA	MAX		GEO	GSE36354_max_u87mg_MACS_MAX_MA0058.3.damo.pwm.bed	54709
1	1208	ESR1	0.351187654647102	1.03797714907678	155	814	1381	267	1381	821	52	6226	2168	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	sgRNA_enh588	GTRD	EXP035790_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	40909
1	1683	FOXA1	0.350572054332749	1.02419069335384	297	815	1403	94	1403	771	101	6084	2119	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1		GTRD	EXP038765_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50304
1	125	AR	0.349254730070068	1.05647960339862	88	816	1229	525	1229	857	29	6293	2191	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHAT_2H	GEO	GSE28950_AR_vcap-dhat-2h_MACS_AR_MA0007.3.damo.pwm.bed	45864
1	1724	FOXA1	0.348995027961906	1.04452518833741	120	817	1239	367	1239	808	40	6261	2180	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048994_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	20773
1	7	AR	0.347425823494837	1.05688746085606	85	818	1227	545	1227	863	28	6296	2192	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	AR stimulated	GTRD	EXP000409_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	43913
1	1996	GATA3	0.347425823494837	1.05688746085606	85	818	1227	545	1227	863	28	6296	2192	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3		GEO	GSE51274_gata3_t47d_MACS_GATA3_MA0037.3.damo.pwm.bed	27000
1	1790	FOXA1	0.346762401636628	1.01836419169139	421	820	1425	36	1425	760	144	5960	2076	FOXA1 LNCaP-abl (Prostate carcinoma) FOXA1	LNCaP-abl (Prostate carcinoma)	NULL	FOXA1	SHCREB1	GEO	GSE63034_foxa1_lncap-abl-shcreb1_MACS_FOXA1_MA0148.4.damo.pwm.bed	156193
1	622	CTCF	0.345885861413769	1.09076840327944	47	821	1147	1002	1147	990	15	6334	2205	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	progestin R5020-stimulated	GTRD	EXP033166_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42207
1	4019	TP53	0.345554702880553	1.0573271350024	82	822	1226	570	1226	873	27	6299	2193	TP53 keratinocytes TP53	keratinocytes	NULL	TP53		GEO	GSE56674_tp53_keratinocyte_MACS_TP53_MA0106.3.damo.pwm.bed	4054
1	632	CTCF	0.343721541120354	1.09406137052104	44	823	1131	1072	1131	1010	14	6337	2206	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036784_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56925
1	803	CTCF	0.343721541120354	1.09406137052104	44	823	1131	1072	1131	1010	14	6337	2206	CTCF OCI-LY1 (diffuse large B-cell lymphoma) CTCF	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP040321_OCI-LY1--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50544
1	853	CTCF	0.343721541120354	1.09406137052104	44	823	1131	1072	1131	1010	14	6337	2206	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF	Plasmids: pGK-dCas9-SunTag (Addgene #100943) + pEF1a-NLS-scFvGCN4-DNMT3A (Addgene #100941) + pEf1a-MIR152-gRNA-GFP	GTRD	EXP048005_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43259
1	3201	OTX2	0.343721541120354	1.09406137052104	44	823	1131	1072	1131	1010	14	6337	2206	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038199_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	69542
1	1725	FOXA1	0.342236616631265	1.02880194349606	195	827	1390	196	1390	804	66	6186	2154	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: knockdown HNF4G	GTRD	EXP048995_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	43382
1	441	CTCF	0.341468471065458	1.09786419358834	41	828	1123	1155	1155	1040	13	6340	2207	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ANE_skeletal_muscle_myoblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44860
1	456	CTCF	0.341468471065458	1.09786419358834	41	828	1123	1155	1155	1040	13	6340	2207	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF	6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour	ENCODE	ENCSR000BLX_SK-N-SH_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47999
1	1700	FOXA1	0.341462205731991	1.02608177929373	221	830	1401	159	1401	797	75	6160	2145	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048436_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	42154
1	1336	ESR1	0.33911382683891	1.10230432967237	38	831	1109	1238	1238	1060	12	6343	2208	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Rad1901	GTRD	EXP048582_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12118
1	2578	JUNB	0.33815519154422	1.01599535112548	423	832	1429	32	1429	764	145	5958	2075	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: transformed	GTRD	EXP048570_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	69302
1	341	CEBPA	0.337578368847989	1.05948696122318	70	833	1223	666	1223	907	23	6311	2197	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 8 hrs	GTRD	EXP053364_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	48915
1	344	CEBPA	0.337578368847989	1.05948696122318	70	833	1223	666	1223	907	23	6311	2197	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 24 hrs	GTRD	EXP053366_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	52197
1	439	CTCF	0.336641544704213	1.10755558330017	35	835	1098	1318	1318	1080	11	6346	2209	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000AMA_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46833
1	877	CTCF	0.336641544704213	1.10755558330017	35	835	1098	1318	1318	1080	11	6346	2209	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: no stress  Source: T47D whole cell	GTRD	EXP053044_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31916
1	925	CTCF	0.336641544704213	1.10755558330017	35	835	1098	1318	1318	1080	11	6346	2209	CTCF MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line) C	MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line)	NULL	CTCF		GTRD	EXP057868_MCF7L-TamR-immortalized-breast-epithelial--tamoxifen-resistant-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36036
1	345	CEBPA	0.335439778121785	1.06015454162182	67	838	1220	710	1220	923	22	6314	2198	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 24 hrs	GTRD	EXP053366_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	51032
1	949	CTCF	0.335439778121785	1.06015454162182	67	838	1220	710	1220	923	22	6314	2198	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12892_MACS_CTCF_MA0139.1.damo.pwm.bed	63003
1	1153	ESR1	0.334031093974662	1.11386127957705	32	840	1085	1410	1410	1110	10	6349	2210	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	1 h with 10 nM Estradiol (Myers)	ENCODE	ENCSR000BIY_Ishikawa_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22549
1	3025	NFKB2	0.334031093974662	1.11386127957705	32	840	1085	1410	1410	1110	10	6349	2210	NFKB2 GM12878 (female B-cells lymphoblastoid cell line) NFKB2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFKB2	NA	GTRD	EXP054689_GM12878--female-B-cells-lymphoblastoid-cell-line-_NFKB2_MACS_NFKB2_MA0778.1.damo.pwm.bed	43722
1	132	AR	0.333232617171564	1.06088775447633	64	842	1218	747	1218	936	21	6317	2199	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_1C26	GEO	GSE32892_AR_vcap-r1881-1c26_MACS_AR_MA0007.3.damo.pwm.bed	15595
1	1196	ESR1	0.333232617171564	1.06088775447633	64	842	1218	747	1218	936	21	6317	2199	ESR1 LTED (breast cancer) ESR1	LTED (breast cancer)	NULL	ESR1	none	GTRD	EXP033908_LTED--breast-cancer-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14962
1	1323	ESR1	0.333105171500996	1.0359439458608	122	844	1382	356	1382	861	41	6259	2179	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p21;	GTRD	EXP047706_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	28169
1	865	CTCF	0.331255599342771	1.12157288593514	29	845	1076	1504	1504	1140	9	6352	2211	CTCF ID00014 (lymphoblastoid cell, DiGeorge syndrome) CTCF	ID00014 (lymphoblastoid cell, DiGeorge syndrome)	NULL	CTCF	Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 34	GTRD	EXP048875_ID00014--lymphoblastoid-cell--DiGeorge-syndrome-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39999
1	1216	ESR1	0.331255599342771	1.12157288593514	29	845	1076	1504	1504	1140	9	6352	2211	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	10 nM Estradiol	GTRD	EXP036366_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19410
1	22	AR	0.330721344928974	1.04431160506744	90	847	1241	511	1241	866	30	6291	2190	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT for 4h	GTRD	EXP031106_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	40812
1	1573	FOSL2	0.32881714741714	1.02990561120489	142	848	1388	306	1388	847	48	6239	2172	FOSL2 MCF7 (Invasive ductal breast carcinoma) FOSL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOSL2		ENCODE	ENCSR000BUI_MCF-7_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	24619
1	1687	FOXA1	0.328645446800707	1.01342193040862	422	849	1436	33	1436	773	145	5959	2075	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Cocktail_90	GTRD	EXP038788_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	71083
1	1787	FOXA1	0.328514130333038	1.02610960997585	168	850	1400	236	1400	829	57	6213	2163	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE59530_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	27941
1	506	CTCF	0.328278849492577	1.13121759951433	26	851	1057	1602	1602	1170	8	6355	2212	CTCF GM12866 (male B-cells) CTCF	GM12866 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRF_GM12866_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45845
1	558	CTCF	0.328278849492577	1.13121759951433	26	851	1057	1602	1602	1170	8	6355	2212	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	E2_SHCTCF	Array Express	ERP000209_ctcf_mcf7-e2-shctcf_MACS_CTCF_MA0139.1.damo.pwm.bed	32561
1	2140	HNF4A	0.328278849492577	1.13121759951433	26	851	1057	1602	1602	1170	8	6355	2212	HNF4A Caco-2 (colon adenocarcinoma) HNF4A	Caco-2 (colon adenocarcinoma)	BTO:0000195	HNF4A	DIFF	GEO	GSE23436_hnf4a_caco2-diff_MACS_HNF4A_MA0114.4.damo.pwm.bed	37015
1	4090	USF2	0.328278849492577	1.13121759951433	26	851	1057	1602	1602	1170	8	6355	2212	USF2 IMR90 (lung fibroblasts) USF2	IMR90 (lung fibroblasts)	NULL	USF2		GTRD	EXP039798_IMR90--lung-fibroblasts-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	32729
1	1957	GATA3	0.327087797295782	1.02957559290877	139	855	1389	314	1389	853	47	6242	2173	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BMX_T47D_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	34650
1	540	CTCF	0.326562317268313	1.04426913627245	84	856	1242	557	1242	885	28	6297	2192	CTCF keratinocytes CTCF	keratinocytes	NULL	CTCF		ENCODE	ENCSR000DWX_keratinocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55204
1	388	CEBPB	0.326125978743702	1.0635905690646	55	857	1211	875	1211	981	18	6326	2202	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047814_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	41566
1	1969	GATA3	0.326125978743702	1.0635905690646	55	857	1211	875	1211	981	18	6326	2202	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2, DEX	GTRD	EXP037457_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	18053
1	1678	FOXA1	0.325362783167074	1.02265378334594	188	859	1412	204	1412	825	64	6193	2156	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1		GTRD	EXP038434_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	41798
1	389	CEBPB	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: untreated, IAV NS1(EP mRNA)	GTRD	EXP047815_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	18251
1	564	CTCF	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	CTCF MCF10A (breast epithelial cells) CTCF	MCF10A (breast epithelial cells)	BTO:0001939	CTCF		Array Express	ERP000783_ctcf_mcf10a_MACS_CTCF_MA0139.1.damo.pwm.bed	30466
1	631	CTCF	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036701_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41491
1	909	CTCF	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	CTCF RO01746 (CD14+ monocytes) CTCF	RO01746 (CD14+ monocytes)	NULL	CTCF	Treatment: None;	GTRD	EXP054064_RO01746--CD14--monocytes-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39399
1	1967	GATA3	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	ICI	GTRD	EXP037455_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	7363
1	2688	MAX	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	MAX HCT-116 (colon carcinoma) MAX	HCT-116 (colon carcinoma)	BTO:0001109	MAX		ENCODE	ENCSR000BSH_HCT116_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	18443
1	3212	OTX2	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	OTX2 retina OTX2	retina	BTO:0001175	OTX2	pigment	GEO	GSE60024_otx2_retinal-pigment_MACS_OTX2_MA0712.2.damo.pwm.bed	13696
1	3980	TP53	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #90	GTRD	EXP048270_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	4034
1	4087	USF2	0.325050290729269	1.14362386504245	23	860	1032	1739	1739	1210	7	6358	2213	USF2 HepG2 (hepatoblastoma) USF2	HepG2 (hepatoblastoma)	BTO:0000599	USF2		GTRD	EXP038547_HepG2--hepatoblastoma-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	23582
1	477	CTCF	0.323564306269719	1.06470817717102	52	869	1206	921	1206	999	17	6329	2203	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000DMA_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57087
1	797	CTCF	0.323564306269719	1.06470817717102	52	869	1206	921	1206	999	17	6329	2203	CTCF GM23338 CTCF	GM23338	NULL	CTCF		GTRD	EXP040259_GM23338_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	66821
1	4033	TP63	0.323564306269719	1.06470817717102	52	869	1206	921	1206	999	17	6329	2203	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-dnRAS and 3 ng/ml of TGF-beta3 for 1.5 hrs	GTRD	EXP033939_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	3037
1	650	CTCF	0.321496123165089	1.16017240676656	20	872	993	1901	1901	1260	6	6361	2214	CTCF COLO-829 (melanoma) CTCF	COLO-829 (melanoma)	NULL	CTCF		GTRD	EXP037459_COLO-829--melanoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33045
1	1369	ESR1	0.321496123165089	1.16017240676656	20	872	993	1901	1901	1260	6	6361	2214	ESR1 primary endometrium cancer ESR1	primary endometrium cancer	NULL	ESR1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053241_primary-endometrium-cancer_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9329
1	1930	GATA2	0.321496123165089	1.16017240676656	20	872	993	1901	1901	1260	6	6361	2214	GATA2 GATA2	NA	NA	GATA2	NA	NA	ENCSR000EVW_endothelial_cell_of_umbilical_vein_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	22412
1	2604	JUND	0.321496123165089	1.16017240676656	20	872	993	1901	1901	1260	6	6361	2214	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	10087
1	2605	JUND	0.321496123165089	1.16017240676656	20	872	993	1901	1901	1260	6	6361	2214	JUND GM12878 (female B-cells lymphoblastoid cell line) JUND	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUND	NULL	GTRD	EXP000436_GM12878--female-B-cells-_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	10101
1	3902	TFAP2C	0.321496123165089	1.16017240676656	20	872	993	1901	1901	1260	6	6361	2214	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047542_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	35300
1	354	CEBPB	0.320886310613898	1.06596632143031	49	878	1203	967	1203	1020	16	6332	2204	CEBPB Ishikawa (endometrial adenocarcinoma) CEBPB	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	CEBPB		ENCODE	ENCSR000BTT_Ishikawa_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	24753
1	1968	GATA3	0.319884942883344	1.04420558685205	75	879	1243	632	1243	918	25	6306	2195	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GTRD	EXP037456_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	22785
1	467	CTCF	0.319718586889748	1.03404623090483	101	880	1384	440	1384	901	34	6280	2186	CTCF GM12892 (female B-cells lymphoblastoid cell line) CTCF	GM12892 (female B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DKY_GM12892_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	120943
1	196	AR	0.31807641266475	1.06739503213717	46	881	1197	1028	1197	1040	15	6335	2205	AR DUCaP (prostate carcinoma) AR	DUCaP (prostate carcinoma)	NULL	AR	ANDROGEN	GEO	GSE70679_AR_ducap-androgen_MACS_AR_MA0007.3.damo.pwm.bed	21213
1	544	CTCF	0.31807641266475	1.06739503213717	46	881	1197	1028	1197	1040	15	6335	2205	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF	6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hour	ENCODE	ENCSR000DXQ_SK-N-SH_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58517
1	2856	MYC	0.31807641266475	1.06739503213717	46	881	1197	1028	1197	1040	15	6335	2205	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881+Doxycycline	GTRD	EXP037069_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	26022
1	665	CTCF	0.317502198088279	1.1833484880642	17	884	947	2066	2066	1300	5	6364	2215	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		GTRD	EXP038269_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27713
1	2143	HNF4A	0.317502198088279	1.1833484880642	17	884	947	2066	2066	1300	5	6364	2215	HNF4A GP5d (colon adenocarcinoma) HNF4A	GP5d (colon adenocarcinoma)	NULL	HNF4A		GEO	GSE51234_hnf4a_gp5d_MACS_HNF4A_MA0114.4.damo.pwm.bed	11720
1	3002	NFE2L2	0.317502198088279	1.1833484880642	17	884	947	2066	2066	1300	5	6364	2215	NFE2L2 A549 (lung carcinoma) NFE2L2	A549 (lung carcinoma)	BTO:0000018	NFE2L2	CellType: human lung adenocarcinoma epithelial A549 cells Genotype: wildtype	GTRD	EXP048467_A549--lung-carcinoma-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	13668
1	3023	NFKB1	0.317502198088279	1.1833484880642	17	884	947	2066	2066	1300	5	6364	2215	NFKB1 GM12878 (female B-cells lymphoblastoid cell line) NFKB1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFKB1		GTRD	EXP054688_GM12878--female-B-cells-lymphoblastoid-cell-line-_NFKB1_MACS_NFKB1_MA0105.4.damo.pwm.bed	16606
1	3779	TCF12	0.317502198088279	1.1833484880642	17	884	947	2066	2066	1300	5	6364	2215	TCF12 WA01 (H1, human embryonic stem cells) TCF12	WA01 (H1, human embryonic stem cells)	NULL	TCF12	NA	ENCODE	ENCSR000BIT_H1-hESC_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	32290
1	1248	ESR1	0.316742029541221	1.02339535421918	147	889	1410	290	1410	863	50	6234	2170	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	20min E2	GTRD	EXP038338_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	43395
1	1742	FOXA1	0.316742029541221	1.02339535421918	147	889	1410	290	1410	863	50	6234	2170	FOXA1 primary breast cancer FOXA1	primary breast cancer	NULL	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053239_primary-breast-cancer_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	22286
1	2067	GRHL2	0.316522814068103	1.01832750698589	196	891	1426	195	1426	837	67	6185	2153	GRHL2 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) GRHL2	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048444_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	42494
1	3	AR	0.31609997357376	1.02727990075832	121	892	1393	362	1393	882	41	6260	2179	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	FOXA1	Array Express	ERP003503_AR_lncap-foxa1_MACS_AR_MA0007.3.damo.pwm.bed	48491
1	2412	JUN	0.31609997357376	1.02727990075832	121	892	1393	362	1393	882	41	6260	2179	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	29182
1	1159	ESR1	0.315754230862861	1.02027540293805	170	894	1417	235	1417	849	58	6211	2162	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	Array Express	ERP000209_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	54951
1	1327	ESR1	0.315514483924497	1.03336373499699	95	895	1385	478	1385	919	32	6286	2188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p22;	GTRD	EXP047710_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24135
1	3932	TFAP2C	0.315514483924497	1.03336373499699	95	895	1385	478	1385	919	32	6286	2188	TFAP2C A375 (malignant melanoma) TFAP2C	A375 (malignant melanoma)	BTO:0002806	TFAP2C	DMSO	GEO	GSE41234_tfap2c_a375-dmso_MACS_TFAP2C_MA0814.2.damo.pwm.bed	64172
1	545	CTCF	0.315115643691458	1.0690308547834	43	897	1194	1101	1194	1060	14	6338	2206	CTCF WERI-Rb-1 (retinoblastoma) CTCF	WERI-Rb-1 (retinoblastoma)	BTO:0001178	CTCF		ENCODE	ENCSR000DXW_WERI-Rb-1_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56123
1	626	CTCF	0.315115643691458	1.0690308547834	43	897	1194	1101	1194	1060	14	6338	2206	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		GTRD	EXP035951_HEK293--embryonic-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52324
1	340	CEBPA	0.315080990181087	1.04416332273485	69	899	1244	687	1244	943	23	6312	2197	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 8 hrs	GTRD	EXP053364_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	48052
1	1069	EGR2	0.315080990181087	1.04416332273485	69	899	1244	687	1244	943	23	6312	2197	EGR2 HEK293 (embryonic kidney) EGR2	HEK293 (embryonic kidney)	NULL	EGR2	NA	GTRD	EXP035947_HEK293--embryonic-kidney-_EGR2_MACS_EGR2_MA0472.2.damo.pwm.bed	69670
1	1212	ESR1	0.315080990181087	1.04416332273485	69	899	1244	687	1244	943	23	6312	2197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 treatment	GTRD	EXP036168_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	18212
1	1993	GATA3	0.314152653780525	1.02683415692787	118	902	1395	377	1395	891	40	6263	2180	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GEO	GSE40129_gata3_mcf7-e2_MACS_GATA3_MA0037.3.damo.pwm.bed	23777
1	3915	TFAP2C	0.313156773067191	1.02248273533401	141	903	1413	310	1413	875	48	6240	2172	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	E2	GEO	GSE23852_tfap2c_mcf7-e2_MACS_TFAP2C_MA0524.2.damo.pwm.bed	40376
1	19	AR	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1000 nM CPA	GTRD	EXP030505_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3346
1	2628	KLF11	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	KLF11 hMADS-3 (adipose-derived stem cells) KLF11	hMADS-3 (adipose-derived stem cells)	NULL	KLF11	differentiaiton inductors	GTRD	EXP033779_hMADS-3--adipose-derived-stem-cells-_KLF11_MACS_KLF11_MA1512.1.damo.pwm.bed	24475
1	2678	MAFK	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	MAFK WA01 (H1, human embryonic stem cells) MAFK	WA01 (H1, human embryonic stem cells)	NULL	MAFK	NA	ENCODE	ENCSR000EBS_H1-hESC_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	11108
1	2769	MXI1	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	MXI1 HeLa S3 (cervical adenocarcinoma) MXI1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MXI1	NA	ENCODE	ENCSR000ECU_HeLa-S3_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	14271
1	2802	MYC	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	MYC HUVEC-C (HUVEC, umbilical vein endothelial cells) MYC	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MYC	NULL	GTRD	EXP000986_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	29309
1	2994	NFE2	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	NFE2 erythroid cells NFE2	erythroid cells	NULL	NFE2	R3R4	GEO	GSE43625_nfe2_erythroid-r3r4_MACS_NFE2_MA0841.1.damo.pwm.bed	16771
1	3305	PRDM1	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	PRDM1 HEK293 (embryonic kidney) PRDM1	HEK293 (embryonic kidney)	NULL	PRDM1		GTRD	EXP039715_HEK293--embryonic-kidney-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	15602
1	3500	RUNX1	0.312877681275736	1.2181225263781	14	904	879	2252	2252	1340	4	6367	2216	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE68976_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	17007
1	3022	NFKB1	0.312391397507827	1.01937571974247	164	912	1418	246	1418	859	56	6217	2164	NFKB1 MCF10A-ER-Src NFKB1	MCF10A-ER-Src	NULL	NFKB1	Genotype: transformed	GTRD	EXP048574_MCF10A-ER-Src_NFKB1_MACS_NFKB1_MA0105.4.damo.pwm.bed	38428
1	3569	SMAD3	0.31109966376008	1.03259599824373	89	913	1387	515	1387	938	30	6292	2190	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047900_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	39240
1	576	CTCF	0.310676546867332	1.01890255279351	161	914	1423	253	1423	863	55	6220	2165	CTCF normal epidermal keratinocytes CTCF	normal epidermal keratinocytes	NULL	CTCF	NULL	GTRD	EXP000600_normal-epidermal-keratinocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	89606
1	1050	EBF1	0.308641910927599	1.07313092668964	37	915	1184	1264	1264	1120	12	6344	2208	EBF1 GM12878 (female B-cells lymphoblastoid cell line) EBF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EBF1	NA	ENCODE	ENCSR000BGU_GM12878_EBF1_MACS_EBF1_MA0154.4.damo.pwm.bed	63565
1	1682	FOXA1	0.30846562329785	1.00973850449364	322	916	1443	81	1443	813	111	6059	2109	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1		GTRD	EXP038764_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	59360
1	491	CTCF	0.307266391068588	1.27609180637443	11	917	809	2426	2426	1380	3	6370	2217	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		ENCODE	ENCSR000DNI_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30745
1	866	CTCF	0.307266391068588	1.27609180637443	11	917	809	2426	2426	1380	3	6370	2217	CTCF ID00015 (lymphoblastoid cell) CTCF	ID00015 (lymphoblastoid cell)	NULL	CTCF	Genotype: wildtype Cell type: lymphoblastoid cell	GTRD	EXP048876_ID00015--lymphoblastoid-cell-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26561
1	2702	MAX	0.307266391068588	1.27609180637443	11	917	809	2426	2426	1380	3	6370	2217	MAX GM12878 (female B-cells lymphoblastoid cell line) MAX	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MAX	NULL	GTRD	EXP000438_GM12878--female-B-cells-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	20743
1	3456	RUNX1	0.307266391068588	1.27609180637443	11	917	809	2426	2426	1380	3	6370	2217	RUNX1 K562 (myelogenous leukemia) RUNX1	K562 (myelogenous leukemia)	NULL	RUNX1	24 hours following induction with TPA	GTRD	EXP000587_K562--myelogenous-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	14938
1	3539	RXRA	0.307266391068588	1.27609180637443	11	917	809	2426	2426	1380	3	6370	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	11466
1	393	CEBPB	0.30520247643994	1.01514928431327	175	922	1430	226	1430	859	60	6206	2160	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: without treatment of R1881 (methyltrienolone)	GTRD	EXP048167_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	82167
1	106	AR	0.305062148854073	1.075745787143	34	923	1180	1349	1349	1150	11	6347	2209	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052947_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	9986
1	334	CEBPA	0.304363040101295	1.04414557734002	57	924	1247	839	1247	1000	19	6324	2201	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 2 hrs	GTRD	EXP053361_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	41403
1	337	CEBPA	0.304363040101295	1.04414557734002	57	924	1247	839	1247	1000	19	6324	2201	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 100 nM 1,25(OH)2D3 for 2 hrs	GTRD	EXP053362_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	42883
1	902	CTCF	0.304363040101295	1.04414557734002	57	924	1247	839	1247	1000	19	6324	2201	CTCF HSMM (skeletal muscle myoblasts) CTCF	HSMM (skeletal muscle myoblasts)	NULL	CTCF	Treatment: None;	GTRD	EXP054039_HSMM--skeletal-muscle-myoblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58345
1	1265	ESR1	0.301666007926574	1.01924851418576	123	927	1419	351	1419	899	42	6258	2178	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038378_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	33120
1	1070	EGR2	0.301391414342472	1.04412455431282	54	928	1250	886	1250	1020	18	6327	2202	EGR2 HEK293 (embryonic kidney) EGR2	HEK293 (embryonic kidney)	NULL	EGR2	NA	GTRD	EXP039511_HEK293--embryonic-kidney-_EGR2_MACS_EGR2_MA0472.2.damo.pwm.bed	60646
1	638	CTCF	0.301192503922972	1.07888780809132	31	929	1169	1439	1439	1180	10	6350	2210	CTCF DOHH2 (diffuse large B-cell lymphoma) CTCF	DOHH2 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036846_DOHH2--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41661
1	770	CTCF	0.301192503922972	1.07888780809132	31	929	1169	1439	1439	1180	10	6350	2210	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040063_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38230
1	772	CTCF	0.301192503922972	1.07888780809132	31	929	1169	1439	1439	1180	10	6350	2210	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040071_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36454
1	894	CTCF	0.301192503922972	1.07888780809132	31	929	1169	1439	1439	1180	10	6350	2210	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF	Treatment: None;	GTRD	EXP054031_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43983
1	918	CTCF	0.301192503922972	1.07888780809132	31	929	1169	1439	1439	1180	10	6350	2210	CTCF HAP1 (chronic myelogenous leukemia) CTCF	HAP1 (chronic myelogenous leukemia)	NULL	CTCF	Genotype: wildtype;	GTRD	EXP055795_HAP1--chronic-myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39480
1	2211	IRF4	0.301192503922972	1.07888780809132	31	929	1169	1439	1439	1180	10	6350	2210	IRF4 MM1.S (plasma cell myeloma) IRF4	MM1.S (plasma cell myeloma)	BTO:0003933	IRF4		GEO	GSE49224_irf4_mm1s_MACS_IRF4_MA1419.1.damo.pwm.bed	50917
1	384	CEBPB	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	CEBPB OCI-AML3 CEBPB	OCI-AML3	BTO:0004620	CEBPB	Control No Treatment	GTRD	EXP040655_OCI-AML3_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	8826
1	1061	EGR1	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	EGR1 Ishikawa (endometrial adenocarcinoma) EGR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	EGR1		ENCODE	ENCSR000BSQ_Ishikawa_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	12135
1	1551	FOS	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	7757
1	2102	HIF1A	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siSMAD3; Genotype: SMAD3 knockout;	GTRD	EXP057827_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	5321
1	2150	HNF4G	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	HNF4G liver HNF4G	liver	BTO:0000759	HNF4G		GTRD	EXP039746_liver_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	10104
1	2406	JUN	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	11284
1	2408	JUN	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	11384
1	2725	MEF2A	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	MEF2A SK-N-SH (neuroblastoma) MEF2A	SK-N-SH (neuroblastoma)	BTO:0001620	MEF2A	NA	ENCODE	ENCSR000BVC_SK-N-SH_MEF2A_MACS_MEF2A_MA0052.4.damo.pwm.bed	9469
1	2927	MYC	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	SHTERC	GEO	GSE60223_myc_p493-shterc_MACS_MYC_MA0147.3.damo.pwm.bed	11477
1	3125	NR3C1	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	NR3C1 breast tumor NR3C1	breast tumor	NULL	NR3C1	Male	GTRD	EXP040669_breast-tumor_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1342
1	3536	RXRA	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	9751
1	4065	TWIST1	0.299881607182258	1.3920466905208	8	935	648	2675	2675	1420	2	6373	2218	TWIST1 SHEP-21N TWIST1	SHEP-21N	NA	TWIST1	DOX_0H	GEO	GSE80151_twist1_shep21-dox-0h_MACS_TWIST1_MA1123.2.damo.pwm.bed	17782
1	1314	ESR1	0.299627373984295	1.01862119144096	120	947	1424	367	1424	913	41	6261	2179	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047663_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24013
1	1791	FOXA1	0.298903471999497	1.00512877105943	413	948	1454	40	1454	814	143	5968	2077	FOXA1 LNCaP-abl (Prostate carcinoma) FOXA1	LNCaP-abl (Prostate carcinoma)	NULL	FOXA1	SHCTR	GEO	GSE63034_foxa1_lncap-abl-shctr_MACS_FOXA1_MA0148.4.damo.pwm.bed	150309
1	1657	FOXA1	0.298274519707271	1.04410355150189	51	949	1251	932	1251	1040	17	6330	2203	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033209_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	24766
1	3916	TFAP2C	0.297959107646202	1.01506418607573	140	950	1431	313	1431	898	48	6241	2172	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	E2	GEO	GSE23852_tfap2c_mcf7-e2_MACS_TFAP2C_MA0814.2.damo.pwm.bed	39682
1	3929	TFAP2C	0.297739134833098	1.00805143829229	252	951	1448	125	1448	841	87	6129	2133	TFAP2C SK-BR-3 (breast adenocarcinoma) TFAP2C	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	TFAP2C		GEO	GSE36351_tfap2c_skbr3_MACS_TFAP2C_MA0814.2.damo.pwm.bed	91147
1	512	CTCF	0.296967796107562	1.08273270163674	28	952	1159	1531	1531	1210	9	6353	2211	CTCF GM12873 (female B-cells) CTCF	GM12873 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRP_GM12873_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42772
1	604	CTCF	0.296967796107562	1.08273270163674	28	952	1159	1531	1531	1210	9	6353	2211	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	oestrogen, CTCF siRNA	GTRD	EXP030931_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36803
1	824	CTCF	0.296967796107562	1.08273270163674	28	952	1159	1531	1531	1210	9	6353	2211	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siNIPBL(siRNA)	GTRD	EXP047780_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37519
1	2576	JUNB	0.295983648093108	1.00833636882556	226	955	1447	158	1447	853	78	6155	2142	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	46445
1	3574	SMAD3	0.29519573890436	1.01034780203091	180	956	1441	217	1441	871	62	6201	2158	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047903_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	29796
1	578	CTCF	0.294993338753874	1.0440825688776	48	957	1252	982	1252	1060	16	6333	2204	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000777_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69154
1	582	CTCF	0.294993338753874	1.0440825688776	48	957	1252	982	1252	1060	16	6333	2204	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000781_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57927
1	965	CTCF	0.294993338753874	1.0440825688776	48	957	1252	982	1252	1060	16	6333	2204	CTCF GP5d (colon adenocarcinoma) CTCF	GP5d (colon adenocarcinoma)	NULL	CTCF		GEO	GSE51234_ctcf_gp5d_MACS_CTCF_MA0139.1.damo.pwm.bed	45854
1	3921	TFAP2C	0.294847778666132	1.00716259497668	246	960	1450	133	1450	848	85	6135	2135	TFAP2C BT-474 (breast invasive ductal carcinoma) TFAP2C	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	TFAP2C		GEO	GSE36351_tfap2c_bt474_MACS_TFAP2C_MA0524.2.damo.pwm.bed	92132
1	1339	ESR1	0.292298358092087	1.08754403506354	25	961	1152	1657	1657	1260	8	6356	2212	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Tamoxifen	GTRD	EXP048585_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12291
1	320	CEBPA	0.29152490651005	1.0440616064104	45	962	1255	1054	1255	1090	15	6336	2205	CEBPA MV-4-11 (Childhood acute monocytic leukemia) CEBPA	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	CEBPA		GTRD	EXP037965_MV4-11--childhood-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	39886
1	532	CTCF	0.29152490651005	1.0440616064104	45	962	1255	1054	1255	1090	15	6336	2205	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVH_kidney_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54942
1	1808	FOXA1	0.290123783176153	1.00331386069932	346	964	1464	69	1464	832	120	6035	2100	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	E2	GEO	GSE72249_foxa1_zr751-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	63618
1	1325	ESR1	0.288784000395656	1.01498004202908	105	965	1432	422	1432	940	36	6276	2184	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p22;	GTRD	EXP047708_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22985
1	8	AR	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	NT	GTRD	EXP000723_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1441
1	235	ASCL1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	ASCL1 NCI-H128 (small cell lung carcinoma) ASCL1	NCI-H128 (small cell lung carcinoma)	BTO:0003025	ASCL1		GEO	GSE69394_ascl1_h128_MACS_ASCL1_MA1100.2.damo.pwm.bed	6074
1	1010	E2F1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	E2F1 OCI-LY1 (diffuse large B-cell lymphoma) E2F1	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	E2F1	DMSO	GTRD	EXP032102_OCI-LY1--diffuse-large-B-cell-lymphoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	13012
1	1183	ESR1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	ETOH (ethanol)	GTRD	EXP000881_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	657
1	1221	ESR1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor A	GTRD	EXP036408_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1706
1	1455	ETS1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	ETS1 CD4+ CD25+ CD45RA+ T-cells ETS1	CD4+ CD25+ CD45RA+ T-cells	NULL	ETS1		GTRD	EXP032567_CD4--CD25--CD45RA--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	10880
1	1500	FLI1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049959_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	12717
1	1718	FOXA1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #3	GTRD	EXP048496_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	1990
1	1942	GATA2	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	GATA2 WA09 (embryonic stem cells) GATA2	WA09 (embryonic stem cells)	NULL	GATA2	BMP4 for 3 day	GTRD	EXP040707_WA09--embryonic-stem-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	5104
1	2124	HNF4A	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	NULL	GTRD	EXP000306_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	15842
1	2139	HNF4A	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	HNF4A hiPSC HNF4A	hiPSC	NULL	HNF4A	Developmental stage: day 8;	GTRD	EXP057766_hiPSC_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	7382
1	2148	HNF4A	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	HNF4A HCT-116 (colon carcinoma) HNF4A	HCT-116 (colon carcinoma)	BTO:0001109	HNF4A		GEO	GSE62890_hnf4a_hct166_MACS_HNF4A_MA0114.4.damo.pwm.bed	5293
1	2203	IRF2	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	IRF2 K562 (myelogenous leukemia) IRF2	K562 (myelogenous leukemia)	NULL	IRF2		ENCODE	ENCSR376WCJ_K562_IRF2_MACS_IRF2_MA0051.1.damo.pwm.bed	12603
1	2299	JUN	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	8665
1	2300	JUN	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	12303
1	2457	JUN	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	7705
1	2715	MAX	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX	CMYC_1H	GEO	GSE36354_max_p493-cmyc-1h_MACS_MAX_MA0058.3.damo.pwm.bed	16594
1	2716	MAX	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX	CMYC_24H	GEO	GSE36354_max_p493-cmyc-24h_MACS_MAX_MA0058.3.damo.pwm.bed	12033
1	2805	MYC	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000990_GM12878--female-B-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7610
1	2806	MYC	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000990_GM12878--female-B-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7953
1	2999	NFE2L2	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	NFE2L2 HAEC (human aortic endothelial cells) NFE2L2	HAEC (human aortic endothelial cells)	NULL	NFE2L2	oxpapc, 4h	GTRD	EXP038047_HAEC--human-aortic-endothelial-cells-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	2664
1	3038	NKX2-5	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	NKX2-5 BGO3 (embryonic stem cells) NKX2-5	BGO3 (embryonic stem cells)	NULL	NKX2-5	Treatment: no	GTRD	EXP049256_BGO3--embryonic-stem-cells-_NKX2-5_MACS_NKX2-5_MA0503.1.damo.pwm.bed	9492
1	3198	OTX2	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036801_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	19474
1	3317	RARG	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM CD437 for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048632_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA0859.1.damo.pwm.bed	1102
1	3418	REST	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	REST liver REST	liver	BTO:0000759	REST		GTRD	EXP039422_liver_REST_MACS_REST_MA0138.2.damo.pwm.bed	13352
1	3423	REST	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST	Treatment: None;	GTRD	EXP054063_K562--myelogenous-leukemia-_REST_MACS_REST_MA0138.2.damo.pwm.bed	5093
1	3486	RUNX1	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: 600 ng/ml doxycycline; Genotype: CBFB-MYH11 knockdown construct, RUNX1 knockdown;	GTRD	EXP058217_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	18869
1	3592	SOX17	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	SOX17 HUES64 (embryonic stem cells) SOX17	HUES64 (embryonic stem cells)	NULL	SOX17	NA	GTRD	EXP036750_HUES64--embryonic-stem-cells-_SOX17_MACS_SOX17_MA0078.1.damo.pwm.bed	14803
1	3642	SP3	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	SP3 HEK293 (embryonic kidney) SP3	HEK293 (embryonic kidney)	NULL	SP3	NA	GTRD	EXP039318_HEK293--embryonic-kidney-_SP3_MACS_SP3_MA0746.2.damo.pwm.bed	10472
1	3773	TBX5	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5		GTRD	EXP037715_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	10142
1	3818	TCF7L2	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036767_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	6720
1	3953	TP53	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	TP53 BC3 TP53	BC3	NA	TP53	NUT	Array Express	ERP014035_tp53_bc3-nut_MACS_TP53_MA0106.3.damo.pwm.bed	462
1	3991	TP53	0.288395129221883	1.73993121849789	5	966	468	2973	2973	1470	1	6376	2219	TP53 NCI-H460 (Large cell lung carcinoma) TP53	NCI-H460 (Large cell lung carcinoma)	BTO:0002207	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051020_NCI-H460--Large-cell-lung-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	1719
1	574	CTCF	0.287841155511301	1.04404066407078	42	999	1257	1124	1257	1130	14	6339	2206	CTCF HUVEC-C (HUVEC, umbilical vein endothelial cells) CTCF	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	CTCF	NULL	GTRD	EXP000598_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48775
1	1407	ESR1	0.287582997803041	1.02743285348258	62	1000	1392	769	1392	1050	21	6319	2199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_TNF	GEO	GSE59530_esr1_mcf7-e2-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	18407
1	888	CTCF	0.287067135954856	1.01912297566284	82	1001	1420	570	1420	997	28	6299	2192	CTCF MOLM-13(acute monocytic leukemia(AML), Homo sapiens) CTCF	MOLM-13(acute monocytic leukemia(AML), Homo sapiens)	BTO:0004175	CTCF	Treatment: treated with 1:10.000 DMSO for 48hr	GTRD	EXP053099_MOLM-13-acute-monocytic-leukemia-AML---Homo-sapiens-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	77437
1	328	CEBPA	0.287056298091654	1.09373598377495	22	1002	1135	1797	1797	1310	7	6359	2213	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047677_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	33345
1	1186	ESR1	0.287056298091654	1.09373598377495	22	1002	1135	1797	1797	1310	7	6359	2213	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	ETOH (ethanol)	GTRD	EXP000884_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3683
1	1232	ESR1	0.287056298091654	1.09373598377495	22	1002	1135	1797	1797	1310	7	6359	2213	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP037445_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7316
1	1401	ESR1	0.287056298091654	1.09373598377495	22	1002	1135	1797	1797	1310	7	6359	2213	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_10M	GEO	GSE54855_esr1_mcf7-e2-10m_MACS_ESR1_MA0112.3.damo.pwm.bed	4345
1	2155	HOXA9	0.287056298091654	1.09373598377495	22	1002	1135	1797	1797	1310	7	6359	2213	HOXA9 HEK293-FT (human embryonic kidney, female transformed) HOXA9	HEK293-FT (human embryonic kidney, female transformed)	NULL	HOXA9	NUP98-HOXA9-FLAG expression	GTRD	EXP036954_HEK293-FT--human-embryonic-kidney--female-transformed-_HOXA9_MACS_HOXA9_MA0594.2.damo.pwm.bed	29639
1	3871	TFAP2A	0.287056298091654	1.09373598377495	22	1002	1135	1797	1797	1310	7	6359	2213	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GEO	GSE60270_tfap2a_mcf7_MACS_TFAP2A_MA0872.1.damo.pwm.bed	9161
1	1172	ESR1	0.2858403067543	1.01079679089273	122	1008	1440	356	1440	935	42	6259	2178	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1		Array Express	ERP000783_esr1_zr751_MACS_ESR1_MA0112.3.damo.pwm.bed	25666
1	947	CTCF	0.284453227711667	1.02658304343821	59	1009	1396	805	1396	1070	20	6322	2200	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12890_MACS_CTCF_MA0139.1.damo.pwm.bed	62500
1	1245	ESR1	0.284453227711667	1.02658304343821	59	1009	1396	805	1396	1070	20	6322	2200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	NoTreat	GTRD	EXP038335_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13663
1	1271	ESR1	0.284453227711667	1.02658304343821	59	1009	1396	805	1396	1070	20	6322	2200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	none	GTRD	EXP038384_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12869
1	2636	KLF4	0.284392171477244	1.01818142221734	79	1012	1427	599	1427	1010	27	6302	2193	KLF4 BJ (fibroblasts) KLF4	BJ (fibroblasts)	NULL	KLF4	INDUCED	GEO	GSE36570_klf4_bj-induced_MACS_KLF4_MA0039.4.damo.pwm.bed	45085
1	2160	HOXB13	0.283969143433202	1.00521582076575	182	1013	1451	215	1451	893	63	6199	2157	HOXB13 VCaP (prostate carcinoma) HOXB13	VCaP (prostate carcinoma)	BTO:0003215	HOXB13	siCtl	GTRD	EXP038437_VCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	61301
1	698	CTCF	0.283907311608562	1.04401974182929	39	1014	1258	1206	1258	1160	13	6342	2207	CTCF VCaP (prostate carcinoma) CTCF	VCaP (prostate carcinoma)	BTO:0003215	CTCF		GTRD	EXP039523_VCaP--prostate-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39202
1	808	CTCF	0.283907311608562	1.04401974182929	39	1014	1258	1206	1258	1160	13	6342	2207	CTCF CD34+ stem cells-derived erythroblasts CTCF	CD34+ stem cells-derived erythroblasts	NULL	CTCF	Adult	GTRD	EXP040426_CD34--stem-cells-derived-erythroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48367
1	3920	TFAP2C	0.283222137774586	1.00765000686721	139	1016	1449	314	1449	926	48	6242	2172	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	ETOH	GEO	GSE23852_tfap2c_mcf7-etoh_MACS_TFAP2C_MA0815.1.damo.pwm.bed	44638
1	4054	TP63	0.282225750259615	1.00457176294981	179	1017	1462	221	1462	900	62	6202	2158	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	caRAS_TGFB	GEO	GSE60814_tp63_hacat-caras-tgfb_MACS_TP63_MA0525.2.damo.pwm.bed	11712
1	1792	FOXA1	0.281631495955636	1.00174007200337	262	1018	1471	116	1471	868	91	6119	2129	FOXA1 LNCaP-abl (Prostate carcinoma) FOXA1	LNCaP-abl (Prostate carcinoma)	NULL	FOXA1		GEO	GSE63034_foxa1_lncap-abl_MACS_FOXA1_MA0148.4.damo.pwm.bed	67466
1	1289	ESR1	0.281486538845306	1.00909863924631	116	1019	1444	383	1444	949	40	6265	2180	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	Tam-Responsive	GTRD	EXP038793_ZR-75-1--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22743
1	295	BHLHE40	0.281050780403294	1.10199883623063	19	1020	1110	1956	1956	1360	6	6362	2214	BHLHE40 BHLHE40	NA	NA	BHLHE40	NA	NA	ENCSR517QHU_GM12878_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	27839
1	685	CTCF	0.281050780403294	1.10199883623063	19	1020	1110	1956	1956	1360	6	6362	2214	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039438_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29178
1	747	CTCF	0.281050780403294	1.10199883623063	19	1020	1110	1956	1956	1360	6	6362	2214	CTCF thyroid gland CTCF	thyroid gland	NULL	CTCF		GTRD	EXP039861_thyroid-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30049
1	1009	E2F1	0.281050780403294	1.10199883623063	19	1020	1110	1956	1956	1360	6	6362	2214	E2F1 MCF7 (Invasive ductal breast carcinoma) E2F1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F1	NULL	GTRD	EXP000663_MCF7--Invasive-ductal-breast-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	15415
1	3669	SPI1	0.281050780403294	1.10199883623063	19	1020	1110	1956	1956	1360	6	6362	2214	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1	Characteristic: robotic ChIP-seq;	GTRD	EXP054624_GM12878--female-B-cells-lymphoblastoid-cell-line-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	39336
1	361	CEBPB	0.280694415302916	1.00187711233149	239	1025	1469	143	1469	879	83	6142	2137	CEBPB IMR90 (lung fibroblasts) CEBPB	IMR90 (lung fibroblasts)	NULL	CEBPB		ENCODE	ENCSR000EFM_IMR-90_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	167175
1	1378	ESR1	0.279679615914025	1.04399883965656	36	1026	1260	1288	1288	1190	12	6345	2208	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 16 hrs;	GTRD	EXP057863_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7751
1	2803	MYC	0.279679615914025	1.04399883965656	36	1026	1260	1288	1288	1190	12	6345	2208	MYC normal epidermal keratinocytes MYC	normal epidermal keratinocytes	NULL	MYC	NULL	GTRD	EXP000989_normal-epidermal-keratinocytes_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13771
1	170	AR	0.279162325839661	1.01127246459083	93	1028	1439	489	1439	985	32	6288	2188	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H_SHFOXP1	GEO	GSE58428_AR_vcap-dht24h-shfoxp1_MACS_AR_MA0007.3.damo.pwm.bed	43327
1	1190	ESR1	0.277742538931347	1.02460728886002	53	1029	1402	905	1402	1110	18	6328	2202	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	E2	GTRD	EXP001016_H3396--breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	18111
1	1813	FOXA1	0.277589790054851	0.998516433647246	465	1030	1483	23	1483	845	162	5916	2058	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DMSO	GEO	GSE83860_foxa1_lncap-dmso_MACS_FOXA1_MA0148.4.damo.pwm.bed	177567
1	2058	GRHL2	0.27739742152696	0.999444256587035	316	1031	1481	85	1481	866	110	6065	2110	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	No treatment	GTRD	EXP037435_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	59389
1	154	AR	0.277051739383304	1.00517240733877	130	1032	1452	333	1452	939	45	6251	2175	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR	GEO	GSE52725_AR_lncap-shctr_MACS_AR_MA0007.3.damo.pwm.bed	51338
1	1316	ESR1	0.276595904112668	1.01019960165852	90	1033	1442	511	1442	995	31	6291	2189	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p19;	GTRD	EXP047699_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20433
1	1640	FOXA1	0.275116894069079	0.99888667402991	290	1034	1482	99	1482	872	101	6091	2119	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	E2_TAM	Array Express	ERP000380_foxa1_zr751-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	50437
1	749	CTCF	0.275102006755435	1.04397795752324	33	1035	1262	1379	1379	1230	11	6348	2209	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039866_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39186
1	1341	ESR1	0.275102006755435	1.04397795752324	33	1035	1262	1379	1379	1230	11	6348	2209	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP048587_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14604
1	3237	PKNOX1	0.275102006755435	1.04397795752324	33	1035	1262	1379	1379	1230	11	6348	2209	PKNOX1 HEK293T (embryonic kidney) PKNOX1	HEK293T (embryonic kidney)	BTO:0002181	PKNOX1	NA	GTRD	EXP039342_HEK293T--embryonic-kidney-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	28993
1	1191	ESR1	0.275026731367346	1.00178114923858	167	1038	1470	238	1470	915	58	6214	2162	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	oestrogen	GTRD	EXP030928_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	58978
1	1643	FOXA1	0.274543943985054	0.997543921612528	499	1039	1486	17	1486	847	174	5882	2046	FOXA1 MDA-MB-453 (breast adenocarcinoma) FOXA1	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	FOXA1		Array Express	ERP001226_foxa1_mdamb453_MACS_FOXA1_MA0148.4.damo.pwm.bed	121163
1	581	CTCF	0.274124290514877	1.02344886136024	50	1040	1404	945	1404	1130	17	6331	2203	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000780_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	66982
1	616	CTCF	0.274124290514877	1.02344886136024	50	1040	1404	945	1404	1130	17	6331	2203	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	5-aza-2’-deoxycytidine (decitabine; Sigma, A3656) dissolved in DMSO to 10mM. Drug was administered at 1uM daily for 3 days. Control K562 cells were mock treated with DMSO.	GTRD	EXP032764_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	62574
1	856	CTCF	0.274124290514877	1.02344886136024	50	1040	1404	945	1404	1130	17	6331	2203	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:unsynchronized	GTRD	EXP048091_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45753
1	1351	ESR1	0.274124290514877	1.02344886136024	50	1040	1404	945	1404	1130	17	6331	2203	ESR1 MDA-MB-231 (breast adenocarcinoma) ESR1	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	ESR1	Treatment: E2, 100 nM, 0 min Genotype: ER-alfa L540Q	GTRD	EXP049533_MDA-MB-231--breast-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	58920
1	1916	GATA1	0.274124290514877	1.02344886136024	50	1040	1404	945	1404	1130	17	6331	2203	GATA1 CD34+ bone marrow cell-derived erythroid progenitors GATA1	CD34+ bone marrow cell-derived erythroid progenitors	NULL	GATA1		GTRD	EXP038306_CD34--bone-marrow-cell-derived-erythroid-progenitors_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	72354
1	2814	MYC	0.274124290514877	1.02344886136024	50	1040	1404	945	1404	1130	17	6331	2203	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC	NULL	GTRD	EXP001022_MCF7--Invasive-ductal-breast-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	25704
1	715	CTCF	0.273980014571718	1.11357510205721	16	1046	1087	2127	2127	1420	5	6365	2215	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039620_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27971
1	718	CTCF	0.273980014571718	1.11357510205721	16	1046	1087	2127	2127	1420	5	6365	2215	CTCF thyroid gland CTCF	thyroid gland	NULL	CTCF		GTRD	EXP039645_thyroid-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29296
1	1199	ESR1	0.273980014571718	1.11357510205721	16	1046	1087	2127	2127	1420	5	6365	2215	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	1hr with 100nM E2, crosslinked with 1% formaldehyde	GTRD	EXP034119_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6035
1	2766	MNT	0.273980014571718	1.11357510205721	16	1046	1087	2127	2127	1420	5	6365	2215	MNT HepG2 (hepatoblastoma) MNT	HepG2 (hepatoblastoma)	BTO:0000599	MNT	NA	GTRD	EXP040038_HepG2--hepatoblastoma-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	32142
1	3950	THRB	0.273980014571718	1.11357510205721	16	1046	1087	2127	2127	1420	5	6365	2215	THRB HepG2 (hepatoblastoma) THRB	HepG2 (hepatoblastoma)	BTO:0000599	THRB	NA	GTRD	EXP039315_HepG2--hepatoblastoma-_THRB_MACS_THRB_MA1574.1.damo.pwm.bed	15992
1	3570	SMAD3	0.27395599342837	1.0090566766354	87	1051	1445	530	1445	1010	30	6294	2190	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047900_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	38463
1	466	CTCF	0.272729660545723	1.01361534548904	67	1052	1435	710	1435	1070	23	6314	2197	CTCF GM12891 (male B- cells lymphoblastoid cell line) CTCF	GM12891 (male B- cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DKX_GM12891_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	94019
1	1495	FLI1	0.270299821061798	1.02214831355157	47	1053	1414	1002	1414	1160	16	6334	2204	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047963_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	59048
1	509	CTCF	0.270101143065108	1.04395709540007	30	1054	1265	1473	1473	1260	10	6351	2210	CTCF GM12869 (female B-cells) CTCF	GM12869 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRJ_GM12869_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48219
1	634	CTCF	0.270101143065108	1.04395709540007	30	1054	1265	1473	1473	1260	10	6351	2210	CTCF OCI-LY7 (diffuse large B-cell lymphoma) CTCF	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036842_OCI-LY7--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41743
1	804	CTCF	0.270101143065108	1.04395709540007	30	1054	1265	1473	1473	1260	10	6351	2210	CTCF SH-SY5Y (neuroblastoma) CTCF	SH-SY5Y (neuroblastoma)	BTO:0000793	CTCF		GTRD	EXP040383_SH-SY5Y--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45030
1	1332	ESR1	0.270101143065108	1.04395709540007	30	1054	1265	1473	1473	1260	10	6351	2210	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	Treatment: 10 nM Estradiol for 1 hour	GTRD	EXP048233_Ishikawa--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23628
1	1757	FOXA1	0.269395858716203	0.996737800670364	298	1058	1487	92	1487	879	104	6083	2116	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	ETOH	GEO	GSE28264_foxa1_lncap-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	79220
1	1266	ESR1	0.268943588692449	1.00024024226462	138	1059	1472	316	1472	949	48	6243	2172	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038379_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42927
1	1774	FOXA1	0.267806403104429	0.998042834027252	175	1060	1485	226	1485	924	61	6206	2159	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GEO	GSE52725_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	40719
1	1776	FOXA1	0.267482321432517	0.995568607751179	458	1061	1489	25	1489	858	160	5923	2060	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	R1881	GEO	GSE56086_foxa1_vcap-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	206835
1	423	CREB1	0.266239876694155	1.02067722800142	44	1062	1415	1072	1415	1180	15	6337	2205	CREB1 HepG2 (hepatoblastoma) CREB1	HepG2 (hepatoblastoma)	BTO:0000599	CREB1		GTRD	EXP040314_HepG2--hepatoblastoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	33282
1	596	CTCF	0.266239876694155	1.02067722800142	44	1062	1415	1072	1415	1180	15	6337	2205	CTCF skeletal muscles and myoblasts CTCF	skeletal muscles and myoblasts	NULL	CTCF		GTRD	EXP030402_skeletal-muscles-and-myoblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49942
1	362	CEBPB	0.265538188804022	1.00512971154509	78	1064	1453	604	1453	1040	27	6303	2193	CEBPB K562 (myelogenous leukemia) CEBPB	K562 (myelogenous leukemia)	NULL	CEBPB		ENCODE	ENCSR000EHE_K562_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	64969
1	175	AR	0.265328202805781	1.13094977271239	13	1065	1062	2306	2306	1480	4	6368	2216	AR AR	NA	NA	AR	NA	GEO	GSE58478_AR_22rv1-arvs_MACS_AR_MA0007.3.damo.pwm.bed	1883
1	1677	FOXA1	0.265328202805781	1.13094977271239	13	1065	1062	2306	2306	1480	4	6368	2216	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	ShMEN1	GTRD	EXP038334_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	3931
1	2719	MAX	0.265328202805781	1.13094977271239	13	1065	1062	2306	2306	1480	4	6368	2216	MAX NCI-H128 (small cell lung carcinoma) MAX	NCI-H128 (small cell lung carcinoma)	BTO:0003025	MAX		GEO	GSE41105_max_h128_MACS_MAX_MA0058.3.damo.pwm.bed	20272
1	3763	TAL1	0.265328202805781	1.13094977271239	13	1065	1062	2306	2306	1480	4	6368	2216	TAL1 K562 (myelogenous leukemia) TAL1	K562 (myelogenous leukemia)	NULL	TAL1	NA	ENCODE	ENCSR000EHB_K562_TAL1_MACS_TAL1_MA0140.2.damo.pwm.bed	29369
1	479	CTCF	0.264578679595145	1.04393625325783	27	1069	1269	1564	1564	1300	9	6354	2211	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DME_LNCaP_clone_FGC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31196
1	487	CTCF	0.264578679595145	1.04393625325783	27	1069	1269	1564	1564	1300	9	6354	2211	CTCF medulloblastoma CTCF	medulloblastoma	NULL	CTCF		ENCODE	ENCSR000DMY_medulloblastoma_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37314
1	969	CTCF	0.264578679595145	1.04393625325783	27	1069	1269	1564	1564	1300	9	6354	2211	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	NEUR	GEO	GSE52457_ctcf_h1-neur_MACS_CTCF_MA0139.1.damo.pwm.bed	51425
1	2476	JUNB	0.264578679595145	1.04393625325783	27	1069	1269	1564	1564	1300	9	6354	2211	JUNB K562 (myelogenous leukemia) JUNB	K562 (myelogenous leukemia)	NULL	JUNB		ENCODE	ENCSR000DJY_K562_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	20337
1	2590	JUND	0.264578679595145	1.04393625325783	27	1069	1269	1564	1564	1300	9	6354	2211	JUND SK-N-SH (neuroblastoma) JUND	SK-N-SH (neuroblastoma)	BTO:0001620	JUND		ENCODE	ENCSR000BSK_SK-N-SH_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	35878
1	4122	YY1	0.264578679595145	1.04393625325783	27	1069	1269	1564	1564	1300	9	6354	2211	YY1 GM12878 (female B-cells lymphoblastoid cell line) YY1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000BNP_GM12878_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	67878
1	1491	FLI1	0.262543766463598	1.00362273911813	75	1075	1463	632	1463	1060	26	6306	2194	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	no doxycycline, serum-induction	GTRD	EXP038248_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	64968
1	158	AR	0.261908675708849	1.01899907138739	41	1076	1421	1155	1421	1220	14	6340	2206	AR AR	NA	NA	AR	NA	GEO	GSE55062_AR_vcap-dht-mdv3100_MACS_AR_MA0007.3.damo.pwm.bed	15178
1	773	CTCF	0.261908675708849	1.01899907138739	41	1076	1421	1155	1421	1220	14	6340	2206	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP040072_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42215
1	1809	FOXA1	0.260000315657919	0.993247636125996	377	1078	1500	53	1500	877	132	6004	2088	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1		GEO	GSE72249_foxa1_zr751_MACS_FOXA1_MA0148.4.damo.pwm.bed	75734
1	1408	ESR1	0.259441768160487	1.00199698676503	72	1079	1468	651	1468	1070	25	6309	2195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE59530_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	21572
1	56	AR	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR		GTRD	EXP036887_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	228
1	277	BACH2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	BACH2 OCI-LY7 (diffuse large B-cell lymphoma) BACH2	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	BACH2		GEO	GSE69558_bach2_ocily7_MACS_BACH2_MA1101.2.damo.pwm.bed	1889
1	289	BCL6B	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	BCL6B HEK293 (embryonic kidney) BCL6B	HEK293 (embryonic kidney)	NULL	BCL6B	NA	GTRD	EXP040074_HEK293--embryonic-kidney-_BCL6B_MACS_BCL6B_MA0731.1.damo.pwm.bed	1777
1	302	CDX2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	CDX2 Caco-2 (colon adenocarcinoma) CDX2	Caco-2 (colon adenocarcinoma)	BTO:0000195	CDX2	PROLIF	GEO	GSE23436_cdx2_caco2-prolif_MACS_CDX2_MA0465.2.damo.pwm.bed	2743
1	414	CREB1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	CREB1 A549 (lung carcinoma) CREB1	A549 (lung carcinoma)	BTO:0000018	CREB1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRA_A549_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	4109
1	608	CTCF	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	CTCF CD34+ hematopoietic stem cells-derived proerythroblasts CTCF	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	CTCF	2-trimester fetal liver	GTRD	EXP031445_CD34--hematopoietic-stem-cells-derived-proerythroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	2336
1	1020	E2F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	E2F1 Raji (Burkitt lymphoma) E2F1	Raji (Burkitt lymphoma)	BTO:0001154	E2F1	100 nM of JQ1	GTRD	EXP035851_Raji--Burkitt-lymphoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	6888
1	1021	E2F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	E2F1 MM1.S (plasma cell myeloma) E2F1	MM1.S (plasma cell myeloma)	BTO:0003933	E2F1	none	GTRD	EXP037393_MM1.S--plasma-cell-myeloma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	7019
1	1041	E2F4	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	TAM	GEO	GSE41561_e2f4_mcf7-tam_MACS_E2F4_MA0470.2.damo.pwm.bed	3273
1	1112	EOMES	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	EOMES HUES64 (embryonic stem cells) EOMES	HUES64 (embryonic stem cells)	NULL	EOMES	NA	GTRD	EXP036702_HUES64--embryonic-stem-cells-_EOMES_MACS_EOMES_MA0800.1.damo.pwm.bed	6888
1	1362	ESR1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM R5020 for45 mins Genotype: ER+/PR+	GTRD	EXP049947_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	611
1	1445	ESRRA	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	ESRRA A549 (lung carcinoma) ESRRA	A549 (lung carcinoma)	BTO:0000018	ESRRA		ENCODE	ENCSR473SUA_A549_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	2584
1	1450	ETS1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	ETS1 GM12878 (female B-cells lymphoblastoid cell line) ETS1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETS1		ENCODE	ENCSR000BKA_GM12878_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	6666
1	1474	ETV1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	ETV1 GIST882 (Gastrointestinal stromal tumor) ETV1	GIST882 (Gastrointestinal stromal tumor)	NULL	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048910_GIST882--Gastrointestinal-stromal-tumor-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	6643
1	1488	FLI1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	FLI1 megakaryocytes FLI1	megakaryocytes	NULL	FLI1	NULL	GTRD	EXP000354_megakaryocytes_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	7348
1	1497	FLI1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048206_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	13219
1	1511	FLI1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHGFP_48H	GEO	GSE61944_fli1_skmnc-shgfp-48h_MACS_FLI1_MA0475.2.damo.pwm.bed	4122
1	1512	FLI1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHGFP_96H	GEO	GSE61944_fli1_skmnc-shgfp-96h_MACS_FLI1_MA0475.2.damo.pwm.bed	3773
1	1562	FOS	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	FOS MV-4-11 (Childhood acute monocytic leukemia) FOS	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	FOS		GEO	GSE64862_fos_mv411_MACS_FOS_MA0476.1.damo.pwm.bed	4941
1	1824	FOXA2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	FOXA2 endometrioid adenocarcinoma FOXA2	endometrioid adenocarcinoma	NULL	FOXA2	tumor C	GTRD	EXP036411_endometrioid-adenocarcinoma_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	455
1	1872	GABPA	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	GABPA SK-N-SH (neuroblastoma) GABPA	SK-N-SH (neuroblastoma)	BTO:0001620	GABPA		ENCODE	ENCSR000BTG_SK-N-SH_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	9376
1	1953	GATA2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	GATA2 CD34+ cells GATA2	CD34+ cells	NULL	GATA2	DMSO	GEO	GSE60792_gata2_cd34-dmso_MACS_GATA2_MA0036.3.damo.pwm.bed	5479
1	2008	GATA4	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036707_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	5149
1	2049	GFI1B	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: GSK-LSD1 for 48 hrs; Genotype: wildtype;	GTRD	EXP058349_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1691
1	2114	HNF1A	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HNF1A NY15 (pancreatic cancer-derived cells) HNF1A	NY15 (pancreatic cancer-derived cells)	NULL	HNF1A		GTRD	EXP048083_NY15--pancreatic-cancer-derived-cells-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	2564
1	2130	HNF4A	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036715_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	4110
1	2131	HNF4A	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036715_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	4716
1	2141	HNF4A	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HNF4A Caco-2 (colon adenocarcinoma) HNF4A	Caco-2 (colon adenocarcinoma)	BTO:0000195	HNF4A	PROLIF	GEO	GSE23436_hnf4a_caco2-prolif_MACS_HNF4A_MA0114.4.damo.pwm.bed	12193
1	2142	HNF4A	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HNF4A GP5d (colon adenocarcinoma) HNF4A	GP5d (colon adenocarcinoma)	NULL	HNF4A	SIRAD21	GEO	GSE51234_hnf4a_gp5d-sirad21_MACS_HNF4A_MA0114.4.damo.pwm.bed	1441
1	2144	HNF4A	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HNF4A LoVo (colorectal adenocarcinoma) HNF4A	LoVo (colorectal adenocarcinoma)	BTO:0000666	HNF4A	PHASEM	GEO	GSE51290_hnf4a_lovo-phaseM_MACS_HNF4A_MA0114.4.damo.pwm.bed	1262
1	2157	HOXA9	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HOXA9 SEM (childhood B acute lymphoblastic leukemia) HOXA9	SEM (childhood B acute lymphoblastic leukemia)	NULL	HOXA9		GEO	GSE38339_hoxa9_sem_MACS_HOXA9_MA0594.2.damo.pwm.bed	3503
1	2187	HSF1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1		GEO	GSE38901_hsf1_mcf7_MACS_HSF1_MA0486.2.damo.pwm.bed	821
1	2188	HSF1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HSF1 NCI-H441 (squamous cell lung carcinoma ) HSF1	NCI-H441 (squamous cell lung carcinoma )	BTO:0001910	HSF1		GEO	GSE38901_hsf1_ncih441_MACS_HSF1_MA0486.2.damo.pwm.bed	861
1	2189	HSF1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HSF1 SK-BR-3 (breast adenocarcinoma) HSF1	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	HSF1		GEO	GSE38901_hsf1_skbr3_MACS_HSF1_MA0486.2.damo.pwm.bed	2547
1	2192	HSF1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1		GEO	GSE45852_hsf1_mcf7_MACS_HSF1_MA0486.2.damo.pwm.bed	574
1	2199	IRF1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	IRF1 K562 (myelogenous leukemia) IRF1	K562 (myelogenous leukemia)	NULL	IRF1	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000EGU_K562_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	470
1	2204	IRF2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	IRF2 CD34+ hematopoietic stem cells-derived proerythroblasts IRF2	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	IRF2	adult bone marrow	GTRD	EXP031449_CD34--hematopoietic-stem-cells-derived-proerythroblasts_IRF2_MACS_IRF2_MA0051.1.damo.pwm.bed	2491
1	2209	IRF3	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	IRF3 SK-N-SH (neuroblastoma) IRF3	SK-N-SH (neuroblastoma)	BTO:0001620	IRF3	NA	GTRD	EXP040104_SK-N-SH--neuroblastoma-_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	5069
1	2735	MEF2B	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: D83V-MEF2B-V5;	GTRD	EXP055131_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	4026
1	2738	MEF2B	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	MEF2B DOHH2 (diffuse large B-cell lymphoma) MEF2B	DOHH2 (diffuse large B-cell lymphoma)	NULL	MEF2B		GEO	GSE69558_mef2b_dohh2_MACS_MEF2B_MA0660.1.damo.pwm.bed	5836
1	2758	MITF	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	MITF retina MITF	retina	BTO:0001175	MITF	pigment	GEO	GSE60024_mitf_retinal-pigment_MACS_MITF_MA0620.3.damo.pwm.bed	2212
1	3054	NR2C2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	NR2C2 HepG2 (hepatoblastoma) NR2C2	HepG2 (hepatoblastoma)	BTO:0000599	NR2C2	NULL	GTRD	EXP000578_HepG2--hepatoblastoma-_NR2C2_MACS_NR2C2_MA1536.1.damo.pwm.bed	5363
1	3171	NRF1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	NRF1 K562 (myelogenous leukemia) NRF1	K562 (myelogenous leukemia)	NULL	NRF1		ENCODE	ENCSR000EHH_K562_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	4672
1	3183	NRF1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	NRF1 Namalwa (Burkitt lymphoma) NRF1	Namalwa (Burkitt lymphoma)	BTO:0003289	NRF1		GEO	GSE53133_nrf1_namalwa_MACS_NRF1_MA0506.1.damo.pwm.bed	5411
1	3261	POU5F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under normal conditions	GTRD	EXP047914_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	10568
1	3262	POU5F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under normal conditions	GTRD	EXP047914_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	9222
1	3264	POU5F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under heat shock conditions	GTRD	EXP047915_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	7316
1	3267	POU5F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator) and Klf4 addition for 5 days Passage: 8	GTRD	EXP048945_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	1724
1	3268	POU5F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2-VP16 (strong activator) and Klf4 addition for 5 days Passage: 8	GTRD	EXP048945_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	1712
1	3273	POU5F1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	POU5F1 iPSC (induced pluripotent stem cells) POU5F1	iPSC (induced pluripotent stem cells)	NULL	POU5F1	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048953_iPSC--induced-pluripotent-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	8701
1	3307	PRDM4	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	PRDM4 HEK293 (embryonic kidney) PRDM4	HEK293 (embryonic kidney)	NULL	PRDM4	NA	GTRD	EXP039415_HEK293--embryonic-kidney-_PRDM4_MACS_PRDM4_MA1647.1.damo.pwm.bed	2958
1	3313	RARA	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA0729.1.damo.pwm.bed	2773
1	3332	RELA	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RELA GM12892 (female B-cells lymphoblastoid cell line) RELA	GM12892 (female B-cells lymphoblastoid cell line)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EAN_GM12892_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	2766
1	3335	RELA	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RELA GM18526 (B – cells Lymphoblastoid Cell Lines) RELA	GM18526 (B – cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBA_GM18526_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	3221
1	3338	RELA	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RELA GM19193 (female B-cells Lymphoblastoid Cell Lines) RELA	GM19193 (female B-cells Lymphoblastoid Cell Lines)	NULL	RELA	human recombinant TNF-alpha from eBioscience [product# 14-8329-62] (Snyder)	ENCODE	ENCSR000EBM_GM19193_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	3507
1	3448	RFX5	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RFX5 SK-N-SH (neuroblastoma) RFX5	SK-N-SH (neuroblastoma)	BTO:0001620	RFX5	NA	ENCODE	ENCSR000EHY_SK-N-SH_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	4369
1	3463	RUNX1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RUNX1 CD4+ CD25- T-cells RUNX1	CD4+ CD25- T-cells	NULL	RUNX1		GTRD	EXP032572_CD4--CD25--T-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3418
1	3475	RUNX1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: Al-10-49 (1uM) for 6 hr; CellType: human inv(16) leukemia cell line;	GTRD	EXP047573_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	7243
1	3483	RUNX1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RUNX1 LPS141 (Dedifferentiated liposarcoma) RUNX1	LPS141 (Dedifferentiated liposarcoma)	NULL	RUNX1		GTRD	EXP057977_LPS141--Dedifferentiated-liposarcoma-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3506
1	3491	RUNX1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GEO	GSE45738_runx1_kasumi1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12209
1	3616	SOX2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	SOX2 glioma SOX2	glioma	NA	SOX2	stem	GEO	GSE67282_sox2_gsc_MACS_SOX2_MA0143.4.damo.pwm.bed	3094
1	3633	SP1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	SP1 HUES64 (embryonic stem cells) SP1	HUES64 (embryonic stem cells)	NULL	SP1		GTRD	EXP036754_HUES64--embryonic-stem-cells-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	8672
1	3674	SPI1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	SPI1 OCI-LY3 (diffuse large B-cell lymphoma) SPI1	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPI1	SHCTR	GEO	GSE56857_spi1_ocily3-shctr_MACS_SPI1_MA0080.5.damo.pwm.bed	2094
1	3720	STAT1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	Interferon gamma treatment - 6 hours (Snyder)	ENCODE	ENCSR000EHJ_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	1727
1	3958	TP53	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	irradiation 0h	GTRD	EXP036824_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	566
1	3982	TP53	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	TP53 PHA-simulated human T-lynphocytes TP53	PHA-simulated human T-lynphocytes	NULL	TP53	Treatment: 0.3 ug/ml Doxorubicin for 24 hrs Source: healthy volunteer #104	GTRD	EXP048273_PHA-simulated-human-T-lynphocytes_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	212
1	4079	USF2	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	USF2 GM12878 (female B-cells lymphoblastoid cell line) USF2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	USF2		ENCODE	ENCSR000DZU_GM12878_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	4036
1	4115	XBP1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	XBP1 HS578T (invasive ductal breast carcinoma) XBP1	HS578T (invasive ductal breast carcinoma)	BTO:0003885	XBP1	HYPO_GLUDEP	GEO	GSE49952_xbp1_hs578t-hypo-gludep_MACS_XBP1_MA0844.1.damo.pwm.bed	2332
1	4137	YY1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Asp380Tyr)	GTRD	EXP038607_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2034
1	4141	YY1	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038611_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2571
1	4158	ZFX	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	ZFX DAOY (medulloblastoma) ZFX	DAOY (medulloblastoma)	BTO:0004328	ZFX	NA	GEO	GSE45394_zfx_daoy_MACS_ZFX_MA0146.2.damo.pwm.bed	7312
1	4161	ZNF143	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	ZNF143 HEK293T (embryonic kidney) ZNF143	HEK293T (embryonic kidney)	BTO:0002181	ZNF143		GEO	GSE39263_znf143_hek293t_MACS_ZNF143_MA0088.2.damo.pwm.bed	1903
1	4166	ZNF740	0.259337975566161	Inf	2	1080	1	3390	3390	1490	0	6379	2220	ZNF740 K562 (myelogenous leukemia) ZNF740	K562 (myelogenous leukemia)	NULL	ZNF740	NA	ENCODE	ENCSR737UST_K562_ZNF740_MACS_ZNF740_MA0753.2.damo.pwm.bed	2764
1	529	CTCF	0.258398777939299	1.04391543106735	24	1153	1275	1691	1691	1370	8	6357	2212	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUU_fibroblast_of_mammary_gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37332
1	1956	GATA2	0.258398777939299	1.04391543106735	24	1153	1275	1691	1691	1370	8	6357	2212	GATA2 TF-1 (erythroleukemia) GATA2	TF-1 (erythroleukemia)	BTO:0004760	GATA2		GEO	GSE73207_gata2_tf1_MACS_GATA2_MA0036.3.damo.pwm.bed	50857
1	2128	HNF4A	0.258398777939299	1.04391543106735	24	1153	1275	1691	1691	1370	8	6357	2212	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	none	GTRD	EXP030930_HepG2--hepatoblastoma-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	37426
1	2069	GRHL2	0.258045480843136	0.995084029717762	123	1156	1490	351	1490	999	43	6258	2177	GRHL2 MCF7 WS8 cells GRHL2	MCF7 WS8 cells	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048455_MCF7-WS8-cells_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	27719
1	2857	MYC	0.257261855379075	1.01706607444178	38	1157	1428	1238	1428	1270	13	6343	2207	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881+Doxycycline	GTRD	EXP037069_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	21742
1	130	AR	0.256222632665771	1.00023761597563	69	1158	1473	687	1473	1110	24	6312	2196	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_10C26	GEO	GSE32892_AR_vcap-r1881-10c26_MACS_AR_MA0007.3.damo.pwm.bed	16533
1	1707	FOXA1	0.25551858901596	0.992180439265126	174	1159	1502	229	1502	963	61	6207	2159	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048446_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	36763
1	1702	FOXA1	0.254371064706823	0.991224680331383	228	1160	1507	156	1507	941	80	6153	2140	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048438_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45395
1	174	AR	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	AR AR	NA	NA	AR	NA	GEO	GSE58478_AR_22rv1-arfl-arvs_MACS_AR_MA0007.3.damo.pwm.bed	1954
1	601	CTCF	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	CTCF CD4+ T-cells CTCF	CD4+ T-cells	NULL	CTCF		GTRD	EXP030880_CD4--T-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22927
1	1013	E2F1	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Vehicle	GTRD	EXP032858_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	15138
1	1402	ESR1	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_120M	GEO	GSE54855_esr1_mcf7-e2-120m_MACS_ESR1_MA0112.3.damo.pwm.bed	1537
1	1483	ETV6	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	ETV6 GM12878 (female B-cells lymphoblastoid cell line) ETV6	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETV6		ENCODE	ENCSR626VUC_GM12878_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	16719
1	2040	GATA6	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	GATA6 Caco-2 (colon adenocarcinoma) GATA6	Caco-2 (colon adenocarcinoma)	BTO:0000195	GATA6	PROLIF	GEO	GSE23436_gata6_caco2-prolif_MACS_GATA6_MA1104.2.damo.pwm.bed	13040
1	2800	MYC	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC	NULL	GTRD	EXP000439_GM12878--female-B-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	19483
1	3034	NFYC	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	NFYC HepG2 (hepatoblastoma) NFYC	HepG2 (hepatoblastoma)	BTO:0000599	NFYC	NA	GTRD	EXP039903_HepG2--hepatoblastoma-_NFYC_MACS_NFYC_MA1644.1.damo.pwm.bed	10909
1	3361	RELA	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	Treatment: confluent, treated with Scr siRNA Passage: 4	GTRD	EXP049054_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13554
1	3481	RUNX1	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	RUNX1 pre-B-lymphoblast cells with BCP-ALL RUNX1	pre-B-lymphoblast cells with BCP-ALL	NULL	RUNX1	DIsease: human precursor leukemia (BCP-ALL) Tissue: bone marrow	GTRD	EXP048192_pre-B-lymphoblast-cells-with-BCP-ALL_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	16702
1	3540	RXRA	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	10992
1	3842	TEAD4	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	TEAD4 MDA-MB-231 (breast adenocarcinoma) TEAD4	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	TEAD4		GEO	GSE66081_tead4_mdamb231_MACS_TEAD4_MA0809.2.damo.pwm.bed	11914
1	3879	TFAP2C	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047534_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	9989
1	3880	TFAP2C	0.254111756599902	1.15992106063277	10	1161	999	2487	2487	1550	3	6371	2217	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047534_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	9543
1	1639	FOXA1	0.253875938740969	0.990976458398581	265	1175	1509	110	1509	931	93	6116	2127	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	E2_TAM	Array Express	ERP000380_foxa1_t47d-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	40029
1	1780	FOXA1	0.252875497372833	0.99832715397748	66	1176	1484	727	1484	1130	23	6315	2197	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT24H	GEO	GSE58428_foxa1_lncap-dht24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	11460
1	1206	ESR1	0.25238340812885	0.990996995768925	151	1177	1508	282	1508	989	53	6230	2167	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP035788_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	35876
1	535	CTCF	0.252243557324785	1.01481455267591	35	1178	1433	1318	1433	1310	12	6346	2208	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVQ_fibroblast_of_villous_mesenchyme_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46685
1	819	CTCF	0.252243557324785	1.01481455267591	35	1178	1433	1318	1433	1310	12	6346	2208	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siCtrl(siRNA)	GTRD	EXP047775_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42871
1	507	CTCF	0.251366897256217	1.04389462879954	21	1180	1278	1852	1852	1440	7	6360	2213	CTCF GM12867 (female B-cells) CTCF	GM12867 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRH_GM12867_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40953
1	709	CTCF	0.251366897256217	1.04389462879954	21	1180	1278	1852	1852	1440	7	6360	2213	CTCF prostate gland CTCF	prostate gland	BTO:0001129	CTCF		GTRD	EXP039579_prostate-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34113
1	1363	ESR1	0.251366897256217	1.04389462879954	21	1180	1278	1852	1852	1440	7	6360	2213	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM E2 + 10 nM R5020 for45 mins Genotype: ER+/PR+	GTRD	EXP049948_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4653
1	2269	JUN	0.251366897256217	1.04389462879954	21	1180	1278	1852	1852	1440	7	6360	2213	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	23530
1	2276	JUN	0.251366897256217	1.04389462879954	21	1180	1278	1852	1852	1440	7	6360	2213	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	23771
1	2917	MYC	0.251366897256217	1.04389462879954	21	1180	1278	1852	1852	1440	7	6360	2213	MYC BJ (fibroblasts) MYC	BJ (fibroblasts)	NULL	MYC	INDUCED	GEO	GSE36570_myc_bj-induced_MACS_MYC_MA0147.3.damo.pwm.bed	20603
1	621	CTCF	0.251117561105712	1.00281464730952	49	1186	1465	967	1465	1210	17	6332	2203	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	unstimulated	GTRD	EXP033165_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42556
1	1300	ESR1	0.251117561105712	1.00281464730952	49	1186	1465	967	1465	1210	17	6332	2203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 for 3h	GTRD	EXP040895_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9309
1	4044	TP63	0.251117561105712	1.00281464730952	49	1186	1465	967	1465	1210	17	6332	2203	TP63 HCC95 (squamous cell lung carcinoma) TP63	HCC95 (squamous cell lung carcinoma)	NULL	TP63		GEO	GSE46837_tp63_hcc95_MACS_TP63_MA0525.2.damo.pwm.bed	2893
1	1276	ESR1	0.250967141547826	0.992446574728386	97	1189	1501	468	1501	1050	34	6284	2186	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038389_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	44589
1	1971	GATA3	0.250325438015623	0.989967543324492	148	1190	1510	287	1510	996	52	6233	2168	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GTRD	EXP039573_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	36204
1	3363	RELA	0.249387955412988	0.996244906299799	63	1191	1488	753	1488	1140	22	6318	2198	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	Treatment: confluent, treated with Notch1 siRNA and stimulated with IL-1beta Passsage: 4	GTRD	EXP049056_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	60447
1	401	CEBPB	0.247357322224087	0.988169311757622	179	1192	1512	221	1512	975	63	6202	2157	CEBPB LS180 (colon cancer) CEBPB	LS180 (colon cancer)	NULL	CEBPB		GEO	GSE31939_cebpb_ls180_MACS_CEBPB_MA0466.2.damo.pwm.bed	92692
1	3021	NFKB1	0.246810843060848	1.00023675326044	46	1193	1474	1028	1474	1230	16	6335	2204	NFKB1 MCF10A-ER-Src NFKB1	MCF10A-ER-Src	NULL	NFKB1	Genotype: non-transformed	GTRD	EXP048573_MCF10A-ER-Src_NFKB1_MACS_NFKB1_MA0105.4.damo.pwm.bed	8653
1	4056	TP63	0.246810843060848	1.00023675326044	46	1193	1474	1028	1474	1230	16	6335	2204	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	LacZ	GEO	GSE60814_tp63_hacat-lacz-not_MACS_TP63_MA0525.2.damo.pwm.bed	2691
1	633	CTCF	0.246782184323306	1.01215767623542	32	1195	1437	1410	1437	1350	11	6349	2209	CTCF OCI-LY7 (diffuse large B-cell lymphoma) CTCF	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	CTCF		GTRD	EXP036841_OCI-LY7--diffuse-large-B-cell-lymphoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43733
1	3386	RELA	0.246782184323306	1.01215767623542	32	1195	1437	1410	1437	1350	11	6349	2209	RELA LNCaP (prostate carcinoma) RELA	LNCaP (prostate carcinoma)	BTO:0001321	RELA	SIFOXA1_TNFA	GEO	GSE83860_rela_lncap-sifoxa1-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	16220
1	2417	JUN	0.246186326545248	0.988143422075852	125	1197	1513	345	1513	1020	44	6256	2176	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	30780
1	956	CTCF	0.245745754160561	0.993966326225096	60	1198	1499	797	1499	1160	21	6321	2199	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19238_MACS_CTCF_MA0139.1.damo.pwm.bed	63960
1	486	CTCF	0.245444120154984	0.989210106684044	91	1199	1511	506	1511	1070	32	6290	2188	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DMV_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73190
1	2418	JUN	0.243845192302761	0.986836925991187	122	1200	1514	356	1514	1020	43	6259	2177	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	30390
1	511	CTCF	0.24319152332755	1.04387384642535	18	1201	1284	1996	1996	1490	6	6363	2214	CTCF GM12872 (male B-cells) CTCF	GM12872 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRN_GM12872_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35699
1	597	CTCF	0.24319152332755	1.04387384642535	18	1201	1284	1996	1996	1490	6	6363	2214	CTCF HUVEC-C (HUVEC, umbilical vein endothelial cells) CTCF	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	CTCF		GTRD	EXP030403_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37816
1	2122	HNF4A	0.24319152332755	1.04387384642535	18	1201	1284	1996	1996	1490	6	6363	2214	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A		Array Express	ERP000209_hnf4a_hepg2_MACS_HNF4A_MA0114.4.damo.pwm.bed	29845
1	204	AR	0.241932417486712	0.991461958794034	57	1204	1503	839	1503	1180	20	6324	2200	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH1_DHT	GEO	GSE79128_AR_vcap-sh1-dht_MACS_AR_MA0007.3.damo.pwm.bed	26210
1	313	CEBPA	0.241932417486712	0.991461958794034	57	1204	1503	839	1503	1180	20	6324	2200	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	dmso	GTRD	EXP000947_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	41983
1	368	CEBPB	0.241932417486712	0.991461958794034	57	1204	1503	839	1503	1180	20	6324	2200	CEBPB MV-4-11 (Childhood acute monocytic leukemia) CEBPB	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	CEBPB		GTRD	EXP037966_MV4-11--childhood-acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	56973
1	390	CEBPB	0.241932417486712	0.991461958794034	57	1204	1503	839	1503	1180	20	6324	2200	CEBPB THP-1 (acute monocytic leukemia) CEBPB	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPB	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA)	GTRD	EXP047816_THP-1--acute-monocytic-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	40757
1	818	CTCF	0.240784040078777	1.00897390445162	29	1208	1446	1504	1504	1390	10	6352	2210	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: untreated, eGFP(EP mRNA), siCtrl(siRNA)	GTRD	EXP047774_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41424
1	1344	ESR1	0.239678878289047	0.985146642526268	255	1209	1520	122	1520	950	90	6126	2130	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP048609_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	99509
1	68	AR	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	AR MCF-7 C4-12 (invasive breast ductal carcinoma) AR	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	AR	Female	GTRD	EXP040661_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1516
1	463	CTCF	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	CTCF GM10248 (male B-cells) CTCF	GM10248 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DKP_GM10248_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17330
1	1113	EOMES	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	EOMES HUES64 (embryonic stem cells) EOMES	HUES64 (embryonic stem cells)	NULL	EOMES	NA	GTRD	EXP036785_HUES64--embryonic-stem-cells-_EOMES_MACS_EOMES_MA0800.1.damo.pwm.bed	19498
1	1198	ESR1	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	1hr with ethanol, crosslinked with 1% formaldehyde	GTRD	EXP034118_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1252
1	1550	FOS	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	8181
1	1552	FOS	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	7915
1	1553	FOS	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047824_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	7802
1	1975	GATA3	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	GATA3 A1A3(breast cancer cells) GATA3	A1A3(breast cancer cells)	NULL	GATA3	Treatment: 1hr EtOH, PBS 72 hr CellLine: A1A3 from T47D cell line	GTRD	EXP048402_A1A3-breast-cancer-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	4616
1	2121	HNF4A	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEU_HepG2_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	16323
1	2701	MAX	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	MAX K562 (myelogenous leukemia) MAX	K562 (myelogenous leukemia)	NULL	MAX		ENCODE	ENCSR000FAE_K562_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	9399
1	2762	MNT	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	MNT K562 (myelogenous leukemia) MNT	K562 (myelogenous leukemia)	NULL	MNT	NA	GTRD	EXP039391_K562--myelogenous-leukemia-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	14983
1	2794	MYC	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	Interferon gamma treatment - 30 minutes (Snyder)	ENCODE	ENCSR000EGS_K562_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16280
1	3078	NR2F2	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	NR2F2 uterus NR2F2	uterus	BTO:0001424	NR2F2	STROMA_ENDOMETRIUM	GEO	GSE52008_nr2f2_stroma-endometrium_MACS_NR2F2_MA1111.1.damo.pwm.bed	16401
1	3402	REST	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		ENCODE	ENCSR000BQS_GM12878_REST_MACS_REST_MA0138.2.damo.pwm.bed	13304
1	3530	RXRA	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	10246
1	3604	SOX2	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048955_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	5471
1	3837	TEAD4	0.238113376549571	1.21788307728296	7	1210	887	2768	2768	1620	2	6374	2218	TEAD4 SK-N-SH (neuroblastoma) TEAD4	SK-N-SH (neuroblastoma)	BTO:0001620	TEAD4		ENCODE	ENCSR000BUQ_SK-N-SH_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	21714
1	1210	ESR1	0.237762522059974	0.983311965641613	164	1227	1522	246	1522	998	58	6217	2162	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nM E2, 120min	GTRD	EXP035984_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	45848
1	4165	ZNF263	0.237485396795839	0.985586605024351	68	1228	1519	703	1519	1150	24	6313	2196	ZNF263 HEK293 (embryonic kidney) ZNF263	HEK293 (embryonic kidney)	NULL	ZNF263	NA	ENCODE	ENCSR000EVD_HEK293_ZNF263_MACS_ZNF263_MA0528.2.damo.pwm.bed	95450
1	488	CTCF	0.237326541368544	0.99398535661275	40	1229	1498	1189	1498	1310	14	6341	2206	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		ENCODE	ENCSR000DNA_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43187
1	1230	ESR1	0.236540971519155	0.983529200933781	82	1230	1521	570	1521	1110	29	6299	2191	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TNFa for 45m	GTRD	EXP036983_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22345
1	134	AR	0.236528443132062	0.9825318156763	113	1231	1524	397	1524	1050	40	6268	2180	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881	GEO	GSE32892_AR_vcap-r1881_MACS_AR_MA0007.3.damo.pwm.bed	44834
1	457	CTCF	0.234123464512449	1.00508771570248	26	1232	1455	1602	1602	1430	9	6355	2211	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF		ENCODE	ENCSR000BNH_H1-hESC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44002
1	642	CTCF	0.234123464512449	1.00508771570248	26	1232	1455	1602	1602	1430	9	6355	2211	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GTRD	EXP036854_MM1.S--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37929
1	828	CTCF	0.234123464512449	1.00508771570248	26	1232	1455	1602	1602	1430	9	6355	2211	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siWAPL(siRNA)	GTRD	EXP047784_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37205
1	901	CTCF	0.234123464512449	1.00508771570248	26	1232	1455	1602	1602	1430	9	6355	2211	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF	Treatment: None;	GTRD	EXP054038_GM12878--female-B-cells-lymphoblastoid-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43477
1	1146	ERG	0.234123464512449	1.00508771570248	26	1232	1455	1602	1602	1430	9	6355	2211	ERG Jurkat (T-cells) ERG	Jurkat (T-cells)	BTO:0000661	ERG		GEO	GSE49091_erg_jurkat_MACS_ERG_MA0474.2.damo.pwm.bed	37494
1	2032	GATA6	0.234123464512449	1.00508771570248	26	1232	1455	1602	1602	1430	9	6355	2211	GATA6 WA01 (H1, human embryonic stem cells) GATA6	WA01 (H1, human embryonic stem cells)	NULL	GATA6		GTRD	EXP037214_WA01--H1--human-embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	70384
1	3230	PDX1	0.234123464512449	1.00508771570248	26	1232	1455	1602	1602	1430	9	6355	2211	PDX1 iPS (derived pancreatic precursor cells) PDX1	iPS (derived pancreatic precursor cells)	NULL	PDX1		GTRD	EXP047965_iPS--derived-pancreatic-precursor-cells-_PDX1_MACS_PDX1_MA0132.2.damo.pwm.bed	34092
1	2099	HIF1A	0.233941298776285	0.98201710624456	209	1239	1528	176	1528	981	74	6172	2146	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: siCtrl;	GTRD	EXP057821_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	51217
1	1372	ESR1	0.233900415366165	0.98304659411169	65	1240	1523	738	1523	1170	23	6316	2197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM 17-beta-estradiol for 30 mins Genotype: pS118-ER	GTRD	EXP053338_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23977
1	272	BACH2	0.233409592537945	1.04385308391579	15	1241	1287	2200	2200	1580	5	6366	2215	BACH2 B-cells BACH2	B-cells	NULL	BACH2		GTRD	EXP040449_B-cells_BACH2_MACS_BACH2_MA1101.2.damo.pwm.bed	13854
1	681	CTCF	0.233409592537945	1.04385308391579	15	1241	1287	2200	2200	1580	5	6366	2215	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP039402_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31219
1	739	CTCF	0.233409592537945	1.04385308391579	15	1241	1287	2200	2200	1580	5	6366	2215	CTCF right lobe of liver CTCF	right lobe of liver	NULL	CTCF		GTRD	EXP039782_right-lobe-of-liver_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31020
1	758	CTCF	0.233409592537945	1.04385308391579	15	1241	1287	2200	2200	1580	5	6366	2215	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP039983_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32429
1	1948	GATA2	0.233409592537945	1.04385308391579	15	1241	1287	2200	2200	1580	5	6366	2215	GATA2 TF-1 (erythroleukemia) GATA2	TF-1 (erythroleukemia)	BTO:0004760	GATA2	Genotype: wildtype; Treatment: DOX for 6 days;	GTRD	EXP055346_TF-1--erythroleukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	36006
1	3918	TFAP2C	0.233297491486161	0.980674690051813	141	1246	1530	310	1530	1030	50	6240	2170	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	ETOH	GEO	GSE23852_tfap2c_mcf7-etoh_MACS_TFAP2C_MA0524.2.damo.pwm.bed	44966
1	1706	FOXA1	0.230476944799067	0.980281135403518	203	1247	1534	187	1534	989	72	6178	2148	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048445_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45932
1	1308	ESR1	0.23016234986864	0.980277550511665	62	1248	1535	769	1535	1180	22	6319	2198	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040957_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14952
1	2705	MAX	0.23016234986864	0.980277550511665	62	1248	1535	769	1535	1180	22	6319	2198	MAX HeLa (cervical adenocarcinoma) MAX	HeLa (cervical adenocarcinoma)	BTO:0000567	MAX		GTRD	EXP031874_HeLa--cervical-adenocarcinoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	35271
1	2720	MAX	0.23016234986864	0.980277550511665	62	1248	1535	769	1535	1180	22	6319	2198	MAX NCI-H2171 (small cell lung carcinoma) MAX	NCI-H2171 (small cell lung carcinoma)	NULL	MAX		GEO	GSE41105_max_ncih2171_MACS_MAX_MA0058.3.damo.pwm.bed	61822
1	1722	FOXA1	0.229792048001411	0.982401081700109	342	1251	1525	72	1525	949	121	6039	2099	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048988_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	102672
1	1786	FOXA1	0.229595462043653	0.978792672515968	152	1252	1538	277	1538	1020	54	6229	2166	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	TNF	GEO	GSE59530_foxa1_mcf7-tnf_MACS_FOXA1_MA0148.4.damo.pwm.bed	33103
1	1801	FOXA1	0.229298949516807	0.981641561849733	305	1253	1529	90	1529	957	108	6076	2112	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	DEX	GEO	GSE72249_foxa1_mcf7-dex_MACS_FOXA1_MA0148.4.damo.pwm.bed	49909
1	1306	ESR1	0.229256457556479	0.982195618659979	48	1254	1526	982	1526	1250	17	6333	2203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040955_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11485
1	2650	KLF5	0.229256457556479	0.982195618659979	48	1254	1526	982	1526	1250	17	6333	2203	KLF5 KATOIII (signet ring cell gastric adenocarcinoma) KLF5	KATOIII (signet ring cell gastric adenocarcinoma)	NULL	KLF5		GEO	GSE51705_klf5_katoiii_MACS_KLF5_MA0599.1.damo.pwm.bed	23900
1	236	ASCL1	0.226626900552526	1.00023589678748	23	1256	1476	1739	1739	1490	8	6358	2212	ASCL1 NCI-H2107 (small cell lung carcinoma) ASCL1	NCI-H2107 (small cell lung carcinoma)	NULL	ASCL1		GEO	GSE69394_ascl1_h2107_MACS_ASCL1_MA1100.2.damo.pwm.bed	22389
1	912	CTCF	0.226626900552526	1.00023589678748	23	1256	1476	1739	1739	1490	8	6358	2212	CTCF GM10847 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM10847 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054511_GM10847--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38343
1	1170	ESR1	0.226626900552526	1.00023589678748	23	1256	1476	1739	1739	1490	8	6358	2212	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	E2_TAM	Array Express	ERP000380_esr1_zr751-e2-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	6017
1	1514	FOS	0.226626900552526	1.00023589678748	23	1256	1476	1739	1739	1490	8	6358	2212	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS		ENCODE	ENCSR000DKB_K562_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	17072
1	3190	ONECUT1	0.226626900552526	1.00023589678748	23	1256	1476	1739	1739	1490	8	6358	2212	ONECUT1 H9 ONECUT1	H9	NULL	ONECUT1	NA	Array Express	ERP004206_onecut1_esc-h9_MACS_ONECUT1_MA0679.2.damo.pwm.bed	44659
1	2066	GRHL2	0.225140816139278	0.977493161062776	194	1261	1541	198	1541	1000	69	6187	2151	GRHL2 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) GRHL2	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048443_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	40526
1	837	CTCF	0.224529455733171	0.978339771591513	45	1262	1539	1054	1539	1280	16	6336	2204	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 180min + Flavopiridol 60min	GTRD	EXP047804_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49240
1	3368	RELA	0.224529455733171	0.978339771591513	45	1262	1539	1054	1539	1280	16	6336	2204	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: M tri-DAP	GTRD	EXP049367_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	14111
1	1806	FOXA1	0.223322697630527	0.976510431011278	191	1264	1544	200	1544	1000	68	6190	2152	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1		GEO	GSE72249_foxa1_t47d_MACS_FOXA1_MA0148.4.damo.pwm.bed	24079
1	133	AR	0.223234016689988	0.973857062742357	70	1265	1557	666	1557	1160	25	6311	2195	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_1C30	GEO	GSE32892_AR_vcap-r1881-1c30_MACS_AR_MA0007.3.damo.pwm.bed	20833
1	2478	JUNB	0.223234016689988	0.973857062742357	70	1265	1557	666	1557	1160	25	6311	2195	JUNB GM12878 (female B-cells lymphoblastoid cell line) JUNB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	JUNB		ENCODE	ENCSR897MMC_GM12878_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	34237
1	3568	SMAD3	0.223234016689988	0.973857062742357	70	1265	1557	666	1557	1160	25	6311	2195	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	CellType: immortalized human mammary epithelial cells Treatment:TGF--beta	GTRD	EXP047899_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	14968
1	421	CREB1	0.222162897560058	0.973914924922898	56	1268	1556	859	1556	1230	20	6325	2200	CREB1 MCF7 (Invasive ductal breast carcinoma) CREB1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CREB1		GTRD	EXP039430_MCF7--Invasive-ductal-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	31589
1	937	CTCF	0.221225726433809	1.04383234124192	12	1269	1292	2359	2359	1640	4	6369	2216	CTCF BL41(Burkitt lymphoma) CTCF	BL41(Burkitt lymphoma)	NULL	CTCF		GEO	GSE31485_ctcf_bl41_MACS_CTCF_MA0139.1.damo.pwm.bed	25986
1	989	CTCFL	0.221225726433809	1.04383234124192	12	1269	1292	2359	2359	1640	4	6369	2216	CTCFL K562 (myelogenous leukemia) CTCFL	K562 (myelogenous leukemia)	NULL	CTCFL	NA	ENCODE	ENCSR000BNK_K562_CTCFL_MACS_CTCFL_MA1102.2.damo.pwm.bed	21216
1	1468	ETS1	0.221225726433809	1.04383234124192	12	1269	1292	2359	2359	1640	4	6369	2216	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048200_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	30436
1	1665	FOXA1	0.221225726433809	1.04383234124192	12	1269	1292	2359	2359	1640	4	6369	2216	FOXA1 HUES64 (embryonic stem cells) FOXA1	HUES64 (embryonic stem cells)	NULL	FOXA1		GTRD	EXP036703_HUES64--embryonic-stem-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	9252
1	2984	NEUROG2	0.221225726433809	1.04383234124192	12	1269	1292	2359	2359	1640	4	6369	2216	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037155_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	28932
1	3195	OTX2	0.221225726433809	1.04383234124192	12	1269	1292	2359	2359	1640	4	6369	2216	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036726_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	34253
1	3509	RXRA	0.221225726433809	1.04383234124192	12	1269	1292	2359	2359	1640	4	6369	2216	RXRA HepG2 (hepatoblastoma) RXRA	HepG2 (hepatoblastoma)	BTO:0000599	RXRA		ENCODE	ENCSR000BHU_HepG2_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	19422
1	1703	FOXA1	0.220809682029651	0.976591403918259	236	1276	1542	148	1542	989	84	6145	2136	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048439_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	46104
1	3193	OSR2	0.220120439490216	0.980373828757921	31	1277	1531	1439	1531	1420	11	6350	2209	OSR2 HEK293 (embryonic kidney) OSR2	HEK293 (embryonic kidney)	NULL	OSR2	NA	GTRD	EXP035913_HEK293--embryonic-kidney-_OSR2_MACS_OSR2_MA1646.1.damo.pwm.bed	24856
1	3859	TFAP2A	0.220120439490216	0.980373828757921	31	1277	1531	1439	1531	1420	11	6350	2209	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040709_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	31419
1	3860	TFAP2A	0.220120439490216	0.980373828757921	31	1277	1531	1439	1531	1420	11	6350	2209	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040709_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	32120
1	687	CTCF	0.219493029871331	0.973972531522787	42	1280	1554	1124	1554	1320	15	6339	2205	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039454_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39064
1	1350	ESR1	0.219493029871331	0.973972531522787	42	1280	1554	1124	1554	1320	15	6339	2205	ESR1 MDA-MB-231 (breast adenocarcinoma) ESR1	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	ESR1	Treatment: E2, 100 nM, 45 min Genotype: ER-alfa wildtype	GTRD	EXP049531_MDA-MB-231--breast-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	38641
1	436	CTCF	0.218045867651433	0.994004267331555	20	1282	1491	1901	1901	1560	7	6361	2213	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ALA_endothelial_cell_of_umbilical_vein_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38209
1	445	CTCF	0.218045867651433	0.994004267331555	20	1282	1491	1901	1901	1560	7	6361	2213	CTCF astrocytes CTCF	astrocytes	NULL	CTCF		ENCODE	ENCSR000AOO_astrocyte_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36329
1	1437	ESR2	0.218045867651433	0.994004267331555	20	1282	1491	1901	1901	1560	7	6361	2213	ESR2 U2OS (osteosarcoma) ESR2	U2OS (osteosarcoma)	BTO:0001938	ESR2	NULL	GTRD	EXP000204_U2OS--osteosarcoma-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	11673
1	2272	JUN	0.218045867651433	0.994004267331555	20	1282	1491	1901	1901	1560	7	6361	2213	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	17663
1	2443	JUN	0.218045867651433	0.994004267331555	20	1282	1491	1901	1901	1560	7	6361	2213	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP058063_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	13158
1	3588	SOX13	0.218045867651433	0.994004267331555	20	1282	1491	1901	1901	1560	7	6361	2213	SOX13 HepG2 (hepatoblastoma) SOX13	HepG2 (hepatoblastoma)	BTO:0000599	SOX13	NA	ENCODE	ENCSR445ACU_HepG2_SOX13_MACS_SOX13_MA1120.1.damo.pwm.bed	11547
1	3621	SOX4	0.218045867651433	0.994004267331555	20	1282	1491	1901	1901	1560	7	6361	2213	SOX4 HMLE-Twist-ER (breast cancer) SOX4	HMLE-Twist-ER (breast cancer)	NULL	SOX4	Treatment:doxycicline and TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047893_HMLE-Twist-ER--breast-cancer-_SOX4_MACS_SOX4_MA0867.2.damo.pwm.bed	6514
1	3890	TFAP2C	0.216961059027235	0.968792407358848	78	1289	1568	604	1568	1150	28	6303	2192	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p33; Treatment: 5 days in 5iLAF;	GTRD	EXP047537_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	73524
1	3575	SMAD3	0.215453195217524	0.97326400129354	210	1290	1561	172	1561	1010	75	6171	2145	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047903_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	34315
1	1646	FOXA1	0.215297791322645	0.976544486148796	326	1291	1543	79	1543	971	116	6055	2104	FOXA1 FOXA1	NA	NA	FOXA1	NA	Array Express	ERP003828_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	66695
1	2413	JUN	0.21441520085359	0.968598121563729	117	1292	1569	378	1569	1080	42	6264	2178	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	28879
1	1360	ESR1	0.214335737841173	0.967162756018813	89	1293	1574	515	1574	1130	32	6292	2188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: Vehicle for4 hrs Genotype: ER+/PR+	GTRD	EXP049945_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23242
1	2684	MAFK	0.214335737841173	0.967162756018813	89	1293	1574	515	1574	1130	32	6292	2188	MAFK A549 (lung carcinoma) MAFK	A549 (lung carcinoma)	BTO:0000018	MAFK	NA	ENCODE	ENCSR541WQI_A549_MAFK_MACS_MAFK_MA0496.3.damo.pwm.bed	78790
1	974	CTCF	0.214100488429304	0.968984303665022	39	1295	1564	1206	1564	1360	14	6342	2206	CTCF hESC-1 (Embryonic stem cells) CTCF	hESC-1 (Embryonic stem cells)	NULL	CTCF	NAIVE	GEO	GSE69646_ctcf_esc-naive_MACS_CTCF_MA0139.1.damo.pwm.bed	48958
1	1138	ERG	0.214100488429304	0.968984303665022	39	1295	1564	1206	1564	1360	14	6342	2206	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG		GTRD	EXP053004_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	70420
1	2804	MYC	0.214100488429304	0.968984303665022	39	1295	1564	1206	1564	1360	14	6342	2206	MYC normal epidermal keratinocytes MYC	normal epidermal keratinocytes	NULL	MYC	NULL	GTRD	EXP000989_normal-epidermal-keratinocytes_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13748
1	1918	GATA1	0.213264431230658	0.974029884231768	28	1298	1552	1531	1552	1460	10	6353	2210	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		GTRD	EXP040807_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	55554
1	2855	MYC	0.213264431230658	0.974029884231768	28	1298	1552	1531	1552	1460	10	6353	2210	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881	GTRD	EXP037068_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	20682
1	946	CTCF	0.211847843180333	0.96431452889948	61	1300	1587	785	1587	1220	22	6320	2198	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm12878_MACS_CTCF_MA0139.1.damo.pwm.bed	64122
1	1741	FOXA1	0.21184212991814	0.966761781387105	114	1301	1576	392	1576	1090	41	6267	2179	FOXA1 primary prostate cancer FOXA1	primary prostate cancer	NULL	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053235_primary-prostate-cancer_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	18091
1	193	AR	0.211748190925561	0.965878028088881	100	1302	1583	446	1583	1110	36	6281	2184	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	R1881_SICTR	GEO	GSE70161_AR_mdamb453-r1881-sictr_MACS_AR_MA0007.3.damo.pwm.bed	21354
1	1710	FOXA1	0.211097591664721	0.970153723894479	187	1303	1563	209	1563	1020	67	6194	2153	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048449_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	41804
1	1262	ESR1	0.210657183354742	0.968401401366027	156	1304	1570	264	1570	1050	56	6225	2164	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline	GTRD	EXP038375_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	58051
1	80	AR	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048992_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	6850
1	274	BACH2	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	BACH2 B-cells BACH2	B-cells	NULL	BACH2	siBACH2	GTRD	EXP040450_B-cells_BACH2_MACS_BACH2_MA1470.1.damo.pwm.bed	2802
1	276	BACH2	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	BACH2 DOHH2 (diffuse large B-cell lymphoma) BACH2	DOHH2 (diffuse large B-cell lymphoma)	NULL	BACH2		GEO	GSE69558_bach2_dohh2_MACS_BACH2_MA1101.2.damo.pwm.bed	4297
1	990	CTCFL	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	CTCFL Delta47 (plasma cell myeloma) CTCFL	Delta47 (plasma cell myeloma)	NULL	CTCFL	NA	GEO	GSE70764_ctcfl_delta47_MACS_CTCFL_MA1102.2.damo.pwm.bed	13249
1	1072	EHF	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	EHF epidermal keratinocytes EHF	epidermal keratinocytes	NULL	EHF	day3 of differentiation	GTRD	EXP037599_epidermal-keratinocytes_EHF_MACS_EHF_MA0598.3.damo.pwm.bed	1139
1	1185	ESR1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	ETOH (ethanol)	GTRD	EXP000883_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	346
1	1390	ESR1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	SIGATA_E2	GEO	GSE40129_esr1_zr751-sigata-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	1095
1	1396	ESR1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	ETOH	GEO	GSE51022_esr1_mdamb134vi-etoh_MACS_ESR1_MA0112.3.damo.pwm.bed	367
1	1447	ESRRA	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	ESRRA BT-474 (breast invasive ductal carcinoma) ESRRA	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	ESRRA		GEO	GSE75876_esrra_bt474_MACS_ESRRA_MA0592.3.damo.pwm.bed	2379
1	1470	ETS1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF_1H	GEO	GSE41166_ets1_huvec-vegf-1h_MACS_ETS1_MA0098.3.damo.pwm.bed	15427
1	1546	FOS	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	1488
1	1547	FOS	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	1379
1	1548	FOS	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	1395
1	1549	FOS	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	FOS THP-1 (acute monocytic leukemia) FOS	THP-1 (acute monocytic leukemia)	BTO:0001370	FOS	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047823_THP-1--acute-monocytic-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	1415
1	1892	GATA1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		ENCODE	ENCSR000EFT_K562_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	14403
1	1896	GATA1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	GATA1 megakaryocytes GATA1	megakaryocytes	NULL	GATA1	NULL	GTRD	EXP000351_megakaryocytes_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	8784
1	1897	GATA1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	GATA1 megakaryocytes GATA1	megakaryocytes	NULL	GATA1	NULL	GTRD	EXP000351_megakaryocytes_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	9298
1	1937	GATA2	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2	bmp	GTRD	EXP000942_K562--myelogenous-leukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	10516
1	1990	GATA3	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GEO	GSE29180_gata3_jurkat_MACS_GATA3_MA0037.3.damo.pwm.bed	4035
1	2006	GATA3	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	GATA3 CD4 GATA3	CD4	NA	GATA3	TH2	GEO	GSE72266_gata3_cd4-th2_MACS_GATA3_MA0037.3.damo.pwm.bed	4444
1	2111	HMBOX1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	HMBOX1 HeLa (cervical adenocarcinoma) HMBOX1	HeLa (cervical adenocarcinoma)	BTO:0000567	HMBOX1	NA	GEO	GSE46237_hmbox1_hela_MACS_HMBOX1_MA0895.1.damo.pwm.bed	1801
1	2147	HNF4A	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	HNF4A HCT-116 (colon carcinoma) HNF4A	HCT-116 (colon carcinoma)	BTO:0001109	HNF4A	TCF4	GEO	GSE62890_hnf4a_hct166-tcf4_MACS_HNF4A_MA0114.4.damo.pwm.bed	1987
1	2186	HSF1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	HSF1 MCF10A (breast epithelial cells) HSF1	MCF10A (breast epithelial cells)	BTO:0001939	HSF1	HEAT	GEO	GSE38901_hsf1_mcf10a-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	3514
1	2195	HSF1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	HSF1 U2OS (osteosarcoma) HSF1	U2OS (osteosarcoma)	BTO:0001938	HSF1	HEAT	GEO	GSE60984_hsf1_u2os-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	7517
1	2200	IRF1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	IRF1 HAEC (human aortic endothelial cells) IRF1	HAEC (human aortic endothelial cells)	NULL	IRF1	IL1b, 4h	GTRD	EXP038038_HAEC--human-aortic-endothelial-cells-_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	5797
1	2293	JUN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	8998
1	2294	JUN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	8935
1	2296	JUN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	8721
1	2298	JUN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	oxpapc, 4h	GTRD	EXP038044_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	7998
1	2380	JUN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	6534
1	2461	JUN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	1963
1	2468	JUN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	1821
1	2902	MYC	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057893_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	3272
1	2938	MYCN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	MYCN Tet21N (neuroblastoma) MYCN	Tet21N (neuroblastoma)	BTO:0004654	MYCN	None	GTRD	EXP036325_Tet21N--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	4261
1	2944	MYCN	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	MYCN IMR-5 (Neuroblastoma) MYCN	IMR-5 (Neuroblastoma)	NULL	MYCN	Treatment: 1uM CD532 for 4 hr	GTRD	EXP048885_IMR-5--Neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	11652
1	3006	NFE2L2	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	NFE2L2 A375 (malignant melanoma) NFE2L2	A375 (malignant melanoma)	BTO:0002806	NFE2L2	DMSO	GEO	GSE57431_NFE2L2_a375-dmso_MACS_NFE2L2_MA0150.2.damo.pwm.bed	6056
1	3036	NKX2-5	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	NKX2-5 embryonic stem cells NKX2-5	embryonic stem cells	NULL	NKX2-5	Treatment: no	GTRD	EXP049255_embryonic-stem-cells_NKX2-5_MACS_NKX2-5_MA0503.1.damo.pwm.bed	8329
1	3358	RELA	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	RELA HAEC (human aortic endothelial cells) RELA	HAEC (human aortic endothelial cells)	NULL	RELA	control, 4h	GTRD	EXP038048_HAEC--human-aortic-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	10520
1	3394	REST	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	REST HepG2 (hepatoblastoma) REST	HepG2 (hepatoblastoma)	BTO:0000599	REST		ENCODE	ENCSR000BJL_HepG2_REST_MACS_REST_MA0138.2.damo.pwm.bed	4247
1	3401	REST	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	REST PANC1 (pancreatic ductal adenocarcinoma) REST	PANC1 (pancreatic ductal adenocarcinoma)	NULL	REST		ENCODE	ENCSR000BPK_Panc1_REST_MACS_REST_MA0138.2.damo.pwm.bed	13496
1	3413	REST	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		GTRD	EXP036860_WA01--H1--human-embryonic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	4810
1	3433	REST	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	REST CD4 REST	CD4	NA	REST		GEO	GSE49570_rest_cd4t_MACS_REST_MA0138.2.damo.pwm.bed	7540
1	3499	RUNX1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	RUNX1 U937 (adult acute monocytic leukemia) RUNX1	U937 (adult acute monocytic leukemia)	BTO:0001412	RUNX1		GEO	GSE65427_runx1_u937_MACS_RUNX1_MA0002.2.damo.pwm.bed	5566
1	3502	RUNX1	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	RUNX1 CD34+ cells RUNX1	CD34+ cells	NULL	RUNX1	FETAL	GEO	GSE70660_runx1_cd34-fetal_MACS_RUNX1_MA0002.2.damo.pwm.bed	5025
1	3564	SMAD3	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047889_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA0795.1.damo.pwm.bed	2749
1	3894	TFAP2C	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047539_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	8863
1	3994	TP53	0.210626288741633	1.39180099389395	4	1305	660	3105	3105	1690	1	6377	2219	TP53 UACC62 TP53	UACC62	BTO:0004152	TP53	Treatment: 4GY for 2hrs;	GTRD	EXP051023_UACC62_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	333
1	1319	ESR1	0.210013545316765	0.963021985066671	72	1352	1596	651	1596	1200	26	6309	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle(DMSO 2 hr); Passage: p20;	GTRD	EXP047702_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16489
1	483	CTCF	0.209213848215996	0.964834666072031	111	1353	1586	401	1586	1110	40	6270	2180	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		ENCODE	ENCSR000DMO_MCF-7_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	93848
1	238	ASCL1	0.208294131524676	0.963231771200263	36	1354	1590	1288	1590	1410	13	6345	2207	ASCL1 NCI-H889 (small cell lung carcinoma) ASCL1	NCI-H889 (small cell lung carcinoma)	BTO:0005667	ASCL1		GEO	GSE69394_ascl1_h889_MACS_ASCL1_MA1100.2.damo.pwm.bed	32075
1	499	CTCF	0.208294131524676	0.963231771200263	36	1354	1590	1288	1590	1410	13	6345	2207	CTCF BE2C CTCF	BE2C	NULL	CTCF		ENCODE	ENCSR000DQD_BE2C_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48616
1	1180	ESR1	0.208294131524676	0.963231771200263	36	1354	1590	1288	1590	1410	13	6345	2207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	hormone starved for 3 days, treated with 10 nM β-estradiol for 45 minutes	GTRD	EXP000178_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10444
1	1492	FLI1	0.208294131524676	0.963231771200263	36	1354	1590	1288	1590	1410	13	6345	2207	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047960_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	48940
1	2119	HNF1B	0.208294131524676	0.963231771200263	36	1354	1590	1288	1590	1410	13	6345	2207	HNF1B PDAC HNF1B	PDAC	NA	HNF1B	NA	GEO	GSE64557_hnf1b_pdac_MACS_HNF1B_MA0153.2.damo.pwm.bed	24747
1	3561	SIX2	0.208294131524676	0.963231771200263	36	1354	1590	1288	1590	1410	13	6345	2207	SIX2 kidney SIX2	kidney	BTO:0000671	SIX2	fetal_17w	GEO	GSE75948_six2_fetal-kidney-17w_MACS_SIX2_MA1119.1.damo.pwm.bed	43926
1	504	CTCF	0.208008262998464	0.985702107456476	17	1360	1515	2066	2066	1650	6	6364	2214	CTCF GM12864 (male B-cells) CTCF	GM12864 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRB_GM12864_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36934
1	527	CTCF	0.208008262998464	0.985702107456476	17	1360	1515	2066	2066	1650	6	6364	2214	CTCF HL-60 (acute myeloid leukemia) CTCF	HL-60 (acute myeloid leukemia)	BTO:0000738	CTCF		ENCODE	ENCSR000DUP_HL-60_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31926
1	871	CTCF	0.208008262998464	0.985702107456476	17	1360	1515	2066	2066	1650	6	6364	2214	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF	Genotype: CTCF knockout	GTRD	EXP049757_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35186
1	1894	GATA1	0.208008262998464	0.985702107456476	17	1360	1515	2066	2066	1650	6	6364	2214	GATA1 erythroblasts GATA1	erythroblasts	NULL	GATA1		ENCODE	ENCSR000EXP_erythroblast_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	28149
1	1275	ESR1	0.207714964129797	0.960531715131864	58	1364	1600	824	1600	1260	21	6323	2199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038388_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	24996
1	1324	ESR1	0.207714964129797	0.960531715131864	58	1364	1600	824	1600	1260	21	6323	2199	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p21;	GTRD	EXP047707_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13123
1	1649	FOXA1	0.207714964129797	0.960531715131864	58	1364	1600	824	1600	1260	21	6323	2199	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	NULL	GTRD	EXP000618_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	8401
1	2693	MAX	0.207714964129797	0.960531715131864	58	1364	1600	824	1600	1260	21	6323	2199	MAX MCF7 (Invasive ductal breast carcinoma) MAX	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MAX		ENCODE	ENCSR000BUL_MCF-7_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	27761
1	3369	RELA	0.206347628837085	0.959793016616655	69	1368	1605	687	1605	1220	25	6312	2195	RELA A549 (lung carcinoma) RELA	A549 (lung carcinoma)	BTO:0000018	RELA	Treatment: TNFa induction (12 hours);	GTRD	EXP054133_A549--lung-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	38662
1	71	AR	0.205633006564007	0.96628063095373	25	1369	1578	1657	1657	1530	9	6356	2211	AR HEE (human epididymis epithelial cells) AR	HEE (human epididymis epithelial cells)	NULL	AR	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048158_HEE--human-epididymis-epithelial-cells-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13487
1	538	CTCF	0.205633006564007	0.96628063095373	25	1369	1578	1657	1657	1530	9	6356	2211	CTCF NB4 (acute promyelocytic leukemia ) CTCF	NB4 (acute promyelocytic leukemia )	NULL	CTCF		ENCODE	ENCSR000DWN_NB4_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42878
1	826	CTCF	0.205633006564007	0.96628063095373	25	1369	1578	1657	1657	1530	9	6356	2211	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA), siWAPL(siRNA)	GTRD	EXP047782_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37402
1	1189	ESR1	0.205633006564007	0.96628063095373	25	1369	1578	1657	1657	1530	9	6356	2211	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	E2	GTRD	EXP001013_H3396--breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5305
1	2007	GATA3	0.205633006564007	0.96628063095373	25	1369	1578	1657	1657	1530	9	6356	2211	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GEO	GSE76181_gata3_jurkat_MACS_GATA3_MA0037.3.damo.pwm.bed	39697
1	1708	FOXA1	0.205396017582069	0.966691647105054	178	1374	1577	224	1577	1060	64	6203	2156	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048447_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	39083
1	140	AR	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	AR AR	NA	NA	AR	NA	GEO	GSE40050_AR_lncap-dht_MACS_AR_MA0007.3.damo.pwm.bed	1373
1	655	CTCF	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	control; 100 nM 17-beta-estradiol for 0h	GTRD	EXP037646_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	13190
1	861	CTCF	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: mock infected, time post infection 24 hr	GTRD	EXP048655_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22628
1	936	CTCF	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	CTCF BJAB (Burkitt lymphoma) CTCF	BJAB (Burkitt lymphoma)	BTO:0001931	CTCF		GEO	GSE31485_ctcf_bjab_MACS_CTCF_MA0139.1.damo.pwm.bed	23098
1	1477	ETV1	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	ETV1 GIST ETV1	GIST	NA	ETV1		GEO	GSE22441_etv1_gist_MACS_ETV1_MA0761.2.damo.pwm.bed	18622
1	1690	FOXA1	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	FOXA1 HepG2 (hepatoblastoma) FOXA1	HepG2 (hepatoblastoma)	BTO:0000599	FOXA1		GTRD	EXP039801_HepG2--hepatoblastoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4595
1	2807	MYC	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	MYC HeLa S3 (cervical adenocarcinoma) MYC	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MYC	NULL	GTRD	EXP000991_HeLa-S3--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	6830
1	2978	NEUROG2	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037152_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	26855
1	3069	NR2F1	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	NR2F1 GM12878 (female B-cells lymphoblastoid cell line) NR2F1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2F1	NA	GTRD	EXP040024_GM12878--female-B-cells-_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	16135
1	3406	REST	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	REST Ishikawa (endometrial adenocarcinoma) REST	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	REST		ENCODE	ENCSR000BUU_Ishikawa_REST_MACS_REST_MA0138.2.damo.pwm.bed	10003
1	3531	RXRA	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	10380
1	3756	STAT5B	0.205113744871594	1.04381161837486	9	1375	1299	2585	2585	1750	3	6372	2217	STAT5B T-cells STAT5B	T-cells	NULL	STAT5B	IL-2	GTRD	EXP000399_T-cells_STAT5B_MACS_STAT5B_MA1625.1.damo.pwm.bed	17412
1	470	CTCF	0.204689393960831	0.959236867753872	80	1387	1607	585	1607	1190	29	6301	2191	CTCF GM19239 (male B-cells lymphoblastoid cell line) CTCF	GM19239 (male B-cells lymphoblastoid cell line)	NULL	CTCF		ENCODE	ENCSR000DLE_GM19239_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	100872
1	3889	TFAP2C	0.204689393960831	0.959236867753872	80	1387	1607	585	1607	1190	29	6301	2191	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p33; Treatment: 5 days in 5iLAF;	GTRD	EXP047537_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	73500
1	3919	TFAP2C	0.204198144793897	0.964127686708479	147	1389	1588	290	1588	1090	53	6234	2167	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	ETOH	GEO	GSE23852_tfap2c_mcf7-etoh_MACS_TFAP2C_MA0814.2.damo.pwm.bed	45573
1	1273	ESR1	0.203779953102598	0.960679436688382	105	1390	1598	422	1598	1140	38	6276	2182	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	none	GTRD	EXP038386_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22462
1	492	CTCF	0.203384206511478	0.956372662763574	55	1391	1632	875	1632	1300	20	6326	2200	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		ENCODE	ENCSR000DPF_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54615
1	1767	FOXA1	0.202847690360255	0.973853856359926	415	1392	1560	39	1560	997	148	5966	2072	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	SICTR	GEO	GSE40129_foxa1_mcf7-sictr_MACS_FOXA1_MA0148.4.damo.pwm.bed	77862
1	2570	JUNB	0.20248312062974	0.968000472409168	234	1393	1572	150	1572	1040	84	6147	2136	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	46448
1	96	AR	0.202001591832268	0.956523844816548	33	1394	1627	1379	1627	1470	12	6348	2208	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: 10 nM DHT+10 uM MDV3100 TF: full-length AR (AR-FL)	GTRD	EXP049393_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	8134
1	530	CTCF	0.202001591832268	0.956523844816548	33	1394	1627	1379	1627	1470	12	6348	2208	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUX_fibroblast_of_pulmonary_artery_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46643
1	679	CTCF	0.202001591832268	0.956523844816548	33	1394	1627	1379	1627	1470	12	6348	2208	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039388_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37673
1	928	CTCF	0.202001591832268	0.956523844816548	33	1394	1627	1379	1627	1470	12	6348	2208	CTCF MDA-MB-157 (triple negative breast carcinoma) CTCF	MDA-MB-157 (triple negative breast carcinoma)	NULL	CTCF	Treatment: untreated;	GTRD	EXP058203_MDA-MB-157--triple-negative-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41339
1	1689	FOXA1	0.202001591832268	0.956523844816548	33	1394	1627	1379	1627	1470	12	6348	2208	FOXA1 liver FOXA1	liver	BTO:0000759	FOXA1		GTRD	EXP039777_liver_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	13900
1	3923	TFAP2C	0.201647948304696	0.968217934213356	248	1399	1571	128	1571	1030	89	6133	2131	TFAP2C BT-474 (breast invasive ductal carcinoma) TFAP2C	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	TFAP2C		GEO	GSE36351_tfap2c_bt474_MACS_TFAP2C_MA0815.1.damo.pwm.bed	92008
1	1349	ESR1	0.201267423712859	0.95622042552055	77	1400	1633	609	1633	1210	28	6304	2192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: E2 (estrogen) for 45 min  Genotype: wildtype TET2 Passage: 6-10	GTRD	EXP048693_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29313
1	832	CTCF	0.198833929292992	0.951777960901113	52	1401	1644	921	1644	1320	19	6329	2201	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 30min	GTRD	EXP047799_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54662
1	560	CTCF	0.198574617544573	0.952498087334803	63	1402	1642	753	1642	1270	23	6318	2197	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	E2	Array Express	ERP000380_ctcf_mcf7-e2_MACS_CTCF_MA0139.1.damo.pwm.bed	48262
1	1747	FOXA1	0.198372537862987	0.972322176991562	420	1403	1562	37	1562	1000	150	5961	2070	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058102_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	100880
1	683	CTCF	0.198037075758032	0.950632978920018	41	1404	1646	1155	1646	1400	15	6340	2205	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039407_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	43168
1	4036	TP63	0.197729206731343	0.952982064818248	74	1405	1638	640	1638	1230	27	6307	2193	TP63 surface ectoderm cells TP63	surface ectoderm cells	NULL	TP63	Treatment: Doxycycline for 2 days  Geenotype: TetO:Tp63+/-	GTRD	EXP053349_surface-ectoderm-cells_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	8660
1	3852	TFAP2A	0.19754618926874	0.960553300011352	152	1406	1599	277	1599	1090	55	6229	2165	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GTRD	EXP032577_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	39514
1	2024	GATA4	0.197433826397017	0.959348675661476	138	1407	1606	316	1606	1110	50	6243	2170	GATA4 BJ (fibroblasts) GATA4	BJ (fibroblasts)	NULL	GATA4	Genotype: Clonal FOXA2 doxycycline inducible cells, FOXA2 and GATA4 coexpressing	GTRD	EXP049377_BJ--fibroblasts-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	53558
1	1750	FOXA1	0.197190207443016	0.968933649907495	318	1408	1567	84	1567	1020	114	6063	2106	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058105_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	62226
1	264	ATF7	0.197024518402994	0.956599043569506	22	1409	1620	1797	1797	1610	8	6359	2212	ATF7 MCF7 (Invasive ductal breast carcinoma) ATF7	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ATF7	NA	GTRD	EXP039990_MCF7--Invasive-ductal-breast-carcinoma-_ATF7_MACS_ATF7_MA0834.1.damo.pwm.bed	16845
1	310	CEBPA	0.197024518402994	0.956599043569506	22	1409	1620	1797	1797	1610	8	6359	2212	CEBPA mesenchymal stem cells-derived adipocytes CEBPA	mesenchymal stem cells-derived adipocytes	NULL	CEBPA	NULL	GTRD	EXP000565_mesenchymal-stem-cells-derived-adipocytes_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	24225
1	327	CEBPA	0.197024518402994	0.956599043569506	22	1409	1620	1797	1797	1610	8	6359	2212	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047677_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	31193
1	514	CTCF	0.197024518402994	0.956599043569506	22	1409	1620	1797	1797	1610	8	6359	2212	CTCF GM12875 (female B-cells) CTCF	GM12875 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRU_GM12875_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40047
1	934	CTCF	0.197024518402994	0.956599043569506	22	1409	1620	1797	1797	1610	8	6359	2212	CTCF hASC (preadipocytes) CTCF	hASC (preadipocytes)	NULL	CTCF		GEO	GSE21366_ctcf_asc_MACS_CTCF_MA0139.1.damo.pwm.bed	34585
1	3791	TCF3	0.197024518402994	0.956599043569506	22	1409	1620	1797	1797	1610	8	6359	2212	TCF3 Kasumi-1 (acute myeloblastic leukemia) TCF3	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF3		GEO	GSE43834_TCF3_kasumi1_MACS_TCF3_MA0522.3.damo.pwm.bed	39831
1	3885	TFAP2C	0.197024518402994	0.956599043569506	22	1409	1620	1797	1797	1610	8	6359	2212	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047536_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	24035
1	62	AR	0.195923623576303	0.974086984724721	14	1416	1545	2252	2252	1740	5	6367	2215	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	dihydrotestosterone  (DHT)	GTRD	EXP038190_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3202
1	495	CTCF	0.195923623576303	0.974086984724721	14	1416	1545	2252	2252	1740	5	6367	2215	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPP_fibroblast_of_pedal_digit_skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30004
1	680	CTCF	0.195923623576303	0.974086984724721	14	1416	1545	2252	2252	1740	5	6367	2215	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP039398_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35331
1	1762	FOXA1	0.195923623576303	0.974086984724721	14	1416	1545	2252	2252	1740	5	6367	2215	FOXA1 HuH7 (hepatocellular carcinoma) FOXA1	HuH7 (hepatocellular carcinoma)	BTO:0001950	FOXA1	ASYNC	GEO	GSE39241_foxa1_huh7-async_MACS_FOXA1_MA0148.4.damo.pwm.bed	4491
1	3163	NR4A1	0.195923623576303	0.974086984724721	14	1416	1545	2252	2252	1740	5	6367	2215	NR4A1 Kasumi-1 (acute myeloblastic leukemia) NR4A1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	NR4A1	NA	GEO	GSE79491_nr4a1_kasumi1_MACS_NR4A1_MA1112.2.damo.pwm.bed	15572
1	3328	REL	0.195923623576303	0.974086984724721	14	1416	1545	2252	2252	1740	5	6367	2215	REL GM12878 (female B-cells lymphoblastoid cell line) REL	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REL	NA	GTRD	EXP054687_GM12878--female-B-cells-lymphoblastoid-cell-line-_REL_MACS_REL_MA0101.1.damo.pwm.bed	21898
1	3403	REST	0.195923623576303	0.974086984724721	14	1416	1545	2252	2252	1740	5	6367	2215	REST MCF7 (Invasive ductal breast carcinoma) REST	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	REST		ENCODE	ENCSR000BSP_MCF-7_REST_MACS_REST_MA0138.2.damo.pwm.bed	8608
1	490	CTCF	0.195130549082926	0.948599948907994	30	1423	1655	1473	1655	1520	11	6351	2209	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		ENCODE	ENCSR000DND_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42176
1	730	CTCF	0.195130549082926	0.948599948907994	30	1423	1655	1473	1655	1520	11	6351	2209	CTCF PANC1 (pancreatic ductal adenocarcinoma) CTCF	PANC1 (pancreatic ductal adenocarcinoma)	NULL	CTCF		GTRD	EXP039705_PANC1--pancreatic-ductal-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35937
1	916	CTCF	0.195130549082926	0.948599948907994	30	1423	1655	1473	1655	1520	11	6351	2209	CTCF GM19099 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM19099 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054529_GM19099--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41850
1	3280	POU5F1	0.195130549082926	0.948599948907994	30	1423	1655	1473	1655	1520	11	6351	2209	POU5F1 hESC-1 (Embryonic stem cells) POU5F1	hESC-1 (Embryonic stem cells)	NULL	POU5F1	NAIVE	GEO	GSE69646_pou5f1_esc-naive_MACS_POU5F1_MA1115.1.damo.pwm.bed	38282
1	1297	ESR1	0.194065621273998	0.949496176852024	71	1427	1652	659	1652	1250	26	6310	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	5 nM E2 for 30 min	GTRD	EXP040892_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20218
1	1229	ESR1	0.193229886726853	0.950311687355049	82	1428	1647	570	1647	1220	30	6299	2190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	IL1b for 45m	GTRD	EXP036982_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23633
1	3845	TFAP2A	0.193229886726853	0.950311687355049	82	1428	1647	570	1647	1220	30	6299	2190	TFAP2A HeLa S3 (cervical adenocarcinoma) TFAP2A	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2A	None	GTRD	EXP010503_HeLa-S3--cervical-adenocarcinoma-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	20807
1	198	AR	0.192233287147615	0.943989688729912	38	1430	1669	1238	1669	1450	14	6343	2206	AR AR	NA	NA	AR	NA	GEO	GSE71704_AR_c42_MACS_AR_MA0007.3.damo.pwm.bed	11087
1	3933	TFAP2C	0.192107126593161	0.950917043474779	93	1431	1645	489	1645	1190	34	6288	2186	TFAP2C A375 (malignant melanoma) TFAP2C	A375 (malignant melanoma)	BTO:0002806	TFAP2C	DMSO	GEO	GSE41234_tfap2c_a375-dmso_MACS_TFAP2C_MA0815.1.damo.pwm.bed	66171
1	1246	ESR1	0.191236200901664	0.957222164087236	157	1432	1611	262	1611	1100	57	6224	2163	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	5min E2	GTRD	EXP038336_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	48348
1	1631	FOXA1	0.189887260699736	0.967504927070883	365	1433	1573	59	1573	1020	131	6016	2089	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BKY_T47D_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	75371
1	42	AR	0.187934196652822	0.948887473030693	101	1434	1653	440	1653	1180	37	6280	2183	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR	DHT+MDV3100	GTRD	EXP034149_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	22525
1	383	CEBPB	0.187560880712517	0.939095280733438	27	1435	1682	1564	1682	1560	10	6354	2210	CEBPB monocyte-derived macrophages CEBPB	monocyte-derived macrophages	NULL	CEBPB		GTRD	EXP040652_monocyte-derived-macrophages_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	30539
1	498	CTCF	0.187560880712517	0.939095280733438	27	1435	1682	1564	1682	1560	10	6354	2210	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPY_fibroblast_of_the_aortic_adventitia_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40530
1	629	CTCF	0.187151335318782	0.944156940994764	19	1437	1666	1956	1956	1690	7	6362	2213	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036699_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36719
1	640	CTCF	0.187151335318782	0.944156940994764	19	1437	1666	1956	1956	1690	7	6362	2213	CTCF PC9 (lung adenocarcinoma) CTCF	PC9 (lung adenocarcinoma)	NULL	CTCF		GTRD	EXP036850_PC9--lung-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29589
1	1441	ESR2	0.187151335318782	0.944156940994764	19	1437	1666	1956	1956	1690	7	6362	2213	ESR2 MDA-MB-231ERb(triple negative breast cancer) ESR2	MDA-MB-231ERb(triple negative breast cancer)	NULL	ESR2	Treatment: 10 nM LY500307 for 3 hr Passage: 20-25	GTRD	EXP048150_MDA-MB-231ERb-triple-negative-breast-cancer-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	13382
1	312	CEBPA	0.186709467746419	0.94949811656035	112	1440	1651	399	1651	1160	41	6269	2179	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	bio	GTRD	EXP000946_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	63716
1	48	AR	0.186297325247267	0.943652160180216	76	1441	1671	619	1671	1240	28	6305	2192	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	siOCT1	GTRD	EXP036096_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	30214
1	3872	TFAP2C	0.186297325247267	0.943652160180216	76	1441	1671	619	1671	1240	28	6305	2192	TFAP2C HeLa S3 (cervical adenocarcinoma) TFAP2C	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2C	None	GTRD	EXP010559_HeLa-S3--cervical-adenocarcinoma-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	21537
1	1357	ESR1	0.185983835780123	0.936327458760901	35	1443	1699	1318	1699	1490	13	6346	2207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM Dexamethasone for 60 mins Genotype: ER+/PR+	GTRD	EXP049940_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8382
1	1518	FOS	0.185726418306771	0.964863018804707	339	1444	1585	74	1585	1030	122	6042	2098	FOS FOS	NA	NA	FOS	NA	NA	ENCSR000DOT_MCF_10A_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	62586
1	339	CEBPA	0.185591902119173	0.938835410611287	54	1445	1685	886	1685	1340	20	6327	2200	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 8 hrs	GTRD	EXP053363_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	41763
1	455	CTCF	0.185591902119173	0.938835410611287	54	1445	1685	886	1685	1340	20	6327	2200	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000BIE_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56292
1	831	CTCF	0.185591902119173	0.938835410611287	54	1445	1685	886	1685	1340	20	6327	2200	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Pam3csk4 treated (025m)	GTRD	EXP047798_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57379
1	833	CTCF	0.185591902119173	0.938835410611287	54	1445	1685	886	1685	1340	20	6327	2200	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 45min	GTRD	EXP047800_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55571
1	1321	ESR1	0.185591902119173	0.938835410611287	54	1445	1685	886	1685	1340	20	6327	2200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p20;	GTRD	EXP047704_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11644
1	197	AR	0.183590001103251	0.934563066491358	43	1450	1704	1101	1704	1420	16	6338	2204	AR AR	NA	NA	AR	NA	GEO	GSE71704_AR_c42-shpsa_MACS_AR_MA0007.3.damo.pwm.bed	14077
1	950	CTCF	0.183590001103251	0.934563066491358	43	1450	1704	1101	1704	1420	16	6338	2204	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18486_MACS_CTCF_MA0139.1.damo.pwm.bed	57283
1	2788	MYC	0.183590001103251	0.934563066491358	43	1450	1704	1101	1704	1420	16	6338	2204	MYC MCF7 (Invasive ductal breast carcinoma) MYC	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	MYC		ENCODE	ENCSR000DMQ_MCF-7_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	29267
1	2789	MYC	0.183590001103251	0.934563066491358	43	1450	1704	1101	1704	1420	16	6338	2204	MYC MYC	NA	NA	MYC	NA	NA	ENCSR000DOM_MCF_10A_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12059
1	3093	NR3C1	0.183590001103251	0.934563066491358	43	1450	1704	1101	1704	1420	16	6338	2204	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	100 nM DEX	GTRD	EXP030498_LNCaP--prostate-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17237
1	3203	OTX2	0.183590001103251	0.934563066491358	43	1450	1704	1101	1704	1420	16	6338	2204	OTX2 D341 Med (medulloblastoma) OTX2	D341 Med (medulloblastoma)	NULL	OTX2	CRISPR.GFP1	GTRD	EXP038202_D341-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	65967
1	165	AR	0.183547244096851	0.954124429791456	173	1456	1635	232	1635	1110	63	6208	2157	AR prostate AR	prostate	NULL	AR	cancer	GEO	GSE56288_AR_prostate-cancer_MACS_AR_MA0007.3.damo.pwm.bed	77818
1	1704	FOXA1	0.182985731168525	0.959806150816154	257	1457	1604	120	1604	1060	93	6124	2127	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min ethanol	GTRD	EXP048440_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50876
1	1652	FOXA1	0.182515913687356	0.941955898439151	84	1458	1677	557	1677	1230	31	6297	2189	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	regular medium	GTRD	EXP000721_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	15841
1	3846	TFAP2A	0.182515913687356	0.941955898439151	84	1458	1677	557	1677	1230	31	6297	2189	TFAP2A HeLa S3 (cervical adenocarcinoma) TFAP2A	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2A	None	GTRD	EXP010503_HeLa-S3--cervical-adenocarcinoma-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	21503
1	3200	OTX2	0.18221419348963	0.937230458611143	62	1460	1695	769	1695	1310	23	6319	2197	OTX2 D283 Med (medulloblastoma) OTX2	D283 Med (medulloblastoma)	NULL	OTX2		GTRD	EXP038197_D283-Med--medulloblastoma-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	98089
1	6	AR	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	Vehicle	GTRD	EXP000408_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2386
1	1863	FOXP1	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	FOXP1 HepG2 (hepatoblastoma) FOXP1	HepG2 (hepatoblastoma)	BTO:0000599	FOXP1	NA	GTRD	EXP039780_HepG2--hepatoblastoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	5018
1	2103	HIF1A	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siSMAD3; Genotype: SMAD3 knockout;	GTRD	EXP057827_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	4799
1	2115	HNF1A	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	HNF1A HEE (human epididymis epithelial cells) HNF1A	HEE (human epididymis epithelial cells)	NULL	HNF1A	Treatment: untreated	GTRD	EXP048856_HEE--human-epididymis-epithelial-cells-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	15643
1	2455	JUN	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	10762
1	2587	JUND	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	JUND WA01 (H1, human embryonic stem cells) JUND	WA01 (H1, human embryonic stem cells)	NULL	JUND		ENCODE	ENCSR000BKP_H1-hESC_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	13533
1	2899	MYC	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	MYC Tet21N (neuroblastoma) MYC	Tet21N (neuroblastoma)	BTO:0004654	MYC	Treatment: 1ug/mL doxycycline for 7 days prior to harvest Genotype: wildtype MYC Passage: 10 -15  Cell type: neuroblastoma cell line	GTRD	EXP053294_Tet21N--neuroblastoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13255
1	2900	MYC	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	MYC Tet21N (neuroblastoma) MYC	Tet21N (neuroblastoma)	BTO:0004654	MYC	Treatment: 1ug/mL doxycycline for 7 days prior to harvest Genotype: wildtype MYC Passage: 10 -15  Cell type: neuroblastoma cell line	GTRD	EXP053294_Tet21N--neuroblastoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	14186
1	2967	NEUROG2	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037146_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	14372
1	3175	NRF1	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	NRF1 HepG2 (hepatoblastoma) NRF1	HepG2 (hepatoblastoma)	BTO:0000599	NRF1		ENCODE	ENCSR853ADA_HepG2_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	13206
1	3221	PAX6	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	PAX6 EndoC-betaH2 (immortalized pancreatic beta cells) PAX6	EndoC-betaH2 (immortalized pancreatic beta cells)	NULL	PAX6	NA	GTRD	EXP037896_EndoC-betaH2--immortalized-pancreatic-beta-cells-_PAX6_MACS_PAX6_MA0069.1.damo.pwm.bed	5528
1	3226	PBX3	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	PBX3 A549 (lung carcinoma) PBX3	A549 (lung carcinoma)	BTO:0000018	PBX3	NA	ENCODE	ENCSR000BTN_A549_PBX3_MACS_PBX3_MA1114.1.damo.pwm.bed	7138
1	3318	RARG	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM CD437 for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048632_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA0860.1.damo.pwm.bed	1140
1	3411	REST	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		GTRD	EXP031113_K562--myelogenous-leukemia-_REST_MACS_REST_MA0138.2.damo.pwm.bed	5954
1	3412	REST	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	REST acute promyelocytic leukemia blasts REST	acute promyelocytic leukemia blasts	BTO:0004585	REST		GTRD	EXP031799_acute-promyelocytic-leukemia-blasts_REST_MACS_REST_MA0138.2.damo.pwm.bed	8131
1	3470	RUNX1	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	RUNX1 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) RUNX1	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	RUNX1		GTRD	EXP037833_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	23207
1	3473	RUNX1	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	RUNX1 HL-60 (acute myeloid leukemia) RUNX1	HL-60 (acute myeloid leukemia)	BTO:0000738	RUNX1		GTRD	EXP040800_HL-60--acute-myeloid-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12472
1	3479	RUNX1	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	RUNX1 pre-B-lymphoblast cells with BCP-ALL RUNX1	pre-B-lymphoblast cells with BCP-ALL	NULL	RUNX1	DIsease: human precursor leukemia (BCP-ALL) Tissue: bone marrow	GTRD	EXP048190_pre-B-lymphoblast-cells-with-BCP-ALL_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12128
1	3501	RUNX1	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	RUNX1 CD34+ cells RUNX1	CD34+ cells	NULL	RUNX1	ADULT	GEO	GSE70660_runx1_cd34-adult_MACS_RUNX1_MA0002.2.damo.pwm.bed	8322
1	3512	RXRA	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	RXRA SK-N-SH (neuroblastoma) RXRA	SK-N-SH (neuroblastoma)	BTO:0001620	RXRA		ENCODE	ENCSR000BVG_SK-N-SH_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	12879
1	3693	SPIB	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	SPIB OCI-LY10 (diffuse large B-cell lymphoma) SPIB	OCI-LY10 (diffuse large B-cell lymphoma)	NULL	SPIB		GEO	GSE56857_spib_ocily10_MACS_SPIB_MA0081.2.damo.pwm.bed	16554
1	3696	SPIB	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	SPIB OCI-LY3 (diffuse large B-cell lymphoma) SPIB	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPIB		GEO	GSE56857_spib_ocily3_MACS_SPIB_MA0081.2.damo.pwm.bed	23781
1	3809	TCF7L2	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	TCF7L2 HEK293 (embryonic kidney) TCF7L2	HEK293 (embryonic kidney)	NULL	TCF7L2		ENCODE	ENCSR000EUY_HEK293_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	6815
1	3817	TCF7L2	0.181599716311644	1.0437909152858	6	1461	1311	2870	2870	1880	2	6375	2218	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036766_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	11846
1	338	CEBPA	0.1808369722255	0.9333266865128	51	1485	1715	932	1715	1380	19	6330	2201	CEBPA THP-1 (acute monocytic leukemia) CEBPA	THP-1 (acute monocytic leukemia)	BTO:0001370	CEBPA	Treatment: 0.1 % EtOH for 8 hrs	GTRD	EXP053363_THP-1--acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	40326
1	829	CTCF	0.1808369722255	0.9333266865128	51	1485	1715	932	1715	1380	19	6330	2201	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: untreated	GTRD	EXP047796_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51409
1	1987	GATA3	0.1808369722255	0.9333266865128	51	1485	1715	932	1715	1380	19	6330	2201	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	Treatment: with Estrogen;	GTRD	EXP058227_MCF7--Invasive-ductal-breast-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	10636
1	472	CTCF	0.180779286585405	0.956673982613326	11	1488	1613	2426	2426	1840	4	6370	2216	CTCF GM20000 (B-cells) CTCF	GM20000 (B-cells)	NULL	CTCF		ENCODE	ENCSR000DLG_GM20000_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	25439
1	740	CTCF	0.180779286585405	0.956673982613326	11	1488	1613	2426	2426	1840	4	6370	2216	CTCF coronary artery CTCF	coronary artery	BTO:0000290	CTCF		GTRD	EXP039802_coronary-artery_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27678
1	814	CTCF	0.180779286585405	0.956673982613326	11	1488	1613	2426	2426	1840	4	6370	2216	CTCF HCT-116-RAD21-mAC CTCF	HCT-116-RAD21-mAC	NULL	CTCF	500uM auxin (360 min)	GTRD	EXP040680_HCT-116-RAD21-mAC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22257
1	1017	E2F1	0.180779286585405	0.956673982613326	11	1488	1613	2426	2426	1840	4	6370	2216	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032865_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	18280
1	1060	EGR1	0.180779286585405	0.956673982613326	11	1488	1613	2426	2426	1840	4	6370	2216	EGR1 HCT-116 (colon carcinoma) EGR1	HCT-116 (colon carcinoma)	BTO:0001109	EGR1		ENCODE	ENCSR000BRZ_HCT116_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	9603
1	1462	ETS1	0.180779286585405	0.956673982613326	11	1488	1613	2426	2426	1840	4	6370	2216	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF stimulation for 12hours	GTRD	EXP038277_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	30365
1	2808	MYC	0.180779286585405	0.956673982613326	11	1488	1613	2426	2426	1840	4	6370	2216	MYC HeLa S3 (cervical adenocarcinoma) MYC	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MYC	NULL	GTRD	EXP000991_HeLa-S3--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7115
1	3928	TFAP2C	0.179940807462669	0.957962634018556	251	1495	1610	126	1610	1080	91	6130	2129	TFAP2C SK-BR-3 (breast adenocarcinoma) TFAP2C	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	TFAP2C		GEO	GSE36351_tfap2c_skbr3_MACS_TFAP2C_MA0524.2.damo.pwm.bed	94946
1	534	CTCF	0.179212267735504	0.927391552192938	32	1496	1782	1410	1782	1560	12	6349	2208	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVP_endothelial_cell_of_umbilical_vein_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48130
1	987	CTCF	0.179212267735504	0.927391552192938	32	1496	1782	1410	1782	1560	12	6349	2208	CTCF VCaP (prostate carcinoma) CTCF	VCaP (prostate carcinoma)	BTO:0003215	CTCF	ETOH	GEO	GSE84432_ctcf_vcap-etoh_MACS_CTCF_MA0139.1.damo.pwm.bed	36873
1	405	CEBPB	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	CEBPB hMSC CEBPB	hMSC	NA	CEBPB		GEO	GSE68864_cebpb_hmsc_MACS_CEBPB_MA0466.2.damo.pwm.bed	26163
1	1982	GATA3	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049904_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	4722
1	1983	GATA3	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049905_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	4076
1	2248	JUN	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17712
1	2249	JUN	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17016
1	2252	JUN	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	17146
1	2253	JUN	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17033
1	2254	JUN	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	17637
1	2521	JUNB	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	11003
1	2525	JUNB	0.179132623287111	0.927482911838212	24	1498	1770	1691	1770	1650	9	6357	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	11065
1	82	AR	0.179131839907092	0.938573313067038	81	1508	1690	579	1690	1260	30	6300	2190	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: control	GTRD	EXP049186_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28053
1	4164	ZNF143	0.178889660100053	0.93597439007661	70	1509	1700	666	1700	1290	26	6311	2194	ZNF143 MCF7 (Invasive ductal breast carcinoma) ZNF143	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ZNF143		GEO	GSE76454_znf143_mcf7_MACS_ZNF143_MA0088.2.damo.pwm.bed	48028
1	358	CEBPB	0.178401851975561	0.957010860126753	248	1510	1612	128	1612	1080	90	6133	2130	CEBPB HeLa S3 (cervical adenocarcinoma) CEBPB	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CEBPB		ENCODE	ENCSR000EDA_HeLa-S3_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	94544
1	2161	HOXB13	0.17836579495622	0.95284487257084	192	1511	1639	199	1639	1120	70	6189	2150	HOXB13 VCaP (prostate carcinoma) HOXB13	VCaP (prostate carcinoma)	BTO:0003215	HOXB13	siERG	GTRD	EXP038438_VCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	69679
1	900	CTCF	0.177858713245613	0.927299962027562	40	1512	1785	1189	1785	1500	15	6341	2205	CTCF NHDF-Ad (adult dermal fibroblasts) CTCF	NHDF-Ad (adult dermal fibroblasts)	NULL	CTCF	Treatment: None;	GTRD	EXP054037_NHDF-Ad--adult-dermal-fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54702
1	1335	ESR1	0.177858713245613	0.927299962027562	40	1512	1785	1189	1785	1500	15	6341	2205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	800	GTRD	EXP048581_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	10805
1	1326	ESR1	0.177595190420378	0.943310538476317	114	1514	1675	392	1675	1190	42	6267	2178	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p22;	GTRD	EXP047709_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	26762
1	516	CTCF	0.17582853158467	0.927208140468353	48	1515	1787	982	1787	1430	18	6333	2202	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTA_brain_microvascular_endothelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	59572
1	577	CTCF	0.17582853158467	0.927208140468353	48	1515	1787	982	1787	1430	18	6333	2202	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000776_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57566
1	724	CTCF	0.17582853158467	0.927208140468353	48	1515	1787	982	1787	1430	18	6333	2202	CTCF bipolar neuron CTCF	bipolar neuron	NULL	CTCF	0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day	GTRD	EXP039689_bipolar-neuron_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58024
1	3736	STAT3	0.175740047923407	0.937426015460755	89	1518	1694	515	1694	1240	33	6292	2187	STAT3 HCC70 (ductal breast carcinoma) STAT3	HCC70 (ductal breast carcinoma)	NULL	STAT3	ethanol	GTRD	EXP037703_HCC70--ductal-breast-carcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	28028
1	11	AR	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ethanol	GTRD	EXP000730_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	5727
1	592	CTCF	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF		GTRD	EXP030398_GM12878--female-B-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33576
1	643	CTCF	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP036855_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30461
1	870	CTCF	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF	Genotype: wildtype	GTRD	EXP049756_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29994
1	903	CTCF	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	CTCF NA-A (astrocytes) CTCF	NA-A (astrocytes)	NULL	CTCF	Treatment: None;	GTRD	EXP054040_NA-A--astrocytes-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37670
1	1346	ESR1	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: E2 (estrogen) for 45 min  Genotype: wildtype TET2 Passage: 6-10	GTRD	EXP048686_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7663
1	1616	FOSL2	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	11846
1	2149	HNF4G	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	HNF4G HepG2 (hepatoblastoma) HNF4G	HepG2 (hepatoblastoma)	BTO:0000599	HNF4G		ENCODE	ENCSR000BNJ_HepG2_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	28815
1	2588	JUND	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	JUND A549 (lung carcinoma) JUND	A549 (lung carcinoma)	BTO:0000018	JUND	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRF_A549_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	14874
1	2892	MYC	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047491_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13387
1	3551	RXRA	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	RXRA MCF7 (Invasive ductal breast carcinoma) RXRA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RXRA	Treatment: none;	GTRD	EXP054366_MCF7--Invasive-ductal-breast-carcinoma-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	35916
1	4121	YY1	0.175584804288548	0.927574041832719	16	1519	1758	2127	2127	1800	6	6365	2214	YY1 K562 (myelogenous leukemia) YY1	K562 (myelogenous leukemia)	NULL	YY1		ENCODE	ENCSR000BMH_K562_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	26993
1	2365	JUN	0.175453177672588	0.939342809113454	100	1531	1681	446	1681	1220	37	6281	2183	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	16234
1	1832	FOXA2	0.17521714704884	0.964976914329722	470	1532	1584	22	1584	1050	169	5911	2051	FOXA2 KerCT (keratenocytes) FOXA2	KerCT (keratenocytes)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049289_KerCT--keratenocytes-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	112221
1	1632	FOXA1	0.174643560219104	0.950180287923813	186	1533	1649	211	1649	1130	68	6195	2152	FOXA1 HepG2 (hepatoblastoma) FOXA1	HepG2 (hepatoblastoma)	BTO:0000599	FOXA1		ENCODE	ENCSR000BLE_HepG2_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	92811
1	1779	FOXA1	0.174149217312698	0.942112069674388	122	1534	1676	356	1676	1190	45	6259	2175	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GEO	GSE56288_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	22516
1	1751	FOXA1	0.173031703540324	0.961296738929144	385	1535	1597	48	1597	1060	139	5996	2081	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058106_ZR-75-1--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	82035
1	84	AR	0.172487742094706	0.934116144836111	86	1536	1711	534	1711	1260	32	6295	2188	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: case	GTRD	EXP049252_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	29541
1	394	CEBPB	0.172487742094706	0.934116144836111	86	1536	1711	534	1711	1260	32	6295	2188	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048168_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	50853
1	2640	KLF5	0.172487742094706	0.934116144836111	86	1536	1711	534	1711	1260	32	6295	2188	KLF5 BICR31 (Tongue squamous cell carcinoma cell) KLF5	BICR31 (Tongue squamous cell carcinoma cell)	NULL	KLF5	Treatment: untreated Tumor: Head and neck squamous cell carcinomas	GTRD	EXP049087_BICR31-Tongue-squamous-cell-carcinoma-cell-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	22483
1	2790	MYC	0.172475667631519	0.936454224520251	97	1539	1698	468	1698	1240	36	6284	2184	MYC MYC	NA	NA	MYC	NA	NA	ENCSR000DOS_MCF_10A_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	33013
1	1381	ESR1	0.172143905891802	0.938308959335555	108	1540	1691	412	1691	1210	40	6273	2180	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: with Estrogen;	GTRD	EXP058225_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	35934
1	1254	ESR1	0.172044301424775	0.931087688242852	75	1541	1721	632	1721	1300	28	6306	2192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	1280min E2	GTRD	EXP038344_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20695
1	3610	SOX2	0.172044301424775	0.931087688242852	75	1541	1721	632	1721	1300	28	6306	2192	SOX2 BJ (fibroblasts) SOX2	BJ (fibroblasts)	NULL	SOX2	INDUCED	GEO	GSE36570_sox2_bj-induced_MACS_SOX2_MA0143.4.damo.pwm.bed	76252
1	3874	TFAP2C	0.172044301424775	0.931087688242852	75	1541	1721	632	1721	1300	28	6306	2192	TFAP2C HeLa S3 (cervical adenocarcinoma) TFAP2C	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2C	None	GTRD	EXP010559_HeLa-S3--cervical-adenocarcinoma-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	21482
1	4046	TP63	0.172044301424775	0.931087688242852	75	1541	1721	632	1721	1300	28	6306	2192	TP63 TT (hereditary thyroid gland medullary carcinoma) TP63	TT (hereditary thyroid gland medullary carcinoma)	BTO:0003074	TP63		GEO	GSE46837_tp63_tt_MACS_TP63_MA0525.2.damo.pwm.bed	6066
1	369	CEBPB	0.171821563384843	0.916834608749489	29	1545	1817	1504	1817	1620	11	6352	2209	CEBPB monocyte-derived macrophages CEBPB	monocyte-derived macrophages	NULL	CEBPB	IFN-gamma	GTRD	EXP038588_monocyte-derived-macrophages_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	38296
1	501	CTCF	0.171821563384843	0.916834608749489	29	1545	1817	1504	1817	1620	11	6352	2209	CTCF Caco-2 (colon adenocarcinoma) CTCF	Caco-2 (colon adenocarcinoma)	BTO:0000195	CTCF		ENCODE	ENCSR000DQN_Caco-2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41356
1	518	CTCF	0.171821563384843	0.916834608749489	29	1545	1817	1504	1817	1620	11	6352	2209	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTI_cardiac_muscle_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	47405
1	591	CTCF	0.171821563384843	0.916834608749489	29	1545	1817	1504	1817	1620	11	6352	2209	CTCF GM12871 (male B-cells) CTCF	GM12871 (male B-cells)	NULL	CTCF		GTRD	EXP011189_GM12871--male-B-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49665
1	1647	FOXA1	0.170854375965014	0.963863278580957	489	1549	1589	19	1589	1050	176	5892	2044	FOXA1 FOXA1	NA	NA	FOXA1	NA	Array Express	ERP003828_foxa1_zr751_MACS_FOXA1_MA0148.4.damo.pwm.bed	148244
1	1960	GATA3	0.17053655597315	0.920372157069637	45	1550	1812	1054	1812	1470	17	6336	2203	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		ENCODE	ENCSR000EWS_MCF-7_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	10588
1	1745	FOXA1	0.170508852625329	0.954800924693195	275	1551	1634	103	1634	1100	100	6106	2120	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with 10 nM estrogen for 45 mins;	GTRD	EXP058100_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	47742
1	4034	TP63	0.170074907722574	0.94534593072139	166	1552	1663	241	1663	1150	61	6215	2159	TP63 JHU-029 (laryngeal squamous cell carcinoma) TP63	JHU-029 (laryngeal squamous cell carcinoma)	BTO:0003888	TP63		GTRD	EXP037974_JHU-029--laryngeal-squamous-cell-carcinoma-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	15762
1	751	CTCF	0.169626795467786	0.912972472186574	21	1553	1830	1852	1852	1740	8	6360	2212	CTCF liver CTCF	liver	BTO:0000759	CTCF		GTRD	EXP039898_liver_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35118
1	1144	ERG	0.169626795467786	0.912972472186574	21	1553	1830	1852	1852	1740	8	6360	2212	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG		GEO	GSE37752_erg_rwpe1_MACS_ERG_MA0474.2.damo.pwm.bed	5763
1	2270	JUN	0.169626795467786	0.912972472186574	21	1553	1830	1852	1852	1740	8	6360	2212	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	23767
1	2643	KLF5	0.169626795467786	0.912972472186574	21	1553	1830	1852	1852	1740	8	6360	2212	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049095_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	18312
1	3071	NR2F2	0.169626795467786	0.912972472186574	21	1553	1830	1852	1852	1740	8	6360	2212	NR2F2 K562 (myelogenous leukemia) NR2F2	K562 (myelogenous leukemia)	NULL	NR2F2		ENCODE	ENCSR000BRS_K562_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	40180
1	3869	TFAP2A	0.169626795467786	0.912972472186574	21	1553	1830	1852	1852	1740	8	6360	2212	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GEO	GSE60270_tfap2a_mcf7_MACS_TFAP2A_MA0003.4.damo.pwm.bed	8755
1	3886	TFAP2C	0.169626795467786	0.912972472186574	21	1553	1830	1852	1852	1740	8	6360	2212	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047536_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	23385
1	4032	TP63	0.169331535009164	0.935617383465306	105	1560	1702	422	1702	1230	39	6276	2181	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-caRAS and 3 ng/ml of TGF-beta3 for 1.5 hrs	GTRD	EXP033938_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	6684
1	1771	FOXA1	0.169143821630605	0.930594055009222	83	1561	1725	565	1725	1280	31	6298	2189	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1	FOXA1_ARQ6540X	GEO	GSE47987_foxa1_du145-foxa1-arq6540x_MACS_FOXA1_MA0148.4.damo.pwm.bed	50677
1	3844	TFAP2A	0.169143821630605	0.930594055009222	83	1561	1725	565	1725	1280	31	6298	2189	TFAP2A HeLa S3 (cervical adenocarcinoma) TFAP2A	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2A	None	GTRD	EXP010503_HeLa-S3--cervical-adenocarcinoma-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	20858
1	849	CTCF	0.168779683650765	0.921303377885399	53	1563	1805	905	1805	1420	20	6328	2200	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under heat shock conditions	GTRD	EXP047930_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	71672
1	1312	ESR1	0.168779683650765	0.921303377885399	53	1563	1805	905	1805	1420	20	6328	2200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040961_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12629
1	1430	ESR1	0.168779683650765	0.921303377885399	53	1563	1805	905	1805	1420	20	6328	2200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE71276_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	16082
1	2053	GLIS1	0.168779683650765	0.921303377885399	53	1563	1805	905	1805	1420	20	6328	2200	GLIS1 HEK293 (embryonic kidney) GLIS1	HEK293 (embryonic kidney)	NULL	GLIS1	NA	GTRD	EXP035916_HEK293--embryonic-kidney-_GLIS1_MACS_GLIS1_MA0735.1.damo.pwm.bed	65165
1	2687	MAX	0.168779683650765	0.921303377885399	53	1563	1805	905	1805	1420	20	6328	2200	MAX K562 (myelogenous leukemia) MAX	K562 (myelogenous leukemia)	NULL	MAX		ENCODE	ENCSR000BLP_K562_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	73610
1	2415	JUN	0.168402369467171	0.938876843824201	127	1568	1684	342	1684	1200	47	6254	2173	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	30872
1	1214	ESR1	0.168325524175533	0.926931278623988	72	1569	1792	651	1792	1340	27	6309	2193	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 treatment	GTRD	EXP036170_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15658
1	1290	ESR1	0.168269870350209	0.948052101159739	202	1570	1659	189	1659	1140	74	6179	2146	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Tam-Responsive	GTRD	EXP038794_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	41609
1	1178	ESR1	0.167710904648539	0.946344159154055	188	1571	1661	204	1661	1150	69	6193	2151	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LY2	Array Express	ERP003844_esr1_ly2_MACS_ESR1_MA0112.3.damo.pwm.bed	57056
1	1329	ESR1	0.167689376551405	0.94010435361155	138	1572	1680	316	1680	1190	51	6243	2169	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	Treatment: 100 nM estradiol (E2) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048178_MDA-MB-134--invasive-lobular-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	37017
1	2022	GATA4	0.166299127622514	0.930170924122837	91	1573	1728	506	1728	1270	34	6290	2186	GATA4 BJ (fibroblasts) GATA4	BJ (fibroblasts)	NULL	GATA4	Genotype: V5-untarged	GTRD	EXP049304_BJ--fibroblasts-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	104447
1	2574	JUNB	0.165939802860386	0.949880788350868	238	1574	1650	145	1650	1120	87	6143	2133	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	47314
1	1949	GATA2	0.16591070644514	0.936608569647122	124	1575	1697	349	1697	1210	46	6257	2174	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2		GEO	GSE38391_gata2_lncap_MACS_GATA2_MA0036.3.damo.pwm.bed	57820
1	1681	FOXA1	0.165291220637288	0.958433432021178	395	1576	1609	44	1609	1080	143	5986	2077	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP038763_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	66240
1	1810	FOXA1	0.165258414464714	0.947100856133988	210	1577	1660	172	1660	1140	77	6171	2143	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE80808_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	34605
1	515	CTCF	0.165124367457862	0.909430918275563	34	1578	1848	1349	1848	1590	13	6347	2207	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DSU_astrocyte_of_the_spinal_cord_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49784
1	16	AR	0.16492559817129	0.912684219934822	42	1579	1837	1124	1837	1510	16	6339	2204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	100 nM DHT	GTRD	EXP030500_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12326
1	1978	GATA3	0.16492559817129	0.912684219934822	42	1579	1837	1124	1837	1510	16	6339	2204	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049896_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	13101
1	90	AR	0.163865555452081	0.91488094974437	50	1581	1825	945	1825	1450	19	6331	2201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype	GTRD	EXP049282_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	16653
1	1376	ESR1	0.163865555452081	0.91488094974437	50	1581	1825	945	1825	1450	19	6331	2201	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: treated with E2 for 1 hr;	GTRD	EXP057859_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12230
1	953	CTCF	0.163686292393518	0.904170340063373	26	1583	1877	1602	1877	1690	10	6355	2210	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18951_MACS_CTCF_MA0139.1.damo.pwm.bed	43977
1	1830	FOXA2	0.163686292393518	0.904170340063373	26	1583	1877	1602	1877	1690	10	6355	2210	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2		GTRD	EXP039928_liver_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	12337
1	2854	MYC	0.163686292393518	0.904170340063373	26	1583	1877	1602	1877	1690	10	6355	2210	MYC LNCaP (prostate carcinoma) MYC	LNCaP (prostate carcinoma)	BTO:0001321	MYC	R1881	GTRD	EXP037068_LNCaP--prostate-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	18287
1	1330	ESR1	0.163581232263157	0.932245036263386	110	1586	1719	404	1719	1240	41	6271	2179	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	Treatment: a cocktail of 10 µM forskolin plus 100 µM 3-isobutyl-1-methylxanthine (FI) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048179_MDA-MB-134--invasive-lobular-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29685
1	1789	FOXA1	0.163375051949326	0.934240398108922	121	1587	1710	362	1710	1220	45	6260	2175	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE60270_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	19430
1	1755	FOXA1	0.163345557476042	0.952101984945747	288	1588	1643	100	1643	1110	105	6093	2115	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	ETOH	GEO	GSE23852_foxa1_mcf7-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	50862
1	4031	TP63	0.163091654190841	0.926745530873357	88	1589	1793	525	1793	1300	33	6293	2187	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-LacZ and 3 ng/ml of TGF-beta3 for 1.5 hrs	GTRD	EXP033937_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	6048
1	1252	ESR1	0.162967126017462	0.935896963765106	132	1590	1701	323	1701	1200	49	6249	2171	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	320min E2	GTRD	EXP038342_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	30630
1	2597	JUND	0.161791385270288	0.944538400208772	204	1591	1664	184	1664	1150	75	6177	2145	JUND HepG2 (hepatoblastoma) JUND	HepG2 (hepatoblastoma)	BTO:0000599	JUND		ENCODE	ENCSR000EEI_HepG2_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	75441
1	625	CTCF	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	CTCF embryonic stem cells CTCF	embryonic stem cells	NULL	CTCF		GTRD	EXP035701_embryonic-stem-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29273
1	720	CTCF	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	CTCF thoracic aorta CTCF	thoracic aorta	NULL	CTCF		GTRD	EXP039667_thoracic-aorta_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29819
1	750	CTCF	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP039880_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31897
1	779	CTCF	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	CTCF RWPE1 (prostate epithelial cells) CTCF	RWPE1 (prostate epithelial cells)	BTO:0003709	CTCF		GTRD	EXP040101_RWPE1--prostate-epithelial-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	25505
1	1012	E2F1	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032857_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	18949
1	1044	E2F6	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	E2F6 WA01 (H1, human embryonic stem cells) E2F6	WA01 (H1, human embryonic stem cells)	NULL	E2F6		ENCODE	ENCSR000BSI_H1-hESC_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	38756
1	1215	ESR1	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	10nM Estradiol + 10 nM R5020	GTRD	EXP036364_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14985
1	1240	ESR1	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	White Medium	GTRD	EXP037778_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3020
1	1934	GATA2	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2	NULL	GTRD	EXP000524_K562--myelogenous-leukemia-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	24373
1	2771	MXI1	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	MXI1 IMR90 (lung fibroblasts) MXI1	IMR90 (lung fibroblasts)	NULL	MXI1	NA	ENCODE	ENCSR000EFE_IMR-90_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	31521
1	2933	MYC	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	Doxy	GEO	GSE77356_myc_u2os-dox_MACS_MYC_MA0147.3.damo.pwm.bed	20189
1	3137	NR3C1	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	NR3C1 Ishikawa (endometrial adenocarcinoma) NR3C1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	NR3C1	Treatment: 100 nM Dexamethasone for 1 hour	GTRD	EXP048234_Ishikawa--endometrial-adenocarcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	10171
1	4118	YY1	0.161649170875361	0.904365932117798	13	1592	1864	2306	2306	1920	5	6368	2215	YY1 GM12891 (male B- cells lymphoblastoid cell line) YY1	GM12891 (male B- cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000BKJ_GM12891_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	21680
1	386	CEBPB	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	CEBPB HL-60 (acute myeloid leukemia) CEBPB	HL-60 (acute myeloid leukemia)	BTO:0000738	CEBPB		GTRD	EXP040801_HL-60--acute-myeloid-leukemia-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	11047
1	503	CTCF	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	CTCF GM12801 (male B-cells) CTCF	GM12801 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DQY_GM12801_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21229
1	883	CTCF	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  Source: T47D whole cell	GTRD	EXP053050_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22871
1	1004	DUX4	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	DUX4 HEK293 (embryonic kidney) DUX4	HEK293 (embryonic kidney)	NULL	DUX4		GEO	GSE75791_dux4_hek293_MACS_DUX4_MA0468.1.damo.pwm.bed	8376
1	1052	EBF1	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	EBF1 hASC (preadipocytes) EBF1	hASC (preadipocytes)	NULL	EBF1	NA	GEO	GSE54889_ebf1_asc_MACS_EBF1_MA0154.4.damo.pwm.bed	9666
1	1285	ESR1	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GTRD	EXP038777_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1693
1	2404	JUN	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	11840
1	2405	JUN	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	11285
1	2407	JUN	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	11204
1	2409	JUN	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	11437
1	2410	JUN	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	11008
1	2411	JUN	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 012Passage: P3-6	GTRD	EXP048212_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	12135
1	2811	MYC	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000994_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15406
1	2812	MYC	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000994_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16161
1	2853	MYC	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	MYC GEN2.2 (blastic plasmacytoid dendritic cell neoplasm) MYC	GEN2.2 (blastic plasmacytoid dendritic cell neoplasm)	NULL	MYC		GTRD	EXP036998_GEN2.2--blastic-plasmacytoid-dendritic-cell-neoplasm-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16602
1	2961	MYOG	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	MYOG RH4 (alveolar rhabdomyosarcoma) MYOG	RH4 (alveolar rhabdomyosarcoma)	NULL	MYOG	NA	GTRD	EXP037531_RH4--alveolar-rhabdomyosarcoma-_MYOG_MACS_MYOG_MA0500.2.damo.pwm.bed	16244
1	2973	NEUROG2	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037149_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	21813
1	3233	PHOX2B	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	PHOX2B BE2C PHOX2B	BE2C	NULL	PHOX2B	Treatment: untreated	GTRD	EXP049479_BE2C_PHOX2B_MACS_PHOX2B_MA0681.2.damo.pwm.bed	48348
1	3289	PPARG	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034424_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	13671
1	3529	RXRA	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	10567
1	3532	RXRA	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	11588
1	3533	RXRA	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	10854
1	3535	RXRA	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	7123
1	3538	RXRA	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	11428
1	3587	SOX10	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	SOX10 501Mel (melanoma) SOX10	501Mel (melanoma)	BTO:0002956	SOX10	NA	GEO	GSE61965_sox10_501mel_MACS_SOX10_MA0442.2.damo.pwm.bed	2863
1	3843	TEAD4	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	TEAD4 HuCCT1 (intrahepatic cholangiocarcinoma) TEAD4	HuCCT1 (intrahepatic cholangiocarcinoma)	BTO:0003911	TEAD4		GEO	GSE68296_tead4_hucct1_MACS_TEAD4_MA0809.2.damo.pwm.bed	7660
1	3881	TFAP2C	0.160636165683904	0.927664943041428	8	1605	1731	2675	2675	2000	3	6373	2217	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047534_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	9803
1	346	CEBPA	0.159798492232111	0.92310732868285	85	1632	1801	545	1801	1330	32	6296	2188	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA		GTRD	EXP058118_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	63304
1	2100	HIF1A	0.159798492232111	0.92310732868285	85	1632	1801	545	1801	1330	32	6296	2188	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siCtrl;	GTRD	EXP057826_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	39523
1	3850	TFAP2A	0.159569462188532	0.936610546743223	151	1634	1696	282	1696	1200	56	6230	2164	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GTRD	EXP032577_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	37642
1	1746	FOXA1	0.158961903290262	0.953522003003834	349	1635	1636	66	1636	1110	127	6032	2093	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Treatment: hormone-deprived cells treated with vehicle;	GTRD	EXP058101_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	68019
1	1532	FOS	0.158953445555389	0.903973946162145	39	1636	1880	1206	1880	1570	15	6342	2205	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	8615
1	3849	TFAP2A	0.158953445555389	0.903973946162145	39	1636	1880	1206	1880	1570	15	6342	2205	TFAP2A H9-derived neural crest cells TFAP2A	H9-derived neural crest cells	NULL	TFAP2A		GTRD	EXP030996_H9-derived-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	55302
1	396	CEBPB	0.158904466314228	0.937773365752659	162	1638	1693	252	1693	1190	60	6219	2160	CEBPB JB6 (Human anaplastic large cell lymphoma) CEBPB	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	CEBPB	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053280_JB6--Human-anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	103437
1	452	CTCF	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000AUV_B_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40097
1	841	CTCF	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: dexamethasone 6hr	GTRD	EXP047812_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36132
1	1493	FLI1	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047961_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	24618
1	1935	GATA2	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	NULL	GTRD	EXP000673_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	20017
1	2606	JUND	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	7269
1	2607	JUND	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	7302
1	2608	JUND	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	7355
1	2609	JUND	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	JUND Calu-3 (lung adenocarcinoma) JUND	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUND		GTRD	EXP037684_Calu-3--lung-adenocarcinoma-_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	7378
1	2891	MYC	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047491_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13685
1	3794	TCF4	0.158733436697471	0.89434414604457	18	1639	1907	1996	1996	1850	7	6363	2213	TCF4 CAL-1 (plasmacytoid dendritic neoplasm) TCF4	CAL-1 (plasmacytoid dendritic neoplasm)	NULL	TCF4		GTRD	EXP037180_CAL-1--plasmacytoid-dendritic-neoplasm-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	31575
1	938	CTCF	0.158694008815072	0.907747185528551	47	1649	1851	1002	1851	1500	18	6334	2202	CTCF BCBL-1 (B-cell lymphoma) CTCF	BCBL-1 (B-cell lymphoma)	BTO:0002727	CTCF		GEO	GSE38411_ctcf_bcbl1_MACS_CTCF_MA0139.1.damo.pwm.bed	67252
1	2223	JUN	0.158694008815072	0.907747185528551	47	1649	1851	1002	1851	1500	18	6334	2202	JUN HepG2 (hepatoblastoma) JUN	HepG2 (hepatoblastoma)	BTO:0000599	JUN		ENCODE	ENCSR000EEK_HepG2_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	20528
1	2572	JUNB	0.15840286893147	0.945735715089005	237	1651	1662	147	1662	1150	87	6144	2133	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	47147
1	162	AR	0.157981147410944	0.898267868449538	31	1652	1893	1439	1893	1660	12	6350	2208	AR LHSAR (prostate epithelial cells) AR	LHSAR (prostate epithelial cells)	NULL	AR	HOXB13	GEO	GSE56288_AR_lhsar-hoxb13_MACS_AR_MA0007.3.damo.pwm.bed	19730
1	202	AR	0.157981147410944	0.898267868449538	31	1652	1893	1439	1893	1660	12	6350	2208	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT	GEO	GSE79128_AR_vcap-dht_MACS_AR_MA0007.3.damo.pwm.bed	19055
1	3861	TFAP2A	0.157981147410944	0.898267868449538	31	1652	1893	1439	1893	1660	12	6350	2208	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040709_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	30609
1	2368	JUN	0.157433348674001	0.923324755329167	93	1655	1799	489	1799	1310	35	6288	2185	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	16150
1	2371	JUN	0.157433348674001	0.923324755329167	93	1655	1799	489	1799	1310	35	6288	2185	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	15447
1	1305	ESR1	0.156359052213332	0.91239405150699	63	1657	1839	753	1839	1420	24	6318	2196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040954_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15558
1	2573	JUNB	0.155244009352969	0.94344557449898	231	1658	1673	154	1673	1160	85	6150	2135	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	46653
1	2575	JUNB	0.155244009352969	0.94344557449898	231	1658	1673	154	1673	1160	85	6150	2135	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	46653
1	1642	FOXA1	0.155097522975315	0.952724318310188	368	1660	1641	57	1660	1120	134	6013	2086	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		Array Express	ERP001226_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	62934
1	556	CTCF	0.154640745355229	0.888720808660197	23	1661	1929	1739	1929	1780	9	6358	2211	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR822CEA_neural_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41722
1	2250	JUN	0.154640745355229	0.888720808660197	23	1661	1929	1739	1929	1780	9	6358	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	17206
1	2251	JUN	0.154640745355229	0.888720808660197	23	1661	1929	1739	1929	1780	9	6358	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	dexametasone	GTRD	EXP033443_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17843
1	2314	JUN	0.154640745355229	0.888720808660197	23	1661	1929	1739	1929	1780	9	6358	2211	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	15258
1	2522	JUNB	0.154640745355229	0.888720808660197	23	1661	1929	1739	1929	1780	9	6358	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	11162
1	3949	THAP11	0.154640745355229	0.888720808660197	23	1661	1929	1739	1929	1780	9	6358	2211	THAP11 HepG2 (hepatoblastoma) THAP11	HepG2 (hepatoblastoma)	BTO:0000599	THAP11	NA	GTRD	EXP039449_HepG2--hepatoblastoma-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	32459
1	1802	FOXA1	0.154088491302297	0.948885719385239	309	1667	1654	89	1667	1140	113	6072	2107	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE72249_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	50531
1	18	AR	0.152569349610853	0.894044403534554	36	1668	1917	1288	1917	1620	14	6345	2206	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GTRD	EXP030504_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	10285
1	52	AR	0.152124313191411	0.920262338701346	98	1669	1813	460	1813	1310	37	6283	2183	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	treated for 24 hours with 2μg/mL aphidicolin +3 hour 10nm DHT	GTRD	EXP036468_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	29688
1	1943	GATA2	0.152063306148996	0.906709121989458	60	1670	1855	797	1855	1440	23	6321	2197	GATA2 endometrial stromal cells GATA2	endometrial stromal cells	NULL	GATA2		GTRD	EXP040835_endometrial-stromal-cells_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	52185
1	169	AR	0.150823769691481	0.908943234682239	68	1671	1849	703	1849	1410	26	6313	2194	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H_SHFOXA1	GEO	GSE58428_AR_vcap-dht24h-shfoxa1_MACS_AR_MA0007.3.damo.pwm.bed	30949
1	254	ATF3	0.150196992092388	0.885104896250845	28	1672	1943	1531	1943	1720	11	6353	2209	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		GTRD	EXP039361_K562--myelogenous-leukemia-_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	20308
1	684	CTCF	0.150196992092388	0.885104896250845	28	1672	1943	1531	1943	1720	11	6353	2209	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		GTRD	EXP039434_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39320
1	716	CTCF	0.150196992092388	0.885104896250845	28	1672	1943	1531	1943	1720	11	6353	2209	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP039638_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45693
1	1337	ESR1	0.150196992092388	0.885104896250845	28	1672	1943	1531	1943	1720	11	6353	2209	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	H3B-5942	GTRD	EXP048583_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11632
1	311	CEBPA	0.149969174775213	0.920638804394141	106	1676	1811	420	1811	1300	40	6275	2180	CEBPA U937 (adult acute monocytic leukemia) CEBPA	U937 (adult acute monocytic leukemia)	BTO:0001412	CEBPA	bio	GTRD	EXP000946_U937--adult-acute-monocytic-leukemia-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	61348
1	304	CDX2	0.149350891021303	0.91069571233027	76	1677	1844	619	1844	1380	29	6305	2191	CDX2 LS180 (colon cancer) CDX2	LS180 (colon cancer)	NULL	CDX2	125	GEO	GSE31939_cdx2_ls180-125_MACS_CDX2_MA0465.2.damo.pwm.bed	28703
1	3873	TFAP2C	0.149350891021303	0.91069571233027	76	1677	1844	619	1844	1380	29	6305	2191	TFAP2C HeLa S3 (cervical adenocarcinoma) TFAP2C	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TFAP2C	None	GTRD	EXP010559_HeLa-S3--cervical-adenocarcinoma-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	21954
1	1400	ESR1	0.147826759170891	0.920949433209606	114	1679	1810	392	1810	1290	43	6267	2177	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LY2_ETOH	GEO	GSE54592_esr1_ly2-etoh_MACS_ESR1_MA0112.3.damo.pwm.bed	29123
1	1192	ESR1	0.147727106448512	0.912101947728662	84	1680	1840	557	1840	1360	32	6297	2188	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	vehicle	GTRD	EXP030929_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20054
1	2675	MAFF	0.147592293648176	0.900509239758271	57	1681	1886	839	1886	1470	22	6324	2198	MAFF HeLa S3 (cervical adenocarcinoma) MAFF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MAFF	NA	ENCODE	ENCSR140DSL_HeLa-S3_MAFF_MACS_MAFF_MA0495.3.damo.pwm.bed	48859
1	131	AR	0.147455575262942	0.890835588971942	41	1682	1925	1155	1925	1590	16	6340	2204	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881_10C30	GEO	GSE32892_AR_vcap-r1881-10c30_MACS_AR_MA0007.3.damo.pwm.bed	10411
1	1845	FOXA2	0.147259319821997	0.932783598416253	180	1683	1718	217	1718	1210	67	6201	2153	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Genotype: clonal FOXA2 doxycycline inducible cells, OXA2 GATA4 Coexpressing	GTRD	EXP049380_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	74487
1	1812	FOXA1	0.146059727333177	0.952835519459874	459	1684	1640	24	1684	1120	167	5922	2053	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT	GEO	GSE83860_foxa1_lncap-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	185046
1	2370	JUN	0.146006577014358	0.913250913023739	92	1685	1828	498	1828	1340	35	6289	2185	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	15299
1	3931	TFAP2C	0.146006577014358	0.913250913023739	92	1685	1828	498	1828	1340	35	6289	2185	TFAP2C A375 (malignant melanoma) TFAP2C	A375 (malignant melanoma)	BTO:0002806	TFAP2C	DMSO	GEO	GSE41234_tfap2c_a375-dmso_MACS_TFAP2C_MA0524.2.damo.pwm.bed	65829
1	64	AR	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	dihydrotestosterone (DHT)	GTRD	EXP038192_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	4218
1	774	CTCF	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	CTCF heart left ventricle CTCF	heart left ventricle	NULL	CTCF		GTRD	EXP040077_heart-left-ventricle_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34125
1	794	CTCF	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	CTCF KMS-11 (Plasma cell myeloma) CTCF	KMS-11 (Plasma cell myeloma)	BTO:0003932	CTCF		GTRD	EXP040254_KMS-11--Plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29708
1	876	CTCF	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  Source: T47D whole cell	GTRD	EXP053043_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29020
1	964	CTCF	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	CTCF GP5d (colon adenocarcinoma) CTCF	GP5d (colon adenocarcinoma)	NULL	CTCF	SIRAD21	GEO	GSE51234_ctcf_gp5d-sirad21_MACS_CTCF_MA0139.1.damo.pwm.bed	23882
1	1617	FOSL2	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	12162
1	1618	FOSL2	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	12298
1	2776	MYB	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	MYB AML (monocytes and acute myeloid leukemia) MYB	AML (monocytes and acute myeloid leukemia)	NULL	MYB	Treatment: LSD1 inhibitor OG86	GTRD	EXP049357_AML--monocytes-and-acute-myeloid-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	24880
1	2987	NEUROG2	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037156_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	34688
1	3672	SPI1	0.145995341868883	0.869495020013827	15	1687	2026	2200	2200	1970	6	6366	2214	SPI1 H929 (plasma cell myeloma) SPI1	H929 (plasma cell myeloma)	BTO:0002416	SPI1		GEO	GSE56857_spi1_ncih929_MACS_SPI1_MA0080.5.damo.pwm.bed	23485
1	942	CTCF	0.14571165940823	0.882569807700177	33	1697	1950	1379	1950	1680	13	6348	2207	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GEO	GSE43743_ctcf_mm1s_MACS_CTCF_MA0139.1.damo.pwm.bed	54246
1	1366	ESR1	0.14571165940823	0.882569807700177	33	1697	1950	1379	1950	1680	13	6348	2207	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053229_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	7503
1	1775	FOXA1	0.144604014357522	0.953199148992303	484	1699	1637	20	1699	1120	176	5897	2044	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	ETOH	GEO	GSE56086_foxa1_vcap-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	199138
1	309	CEBPA	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	CEBPA mesenchymal stem cells-derived adipocytes CEBPA	mesenchymal stem cells-derived adipocytes	NULL	CEBPA	NULL	GTRD	EXP000565_mesenchymal-stem-cells-derived-adipocytes_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	24151
1	447	CTCF	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000APM_fibroblast_of_dermis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36167
1	1088	ELF1	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	ELF1 MCF7 (Invasive ductal breast carcinoma) ELF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELF1		GTRD	EXP040154_MCF7--Invasive-ductal-breast-carcinoma-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	13690
1	2271	JUN	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	19299
1	2273	JUN	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	19985
1	2348	JUN	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	15260
1	2444	JUN	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP058063_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	13780
1	3359	RELA	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	RELA HAEC (human aortic endothelial cells) RELA	HAEC (human aortic endothelial cells)	NULL	RELA	IL1b, 4h	GTRD	EXP038049_HAEC--human-aortic-endothelial-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	24123
1	3870	TFAP2A	0.144460360080304	0.869392432174631	20	1700	2036	1901	2036	1880	8	6361	2212	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GEO	GSE60270_tfap2a_mcf7_MACS_TFAP2A_MA0810.1.damo.pwm.bed	8794
1	478	CTCF	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	CTCF kidney CTCF	kidney	BTO:0000671	CTCF		ENCODE	ENCSR000DMC_kidney_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24703
1	728	CTCF	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP039700_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26590
1	1053	EBF1	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	EBF1 LCL (lymphoblastoid cell line) EBF1	LCL (lymphoblastoid cell line)	NULL	EBF1	NA	GEO	GSE75503_ebf1_lcl_MACS_EBF1_MA0154.4.damo.pwm.bed	15846
1	1380	ESR1	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	ESR1 MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line) E	MCF7L-TamR(immortalized breast epithelial, tamoxifen resistant cell line)	NULL	ESR1		GTRD	EXP057867_MCF7L-TamR-immortalized-breast-epithelial--tamoxifen-resistant-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2344
1	1391	ESR1	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	ESR1 breast ESR1	breast	NA	ESR1	tumor_GOODOUTCOME	GEO	GSE40867_esr1_breast-cancer-goodOutcome_MACS_ESR1_MA0112.3.damo.pwm.bed	2193
1	1475	ETV1	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	ETV1 A375 (malignant melanoma) ETV1	A375 (malignant melanoma)	BTO:0002806	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048911_A375--malignant-melanoma-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	7705
1	1962	GATA3	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	GATA3 Th1-cells GATA3	Th1-cells	BTO:0001678	GATA3		GTRD	EXP031083_Th1-cells_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	14516
1	2979	NEUROG2	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037152_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	27188
1	3232	PHOX2B	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	PHOX2B CLB-Ga (neuroblastoma) PHOX2B	CLB-Ga (neuroblastoma)	NULL	PHOX2B	none	GTRD	EXP039004_CLB-Ga--neuroblastoma-_PHOX2B_MACS_PHOX2B_MA0681.2.damo.pwm.bed	43820
1	3239	PKNOX1	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	PKNOX1 HeLa (cervical adenocarcinoma) PKNOX1	HeLa (cervical adenocarcinoma)	BTO:0000567	PKNOX1	NA	GTRD	EXP047569_HeLa--cervical-adenocarcinoma-_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	5710
1	3472	RUNX1	0.144196325621766	0.869597446789358	10	1709	2014	2487	2487	2070	4	6371	2216	RUNX1 SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) RUNX1	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	RUNX1	RUNX1-EVI1 KD after 10 days	GTRD	EXP037837_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	32033
1	1817	FOXA2	0.143612117709163	0.921421370873864	130	1720	1804	333	1804	1290	49	6251	2171	FOXA2 FOXA2	NA	NA	FOXA2	NA	Array Express	ERP003828_foxa2_mdamb231_MACS_FOXA2_MA0047.3.damo.pwm.bed	55973
1	2672	MAFB	0.142930456977808	0.893742955254026	54	1721	1919	886	1919	1510	21	6327	2199	MAFB pancreatic islets MAFB	pancreatic islets	NULL	MAFB	NA	Array Express	ERP004003_mafb_islet_MACS_MAFB_MA0117.2.damo.pwm.bed	48470
1	347	CEBPA	0.142838647746793	0.909437674056291	89	1722	1847	515	1847	1360	34	6292	2186	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA		GTRD	EXP058118_Kasumi-1--acute-myeloblastic-leukemia-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	64358
1	95	AR	0.142410497801254	0.915002717467915	108	1723	1824	412	1824	1320	41	6273	2179	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: 10 nM DHT+ 500 nM JQ1 for 6 hrs  TF: full-length AR (AR-FL)	GTRD	EXP049392_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	45010
1	513	CTCF	0.141646816194159	0.869289682891643	25	1724	2045	1657	2045	1810	10	6356	2210	CTCF GM12874 (male B-cells) CTCF	GM12874 (male B-cells)	NULL	CTCF		ENCODE	ENCSR000DRR_GM12874_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42119
1	695	CTCF	0.141646816194159	0.869289682891643	25	1724	2045	1657	2045	1810	10	6356	2210	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP039475_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38959
1	517	CTCF	0.141313211013241	0.880683139282978	38	1726	1957	1238	1957	1640	15	6343	2205	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTF_cardiac_fibroblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48643
1	1530	FOS	0.141313211013241	0.880683139282978	38	1726	1957	1238	1957	1640	15	6343	2205	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	8690
1	1531	FOS	0.141313211013241	0.880683139282978	38	1726	1957	1238	1957	1640	15	6343	2205	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	9079
1	1980	GATA3	0.141313211013241	0.880683139282978	38	1726	1957	1238	1957	1640	15	6343	2205	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049898_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	13449
1	3559	SIX2	0.141313211013241	0.880683139282978	38	1726	1957	1238	1957	1640	15	6343	2205	SIX2 HEK SIX2	HEK	NA	SIX2		GEO	GSE73865_six2_hek_MACS_SIX2_MA1119.1.damo.pwm.bed	48175
1	2364	JUN	0.141262529653674	0.910726587319596	97	1731	1843	468	1843	1350	37	6284	2183	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	15955
1	1572	FOSL2	0.140817955440731	0.903379903752932	78	1732	1884	604	1884	1410	30	6303	2190	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BQO_A549_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	31860
1	1154	ESR1	0.140578105216754	0.915679929180819	116	1733	1823	383	1823	1310	44	6265	2176	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	1 h with 100 nM Genistein (Myers)	ENCODE	ENCSR000BJS_T47D_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	27112
1	1637	FOXA1	0.140240486553576	0.938207133285872	265	1734	1692	110	1734	1180	98	6116	2122	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		Array Express	ERP000380_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	47172
1	13	AR	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	ethanol	GTRD	EXP000732_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1354
1	173	AR	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	ETOH24H	GEO	GSE58428_AR_vcap-etoh24h_MACS_AR_MA0007.3.damo.pwm.bed	550
1	326	CEBPA	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047670_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	7785
1	363	CEBPB	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	CEBPB GM12878 (female B-cells lymphoblastoid cell line) CEBPB	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CEBPB		ENCODE	ENCSR681NOM_GM12878_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	2717
1	976	CTCF	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	2D3	GEO	GSE69962_ctcf_thp1-2d3_MACS_CTCF_MA0139.1.damo.pwm.bed	7179
1	995	CUX1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	ENCODE	ENCSR000EFO_K562_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	3142
1	1129	ERG	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	ERG HAEC (human aortic endothelial cells) ERG	HAEC (human aortic endothelial cells)	NULL	ERG	TNFa, 4h	GTRD	EXP038041_HAEC--human-aortic-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	7127
1	1345	ESR1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: DMSO for 45 min  Genotype: wildtype TET2 Passage: 6-10	GTRD	EXP048685_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1138
1	1868	GABPA	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	GABPA HeLa S3 (cervical adenocarcinoma) GABPA	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	GABPA		ENCODE	ENCSR000BHS_HeLa-S3_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	8010
1	1925	GATA1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	GATA1 CD34+ cells GATA1	CD34+ cells	NULL	GATA1	ERYTH_BMP	GEO	GSE29194_gata1_CD34-eryth-bmp_MACS_GATA1_MA0035.4.damo.pwm.bed	17205
1	2146	HNF4A	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	HNF4A HCT-116 (colon carcinoma) HNF4A	HCT-116 (colon carcinoma)	BTO:0001109	HNF4A	TCF4_DOX	GEO	GSE62890_hnf4a_hct166-tcf4-dox_MACS_HNF4A_MA0114.4.damo.pwm.bed	1674
1	2152	HNF4G	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	HNF4G LNCaP (prostate carcinoma) HNF4G	LNCaP (prostate carcinoma)	BTO:0001321	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression	GTRD	EXP048991_LNCaP--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	4215
1	2198	IRF1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	IRF1 K562 (myelogenous leukemia) IRF1	K562 (myelogenous leukemia)	NULL	IRF1	Interferon alpha treatment - 6 hours (Snyder)	ENCODE	ENCSR000EGL_K562_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	2136
1	2201	IRF1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	IRF1 HAEC (human aortic endothelial cells) IRF1	HAEC (human aortic endothelial cells)	NULL	IRF1	TNFa, 4h	GTRD	EXP038039_HAEC--human-aortic-endothelial-cells-_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	3737
1	2462	JUN	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	1912
1	2463	JUN	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	1998
1	2464	JUN	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	1855
1	2465	JUN	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	1840
1	2466	JUN	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	1822
1	2467	JUN	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: RUNX1/ETO knockdown;	GTRD	EXP058212_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	1775
1	2474	JUN	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE71976_jun_bt549_MACS_JUN_MA0488.1.damo.pwm.bed	3138
1	2477	JUNB	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUNB K562 (myelogenous leukemia) JUNB	K562 (myelogenous leukemia)	NULL	JUNB		ENCODE	ENCSR795IYP_K562_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	4064
1	2586	JUND	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	JUND WA01 (H1, human embryonic stem cells) JUND	WA01 (H1, human embryonic stem cells)	NULL	JUND		ENCODE	ENCSR000BKP_H1-hESC_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	10405
1	2651	KLF5	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	KLF5 YCC3 (gastric adenocarcinoma) KLF5	YCC3 (gastric adenocarcinoma)	NULL	KLF5		GEO	GSE51705_klf5_ycc3_MACS_KLF5_MA0599.1.damo.pwm.bed	1889
1	2745	MEF2D	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	MEF2D K562 (myelogenous leukemia) MEF2D	K562 (myelogenous leukemia)	NULL	MEF2D	NA	GTRD	EXP039833_K562--myelogenous-leukemia-_MEF2D_MACS_MEF2D_MA0773.1.damo.pwm.bed	4753
1	2767	MXI1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	MXI1 GM12878 (female B-cells lymphoblastoid cell line) MXI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MXI1	NA	ENCODE	ENCSR000DZI_GM12878_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	4537
1	2781	MYBL2	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	MYBL2 HeLa (cervical adenocarcinoma) MYBL2	HeLa (cervical adenocarcinoma)	BTO:0000567	MYBL2	NA	GTRD	EXP030954_HeLa--cervical-adenocarcinoma-_MYBL2_MACS_MYBL2_MA0777.1.damo.pwm.bed	1778
1	2820	MYC	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC		GTRD	EXP035848_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7188
1	2830	MYC	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt	GTRD	EXP036033_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	12066
1	2901	MYC	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057893_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	2647
1	3099	NR3C1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	NR3C1 MDA-MB-231 (breast adenocarcinoma) NR3C1	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	NR3C1	dexametasone	GTRD	EXP033449_MDA-MB-231--breast-adenocarcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1353
1	3292	PPARG	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034433_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	12068
1	3391	REST	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		ENCODE	ENCSR000BGF_GM12878_REST_MACS_REST_MA0138.2.damo.pwm.bed	5824
1	3424	REST	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		GTRD	EXP054611_GM12878--female-B-cells-lymphoblastoid-cell-line-_REST_MACS_REST_MA0138.2.damo.pwm.bed	4469
1	3446	RFX5	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	RFX5 IMR90 (lung fibroblasts) RFX5	IMR90 (lung fibroblasts)	NULL	RFX5	NA	ENCODE	ENCSR000EFD_IMR-90_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	3624
1	3494	RUNX1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GEO	GSE62847_runx1_kasumi1_MACS_RUNX1_MA0002.2.damo.pwm.bed	10855
1	3816	TCF7L2	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036765_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	8539
1	3941	TFDP1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	TFDP1 K562 (myelogenous leukemia) TFDP1	K562 (myelogenous leukemia)	NULL	TFDP1		ENCODE	ENCSR017GBO_K562_TFDP1_MACS_TFDP1_MA1122.1.damo.pwm.bed	2868
1	3956	TP53	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	TP53 BJ (fibroblasts) TP53	BJ (fibroblasts)	NULL	TP53	none	GTRD	EXP032953_BJ--fibroblasts-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	480
1	4080	USF2	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	USF2 WA01 (H1, human embryonic stem cells) USF2	WA01 (H1, human embryonic stem cells)	NULL	USF2		ENCODE	ENCSR000ECD_H1-hESC_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	6557
1	4108	VDR	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	VDR LX-2 (hepatic stellate cells) VDR	LX-2 (hepatic stellate cells)	BTO:0003516	VDR	CALCIPOTRIOL	GEO	GSE38103_vdr_lx2-calcipotriol_MACS_VDR_MA0693.2.damo.pwm.bed	1526
1	4153	YY1	0.139933152586306	1.04377023194597	3	1735	1335	3252	3252	2110	1	6378	2219	YY1 WA01 (H1, human embryonic stem cells) YY1	WA01 (H1, human embryonic stem cells)	NULL	YY1		GEO	GSE39096_yy1_esc-h1_MACS_YY1_MA0095.2.damo.pwm.bed	5935
1	1394	ESR1	0.139592877766833	0.905394566543521	86	1777	1857	534	1857	1390	33	6295	2187	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE45822_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	30934
1	864	CTCF	0.138304613725376	0.869186771783534	30	1778	2047	1473	2047	1770	12	6351	2208	CTCF PANC1 (pancreatic ductal adenocarcinoma) CTCF	PANC1 (pancreatic ductal adenocarcinoma)	NULL	CTCF		GTRD	EXP048791_PANC1--pancreatic-ductal-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42756
1	1182	ESR1	0.138304613725376	0.869186771783534	30	1778	2047	1473	2047	1770	12	6351	2208	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Estrogen	GTRD	EXP000559_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8205
1	3586	SNAI2	0.138304613725376	0.869186771783534	30	1778	2047	1473	2047	1770	12	6351	2208	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SNAI2	GEO	GSE55421_snai2_keratinocytes-snai2_MACS_SNAI2_MA0745.2.damo.pwm.bed	12093
1	669	CTCF	0.138254207299321	0.891478633028264	59	1781	1923	805	1923	1500	23	6322	2197	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF		GTRD	EXP038767_MCF7--Invasive-ductal-breast-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49563
1	2367	JUN	0.138234055785044	0.907057663602714	94	1782	1854	482	1854	1370	36	6287	2184	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	15431
1	905	CTCF	0.138060207937994	0.88628092156511	51	1783	1939	932	1939	1550	20	6330	2200	CTCF osteoblasts CTCF	osteoblasts	NULL	CTCF	Treatment: None;	GTRD	EXP054042_osteoblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	56480
1	2222	JUN	0.138060207937994	0.88628092156511	51	1783	1939	932	1939	1550	20	6330	2200	JUN HepG2 (hepatoblastoma) JUN	HepG2 (hepatoblastoma)	BTO:0000599	JUN		ENCODE	ENCSR000EEK_HepG2_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	20853
1	17	AR	0.137915839583448	0.89545534246476	67	1785	1903	710	1903	1470	26	6314	2194	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	100 nM DHT+Dex	GTRD	EXP030501_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	22150
1	252	ATF3	0.137915839583448	0.89545534246476	67	1785	1903	710	1903	1470	26	6314	2194	ATF3 glioblastoma cells ATF3	glioblastoma cells	NULL	ATF3	Dox + Arvanil + BMP7	GTRD	EXP031157_glioblastoma-cells_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	35850
1	890	CTCF	0.137915839583448	0.89545534246476	67	1785	1903	710	1903	1470	26	6314	2194	CTCF Jurkat (T-cells) CTCF	Jurkat (T-cells)	BTO:0000661	CTCF	Treatment: untreated	GTRD	EXP053106_Jurkat--T-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	69416
1	1673	FOXA1	0.137338975130632	0.941355011514484	323	1788	1679	80	1788	1180	119	6058	2101	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	BYL719	GTRD	EXP037593_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	75821
1	1414	ESR1	0.137056114718323	0.879215974953359	43	1789	1965	1101	1965	1620	17	6338	2203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCTR_E2	GEO	GSE60270_esr1_mcf7-shctr-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	13136
1	2134	HNF4A	0.137056114718323	0.879215974953359	43	1789	1965	1101	1965	1620	17	6338	2203	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039657_liver_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	52373
1	1819	FOXA2	0.136975011362553	0.928677262366507	198	1791	1729	193	1791	1240	74	6183	2146	FOXA2 H9 FOXA2	H9	NULL	FOXA2		Array Express	ERP004206_foxa2_esc-h9_MACS_FOXA2_MA0047.3.damo.pwm.bed	130865
1	1807	FOXA1	0.136920829690317	0.943748265834711	362	1792	1670	61	1792	1170	133	6019	2087	FOXA1 ZR-75-1 (invasive ductal carcinoma) FOXA1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	FOXA1	DEX	GEO	GSE72249_foxa1_zr751-dex_MACS_FOXA1_MA0148.4.damo.pwm.bed	72458
1	1315	ESR1	0.136248090446017	0.913509946818397	121	1793	1827	362	1827	1330	46	6260	2174	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047664_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23085
1	1419	ESR1	0.135231966240905	0.927117391045394	195	1794	1790	196	1794	1260	73	6186	2147	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	PROG	GEO	GSE68355_ESR1_mcf7-prog_MACS_ESR1_MA0112.3.damo.pwm.bed	56671
1	619	CTCF	0.134759753173639	0.869083698467778	35	1795	2050	1318	2050	1720	14	6346	2206	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	none	GTRD	EXP033055_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	49563
1	1375	ESR1	0.134759753173639	0.869083698467778	35	1795	2050	1318	2050	1720	14	6346	2206	ESR1 MCF7L-P(immortalized breast epithelial cell line) ESR1	MCF7L-P(immortalized breast epithelial cell line)	NULL	ESR1	Treatment: untreated;	GTRD	EXP057857_MCF7L-P-immortalized-breast-epithelial-cell-line-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6875
1	4113	WT1	0.134759753173639	0.869083698467778	35	1795	2050	1318	2050	1720	14	6346	2206	WT1 K562 (myelogenous leukemia) WT1	K562 (myelogenous leukemia)	NULL	WT1	NA	GTRD	EXP037398_K562--myelogenous-leukemia-_WT1_MACS_WT1_MA1627.1.damo.pwm.bed	117299
1	110	AR	0.133884291171971	0.904917006475147	99	1798	1860	455	1860	1370	38	6282	2182	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052953_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	39193
1	1177	ESR1	0.133884291171971	0.904917006475147	99	1798	1860	455	1860	1370	38	6282	2182	ESR1 ESR1	NA	NA	ESR1	NA	Array Express	ERP003828_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	24033
1	1260	ESR1	0.133848707096724	0.889559860082748	64	1800	1926	747	1926	1490	25	6317	2195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038373_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15427
1	2704	MAX	0.133737728542995	0.884596249070395	56	1801	1948	859	1948	1540	22	6325	2198	MAX HeLa (cervical adenocarcinoma) MAX	HeLa (cervical adenocarcinoma)	BTO:0000567	MAX		GTRD	EXP031874_HeLa--cervical-adenocarcinoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	30007
1	1721	FOXA1	0.133285351892105	0.91755998029881	148	1802	1816	287	1816	1300	56	6233	2164	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: R1881	GTRD	EXP048915_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	34079
1	182	AR	0.132961584809181	0.878035785793812	48	1803	1969	982	1969	1580	19	6333	2201	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881	GEO	GSE62492_AR_lncap-r1881_MACS_AR_MA0007.3.damo.pwm.bed	17613
1	3553	SCRT1	0.132850656389571	0.896550560677833	80	1804	1896	585	1896	1430	31	6301	2189	SCRT1 HEK293 (embryonic kidney) SCRT1	HEK293 (embryonic kidney)	NULL	SCRT1	NA	GTRD	EXP035930_HEK293--embryonic-kidney-_SCRT1_MACS_SCRT1_MA0743.2.damo.pwm.bed	91668
1	4030	TP63	0.132850656389571	0.896550560677833	80	1804	1896	585	1896	1430	31	6301	2189	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	Ad-LacZ	GTRD	EXP033936_HaCaT--keratinocytes-_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	5594
1	293	BHLHE40	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	BHLHE40 HepG2 (hepatoblastoma) BHLHE40	HepG2 (hepatoblastoma)	BTO:0000599	BHLHE40	NA	ENCODE	ENCSR000EDT_HepG2_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	18512
1	541	CTCF	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DWY_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33852
1	1201	ESR1	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	cells transfected with siNCAPD3 and H2 together, and 1hr with 100nM E2, double crosslinked	GTRD	EXP034121_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	4364
1	1348	ESR1	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: E2 (estrogen) for 45 min  Genotype: TET2 knockout Passage: 6-10	GTRD	EXP048688_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6157
1	1432	ESR1	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE72249_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	2755
1	1999	GATA3	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	GATA3 BE2C GATA3	BE2C	NULL	GATA3		GEO	GSE65664_gata3_be2c_MACS_GATA3_MA0037.3.damo.pwm.bed	20942
1	3066	NR2F1	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	NR2F1 HepG2 (hepatoblastoma) NR2F1	HepG2 (hepatoblastoma)	BTO:0000599	NR2F1	NA	GTRD	EXP039919_HepG2--hepatoblastoma-_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	23493
1	3136	NR3C1	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	NR3C1 Ishikawa (endometrial adenocarcinoma) NR3C1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	NR3C1	Treatment: 100 nM Dexamethasone and 10 nM Estradiol for 1 hour	GTRD	EXP048232_Ishikawa--endometrial-adenocarcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	10499
1	3397	REST	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	REST HeLa S3 (cervical adenocarcinoma) REST	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	REST		ENCODE	ENCSR000BMN_HeLa-S3_REST_MACS_REST_MA0138.2.damo.pwm.bed	16329
1	3833	TEAD4	0.132831499178737	0.844549350848785	17	1806	2129	2066	2129	2000	7	6364	2213	TEAD4 WA01 (H1, human embryonic stem cells) TEAD4	WA01 (H1, human embryonic stem cells)	NULL	TEAD4		ENCODE	ENCSR000BRY_H1-hESC_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	43215
1	630	CTCF	0.132167399031919	0.849965663914548	22	1816	2115	1797	2115	1910	9	6359	2211	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036700_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41282
1	645	CTCF	0.132167399031919	0.849965663914548	22	1816	2115	1797	2115	1910	9	6359	2211	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP036857_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41646
1	802	CTCF	0.132167399031919	0.849965663914548	22	1816	2115	1797	2115	1910	9	6359	2211	CTCF smooth muscle cell CTCF	smooth muscle cell	BTO:0004576	CTCF		GTRD	EXP040298_smooth-muscle-cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38771
1	858	CTCF	0.132167399031919	0.849965663914548	22	1816	2115	1797	2115	1910	9	6359	2211	CTCF LUHMES (lund human mesencephalic cells) CTCF	LUHMES (lund human mesencephalic cells)	NULL	CTCF	Sex: female Passages: 3-10 Stage: neural progenitor cells, undifferentiated Treatment: Prior to differentiation, cells were seeded at 3.5 x 10^6 per T75 flask containing complete growth medium and incubated at 37 °C for 24 hr	GTRD	EXP048229_LUHMES--lund-human-mesencephalic-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40427
1	3887	TFAP2C	0.132167399031919	0.849965663914548	22	1816	2115	1797	2115	1910	9	6359	2211	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047536_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	23753
1	2366	JUN	0.131969041317644	0.899095708065538	88	1821	1890	525	1890	1410	34	6293	2186	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	15443
1	1670	FOXA1	0.131625412693312	0.931403642654975	247	1822	1720	132	1822	1220	92	6134	2128	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	No treatment	GTRD	EXP037433_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	42289
1	1709	FOXA1	0.131500996579398	0.9178858185997	156	1823	1815	264	1823	1300	59	6225	2161	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048448_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	31428
1	128	AR	0.131168936507214	0.868980462560639	40	1824	2053	1189	2053	1690	16	6341	2204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1F5	GEO	GSE30623_ar_lncap1f5_MACS_AR_MA0007.3.damo.pwm.bed	13151
1	187	AR	0.131168936507214	0.868980462560639	40	1824	2053	1189	2053	1690	16	6341	2204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GEO	GSE64656_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	10587
1	3866	TFAP2A	0.131168936507214	0.868980462560639	40	1824	2053	1189	2053	1690	16	6341	2204	TFAP2A hiPSC TFAP2A	hiPSC	NULL	TFAP2A	Genotype: wildtype Treatment: hiPSC differentiation into hNCC (passage 2)	GTRD	EXP052981_hiPSC_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	38441
1	325	CEBPA	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	CEBPA SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) CEBPA	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	CEBPA	Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER);	GTRD	EXP047670_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	13619
1	385	CEBPB	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	CEBPB OCI-AML3 CEBPB	OCI-AML3	BTO:0004620	CEBPB	JQ1, 500 nM for 24 h	GTRD	EXP040656_OCI-AML3_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	4029
1	778	CTCF	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	CTCF omental fat pad CTCF	omental fat pad	NULL	CTCF		GTRD	EXP040090_omental-fat-pad_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	10433
1	847	CTCF	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under heat shock conditions	GTRD	EXP047907_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	12526
1	1169	ESR1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2_TAM	Array Express	ERP000380_esr1_t47d-e2-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	655
1	1218	ESR1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP036388_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1231
1	1347	ESR1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: DMSO for 45 min  Genotype: TET2 knockout Passage: 6-10	GTRD	EXP048687_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1026
1	1827	FOXA2	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	FOXA2 HUES64 (embryonic stem cells) FOXA2	HUES64 (embryonic stem cells)	NULL	FOXA2		GTRD	EXP036706_HUES64--embryonic-stem-cells-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	6521
1	2647	KLF5	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049099_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	1270
1	2823	MYC	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC	100 nM of JQ1	GTRD	EXP035850_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	10412
1	2832	MYC	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036034_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15288
1	2833	MYC	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036034_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16078
1	2943	MYCN	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	MYCN IMR-5 (Neuroblastoma) MYCN	IMR-5 (Neuroblastoma)	NULL	MYCN	Treatment: DMSO for 4 hr	GTRD	EXP048884_IMR-5--Neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	12027
1	3231	PDX1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	PDX1 hESC-1 (Embryonic stem cells) PDX1	hESC-1 (Embryonic stem cells)	NULL	PDX1		GEO	GSE58685_pdx1_esc_MACS_PDX1_MA0132.2.damo.pwm.bed	9220
1	3279	POU5F1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	POU5F1 hiPSC POU5F1	hiPSC	NULL	POU5F1		GEO	GSE56567_pou5f1_ipsc_MACS_POU5F1_MA1115.1.damo.pwm.bed	16342
1	3343	RELA	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	RELA GM12892 (female B-cells lymphoblastoid cell line) RELA	GM12892 (female B-cells lymphoblastoid cell line)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000764_GM12892--female-B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11424
1	3390	REST	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		ENCODE	ENCSR000ATM_K562_REST_MACS_REST_MA0138.2.damo.pwm.bed	5172
1	3454	RUNX1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	RUNX1 CMK (acute megakaryoblastic leukemia) RUNX1	CMK (acute megakaryoblastic leukemia)	BTO:0000978	RUNX1		GTRD	EXP000583_CMK--acute-megakaryoblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	11920
1	3459	RUNX1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP031176_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	12688
1	3519	RXRA	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	RXRA monocyte-derived macrophages RXRA	monocyte-derived macrophages	NULL	RXRA	untreated	GTRD	EXP036837_monocyte-derived-macrophages_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	13103
1	3630	SP1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036142_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	13810
1	3748	STAT4	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	STAT4 T-cells STAT4	T-cells	NULL	STAT4	IL-12	GTRD	EXP000395_T-cells_STAT4_MACS_STAT4_MA0518.1.damo.pwm.bed	9254
1	3783	TCF12	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	TCF12 K562 (myelogenous leukemia) TCF12	K562 (myelogenous leukemia)	NULL	TCF12	NA	GTRD	EXP039447_K562--myelogenous-leukemia-_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	19025
1	3786	TCF12	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	TCF12 Kasumi-1 (acute myeloblastic leukemia) TCF12	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF12	NA	GEO	GSE43834_tcf12_kasumi1_MACS_TCF12_MA0521.1.damo.pwm.bed	12148
1	4021	TP53	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53		GEO	GSE58506_tp53_hct166_MACS_TP53_MA0106.3.damo.pwm.bed	424
1	4070	USF1	0.131091513168475	0.869699712880161	5	1827	1988	2973	2973	2260	2	6376	2218	USF1 A549 (lung carcinoma) USF1	A549 (lung carcinoma)	BTO:0000018	USF1	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHX_A549_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	8112
1	139	AR	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	AR LNCaP C4-2B (prostate carcinoma) AR	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	AR	DHT	GEO	GSE40050_AR_c42b-dht_MACS_AR_MA0007.3.damo.pwm.bed	2350
1	732	CTCF	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	CTCF tibial artery CTCF	tibial artery	NULL	CTCF		GTRD	EXP039723_tibial-artery_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29046
1	816	CTCF	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: IFNb treated 6hr, eGFP(EP mRNA)	GTRD	EXP047761_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27682
1	881	CTCF	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: no stress  Source: T47D whole cell	GTRD	EXP053048_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31395
1	1295	ESR1	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	ESR1 breast tumor ESR1	breast tumor	NULL	ESR1	Male	GTRD	EXP040670_breast-tumor_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3484
1	1654	FOXA1	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033206_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	10034
1	2595	JUND	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	JUND WA01 (H1, human embryonic stem cells) JUND	WA01 (H1, human embryonic stem cells)	NULL	JUND		ENCODE	ENCSR000EBZ_H1-hESC_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	15572
1	2645	KLF5	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	KLF5 HCC95 (squamous cell lung carcinoma) KLF5	HCC95 (squamous cell lung carcinoma)	NULL	KLF5	Treatment: Over-expressing KLF5 E419Q	GTRD	EXP049097_HCC95--squamous-cell-lung-carcinoma-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	5979
1	2829	MYC	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector, Doxycycline	GTRD	EXP036032_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	16285
1	2988	NEUROG2	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037157_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	25285
1	3269	POU5F1	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048951_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	11369
1	3453	RUNX1	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	RUNX1 megakaryocytes RUNX1	megakaryocytes	NULL	RUNX1	NULL	GTRD	EXP000353_megakaryocytes_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	32030
1	3684	SPI1	0.130702117399668	0.834656844969897	12	1853	2163	2359	2359	2120	5	6369	2215	SPI1 OCI-LY7 (diffuse large B-cell lymphoma) SPI1	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE69558_spi1_ocily7_MACS_SPI1_MA0080.5.damo.pwm.bed	31725
1	682	CTCF	0.130253930394739	0.853374947197231	27	1866	2106	1564	2106	1850	11	6354	2209	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039406_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37344
1	857	CTCF	0.130253930394739	0.853374947197231	27	1866	2106	1564	2106	1850	11	6354	2209	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:unsynchronized	GTRD	EXP048092_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33861
1	2063	GRHL2	0.129738778066913	0.918170657440674	164	1868	1814	246	1868	1310	62	6217	2158	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	100nm E2 (45 min)	GTRD	EXP040966_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	29051
1	579	CTCF	0.129685953135581	0.887909808138544	69	1869	1935	687	1935	1500	27	6312	2193	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000778_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	85518
1	1302	ESR1	0.129685953135581	0.887909808138544	69	1869	1935	687	1935	1500	27	6312	2193	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040951_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17965
1	10	AR	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1nm R	GTRD	EXP000729_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	596
1	148	AR	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	FOXA1_HIGH	GEO	GSE47987_AR_du145-foxa1-high_MACS_AR_MA0007.3.damo.pwm.bed	330
1	245	ATF3	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ATF3 HepG2 (hepatoblastoma) ATF3	HepG2 (hepatoblastoma)	BTO:0000599	ATF3		ENCODE	ENCSR000BKE_HepG2_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	2220
1	291	BHLHE40	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	BHLHE40 HepG2 (hepatoblastoma) BHLHE40	HepG2 (hepatoblastoma)	BTO:0000599	BHLHE40	NA	ENCODE	ENCSR000BID_HepG2_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	3107
1	429	CREB1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	CREB1 KG1 (acute myeloid leukemia) CREB1	KG1 (acute myeloid leukemia)	BTO:0000670	CREB1	XX65023	GEO	GSE74928_CREB1_kg1-xx65023_MACS_CREB1_MA0018.4.damo.pwm.bed	3319
1	648	CTCF	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	CTCF 226LDM (normal breast luminal cells) CTCF	226LDM (normal breast luminal cells)	NULL	CTCF	untreated	GTRD	EXP036890_226LDM--normal-breast-luminal-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	1417
1	997	CUX1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	ENCODE	ENCSR178NTX_K562_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	446
1	999	CUX1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	GTRD	EXP038272_K562--myelogenous-leukemia-_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	1947
1	1034	E2F4	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	E2F4 HeLa S3 (cervical adenocarcinoma) E2F4	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	E2F4		ENCODE	ENCSR000EVL_HeLa-S3_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	1370
1	1036	E2F4	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	E2F4 mesenchymal stem cells-derived adipocytes E2F4	mesenchymal stem cells-derived adipocytes	NULL	E2F4	NULL	GTRD	EXP000564_mesenchymal-stem-cells-derived-adipocytes_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	5068
1	1048	E2F7	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	E2F7 K562 (myelogenous leukemia) E2F7	K562 (myelogenous leukemia)	NULL	E2F7	NA	GTRD	EXP039849_K562--myelogenous-leukemia-_E2F7_MACS_E2F7_MA0758.1.damo.pwm.bed	337
1	1068	EGR1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	EGR1 HL-60 (acute myeloid leukemia) EGR1	HL-60 (acute myeloid leukemia)	BTO:0000738	EGR1	Treatment: PMA treated (16h)	GTRD	EXP047938_HL-60--acute-myeloid-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	8082
1	1130	ERG	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ERG HAEC (human aortic endothelial cells) ERG	HAEC (human aortic endothelial cells)	NULL	ERG	control, 4h	GTRD	EXP038045_HAEC--human-aortic-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	5549
1	1132	ERG	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048201_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	4390
1	1133	ERG	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048202_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	3857
1	1307	ESR1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040956_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	231
1	1397	ESR1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHESR1	GEO	GSE53531_esr1_mcf7-shesr1_MACS_ESR1_MA0112.3.damo.pwm.bed	16
1	1399	ESR1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LETR	GEO	GSE54592_esr1_letr_MACS_ESR1_MA0112.3.damo.pwm.bed	225
1	1442	ESR2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ESR2 MCF7 (Invasive ductal breast carcinoma) ESR2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR2	C412_E2	GEO	GSE48096_esr2_mcf7c412-e2_MACS_ESR2_MA0258.2.damo.pwm.bed	1581
1	1444	ESRRA	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ESRRA HepG2 (hepatoblastoma) ESRRA	HepG2 (hepatoblastoma)	BTO:0000599	ESRRA	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEW_HepG2_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	897
1	1481	ETV6	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ETV6 K562 (myelogenous leukemia) ETV6	K562 (myelogenous leukemia)	NULL	ETV6		ENCODE	ENCSR000FCE_K562_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	3687
1	1482	ETV6	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ETV6 K562 (myelogenous leukemia) ETV6	K562 (myelogenous leukemia)	NULL	ETV6		ENCODE	ENCSR124BJR_K562_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	4225
1	1499	FLI1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048208_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	13603
1	1513	FLI1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1		GEO	GSE61944_fli1_skmnc_MACS_FLI1_MA0475.2.damo.pwm.bed	2647
1	1855	FOXO1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	FOXO1 B-cells FOXO1	B-cells	NULL	FOXO1	GERMINAL_CENTER	GEO	GSE68349_foxo1_gcb_MACS_FOXO1_MA0480.1.damo.pwm.bed	5068
1	1860	FOXP1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	FOXP1 HBL1 (diffuse large B-cell lymphoma) FOXP1	HBL1 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	GTRD	EXP034307_HBL1--diffuse-large-B-cell-lymphoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	1301
1	1867	GABPA	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GABPA GABPA	NA	NA	GABPA	NA	NA	ENCSR000BGC_GM12878_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	3715
1	1883	GABPA	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GABPA GM12878 (female B-cells lymphoblastoid cell line) GABPA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	GABPA		GTRD	EXP054610_GM12878--female-B-cells-lymphoblastoid-cell-line-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	8469
1	1912	GATA1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	2-trimester fetal liver	GTRD	EXP031447_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	4475
1	1913	GATA1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	2-trimester fetal liver	GTRD	EXP031447_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	4838
1	1947	GATA2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048220_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	4900
1	1998	GATA3	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GEO	GSE60270_gata3_mcf7_MACS_GATA3_MA0037.3.damo.pwm.bed	343
1	2029	GATA6	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GATA6 HUES64 (embryonic stem cells) GATA6	HUES64 (embryonic stem cells)	NULL	GATA6		GTRD	EXP036710_HUES64--embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	6531
1	2046	GFI1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	GFI1 AML (monocytes and acute myeloid leukemia) GFI1	AML (monocytes and acute myeloid leukemia)	NULL	GFI1	Treatment: LSD1 inhibitor OG86	GTRD	EXP049355_AML--monocytes-and-acute-myeloid-leukemia-_GFI1_MACS_GFI1_MA0038.2.damo.pwm.bed	1542
1	2174	HSF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	HSF1 GM12878 (female B-cells lymphoblastoid cell line) HSF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	HSF1		ENCODE	ENCSR009MBP_GM12878_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	3656
1	2175	HSF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1		ENCODE	ENCSR062HDL_MCF-7_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	319
1	2178	HSF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	HSF1 WA09 (embryonic stem cells) HSF1	WA09 (embryonic stem cells)	NULL	HSF1	Treatment: under heat shock conditions	GTRD	EXP047923_WA09--embryonic-stem-cells-_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	1974
1	2180	HSF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	HSF1 BPLER (mammary epithelial cells) HSF1	BPLER (mammary epithelial cells)	NULL	HSF1		GEO	GSE38901_hsf1_bpler_MACS_HSF1_MA0486.2.damo.pwm.bed	939
1	2183	HSF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	HSF1 colon HSF1	colon	NA	HSF1	tumor	GEO	GSE38901_hsf1_colon-tumor_MACS_HSF1_MA0486.2.damo.pwm.bed	796
1	2191	HSF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	HSF1 MCF7 (Invasive ductal breast carcinoma) HSF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	HSF1	CHX_10UM	GEO	GSE45852_hsf1_mcf7-chx-10um_MACS_HSF1_MA0486.2.damo.pwm.bed	882
1	2227	JUN	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000EGH_K562_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	4471
1	2228	JUN	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000EGH_K562_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	3867
1	2633	KLF4	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	KLF4 U87 (glioblastoma) KLF4	U87 (glioblastoma)	NULL	KLF4		GTRD	EXP038480_U87--glioblastoma-_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	314
1	2635	KLF4	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	KLF4 WA09 (embryonic stem cells) KLF4	WA09 (embryonic stem cells)	NULL	KLF4	Treatment: under heat shock conditions	GTRD	EXP047913_WA09--embryonic-stem-cells-_KLF4_MACS_KLF4_MA0039.4.damo.pwm.bed	1387
1	2668	MAF	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: resting;Day:0;	GTRD	EXP047560_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	997
1	2736	MEF2B	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: D83V-MEF2B-V5;	GTRD	EXP055132_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	473
1	2754	MITF	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MITF melanocytes MITF	melanocytes	NULL	MITF	none	GTRD	EXP033917_melanocytes_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	1785
1	2763	MNT	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MNT K562 (myelogenous leukemia) MNT	K562 (myelogenous leukemia)	NULL	MNT	NA	GTRD	EXP039471_K562--myelogenous-leukemia-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	2667
1	2850	MYC	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036779_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	1153
1	2851	MYC	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036779_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	1171
1	2895	MYC	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYC MRC-5 (fetal lung fibroblasts) MYC	MRC-5 (fetal lung fibroblasts)	BTO:0001590	MYC	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048963_MRC-5--fetal-lung-fibroblasts-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	812
1	2896	MYC	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYC MRC-5 (fetal lung fibroblasts) MYC	MRC-5 (fetal lung fibroblasts)	BTO:0001590	MYC	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048963_MRC-5--fetal-lung-fibroblasts-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	951
1	2928	MYC	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	SHTERT	GEO	GSE60223_myc_p493-shtert_MACS_MYC_MA0147.3.damo.pwm.bed	1280
1	2931	MYC	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYC breast MYC	breast	NA	MYC	primary	GEO	GSE66252_myc_primary-breast_MACS_MYC_MA0147.3.damo.pwm.bed	1343
1	2932	MYC	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYC IMEC MYC	IMEC	NA	MYC		GEO	GSE70001_myc_imec_MACS_MYC_MA0147.3.damo.pwm.bed	1498
1	2958	MYOD1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	MYOD1 dermal fibroblasts MYOD1	dermal fibroblasts	BTO:0004419	MYOD1	NA	GTRD	EXP038296_dermal-fibroblasts_MYOD1_MACS_MYOD1_MA0499.2.damo.pwm.bed	3957
1	3029	NFYA	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NFYA K562 (myelogenous leukemia) NFYA	K562 (myelogenous leukemia)	NULL	NFYA	NA	ENCODE	ENCSR000EGR_K562_NFYA_MACS_NFYA_MA0060.3.damo.pwm.bed	4230
1	3042	NR1H3	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR1H3 SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes) NR1H3	SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes)	NULL	NR1H3	NA	GEO	GSE41629_nr1h3_sgbs_MACS_NR1H3_MA0494.1.damo.pwm.bed	543
1	3044	NR1H4	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR1H4 NR1H4	NA	NA	NR1H4	NA	GEO	GSE57227_nr1h4_primaryhepatocyte-gw4064_MACS_NR1H4_MA1110.1.damo.pwm.bed	2031
1	3045	NR2C1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2C1 K562 (myelogenous leukemia) NR2C1	K562 (myelogenous leukemia)	NULL	NR2C1	NA	GTRD	EXP039366_K562--myelogenous-leukemia-_NR2C1_MACS_NR2C1_MA1535.1.damo.pwm.bed	4650
1	3046	NR2C1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2C1 GM12878 (female B-cells lymphoblastoid cell line) NR2C1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2C1	NA	GTRD	EXP039607_GM12878--female-B-cells-_NR2C1_MACS_NR2C1_MA1535.1.damo.pwm.bed	3085
1	3047	NR2C1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2C1 K562 (myelogenous leukemia) NR2C1	K562 (myelogenous leukemia)	NULL	NR2C1	NA	GTRD	EXP039725_K562--myelogenous-leukemia-_NR2C1_MACS_NR2C1_MA1535.1.damo.pwm.bed	2878
1	3050	NR2C2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2C2 HepG2 (hepatoblastoma) NR2C2	HepG2 (hepatoblastoma)	BTO:0000599	NR2C2		ENCODE	ENCSR000EVS_HepG2_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	1714
1	3053	NR2C2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2C2 HepG2 (hepatoblastoma) NR2C2	HepG2 (hepatoblastoma)	BTO:0000599	NR2C2	NULL	GTRD	EXP000578_HepG2--hepatoblastoma-_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	5299
1	3056	NR2C2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2C2 VA13 (transformed lung fibroblasts) NR2C2	VA13 (transformed lung fibroblasts)	NULL	NR2C2		GEO	GSE46237_nr2c2_wi38va13_MACS_NR2C2_MA0504.1.damo.pwm.bed	1134
1	3061	NR2F1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2F1 H9-derived neural crest cells NR2F1	H9-derived neural crest cells	NULL	NR2F1	NA	GTRD	EXP030994_H9-derived-neural-crest-cells_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	4292
1	3074	NR2F2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2F2 H9-derived neural crest cells NR2F2	H9-derived neural crest cells	NULL	NR2F2		GTRD	EXP030995_H9-derived-neural-crest-cells_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	2893
1	3077	NR2F2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR2F2 VA13 (transformed lung fibroblasts) NR2F2	VA13 (transformed lung fibroblasts)	NULL	NR2F2		GEO	GSE46237_nr2f2_wi38va13_MACS_NR2F2_MA1111.1.damo.pwm.bed	3581
1	3147	NR3C1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NR3C1 monocytes of peripheral blood NR3C1	monocytes of peripheral blood	NULL	NR3C1	Treatment: treated with 1 micromolar (1uM) TA for 4 hours; Source: Adult Human Peripheral Blood; Donor:Buffycoat 12;	GTRD	EXP057900_monocytes-of-peripheral-blood_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	1019
1	3169	NRF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NRF1 HeLa S3 (cervical adenocarcinoma) NRF1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NRF1		ENCODE	ENCSR000EDJ_HeLa-S3_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	2695
1	3170	NRF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NRF1 HepG2 (hepatoblastoma) NRF1	HepG2 (hepatoblastoma)	BTO:0000599	NRF1		ENCODE	ENCSR000EEH_HepG2_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	1958
1	3172	NRF1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	NRF1 MCF7 (Invasive ductal breast carcinoma) NRF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NRF1		ENCODE	ENCSR135ANT_MCF-7_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	4422
1	3263	POU5F1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	Treatment: under heat shock conditions	GTRD	EXP047915_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	7724
1	3274	POU5F1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	POU5F1 iPSC (induced pluripotent stem cells) POU5F1	iPSC (induced pluripotent stem cells)	NULL	POU5F1	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048953_iPSC--induced-pluripotent-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	6443
1	3282	PPARG	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	PPARG macrophages PPARG	macrophages	NULL	PPARG		Array Express	ERP008801_pparg_macrophage_MACS_PPARG_MA0066.1.damo.pwm.bed	253
1	3283	PPARG	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	PPARG Simpson Golabi Behmel Syndrome adipocytes PPARG	Simpson Golabi Behmel Syndrome adipocytes	NULL	PPARG	NULL	GTRD	EXP000907_Simpson-Golabi-Behmel-Syndrome-adipocytes_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	5143
1	3298	PPARG	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	PPARG THP-1 (acute monocytic leukemia) PPARG	THP-1 (acute monocytic leukemia)	BTO:0001370	PPARG	DIFF	GEO	GSE25426_pparg_thp1-diff_MACS_PPARG_MA0066.1.damo.pwm.bed	565
1	3304	PRDM1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1	HUES64 dEN	GTRD	EXP036696_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	2886
1	3306	PRDM1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	PRDM1 U266 (plasma cell myeloma) PRDM1	U266 (plasma cell myeloma)	BTO:0001594	PRDM1		GTRD	EXP040447_U266--plasma-cell-myeloma-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	2632
1	3342	RELA	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	RELA GM15510 (B-cells) RELA	GM15510 (B-cells)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000762_GM15510--B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5592
1	3381	RELA	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA		GEO	GSE59530_rela_mcf7_MACS_RELA_MA0107.1.damo.pwm.bed	378
1	3383	RELA	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	RELA L1236 (Hodgkin lymphoma) RELA	L1236 (Hodgkin lymphoma)	NULL	RELA		GEO	GSE63736_rela_l1236_MACS_RELA_MA0107.1.damo.pwm.bed	405
1	3451	RUNX1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	RUNX1 K562 (myelogenous leukemia) RUNX1	K562 (myelogenous leukemia)	NULL	RUNX1		ENCODE	ENCSR414TYY_K562_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	1943
1	3477	RUNX1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	RUNX1 NALM-6 (adult B acute lymphoblastic leukemia) RUNX1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	RUNX1	Tissue: Peripheral blood	GTRD	EXP048188_NALM-6--adult-B-acute-lymphoblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	2464
1	3482	RUNX1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	RUNX1 TF-1 (erythroleukemia) RUNX1	TF-1 (erythroleukemia)	BTO:0004760	RUNX1	Genotype: TF-1-RAD21 Q592*; Treatment: DOX for 6 days;	GTRD	EXP055352_TF-1--erythroleukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	1827
1	3557	SIX1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SIX1 SIX1	NA	NA	SIX1	NA	GEO	GSE75948_six1_fetal-kidney-16w_MACS_SIX1_MA1118.1.damo.pwm.bed	1211
1	3558	SIX1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SIX1 SIX1	NA	NA	SIX1	NA	GEO	GSE75948_six1_fetal-kidney-17w_MACS_SIX1_MA1118.1.damo.pwm.bed	2258
1	3590	SOX17	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SOX17 HUES64 (embryonic stem cells) SOX17	HUES64 (embryonic stem cells)	NULL	SOX17	NA	GTRD	EXP036747_HUES64--embryonic-stem-cells-_SOX17_MACS_SOX17_MA0078.1.damo.pwm.bed	859
1	3593	SOX2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP032066_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	4670
1	3598	SOX2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036753_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	5152
1	3600	SOX2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036809_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	8124
1	3614	SOX2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SOX2 RENVM SOX2	RENVM	NA	SOX2	SHSOX2	GEO	GSE49404_sox2_renvm-shsox2_MACS_SOX2_MA0143.4.damo.pwm.bed	1985
1	3617	SOX2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SOX2 hiPSC SOX2	hiPSC	NULL	SOX2	INHI	GEO	GSE67282_sox2_ipsc-inhi_MACS_SOX2_MA0143.4.damo.pwm.bed	2039
1	3618	SOX2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SOX2 hiPSC SOX2	hiPSC	NULL	SOX2	KDP53_INHI	GEO	GSE67282_sox2_ipsc-kdp53-inhi_MACS_SOX2_MA0143.4.damo.pwm.bed	5053
1	3639	SP2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SP2 HEK293T (embryonic kidney) SP2	HEK293T (embryonic kidney)	BTO:0002181	SP2	NA	Array Express	ERP007114_sp2_hek293t_MACS_SP2_MA0516.2.damo.pwm.bed	8394
1	3673	SPI1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SPI1 OCI-LY10 (diffuse large B-cell lymphoma) SPI1	OCI-LY10 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE56857_spi1_ocily10_MACS_SPI1_MA0080.5.damo.pwm.bed	6570
1	3691	SPI1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1	SAHA	GEO	GSE74999_spi1_k562-saha_MACS_SPI1_MA0080.5.damo.pwm.bed	9337
1	3715	SRF	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053074_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	2934
1	3788	TCF3	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TCF3 Kasumi-1 (acute myeloblastic leukemia) TCF3	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF3	Genotype: overexpress E2A Source: Myeloblast Cell type:  leukemic cell line with an 8;21 chromosome translocation Passage: 4-5	GTRD	EXP053212_Kasumi-1--acute-myeloblastic-leukemia-_TCF3_MACS_TCF3_MA0091.1.damo.pwm.bed	5348
1	3789	TCF3	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TCF3 Kasumi-1 (acute myeloblastic leukemia) TCF3	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF3	Genotype: overexpress E2A Source: Myeloblast Cell type:  leukemic cell line with an 8;21 chromosome translocation Passage: 4-5	GTRD	EXP053212_Kasumi-1--acute-myeloblastic-leukemia-_TCF3_MACS_TCF3_MA0522.3.damo.pwm.bed	4845
1	3793	TCF3	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TCF3 TCF3	NA	NA	TCF3	NA	GEO	GSE72828_tcf3_ra1_MACS_TCF3_MA0522.3.damo.pwm.bed	4794
1	3812	TCF7L2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TCF7L2 HepG2 (hepatoblastoma) TCF7L2	HepG2 (hepatoblastoma)	BTO:0000599	TCF7L2		ENCODE	ENCSR000EVQ_HepG2_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	1381
1	3819	TCF7L2	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TCF7L2 HUES64 (embryonic stem cells) TCF7L2	HUES64 (embryonic stem cells)	NULL	TCF7L2		GTRD	EXP036768_HUES64--embryonic-stem-cells-_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	1729
1	3909	TFAP2C	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058230_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	1031
1	3910	TFAP2C	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058230_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	970
1	3911	TFAP2C	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen +1,6-Hexanediol;	GTRD	EXP058230_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	873
1	3942	TFDP1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TFDP1 MM1.S (plasma cell myeloma) TFDP1	MM1.S (plasma cell myeloma)	BTO:0003933	TFDP1	none	GTRD	EXP037392_MM1.S--plasma-cell-myeloma-_TFDP1_MACS_TFDP1_MA1122.1.damo.pwm.bed	6577
1	3946	THAP11	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036772_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	3160
1	3948	THAP11	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036774_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	1517
1	3966	TP53	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	untreated	GTRD	EXP036873_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	165
1	3968	TP53	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	untreated	GTRD	EXP036875_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	136
1	3998	TP53	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TP53 foreskin fibroblast TP53	foreskin fibroblast	NULL	TP53	Treatment: DMSO for 6 hrs;	GTRD	EXP057959_foreskin-fibroblast_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	710
1	4025	TP53	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TP53 TP53	NA	NA	TP53	NA	GEO	GSE59176_tp53_mdamb175vii_MACS_TP53_MA0106.3.damo.pwm.bed	186
1	4066	TWIST1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	TWIST1 SHEP-21N TWIST1	SHEP-21N	NA	TWIST1	DOX_24H	GEO	GSE80151_twist1_shep21-dox-24h_MACS_TWIST1_MA1123.2.damo.pwm.bed	2273
1	4094	VDR	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	VDR primary foreskin fibroblasts VDR	primary foreskin fibroblasts	BTO:0000452	VDR	vitamin D treated	GTRD	EXP037202_primary-foreskin-fibroblasts_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	208
1	4095	VDR	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	VDR primary foreskin fibroblasts VDR	primary foreskin fibroblasts	BTO:0000452	VDR	vitamin D treated	GTRD	EXP037202_primary-foreskin-fibroblasts_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	128
1	4104	VDR	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	VDR RWPE1 (prostate epithelial cells) VDR	RWPE1 (prostate epithelial cells)	BTO:0003709	VDR	Treatment: vitamin D;	GTRD	EXP058196_RWPE1--prostate-epithelial-cells-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	89
1	4105	VDR	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	VDR RWPE1 (prostate epithelial cells) VDR	RWPE1 (prostate epithelial cells)	BTO:0003709	VDR	Treatment: vitamin D;	GTRD	EXP058196_RWPE1--prostate-epithelial-cells-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	62
1	4131	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 HeLa (cervical adenocarcinoma) YY1	HeLa (cervical adenocarcinoma)	BTO:0000567	YY1		GTRD	EXP036996_HeLa--cervical-adenocarcinoma-_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2764
1	4132	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038602_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	3135
1	4133	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038603_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1844
1	4134	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038604_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2589
1	4136	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038606_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2418
1	4139	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1 hemizygous deletion	GTRD	EXP038609_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1033
1	4140	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Leu366Pro)	GTRD	EXP038610_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1188
1	4142	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038612_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2972
1	4143	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038613_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2017
1	4145	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038615_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	2073
1	4146	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Asp380Tyr)	GTRD	EXP038616_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1459
1	4147	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Lys179*)	GTRD	EXP038617_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1029
1	4151	YY1	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	YY1 Jurkat (T-cells) YY1	Jurkat (T-cells)	BTO:0000661	YY1		GTRD	EXP049911_Jurkat--T-cells-_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	856
1	4157	ZFX	0.129660203043756	Inf	1	1871	1	3585	3585	1820	0	6380	2220	ZFX RPMI-8402 (T acute lymphoblastic leukemia) ZFX	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	ZFX	NA	GEO	GSE43147_zfx_rpmi8402_MACS_ZFX_MA0146.2.damo.pwm.bed	440
1	225	ARNT	0.129432365890105	0.9157378083967	153	2003	1822	272	2003	1370	58	6228	2162	ARNT T47D (invasive ductal carcinoma) ARNT	T47D (invasive ductal carcinoma)	BTO:0001248	ARNT	HAEGIN2	GEO	GSE59935_arnt_t47d-haegin2_MACS_ARNT_MA0004.1.damo.pwm.bed	85556
1	1887	GABPA	0.129344798484074	0.891678941406564	77	2004	1922	609	2004	1510	30	6304	2190	GABPA VCaP (prostate carcinoma) GABPA	VCaP (prostate carcinoma)	BTO:0003215	GABPA	ETOH	GEO	GSE49091_gabpa_vcap-etoh_MACS_GABPA_MA0062.3.damo.pwm.bed	35901
1	838	CTCF	0.129035027997415	0.877060530695831	53	2005	1972	905	2005	1630	21	6328	2199	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 360min + Flavopiridol 240min	GTRD	EXP047805_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	55919
1	3829	TEAD1	0.129035027997415	0.877060530695831	53	2005	1972	905	2005	1630	21	6328	2199	TEAD1 HuCCT1 (intrahepatic cholangiocarcinoma) TEAD1	HuCCT1 (intrahepatic cholangiocarcinoma)	BTO:0003911	TEAD1		GEO	GSE68296_tead1_hucct1_MACS_TEAD1_MA0090.3.damo.pwm.bed	28061
1	1328	ESR1	0.127736686896393	0.855703429070295	32	2007	2100	1410	2100	1840	13	6349	2207	ESR1 MDA-MB-134 (invasive lobular breast carcinoma) ESR1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	ESR1	Treatment: DMSO Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048177_MDA-MB-134--invasive-lobular-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5868
1	3521	RXRA	0.127736686896393	0.855703429070295	32	2007	2100	1410	2100	1840	13	6349	2207	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	39121
1	206	AR	0.127611842171595	0.868877063677175	45	2009	2056	1054	2056	1710	18	6336	2202	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH2_DHT	GEO	GSE79128_AR_vcap-sh2-dht_MACS_AR_MA0007.3.damo.pwm.bed	23313
1	1793	FOXA1	0.127211636427889	0.905815280935115	120	2010	1856	367	2010	1410	46	6261	2174	FOXA1 PDAC FOXA1	PDAC	NA	FOXA1	KOKLF5	GEO	GSE64557_foxa1_pdac-koklf5_MACS_FOXA1_MA0148.4.damo.pwm.bed	30749
1	1173	ESR1	0.126934000124981	0.899419828410178	101	2011	1889	440	2011	1450	39	6280	2181	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	Array Express	ERP000901_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	29112
1	2598	JUND	0.126189737697765	0.923761483024302	213	2012	1798	169	2012	1330	80	6168	2140	JUND HepG2 (hepatoblastoma) JUND	HepG2 (hepatoblastoma)	BTO:0000599	JUND		ENCODE	ENCSR000EEI_HepG2_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	79618
1	36	AR	0.125743771933939	0.88195613164525	66	2013	1952	727	2013	1560	26	6315	2194	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ethanol	GTRD	EXP033418_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	10948
1	2571	JUNB	0.125711108905144	0.926361973993686	235	2014	1795	149	2014	1320	88	6146	2132	JUNB MCF10A-ER-Src JUNB	MCF10A-ER-Src	NULL	JUNB	Genotype: non-transformed	GTRD	EXP048569_MCF10A-ER-Src_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	47280
1	1668	FOXA1	0.125380998931211	0.927481481660771	246	2015	1780	133	2015	1310	92	6135	2128	FOXA1 MCF-7L (invasive ductal carcinoma) FOXA1	MCF-7L (invasive ductal carcinoma)	NULL	FOXA1	tamoxifen	GTRD	EXP037125_MCF-7L--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45331
1	3930	TFAP2C	0.125380998931211	0.927481481660771	246	2015	1780	133	2015	1310	92	6135	2128	TFAP2C SK-BR-3 (breast adenocarcinoma) TFAP2C	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	TFAP2C		GEO	GSE36351_tfap2c_skbr3_MACS_TFAP2C_MA0815.1.damo.pwm.bed	92490
1	98	AR	0.124926046542884	0.857383357298142	37	2017	2097	1264	2097	1790	15	6344	2205	AR VCaP and LTAD cells AR	VCaP and LTAD cells	NULL	AR	Treatment: 24h DHT 1 nM	GTRD	EXP049450_VCaP-and-LTAD-cells_AR_MACS_AR_MA0007.3.damo.pwm.bed	12177
1	1533	FOS	0.124926046542884	0.857383357298142	37	2017	2097	1264	2097	1790	15	6344	2205	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS	E2	GTRD	EXP000619_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	8340
1	3848	TFAP2A	0.124926046542884	0.857383357298142	37	2017	2097	1264	2097	1790	15	6344	2205	TFAP2A H9-derived neural crest cells TFAP2A	H9-derived neural crest cells	NULL	TFAP2A		GTRD	EXP030996_H9-derived-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	55205
1	565	CTCF	0.124129869345179	0.868773501431219	50	2020	2057	945	2057	1670	20	6331	2200	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	TAM	Array Express	ERP000783_ctcf_mcf7-tam_MACS_CTCF_MA0139.1.damo.pwm.bed	41342
1	1242	ESR1	0.124129869345179	0.868773501431219	50	2020	2057	945	2057	1670	20	6331	2200	ESR1 patient-derived pleaural effusion ESR1	patient-derived pleaural effusion	NULL	ESR1	N/A	GTRD	EXP037780_patient-derived-pleaural-effusion_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16823
1	1567	FOSL1	0.124129869345179	0.868773501431219	50	2020	2057	945	2057	1670	20	6331	2200	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA1128.1.damo.pwm.bed	25995
1	1568	FOSL1	0.124129869345179	0.868773501431219	50	2020	2057	945	2057	1670	20	6331	2200	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA1137.1.damo.pwm.bed	25963
1	2591	JUND	0.124129869345179	0.868773501431219	50	2020	2057	945	2057	1670	20	6331	2200	JUND MCF7 (Invasive ductal breast carcinoma) JUND	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUND		ENCODE	ENCSR000BSU_MCF-7_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	9818
1	39	AR	0.124048151640429	0.895654504969507	98	2025	1901	460	2025	1460	38	6283	2182	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR		GTRD	EXP034146_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	27642
1	1738	FOXA1	0.123219988921882	0.928292437365917	265	2026	1730	110	2026	1290	99	6116	2121	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053227_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	56740
1	3826	TEAD1	0.122037274491654	0.880896437879555	71	2027	1955	659	2027	1550	28	6310	2192	TEAD1 T47D (invasive ductal carcinoma) TEAD1	T47D (invasive ductal carcinoma)	BTO:0001248	TEAD1		GTRD	EXP047976_T47D--invasive-ductal-carcinoma-_TEAD1_MACS_TEAD1_MA0090.3.damo.pwm.bed	46299
1	380	CEBPB	0.121984961329211	0.858643571818004	42	2028	2091	1124	2091	1750	17	6339	2203	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP040158_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	24104
1	1333	ESR1	0.121984961329211	0.858643571818004	42	2028	2091	1124	2091	1750	17	6339	2203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	H3B-6545	GTRD	EXP048579_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12463
1	3864	TFAP2A	0.121984961329211	0.858643571818004	42	2028	2091	1124	2091	1750	17	6339	2203	TFAP2A hiPSC TFAP2A	hiPSC	NULL	TFAP2A	Genotype: wildtype Treatment: hiPSC differentiation into hNCC (passage 2)	GTRD	EXP052981_hiPSC_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	38281
1	3865	TFAP2A	0.121984961329211	0.858643571818004	42	2028	2091	1124	2091	1750	17	6339	2203	TFAP2A hiPSC TFAP2A	hiPSC	NULL	TFAP2A	Genotype: wildtype Treatment: hiPSC differentiation into hNCC (passage 2)	GTRD	EXP052981_hiPSC_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	40654
1	4043	TP63	0.121661217575453	0.888741462503605	87	2032	1928	530	2032	1500	34	6294	2186	TP63 EP156T (primary prostate cells) TP63	EP156T (primary prostate cells)	NULL	TP63		GEO	GSE43111_tp63_ep156t_MACS_TP63_MA0525.2.damo.pwm.bed	4469
1	155	AR	0.121541112593545	0.825756263152931	19	2033	2205	1956	2205	2060	8	6362	2212	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHGATA2	GEO	GSE52725_AR_lncap-shgata2_MACS_AR_MA0007.3.damo.pwm.bed	6072
1	468	CTCF	0.121541112593545	0.825756263152931	19	2033	2205	1956	2205	2060	8	6362	2212	CTCF GM13977 (female B-cells) CTCF	GM13977 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DLB_GM13977_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34287
1	780	CTCF	0.121541112593545	0.825756263152931	19	2033	2205	1956	2205	2060	8	6362	2212	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP040107_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33140
1	815	CTCF	0.121541112593545	0.825756263152931	19	2033	2205	1956	2205	2060	8	6362	2212	CTCF CD34+ hematopoietic stem cells CTCF	CD34+ hematopoietic stem cells	NULL	CTCF		GTRD	EXP040768_CD34--hematopoietic-stem-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35044
1	945	CTCF	0.121440660002189	0.834344810991941	24	2037	2176	1691	2176	1970	10	6357	2210	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm10847_MACS_CTCF_MA0139.1.damo.pwm.bed	42527
1	954	CTCF	0.121440660002189	0.834344810991941	24	2037	2176	1691	2176	1970	10	6357	2210	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19099_MACS_CTCF_MA0139.1.damo.pwm.bed	40225
1	2957	MYOD1	0.121440660002189	0.834344810991941	24	2037	2176	1691	2176	1970	10	6357	2210	MYOD1 RH4 (alveolar rhabdomyosarcoma) MYOD1	RH4 (alveolar rhabdomyosarcoma)	NULL	MYOD1	NA	GTRD	EXP037530_RH4--alveolar-rhabdomyosarcoma-_MYOD1_MACS_MYOD1_MA0499.2.damo.pwm.bed	41734
1	3795	TCF4	0.121440660002189	0.834344810991941	24	2037	2176	1691	2176	1970	10	6357	2210	TCF4 GEN2.2 (blastic plasmacytoid dendritic cell neoplasm) TCF4	GEN2.2 (blastic plasmacytoid dendritic cell neoplasm)	NULL	TCF4		GTRD	EXP037181_GEN2.2--blastic-plasmacytoid-dendritic-cell-neoplasm-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	42642
1	1814	FOXA1	0.121386521662939	0.944474051546929	521	2041	1665	15	2041	1240	191	5860	2029	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	TNFA	GEO	GSE83860_foxa1_lncap-tnfa_MACS_FOXA1_MA0148.4.damo.pwm.bed	221475
1	602	CTCF	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	CTCF HeLa (cervical adenocarcinoma) CTCF	HeLa (cervical adenocarcinoma)	BTO:0000567	CTCF		GTRD	EXP030881_HeLa--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16368
1	742	CTCF	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	CTCF vagina CTCF	vagina	BTO:0000243	CTCF		GTRD	EXP039806_vagina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	13945
1	863	CTCF	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: ZIKV-bystander, time post infection 24 hr  ViralStrain: ZIKV-FSS13025	GTRD	EXP048657_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19092
1	1415	ESR1	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCTR	GEO	GSE60270_esr1_mcf7-shctr_MACS_ESR1_MA0112.3.damo.pwm.bed	1730
1	2453	JUN	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	8109
1	2454	JUN	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	9680
1	2458	JUN	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	8644
1	2460	JUN	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	8231
1	2627	KLF11	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	KLF11 hMADS-3 (adipose-derived stem cells) KLF11	hMADS-3 (adipose-derived stem cells)	NULL	KLF11	differentiaiton inductors	GTRD	EXP033778_hMADS-3--adipose-derived-stem-cells-_KLF11_MACS_KLF11_MA1512.1.damo.pwm.bed	21004
1	2722	MECOM	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	MECOM SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) MECOM	SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive)	NULL	MECOM	NA	GTRD	EXP037834_SKH1--chronic-myelogenous-leukemia--BCR-ABL1-positive-_MECOM_MACS_MECOM_MA0029.1.damo.pwm.bed	17326
1	2874	MYC	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected with control vector;	GTRD	EXP047291_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	20762
1	2972	NEUROG2	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037149_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	22910
1	3017	NFIC	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	NFIC HepG2 (hepatoblastoma) NFIC	HepG2 (hepatoblastoma)	BTO:0000599	NFIC	NA	GTRD	EXP040843_HepG2--hepatoblastoma-_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	5681
1	3070	NR2F1	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	NR2F1 GM12878 (female B-cells lymphoblastoid cell line) NR2F1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2F1	NA	GTRD	EXP040024_GM12878--female-B-cells-_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	13490
1	3541	RXRA	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	8106
1	4085	USF2	0.121060132393722	0.811580794459024	7	2042	2248	2768	2768	2350	3	6374	2217	USF2 A549 (lung carcinoma) USF2	A549 (lung carcinoma)	BTO:0000018	USF2		ENCODE	ENCSR563FBT_A549_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	8159
1	586	CTCF	0.120744179683831	0.868669775435394	55	2058	2062	875	2062	1660	22	6326	2198	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF	NULL	GTRD	EXP000992_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	57315
1	265	ATF7	0.120173074973678	0.840097215437594	29	2059	2153	1504	2153	1910	12	6352	2208	ATF7 HepG2 (hepatoblastoma) ATF7	HepG2 (hepatoblastoma)	BTO:0000599	ATF7	NA	GTRD	EXP040022_HepG2--hepatoblastoma-_ATF7_MACS_ATF7_MA0834.1.damo.pwm.bed	30110
1	51	AR	0.119534094668256	0.896304594872603	111	2060	1898	401	2060	1450	43	6270	2177	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	treated for 24 hours with 0.5μM PD-0332991 +3 hour 10nm DHT	GTRD	EXP036466_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	34769
1	1469	ETS1	0.11930004677397	0.811373677637018	14	2061	2264	2252	2264	2190	6	6367	2214	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF_12H	GEO	GSE41166_ets1_huvec-vegf-12h_MACS_ETS1_MA0098.3.damo.pwm.bed	37974
1	1490	FLI1	0.11930004677397	0.811373677637018	14	2061	2264	2252	2264	2190	6	6367	2214	FLI1 Kasumi-1 (acute myeloblastic leukemia) FLI1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	FLI1		GTRD	EXP037191_Kasumi-1--acute-myeloblastic-leukemia-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	34336
1	1986	GATA3	0.11930004677397	0.811373677637018	14	2061	2264	2252	2264	2190	6	6367	2214	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GTRD	EXP053327_Jurkat--T-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	20834
1	1994	GATA3	0.11930004677397	0.811373677637018	14	2061	2264	2252	2264	2190	6	6367	2214	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		GEO	GSE40129_gata3_mcf7_MACS_GATA3_MA0037.3.damo.pwm.bed	3180
1	2937	MYC	0.11930004677397	0.811373677637018	14	2061	2264	2252	2264	2190	6	6367	2214	MYC CD34+ cells MYC	CD34+ cells	NULL	MYC		GEO	GSE85488_myc_cd34_MACS_MYC_MA0147.3.damo.pwm.bed	41778
1	3094	NR3C1	0.119004013027194	0.859616560083778	47	2066	2086	1002	2086	1720	19	6334	2201	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	100 nM Dex	GTRD	EXP030502_LNCaP--prostate-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	24559
1	3384	RELA	0.119004013027194	0.859616560083778	47	2066	2086	1002	2086	1720	19	6334	2201	RELA SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes) RELA	SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes)	NULL	RELA	TNF	GEO	GSE64233_rela_sgbs-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	41020
1	1686	FOXA1	0.118444966382988	0.930272274966168	314	2068	1727	87	2068	1290	117	6067	2103	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	Veh_90	GTRD	EXP038787_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50532
1	381	CEBPB	0.118282448627782	0.844132948924006	34	2069	2139	1349	2139	1850	14	6347	2206	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040177_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	17090
1	557	CTCF	0.118282448627782	0.844132948924006	34	2069	2139	1349	2139	1850	14	6347	2206	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		Array Express	ERP000209_ctcf_hepg2_MACS_CTCF_MA0139.1.damo.pwm.bed	45224
1	1540	FOS	0.118282448627782	0.844132948924006	34	2069	2139	1349	2139	1850	14	6347	2206	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	41266
1	1541	FOS	0.118282448627782	0.844132948924006	34	2069	2139	1349	2139	1850	14	6347	2206	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	41241
1	194	AR	0.116093265423755	0.894940402575529	116	2073	1906	383	2073	1450	45	6265	2175	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR	R1881_SIPIAS1	GEO	GSE70161_AR_mdamb453-r1881-sipias1_MACS_AR_MA0007.3.damo.pwm.bed	27179
1	79	AR	0.116051069316536	0.847133831602236	39	2074	2125	1206	2125	1800	16	6342	2204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression	GTRD	EXP048987_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12596
1	1645	FOXA1	0.11559970601051	0.934854418532444	394	2075	1703	45	2075	1270	146	5987	2074	FOXA1 FOXA1	NA	NA	FOXA1	NA	Array Express	ERP003828_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	132324
1	1318	ESR1	0.114918492075138	0.874360154514056	73	2076	1981	644	2076	1570	29	6308	2191	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500 nM AZD201 2 hr; Passage: p19;	GTRD	EXP047701_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16665
1	1966	GATA3	0.114708819678312	0.886377761998924	97	2077	1938	468	2077	1490	38	6284	2182	GATA3 MDA-MB-231 (breast adenocarcinoma) GATA3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	GATA3		GTRD	EXP035436_MDA-MB-231--breast-adenocarcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	70531
1	1413	ESR1	0.114295281421384	0.868461830638468	65	2078	2063	738	2078	1630	26	6316	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE60270_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	26490
1	1727	FOXA1	0.113662130004109	0.926321735070656	302	2079	1796	91	2079	1320	113	6079	2107	FOXA1 RT4 (Bladder carcinoma cells) FOXA1	RT4 (Bladder carcinoma cells)	NULL	FOXA1	Treatment: not applicable Stage:adult  Tissue: transitional cell papilloma	GTRD	EXP049024_RT4--Bladder-carcinoma-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	59707
1	835	CTCF	0.113636925611078	0.849444750100034	44	2080	2120	1072	2120	1760	18	6337	2202	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 120min	GTRD	EXP047802_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48052
1	1752	FOXA1	0.113017317948206	0.933803821522092	399	2081	1714	43	2081	1280	148	5982	2072	FOXA1 22RV1 (prostate carcinoma) FOXA1	22RV1 (prostate carcinoma)	BTO:0002999	FOXA1	Treatment: DHT10 nM for 24 hrs;	GTRD	EXP058393_22RV1--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	166482
1	927	CTCF	0.111982140569111	0.821597020876531	26	2082	2224	1602	2224	1970	11	6355	2209	CTCF HEK293T (embryonic kidney) CTCF	HEK293T (embryonic kidney)	BTO:0002181	CTCF		GTRD	EXP058188_HEK293T--embryonic-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40898
1	2527	JUNB	0.111982140569111	0.821597020876531	26	2082	2224	1602	2224	1970	11	6355	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	11538
1	31	AR	0.111905254392594	0.878390882103797	86	2084	1967	534	2084	1530	34	6295	2186	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032867_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28447
1	2369	JUN	0.111905254392594	0.878390882103797	86	2084	1967	534	2084	1530	34	6295	2186	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: 17beta estradiol 10nM for 1hr;	GTRD	EXP047660_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	14785
1	283	BATF3	0.111712532767482	0.811166104627903	21	2086	2269	1852	2269	2070	9	6360	2211	BATF3 KK1 (Adult T acute lymphoblastic leukemia) BATF3	KK1 (Adult T acute lymphoblastic leukemia)	NULL	BATF3	Treatment: BirA enzyme were transduced with N-terminally tagged BATF3 (pRCMV/TO-flag-BIOTIN-BATF3-puro)	GTRD	EXP049476_KK1--Adult-T-acute-lymphoblastic-leukemia-_BATF3_MACS_BATF3_MA0835.2.damo.pwm.bed	10506
1	531	CTCF	0.111712532767482	0.811166104627903	21	2086	2269	1852	2269	2070	9	6360	2211	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVA_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37585
1	867	CTCF	0.111712532767482	0.811166104627903	21	2086	2269	1852	2269	2070	9	6360	2211	CTCF ID00014 (lymphoblastoid cell, DiGeorge syndrome) CTCF	ID00014 (lymphoblastoid cell, DiGeorge syndrome)	NULL	CTCF	Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 11	GTRD	EXP048877_ID00014--lymphoblastoid-cell--DiGeorge-syndrome-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38854
1	1354	ESR1	0.111712532767482	0.811166104627903	21	2086	2269	1852	2269	2070	9	6360	2211	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049894_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	5860
1	1505	FLI1	0.111712532767482	0.811166104627903	21	2086	2269	1852	2269	2070	9	6360	2211	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1		GTRD	EXP053003_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	44580
1	237	ASCL1	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	ASCL1 NCI-H82 (small cell lung carcinoma) ASCL1	NCI-H82 (small cell lung carcinoma)	BTO:0003026	ASCL1		GEO	GSE69394_ascl1_h82_MACS_ASCL1_MA1100.2.damo.pwm.bed	22415
1	253	ATF3	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	ATF3 dermal fibroblasts ATF3	dermal fibroblasts	BTO:0004419	ATF3	overexpressed ATF3	GTRD	EXP037426_dermal-fibroblasts_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	17378
1	299	CDX2	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	CDX2 LS174T (colon adenocarcinoma) CDX2	LS174T (colon adenocarcinoma)	BTO:0001553	CDX2		GTRD	EXP038476_LS174T--colon-adenocarcinoma-_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	7149
1	710	CTCF	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039581_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24151
1	783	CTCF	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	CTCF gastrocnemius medialis CTCF	gastrocnemius medialis	NULL	CTCF		GTRD	EXP040134_gastrocnemius-medialis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24694
1	846	CTCF	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	CTCF WA09 (embryonic stem cells) CTCF	WA09 (embryonic stem cells)	NULL	CTCF	Treatment: under normal conditions	GTRD	EXP047906_WA09--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21064
1	884	CTCF	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  + triptolide Source: T47D whole cell	GTRD	EXP053051_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22619
1	1016	E2F1	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	BICALUTAMIDE	GTRD	EXP032863_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	15214
1	1126	ERG	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG		GTRD	EXP037055_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	5383
1	1484	ETV6	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	ETV6 GM12878 (female B-cells lymphoblastoid cell line) ETV6	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ETV6		GTRD	EXP038554_GM12878--female-B-cells-_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	15761
1	1904	GATA1	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 RNAi KD	GTRD	EXP000913_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	16004
1	1905	GATA1	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	GATA1 CD36+ erythroid cells GATA1	CD36+ erythroid cells	NULL	GATA1	BRG1 RNAi KD	GTRD	EXP000913_CD36--erythroid-cells_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	17101
1	2801	MYC	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	MYC HUVEC-C (HUVEC, umbilical vein endothelial cells) MYC	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MYC	NULL	GTRD	EXP000986_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	25750
1	2837	MYC	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036148_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13153
1	2976	NEUROG2	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037151_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	26640
1	3062	NR2F1	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	NR2F1 cranial neural crest cells NR2F1	cranial neural crest cells	NULL	NR2F1	NA	GTRD	EXP035243_cranial-neural-crest-cells_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	29539
1	3063	NR2F1	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	NR2F1 cranial neural crest cells NR2F1	cranial neural crest cells	NULL	NR2F1	NA	GTRD	EXP035243_cranial-neural-crest-cells_NR2F1_MACS_NR2F1_MA1537.1.damo.pwm.bed	29739
1	3100	NR3C1	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	NR3C1 acute myeloblastic leukemia NR3C1	acute myeloblastic leukemia	NULL	NR3C1	dexametasone	GTRD	EXP033653_acute-myeloblastic-leukemia_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	11121
1	3443	RFX3	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	RFX3 HepG2 (hepatoblastoma) RFX3	HepG2 (hepatoblastoma)	BTO:0000599	RFX3	NA	GTRD	EXP039359_HepG2--hepatoblastoma-_RFX3_MACS_RFX3_MA0798.2.damo.pwm.bed	11404
1	3537	RXRA	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA S427F	GTRD	EXP040816_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	11044
1	3612	SOX2	0.111673336502893	0.782506620605724	9	2091	2346	2585	2585	2340	4	6372	2216	SOX2 KYSE70 (esophageal squamous carcinoma) SOX2	KYSE70 (esophageal squamous carcinoma)	NULL	SOX2		GEO	GSE46837_sox2_kyse70_MACS_SOX2_MA0143.4.damo.pwm.bed	4820
1	1225	ESR1	0.111235733019271	0.868357611056456	70	2112	2064	666	2112	1610	28	6311	2192	ESR1 U2OS (osteosarcoma) ESR1	U2OS (osteosarcoma)	BTO:0001938	ESR1	E2	GTRD	EXP036907_U2OS--osteosarcoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	61856
1	1772	FOXA1	0.111235733019271	0.868357611056456	70	2112	2064	666	2112	1610	28	6311	2192	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1	FOXA1_HIGH	GEO	GSE47987_foxa1_du145-foxa1-high_MACS_FOXA1_MA0148.4.damo.pwm.bed	39567
1	1628	FOSL2	0.111184929975017	0.828786723902809	31	2114	2195	1439	2195	1920	13	6350	2207	FOSL2 hESC-1 (Embryonic stem cells) FOSL2	hESC-1 (Embryonic stem cells)	NULL	FOSL2		GEO	GSE69539_fosl2_hesc_MACS_FOSL2_MA0478.1.damo.pwm.bed	32898
1	3351	RELA	0.111184929975017	0.828786723902809	31	2114	2195	1439	2195	1920	13	6350	2207	RELA monocyte-derived macrophages RELA	monocyte-derived macrophages	NULL	RELA	TNF (10ng/ml) for 24 hours	GTRD	EXP036832_monocyte-derived-macrophages_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	52327
1	240	ATF2	0.111133214424957	0.85127263928446	49	2116	2112	967	2116	1730	20	6332	2200	ATF2 HepG2 (hepatoblastoma) ATF2	HepG2 (hepatoblastoma)	BTO:0000599	ATF2	NA	GTRD	EXP039835_HepG2--hepatoblastoma-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	60525
1	1286	ESR1	0.110268478739417	0.911532318685429	205	2117	1841	183	2117	1380	78	6176	2142	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Cocktail_90	GTRD	EXP038789_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42050
1	2447	JUN	0.110244525884997	0.86150110711013	62	2118	2083	769	2118	1660	25	6319	2195	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	25987
1	407	CEBPD	0.109775758161763	0.834031596229986	36	2119	2180	1288	2180	1860	15	6345	2205	CEBPD HAEC (human aortic endothelial cells) CEBPD	HAEC (human aortic endothelial cells)	NULL	CEBPD	IL1b, 4h	GTRD	EXP038037_HAEC--human-aortic-endothelial-cells-_CEBPD_MACS_CEBPD_MA0836.2.damo.pwm.bed	22798
1	547	CTCF	0.109775758161763	0.834031596229986	36	2119	2180	1288	2180	1860	15	6345	2205	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF		ENCODE	ENCSR000DYD_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40976
1	1334	ESR1	0.109775758161763	0.834031596229986	36	2119	2180	1288	2180	1860	15	6345	2205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Saturated H3B-6545	GTRD	EXP048580_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11302
1	2351	JUN	0.109775758161763	0.834031596229986	36	2119	2180	1288	2180	1860	15	6345	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	22918
1	3847	TFAP2A	0.109775758161763	0.834031596229986	36	2119	2180	1288	2180	1860	15	6345	2205	TFAP2A H9-derived neural crest cells TFAP2A	H9-derived neural crest cells	NULL	TFAP2A		GTRD	EXP030996_H9-derived-neural-crest-cells_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	54607
1	4045	TP63	0.109775758161763	0.834031596229986	36	2119	2180	1288	2180	1860	15	6345	2205	TP63 KYSE70 (esophageal squamous carcinoma) TP63	KYSE70 (esophageal squamous carcinoma)	NULL	TP63		GEO	GSE46837_tp63_kyse70_MACS_TP63_MA0525.2.damo.pwm.bed	2712
1	281	BATF3	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	BATF3 GM12878 (female B-cells lymphoblastoid cell line) BATF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	BATF3		GTRD	EXP038551_GM12878--female-B-cells-_BATF3_MACS_BATF3_MA0835.2.damo.pwm.bed	8257
1	296	BHLHE40	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	BHLHE40 GM12878 (female B-cells lymphoblastoid cell line) BHLHE40	GM12878 (female B-cells lymphoblastoid cell line)	NULL	BHLHE40	NA	GTRD	EXP039562_GM12878--female-B-cells-_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	28305
1	505	CTCF	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	CTCF GM12865 (female B-cells) CTCF	GM12865 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRE_GM12865_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33736
1	761	CTCF	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP040012_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30150
1	1331	ESR1	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	Treatment: 100 nM Dexamethasone and 10 nM Estradiol for 1 hour	GTRD	EXP048231_Ishikawa--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14110
1	2537	JUNB	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	9812
1	2779	MYB	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	MYB CD4 MYB	CD4	NA	MYB	TH1	GEO	GSE72266_myb_cd4-th1_MACS_MYB_MA0100.3.damo.pwm.bed	25106
1	2949	MYCN	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	MYCN SH-EP-NMYCER MYCN	SH-EP-NMYCER	NULL	MYCN	Treatment: 200 nM 4-OHT continuously for 3 hrs;	GTRD	EXP058025_SH-EP-NMYCER_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	24014
1	3904	TFAP2C	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047543_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	35290
1	4078	USF1	0.109470706368154	0.794716042083275	16	2125	2314	2127	2314	2190	7	6365	2213	USF1 HCT-116 (colon carcinoma) USF1	HCT-116 (colon carcinoma)	BTO:0001109	USF1		ENCODE	ENCSR000BVK_HCT116_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	10172
1	1569	FOSL1	0.108596956525173	0.852749186430636	54	2135	2108	886	2135	1710	22	6327	2198	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA1142.1.damo.pwm.bed	28048
1	1979	GATA3	0.108596956525173	0.852749186430636	54	2135	2108	886	2135	1710	22	6327	2198	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10	GTRD	EXP049897_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	16786
1	1760	FOXA1	0.108375988123756	0.927363241897504	348	2137	1784	67	2137	1330	130	6033	2090	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHCTR_R1881	GEO	GSE37345_foxa1_lncap-shctr-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	91386
1	1163	ESR1	0.108371117282917	0.884423705060683	107	2138	1949	416	2138	1500	42	6274	2178	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCRT_E2	Array Express	ERP000380_esr1_mcf7-shcrt-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	34084
1	1726	FOXA1	0.108265626221674	0.907512150288207	191	2139	1853	200	2139	1400	73	6190	2147	FOXA1 RT4 (Bladder carcinoma cells) FOXA1	RT4 (Bladder carcinoma cells)	NULL	FOXA1	Treatment: not applicable Stage:adult  Tissue: transitional cell papilloma	GTRD	EXP049023_RT4--Bladder-carcinoma-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	43590
1	519	CTCF	0.10800545640818	0.838079004659137	41	2140	2156	1155	2156	1820	17	6340	2203	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DTL_choroid_plexus_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	54171
1	3365	RELA	0.10800545640818	0.838079004659137	41	2140	2156	1155	2156	1820	17	6340	2203	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	treatment: TNFalfa	GTRD	EXP049364_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11711
1	3072	NR2F2	0.107730709629043	0.904921148335274	180	2142	1859	217	2142	1410	69	6201	2151	NR2F2 MCF7 (Invasive ductal breast carcinoma) NR2F2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR2F2		ENCODE	ENCSR000BUY_MCF-7_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	44802
1	171	AR	0.107450369400699	0.861912065421027	67	2143	2081	710	2143	1640	27	6314	2193	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H_SHRUNX1	GEO	GSE58428_AR_vcap-dht24h-shrunx1_MACS_AR_MA0007.3.damo.pwm.bed	28873
1	1431	ESR1	0.107450369400699	0.861912065421027	67	2143	2081	710	2143	1640	27	6314	2193	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE72249_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	14015
1	2059	GRHL2	0.10617515800995	0.89864843186398	158	2145	1892	260	2145	1430	61	6223	2159	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	control	GTRD	EXP040962_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	28418
1	1695	FOXA1	0.105715116984261	0.880578198504242	104	2146	1962	429	2146	1510	41	6277	2179	FOXA1 breast tumor FOXA1	breast tumor	NULL	FOXA1	Male	GTRD	EXP040666_breast-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	15158
1	1679	FOXA1	0.105502309872125	0.927003168574759	364	2147	1791	60	2147	1330	136	6017	2084	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	siCtl	GTRD	EXP038435_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	140998
1	1735	FOXA1	0.10489522407744	0.903747722257168	185	2148	1883	212	2148	1410	71	6196	2149	FOXA1 LNCaP95 FOXA1	LNCaP95	NULL	FOXA1	Treatment: 10 nM ETOH for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052941_LNCaP95_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	35823
1	40	AR	0.10424021076732	0.896262524848126	155	2149	1899	267	2149	1440	60	6226	2160	AR CWR22 (prostate carcinoma) AR	CWR22 (prostate carcinoma)	BTO:0004594	AR	DHT	GTRD	EXP034147_CWR22--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	55856
1	2284	JUN	0.1039154855265	0.843714309559535	51	2150	2143	932	2150	1740	21	6330	2199	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	49633
1	678	CTCF	0.103570263661048	0.810958073923537	28	2151	2274	1531	2274	1990	12	6353	2208	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039386_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38755
1	917	CTCF	0.103570263661048	0.810958073923537	28	2151	2274	1531	2274	1990	12	6353	2208	CTCF GM19193 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM19193 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054531_GM19193--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40090
1	199	AR	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	AR LNCaP C4-2B (prostate carcinoma) AR	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	AR		GEO	GSE72714_AR_c42b_MACS_AR_MA0007.3.damo.pwm.bed	2716
1	699	CTCF	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP039525_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28813
1	766	CTCF	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	CTCF thyroid gland CTCF	thyroid gland	NULL	CTCF		GTRD	EXP040050_thyroid-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	22949
1	868	CTCF	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	CTCF IMR-5 (Neuroblastoma) CTCF	IMR-5 (Neuroblastoma)	NULL	CTCF		GTRD	EXP048888_IMR-5--Neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27853
1	1051	EBF1	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	EBF1 GM12878 (female B-cells lymphoblastoid cell line) EBF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EBF1	NA	ENCODE	ENCSR000DZQ_GM12878_EBF1_MACS_EBF1_MA0154.4.damo.pwm.bed	17163
1	1118	ERG	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	NT	GTRD	EXP000724_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	6799
1	1476	ETV1	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	ETV1 COLO800 (human melanoma cells) ETV1	COLO800 (human melanoma cells)	NULL	ETV1	Treatment: cells were harvested in log phase growth	GTRD	EXP048912_COLO800--human-melanoma-cells-_ETV1_MACS_ETV1_MA0761.2.damo.pwm.bed	24050
1	1854	FOXO1	0.103179712054607	0.765017566623983	11	2153	2415	2426	2426	2330	5	6370	2215	FOXO1 pre- leukemia stem cells (CD34+ human cord blood cells) FOXO1	pre- leukemia stem cells (CD34+ human cord blood cells)	NULL	FOXO1	Treatment: untreated	GTRD	EXP048924_pre--leukemia-stem-cells--CD34--human-cord-blood-cells-_FOXO1_MACS_FOXO1_MA0480.1.damo.pwm.bed	31644
1	378	CEBPB	0.103119307787549	0.819130787762745	33	2161	2231	1379	2231	1920	14	6348	2206	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039935_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	19276
1	427	CREB1	0.103119307787549	0.819130787762745	33	2161	2231	1379	2231	1920	14	6348	2206	CREB1 LNCaP (prostate carcinoma) CREB1	LNCaP (prostate carcinoma)	BTO:0001321	CREB1		GEO	GSE63034_creb1_lncap_MACS_CREB1_MA0018.4.damo.pwm.bed	15407
1	3528	RXRA	0.103119307787549	0.819130787762745	33	2161	2231	1379	2231	1920	14	6348	2206	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	40969
1	85	AR	0.103056828676515	0.799475013775133	23	2164	2303	1739	2303	2070	10	6358	2210	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Ethanol for 4 hrs	GTRD	EXP049275_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	4164
1	454	CTCF	0.103056828676515	0.799475013775133	23	2164	2303	1739	2303	2070	10	6358	2210	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BHW_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33961
1	536	CTCF	0.103056828676515	0.799475013775133	23	2164	2303	1739	2303	2070	10	6358	2210	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		ENCODE	ENCSR000DWE_K562_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38895
1	2661	LHX2	0.103056828676515	0.799475013775133	23	2164	2303	1739	2303	2070	10	6358	2210	LHX2 retina LHX2	retina	BTO:0001175	LHX2	pigment	GEO	GSE60024_lhx2_retinal-pigment_MACS_LHX2_MA0700.2.damo.pwm.bed	16574
1	3555	SCRT2	0.103056828676515	0.799475013775133	23	2164	2303	1739	2303	2070	10	6358	2210	SCRT2 HEK293 (embryonic kidney) SCRT2	HEK293 (embryonic kidney)	NULL	SCRT2	NA	GTRD	EXP040055_HEK293--embryonic-kidney-_SCRT2_MACS_SCRT2_MA0744.2.damo.pwm.bed	19475
1	3572	SMAD3	0.103054017206705	0.892209610376395	144	2169	1921	302	2169	1460	56	6237	2164	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047902_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA0513.1.damo.pwm.bed	25358
1	331	CEBPA	0.103015976963773	0.876541478647609	101	2170	1975	440	2170	1530	40	6280	2180	CEBPA MOLM-13(acute monocytic leukemia(AML), Homo sapiens) CEBPA	MOLM-13(acute monocytic leukemia(AML), Homo sapiens)	BTO:0004175	CEBPA		GTRD	EXP053322_MOLM-13-acute-monocytic-leukemia-AML---Homo-sapiens-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	79312
1	4029	TP63	0.102864099460091	0.879880932718176	109	2171	1963	409	2171	1510	43	6272	2177	TP63 neonatal keratinocytes TP63	neonatal keratinocytes	NULL	TP63		GTRD	EXP031101_neonatal-keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	6993
1	2062	GRHL2	0.102129638742925	0.885297683690349	125	2172	1942	345	2172	1490	49	6256	2171	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	100nm E2 (45 min)	GTRD	EXP040965_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	23226
1	524	CTCF	0.102083491243408	0.825234445331135	38	2173	2210	1238	2210	1870	16	6343	2204	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000DUG_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52602
1	607	CTCF	0.102083491243408	0.825234445331135	38	2173	2210	1238	2210	1870	16	6343	2204	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF	none	GTRD	EXP030934_HepG2--hepatoblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51256
1	1355	ESR1	0.102083491243408	0.825234445331135	38	2173	2210	1238	2210	1870	16	6343	2204	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049895_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12798
1	3522	RXRA	0.102083491243408	0.825234445331135	38	2173	2210	1238	2210	1870	16	6343	2204	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	41077
1	526	CTCF	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	CTCF HFF-Myc (fetal fibroblasts) CTCF	HFF-Myc (fetal fibroblasts)	NULL	CTCF		ENCODE	ENCSR000DUM_HFF-Myc_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37549
1	644	CTCF	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	CTCF hepatocytes CTCF	hepatocytes	NULL	CTCF		GTRD	EXP036856_hepatocytes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38484
1	703	CTCF	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP039547_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34668
1	733	CTCF	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	CTCF MM1.S (plasma cell myeloma) CTCF	MM1.S (plasma cell myeloma)	BTO:0003933	CTCF		GTRD	EXP039740_MM1.S--plasma-cell-myeloma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31577
1	872	CTCF	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	CTCF GM17942 (lymphoblastoid cell) CTCF	GM17942 (lymphoblastoid cell)	NULL	CTCF	Genotype: 22q11 deletion Cell type: lymphoblastoid cell Age: 6	GTRD	EXP051028_GM17942--lymphoblastoid-cell-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34738
1	979	CTCF	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	CTCF Delta47 (plasma cell myeloma) CTCF	Delta47 (plasma cell myeloma)	NULL	CTCF		GEO	GSE70764_ctcf_delta47_MACS_CTCF_MA0139.1.damo.pwm.bed	29088
1	983	CTCF	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		GEO	GSE76815_ctcf_sknsh_MACS_CTCF_MA0139.1.damo.pwm.bed	37228
1	1125	ERG	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	functional form of the peptide (*ERG inhibitory peptidomimetics*)	GTRD	EXP033708_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	10611
1	2274	JUN	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	18328
1	3903	TFAP2C	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047543_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	34397
1	3905	TFAP2C	0.100871760855318	0.782199006104765	18	2177	2367	1996	2367	2180	8	6363	2212	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C;	GTRD	EXP047543_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	33143
1	1988	GATA3	0.100682946892728	0.829958657042822	43	2188	2193	1101	2193	1830	18	6338	2202	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	DMSO	GEO	GSE29073_gata3_mcf7-dmso_MACS_GATA3_MA0037.3.damo.pwm.bed	9092
1	1251	ESR1	0.100272346841399	0.872298839101248	98	2189	1983	460	2189	1540	39	6283	2181	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	160min E2	GTRD	EXP038341_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	20868
1	1566	FOSL1	0.0990527513765131	0.833717193971154	48	2190	2186	982	2190	1790	20	6333	2200	FOSL1 MDA231-LM2-4175 (breast adenocarcinoma) FOSL1	MDA231-LM2-4175 (breast adenocarcinoma)	NULL	FOSL1	NA	GTRD	EXP038404_MDA231-LM2-4175--breast-adenocarcinoma-_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	25121
1	2639	KLF4	0.0980059133061121	0.895517104304948	173	2191	1902	232	2191	1440	67	6208	2153	KLF4 keratinocytes KLF4	keratinocytes	NULL	KLF4	diff	GEO	GSE57702_klf4_keratinocyte-diff_MACS_KLF4_MA0039.4.damo.pwm.bed	31105
1	1	AR	0.0976697618807546	0.871976076247978	103	2192	1986	434	2192	1540	41	6278	2179	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		Array Express	ERP001226_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	31151
1	37	AR	0.0974828465618038	0.867834025580871	95	2193	2067	478	2193	1580	38	6286	2182	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	10 nmol/l of mibolerone	GTRD	EXP033419_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	37783
1	1193	ESR1	0.0965448356363165	0.903760114107218	219	2194	1882	160	2194	1410	84	6162	2136	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP032284_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	54857
1	3385	RELA	0.0960358456971518	0.80194120577421	30	2195	2297	1473	2297	1990	13	6351	2207	RELA LNCaP (prostate carcinoma) RELA	LNCaP (prostate carcinoma)	BTO:0001321	RELA	DHT_TNFA	GEO	GSE83860_rela_lncap-dht-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	10656
1	3527	RXRA	0.0960358456971518	0.80194120577421	30	2195	2297	1473	2297	1990	13	6351	2207	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	38162
1	3822	TCF7L2	0.0960358456971518	0.80194120577421	30	2195	2297	1473	2297	1990	13	6351	2207	TCF7L2 LNCaP (prostate carcinoma) TCF7L2	LNCaP (prostate carcinoma)	BTO:0001321	TCF7L2		GEO	GSE51621_tcf7l2_lncap_MACS_TCF7L2_MA0523.1.damo.pwm.bed	17348
1	904	CTCF	0.0958416092955535	0.810749584009123	35	2198	2276	1318	2276	1930	15	6346	2205	CTCF HSMM dirived skeletal muscle myotubes CTCF	HSMM dirived skeletal muscle myotubes	NULL	CTCF	Treatment: None;	GTRD	EXP054041_HSMM-dirived-skeletal-muscle-myotubes_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52936
1	1538	FOS	0.0958416092955535	0.810749584009123	35	2198	2276	1318	2276	1930	15	6346	2205	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	42719
1	2120	HNF4A	0.0958416092955535	0.810749584009123	35	2198	2276	1318	2276	1930	15	6346	2205	HNF4A HepG2 (hepatoblastoma) HNF4A	HepG2 (hepatoblastoma)	BTO:0000599	HNF4A		ENCODE	ENCSR000BLF_HepG2_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	49223
1	348	CEBPA	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	CEBPA SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes) CEBPA	SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes)	NULL	CEBPA		GEO	GSE41629_cebpa_sgbs_MACS_CEBPA_MA0102.4.damo.pwm.bed	8140
1	694	CTCF	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	CTCF gastroesophageal sphincter CTCF	gastroesophageal sphincter	NULL	CTCF		GTRD	EXP039474_gastroesophageal-sphincter_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32353
1	855	CTCF	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:synchronized	GTRD	EXP048090_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23677
1	878	CTCF	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 7.5 min  Source: T47D whole cell	GTRD	EXP053045_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24747
1	880	CTCF	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 60 min  Source: T47D whole cell	GTRD	EXP053047_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	25287
1	2887	MYC	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047489_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	11427
1	3145	NR3C1	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	NR3C1 THP-1 (acute monocytic leukemia) NR3C1	THP-1 (acute monocytic leukemia)	BTO:0001370	NR3C1	Treatment: Dex, 100 nM, 1hour Tissue: peripheral blood-derived Sex: male	GTRD	EXP049918_THP-1--acute-monocytic-leukemia-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	12654
1	3194	OSR2	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	OSR2 HEK293 (embryonic kidney) OSR2	HEK293 (embryonic kidney)	NULL	OSR2	NA	GTRD	EXP039901_HEK293--embryonic-kidney-_OSR2_MACS_OSR2_MA1646.1.damo.pwm.bed	13045
1	3392	REST	0.095539634823671	0.753324301920598	13	2201	2457	2306	2457	2320	6	6368	2214	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		ENCODE	ENCSR000BHM_H1-hESC_REST_MACS_REST_MA0138.2.damo.pwm.bed	18201
1	395	CEBPB	0.0954313082157521	0.898705911415496	197	2210	1891	194	2210	1430	76	6184	2144	CEBPB JB6 (Human anaplastic large cell lymphoma) CEBPB	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	CEBPB	Treatment: DMSO for 3 hrs	GTRD	EXP053279_JB6--Human-anaplastic-large-cell-lymphoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	112514
1	1636	FOXA1	0.0953805029252305	0.915775491208652	312	2211	1821	88	2211	1370	118	6069	2102	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2_TAM	Array Express	ERP000380_foxa1_mcf7-e2-tam_MACS_FOXA1_MA0148.4.damo.pwm.bed	47075
1	15	AR	0.0953631129820777	0.789892200363758	25	2212	2331	1657	2331	2070	11	6356	2209	AR metastatic prostate cancer tissue AR	metastatic prostate cancer tissue	NULL	AR	NULL	GTRD	EXP000738_metastatic-prostate-cancer-tissue_AR_MACS_AR_MA0007.3.damo.pwm.bed	5951
1	83	AR	0.0953631129820777	0.789892200363758	25	2212	2331	1657	2331	2070	11	6356	2209	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: exclude	GTRD	EXP049187_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	6307
1	1680	FOXA1	0.0953438286863948	0.922306359319961	381	2214	1803	51	2214	1360	143	6000	2077	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	siERG	GTRD	EXP038436_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	151036
1	1293	ESR1	0.0950974457934182	0.817461013593485	40	2215	2236	1189	2236	1880	17	6341	2203	ESR1 MCF10A (breast epithelial cells) ESR1	MCF10A (breast epithelial cells)	BTO:0001939	ESR1	Cells were lentivirally transduced with MYC-ERVD and stable pools were treated with 100nM 4-OHT for 24h.	GTRD	EXP038958_MCF10A--breast-epithelial-cells-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16931
1	3366	RELA	0.0950974457934182	0.817461013593485	40	2215	2236	1189	2236	1880	17	6341	2203	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: Pam2CSK4	GTRD	EXP049365_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	11561
1	367	CEBPB	0.0950939454347693	0.902103075132574	216	2217	1885	163	2217	1420	83	6165	2137	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	100nM trametinib, 300nM JQ1	GTRD	EXP037882_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	98230
1	2419	JUN	0.094674095472133	0.880709331357214	132	2218	1956	323	2218	1500	52	6249	2168	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	33354
1	112	AR	0.094646071771152	0.863129026688511	92	2219	2080	498	2219	1600	37	6289	2183	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052955_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	36965
1	1886	GABPA	0.0939952852135644	0.822737621201383	45	2220	2221	1054	2221	1830	19	6336	2201	GABPA Jurkat (T-cells) GABPA	Jurkat (T-cells)	BTO:0000661	GABPA		GEO	GSE49091_gabpa_jurkat_MACS_GABPA_MA0062.3.damo.pwm.bed	61896
1	91	AR	0.0935129604148465	0.841487826007307	63	2221	2149	753	2221	1710	26	6318	2194	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L wildtype	GTRD	EXP049284_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	20596
1	143	AR	0.0935129604148465	0.841487826007307	63	2221	2149	753	2221	1710	26	6318	2194	AR AR	NA	NA	AR	NA	GEO	GSE45201_AR_mdamb453-dht_MACS_AR_MA0007.3.damo.pwm.bed	21220
1	869	CTCF	0.0932642187303132	0.772439914213094	20	2223	2398	1901	2398	2170	9	6361	2211	CTCF MIA PaCa-2 (pancreatic ductal adenocarcinoma) CTCF	MIA PaCa-2 (pancreatic ductal adenocarcinoma)	NULL	CTCF	Treatment: none	GTRD	EXP049078_MIA-PaCa-2--pancreatic-ductal-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32801
1	4107	VDR	0.0932642187303132	0.772439914213094	20	2223	2398	1901	2398	2170	9	6361	2211	VDR LX-2 (hepatic stellate cells) VDR	LX-2 (hepatic stellate cells)	BTO:0003516	VDR	CALCIPOTRIOL_TGFB1	GEO	GSE38103_vdr_lx2-calcipotriol-tgfb1_MACS_VDR_MA0693.2.damo.pwm.bed	16554
1	1120	ERG	0.0930181557838731	0.85120330728026	76	2225	2113	619	2225	1650	31	6305	2189	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	regular medium	GTRD	EXP000734_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	41638
1	58	AR	0.0927431599995628	0.871388047014172	113	2226	1987	397	2226	1540	45	6268	2175	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881+Doxycycline	GTRD	EXP037067_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	55308
1	1731	FOXA1	0.0926274648112805	0.867623423127569	105	2227	2068	422	2227	1570	42	6276	2178	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049902_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	16562
1	2060	GRHL2	0.0926274648112805	0.867623423127569	105	2227	2068	422	2227	1570	42	6276	2178	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	control	GTRD	EXP040963_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	18542
1	2416	JUN	0.0925240064758761	0.877554437255391	129	2229	1971	338	2229	1510	51	6252	2169	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	33468
1	1264	ESR1	0.0923155807826127	0.863264823159889	97	2230	2079	468	2230	1590	39	6284	2181	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038377_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42633
1	3913	TFAP2C	0.0917616226467783	0.908119827078549	270	2231	1850	108	2231	1400	103	6111	2117	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE21234_tfap2c_mcf7_MACS_TFAP2C_MA0814.2.damo.pwm.bed	74777
1	1094	ELF3	0.091760601114688	0.858163829801334	89	2232	2095	515	2232	1610	36	6292	2184	ELF3 PDAC ELF3	PDAC	NA	ELF3	SHCTR	GEO	GSE64557_elf3_pdac-shctr_MACS_ELF3_MA0640.2.damo.pwm.bed	53811
1	2068	GRHL2	0.091760601114688	0.858163829801334	89	2232	2095	515	2232	1610	36	6292	2184	GRHL2 MCF7 WS8 cells GRHL2	MCF7 WS8 cells	NULL	GRHL2	Treatment: 45 min ethanol	GTRD	EXP048454_MCF7-WS8-cells_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	22503
1	209	AR	0.0911635246645729	0.830483361984589	55	2234	2190	875	2234	1770	23	6326	2197	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT_TNFA	GEO	GSE83860_AR_lncap-dht-tnfa_MACS_AR_MA0007.3.damo.pwm.bed	20267
1	469	CTCF	0.0911635246645729	0.830483361984589	55	2234	2190	875	2234	1770	23	6326	2197	CTCF GM19238 (female B-cells lymphoblastoid cell lines) CTCF	GM19238 (female B-cells lymphoblastoid cell lines)	NULL	CTCF		ENCODE	ENCSR000DLD_GM19238_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	73749
1	1829	FOXA2	0.0911635246645729	0.830483361984589	55	2234	2190	875	2234	1770	23	6326	2197	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2		GTRD	EXP039847_liver_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	25199
1	1926	GATA1	0.0903217400211405	0.867517869961922	110	2237	2070	404	2237	1570	44	6271	2176	GATA1 CD34+ cells GATA1	CD34+ cells	NULL	GATA1		GEO	GSE52924_gata1_cd34_MACS_GATA1_MA0035.4.damo.pwm.bed	167676
1	3851	TFAP2A	0.0898951924366032	0.879540971378657	142	2238	1964	306	2238	1500	56	6239	2164	TFAP2A MCF7 (Invasive ductal breast carcinoma) TFAP2A	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2A		GTRD	EXP032577_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	36549
1	1803	FOXA1	0.0898472783828289	0.910250723935593	297	2239	1846	94	2239	1390	113	6084	2107	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GEO	GSE72249_foxa1_mcf7_MACS_FOXA1_MA0148.4.damo.pwm.bed	47767
1	548	CTCF	0.0892468011532847	0.794198759527503	32	2240	2324	1410	2324	1990	14	6349	2206	CTCF IMR90 (lung fibroblasts) CTCF	IMR90 (lung fibroblasts)	NULL	CTCF		ENCODE	ENCSR000EFI_IMR-90_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45921
1	550	CTCF	0.0892468011532847	0.794198759527503	32	2240	2324	1410	2324	1990	14	6349	2206	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		ENCODE	ENCSR000EIC_SK-N-SH_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46740
1	109	AR	0.0892436205537319	0.803404042490883	37	2242	2293	1264	2293	1930	16	6344	2204	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection)	GTRD	EXP052952_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	7515
1	122	AR	0.0892436205537319	0.803404042490883	37	2242	2293	1264	2293	1930	16	6344	2204	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Genotype: Renilla knockout; Treatment: shRenilla;	GTRD	EXP058316_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	7970
1	1539	FOS	0.0892436205537319	0.803404042490883	37	2242	2293	1264	2293	1930	16	6344	2204	FOS IMR90 (lung fibroblasts) FOS	IMR90 (lung fibroblasts)	NULL	FOS		GTRD	EXP039888_IMR90--lung-fibroblasts-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	43724
1	1768	FOXA1	0.0891472914444689	0.926498012755217	493	2245	1794	18	2245	1350	184	5888	2036	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	SIGATA	GEO	GSE40129_foxa1_mcf7-sigata_MACS_FOXA1_MA0148.4.damo.pwm.bed	105907
1	796	CTCF	0.0887285649584789	0.810540633363179	42	2246	2279	1124	2279	1880	18	6339	2202	CTCF A673 (Ewing sarcoma) CTCF	A673 (Ewing sarcoma)	BTO:0003768	CTCF		GTRD	EXP040257_A673--Ewing-sarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48974
1	2959	MYOD1	0.0887285649584789	0.810540633363179	42	2246	2279	1124	2279	1880	18	6339	2202	MYOD1 rhabdomyosarcoma MYOD1	rhabdomyosarcoma	NULL	MYOD1	NA	GEO	GSE50413_myod1_Rhabdomyosarcoma_MACS_MYOD1_MA0499.2.damo.pwm.bed	57410
1	50	AR	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	siOCT1	GTRD	EXP036107_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	4993
1	663	CTCF	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GTRD	EXP038267_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26460
1	711	CTCF	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP039586_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32347
1	717	CTCF	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	CTCF breast epithelial cells CTCF	breast epithelial cells	NULL	CTCF		GTRD	EXP039639_breast-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27143
1	940	CTCF	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	CTCF IMR90 (lung fibroblasts) CTCF	IMR90 (lung fibroblasts)	NULL	CTCF		GEO	GSE43070_ctcf_imr90_MACS_CTCF_MA0139.1.damo.pwm.bed	33060
1	1047	E2F6	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	E2F6 K562 (myelogenous leukemia) E2F6	K562 (myelogenous leukemia)	NULL	E2F6	NULL	GTRD	EXP000107_K562--myelogenous-leukemia-_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	33037
1	1619	FOSL2	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2		GTRD	EXP040159_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	12590
1	1667	FOXA1	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	FOXA1 HUES64 (embryonic stem cells) FOXA1	HUES64 (embryonic stem cells)	NULL	FOXA1		GTRD	EXP036787_HUES64--embryonic-stem-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	18406
1	2630	KLF15	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	KLF15 HEK293 (embryonic kidney) KLF15	HEK293 (embryonic kidney)	NULL	KLF15	NA	GTRD	EXP035969_HEK293--embryonic-kidney-_KLF15_MACS_KLF15_MA1513.1.damo.pwm.bed	18181
1	2888	MYC	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047489_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12500
1	3679	SPI1	0.0886582515738769	0.7449445702154	15	2248	2484	2200	2484	2310	7	6366	2213	SPI1 Kasumi-1 (acute myeloblastic leukemia) SPI1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	SPI1	SIRUNX1ETO	GEO	GSE60130_spi1_kasumi1-sirunx1eto_MACS_SPI1_MA0080.5.damo.pwm.bed	47350
1	2471	JUN	0.0886135261954669	0.88554993410269	166	2259	1941	241	2259	1480	65	6215	2155	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GEO	GSE66081_jun_mdamb231_MACS_JUN_MA0489.1.damo.pwm.bed	56305
1	525	CTCF	0.0884725469447786	0.781890519458422	27	2260	2378	1564	2378	2070	12	6354	2208	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DUH_foreskin_fibroblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42484
1	3573	SMAD3	0.0880747056089513	0.887181951111983	174	2261	1937	229	2261	1480	68	6207	2152	SMAD3 HCC1954 (ductal breast carcinoma) SMAD3	HCC1954 (ductal breast carcinoma)	BTO:0005368	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047902_HCC1954--ductal-breast-carcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	31708
1	475	CTCF	0.0878684411182845	0.816229080998602	47	2262	2240	1002	2262	1830	20	6334	2200	CTCF HepG2 (hepatoblastoma) CTCF	HepG2 (hepatoblastoma)	BTO:0000599	CTCF		ENCODE	ENCSR000DLS_HepG2_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	51632
1	523	CTCF	0.0878684411182845	0.816229080998602	47	2262	2240	1002	2262	1830	20	6334	2200	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF		ENCODE	ENCSR000DUB_HeLa-S3_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	50574
1	211	AR	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DMSO	GEO	GSE83860_AR_lncap-dmso_MACS_AR_MA0007.3.damo.pwm.bed	663
1	286	BCL6	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6	Treatment: untreated (control siRNA)	GTRD	EXP052976_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	10792
1	647	CTCF	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	CTCF neutrophils CTCF	neutrophils	NULL	CTCF		GTRD	EXP036863_neutrophils_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16626
1	972	CTCF	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		GEO	GSE68976_ctcf_hek293_MACS_CTCF_MA0139.1.damo.pwm.bed	13531
1	1122	ERG	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	ERG metastatic prostate cancer tissue ERG	metastatic prostate cancer tissue	NULL	ERG	NULL	GTRD	EXP000739_metastatic-prostate-cancer-tissue_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	2641
1	1389	ESR1	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	ESR1 ZR-75-1 (invasive ductal carcinoma) ESR1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	ESR1	SICTR_E2	GEO	GSE40129_esr1_zr751-sictr-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	548
1	1416	ESR1	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHFOXA1_E2	GEO	GSE60270_esr1_mcf7-shfoxa1-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	1039
1	2138	HNF4A	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	HNF4A hiPSC HNF4A	hiPSC	NULL	HNF4A	Developmental stage: day 8;	GTRD	EXP057766_hiPSC_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	6433
1	2194	HSF1	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	HSF1 U2OS (osteosarcoma) HSF1	U2OS (osteosarcoma)	BTO:0001938	HSF1	HEAT_20	GEO	GSE60984_hsf1_u2os-heat-20_MACS_HSF1_MA0486.2.damo.pwm.bed	8570
1	2381	JUN	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	6611
1	2382	JUN	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	7141
1	2384	JUN	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	7175
1	2386	JUN	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	6340
1	2387	JUN	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	6727
1	2475	JUN	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN		GEO	GSE71976_jun_bt549_MACS_JUN_MA0489.1.damo.pwm.bed	3024
1	2783	MYC	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYC GM12878 (female B-cells lymphoblastoid cell line) MYC	GM12878 (female B-cells lymphoblastoid cell line)	NULL	MYC		ENCODE	ENCSR000DKU_GM12878_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	6148
1	2815	MYC	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYC FB8470 (fibroblasts) MYC	FB8470 (fibroblasts)	NULL	MYC	NULL	GTRD	EXP001024_FB8470--fibroblasts-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7817
1	2822	MYC	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC	100 nM of JQ1	GTRD	EXP035850_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	9509
1	2824	MYC	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036030_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15247
1	2864	MYC	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	200 nM OHT (endogenous Myc activated) and 0.2 µg/mL Tetracyclin (Myc transgene repressed)	GTRD	EXP038947_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	8877
1	2865	MYC	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	200 nM OHT (endogenous Myc activated) and 0.2 µg/mL Tetracyclin (Myc transgene repressed)	GTRD	EXP038947_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9709
1	2869	MYC	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 1h	GTRD	EXP038951_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12165
1	2953	MYCN	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	MYCN NGP (neuroblastoma) MYCN	NGP (neuroblastoma)	NULL	MYCN		GEO	GSE80151_mycn_ngp_MACS_MYCN_MA0104.4.damo.pwm.bed	7579
1	3035	NKX2-5	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	NKX2-5 embryonic stem cells NKX2-5	embryonic stem cells	NULL	NKX2-5	Treatment: no	GTRD	EXP049255_embryonic-stem-cells_NKX2-5_MACS_NKX2-5_MA0063.2.damo.pwm.bed	10460
1	3037	NKX2-5	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	NKX2-5 BGO3 (embryonic stem cells) NKX2-5	BGO3 (embryonic stem cells)	NULL	NKX2-5	Treatment: no	GTRD	EXP049256_BGO3--embryonic-stem-cells-_NKX2-5_MACS_NKX2-5_MA0063.2.damo.pwm.bed	9892
1	3243	POU2F2	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	POU2F2 GM12891 (male B- cells lymphoblastoid cell line) POU2F2	GM12891 (male B- cells lymphoblastoid cell line)	NULL	POU2F2		ENCODE	ENCSR000BII_GM12891_POU2F2_MACS_POU2F2_MA0507.1.damo.pwm.bed	8838
1	3250	POU5F1	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP032064_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	15254
1	3345	RELA	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	RELA GM18951 (B-cells Lymphoblastoid Cell Lines) RELA	GM18951 (B-cells Lymphoblastoid Cell Lines)	NULL	RELA	TNF-alpha induced (6h)	GTRD	EXP000768_GM18951--B-cells-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	7727
1	3404	REST	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	REST HL-60 (acute myeloid leukemia) REST	HL-60 (acute myeloid leukemia)	BTO:0000738	REST		ENCODE	ENCSR000BTF_HL-60_REST_MACS_REST_MA0138.2.damo.pwm.bed	8116
1	3415	REST	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	REST A549 (lung carcinoma) REST	A549 (lung carcinoma)	BTO:0000018	REST		GTRD	EXP036864_A549--lung-carcinoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	8073
1	3422	REST	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	REST GM23338 REST	GM23338	NULL	REST		GTRD	EXP045141_GM23338_REST_MACS_REST_MA0138.2.damo.pwm.bed	8092
1	3768	TAL1	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	TAL1 RPMI-8402 (T acute lymphoblastic leukemia) TAL1	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	TAL1	NA	GEO	GSE39179_tal1_rpmi8402_MACS_TAL1_MA0091.1.damo.pwm.bed	3589
1	3775	TBX5	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	G296S mutant	GTRD	EXP037721_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	14389
1	3777	TBX5	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	G296S mutant	GTRD	EXP037725_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	10937
1	3798	TCF4	0.0874595431760779	0.695656909532903	4	2264	2657	3105	3105	2680	2	6377	2218	TCF4 Kasumi-1 (acute myeloblastic leukemia) TCF4	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	TCF4	Genotype: overexpress E2-2 Source: Myeloblast Cell type:  leukemic cell line with an 8;21 chromosome translocation Passage: 4-5	GTRD	EXP053214_Kasumi-1--acute-myeloblastic-leukemia-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	11826
1	1228	ESR1	0.0872822563588266	0.881167559409654	155	2299	1953	267	2299	1510	61	6226	2159	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2 for 45m	GTRD	EXP036981_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	53037
1	3925	TFAP2C	0.087200480296898	0.90460953284316	269	2300	1862	109	2300	1420	103	6112	2117	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE36351_tfap2c_mcf7_MACS_TFAP2C_MA0814.2.damo.pwm.bed	74626
1	3095	NR3C1	0.0867725889630244	0.820864278945121	52	2301	2228	921	2301	1820	22	6329	2198	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	100 nM DHT+Dex	GTRD	EXP030503_LNCaP--prostate-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	29935
1	144	AR	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR	GEO	GSE47120_AR_lncap-shctr_MACS_AR_MA0007.3.damo.pwm.bed	1154
1	247	ATF3	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	ATF3 A549 (lung carcinoma) ATF3	A549 (lung carcinoma)	BTO:0000018	ATF3	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPS_A549_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	9205
1	713	CTCF	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP039612_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19138
1	1427	ESR1	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	ESR1 ESR1	NA	NA	ESR1	NA	GEO	GSE68356_ESR1_mcf7-pg_MACS_ESR1_MA0112.3.damo.pwm.bed	2532
1	1428	ESR1	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	E2	GEO	GSE68356_ESR1_t47d-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	1087
1	1822	FOXA2	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	FOXA2 liver FOXA2	liver	BTO:0000759	FOXA2	NULL	GTRD	EXP000903_liver_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	2907
1	1938	GATA2	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	GATA2 CD34+ hematopoietic stem cells GATA2	CD34+ hematopoietic stem cells	NULL	GATA2		GTRD	EXP031975_CD34--hematopoietic-stem-cells_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	15505
1	1970	GATA3	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	GATA3 CLB-Ga (neuroblastoma) GATA3	CLB-Ga (neuroblastoma)	NULL	GATA3	none	GTRD	EXP039005_CLB-Ga--neuroblastoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	14910
1	2631	KLF16	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	KLF16 K562 (myelogenous leukemia) KLF16	K562 (myelogenous leukemia)	NULL	KLF16	NA	GTRD	EXP039636_K562--myelogenous-leukemia-_KLF16_MACS_KLF16_MA0741.1.damo.pwm.bed	16868
1	2700	MAX	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	MAX WA01 (H1, human embryonic stem cells) MAX	WA01 (H1, human embryonic stem cells)	NULL	MAX		ENCODE	ENCSR000EUP_H1-hESC_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	15082
1	2713	MAX	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	MAX COLO-829 (melanoma) MAX	COLO-829 (melanoma)	NULL	MAX	Treatment: none	GTRD	EXP053272_COLO-829--melanoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	8665
1	2726	MEF2B	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	MEF2B germinal center B-cells MEF2B	germinal center B-cells	NULL	MEF2B	Treatment: tonsil	GTRD	EXP048298_germinal-center-B-cells_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	13279
1	2852	MYC	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	MYC GEN2.2 (blastic plasmacytoid dendritic cell neoplasm) MYC	GEN2.2 (blastic plasmacytoid dendritic cell neoplasm)	NULL	MYC		GTRD	EXP036998_GEN2.2--blastic-plasmacytoid-dendritic-cell-neoplasm-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	12400
1	3265	POU5F1	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2 and Klf4 addition for 5 days Passage: 8	GTRD	EXP048944_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	6094
1	3534	RXRA	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	RXRA JMSU-1 (Bladder carcinoma) RXRA	JMSU-1 (Bladder carcinoma)	NULL	RXRA	genotype: RXRA WT	GTRD	EXP040815_JMSU-1--Bladder-carcinoma-_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	9911
1	3643	SP4	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	SP4 HEK293 (embryonic kidney) SP4	HEK293 (embryonic kidney)	NULL	SP4	NA	GTRD	EXP035954_HEK293--embryonic-kidney-_SP4_MACS_SP4_MA0685.1.damo.pwm.bed	19153
1	3708	SRF	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	SRF GM12878 (female B-cells lymphoblastoid cell line) SRF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SRF		ENCODE	ENCSR000BMI_GM12878_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	9834
1	3755	STAT5B	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	STAT5B T-cells STAT5B	T-cells	NULL	STAT5B	IL-2	GTRD	EXP000399_T-cells_STAT5B_MACS_STAT5B_MA0519.1.damo.pwm.bed	13166
1	4067	TWIST1	0.0867677949737205	0.695561426272998	6	2302	2692	2870	2870	2620	3	6375	2217	TWIST1 SHEP-21N TWIST1	SHEP-21N	NA	TWIST1		GEO	GSE80151_twist1_shep21_MACS_TWIST1_MA1123.2.damo.pwm.bed	19284
1	508	CTCF	0.0864738256640141	0.764611077051583	22	2321	2423	1797	2423	2180	10	6359	2210	CTCF GM12868 (female B-cells) CTCF	GM12868 (female B-cells)	NULL	CTCF		ENCODE	ENCSR000DRI_GM12868_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	44018
1	748	CTCF	0.0864738256640141	0.764611077051583	22	2321	2423	1797	2423	2180	10	6359	2210	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP039864_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38583
1	1669	FOXA1	0.0858240532804761	0.911126190912592	329	2323	1842	78	2323	1410	125	6052	2095	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	tamoxifen	GTRD	EXP037126_MCF7-TamR--invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	68491
1	561	CTCF	0.0855151091983189	0.824709490446926	57	2324	2217	839	2324	1790	24	6324	2196	CTCF MCF7 (Invasive ductal breast carcinoma) CTCF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CTCF	TAM	Array Express	ERP000380_ctcf_mcf7-tam_MACS_CTCF_MA0139.1.damo.pwm.bed	46305
1	1284	ESR1	0.0855151091983189	0.824709490446926	57	2324	2217	839	2324	1790	24	6324	2196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP038775_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16322
1	57	AR	0.0853847912315908	0.859227650547172	104	2326	2088	429	2326	1610	42	6277	2178	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881	GTRD	EXP037066_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	49037
1	2064	GRHL2	0.0853847912315908	0.859227650547172	104	2326	2088	429	2326	1610	42	6277	2178	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	100nm E2 (45 min)	GTRD	EXP040967_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	20068
1	1811	FOXA1	0.084027878737792	0.925215664050612	522	2328	1797	14	2328	1380	195	5859	2025	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT_TNFA	GEO	GSE83860_foxa1_lncap-dht-tnfa_MACS_FOXA1_MA0148.4.damo.pwm.bed	226031
1	755	CTCF	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	CTCF gastrocnemius medialis CTCF	gastrocnemius medialis	NULL	CTCF		GTRD	EXP039954_gastrocnemius-medialis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17791
1	757	CTCF	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039980_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28165
1	760	CTCF	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	CTCF vagina CTCF	vagina	BTO:0000243	CTCF		GTRD	EXP040000_vagina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21502
1	768	CTCF	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	CTCF uterus CTCF	uterus	BTO:0001424	CTCF		GTRD	EXP040058_uterus_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23646
1	2322	JUN	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP039637_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	9631
1	2836	MYC	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036148_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	13706
1	2875	MYC	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected shRNA targeting MYC;	GTRD	EXP047292_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	18209
1	2926	MYC	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	SHCTR	GEO	GSE60223_myc_p493-shctr_MACS_MYC_MA0147.3.damo.pwm.bed	13725
1	2975	NEUROG2	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037150_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	19820
1	3476	RUNX1	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	RUNX1 HEE (human epididymis epithelial cells) RUNX1	HEE (human epididymis epithelial cells)	NULL	RUNX1	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048162_HEE--human-epididymis-epithelial-cells-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	11389
1	3622	SOX6	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	SOX6 K562 (myelogenous leukemia) SOX6	K562 (myelogenous leukemia)	NULL	SOX6	NA	ENCODE	ENCSR788RSW_K562_SOX6_MACS_SOX6_MA0515.1.damo.pwm.bed	23105
1	3759	STAT5B	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	STAT5B STAT5B	NA	NA	STAT5B	NA	GEO	GSE64713_stat5b_cd8-il2_MACS_STAT5B_MA0519.1.damo.pwm.bed	17240
1	4072	USF1	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	USF1 A549 (lung carcinoma) USF1	A549 (lung carcinoma)	BTO:0000018	USF1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BJB_A549_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	9280
1	4117	YY1	0.0833818871699505	0.695465883080831	8	2329	2711	2675	2711	2570	4	6373	2216	YY1 WA01 (H1, human embryonic stem cells) YY1	WA01 (H1, human embryonic stem cells)	NULL	YY1		ENCODE	ENCSR000BKD_H1-hESC_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	24716
1	3124	NR3C1	0.0832370889116441	0.796911358133834	39	2343	2311	1206	2343	1950	17	6342	2203	NR3C1 MCF-7 C4-12 (invasive breast ductal carcinoma) NR3C1	MCF-7 C4-12 (invasive breast ductal carcinoma)	NULL	NR3C1	Female	GTRD	EXP040662_MCF-7-C4-12--invasive-breast-ductal-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	7915
1	746	CTCF	0.0830980400733735	0.787475805370873	34	2344	2335	1349	2344	2010	15	6347	2205	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039845_A549--lung-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	41750
1	1309	ESR1	0.0830980400733735	0.787475805370873	34	2344	2335	1349	2344	2010	15	6347	2205	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (90 min)	GTRD	EXP040958_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	8439
1	2135	HNF4A	0.0829027294776423	0.80433857642298	44	2346	2291	1072	2346	1900	19	6337	2201	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039657_liver_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	61931
1	2101	HIF1A	0.0827977724375241	0.841470536458021	80	2347	2151	585	2347	1690	33	6301	2187	HIF1A PC3(bone mets prostate adenocarcinoma) HIF1A	PC3(bone mets prostate adenocarcinoma)	NULL	HIF1A	Treatment: hypoxia(0.2% O2), siCtrl;	GTRD	EXP057826_PC3-bone-mets-prostate-adenocarcinoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	34121
1	1071	EGR3	0.0827066148610288	0.830706921909102	67	2348	2188	710	2348	1750	28	6314	2192	EGR3 HEK293 (embryonic kidney) EGR3	HEK293 (embryonic kidney)	NULL	EGR3	NA	GTRD	EXP035892_HEK293--embryonic-kidney-_EGR3_MACS_EGR3_MA0732.1.damo.pwm.bed	95395
1	2446	JUN	0.0827066148610288	0.830706921909102	67	2348	2188	710	2348	1750	28	6314	2192	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	25434
1	1797	FOXA1	0.0824897944513306	0.905024750507234	298	2350	1858	92	2350	1430	114	6083	2106	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	PHFRPMIFCS	GEO	GSE69043_foxa1_lncap-phfrpmifcs_MACS_FOXA1_MA0148.4.damo.pwm.bed	76958
1	676	CTCF	0.0824391281507603	0.738635776634404	17	2351	2503	2066	2503	2310	8	6364	2212	CTCF heart left ventricle CTCF	heart left ventricle	NULL	CTCF		GTRD	EXP039370_heart-left-ventricle_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35343
1	765	CTCF	0.0824391281507603	0.738635776634404	17	2351	2503	2066	2503	2310	8	6364	2212	CTCF Peyer's patch CTCF	Peyer's patch	NULL	CTCF		GTRD	EXP040031_Peyer-s-patch_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34238
1	875	CTCF	0.0824391281507603	0.738635776634404	17	2351	2503	2066	2503	2310	8	6364	2212	CTCF T47D (invasive ductal carcinoma) CTCF	T47D (invasive ductal carcinoma)	BTO:0001248	CTCF	Treatment: 110 mM NaCl for 7.5 min  Source: T47D whole cell	GTRD	EXP053042_T47D--invasive-ductal-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28717
1	1825	FOXA2	0.0824391281507603	0.738635776634404	17	2351	2503	2066	2503	2310	8	6364	2212	FOXA2 endometrioid adenocarcinoma FOXA2	endometrioid adenocarcinoma	NULL	FOXA2	tumor E	GTRD	EXP036414_endometrioid-adenocarcinoma_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	8621
1	2536	JUNB	0.0824391281507603	0.738635776634404	17	2351	2503	2066	2503	2310	8	6364	2212	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	9974
1	2541	JUNB	0.0824391281507603	0.738635776634404	17	2351	2503	2066	2503	2310	8	6364	2212	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	10285
1	208	AR	0.0822623711377254	0.775104332228496	29	2357	2391	1504	2391	2080	13	6352	2207	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH3_DHT	GEO	GSE79128_AR_vcap-sh3-dht_MACS_AR_MA0007.3.damo.pwm.bed	14273
1	234	ASCL1	0.0822623711377254	0.775104332228496	29	2357	2391	1504	2391	2080	13	6352	2207	ASCL1 SCLC ASCL1	SCLC	NA	ASCL1	ASCLP	GEO	GSE61197_ascl1_sclc-asclp_MACS_ASCL1_MA1100.2.damo.pwm.bed	30997
1	996	CUX1	0.0822623711377254	0.775104332228496	29	2357	2391	1504	2391	2080	13	6352	2207	CUX1 MCF7 (Invasive ductal breast carcinoma) CUX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CUX1	NA	ENCODE	ENCSR017CEO_MCF-7_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	10881
1	3079	NR2F6	0.0822623711377254	0.775104332228496	29	2357	2391	1504	2391	2080	13	6352	2207	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	ENCODE	ENCSR518WPL_HepG2_NR2F6_MACS_NR2F6_MA0677.1.damo.pwm.bed	32566
1	184	AR	0.0821250033358362	0.849303221676299	93	2361	2121	489	2361	1660	38	6288	2182	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXP1_DHT	GEO	GSE62492_AR_lncap-shfoxp1-dht_MACS_AR_MA0007.3.damo.pwm.bed	34532
1	1950	GATA2	0.0818267355998285	0.867093968301306	130	2362	2071	333	2362	1590	52	6251	2168	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2		GEO	GSE52725_gata2_lncap_MACS_GATA2_MA0036.3.damo.pwm.bed	59875
1	2414	JUN	0.0817372186806275	0.872889069771808	146	2363	1982	295	2363	1550	58	6235	2162	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: non-transformed	GTRD	EXP048571_MCF10A-ER-Src_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	38020
1	1743	FOXA1	0.0816982139603645	0.863646222707428	122	2364	2078	356	2364	1600	49	6259	2171	FOXA1 primary prostate cancer FOXA1	primary prostate cancer	NULL	FOXA1	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053243_primary-prostate-cancer_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	24283
1	3912	TFAP2C	0.0816408655831685	0.899732852488469	265	2365	1887	110	2365	1450	102	6116	2118	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE21234_tfap2c_mcf7_MACS_TFAP2C_MA0524.2.damo.pwm.bed	75207
1	1194	ESR1	0.0814454806256474	0.890950695701753	216	2366	1924	163	2366	1480	84	6165	2136	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP032285_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	48845
1	496	CTCF	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPS_fibroblast_of_gingiva_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45205
1	589	CTCF	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	CTCF FB0167P (progeria fibroblasts) CTCF	FB0167P (progeria fibroblasts)	NULL	CTCF	NULL	GTRD	EXP001025_FB0167P--progeria-fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40258
1	914	CTCF	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	CTCF GM18505 (female B-cells Lymphoblastoid Cell Lines) CTCF	GM18505 (female B-cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054523_GM18505--female-B-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39311
1	2523	JUNB	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	11340
1	2524	JUNB	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	11498
1	2696	MAX	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	MAX HeLa S3 (cervical adenocarcinoma) MAX	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MAX		ENCODE	ENCSR000ECN_HeLa-S3_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	22447
1	3235	PKNOX1	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	PKNOX1 K562 (myelogenous leukemia) PKNOX1	K562 (myelogenous leukemia)	NULL	PKNOX1	NA	ENCODE	ENCSR115SMW_K562_PKNOX1_MACS_PKNOX1_MA0782.2.damo.pwm.bed	27587
1	4081	USF2	0.0803691407825029	0.75818816457068	24	2367	2442	1691	2442	2170	11	6357	2209	USF2 HeLa S3 (cervical adenocarcinoma) USF2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	USF2		ENCODE	ENCSR000ECW_HeLa-S3_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	19106
1	94	AR	0.0803184826115359	0.850112643142648	98	2375	2114	460	2375	1650	40	6283	2180	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: 10 nM DHT for 6 hrs TF: full-length AR (AR-FL)	GTRD	EXP049391_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	40383
1	233	ASCL1	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	ASCL1 SCLC ASCL1	SCLC	NA	ASCL1	ASCLP_NE	GEO	GSE61197_ascl1_sclc-asclp-ne_MACS_ASCL1_MA1100.2.damo.pwm.bed	9966
1	379	CEBPB	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039961_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	5210
1	657	CTCF	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	CTCF E14 retina CTCF	E14 retina	NULL	CTCF		GTRD	EXP037799_E14-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26425
1	664	CTCF	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF	+DOX 3 days, mutant CTCF	GTRD	EXP038268_K562--myelogenous-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24725
1	677	CTCF	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	CTCF esophagus muscularis mucosa CTCF	esophagus muscularis mucosa	NULL	CTCF		GTRD	EXP039379_esophagus-muscularis-mucosa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27434
1	690	CTCF	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	CTCF tibial nerve CTCF	tibial nerve	NULL	CTCF		GTRD	EXP039463_tibial-nerve_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31765
1	1063	EGR1	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	EGR1 K562 (myelogenous leukemia) EGR1	K562 (myelogenous leukemia)	NULL	EGR1		GTRD	EXP039443_K562--myelogenous-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	18376
1	1458	ETS1	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	ETS1 RCC 7860 (Renal cell carcinoma) ETS1	RCC 7860 (Renal cell carcinoma)	BTO:0003781	ETS1		GTRD	EXP037740_786-O--renal-carcinoma-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	18438
1	2075	HAND2	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	HAND2 CLB-Ga (neuroblastoma) HAND2	CLB-Ga (neuroblastoma)	NULL	HAND2	none	GTRD	EXP039006_CLB-Ga--neuroblastoma-_HAND2_MACS_HAND2_MA1638.1.damo.pwm.bed	33850
1	2156	HOXA9	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	HOXA9 HEK293-FT (human embryonic kidney, female transformed) HOXA9	HEK293-FT (human embryonic kidney, female transformed)	NULL	HOXA9	HOXA9-FLAG expression	GTRD	EXP036955_HEK293-FT--human-embryonic-kidney--female-transformed-_HOXA9_MACS_HOXA9_MA0594.2.damo.pwm.bed	19912
1	2665	MAF	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047557_Th17-cells_MAF_MACS_MAF_MA0501.1.damo.pwm.bed	7057
1	2666	MAF	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047557_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	6100
1	2773	MXI1	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	MXI1 SK-N-SH (neuroblastoma) MXI1	SK-N-SH (neuroblastoma)	BTO:0001620	MXI1	NA	ENCODE	ENCSR000EIA_SK-N-SH_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	23453
1	2780	MYBL2	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	MYBL2 HepG2 (hepatoblastoma) MYBL2	HepG2 (hepatoblastoma)	BTO:0000599	MYBL2	NA	ENCODE	ENCSR000BRO_HepG2_MYBL2_MACS_MYBL2_MA0777.1.damo.pwm.bed	9893
1	2885	MYC	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047488_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10358
1	2935	MYC	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	SHRCTR	GEO	GSE77356_myc_u2os-shrctr_MACS_MYC_MA0147.3.damo.pwm.bed	20724
1	2964	NEUROD1	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	NEUROD1 D341 Med (medulloblastoma) NEUROD1	D341 Med (medulloblastoma)	NULL	NEUROD1	shNEUROD1.1579	GTRD	EXP038208_D341-Med--medulloblastoma-_NEUROD1_MACS_NEUROD1_MA1109.1.damo.pwm.bed	22456
1	2989	NEUROG2	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037157_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	23944
1	3438	RFX1	0.0791508379747322	0.695370279899957	10	2376	2725	2487	2725	2530	5	6371	2215	RFX1 MCF7 (Invasive ductal breast carcinoma) RFX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RFX1	NA	GTRD	EXP039737_MCF7--Invasive-ductal-breast-carcinoma-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	11335
1	177	AR	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ETOH_SHCTR	GEO	GSE61268_AR_lncap-etoh-shctr_MACS_AR_MA0007.3.damo.pwm.bed	325
1	271	BACH1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	BACH1 K562 (myelogenous leukemia) BACH1	K562 (myelogenous leukemia)	NULL	BACH1	NA	ENCODE	ENCSR740NPG_K562_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	6121
1	287	BCL6	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6	Treatment: BCL6 targeted siRNA	GTRD	EXP052977_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	5633
1	424	CREB1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	CREB1 MDA-MB-134 (invasive lobular breast carcinoma) CREB1	MDA-MB-134 (invasive lobular breast carcinoma)	NULL	CREB1	Treatment:100 nM estradiol (E2) for 1hr Passage: between 10 and12 CellType: Epithelial ERalpha positive breast cancer cell line	GTRD	EXP048181_MDA-MB-134--invasive-lobular-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	1474
1	862	CTCF	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	CTCF MDM(monocyte derived macrophages) CTCF	MDM(monocyte derived macrophages)	NULL	CTCF	Treatment: ZIKV-bystander, time post infection 24 hr  ViralStrain: ZIKV-FSS13025	GTRD	EXP048656_MDM-monocyte-derived-macrophages-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	10574
1	941	CTCF	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	CTCF monocyte CTCF	monocyte	NA	CTCF	BLOOD	GEO	GSE43098_ctcf_monocytes-blood_MACS_CTCF_MA0139.1.damo.pwm.bed	8073
1	1030	E2F1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	E2F1 LNCaP-abl (Prostate carcinoma) E2F1	LNCaP-abl (Prostate carcinoma)	NULL	E2F1		GEO	GSE67809_e2f1_lncap-abl_MACS_E2F1_MA0024.3.damo.pwm.bed	5388
1	1031	E2F1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	E2F1 mesenchymal E2F1	mesenchymal	NA	E2F1		GEO	GSE77260_e2f1_mesenchymal_MACS_E2F1_MA0024.3.damo.pwm.bed	12859
1	1045	E2F6	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	E2F6 HeLa S3 (cervical adenocarcinoma) E2F6	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	E2F6		ENCODE	ENCSR000EVK_HeLa-S3_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	2946
1	1082	ELF1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ELF1 HCT-116 (colon carcinoma) ELF1	HCT-116 (colon carcinoma)	BTO:0001109	ELF1		ENCODE	ENCSR000BVH_HCT116_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	3975
1	1134	ERG	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048203_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	13500
1	1187	ESR1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	E2	GTRD	EXP000886_Ishikawa--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1063
1	1188	ESR1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ESR1 ECC-1 (endometrial adenocarcinoma) ESR1	ECC-1 (endometrial adenocarcinoma)	BTO:0005365	ESR1	E2	GTRD	EXP000888_ECC-1--endometrial-adenocarcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2084
1	1310	ESR1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040959_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	704
1	1385	ESR1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	E2	GEO	GSE32349_esr1_h3396-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	2486
1	1403	ESR1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_2M	GEO	GSE54855_esr1_mcf7-e2-2m_MACS_ESR1_MA0112.3.damo.pwm.bed	779
1	1452	ETS1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	ETS1 Jurkat E6.1 (T-cells) ETS1	Jurkat E6.1 (T-cells)	BTO:0001948	ETS1	NULL	GTRD	EXP000299_Jurkat-E6.1--T-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	16072
1	1504	FLI1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1		GTRD	EXP053002_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	15043
1	1717	FOXA1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #2	GTRD	EXP048495_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	780
1	1719	FOXA1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #4	GTRD	EXP048497_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	553
1	1850	FOXK1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	FOXK1 HEK293T (embryonic kidney) FOXK1	HEK293T (embryonic kidney)	BTO:0002181	FOXK1	NA	GEO	GSE51673_foxk1_hek293t_MACS_FOXK1_MA0852.2.damo.pwm.bed	2019
1	1869	GABPA	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	GABPA HepG2 (hepatoblastoma) GABPA	HepG2 (hepatoblastoma)	BTO:0000599	GABPA		ENCODE	ENCSR000BJK_HepG2_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	7016
1	1877	GABPA	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	GABPA GM12878 (female B-cells lymphoblastoid cell line) GABPA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	GABPA		ENCODE	ENCSR331HPA_GM12878_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	9338
1	1910	GATA1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bmp	GTRD	EXP000940_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	17526
1	1924	GATA1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	GATA1 CD34+ cells GATA1	CD34+ cells	NULL	GATA1	ERYTH_BIO	GEO	GSE29194_gata1_CD34-eryth-bio_MACS_GATA1_MA0035.4.damo.pwm.bed	15915
1	1945	GATA2	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048218_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	6477
1	2026	GATA4	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	GATA4 KATOIII (signet ring cell gastric adenocarcinoma) GATA4	KATOIII (signet ring cell gastric adenocarcinoma)	NULL	GATA4		GEO	GSE51705_gata4_katoiii_MACS_GATA4_MA0482.2.damo.pwm.bed	792
1	2045	GFI1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	GFI1 AML (monocytes and acute myeloid leukemia) GFI1	AML (monocytes and acute myeloid leukemia)	NULL	GFI1	Treatment: DMSo vehicle	GTRD	EXP049354_AML--monocytes-and-acute-myeloid-leukemia-_GFI1_MACS_GFI1_MA0038.2.damo.pwm.bed	4911
1	2105	HIF1A	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	HIF1A HUVEC-C (HUVEC, umbilical vein endothelial cells) HIF1A	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	HIF1A	HYPOX	GEO	GSE39089_hif1a_huvec-hypox_MACS_HIF1A_MA1106.1.damo.pwm.bed	1890
1	2182	HSF1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	HSF1 BT-20 (breast invasive ductal carcinoma) HSF1	BT-20 (breast invasive ductal carcinoma)	BTO:0001466	HSF1		GEO	GSE38901_hsf1_bt20_MACS_HSF1_MA0486.2.damo.pwm.bed	2325
1	2197	IRF1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	IRF1 K562 (myelogenous leukemia) IRF1	K562 (myelogenous leukemia)	NULL	IRF1	Interferon gamma treatment - 30 minutes (Snyder)	ENCODE	ENCSR000EGK_K562_IRF1_MACS_IRF1_MA0050.2.damo.pwm.bed	1346
1	2667	MAF	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: resting;Day:0;	GTRD	EXP047560_Th17-cells_MAF_MACS_MAF_MA0501.1.damo.pwm.bed	1047
1	2782	MYBL2	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	MYBL2 K562 (myelogenous leukemia) MYBL2	K562 (myelogenous leukemia)	NULL	MYBL2	NA	GTRD	EXP039755_K562--myelogenous-leukemia-_MYBL2_MACS_MYBL2_MA0777.1.damo.pwm.bed	633
1	2795	MYC	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	MYC NB4 (acute promyelocytic leukemia ) MYC	NB4 (acute promyelocytic leukemia )	NULL	MYC		ENCODE	ENCSR000EHR_NB4_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	5911
1	2821	MYC	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	MYC Raji (Burkitt lymphoma) MYC	Raji (Burkitt lymphoma)	BTO:0001154	MYC		GTRD	EXP035848_Raji--Burkitt-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7271
1	2831	MYC	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt	GTRD	EXP036033_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12707
1	2914	MYC	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	CMYC_24H	GEO	GSE36354_myc_p493-cmyc-24h_MACS_MYC_MA0147.3.damo.pwm.bed	4913
1	2920	MYC	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC		GEO	GSE42262_myc_p4936_MACS_MYC_MA0147.3.damo.pwm.bed	5797
1	3182	NRF1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	NRF1 MCF7 (Invasive ductal breast carcinoma) NRF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NRF1		GTRD	EXP038569_MCF7--Invasive-ductal-breast-carcinoma-_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	5113
1	3228	PDX1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	PDX1 H9 PDX1	H9	NULL	PDX1		Array Express	ERP004206_pdx1_esc-h9_MACS_PDX1_MA0132.2.damo.pwm.bed	2003
1	3251	POU5F1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP032064_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	12065
1	3260	POU5F1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	POU5F1 bipolar neuron POU5F1	bipolar neuron	NULL	POU5F1	0.5 μg/mL doxycycline hyclate (CHEBI:34730) for 4 day	GTRD	EXP039660_bipolar-neuron_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	4457
1	3312	RARA	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA0159.1.damo.pwm.bed	3951
1	3314	RARA	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA0730.1.damo.pwm.bed	3161
1	3315	RARA	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	RARA U937 (adult acute monocytic leukemia) RARA	U937 (adult acute monocytic leukemia)	BTO:0001412	RARA	Treatment: 3 mg/mL ATRA for 3 days	GTRD	EXP049794_U937--adult-acute-monocytic-leukemia-_RARA_MACS_RARA_MA1149.1.damo.pwm.bed	4468
1	3325	RBPJ	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	RBPJ LAL-B (All-B patient-derived cell line) RBPJ	LAL-B (All-B patient-derived cell line)	NULL	RBPJ	Treatment: none;	GTRD	EXP055428_LAL-B--All-B-patient-derived-cell-line-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	3904
1	3425	REST	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	REST GM12878 (female B-cells lymphoblastoid cell line) REST	GM12878 (female B-cells lymphoblastoid cell line)	NULL	REST		GTRD	EXP054614_GM12878--female-B-cells-lymphoblastoid-cell-line-_REST_MACS_REST_MA0138.2.damo.pwm.bed	3804
1	3449	RFX5	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	RFX5 A549 (lung carcinoma) RFX5	A549 (lung carcinoma)	BTO:0000018	RFX5	NA	ENCODE	ENCSR064LJN_A549_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	3360
1	3478	RUNX1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	RUNX1 NALM-6 (adult B acute lymphoblastic leukemia) RUNX1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	RUNX1	Tissue: Peripheral blood	GTRD	EXP048189_NALM-6--adult-B-acute-lymphoblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3423
1	3601	SOX2	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2 and Klf4 addition for 5 days Passage: 8	GTRD	EXP048946_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	2800
1	3606	SOX2	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048956_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	675
1	3626	SP1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	SP1 K562 (myelogenous leukemia) SP1	K562 (myelogenous leukemia)	NULL	SP1		ENCODE	ENCSR991ELG_K562_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	7686
1	3688	SPI1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	SPI1 RS4-11 (adult B acute lymphoblastic leukemia) SPI1	RS4-11 (adult B acute lymphoblastic leukemia)	BTO:0004505	SPI1	DEX	GEO	GSE71616_spi1_rsa411-dex_MACS_SPI1_MA0080.5.damo.pwm.bed	15533
1	3758	STAT5B	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	STAT5B CD8 STAT5B	CD8	NA	STAT5B	H9RET	GEO	GSE64713_stat5b_cd8-h9ret_MACS_STAT5B_MA0519.1.damo.pwm.bed	5569
1	3820	TCF7L2	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	TCF7L2 CD34+ cells TCF7L2	CD34+ cells	NULL	TCF7L2	PROG_BIO	GEO	GSE29194_tcf7l2_CD34-prog-bio_MACS_TCF7L2_MA0523.1.damo.pwm.bed	7006
1	3827	TEAD1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	TEAD1 CC-LP-1 (intrahepatic cholangiocarcinoma) TEAD1	CC-LP-1 (intrahepatic cholangiocarcinoma)	NULL	TEAD1		GEO	GSE62272_tead1_cclp1_MACS_TEAD1_MA0090.3.damo.pwm.bed	3431
1	3857	TFAP2A	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040708_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	387
1	3858	TFAP2A	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040708_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	495
1	3945	THAP11	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	THAP11 HUES64 (embryonic stem cells) THAP11	HUES64 (embryonic stem cells)	NULL	THAP11	NA	GTRD	EXP036770_HUES64--embryonic-stem-cells-_THAP11_MACS_THAP11_MA1573.1.damo.pwm.bed	2156
1	4009	TP53	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53		GEO	GSE31558_tp53_imr90_MACS_TP53_MA0106.3.damo.pwm.bed	620
1	4068	USF1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	USF1 GM12878 (female B-cells lymphoblastoid cell line) USF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	USF1		ENCODE	ENCSR000BGI_GM12878_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	8568
1	4083	USF2	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2		ENCODE	ENCSR000EHG_K562_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	3176
1	4091	USF2	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2	Treatment: no	GTRD	EXP048312_K562--myelogenous-leukemia-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	4553
1	4100	VDR	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	EtOH for 24h	GTRD	EXP037994_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	3874
1	4109	VDR	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	VDR LX-2 (hepatic stellate cells) VDR	LX-2 (hepatic stellate cells)	BTO:0003516	VDR		GEO	GSE38103_vdr_lx2_MACS_VDR_MA0693.2.damo.pwm.bed	1303
1	4144	YY1	0.0785416391878761	0.695752332916919	2	2395	2591	3390	3390	2790	1	6379	2219	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038614_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	4138
1	1831	FOXA2	0.0778877906531344	0.863701471228566	132	2461	2077	323	2461	1620	53	6249	2167	FOXA2 HepG2 (hepatoblastoma) FOXA2	HepG2 (hepatoblastoma)	BTO:0000599	FOXA2		GTRD	EXP039957_HepG2--hepatoblastoma-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	64510
1	100	AR	0.0778617867477272	0.825891436311033	69	2462	2202	687	2462	1780	29	6312	2191	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049574_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	27020
1	1311	ESR1	0.0778617867477272	0.825891436311033	69	2462	2202	687	2462	1780	29	6312	2191	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	100nm E2 (45 min)	GTRD	EXP040960_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17136
1	2445	JUN	0.0778617867477272	0.825891436311033	69	2462	2202	687	2462	1780	29	6312	2191	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	27177
1	1759	FOXA1	0.077842826142453	0.872288341306037	156	2465	1984	264	2465	1570	62	6225	2158	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	1F5	GEO	GSE30623_foxa1_lncap1f5_MACS_FOXA1_MA0148.4.damo.pwm.bed	33623
1	59	AR	0.0777491330579777	0.791129357800419	41	2466	2329	1155	2466	1980	18	6340	2202	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GTRD	EXP037262_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13621
1	3926	TFAP2C	0.0776595807049837	0.874603929871757	164	2467	1979	246	2467	1560	65	6217	2155	TFAP2C MDA-MB-453 (breast adenocarcinoma) TFAP2C	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	TFAP2C		GEO	GSE36351_tfap2c_mdamb453_MACS_TFAP2C_MA0524.2.damo.pwm.bed	65102
1	1846	FOXA2	0.0775576372695947	0.798747066680497	46	2468	2308	1028	2468	1930	20	6335	2200	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Genotype: Clonal FOXA2 doxycycline inducible cells, CDT1	GTRD	EXP049381_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	19641
1	2137	HNF4A	0.0775576372695947	0.798747066680497	46	2468	2308	1028	2468	1930	20	6335	2200	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039987_liver_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	47525
1	1656	FOXA1	0.0775045818986316	0.781581156954863	36	2470	2379	1288	2470	2050	16	6345	2204	FOXA1 CyT49-derived endodermal cells FOXA1	CyT49-derived endodermal cells	NULL	FOXA1	none	GTRD	EXP033208_CyT49-derived-endodermal-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	17166
1	135	AR	0.0770557985718181	0.804960740458685	51	2471	2290	932	2471	1900	22	6330	2198	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GEO	GSE32892_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	11909
1	1795	FOXA1	0.0769505710354025	0.893987583708533	253	2472	1918	123	2472	1500	98	6128	2122	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		GEO	GSE64656_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	72532
1	297	BHLHE40	0.0767967844278705	0.733707589706333	19	2473	2516	1956	2516	2320	9	6362	2211	BHLHE40 IMR90 (lung fibroblasts) BHLHE40	IMR90 (lung fibroblasts)	NULL	BHLHE40	NA	GTRD	EXP039939_IMR90--lung-fibroblasts-_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	37168
1	584	CTCF	0.0767967844278705	0.733707589706333	19	2473	2516	1956	2516	2320	9	6362	2211	CTCF CD36+ erythroid cells CTCF	CD36+ erythroid cells	NULL	CTCF	BRG1 KD shLuc control	GTRD	EXP000909_CD36--erythroid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34810
1	741	CTCF	0.0767967844278705	0.733707589706333	19	2473	2516	1956	2516	2320	9	6362	2211	CTCF pancreas CTCF	pancreas	BTO:0000988	CTCF		GTRD	EXP039805_pancreas_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	33645
1	2275	JUN	0.0767967844278705	0.733707589706333	19	2473	2516	1956	2516	2320	9	6362	2211	JUN RCC 7860 (Renal cell carcinoma) JUN	RCC 7860 (Renal cell carcinoma)	BTO:0003781	JUN		GTRD	EXP037742_786-O--renal-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	18228
1	3711	SRF	0.0767967844278705	0.733707589706333	19	2473	2516	1956	2516	2320	9	6362	2211	SRF MCF7 (Invasive ductal breast carcinoma) SRF	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	SRF		ENCODE	ENCSR000BVA_MCF-7_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	7099
1	825	CTCF	0.07663564938862	0.769271329008029	31	2478	2403	1439	2478	2110	14	6350	2206	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siNIPBL(siRNA)	GTRD	EXP047781_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40366
1	951	CTCF	0.07663564938862	0.769271329008029	31	2478	2403	1439	2478	2110	14	6350	2206	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18505_MACS_CTCF_MA0139.1.damo.pwm.bed	44479
1	952	CTCF	0.07663564938862	0.769271329008029	31	2478	2403	1439	2478	2110	14	6350	2206	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm18526_MACS_CTCF_MA0139.1.damo.pwm.bed	45767
1	1964	GATA3	0.07663564938862	0.769271329008029	31	2478	2403	1439	2478	2110	14	6350	2206	GATA3 MDA-MB-231 (breast adenocarcinoma) GATA3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	GATA3		GTRD	EXP035434_MDA-MB-231--breast-adenocarcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	17713
1	108	AR	0.0763303194085577	0.810121343757091	56	2482	2281	859	2482	1870	24	6325	2196	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052951_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	17694
1	3927	TFAP2C	0.076099781854599	0.869523579922939	153	2483	2025	272	2483	1590	61	6228	2159	TFAP2C MDA-MB-453 (breast adenocarcinoma) TFAP2C	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	TFAP2C		GEO	GSE36351_tfap2c_mdamb453_MACS_TFAP2C_MA0814.2.damo.pwm.bed	59788
1	391	CEBPB	0.0758908557648428	0.86028978356902	129	2484	2085	338	2484	1640	52	6252	2168	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: without treatment of R1881 (methyltrienolone)	GTRD	EXP048165_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	82129
1	3012	NFIC	0.0754426119260176	0.814471850113234	61	2485	2243	785	2485	1840	26	6320	2194	NFIC Ishikawa (endometrial adenocarcinoma) NFIC	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	NFIC	NA	ENCODE	ENCSR000BUT_Ishikawa_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	35059
1	3367	RELA	0.0754426119260176	0.814471850113234	61	2485	2243	785	2485	1840	26	6320	2194	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: Poly I:C	GTRD	EXP049366_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	21099
1	1788	FOXA1	0.0751424472421449	0.893309271162345	258	2487	1920	119	2487	1510	100	6123	2120	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE60270_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	64535
1	2644	KLF5	0.0748482793181191	0.752819681368491	26	2488	2466	1602	2488	2190	12	6355	2208	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 WT	GTRD	EXP049096_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	20113
1	481	CTCF	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	CTCF lung CTCF	lung	BTO:0000763	CTCF		ENCODE	ENCSR000DMH_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24478
1	705	CTCF	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP039550_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30524
1	991	CTCFL	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	CTCFL K562 (myelogenous leukemia) CTCFL	K562 (myelogenous leukemia)	NULL	CTCFL	NA	GEO	GSE70764_ctcfl_k562_MACS_CTCFL_MA1102.2.damo.pwm.bed	30120
1	1046	E2F6	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	E2F6 K562 (myelogenous leukemia) E2F6	K562 (myelogenous leukemia)	NULL	E2F6		ENCODE	ENCSR000EWJ_K562_E2F6_MACS_E2F6_MA0471.2.damo.pwm.bed	30229
1	1115	EOMES	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	EOMES hESC-1 (Embryonic stem cells) EOMES	hESC-1 (Embryonic stem cells)	NULL	EOMES	NA	GEO	GSE26097_eomes_esc_MACS_EOMES_MA0800.1.damo.pwm.bed	31879
1	1691	FOXA1	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	FOXA1 liver FOXA1	liver	BTO:0000759	FOXA1		GTRD	EXP039865_liver_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	7027
1	2982	NEUROG2	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037154_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	34191
1	2986	NEUROG2	0.0747288717949524	0.69527461667386	12	2489	2744	2359	2744	2530	6	6369	2214	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037156_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	35358
1	54	AR	0.074474156819083	0.847067730921831	105	2497	2126	422	2497	1680	43	6276	2177	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	2μg/mL aphidicolin for 15 hours, followed by washout and treatment with 50ng/mL nocodozole for 9 hours +3 hour 10nm DHT	GTRD	EXP036470_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	32748
1	45	AR	0.0742984826191263	0.863718454594108	142	2498	2076	306	2498	1630	57	6239	2163	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	10 nmol/l of mibolerone	GTRD	EXP034504_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	60764
1	28	AR	0.0733466441755319	0.821390500329299	71	2499	2226	659	2499	1790	30	6310	2190	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032861_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	23707
1	1641	FOXA1	0.0730170901302157	0.904445231959989	353	2500	1863	64	2500	1480	135	6028	2085	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1		Array Express	ERP001226_foxa1_lncap_MACS_FOXA1_MA0148.4.damo.pwm.bed	93742
1	1844	FOXA2	0.0727810592585381	0.880986118801735	206	2501	1954	181	2501	1550	81	6175	2139	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: addition of 200 uM mimosine over night Genotype: Clonal FOXA2 doxycycline inducible cells	GTRD	EXP049379_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	79400
1	1338	ESR1	0.0727188952291642	0.785945805158368	43	2502	2340	1101	2502	1980	19	6338	2201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Saturated H3B-5942	GTRD	EXP048584_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11647
1	1834	FOXA2	0.0727188952291642	0.785945805158368	43	2502	2340	1101	2502	1980	19	6338	2201	FOXA2 definitive endoderm(dEN, ES derived) FOXA2	definitive endoderm(dEN, ES derived)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049292_definitive-endoderm-dEN--ES-derived-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	44513
1	1313	ESR1	0.0723967325860645	0.776368619594134	38	2504	2388	1238	2504	2040	17	6343	2203	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047662_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	6903
1	2154	HNF4G	0.0722706176651621	0.800048832218352	53	2505	2301	905	2505	1900	23	6328	2197	HNF4G 22RV1 (prostate carcinoma) HNF4G	22RV1 (prostate carcinoma)	BTO:0002999	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: knockdown HNF4G	GTRD	EXP048997_22RV1--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	13939
1	47	AR	0.0721956585495536	0.82418137013668	76	2506	2219	619	2506	1780	32	6305	2188	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	siControl	GTRD	EXP036095_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	33563
1	172	AR	0.0721956585495536	0.82418137013668	76	2506	2219	619	2506	1780	32	6305	2188	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	DHT24H	GEO	GSE58428_AR_vcap-dht24h_MACS_AR_MA0007.3.damo.pwm.bed	33157
1	1001	DUX4	0.0716583702936376	0.729745810068923	21	2508	2529	1852	2529	2300	10	6360	2210	DUX4 myoblasts DUX4	myoblasts	NULL	DUX4	myoblasts transduced with lentivirus carrying DUX4	GTRD	EXP000278_myoblasts_DUX4_MACS_DUX4_MA0468.1.damo.pwm.bed	36449
1	1879	GABPA	0.0716583702936376	0.729745810068923	21	2508	2529	1852	2529	2300	10	6360	2210	GABPA CUTLL1 (T-cell lymphoblastic lymphoma 1) GABPA	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	GABPA	vehicle	GTRD	EXP032405_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	60147
1	2691	MAX	0.0716583702936376	0.729745810068923	21	2508	2529	1852	2529	2300	10	6360	2210	MAX HepG2 (hepatoblastoma) MAX	HepG2 (hepatoblastoma)	BTO:0000599	MAX		ENCODE	ENCSR000BTM_HepG2_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	34215
1	2962	NEUROD1	0.0716583702936376	0.729745810068923	21	2508	2529	1852	2529	2300	10	6360	2210	NEUROD1 D341 Med (medulloblastoma) NEUROD1	D341 Med (medulloblastoma)	NULL	NEUROD1		GTRD	EXP038201_D341-Med--medulloblastoma-_NEUROD1_MACS_NEUROD1_MA1109.1.damo.pwm.bed	49182
1	1147	ERG	0.0715144331267334	0.764203178686699	33	2512	2425	1379	2512	2110	15	6348	2205	ERG TSU-1621-MT (adult acute myeloid leukemia) ERG	TSU-1621-MT (adult acute myeloid leukemia)	NULL	ERG	ATRA	GEO	GSE60477_erg_tsu1621mt-atra_MACS_ERG_MA0474.2.damo.pwm.bed	70044
1	404	CEBPB	0.0710895277383129	0.836181545789306	94	2513	2160	482	2513	1720	39	6287	2181	CEBPB hMSC CEBPB	hMSC	NA	CEBPB	DMI_LOW	GEO	GSE68864_cebpb_hmsc-dmi-low_MACS_CEBPB_MA0466.2.damo.pwm.bed	68585
1	113	AR	0.071002737222507	0.826631415801456	81	2514	2201	579	2514	1760	34	6300	2186	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  transfected twice with with 5nM of siControl every 24 hours, 100nM of DHT for 2 hrs	GTRD	EXP052982_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28285
1	1664	FOXA1	0.0706296182230547	0.843467442845996	107	2515	2144	416	2515	1690	44	6274	2176	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	DHT 10 nM	GTRD	EXP036101_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	26826
1	2023	GATA4	0.0706296182230547	0.843467442845996	107	2515	2144	416	2515	1690	44	6274	2176	GATA4 BJ (fibroblasts) GATA4	BJ (fibroblasts)	NULL	GATA4	Genotype: Clonal FOXA2 doxycycline inducible cells	GTRD	EXP049376_BJ--fibroblasts-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	116368
1	1393	ESR1	0.0703790436473552	0.695178893345956	14	2517	2752	2252	2752	2510	7	6367	2213	ESR1 VCaP (prostate carcinoma) ESR1	VCaP (prostate carcinoma)	BTO:0003215	ESR1	E2_ERA	GEO	GSE43985_esr1_vcap-e2-era_MACS_ESR1_MA0112.3.damo.pwm.bed	12562
1	3150	NR3C1	0.0703790436473552	0.695178893345956	14	2517	2752	2252	2752	2510	7	6367	2213	NR3C1 HeLa-B2 NR3C1	HeLa-B2	NA	NR3C1	TA_TNFA	GEO	GSE24518_nr3c1_helab2-ta-tnfa_MACS_NR3C1_MA0113.3.damo.pwm.bed	5431
1	4035	TP63	0.0703790436473552	0.695178893345956	14	2517	2752	2252	2752	2510	7	6367	2213	TP63 keratinocytes TP63	keratinocytes	NULL	TP63	Genotype: shRNA shSC Cells were harvested by scraping from plates and washed twice in 1× PBS before storage at -80°C.	GTRD	EXP048286_keratinocytes_TP63_MACS_TP63_MA0525.2.damo.pwm.bed	895
1	366	CEBPB	0.0700692290159262	0.876949828318139	200	2520	1974	190	2520	1560	79	6181	2141	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	300nM JQ1	GTRD	EXP037881_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	84027
1	24	AR	0.0698304833495493	0.748262284219199	28	2521	2473	1531	2521	2180	13	6353	2207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032853_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	5030
1	250	ATF3	0.0698304833495493	0.748262284219199	28	2521	2473	1531	2521	2180	13	6353	2207	ATF3 liver ATF3	liver	BTO:0000759	ATF3		ENCODE	ENCSR205FOW_liver_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	15186
1	533	CTCF	0.0698304833495493	0.748262284219199	28	2521	2473	1531	2521	2180	13	6353	2207	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DVI_retinal_pigment_epithelial_cell_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46121
1	915	CTCF	0.0698304833495493	0.748262284219199	28	2521	2473	1531	2521	2180	13	6353	2207	CTCF GM18526 (B – cells Lymphoblastoid Cell Lines) CTCF	GM18526 (B – cells Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054525_GM18526--B-–-cells-Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42615
1	4042	TP63	0.0697820805707129	0.828797411218163	86	2525	2194	534	2525	1750	36	6295	2184	TP63 keratinocytes TP63	keratinocytes	NULL	TP63		GEO	GSE33571_tp63_keratinocytes_MACS_TP63_MA0525.2.damo.pwm.bed	24961
1	183	AR	0.0697157895554201	0.837597356542856	99	2526	2158	455	2526	1710	41	6282	2179	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR_DHT	GEO	GSE62492_AR_lncap-shctr-dht_MACS_AR_MA0007.3.damo.pwm.bed	36882
1	3924	TFAP2C	0.0694987330875316	0.889114985191357	262	2527	1927	116	2527	1520	102	6119	2118	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE36351_tfap2c_mcf7_MACS_TFAP2C_MA0524.2.damo.pwm.bed	73691
1	3132	NR3C1	0.0681209267514838	0.820125488751819	78	2528	2229	604	2528	1790	33	6303	2187	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 20 min;	GTRD	EXP047630_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	20685
1	1758	FOXA1	0.0680950544463404	0.781270914861181	45	2529	2381	1054	2529	1990	20	6336	2200	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	1F5_SIFOXA1	GEO	GSE30623_foxa1_lncap1f5-sifoxa1_MACS_FOXA1_MA0148.4.damo.pwm.bed	8900
1	2123	HNF4A	0.0680950544463404	0.781270914861181	45	2529	2381	1054	2529	1990	20	6336	2200	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		Array Express	ERP002306_hnf4a_liver_MACS_HNF4A_MA0114.4.damo.pwm.bed	43415
1	1754	FOXA1	0.0680329602062375	0.896008017337624	316	2531	1900	85	2531	1510	122	6065	2098	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE23852_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	60110
1	1282	ESR1	0.0672238932753031	0.854229660183831	138	2532	2103	316	2532	1650	56	6243	2164	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siNT	GTRD	EXP038770_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	45111
1	1155	ESR1	0.0669624546868937	0.726486856052497	23	2533	2540	1739	2540	2270	11	6358	2209	ESR1 Ishikawa (endometrial adenocarcinoma) ESR1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	ESR1	1 h with 100 nM Genistein (Myers)	ENCODE	ENCSR000BKL_Ishikawa_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	25936
1	2495	JUNB	0.0669624546868937	0.726486856052497	23	2533	2540	1739	2540	2270	11	6358	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	14257
1	2526	JUNB	0.0669624546868937	0.726486856052497	23	2533	2540	1739	2540	2270	11	6358	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB		GTRD	EXP039779_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	11341
1	3152	NR3C1	0.0669624546868937	0.726486856052497	23	2533	2540	1739	2540	2270	11	6358	2209	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	1F5_SIFOXA1	GEO	GSE30623_nr3c1_lncap-1f5-sifoxa1_MACS_NR3C1_MA0113.3.damo.pwm.bed	14366
1	97	AR	0.0668350600223822	0.759756460335728	35	2537	2438	1318	2537	2100	16	6346	2204	AR VCaP and LTAD cells AR	VCaP and LTAD cells	NULL	AR	Treatment: 24h DHT 10 nM	GTRD	EXP049449_VCaP-and-LTAD-cells_AR_MACS_AR_MA0007.3.damo.pwm.bed	12487
1	2504	JUNB	0.0668350600223822	0.759756460335728	35	2537	2438	1318	2537	2100	16	6346	2204	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	16529
1	1426	ESR1	0.0667589952529325	0.805668974943426	65	2539	2289	738	2539	1860	28	6316	2192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2PG	GEO	GSE68356_ESR1_mcf7-e2pg_MACS_ESR1_MA0112.3.damo.pwm.bed	14523
1	1732	FOXA1	0.0665619449146335	0.877756375019727	218	2540	1970	162	2540	1560	86	6163	2134	FOXA1 T47D (invasive ductal carcinoma) FOXA1	T47D (invasive ductal carcinoma)	BTO:0001248	FOXA1	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049903_T47D--invasive-ductal-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	50363
1	29	AR	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	BICALUTAMIDE	GTRD	EXP032864_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3028
1	119	AR	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	AR primary prostate cancer AR	primary prostate cancer	NULL	AR	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053233_primary-prostate-cancer_AR_MACS_AR_MA0007.3.damo.pwm.bed	4520
1	873	CTCF	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	CTCF GM12878 (female B-cells lymphoblastoid cell line) CTCF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CTCF	Genotype: wildtype Cell type: lymphoblastoid cell Age: no	GTRD	EXP051029_GM12878--female-B-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31343
1	1404	ESR1	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_40M	GEO	GSE54855_esr1_mcf7-e2-40m_MACS_ESR1_MA0112.3.damo.pwm.bed	4274
1	2535	JUNB	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	9948
1	2539	JUNB	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	9928
1	3678	SPI1	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	SPI1 Kasumi-1 (acute myeloblastic leukemia) SPI1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	SPI1	SICTR	GEO	GSE60130_spi1_kasumi1-sictr_MACS_SPI1_MA0080.5.damo.pwm.bed	52779
1	3732	STAT3	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	STAT3 HeLa S3 (cervical adenocarcinoma) STAT3	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	STAT3		ENCODE	ENCSR000EDC_HeLa-S3_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	8628
1	3906	TFAP2C	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen;	GTRD	EXP058229_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	5335
1	3907	TFAP2C	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen;	GTRD	EXP058229_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	5293
1	3908	TFAP2C	0.0662113239312279	0.695083109859585	16	2541	2755	2127	2755	2470	8	6365	2212	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C	Treatment: with Estrogen;	GTRD	EXP058229_MCF7--Invasive-ductal-breast-carcinoma-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	5311
1	25	AR	0.0660225955598718	0.809700192798212	70	2552	2282	666	2552	1830	30	6311	2190	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032854_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	21369
1	2074	GRHL2	0.0660225955598718	0.809700192798212	70	2552	2282	666	2552	1830	30	6311	2190	GRHL2 PEO1 (ovarian cystadenocarcinoma) GRHL2	PEO1 (ovarian cystadenocarcinoma)	NULL	GRHL2		GEO	GSE71018_grhl2_peo1_MACS_GRHL2_MA1105.2.damo.pwm.bed	16801
1	44	AR	0.06566450110002	0.841066930760346	114	2554	2152	392	2554	1700	47	6267	2173	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	ethanol	GTRD	EXP034503_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	25754
1	374	CEBPB	0.0652505379394858	0.744342156369129	30	2555	2495	1473	2555	2170	14	6351	2206	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB		GTRD	EXP039590_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	19721
1	1150	ERG	0.0652505379394858	0.744342156369129	30	2555	2495	1473	2555	2170	14	6351	2206	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	SH1_DHT	GEO	GSE79128_erg_vcap-sh1-dht_MACS_ERG_MA0474.2.damo.pwm.bed	14781
1	4055	TP63	0.0648570098284386	0.8270989438891	93	2557	2200	489	2557	1750	39	6288	2181	TP63 HaCaT (keratinocytes) TP63	HaCaT (keratinocytes)	BTO:0000552	TP63	dnRAS_TGFB	GEO	GSE60814_tp63_hacat-dnras-tgfb_MACS_TP63_MA0525.2.damo.pwm.bed	7195
1	3934	TFAP4	0.0643070373179395	0.816302435791109	80	2558	2238	585	2558	1790	34	6301	2186	TFAP4 SNU175 (adenocarcinoma) TFAP4	SNU175 (adenocarcinoma)	NULL	TFAP4	NA	GTRD	EXP037552_SNU175--adenocarcinoma-_TFAP4_MACS_TFAP4_MA0691.1.damo.pwm.bed	50260
1	2277	JUN	0.063833948983957	0.777032006022538	47	2559	2386	1002	2559	1980	21	6334	2199	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	44456
1	2279	JUN	0.063833948983957	0.777032006022538	47	2559	2386	1002	2559	1980	21	6334	2199	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	48726
1	2596	JUND	0.0636002724716652	0.847324403934664	132	2561	2124	323	2561	1670	54	6249	2166	JUND HeLa S3 (cervical adenocarcinoma) JUND	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	JUND		ENCODE	ENCSR000EDH_HeLa-S3_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	36650
1	3495	RUNX1	0.0634156926476467	0.767554479015443	42	2562	2410	1124	2562	2030	19	6339	2201	RUNX1 BONE RUNX1	BONE	NA	RUNX1	MARROW	GEO	GSE64862_runx1_bone-marrow_MACS_RUNX1_MA0002.2.damo.pwm.bed	74256
1	967	CTCF	0.0626572362031067	0.723755006393859	25	2563	2548	1657	2563	2260	12	6356	2208	CTCF WA01 (H1, human embryonic stem cells) CTCF	WA01 (H1, human embryonic stem cells)	NULL	CTCF	MESEN_STEM	GEO	GSE52457_ctcf_h1-mesen-stem_MACS_CTCF_MA0139.1.damo.pwm.bed	43159
1	3356	RELA	0.0626572362031067	0.723755006393859	25	2563	2548	1657	2563	2260	12	6356	2208	RELA RCC 7860 (Renal cell carcinoma) RELA	RCC 7860 (Renal cell carcinoma)	BTO:0003781	RELA		GTRD	EXP037741_786-O--renal-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	33859
1	930	CTCF	0.0625448321757541	0.75582149903181	37	2565	2454	1264	2565	2090	17	6344	2203	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: 3 uM final concentration of CBL0137 for 6hrs;	GTRD	EXP058382_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	46769
1	3523	RXRA	0.0625448321757541	0.75582149903181	37	2565	2454	1264	2565	2090	17	6344	2203	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	43444
1	69	AR	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation ,  ethanol,  knockout control Genotype: wildtype Source: prostate cancer cells	GTRD	EXP048074_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3986
1	176	AR	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	AR LNCaP C4-2B (prostate carcinoma) AR	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	AR	R1881_SHCTR	GEO	GSE61268_AR_c42b-r1881-shctr_MACS_AR_MA0007.3.damo.pwm.bed	3114
1	600	CTCF	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	CTCF normal lung fibroblasts CTCF	normal lung fibroblasts	NULL	CTCF		GTRD	EXP030406_normal-lung-fibroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	37174
1	752	CTCF	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	CTCF prostate gland CTCF	prostate gland	BTO:0001129	CTCF		GTRD	EXP039929_prostate-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30599
1	993	CTCFL	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	CTCFL OVCAR8 (high grade ovarian serous adenocarcinoma) CTCFL	OVCAR8 (high grade ovarian serous adenocarcinoma)	BTO:0003054	CTCFL	NA	GEO	GSE70764_ctcfl_ovcar8_MACS_CTCFL_MA1102.2.damo.pwm.bed	27711
1	2242	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	16936
1	2244	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17341
1	2246	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16365
1	2247	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	16922
1	2256	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17514
1	2257	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	17363
1	2259	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	17103
1	2260	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17368
1	2261	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18619
1	2312	JUN	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	10989
1	2882	MYC	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047486_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	14978
1	4114	WT1	0.0622689611420363	0.694987266158022	18	2567	2766	1996	2766	2440	9	6363	2211	WT1 HEK293 (embryonic kidney) WT1	HEK293 (embryonic kidney)	NULL	WT1	NA	GTRD	EXP039730_HEK293--embryonic-kidney-_WT1_MACS_WT1_MA1627.1.damo.pwm.bed	11951
1	955	CTCF	0.0610549436045496	0.740931832088671	32	2584	2499	1410	2584	2160	15	6349	2205	CTCF CTCF	NA	NA	CTCF	NA	GEO	GSE50893_ctcf_gm19193_MACS_CTCF_MA0139.1.damo.pwm.bed	46307
1	978	CTCF	0.0610549436045496	0.740931832088671	32	2584	2499	1410	2584	2160	15	6349	2205	CTCF K562 (myelogenous leukemia) CTCF	K562 (myelogenous leukemia)	NULL	CTCF		GEO	GSE70482_ctcf_k562_MACS_CTCF_MA0139.1.damo.pwm.bed	44145
1	3800	TCF4	0.0609731759872192	0.848442297617286	142	2586	2122	306	2586	1670	58	6239	2162	TCF4 TMD8 (diffuse large B-cell lymphoma) TCF4	TMD8 (diffuse large B-cell lymphoma)	NULL	TCF4	Treatment: 60ng/ml  Tetracyclin for 24 hrs; Genotype: inducible TCF4 expression;	GTRD	EXP058278_TMD8--diffuse-large-B-cell-lymphoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	229894
1	23	AR	0.0607339868114148	0.8126922447078	82	2587	2245	570	2587	1800	35	6299	2185	AR VCS2 (prostate carcinoma) AR	VCS2 (prostate carcinoma)	NULL	AR	DHT for 4h	GTRD	EXP031107_VCS2--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	43041
1	1833	FOXA2	0.0604747514341109	0.899626043214312	401	2588	1888	42	2588	1510	154	5980	2066	FOXA2 KerCT (keratenocytes) FOXA2	KerCT (keratenocytes)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049290_KerCT--keratenocytes-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	82979
1	2061	GRHL2	0.0603690400707895	0.825612350887536	100	2589	2209	446	2589	1750	42	6281	2178	GRHL2 MCF7 (Invasive ductal breast carcinoma) GRHL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GRHL2	control	GTRD	EXP040964_MCF7--Invasive-ductal-breast-carcinoma-_GRHL2_MACS_GRHL2_MA1105.2.damo.pwm.bed	18648
1	4163	ZNF143	0.0599353679772591	0.787535272220686	59	2590	2334	805	2590	1910	26	6322	2194	ZNF143 MCF7 (Invasive ductal breast carcinoma) ZNF143	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ZNF143	E2	GEO	GSE76454_znf143_mcf7-e2_MACS_ZNF143_MA0088.2.damo.pwm.bed	40933
1	87	AR	0.0594527702930108	0.763793864192832	44	2591	2426	1072	2591	2030	20	6337	2200	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout	GTRD	EXP049278_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12962
1	1161	ESR1	0.0594527702930108	0.763793864192832	44	2591	2426	1072	2591	2030	20	6337	2200	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_TAM	Array Express	ERP000380_esr1_mcf7-e2-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	10943
1	2281	JUN	0.0594527702930108	0.763793864192832	44	2591	2426	1072	2591	2030	20	6337	2200	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	45422
1	2282	JUN	0.0594527702930108	0.763793864192832	44	2591	2426	1072	2591	2030	20	6337	2200	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	40228
1	61	AR	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	dihydrotestosterone  (DHT)	GTRD	EXP038188_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2494
1	180	AR	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881_SHCTR	GEO	GSE61268_AR_lncap-r1881-shctr_MACS_AR_MA0007.3.damo.pwm.bed	1085
1	660	CTCF	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	CTCF E23 retina CTCF	E23 retina	NULL	CTCF		GTRD	EXP037802_E23-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	20748
1	764	CTCF	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	CTCF right atrium auricular region CTCF	right atrium auricular region	NULL	CTCF		GTRD	EXP040028_right-atrium-auricular-region_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18372
1	933	CTCF	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	CTCF hESC-1 (Embryonic stem cells) CTCF	hESC-1 (Embryonic stem cells)	NULL	CTCF		GEO	GSE20650_ctcf_esc_MACS_CTCF_MA0139.1.damo.pwm.bed	17383
1	1439	ESR2	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	ESR2 MDA-MB-231ERb(triple negative breast cancer) ESR2	MDA-MB-231ERb(triple negative breast cancer)	NULL	ESR2	Treatment: ethanol vehicle for 3 hr Passages: 20-25	GTRD	EXP048148_MDA-MB-231ERb-triple-negative-breast-cancer-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	6896
1	1520	FOS	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS		ENCODE	ENCSR000FAI_K562_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	11360
1	1870	GABPA	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	GABPA K562 (myelogenous leukemia) GABPA	K562 (myelogenous leukemia)	NULL	GABPA		ENCODE	ENCSR000BLO_K562_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	21220
1	1963	GATA3	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	GATA3 Th2-cells GATA3	Th2-cells	BTO:0001679	GATA3		GTRD	EXP031084_Th2-cells_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	13453
1	2004	GATA3	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	GATA3 thymocytes GATA3	thymocytes	NULL	GATA3		GEO	GSE71751_gata3_thymocyte_MACS_GATA3_MA0037.3.damo.pwm.bed	7129
1	2456	JUN	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	10803
1	2459	JUN	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	JUN Kasumi-1 (acute myeloblastic leukemia) JUN	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	JUN	Genotype: control (scrambled shRNA);	GTRD	EXP058211_Kasumi-1--acute-myeloblastic-leukemia-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	11223
1	2472	JUN	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN	TNF	GEO	GSE71976_jun_bt549-tnf_MACS_JUN_MA0488.1.damo.pwm.bed	3461
1	2473	JUN	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	JUN BT-549 (breast invasive ductal carcinoma) JUN	BT-549 (breast invasive ductal carcinoma)	BTO:0002548	JUN	TNF	GEO	GSE71976_jun_bt549-tnf_MACS_JUN_MA0489.1.damo.pwm.bed	3168
1	2749	MEIS1	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	MEIS1 SEM (childhood B acute lymphoblastic leukemia) MEIS1	SEM (childhood B acute lymphoblastic leukemia)	NULL	MEIS1	NA	GEO	GSE38339_meis1_sem_MACS_MEIS1_MA0498.2.damo.pwm.bed	11850
1	2916	MYC	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	MYC U-87MG MYC	U-87MG	NA	MYC		GEO	GSE36354_myc_u87mg_MACS_MYC_MA0147.3.damo.pwm.bed	14134
1	2921	MYC	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	MYC HeLa (cervical adenocarcinoma) MYC	HeLa (cervical adenocarcinoma)	BTO:0000567	MYC		GEO	GSE44672_myc_hela_MACS_MYC_MA0147.3.damo.pwm.bed	8042
1	2970	NEUROG2	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037148_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	26086
1	2974	NEUROG2	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037150_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	20259
1	3016	NFIC	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	NFIC HepG2 (hepatoblastoma) NFIC	HepG2 (hepatoblastoma)	BTO:0000599	NFIC	NA	GTRD	EXP040843_HepG2--hepatoblastoma-_NFIC_MACS_NFIC_MA0119.1.damo.pwm.bed	6619
1	3215	PAX5	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	PAX5 GM12892 (female B-cells lymphoblastoid cell line) PAX5	GM12892 (female B-cells lymphoblastoid cell line)	NULL	PAX5		ENCODE	ENCSR000BJI_GM12892_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	20641
1	3266	POU5F1	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2 and Klf4 addition for 5 days Passage: 8	GTRD	EXP048944_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	5094
1	3349	RELA	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	RELA BEAS-2B (bronchial epithelium) RELA	BEAS-2B (bronchial epithelium)	NULL	RELA	TNF	GTRD	EXP036256_BEAS-2B--bronchial-epithelium-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	4845
1	3382	RELA	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	RELA CD4 RELA	CD4	NA	RELA	TH1_DMSO	GEO	GSE62482_rela_cd4-th1-dmso_MACS_RELA_MA0107.1.damo.pwm.bed	10067
1	3399	REST	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	REST HepG2 (hepatoblastoma) REST	HepG2 (hepatoblastoma)	BTO:0000599	REST		ENCODE	ENCSR000BOT_HepG2_REST_MACS_REST_MA0138.2.damo.pwm.bed	14873
1	4102	VDR	0.059448514424535	0.608448466186969	7	2595	2987	2768	2987	2780	4	6374	2216	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 24h	GTRD	EXP037995_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	23902
1	99	AR	0.0593393131634433	0.827386480497682	105	2621	2199	422	2621	1750	44	6276	2176	AR LTAD (long term androgen deprivation) AR	LTAD (long term androgen deprivation)	NULL	AR	Treatment: 24h DHT 10 nM siControl treated	GTRD	EXP049451_LTAD--long-term-androgen-deprivation-_AR_MACS_AR_MA0007.3.damo.pwm.bed	41997
1	30	AR	0.059025359564527	0.818080432959309	92	2622	2235	498	2622	1780	39	6289	2181	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Vehicle	GTRD	EXP032866_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28284
1	493	CTCF	0.0586988475720961	0.721428607816587	27	2623	2552	1564	2623	2250	13	6354	2207	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPG_fibroblast_of_upper_leg_skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	48760
1	3080	NR2F6	0.0586988475720961	0.721428607816587	27	2623	2552	1564	2623	2250	13	6354	2207	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	ENCODE	ENCSR518WPL_HepG2_NR2F6_MACS_NR2F6_MA0728.1.damo.pwm.bed	32566
1	38	AR	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	AR ovarian granulosa cells AR	ovarian granulosa cells	NULL	AR		GTRD	EXP033702_ovarian-granulosa-cells_AR_MACS_AR_MA0007.3.damo.pwm.bed	9053
1	603	CTCF	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	CTCF Jurkat (T-cells) CTCF	Jurkat (T-cells)	BTO:0000661	CTCF		GTRD	EXP030882_Jurkat--T-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18929
1	672	CTCF	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	CTCF sigmoid colon CTCF	sigmoid colon	BTO:0000645	CTCF		GTRD	EXP039310_sigmoid-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23041
1	675	CTCF	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	CTCF esophagus muscularis mucosa CTCF	esophagus muscularis mucosa	NULL	CTCF		GTRD	EXP039334_esophagus-muscularis-mucosa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28424
1	767	CTCF	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	CTCF esophagus muscularis mucosa CTCF	esophagus muscularis mucosa	NULL	CTCF		GTRD	EXP040054_esophagus-muscularis-mucosa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23266
1	813	CTCF	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	CTCF HCT-116-RAD21-mAC CTCF	HCT-116-RAD21-mAC	NULL	CTCF	N/A	GTRD	EXP040679_HCT-116-RAD21-mAC_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18959
1	1278	ESR1	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP038760_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	2949
1	2044	GATA6	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	GATA6 HUG1N GATA6	HUG1N	NA	GATA6		GEO	GSE51936_gata6_hug1n_MACS_GATA6_MA1104.2.damo.pwm.bed	5077
1	2619	JUND	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	8423
1	2941	MYCN	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	MYCN Kelly (neuroblastoma) MYCN	Kelly (neuroblastoma)	NULL	MYCN		GTRD	EXP038398_Kelly--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	25563
1	2954	MYCN	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	MYCN SHEP-21N MYCN	SHEP-21N	NA	MYCN	DOX_0H	GEO	GSE80151_mycn_shep21-dox-0h_MACS_MYCN_MA0104.4.damo.pwm.bed	17864
1	2971	NEUROG2	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037148_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	25678
1	2977	NEUROG2	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	2 DPT	GTRD	EXP037151_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	25527
1	3064	NR2F1	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	NR2F1 cranial neural crest cells NR2F1	cranial neural crest cells	NULL	NR2F1	NA	GTRD	EXP035243_cranial-neural-crest-cells_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	28286
1	3417	REST	0.0586437337984861	0.625744174206939	9	2625	2945	2585	2945	2720	5	6372	2215	REST liver REST	liver	BTO:0000759	REST		GTRD	EXP039414_liver_REST_MACS_REST_MA0138.2.damo.pwm.bed	12400
1	2503	JUNB	0.0585996135108931	0.752312991986555	39	2640	2467	1206	2640	2100	18	6342	2202	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	19139
1	3526	RXRA	0.0585996135108931	0.752312991986555	39	2640	2467	1206	2640	2100	18	6342	2202	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	43203
1	2493	JUNB	0.0585642046570194	0.694891362184464	20	2642	2783	1901	2783	2440	10	6361	2210	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	13575
1	2881	MYC	0.0585642046570194	0.694891362184464	20	2642	2783	1901	2783	2440	10	6361	2210	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047486_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	15676
1	3015	NFIC	0.0585642046570194	0.694891362184464	20	2642	2783	1901	2783	2440	10	6361	2210	NFIC K562 (myelogenous leukemia) NFIC	K562 (myelogenous leukemia)	NULL	NFIC	NA	GTRD	EXP039955_K562--myelogenous-leukemia-_NFIC_MACS_NFIC_MA1527.1.damo.pwm.bed	21290
1	20	AR	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1000 nM RU486	GTRD	EXP030506_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	920
1	246	ATF3	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		ENCODE	ENCSR000BNU_K562_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	11145
1	673	CTCF	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039321_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16199
1	714	CTCF	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	CTCF sigmoid colon CTCF	sigmoid colon	BTO:0000645	CTCF		GTRD	EXP039618_sigmoid-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15835
1	1166	ESR1	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		Array Express	ERP000380_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	991
1	1796	FOXA1	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	ETOH	GEO	GSE69043_foxa1_lncap-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	802
1	1851	FOXK2	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	FOXK2 HepG2 (hepatoblastoma) FOXK2	HepG2 (hepatoblastoma)	BTO:0000599	FOXK2	NA	ENCODE	ENCSR171FUX_HepG2_FOXK2_MACS_FOXK2_MA1103.2.damo.pwm.bed	6369
1	1972	GATA3	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	GATA3 WA09 (embryonic stem cells) GATA3	WA09 (embryonic stem cells)	NULL	GATA3	BMP4 for 3 day	GTRD	EXP040702_WA09--embryonic-stem-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	9231
1	2030	GATA6	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	GATA6 HUES64 (embryonic stem cells) GATA6	HUES64 (embryonic stem cells)	NULL	GATA6		GTRD	EXP036793_HUES64--embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	24536
1	2390	JUN	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	10385
1	2392	JUN	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	11327
1	2638	KLF4	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	KLF4 hiPSC KLF4	hiPSC	NULL	KLF4		GEO	GSE56567_klf4_ipsc_MACS_KLF4_MA0039.4.damo.pwm.bed	6113
1	2791	MYC	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	MYC A549 (lung carcinoma) MYC	A549 (lung carcinoma)	BTO:0000018	MYC		ENCODE	ENCSR000DYC_A549_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	8965
1	2863	MYC	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC	na	GTRD	EXP037785_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9626
1	2969	NEUROG2	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037147_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	12616
1	3068	NR2F1	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	NR2F1 GM12878 (female B-cells lymphoblastoid cell line) NR2F1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2F1	NA	GTRD	EXP040024_GM12878--female-B-cells-_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	15052
1	3096	NR3C1	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	NR3C1 embryonic kidney NR3C1	embryonic kidney	NULL	NR3C1	dexamethasone	GTRD	EXP032209_embryonic-kidney_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3085
1	3395	REST	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	REST PANC1 (pancreatic ductal adenocarcinoma) REST	PANC1 (pancreatic ductal adenocarcinoma)	NULL	REST		ENCODE	ENCSR000BJO_Panc1_REST_MACS_REST_MA0138.2.damo.pwm.bed	16643
1	3554	SCRT1	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	SCRT1 HEK293 (embryonic kidney) SCRT1	HEK293 (embryonic kidney)	NULL	SCRT1	NA	GTRD	EXP039621_HEK293--embryonic-kidney-_SCRT1_MACS_SCRT1_MA0743.2.damo.pwm.bed	3961
1	3757	STAT5B	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	STAT5B CD8 STAT5B	CD8	NA	STAT5B	H9	GEO	GSE64713_stat5b_cd8-h9_MACS_STAT5B_MA0519.1.damo.pwm.bed	15254
1	3765	TAL1	0.0581120447203985	0.579558632597023	5	2645	3098	2973	3098	2910	3	6376	2217	TAL1 CHRF28811 TAL1	CHRF28811	NA	TAL1	NA	Array Express	ERP008568_tal1_chrf28811_MACS_TAL1_MA0091.1.damo.pwm.bed	17028
1	46	AR	0.057199215730617	0.737935712003145	34	2666	2510	1349	2666	2180	16	6347	2204	AR BicR (prostate cancer) AR	BicR (prostate cancer)	NULL	AR	DHT 10 nM	GTRD	EXP034604_BicR--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	8777
1	373	CEBPB	0.057199215730617	0.737935712003145	34	2666	2510	1349	2666	2180	16	6347	2204	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039561_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	18054
1	2505	JUNB	0.057199215730617	0.737935712003145	34	2666	2510	1349	2666	2180	16	6347	2204	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	16574
1	2880	MYC	0.057199215730617	0.737935712003145	34	2666	2510	1349	2666	2180	16	6347	2204	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047485_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	21280
1	1794	FOXA1	0.0569860868826787	0.837007381527917	128	2670	2159	341	2670	1720	53	6253	2167	FOXA1 PDAC FOXA1	PDAC	NA	FOXA1	SHCTR	GEO	GSE64557_foxa1_pdac-shctr_MACS_FOXA1_MA0148.4.damo.pwm.bed	35480
1	1588	FOSL2	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	9111
1	1590	FOSL2	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	9369
1	1591	FOSL2	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	9369
1	1604	FOSL2	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	10801
1	2262	JUN	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	5442
1	2264	JUN	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	5419
1	2266	JUN	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	5443
1	2267	JUN	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	5454
1	2268	JUN	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	5458
1	2890	MYC	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047490_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9458
1	3374	RELA	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	RELA HUVEC-C (HUVEC, umbilical vein endothelial cells) RELA	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	RELA	TNF_30M	GEO	GSE34500_rela_huvec-tnf-30m_MACS_RELA_MA0107.1.damo.pwm.bed	16788
1	3560	SIX2	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	SIX2 kidney SIX2	kidney	BTO:0000671	SIX2	fetal_16w	GEO	GSE75948_six2_fetal-kidney-16w_MACS_SIX2_MA1119.1.damo.pwm.bed	22009
1	3629	SP1	0.0568490973491162	0.637242685743649	11	2671	2906	2426	2906	2670	6	6370	2214	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036140_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	36295
1	2072	GRHL2	0.0566422739377196	0.812218768228495	89	2684	2246	515	2684	1820	38	6292	2182	GRHL2 OVCA429 (ovarian cystadenocarcinoma) GRHL2	OVCA429 (ovarian cystadenocarcinoma)	BTO:0002564	GRHL2		GEO	GSE71018_grhl2_ovca429_MACS_GRHL2_MA1105.2.damo.pwm.bed	25102
1	35	AR	0.0558605719525721	0.814855504160979	94	2685	2242	482	2685	1800	40	6287	2180	AR LNCaP C4-2 (prostate carcinoma) AR	LNCaP C4-2 (prostate carcinoma)	BTO:0005672	AR	10 nmol/l of mibolerone	GTRD	EXP033417_LNCaP-C4-2--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	30795
1	88	AR	0.0557926743980802	0.760382151282364	46	2686	2435	1028	2686	2050	21	6335	2199	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and vector	GTRD	EXP049280_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13819
1	580	CTCF	0.0557926743980802	0.760382151282364	46	2686	2435	1028	2686	2050	21	6335	2199	CTCF lymphoblastoid cells CTCF	lymphoblastoid cells	NULL	CTCF	NULL	GTRD	EXP000779_lymphoblastoid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	58835
1	2278	JUN	0.0557926743980802	0.760382151282364	46	2686	2435	1028	2686	2050	21	6335	2199	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	43381
1	1117	ERF	0.0550944775411819	0.694795397882042	22	2689	2786	1797	2786	2420	11	6359	2209	ERF VCaP (prostate carcinoma) ERF	VCaP (prostate carcinoma)	BTO:0003215	ERF	NA	GTRD	EXP038639_VCaP--prostate-carcinoma-_ERF_MACS_ERF_MA0760.1.damo.pwm.bed	10409
1	1202	ESR1	0.0550944775411819	0.694795397882042	22	2689	2786	1797	2786	2420	11	6359	2209	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	cells transfected with siCTL, and 1hr with 100nM E2, double crosslinked	GTRD	EXP034122_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	9993
1	2012	GATA4	0.0550944775411819	0.694795397882042	22	2689	2786	1797	2786	2420	11	6359	2209	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4	shGATA4	GTRD	EXP036791_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	50386
1	2315	JUN	0.0550944775411819	0.694795397882042	22	2689	2786	1797	2786	2420	11	6359	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	15895
1	2334	JUN	0.0550944775411819	0.694795397882042	22	2689	2786	1797	2786	2420	11	6359	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	13892
1	2499	JUNB	0.0550944775411819	0.694795397882042	22	2689	2786	1797	2786	2420	11	6359	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	14093
1	3353	RELA	0.0550499196776416	0.719420765060027	29	2695	2554	1504	2695	2250	14	6352	2206	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	IL1b+ICI	GTRD	EXP036979_MCF7--Invasive-ductal-breast-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	8982
1	1237	ESR1	0.0549620560621389	0.74916359484	41	2696	2471	1155	2696	2110	19	6340	2201	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siNT	GTRD	EXP037656_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12363
1	721	CTCF	0.0545911233473821	0.645428499878201	13	2697	2886	2306	2886	2630	7	6368	2213	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039677_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29863
1	2620	JUND	0.0545911233473821	0.645428499878201	13	2697	2886	2306	2886	2630	7	6368	2213	JUND PC3(bone mets prostate adenocarcinoma) JUND	PC3(bone mets prostate adenocarcinoma)	NULL	JUND		GEO	GSE29808_jund_pc3_MACS_JUND_MA0491.2.damo.pwm.bed	5373
1	3466	RUNX1	0.0545911233473821	0.645428499878201	13	2697	2886	2306	2886	2630	7	6368	2213	RUNX1 MV-4-11 (Childhood acute monocytic leukemia) RUNX1	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	RUNX1		GTRD	EXP037302_MV4-11--childhood-acute-monocytic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	35842
1	1648	FOXA1	0.0542396580008157	0.806041377591669	86	2700	2288	534	2700	1840	37	6295	2183	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GTRD	EXP000617_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	12259
1	3128	NR3C1	0.0536459313129771	0.735280690651756	36	2701	2514	1288	2701	2170	17	6345	2203	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 20 min;	GTRD	EXP047626_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	9131
1	2450	JUN	0.0530997080324557	0.780647776865535	63	2702	2383	753	2702	1950	28	6318	2192	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	24483
1	1280	ESR1	0.0530903584775855	0.774072840916235	58	2703	2395	824	2703	1970	26	6323	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP038768_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	19301
1	1317	ESR1	0.0530903584775855	0.774072840916235	58	2703	2395	824	2703	1970	26	6323	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 500nM RAD001 2hr; Passage: p19;	GTRD	EXP047700_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	13154
1	1160	ESR1	0.0529476830715633	0.786331281429749	68	2705	2339	703	2705	1920	30	6313	2190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		Array Express	ERP000209_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	15953
1	2912	MYC	0.0528772781121099	0.766381138322033	53	2706	2412	905	2706	2010	24	6328	2196	MYC NCI-H2171 (small cell lung carcinoma) MYC	NCI-H2171 (small cell lung carcinoma)	NULL	MYC		GEO	GSE36354_myc_ncih2171_MACS_MYC_MA0147.3.damo.pwm.bed	50449
1	1958	GATA3	0.0527849057176202	0.87558676168812	276	2707	1978	102	2707	1600	109	6105	2111	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		ENCODE	ENCSR000BST_MCF-7_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	64723
1	1662	FOXA1	0.0527759641309723	0.86680769083803	233	2708	2072	153	2708	1640	93	6148	2127	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	shTET1	GTRD	EXP035558_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	51828
1	121	AR	0.052667139258785	0.791291083307904	73	2709	2327	644	2709	1890	32	6308	2188	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nm DHT;	GTRD	EXP054343_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	26289
1	1195	ESR1	0.052667139258785	0.791291083307904	73	2709	2327	644	2709	1890	32	6308	2188	ESR1 MCF10A (breast epithelial cells) ESR1	MCF10A (breast epithelial cells)	BTO:0001939	ESR1		GTRD	EXP033710_MCF10A--breast-epithelial-cells-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23066
1	1575	FOSL2	0.0524050968199137	0.757271754517928	48	2711	2452	982	2711	2050	22	6333	2198	FOSL2 MCF7 (Invasive ductal breast carcinoma) FOSL2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOSL2		ENCODE	ENCSR546KCN_MCF-7_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	10597
1	2420	JUN	0.0521824298538457	0.884774656734031	338	2712	1947	75	2712	1580	132	6043	2088	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	58529
1	1032	E2F4	0.0521349293644762	0.651543860620919	15	2713	2867	2200	2867	2590	8	6366	2212	E2F4 E2F4	NA	NA	E2F4	NA	NA	ENCSR000DOR_MCF_10A_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	15920
1	2983	NEUROG2	0.0521349293644762	0.651543860620919	15	2713	2867	2200	2867	2590	8	6366	2212	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	1 DPT	GTRD	EXP037154_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	33209
1	3943	TFE3	0.0518501752576966	0.694699373193812	24	2715	2792	1691	2792	2400	12	6357	2208	TFE3 HepG2 (hepatoblastoma) TFE3	HepG2 (hepatoblastoma)	BTO:0000599	TFE3	NA	GTRD	EXP040043_HepG2--hepatoblastoma-_TFE3_MACS_TFE3_MA0831.2.damo.pwm.bed	28555
1	583	CTCF	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	CTCF CD34+ hematopoietic stem cells CTCF	CD34+ hematopoietic stem cells	NULL	CTCF		GTRD	EXP000908_CD34--hematopoietic-stem-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	9873
1	735	CTCF	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	CTCF suprapubic skin CTCF	suprapubic skin	NULL	CTCF		GTRD	EXP039759_suprapubic-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	9846
1	762	CTCF	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	CTCF suprapubic skin CTCF	suprapubic skin	NULL	CTCF		GTRD	EXP040026_suprapubic-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	6679
1	1119	ERG	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	siERG	GTRD	EXP000726_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	3130
1	1342	ESR1	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1	Treatment: Hormone-deprived media using RPMI1640 without phenol red and 10% charcoal-stripped FBS) for 5-7 days	GTRD	EXP048597_T47D--invasive-ductal-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	852
1	1429	ESR1	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	ESR1 ESR1	NA	NA	ESR1	NA	GEO	GSE68356_ESR1_t47d-e2pg_MACS_ESR1_MA0112.3.damo.pwm.bed	514
1	1457	ETS1	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	ETS1 CD4+ CD25- T-cells ETS1	CD4+ CD25- T-cells	NULL	ETS1		GTRD	EXP032569_CD4--CD25--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	11658
1	1911	GATA1	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bmp	GTRD	EXP000940_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	18842
1	1928	GATA2	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2		ENCODE	ENCSR000BKM_K562_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	16843
1	2017	GATA4	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037718_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	7862
1	2145	HNF4A	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	HNF4A LoVo (colorectal adenocarcinoma) HNF4A	LoVo (colorectal adenocarcinoma)	BTO:0000666	HNF4A	PHASES	GEO	GSE51290_hnf4a_lovo-phaseS_MACS_HNF4A_MA0114.4.damo.pwm.bed	5483
1	2383	JUN	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	6375
1	2385	JUN	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048209_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	6447
1	2751	MGA	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MGA K562 (myelogenous leukemia) MGA	K562 (myelogenous leukemia)	NULL	MGA	NA	GTRD	EXP040079_K562--myelogenous-leukemia-_MGA_MACS_MGA_MA0801.1.damo.pwm.bed	5244
1	2772	MXI1	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MXI1 K562 (myelogenous leukemia) MXI1	K562 (myelogenous leukemia)	NULL	MXI1	NA	ENCODE	ENCSR000EGZ_K562_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	7695
1	2816	MYC	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MYC FB8470 (fibroblasts) MYC	FB8470 (fibroblasts)	NULL	MYC	NULL	GTRD	EXP001024_FB8470--fibroblasts-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7173
1	2817	MYC	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MYC D54 (H54, Human glioblastoma) MYC	D54 (H54, Human glioblastoma)	NULL	MYC	NULL	GTRD	EXP001028_D54--glioblastoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	6358
1	2868	MYC	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 1h	GTRD	EXP038951_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	12455
1	2897	MYC	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MYC CUTLL1 (T-cell lymphoblastic lymphoma 1) MYC	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	MYC	Treatment: no	GTRD	EXP049351_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	4282
1	2898	MYC	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MYC CUTLL1 (T-cell lymphoblastic lymphoma 1) MYC	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	MYC	Treatment: no	GTRD	EXP049351_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	4601
1	2945	MYCN	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	MYCN HIV-1 latently-infected central memory T cells cultured from uninfected pri	HIV-1 latently-infected central memory T cells cultured from uninfected primary T cells	NULL	MYCN	mTreatment: mycn-low lvl induced by 16 hr doxycycline	GTRD	EXP048926_HIV-1-latently-infected-central-memory-T-cells-cultured-from-uninfected-primary-T-cells_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	13502
1	3028	NFYA	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	NFYA HeLa S3 (cervical adenocarcinoma) NFYA	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	NFYA	NA	ENCODE	ENCSR000DNS_HeLa-S3_NFYA_MACS_NFYA_MA0060.3.damo.pwm.bed	4589
1	3052	NR2C2	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	NR2C2 K562 (myelogenous leukemia) NR2C2	K562 (myelogenous leukemia)	NULL	NR2C2		ENCODE	ENCSR750LYM_K562_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	9018
1	3291	PPARG	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034426_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	6490
1	3396	REST	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	REST PFSK1 (primitive neuroectodermal tumor) REST	PFSK1 (primitive neuroectodermal tumor)	NULL	REST		ENCODE	ENCSR000BJP_PFSK-1_REST_MACS_REST_MA0138.2.damo.pwm.bed	5280
1	3421	REST	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	REST A549 (lung carcinoma) REST	A549 (lung carcinoma)	BTO:0000018	REST		GTRD	EXP040092_A549--lung-carcinoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	6828
1	3455	RUNX1	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	RUNX1 K562 (myelogenous leukemia) RUNX1	K562 (myelogenous leukemia)	NULL	RUNX1		GTRD	EXP000585_K562--myelogenous-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	4757
1	3714	SRF	0.0516804587641086	0.521711518842754	3	2716	3266	3252	3266	3080	2	6378	2218	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053073_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	5115
1	1124	ERG	0.0516784128798262	0.717667754887993	31	2744	2561	1439	2744	2250	15	6350	2205	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	mutational form of the peptide (*ERG inhibitory peptidomimetics*)	GTRD	EXP033707_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	17616
1	1576	FOSL2	0.0516784128798262	0.717667754887993	31	2744	2561	1439	2744	2250	15	6350	2205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	18937
1	2329	JUN	0.0516784128798262	0.717667754887993	31	2744	2561	1439	2744	2250	15	6350	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	22511
1	207	AR	0.0516002666495882	0.746319432062519	43	2747	2481	1101	2747	2110	20	6338	2200	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH2_R1881	GEO	GSE79128_AR_vcap-sh2-r1881_MACS_AR_MA0007.3.damo.pwm.bed	25393
1	166	AR	0.0512870085761143	0.802970711539434	88	2748	2296	525	2748	1860	38	6293	2182	AR prostate AR	prostate	NULL	AR		GEO	GSE56288_AR_prostate-normal_MACS_AR_MA0007.3.damo.pwm.bed	47546
1	1420	ESR1	0.0506653312625586	0.841810456836032	158	2749	2148	260	2749	1720	65	6223	2155	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	R5020	GEO	GSE68355_ESR1_mcf7-r5020_MACS_ESR1_MA0112.3.damo.pwm.bed	44488
1	1711	FOXA1	0.0504561023404987	0.851729637154137	187	2750	2111	209	2750	1690	76	6194	2144	FOXA1 MCF7 WS8 cells FOXA1	MCF7 WS8 cells	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048450_MCF7-WS8-cells_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	45540
1	78	AR	0.0499777897494806	0.770999855785461	60	2751	2402	797	2751	1980	27	6321	2193	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048986_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	24009
1	1409	ESR1	0.0497395385681305	0.763383126182451	55	2752	2430	875	2752	2020	25	6326	2195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHCTR_E2_TNF	GEO	GSE59530_esr1_mcf7-shctr-e2-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	30131
1	1425	ESR1	0.0497395385681305	0.763383126182451	55	2752	2430	875	2752	2020	25	6326	2195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE68356_ESR1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	11742
1	359	CEBPB	0.049644170666233	0.859034093533559	216	2754	2090	163	2754	1670	87	6165	2133	CEBPB HepG2 (hepatoblastoma) CEBPB	HepG2 (hepatoblastoma)	BTO:0000599	CEBPB		ENCODE	ENCSR000EEE_HepG2_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	122200
1	442	CTCF	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000ANO_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36010
1	1527	FOS	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	14073
1	1596	FOSL2	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	13214
1	1961	GATA3	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3		ENCODE	ENCSR000EWV_MCF-7_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	3208
1	2241	JUN	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17019
1	2243	JUN	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	16172
1	2245	JUN	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN		GTRD	EXP033442_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	16330
1	2255	JUN	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17925
1	2258	JUN	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	JUN MDA-MB-231 (breast adenocarcinoma) JUN	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	JUN	compaund A	GTRD	EXP033444_MDA-MB-231--breast-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17963
1	3009	NFIB	0.0496221743582037	0.656278901420802	17	2755	2852	2066	2852	2560	9	6364	2211	NFIB MCF7 (Invasive ductal breast carcinoma) NFIB	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NFIB	NA	GTRD	EXP039948_MCF7--Invasive-ductal-breast-carcinoma-_NFIB_MACS_NFIB_MA1643.1.damo.pwm.bed	12566
1	1565	FOSL1	0.0492637481930055	0.754423363888471	50	2765	2456	945	2765	2060	23	6331	2197	FOSL1 K562 (myelogenous leukemia) FOSL1	K562 (myelogenous leukemia)	NULL	FOSL1	NA	ENCODE	ENCSR239ZLZ_K562_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	31556
1	1981	GATA3	0.0489779567426539	0.796548161005317	85	2766	2312	545	2766	1870	37	6296	2183	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049899_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	36388
1	943	CTCF	0.0488185897213593	0.694603288062761	26	2767	2793	1602	2793	2390	13	6355	2207	CTCF SUM159PT (Triple negative breast cancer) CTCF	SUM159PT (Triple negative breast cancer)	NULL	CTCF		GEO	GSE46055_ctcf_sum159_MACS_CTCF_MA0139.1.damo.pwm.bed	44148
1	3352	RELA	0.0488185897213593	0.694603288062761	26	2767	2793	1602	2793	2390	13	6355	2207	RELA SW480 (colon adenocarcinoma) RELA	SW480 (colon adenocarcinoma)	BTO:0000038	RELA	TNF-alpha 16 h	GTRD	EXP036903_SW480--colon-adenocarcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	14544
1	242	ATF2	0.0485566791579675	0.716121784839478	33	2769	2564	1379	2769	2240	16	6348	2204	ATF2 K562 (myelogenous leukemia) ATF2	K562 (myelogenous leukemia)	NULL	ATF2	NA	GTRD	EXP039995_K562--myelogenous-leukemia-_ATF2_MACS_ATF2_MA1632.1.damo.pwm.bed	43248
1	827	CTCF	0.0485566791579675	0.716121784839478	33	2769	2564	1379	2769	2240	16	6348	2204	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA), siWAPL(siRNA)	GTRD	EXP047783_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40823
1	1238	ESR1	0.0485566791579675	0.716121784839478	33	2769	2564	1379	2769	2240	16	6348	2204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	White Medium + E2	GTRD	EXP037775_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	17939
1	2879	MYC	0.0485566791579675	0.716121784839478	33	2769	2564	1379	2769	2240	16	6348	2204	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047485_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	20193
1	2280	JUN	0.0484867883577841	0.743736890096763	45	2773	2497	1054	2773	2110	21	6336	2199	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	42268
1	1737	FOXA1	0.0483128815472897	0.839431686889742	160	2774	2154	254	2774	1730	66	6221	2154	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	Treatment: FA (control)	GTRD	EXP053226_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	31696
1	1653	FOXA1	0.047490675940391	0.854794965875763	210	2775	2102	172	2775	1680	85	6171	2135	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	regular medium	GTRD	EXP000722_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	46078
1	1074	EHF	0.0474345241218342	0.806053153165754	100	2776	2286	446	2776	1840	43	6281	2177	EHF RWPE1 (prostate epithelial cells) EHF	RWPE1 (prostate epithelial cells)	BTO:0003709	EHF	Infection: retrovirus expressing FLAG-EHF Treatment: nearly confluent 150 mm dishes were treated with 1% formaldehyde, and harvested in Farnham lysis buffer and a crude nuclear pellet collected after centrifugation	GTRD	EXP048485_RWPE1--prostate-epithelial-cells-_EHF_MACS_EHF_MA0598.3.damo.pwm.bed	33866
1	3506	RUNX2	0.0474345241218342	0.806053153165754	100	2776	2286	446	2776	1840	43	6281	2177	RUNX2 MCF7 (Invasive ductal breast carcinoma) RUNX2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RUNX2	Full Medium + Doxycycline	GTRD	EXP037781_MCF7--Invasive-ductal-breast-carcinoma-_RUNX2_MACS_RUNX2_MA0511.2.damo.pwm.bed	43261
1	43	AR	0.0474324211455206	0.825054933641061	131	2778	2214	328	2778	1770	55	6250	2165	AR LNCaP C4-2 (prostate carcinoma) AR	LNCaP C4-2 (prostate carcinoma)	BTO:0005672	AR	10 nmol/l of mibolerone	GTRD	EXP034502_LNCaP-C4-2--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	52310
1	1635	FOXA1	0.0474324211455206	0.825054933641061	131	2778	2214	328	2778	1770	55	6250	2165	FOXA1 A549 (lung carcinoma) FOXA1	A549 (lung carcinoma)	BTO:0000018	FOXA1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRD_A549_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	35292
1	205	AR	0.0473240048801474	0.73077847522855	40	2780	2524	1189	2780	2160	19	6341	2201	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	SH1_R1881	GEO	GSE79128_AR_vcap-sh1-r1881_MACS_AR_MA0007.3.damo.pwm.bed	22606
1	1128	ERG	0.0471310871088625	0.66004770141659	19	2781	2843	1956	2843	2530	10	6362	2210	ERG Kasumi-1 (acute myeloblastic leukemia) ERG	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	ERG		GTRD	EXP037192_Kasumi-1--acute-myeloblastic-leukemia-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	47151
1	1494	FLI1	0.0471310871088625	0.66004770141659	19	2781	2843	1956	2843	2530	10	6362	2210	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1		GTRD	EXP047962_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	34804
1	2497	JUNB	0.0471310871088625	0.66004770141659	19	2781	2843	1956	2843	2530	10	6362	2210	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	13466
1	2498	JUNB	0.0471310871088625	0.66004770141659	19	2781	2843	1956	2843	2530	10	6362	2210	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	13418
1	3935	TFAP4	0.0470992183145203	0.780334873391016	72	2785	2384	651	2785	1940	32	6309	2188	TFAP4 SNU175 (adenocarcinoma) TFAP4	SNU175 (adenocarcinoma)	NULL	TFAP4	NA	GTRD	EXP037552_SNU175--adenocarcinoma-_TFAP4_MACS_TFAP4_MA1570.1.damo.pwm.bed	44386
1	471	CTCF	0.047077345386751	0.768139385180422	62	2786	2407	769	2786	1990	28	6319	2192	CTCF GM19240 (B cells Lymphoblastoid Cell Lines) CTCF	GM19240 (B cells Lymphoblastoid Cell Lines)	NULL	CTCF		ENCODE	ENCSR000DLF_GM19240_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	84690
1	53	AR	0.0469242884346803	0.785336179910494	77	2787	2342	609	2787	1910	34	6304	2186	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	treated for 24 hours with 1mM hydroxyurea +3 hour 10nm DHT	GTRD	EXP036469_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	22673
1	3585	SNAI2	0.0469242884346803	0.785336179910494	77	2787	2342	609	2787	1910	34	6304	2186	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SNAI2_diff	GEO	GSE55421_snai2_keratinocytes-snai2-diff_MACS_SNAI2_MA0745.2.damo.pwm.bed	59854
1	392	CEBPB	0.0465814062267301	0.819452124960858	123	2789	2230	351	2789	1790	52	6258	2168	CEBPB HEE (human epididymis epithelial cells) CEBPB	HEE (human epididymis epithelial cells)	NULL	CEBPB	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048166_HEE--human-epididymis-epithelial-cells-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	86302
1	400	CEBPB	0.0464148061327783	0.852600406659101	207	2790	2110	180	2790	1690	84	6174	2136	CEBPB LS180 (colon cancer) CEBPB	LS180 (colon cancer)	NULL	CEBPB	125	GEO	GSE31939_cebpb_ls180-125_MACS_CEBPB_MA0466.2.damo.pwm.bed	116278
1	2356	JUN	0.0459859329139208	0.694507142431799	28	2791	2795	1531	2795	2370	14	6353	2206	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	6390
1	2359	JUN	0.0459859329139208	0.694507142431799	28	2791	2795	1531	2795	2370	14	6353	2206	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	5839
1	1283	ESR1	0.0459024907315845	0.79727518828697	92	2793	2310	498	2793	1870	40	6289	2180	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siFOXA1	GTRD	EXP038771_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	29996
1	127	AR	0.0456607116909894	0.714746307711722	35	2794	2568	1318	2794	2230	17	6346	2203	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	1F5_SIFOXA1	GEO	GSE30623_ar_lncap1f5-sifoxa1_MACS_AR_MA0007.3.damo.pwm.bed	22086
1	426	CREB1	0.0456607116909894	0.714746307711722	35	2794	2568	1318	2794	2230	17	6346	2203	CREB1 LNCaP-abl (Prostate carcinoma) CREB1	LNCaP-abl (Prostate carcinoma)	NULL	CREB1		GEO	GSE63034_creb1_lncap-abl_MACS_CREB1_MA0018.4.damo.pwm.bed	19479
1	588	CTCF	0.0456607116909894	0.714746307711722	35	2794	2568	1318	2794	2230	17	6346	2203	CTCF FB8470 (fibroblasts) CTCF	FB8470 (fibroblasts)	NULL	CTCF	NULL	GTRD	EXP001023_FB8470--fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45900
1	1141	ERG	0.0456607116909894	0.714746307711722	35	2794	2568	1318	2794	2230	17	6346	2203	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	DHAT_2H	GEO	GSE28950_erg_vcap-dhat-2h_MACS_ERG_MA0474.2.damo.pwm.bed	20614
1	3660	SPI1	0.0456607116909894	0.714746307711722	35	2794	2568	1318	2794	2230	17	6346	2203	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: Pam3csk4 treated 4hr, eGFP(EP mRNA)	GTRD	EXP047818_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	61570
1	2331	JUN	0.0447052717089346	0.663113765056366	21	2799	2841	1852	2841	2500	11	6360	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	15925
1	2692	MAX	0.0447052717089346	0.663113765056366	21	2799	2841	1852	2841	2500	11	6360	2209	MAX Ishikawa (endometrial adenocarcinoma) MAX	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	MAX		ENCODE	ENCSR000BTY_Ishikawa_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	28424
1	1756	FOXA1	0.0446820992503509	0.841844299198462	180	2801	2147	217	2801	1720	74	6201	2146	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	DHT	GEO	GSE28264_foxa1_lncap-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	46187
1	2283	JUN	0.0445045149642694	0.728850480235555	42	2802	2533	1124	2802	2150	20	6339	2200	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	TNFa, 4h	GTRD	EXP038042_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	39717
1	3364	RELA	0.0445045149642694	0.728850480235555	42	2802	2533	1124	2802	2150	20	6339	2200	RELA Detroit 562 (Pharyngeal squamous cell carcinoma) RELA	Detroit 562 (Pharyngeal squamous cell carcinoma)	BTO:0000834	RELA	Treatment: LPS	GTRD	EXP049363_Detroit-562--Pharyngeal-squamous-cell-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	13527
1	1661	FOXA1	0.0444580201877632	0.864160098260977	265	2804	2075	110	2804	1660	106	6116	2114	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	shCtrl	GTRD	EXP035557_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	67734
1	3589	SOX13	0.0443711456347493	0.76546943850233	64	2805	2414	747	2805	1990	29	6317	2191	SOX13 HepG2 (hepatoblastoma) SOX13	HepG2 (hepatoblastoma)	BTO:0000599	SOX13	NA	GTRD	EXP040100_HepG2--hepatoblastoma-_SOX13_MACS_SOX13_MA1120.1.damo.pwm.bed	45807
1	1358	ESR1	0.0443213533707903	0.782605511041187	79	2806	2345	599	2806	1920	35	6302	2185	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 15 mins of 10nM Estradiol and then 10nM Estradiol + 10 nM Dexamethasone for 60 mins Genotype: ER+/PR+	GTRD	EXP049941_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	22831
1	2303	JUN	0.0441009364967465	0.758031631247664	59	2807	2451	805	2807	2020	27	6322	2193	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	52776
1	3525	RXRA	0.0433383864385153	0.694410936243772	30	2808	2797	1473	2808	2360	15	6351	2205	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	40196
1	2599	JUND	0.0429125525297098	0.739220139075771	49	2809	2502	967	2809	2090	23	6332	2197	JUND K562 (myelogenous leukemia) JUND	K562 (myelogenous leukemia)	NULL	JUND		ENCODE	ENCSR000EGN_K562_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	32242
1	2425	JUN	0.0426766857607309	0.875875705964179	345	2810	1977	70	2810	1620	136	6036	2084	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	59771
1	1761	FOXA1	0.0423723619790509	0.866721257905842	291	2811	2073	98	2811	1660	116	6090	2104	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHFOXA1_R1881	GEO	GSE37345_foxa1_lncap-shfoxa1-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	74518
1	89	AR	0.042368579467998	0.665652761724608	23	2812	2834	1739	2834	2460	12	6358	2208	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype	GTRD	EXP049281_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	5092
1	1340	ESR1	0.042368579467998	0.665652761724608	23	2812	2834	1739	2834	2460	12	6358	2208	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Fulvestrant	GTRD	EXP048586_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	14143
1	3081	NR2F6	0.042368579467998	0.665652761724608	23	2812	2834	1739	2834	2460	12	6358	2208	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	GTRD	EXP039812_HepG2--hepatoblastoma-_NR2F6_MACS_NR2F6_MA0677.1.damo.pwm.bed	37608
1	1764	FOXA1	0.042336804749663	0.84605042768749	203	2815	2127	187	2815	1710	83	6178	2137	FOXA1 NCI-H3122 (lung adenocarcinoma) FOXA1	NCI-H3122 (lung adenocarcinoma)	NULL	FOXA1		GEO	GSE39998_foxa1_ncih3122_MACS_FOXA1_MA0148.4.damo.pwm.bed	43698
1	1733	FOXA1	0.0421431171753421	0.827574555941425	153	2816	2198	272	2816	1760	64	6228	2156	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	siOCT1	GTRD	EXP051010_LNCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	37046
1	2429	JUN	0.0418842940021592	0.727096851944074	44	2817	2538	1072	2817	2140	21	6337	2199	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	38816
1	1383	ESR1	0.0418432310346323	0.762970957216552	66	2818	2432	727	2818	1990	30	6315	2190	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GEO	GSE14664_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	45439
1	2448	JUN	0.0418432310346323	0.762970957216552	66	2818	2432	727	2818	1990	30	6315	2190	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	24896
1	623	CTCF	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	CTCF BEAS-2B (bronchial epithelium) CTCF	BEAS-2B (bronchial epithelium)	NULL	CTCF		GTRD	EXP033453_BEAS-2B--bronchial-epithelium-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19835
1	781	CTCF	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	CTCF stomach CTCF	stomach	BTO:0001307	CTCF		GTRD	EXP040118_stomach_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21775
1	782	CTCF	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	CTCF adrenal gland CTCF	adrenal gland	BTO:0000047	CTCF		GTRD	EXP040128_adrenal-gland_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24675
1	1116	ERF	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	ERF VCaP (prostate carcinoma) ERF	VCaP (prostate carcinoma)	BTO:0003215	ERF	NA	GTRD	EXP038638_VCaP--prostate-carcinoma-_ERF_MACS_ERF_MA0760.1.damo.pwm.bed	5056
1	1152	ERG	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	SH3_DHT	GEO	GSE79128_erg_vcap-sh3-dht_MACS_ERG_MA0474.2.damo.pwm.bed	9849
1	1406	ESR1	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2_JQ1	GEO	GSE55921_esr1_mcf7-e2-jq1_MACS_ESR1_MA0112.3.damo.pwm.bed	2603
1	1589	FOSL2	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP039650_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	9257
1	1605	FOSL2	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	11047
1	1606	FOSL2	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	10994
1	1607	FOSL2	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039757_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	10955
1	2263	JUN	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	5450
1	2265	JUN	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	JUN Calu-3 (lung adenocarcinoma) JUN	Calu-3 (lung adenocarcinoma)	BTO:0002750	JUN		GTRD	EXP037683_Calu-3--lung-adenocarcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	5596
1	2697	MAX	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	MAX HepG2 (hepatoblastoma) MAX	HepG2 (hepatoblastoma)	BTO:0000599	MAX		ENCODE	ENCSR000EDS_HepG2_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	22343
1	2798	MYC	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000311_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	20159
1	2886	MYC	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047488_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11025
1	2889	MYC	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047490_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	9268
1	3126	NR3C1	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: untreated;	GTRD	EXP047624_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4063
1	3484	RUNX1	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	RUNX1 cord blood CD34 cells RUNX1	cord blood CD34 cells	NULL	RUNX1	Genotype: RUNX1mut transduced;	GTRD	EXP058042_cord-blood-CD34-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	39384
1	3518	RXRA	0.0418400696012057	0.579228648257507	10	2820	3119	2487	3119	2810	6	6371	2214	RXRA UPR9 (hematopoietic stem cells) RXRA	UPR9 (hematopoietic stem cells)	NULL	RXRA	5 hours zinc	GTRD	EXP000750_UPR9--hematopoietic-stem-cells-_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	25729
1	73	AR	0.0416976686080658	0.78448371676024	86	2839	2344	534	2839	1910	38	6295	2182	AR LNCaP-abl (Prostate carcinoma) AR	LNCaP-abl (Prostate carcinoma)	NULL	AR	Treatment: vehicle (DMSO) of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive	GTRD	EXP048900_LNCaP-abl--Prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	18604
1	60	AR	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	NOV induced	GTRD	EXP037263_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2249
1	460	CTCF	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	CTCF Ishikawa (endometrial adenocarcinoma) CTCF	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	CTCF	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BQE_Ishikawa_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19255
1	734	CTCF	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	CTCF ovary CTCF	ovary	BTO:0000975	CTCF		GTRD	EXP039745_ovary_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17703
1	763	CTCF	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	CTCF tibial nerve CTCF	tibial nerve	NULL	CTCF		GTRD	EXP040027_tibial-nerve_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32418
1	1029	E2F1	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	E2F1 HMEC-1 E2F1	HMEC-1	NA	E2F1		GEO	GSE62425_e2f1_hmec_MACS_E2F1_MA0024.3.damo.pwm.bed	11947
1	1853	FOXK2	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	FOXK2 K562 (myelogenous leukemia) FOXK2	K562 (myelogenous leukemia)	NULL	FOXK2	NA	ENCODE	ENCSR508DQA_K562_FOXK2_MACS_FOXK2_MA1103.2.damo.pwm.bed	15539
1	1931	GATA2	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	GATA2 K562 (myelogenous leukemia) GATA2	K562 (myelogenous leukemia)	NULL	GATA2		ENCODE	ENCSR000EWG_K562_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	19220
1	2027	GATA4	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	GATA4 YCC3 (gastric adenocarcinoma) GATA4	YCC3 (gastric adenocarcinoma)	NULL	GATA4		GEO	GSE51705_gata4_ycc3_MACS_GATA4_MA0482.2.damo.pwm.bed	5733
1	2922	MYC	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	Doxy	GEO	GSE44672_myc_u2os-dox_MACS_MYC_MA0147.3.damo.pwm.bed	16264
1	4077	USF1	0.0416311955923235	0.556150509382417	8	2840	3190	2675	3190	2900	5	6373	2215	USF1 SK-N-SH (neuroblastoma) USF1	SK-N-SH (neuroblastoma)	BTO:0001620	USF1		ENCODE	ENCSR000BTZ_SK-N-SH_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	10024
1	2423	JUN	0.0415286923309029	0.876433967631779	358	2850	1976	62	2850	1630	141	6023	2079	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	63694
1	1291	ESR1	0.04142916430962	0.816265902107724	132	2851	2239	323	2851	1800	56	6249	2164	ESR1 breast tumour metastasis ESR1	breast tumour metastasis	NULL	ESR1	Metastasis	GTRD	EXP038796_breast-tumour-metastasis_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	42475
1	123	AR	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Genotype: GREB1 knockout; Treatment: shGREB1;	GTRD	EXP058317_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2695
1	126	AR	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GEO	GSE28950_AR_vcap_MACS_AR_MA0007.3.damo.pwm.bed	3623
1	658	CTCF	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	CTCF E16 retina CTCF	E16 retina	NULL	CTCF		GTRD	EXP037800_E16-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	29622
1	686	CTCF	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP039453_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24899
1	726	CTCF	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039696_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27484
1	744	CTCF	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP039832_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32256
1	817	CTCF	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: IFNb treated 6hr, IAV NS1(EP mRNA)	GTRD	EXP047762_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26399
1	1952	GATA2	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	GATA2 CD34+ cells GATA2	CD34+ cells	NULL	GATA2	ACY957	GEO	GSE60792_gata2_cd34-acy957_MACS_GATA2_MA0036.3.damo.pwm.bed	23910
1	2010	GATA4	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036789_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	33448
1	3467	RUNX1	0.0412210829803374	0.595693301848176	12	2852	3059	2359	3059	2760	7	6369	2213	RUNX1 THP-1 (acute monocytic leukemia) RUNX1	THP-1 (acute monocytic leukemia)	BTO:0001370	RUNX1		GTRD	EXP037304_THP-1--acute-monocytic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	24774
1	2424	JUN	0.0411067941860574	0.87439365135657	347	2862	1980	68	2862	1640	137	6034	2083	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	59515
1	92	AR	0.0411011838278454	0.747147843773526	56	2863	2479	859	2863	2070	26	6325	2194	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout	GTRD	EXP049286_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	15036
1	1236	ESR1	0.0411011838278454	0.747147843773526	56	2863	2479	859	2863	2070	26	6325	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	siCTCF	GTRD	EXP037655_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	16137
1	932	CTCF	0.0408626354785975	0.694314669441448	32	2865	2798	1410	2865	2360	16	6349	2204	CTCF HT1080 (fibrosarcoma) CTCF	HT1080 (fibrosarcoma)	NULL	CTCF	Treatment: 3 uM final concentration of CBL0137 for 6hrs;	GTRD	EXP058384_HT1080--fibrosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45723
1	2502	JUNB	0.0408626354785975	0.694314669441448	32	2865	2798	1410	2865	2360	16	6349	2204	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	16019
1	1685	FOXA1	0.0406486404663927	0.872224751543178	336	2867	1985	77	2867	1640	133	6045	2087	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1		GTRD	EXP038772_MCF7--Invasive-ductal-breast-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	65377
1	1769	FOXA1	0.0401525034488214	0.853604095253255	242	2868	2105	138	2868	1700	98	6139	2122	FOXA1 MDA-MB-453 (breast adenocarcinoma) FOXA1	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	FOXA1	DHT	GEO	GSE45201_foxa1_mdamb453-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	61439
1	5	AR	0.0401332326946171	0.66778630854266	25	2869	2829	1657	2869	2450	13	6356	2207	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	AR stimulated	GTRD	EXP000407_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	10563
1	822	CTCF	0.0401332326946171	0.66778630854266	25	2869	2829	1657	2869	2450	13	6356	2207	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF	Treatment: Pam3csk4 treated 7hr+Flavopiridol 3hr, IAV NS1(EP mRNA), siCtrl(siRNA)	GTRD	EXP047778_THP-1--acute-monocytic-leukemia-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34452
1	2054	GLIS1	0.0401332326946171	0.66778630854266	25	2869	2829	1657	2869	2450	13	6356	2207	GLIS1 HEK293 (embryonic kidney) GLIS1	HEK293 (embryonic kidney)	NULL	GLIS1	NA	GTRD	EXP039340_HEK293--embryonic-kidney-_GLIS1_MACS_GLIS1_MA0735.1.damo.pwm.bed	35774
1	190	AR	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	RPMIFBS	GEO	GSE69043_AR_lncap-rpmifbs_MACS_AR_MA0007.3.damo.pwm.bed	4426
1	628	CTCF	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	CTCF HUES64 (embryonic stem cells) CTCF	HUES64 (embryonic stem cells)	NULL	CTCF		GTRD	EXP036698_HUES64--embryonic-stem-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32556
1	2615	JUND	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	13272
1	2637	KLF4	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	KLF4 MCF7 (Invasive ductal breast carcinoma) KLF4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	KLF4		GEO	GSE41561_klf4_mcf7_MACS_KLF4_MA0039.4.damo.pwm.bed	6369
1	2793	MYC	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC		ENCODE	ENCSR000EGJ_K562_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	30342
1	2951	MYCN	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	MYCN BE2C MYCN	BE2C	NULL	MYCN		GEO	GSE80151_mycn_be2c_MACS_MYCN_MA0104.4.damo.pwm.bed	28694
1	3550	RXRA	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	RXRA MCF7 (Invasive ductal breast carcinoma) RXRA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RXRA	Treatment: none;	GTRD	EXP054366_MCF7--Invasive-ductal-breast-carcinoma-_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	35077
1	3651	SPI1	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	IL-4	GTRD	EXP036836_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	38881
1	3694	SPIB	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	SPIB OCI-LY3 (diffuse large B-cell lymphoma) SPIB	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPIB	SHCTR	GEO	GSE56857_spib_ocily3-shctr_MACS_SPIB_MA0081.2.damo.pwm.bed	25043
1	3734	STAT3	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	STAT3 MDA-MB-157 (triple negative breast carcinoma) STAT3	MDA-MB-157 (triple negative breast carcinoma)	NULL	STAT3	ethanol	GTRD	EXP037700_MDA-MB-157--breast-carcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	18608
1	3735	STAT3	0.0401324273525608	0.608017967866724	14	2872	3013	2252	3013	2710	8	6367	2212	STAT3 MDA-MB-231 (breast adenocarcinoma) STAT3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	STAT3	ethanol	GTRD	EXP037701_MDA-MB-231--breast-adenocarcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	18234
1	659	CTCF	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	CTCF E18 retina CTCF	E18 retina	NULL	CTCF		GTRD	EXP037801_E18-retina_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19936
1	722	CTCF	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	CTCF stomach CTCF	stomach	BTO:0001307	CTCF		GTRD	EXP039678_stomach_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16025
1	1871	GABPA	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	GABPA A549 (lung carcinoma) GABPA	A549 (lung carcinoma)	BTO:0000018	GABPA	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPY_A549_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	13968
1	2699	MAX	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	MAX NB4 (acute promyelocytic leukemia ) MAX	NB4 (acute promyelocytic leukemia )	NULL	MAX		ENCODE	ENCSR000EHS_NB4_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	10368
1	2827	MYC	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector	GTRD	EXP036031_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	12073
1	2849	MYC	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036778_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	18846
1	2873	MYC	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected with control vector;	GTRD	EXP047291_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	20054
1	2947	MYCN	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	MYCN BE2C MYCN	BE2C	NULL	MYCN	Treatment: untreated	GTRD	EXP049482_BE2C_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	17811
1	3018	NFIC	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	NFIC HepG2 (hepatoblastoma) NFIC	HepG2 (hepatoblastoma)	BTO:0000599	NFIC	NA	GTRD	EXP040843_HepG2--hepatoblastoma-_NFIC_MACS_NFIC_MA1527.1.damo.pwm.bed	6415
1	3197	OTX2	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	OTX2 HUES64 (embryonic stem cells) OTX2	HUES64 (embryonic stem cells)	NULL	OTX2		GTRD	EXP036800_HUES64--embryonic-stem-cells-_OTX2_MACS_OTX2_MA0712.2.damo.pwm.bed	23736
1	3320	RARG	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM DMSO for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048635_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA1553.1.damo.pwm.bed	1522
1	3321	RARG	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM CD437 for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048636_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA1553.1.damo.pwm.bed	809
1	3492	RUNX1	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1		GEO	GSE46044_runx1_me1_MACS_RUNX1_MA0002.2.damo.pwm.bed	18632
1	3677	SPI1	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	SPI1 dendrite SPI1	dendrite	NA	SPI1		GEO	GSE58864_spi1_dendrite_MACS_SPI1_MA0080.5.damo.pwm.bed	13571
1	4101	VDR	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 24h	GTRD	EXP037995_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	22439
1	4126	YY1	0.0399270141781822	0.521486592802506	6	2883	3294	2870	3294	3020	4	6375	2216	YY1 SK-N-SH (neuroblastoma) YY1	SK-N-SH (neuroblastoma)	BTO:0001620	YY1		ENCODE	ENCSR000BSM_SK-N-SH_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	16678
1	1277	ESR1	0.039624551612384	0.766973366509211	73	2899	2411	644	2899	1980	33	6308	2187	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Doxycycline + E2	GTRD	EXP038390_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	39421
1	147	AR	0.0394453637441751	0.725493804753905	46	2900	2546	1028	2900	2160	22	6335	2198	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	FOXA1_ARQ6540X	GEO	GSE47987_AR_du145-foxa1-arq6540x_MACS_AR_MA0007.3.damo.pwm.bed	19896
1	1361	ESR1	0.0388910187628052	0.822036655253616	152	2901	2222	277	2901	1800	64	6229	2156	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: 10 nM E2 for4 hrs Genotype: ER+/PR+	GTRD	EXP049946_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	46823
1	1612	FOSL2	0.0387791446527171	0.617582451136268	16	2902	2974	2127	2974	2670	9	6365	2211	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	14809
1	1614	FOSL2	0.0387791446527171	0.617582451136268	16	2902	2974	2127	2974	2670	9	6365	2211	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	14800
1	1615	FOSL2	0.0387791446527171	0.617582451136268	16	2902	2974	2127	2974	2670	9	6365	2211	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	15144
1	2317	JUN	0.0387791446527171	0.617582451136268	16	2902	2974	2127	2974	2670	9	6365	2211	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	9886
1	2538	JUNB	0.0387791446527171	0.617582451136268	16	2902	2974	2127	2974	2670	9	6365	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	10228
1	2540	JUNB	0.0387791446527171	0.617582451136268	16	2902	2974	2127	2974	2670	9	6365	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP039868_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	10285
1	3769	TAL1	0.0387791446527171	0.617582451136268	16	2902	2974	2127	2974	2670	9	6365	2211	TAL1 MOLT3 (adult T acute lymphoblastic leukemia) TAL1	MOLT3 (adult T acute lymphoblastic leukemia)	NULL	TAL1	NA	GEO	GSE59657_tal1_molt3_MACS_TAL1_MA0091.1.damo.pwm.bed	26905
1	2593	JUND	0.0387412159322099	0.7450674914467	58	2909	2483	824	2909	2070	27	6323	2193	JUND K562 (myelogenous leukemia) JUND	K562 (myelogenous leukemia)	NULL	JUND		ENCODE	ENCSR000DJX_K562_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	32681
1	1701	FOXA1	0.0383030342427564	0.847527187602281	228	2910	2123	156	2910	1730	93	6153	2127	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-7 4OHT	GTRD	EXP048437_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	44391
1	377	CEBPB	0.0381301104536053	0.711387003149878	41	2911	2574	1155	2911	2210	20	6340	2200	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039871_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	22591
1	411	CEBPG	0.0381301104536053	0.711387003149878	41	2911	2574	1155	2911	2210	20	6340	2200	CEBPG K562 (myelogenous leukemia) CEBPG	K562 (myelogenous leukemia)	NULL	CEBPG	NA	GTRD	EXP039945_K562--myelogenous-leukemia-_CEBPG_MACS_CEBPG_MA0838.1.damo.pwm.bed	46662
1	412	CEBPG	0.0381301104536053	0.711387003149878	41	2911	2574	1155	2911	2210	20	6340	2200	CEBPG K562 (myelogenous leukemia) CEBPG	K562 (myelogenous leukemia)	NULL	CEBPG	NA	GTRD	EXP039945_K562--myelogenous-leukemia-_CEBPG_MACS_CEBPG_MA1636.1.damo.pwm.bed	43612
1	446	CTCF	0.0381301104536053	0.711387003149878	41	2911	2574	1155	2911	2210	20	6340	2200	CTCF osteoblasts CTCF	osteoblasts	NULL	CTCF		ENCODE	ENCSR000APF_osteoblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	52957
1	2654	KLF9	0.0381301104536053	0.711387003149878	41	2911	2574	1155	2911	2210	20	6340	2200	KLF9 GBM1A KLF9	GBM1A	NA	KLF9	NA	GEO	GSE62211_klf9_gbm1a_MACS_KLF9_MA1107.2.damo.pwm.bed	63426
1	3645	SPI1	0.0381301104536053	0.711387003149878	41	2911	2574	1155	2911	2210	20	6340	2200	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1		ENCODE	ENCSR000BGQ_GM12878_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	71614
1	2346	JUN	0.0380044633547729	0.669601274791896	27	2917	2828	1564	2917	2440	14	6354	2206	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	22588
1	142	AR	0.0377505919905324	0.853885402238336	257	2918	2104	120	2918	1710	104	6124	2116	AR AR	NA	NA	AR	NA	GEO	GSE43785_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	88696
1	403	CEBPB	0.0374341608745914	0.775244700186696	85	2919	2389	545	2919	1950	38	6296	2182	CEBPB hMSC CEBPB	hMSC	NA	CEBPB	DMI_HI	GEO	GSE68864_cebpb_hmsc-dmi-hi_MACS_CEBPB_MA0466.2.damo.pwm.bed	64807
1	453	CTCF	0.0372840926597591	0.625214794314366	18	2920	2960	1996	2960	2630	10	6363	2210	CTCF A549 (lung carcinoma) CTCF	A549 (lung carcinoma)	BTO:0000018	CTCF	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHV_A549_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	32812
1	913	CTCF	0.0372840926597591	0.625214794314366	18	2920	2960	1996	2960	2630	10	6363	2210	CTCF GM18486 (Lymphoblastoid Cell Lines) CTCF	GM18486 (Lymphoblastoid Cell Lines)	NULL	CTCF		GTRD	EXP054521_GM18486--Lymphoblastoid-Cell-Lines-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	38745
1	3234	PHOX2B	0.0372840926597591	0.625214794314366	18	2920	2960	1996	2960	2630	10	6363	2210	PHOX2B Kelly (neuroblastoma) PHOX2B	Kelly (neuroblastoma)	NULL	PHOX2B	Treatment: untreated	GTRD	EXP049489_Kelly--neuroblastoma-_PHOX2B_MACS_PHOX2B_MA0681.2.damo.pwm.bed	116523
1	3582	SNAI2	0.0372665128790036	0.758424068200295	70	2923	2441	666	2923	2010	32	6311	2188	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	LacZ	GEO	GSE55421_snai2_keratinocytes-lacz_MACS_SNAI2_MA0745.2.damo.pwm.bed	22486
1	422	CREB1	0.0371718839024148	0.724021689674296	48	2924	2547	982	2924	2150	23	6333	2197	CREB1 MCF7 (Invasive ductal breast carcinoma) CREB1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CREB1		GTRD	EXP039962_MCF7--Invasive-ductal-breast-carcinoma-_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	35189
1	2421	JUN	0.0370329177142256	0.868021581807908	337	2925	2066	76	2925	1690	134	6044	2086	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	58828
1	2449	JUN	0.0369792787459175	0.75129335563335	65	2926	2469	738	2926	2040	30	6316	2190	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	26542
1	2451	JUN	0.0365368129179321	0.743128751090918	60	2927	2498	797	2927	2070	28	6321	2192	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	23182
1	365	CEBPB	0.0364498996674615	0.821171189308062	159	2928	2227	256	2928	1800	67	6222	2153	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	100nM trametinib	GTRD	EXP037880_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	78320
1	2167	HOXB13	0.0363051430546215	0.793745082950131	110	2929	2326	404	2929	1890	48	6271	2172	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  vehicle for 4 hours	GTRD	EXP049580_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	38217
1	2349	JUN	0.0359832563273156	0.671161364550927	29	2930	2824	1504	2930	2420	15	6352	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	18128
1	2355	JUN	0.0359832563273156	0.671161364550927	29	2930	2824	1504	2930	2420	15	6352	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18172
1	2358	JUN	0.0359832563273156	0.671161364550927	29	2930	2824	1504	2930	2420	15	6352	2205	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	6422
1	1410	ESR1	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHFOXA1_E2_TNF	GEO	GSE59530_esr1_mcf7-shfoxa1-e2-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	9552
1	1449	ESRRA	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	ESRRA SK-BR-3 (breast adenocarcinoma) ESRRA	SK-BR-3 (breast adenocarcinoma)	BTO:0002419	ESRRA	EGF	GEO	GSE81651_esrra_skbr3-egf_MACS_ESRRA_MA0592.3.damo.pwm.bed	14345
1	1592	FOSL2	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	12868
1	2494	JUNB	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	14029
1	2496	JUNB	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039341_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	14370
1	3013	NFIC	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	NFIC K562 (myelogenous leukemia) NFIC	K562 (myelogenous leukemia)	NULL	NFIC	NA	GTRD	EXP039955_K562--myelogenous-leukemia-_NFIC_MACS_NFIC_MA0119.1.damo.pwm.bed	21273
1	3014	NFIC	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	NFIC K562 (myelogenous leukemia) NFIC	K562 (myelogenous leukemia)	NULL	NFIC	NA	GTRD	EXP039955_K562--myelogenous-leukemia-_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	24607
1	4127	YY1	0.0357232640137011	0.63144193156154	20	2933	2932	1901	2933	2590	11	6361	2209	YY1 Ishikawa (endometrial adenocarcinoma) YY1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	YY1		ENCODE	ENCSR000BSY_Ishikawa_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	25215
1	3130	NR3C1	0.0354278953521183	0.768083498819902	82	2941	2408	570	2941	1970	37	6299	2183	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 60 min;	GTRD	EXP047628_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	24312
1	81	AR	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: DHT 100nM 4 hours	GTRD	EXP049020_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1473
1	120	AR	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	AR primary prostate cancer AR	primary prostate cancer	NULL	AR	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053242_primary-prostate-cancer_AR_MACS_AR_MA0007.3.damo.pwm.bed	1324
1	185	AR	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		GEO	GSE62492_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	648
1	191	AR	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXA1_PHFRPMIFCS	GEO	GSE69043_AR_lncap-shfoxa1-phfrpmifcs_MACS_AR_MA0007.3.damo.pwm.bed	778
1	646	CTCF	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	CTCF neutrophils CTCF	neutrophils	NULL	CTCF		GTRD	EXP036862_neutrophils_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	19923
1	692	CTCF	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	CTCF spleen CTCF	spleen	BTO:0001281	CTCF		GTRD	EXP039469_spleen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15524
1	706	CTCF	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	CTCF testis CTCF	testis	BTO:0001363	CTCF		GTRD	EXP039569_testis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18071
1	754	CTCF	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	CTCF breast epithelial cells CTCF	breast epithelial cells	NULL	CTCF		GTRD	EXP039952_breast-epithelial-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15441
1	769	CTCF	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	CTCF HEK293 (embryonic kidney) CTCF	HEK293 (embryonic kidney)	NULL	CTCF		GTRD	EXP040061_HEK293--embryonic-kidney-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	9080
1	944	CTCF	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	CTCF lymphocyte CTCF	lymphocyte	NA	CTCF	blood	GEO	GSE46832_ctcf_lymphocyte-blood_MACS_CTCF_MA0139.1.damo.pwm.bed	15293
1	1023	E2F1	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	E2F1 K562 (myelogenous leukemia) E2F1	K562 (myelogenous leukemia)	NULL	E2F1		GTRD	EXP040307_K562--myelogenous-leukemia-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	7472
1	1025	E2F1	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	E2F1 LNCaP (prostate carcinoma) E2F1	LNCaP (prostate carcinoma)	BTO:0001321	E2F1	Treatment: CDT for 72 hrs Genotype: knockdown with shCON of CON	GTRD	EXP049492_LNCaP--prostate-carcinoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	11731
1	1137	ERG	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG	Treatment: no Genotype: expressing point-mutant(S96E) of ERF	GTRD	EXP049001_RWPE1--prostate-epithelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	749
1	1464	ETS1	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GTRD	EXP038279_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	16295
1	2669	MAF	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047561_Th17-cells_MAF_MACS_MAF_MA0501.1.damo.pwm.bed	6191
1	2747	MEIS1	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	MEIS1 A-673 clone Asp114 (Ewing sarcoma) MEIS1	A-673 clone Asp114 (Ewing sarcoma)	NULL	MEIS1	NA	GTRD	EXP052992_A-673-clone-Asp114--Ewing-sarcoma-_MEIS1_MACS_MEIS1_MA1639.1.damo.pwm.bed	5237
1	2764	MNT	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	MNT K562 (myelogenous leukemia) MNT	K562 (myelogenous leukemia)	NULL	MNT	NA	GTRD	EXP039709_K562--myelogenous-leukemia-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	7549
1	2862	MYC	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC	na	GTRD	EXP037785_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	8931
1	2952	MYCN	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	MYCN Kelly (neuroblastoma) MYCN	Kelly (neuroblastoma)	NULL	MYCN		GEO	GSE80151_mycn_kelly_MACS_MYCN_MA0104.4.damo.pwm.bed	6908
1	2968	NEUROG2	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037147_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	13256
1	3286	PPARG	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034422_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	9670
1	3299	PRDM1	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	PRDM1 HeLa S3 (cervical adenocarcinoma) PRDM1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	PRDM1		ENCODE	ENCSR000ECY_HeLa-S3_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	3577
1	3670	SPI1	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	SPI1 ME-1 (acute myeloid leukemia ) SPI1	ME-1 (acute myeloid leukemia )	NULL	SPI1		GEO	GSE46044_spi1_me1_MACS_SPI1_MA0080.5.damo.pwm.bed	13585
1	3741	STAT3	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	STAT3 AGS (gastric adenocarcinoma) STAT3	AGS (gastric adenocarcinoma)	BTO:0001007	STAT3		GTRD	EXP048899_AGS--gastric-adenocarcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	5908
1	3764	TAL1	0.0353638286226812	0.463578747375783	4	2942	3403	3105	3403	3150	3	6377	2217	TAL1 K562 (myelogenous leukemia) TAL1	K562 (myelogenous leukemia)	NULL	TAL1	NA	ENCODE	ENCSR106FRG_K562_TAL1_MACS_TAL1_MA0140.2.damo.pwm.bed	20262
1	1734	FOXA1	0.0351689228497205	0.781513646880083	97	2967	2380	468	2967	1940	43	6284	2177	FOXA1 LNCaP95 FOXA1	LNCaP95	NULL	FOXA1	Treatment: 10 nM ETOH for 4 hrs Genotype: shGFP transfection	GTRD	EXP052940_LNCaP95_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	17604
1	807	CTCF	0.0341446411749585	0.636615151226167	22	2968	2920	1797	2968	2560	12	6359	2208	CTCF CD34+ stem cells-derived erythroblasts CTCF	CD34+ stem cells-derived erythroblasts	NULL	CTCF	Fetal	GTRD	EXP040425_CD34--stem-cells-derived-erythroblasts_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39787
1	971	CTCF	0.0341446411749585	0.636615151226167	22	2968	2920	1797	2968	2560	12	6359	2208	CTCF erythroid cells CTCF	erythroid cells	NULL	CTCF		GEO	GSE67783_ctcf_erythroid_MACS_CTCF_MA0139.1.damo.pwm.bed	50599
1	2332	JUN	0.0341446411749585	0.636615151226167	22	2968	2920	1797	2968	2560	12	6359	2208	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16703
1	3780	TCF12	0.0341446411749585	0.636615151226167	22	2968	2920	1797	2968	2560	12	6359	2208	TCF12 SK-N-SH (neuroblastoma) TCF12	SK-N-SH (neuroblastoma)	BTO:0001620	TCF12	NA	ENCODE	ENCSR000BSL_SK-N-SH_TCF12_MACS_TCF12_MA0521.1.damo.pwm.bed	47703
1	2918	MYC	0.0340680173346317	0.672514355835238	31	2972	2823	1439	2972	2410	16	6350	2204	MYC NCI-H128 (small cell lung carcinoma) MYC	NCI-H128 (small cell lung carcinoma)	BTO:0003025	MYC		GEO	GSE41105_myc_h128_MACS_MYC_MA0147.3.damo.pwm.bed	29483
1	75	AR	0.0339151391168646	0.709612308841681	45	2973	2581	1054	2973	2200	22	6336	2198	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: non-target siNT+R1881	GTRD	EXP048920_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	16191
1	2166	HOXB13	0.0329632314882261	0.747472441436314	69	2974	2478	687	2974	2050	32	6312	2188	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049560_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	20938
1	494	CTCF	0.0325788374001418	0.64097765232079	24	2975	2898	1691	2975	2520	13	6357	2207	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPM_fibroblast_of_lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	40882
1	500	CTCF	0.0325788374001418	0.64097765232079	24	2975	2898	1691	2975	2520	13	6357	2207	CTCF BJ (fibroblasts) CTCF	BJ (fibroblasts)	NULL	CTCF		ENCODE	ENCSR000DQI_BJ_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	45209
1	1577	FOSL2	0.0325788374001418	0.64097765232079	24	2975	2898	1691	2975	2520	13	6357	2207	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	16894
1	2308	JUN	0.0325788374001418	0.64097765232079	24	2975	2898	1691	2975	2520	13	6357	2207	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	17007
1	3295	PPARG	0.0325788374001418	0.64097765232079	24	2975	2898	1691	2975	2520	13	6357	2207	PPARG HepG2 (hepatoblastoma) PPARG	HepG2 (hepatoblastoma)	BTO:0000599	PPARG		GTRD	EXP039615_HepG2--hepatoblastoma-_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	35923
1	2500	JUNB	0.0322556091069008	0.673696784741656	33	2980	2821	1379	2980	2390	17	6348	2203	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	16195
1	1162	ESR1	0.032010502883315	0.708828011398093	47	2981	2582	1002	2981	2190	23	6334	2197	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	Array Express	ERP000380_esr1_mcf7-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	14114
1	107	AR	0.0319719336469538	0.73062934300555	59	2982	2525	805	2982	2100	28	6322	2192	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10nM DHT for 4 hrs Genotype: shGFP	GTRD	EXP052949_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	20564
1	1888	GABPA	0.0319719336469538	0.73062934300555	59	2982	2525	805	2982	2100	28	6322	2192	GABPA VCaP (prostate carcinoma) GABPA	VCaP (prostate carcinoma)	BTO:0003215	GABPA	R1881	GEO	GSE49091_gabpa_vcap-r1881_MACS_GABPA_MA0062.3.damo.pwm.bed	37450
1	2302	JUN	0.0319719336469538	0.73062934300555	59	2982	2525	805	2982	2100	28	6322	2192	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	54595
1	1847	FOXA2	0.0316041521665873	0.758597438626686	81	2985	2440	579	2985	2000	37	6300	2183	FOXA2 Caco-2 (colon adenocarcinoma) FOXA2	Caco-2 (colon adenocarcinoma)	BTO:0000195	FOXA2		GEO	GSE66218_foxa2_caco2_MACS_FOXA2_MA0047.3.damo.pwm.bed	35643
1	34	AR	0.0310481437606482	0.821727859795071	183	2986	2223	214	2986	1810	77	6198	2143	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Bicalutamide	GTRD	EXP033082_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	42973
1	2333	JUN	0.0310453779424281	0.644703148061399	26	2987	2889	1602	2987	2490	14	6355	2206	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18233
1	2362	JUN	0.0310453779424281	0.644703148061399	26	2987	2889	1602	2987	2490	14	6355	2206	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	5750
1	3668	SPI1	0.0310453779424281	0.644703148061399	26	2987	2889	1602	2987	2490	14	6355	2206	SPI1 GM12878 (female B-cells lymphoblastoid cell line) SPI1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SPI1		GTRD	EXP054623_GM12878--female-B-cells-lymphoblastoid-cell-line-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	47436
1	2034	GATA6	0.030542005418879	0.674737068208667	35	2990	2819	1318	2990	2380	18	6346	2202	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: JNKi;	GTRD	EXP057915_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	76992
1	2501	JUNB	0.030542005418879	0.674737068208667	35	2990	2819	1318	2990	2380	18	6346	2202	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	18283
1	1281	ESR1	0.0302269712247579	0.708100953559585	49	2992	2583	967	2992	2180	24	6332	2196	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GTRD	EXP038769_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	12074
1	1076	ELF1	0.0301599587238635	0.545990475504744	11	2993	3221	2426	3221	2880	7	6370	2213	ELF1 GM12878 (female B-cells lymphoblastoid cell line) ELF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ELF1		ENCODE	ENCSR000BMB_GM12878_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	36841
1	1600	FOSL2	0.0301599587238635	0.545990475504744	11	2993	3221	2426	3221	2880	7	6370	2213	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	8681
1	2021	GATA4	0.0301599587238635	0.545990475504744	11	2993	3221	2426	3221	2880	7	6370	2213	GATA4 A549 (lung carcinoma) GATA4	A549 (lung carcinoma)	BTO:0000018	GATA4		GTRD	EXP048969_A549--lung-carcinoma-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	8725
1	2797	MYC	0.0301599587238635	0.545990475504744	11	2993	3221	2426	3221	2880	7	6370	2213	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC	NULL	GTRD	EXP000311_K562--myelogenous-leukemia-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	21314
1	3065	NR2F1	0.0301599587238635	0.545990475504744	11	2993	3221	2426	3221	2880	7	6370	2213	NR2F1 HepG2 (hepatoblastoma) NR2F1	HepG2 (hepatoblastoma)	BTO:0000599	NR2F1	NA	GTRD	EXP039919_HepG2--hepatoblastoma-_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	20012
1	432	CREM	0.0301001956563009	0.56451217686692	13	2998	3165	2306	3165	2820	8	6368	2212	CREM HepG2 (hepatoblastoma) CREM	HepG2 (hepatoblastoma)	BTO:0000599	CREM	NA	GTRD	EXP040023_HepG2--hepatoblastoma-_CREM_MACS_CREM_MA0609.2.damo.pwm.bed	10738
1	1197	ESR1	0.0301001956563009	0.56451217686692	13	2998	3165	2306	3165	2820	8	6368	2212	ESR1 LTED (breast cancer) ESR1	LTED (breast cancer)	NULL	ESR1	none	GTRD	EXP033909_LTED--breast-cancer-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3518
1	1424	ESR1	0.0301001956563009	0.56451217686692	13	2998	3165	2306	3165	2820	8	6368	2212	ESR1 T47D (invasive ductal carcinoma) ESR1	T47D (invasive ductal carcinoma)	BTO:0001248	ESR1		GEO	GSE68355_ESR1_t47d_MACS_ESR1_MA0112.3.damo.pwm.bed	3626
1	2617	JUND	0.0301001956563009	0.56451217686692	13	2998	3165	2306	3165	2820	8	6368	2212	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	12672
1	3084	NR2F6	0.0301001956563009	0.56451217686692	13	2998	3165	2306	3165	2820	8	6368	2212	NR2F6 K562 (myelogenous leukemia) NR2F6	K562 (myelogenous leukemia)	NULL	NR2F6	NA	GTRD	EXP040021_K562--myelogenous-leukemia-_NR2F6_MACS_NR2F6_MA0728.1.damo.pwm.bed	26732
1	3468	RUNX1	0.0301001956563009	0.56451217686692	13	2998	3165	2306	3165	2820	8	6368	2212	RUNX1 NB4 (acute promyelocytic leukemia ) RUNX1	NB4 (acute promyelocytic leukemia )	NULL	RUNX1		GTRD	EXP037460_NB4--acute-promyelocytic-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	35427
1	1663	FOXA1	0.0299950142377665	0.771399156735888	98	3004	2401	460	3004	1960	44	6283	2176	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	none	GTRD	EXP036100_VCaP--prostate-carcinoma-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	25742
1	2373	JUN	0.0299943807806392	0.762142296402114	88	3005	2434	525	3005	1990	40	6293	2180	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17242
1	74	AR	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	AR LNCaP-abl (Prostate carcinoma) AR	LNCaP-abl (Prostate carcinoma)	NULL	AR	Treatment: GSK126 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive	GTRD	EXP048902_LNCaP-abl--Prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	450
1	104	AR	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR	Treatment: 50 uM VPC14449 for 4 hrs	GTRD	EXP049666_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	94
1	150	AR	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncap-dht100nm_MACS_AR_MA0007.3.damo.pwm.bed	262
1	226	ARNT	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ARNT ARNT	NA	NA	ARNT	NA	GEO	GSE67237_arnt_786o-hif2a_MACS_ARNT_MA0004.1.damo.pwm.bed	5112
1	1065	EGR1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	EGR1 liver EGR1	liver	BTO:0000759	EGR1		GTRD	EXP044797_liver_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	6236
1	1106	ELK1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ELK1 IMR90 (lung fibroblasts) ELK1	IMR90 (lung fibroblasts)	NULL	ELK1		GTRD	EXP039606_IMR90--lung-fibroblasts-_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	1685
1	1123	ERG	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ERG CD34+ hematopoietic stem cells ERG	CD34+ hematopoietic stem cells	NULL	ERG		GTRD	EXP031971_CD34--hematopoietic-stem-cells_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	6968
1	1135	ERG	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ERG HUVEC-C (HUVEC, umbilical vein endothelial cells) ERG	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ERG	Treatment: agent VEGF, timepoint 12 Passage: P3-6	GTRD	EXP048204_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	8121
1	1217	ESR1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	DMSO	GTRD	EXP036387_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	308
1	1256	ESR1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	Tamoxifen-associated	GTRD	EXP038349_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	3067
1	1451	ETS1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ETS1 ETS1	NA	NA	ETS1	NA	NA	ENCSR534VHI_induced_pluripotent_stem_cell_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	8882
1	1453	ETS1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	ETS1 CD4+ CD25+ CD45RA+ T-cells ETS1	CD4+ CD25+ CD45RA+ T-cells	NULL	ETS1		GTRD	EXP032565_CD4--CD25--CD45RA--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	8541
1	1873	GABPA	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	GABPA HL-60 (acute myeloid leukemia) GABPA	HL-60 (acute myeloid leukemia)	BTO:0000738	GABPA		ENCODE	ENCSR000BTK_HL-60_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	7472
1	1933	GATA2	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	GATA2 megakaryocytes GATA2	megakaryocytes	NULL	GATA2	NULL	GTRD	EXP000352_megakaryocytes_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	3278
1	2112	HNF1A	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	HNF1A Caco-2 (colon adenocarcinoma) HNF1A	Caco-2 (colon adenocarcinoma)	BTO:0000195	HNF1A		GTRD	EXP034791_Caco-2--colon-adenocarcinoma-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	1796
1	2181	HSF1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	HSF1 breast HSF1	breast	NA	HSF1	tumor	GEO	GSE38901_hsf1_breast-tumor_MACS_HSF1_MA0486.2.damo.pwm.bed	2186
1	2649	KLF5	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	KLF5 AGS (gastric adenocarcinoma) KLF5	AGS (gastric adenocarcinoma)	BTO:0001007	KLF5		GEO	GSE51705_klf5_ags_MACS_KLF5_MA0599.1.damo.pwm.bed	498
1	2752	MITF	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MITF K562 (myelogenous leukemia) MITF	K562 (myelogenous leukemia)	NULL	MITF		ENCODE	ENCSR000FCB_K562_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	6281
1	2784	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC HeLa S3 (cervical adenocarcinoma) MYC	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	MYC		ENCODE	ENCSR000DLN_HeLa-S3_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	3176
1	2785	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC HepG2 (hepatoblastoma) MYC	HepG2 (hepatoblastoma)	BTO:0000599	MYC		ENCODE	ENCSR000DLR_HepG2_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	6851
1	2860	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC BT168 (glioblastoma stem cells) MYC	BT168 (glioblastoma stem cells)	NULL	MYC	Untreated with Dox	GTRD	EXP037765_BT168--glioblastoma-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	4974
1	2861	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC BT168 (glioblastoma stem cells) MYC	BT168 (glioblastoma stem cells)	NULL	MYC	Untreated with Dox	GTRD	EXP037765_BT168--glioblastoma-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	4356
1	2910	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC MYC	NA	NA	MYC	NA	GEO	GSE30726_myc_ra1_MACS_MYC_MA0147.3.damo.pwm.bed	4724
1	2919	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC MM1.S (plasma cell myeloma) MYC	MM1.S (plasma cell myeloma)	BTO:0003933	MYC	JQ1	GEO	GSE42161_myc_mm1s-jq1_MACS_MYC_MA0147.3.damo.pwm.bed	2305
1	2929	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC HFF (foreskin fibroblast) MYC	HFF (foreskin fibroblast)	NULL	MYC	OHT_SHBPTF	GEO	GSE65544_myc_hff-oht-shbptf_MACS_MYC_MA0147.3.damo.pwm.bed	3617
1	2930	MYC	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	MYC HFF (foreskin fibroblast) MYC	HFF (foreskin fibroblast)	NULL	MYC	OHT	GEO	GSE65544_myc_hff-oht_MACS_MYC_MA0147.3.damo.pwm.bed	4199
1	3156	NR3C1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	NR3C1 NALM-6 (adult B acute lymphoblastic leukemia) NR3C1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	NR3C1	CASP1	GEO	GSE67046_nr3c1_nalm6-casp1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3298
1	3157	NR3C1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	NR3C1 NALM-6 (adult B acute lymphoblastic leukemia) NR3C1	NALM-6 (adult B acute lymphoblastic leukemia)	BTO:0003288	NR3C1		GEO	GSE67046_nr3c1_nalm6_MACS_NR3C1_MA0113.3.damo.pwm.bed	9753
1	3222	PBX1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	PBX1 MCF7 (Invasive ductal breast carcinoma) PBX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	PBX1	NA	GTRD	EXP031466_MCF7--Invasive-ductal-breast-carcinoma-_PBX1_MACS_PBX1_MA0070.1.damo.pwm.bed	776
1	3252	POU5F1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036730_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	8638
1	3255	POU5F1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036732_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	5968
1	3294	PPARG	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034436_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	5421
1	3322	RBPJ	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	RBPJ CUTLL1 (T-cell lymphoblastic lymphoma 1) RBPJ	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	RBPJ	GSI 72 hrs, wash out 4 hrs	GTRD	EXP032408_CUTLL1--T-cell-lymphoblastic-lymphoma-1-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	9423
1	3405	REST	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	REST PANC1 (pancreatic ductal adenocarcinoma) REST	PANC1 (pancreatic ductal adenocarcinoma)	NULL	REST		ENCODE	ENCSR000BUP_Panc1_REST_MACS_REST_MA0138.2.damo.pwm.bed	4192
1	3436	REST	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	REST K562 (myelogenous leukemia) REST	K562 (myelogenous leukemia)	NULL	REST		GEO	GSE70482_rest_k562_MACS_REST_MA0138.2.damo.pwm.bed	5105
1	3462	RUNX1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	RUNX1 CD4+ CD25- T-cells RUNX1	CD4+ CD25- T-cells	NULL	RUNX1		GTRD	EXP032571_CD4--CD25--T-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	2054
1	3511	RXRA	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	RXRA WA01 (H1, human embryonic stem cells) RXRA	WA01 (H1, human embryonic stem cells)	NULL	RXRA		ENCODE	ENCSR000BJW_H1-hESC_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	2723
1	3578	SMAD4	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SMAD4 endoderm SMAD4	endoderm	NA	SMAD4	NA	GEO	GSE29422_smad4_endoderm_MACS_SMAD4_MA1153.1.damo.pwm.bed	4723
1	3599	SOX2	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036809_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	8414
1	3605	SOX2	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2-VP16 (strong activator), Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048956_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	1018
1	3611	SOX2	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SOX2 H9 SOX2	H9	NULL	SOX2		GEO	GSE46837_sox2_h9_MACS_SOX2_MA0143.4.damo.pwm.bed	2116
1	3636	SP1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SP1 A375 (malignant melanoma) SP1	A375 (malignant melanoma)	BTO:0002806	SP1	25 μM A771726	GTRD	EXP036993_A375--malignant-melanoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	5518
1	3704	SRF	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SRF GM12878 (female B-cells lymphoblastoid cell line) SRF	GM12878 (female B-cells lymphoblastoid cell line)	NULL	SRF		ENCODE	ENCSR000BGE_GM12878_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	2174
1	3716	SRF	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 15nM TPA for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053075_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	2205
1	3717	SRF	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 15nM TPA for 24 hours Source: HEL-iMKL1 cells	GTRD	EXP053076_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	1657
1	3746	STAT3	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	STAT3 OCI-LY3 (diffuse large B-cell lymphoma) STAT3	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	STAT3		GEO	GSE50723_stat3_ocily3_MACS_STAT3_MA0144.2.damo.pwm.bed	4627
1	3766	TAL1	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	TAL1 Jurkat (T-cells) TAL1	Jurkat (T-cells)	BTO:0000661	TAL1	NA	GEO	GSE29180_tal1_jurkat_MACS_TAL1_MA0091.1.damo.pwm.bed	2557
1	3856	TFAP2A	0.0299313935167726	0.347856734140256	1	3006	3555	3585	3585	3380	1	6380	2219	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040708_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0003.4.damo.pwm.bed	353
1	973	CTCF	0.0296430108861809	0.578898145552776	15	3054	3139	2200	3139	2800	9	6366	2211	CTCF Jurkat (T-cells) CTCF	Jurkat (T-cells)	BTO:0000661	CTCF		GEO	GSE68976_ctcf_jurkat_MACS_CTCF_MA0139.1.damo.pwm.bed	31435
1	1448	ESRRA	0.0296430108861809	0.578898145552776	15	3054	3139	2200	3139	2800	9	6366	2211	ESRRA BT-474 (breast invasive ductal carcinoma) ESRRA	BT-474 (breast invasive ductal carcinoma)	BTO:0001932	ESRRA	EGF	GEO	GSE81651_esrra_bt474-egf_MACS_ESRRA_MA0592.3.damo.pwm.bed	10551
1	2316	JUN	0.0296430108861809	0.578898145552776	15	3054	3139	2200	3139	2800	9	6366	2211	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	9870
1	2326	JUN	0.0296430108861809	0.578898145552776	15	3054	3139	2200	3139	2800	9	6366	2211	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	14272
1	2342	JUN	0.0296430108861809	0.578898145552776	15	3054	3139	2200	3139	2800	9	6366	2211	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	18456
1	3058	NR2F1	0.0296430108861809	0.578898145552776	15	3054	3139	2200	3139	2800	9	6366	2211	NR2F1 K562 (myelogenous leukemia) NR2F1	K562 (myelogenous leukemia)	NULL	NR2F1	NA	ENCODE	ENCSR970NKQ_K562_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	33816
1	9	AR	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	siERG	GTRD	EXP000725_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2233
1	738	CTCF	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	CTCF uterus CTCF	uterus	BTO:0001424	CTCF		GTRD	EXP039781_uterus_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28074
1	860	CTCF	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	CTCF HCT-116 (colon carcinoma) CTCF	HCT-116 (colon carcinoma)	BTO:0001109	CTCF		GTRD	EXP048607_HCT-116--colon-carcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	18673
1	1446	ESRRA	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	ESRRA MCF7 (Invasive ductal breast carcinoma) ESRRA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESRRA		ENCODE	ENCSR954WVZ_MCF-7_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	5316
1	1471	ETS1	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF_4H	GEO	GSE41166_ets1_huvec-vegf-4h_MACS_ETS1_MA0098.3.damo.pwm.bed	36028
1	1977	GATA3	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	GATA3 BE2C GATA3	BE2C	NULL	GATA3	Treatment: untreated	GTRD	EXP049487_BE2C_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	22831
1	1984	GATA3	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049906_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	2260
1	3075	NR2F2	0.0295917737526988	0.521261454474342	9	3060	3310	2585	3310	2980	6	6372	2214	NR2F2 liver NR2F2	liver	BTO:0000759	NR2F2		GTRD	EXP039783_liver_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	31337
1	1438	ESR2	0.0295565468829831	0.647919027912111	28	3068	2877	1531	3068	2490	15	6353	2205	ESR2 U2OS (osteosarcoma) ESR2	U2OS (osteosarcoma)	BTO:0001938	ESR2	E2	GTRD	EXP000205_U2OS--osteosarcoma-_ESR2_MACS_ESR2_MA0258.2.damo.pwm.bed	22433
1	2350	JUN	0.0295565468829831	0.647919027912111	28	3068	2877	1531	3068	2490	15	6353	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	17349
1	2354	JUN	0.0295565468829831	0.647919027912111	28	3068	2877	1531	3068	2490	15	6353	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17248
1	2562	JUNB	0.0295565468829831	0.647919027912111	28	3068	2877	1531	3068	2490	15	6353	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	15670
1	1715	FOXA1	0.0295327708984816	0.865092079777856	384	3072	2074	49	3072	1730	153	5997	2067	FOXA1 MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) FOXA1	MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant)	NULL	FOXA1	Treatment: 45 min 10^-8 E2	GTRD	EXP048457_MCF7-TamR--invasive-ductal-breast-carcinoma-Tamoxifen-resistant-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	100585
1	1175	ESR1	0.0294738046284796	0.719151453859839	56	3073	2555	859	3073	2160	27	6325	2193	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	GLYC	Array Express	ERP002305_esr1_mcf7-glyc_MACS_ESR1_MA0112.3.damo.pwm.bed	20733
1	2301	JUN	0.0294738046284796	0.719151453859839	56	3073	2555	859	3073	2160	27	6325	2193	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	51822
1	2305	JUN	0.0294738046284796	0.719151453859839	56	3073	2555	859	3073	2160	27	6325	2193	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	50714
1	2306	JUN	0.0294738046284796	0.719151453859839	56	3073	2555	859	3073	2160	27	6325	2193	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	50028
1	2307	JUN	0.0294738046284796	0.719151453859839	56	3073	2555	859	3073	2160	27	6325	2193	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	51796
1	1777	FOXA1	0.0293132406079493	0.860797376363618	357	3078	2084	63	3078	1740	143	6024	2077	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	SHCTR_R1881	GEO	GSE56086_foxa1_vcap-shctr-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	151769
1	1526	FOS	0.02893336022914	0.590392952085344	17	3079	3080	2066	3080	2740	10	6364	2210	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	13551
1	1528	FOS	0.02893336022914	0.590392952085344	17	3079	3080	2066	3080	2740	10	6364	2210	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	13405
1	1529	FOS	0.02893336022914	0.590392952085344	17	3079	3080	2066	3080	2740	10	6364	2210	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	24 hours following induction with TPA	GTRD	EXP000589_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	13741
1	1597	FOSL2	0.02893336022914	0.590392952085344	17	3079	3080	2066	3080	2740	10	6364	2210	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	13454
1	1598	FOSL2	0.02893336022914	0.590392952085344	17	3079	3080	2066	3080	2740	10	6364	2210	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	13717
1	1599	FOSL2	0.02893336022914	0.590392952085344	17	3079	3080	2066	3080	2740	10	6364	2210	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039680_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	13355
1	3806	TCF7	0.02893336022914	0.590392952085344	17	3079	3080	2066	3080	2740	10	6364	2210	TCF7 HepG2 (hepatoblastoma) TCF7	HepG2 (hepatoblastoma)	BTO:0000599	TCF7		GTRD	EXP039875_HepG2--hepatoblastoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	16021
1	1865	FOXP1	0.0289227083202192	0.675657640640307	37	3086	2817	1264	3086	2390	19	6344	2201	FOXP1 LNCaP (prostate carcinoma) FOXP1	LNCaP (prostate carcinoma)	BTO:0001321	FOXP1	NA	GEO	GSE62492_foxp1_lncap-dht_MACS_FOXP1_MA0481.3.damo.pwm.bed	6538
1	210	AR	0.028520799838816	0.727949198342085	63	3087	2536	753	3087	2130	30	6318	2190	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT	GEO	GSE83860_AR_lncap-dht_MACS_AR_MA0007.3.damo.pwm.bed	25368
1	2452	JUN	0.028520799838816	0.727949198342085	63	3087	2536	753	3087	2130	30	6318	2190	JUN MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line) JUN	MDA-MB-231p27CK-DD (breast cancer cells, phosphimimetic p27 cell line)	NULL	JUN		GTRD	EXP058065_MDA-MB-231p27CK-DD--breast-cancer-cells--phosphimimetic-p27-cell-line-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	25269
1	3914	TFAP2C	0.0284334605197059	0.838139100081254	250	3089	2155	127	3089	1790	103	6131	2117	TFAP2C MCF7 (Invasive ductal breast carcinoma) TFAP2C	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TFAP2C		GEO	GSE21234_tfap2c_mcf7_MACS_TFAP2C_MA0815.1.damo.pwm.bed	71805
1	922	CTCF	0.0281198161558781	0.650720833822282	30	3090	2869	1473	3090	2480	16	6351	2204	CTCF MCF7L-P(immortalized breast epithelial cell line) CTCF	MCF7L-P(immortalized breast epithelial cell line)	NULL	CTCF	Treatment: treated with E2 for 4 hrs;	GTRD	EXP057862_MCF7L-P-immortalized-breast-epithelial-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	36084
1	1578	FOSL2	0.0281198161558781	0.650720833822282	30	3090	2869	1473	3090	2480	16	6351	2204	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	18894
1	1579	FOSL2	0.0281198161558781	0.650720833822282	30	3090	2869	1473	3090	2480	16	6351	2204	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039419_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	18904
1	2330	JUN	0.0281198161558781	0.650720833822282	30	3090	2869	1473	3090	2480	16	6351	2204	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	21389
1	2377	JUN	0.02810012025889	0.749114380231234	80	3094	2472	585	3094	2050	37	6301	2183	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	15951
1	497	CTCF	0.028065340401315	0.599779872869975	19	3095	3046	1956	3095	2700	11	6362	2209	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DPV_fibroblast_of_skin_of_abdomen_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39234
1	785	CTCF	0.028065340401315	0.599779872869975	19	3095	3046	1956	3095	2700	11	6362	2209	CTCF esophagus squamous epithelium CTCF	esophagus squamous epithelium	NULL	CTCF		GTRD	EXP040157_esophagus-squamous-epithelium_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30844
1	2339	JUN	0.028065340401315	0.599779872869975	19	3095	3046	1956	3095	2700	11	6362	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	14014
1	2347	JUN	0.028065340401315	0.599779872869975	19	3095	3046	1956	3095	2700	11	6362	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17616
1	2642	KLF5	0.028065340401315	0.599779872869975	19	3095	3046	1956	3095	2700	11	6362	2209	KLF5 HEK293T (embryonic kidney) KLF5	HEK293T (embryonic kidney)	BTO:0002181	KLF5	Treatment: Over-expressing KLF5 E419Q	GTRD	EXP049094_HEK293T--embryonic-kidney-_KLF5_MACS_KLF5_MA0599.1.damo.pwm.bed	25636
1	93	AR	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: vehicle (charcoal stripped) for 6 hrs  TF: full-length AR (AR-FL)	GTRD	EXP049390_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2795
1	279	BATF	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	BATF OCI-LY10 (diffuse large B-cell lymphoma) BATF	OCI-LY10 (diffuse large B-cell lymphoma)	NULL	BATF	NA	GEO	GSE56857_batf_ocily10_MACS_BATF_MA0462.2.damo.pwm.bed	6946
1	776	CTCF	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	CTCF upper lobe of left lung CTCF	upper lobe of left lung	NULL	CTCF		GTRD	EXP040087_upper-lobe-of-left-lung_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	20517
1	787	CTCF	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP040192_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	23005
1	1908	GATA1	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bio	GTRD	EXP000939_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	21913
1	1909	GATA1	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	bio	GTRD	EXP000939_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	22135
1	3067	NR2F1	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	NR2F1 HepG2 (hepatoblastoma) NR2F1	HepG2 (hepatoblastoma)	BTO:0000599	NR2F1	NA	GTRD	EXP039919_HepG2--hepatoblastoma-_NR2F1_MACS_NR2F1_MA1538.1.damo.pwm.bed	15204
1	3430	REST	0.0280139024587479	0.486537716742484	7	3100	3371	2768	3371	3080	5	6374	2215	REST CRC121 (colorectal cancer metastatic stem cells) REST	CRC121 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid integrity;	GTRD	EXP058088_CRC121--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	11778
1	2	AR	0.0277245607287178	0.786533917583977	125	3108	2337	345	3108	1930	55	6256	2165	AR MDA-MB-453 (breast adenocarcinoma) AR	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	AR		Array Express	ERP001226_AR_mdamb453_MACS_AR_MA0007.3.damo.pwm.bed	18097
1	1783	FOXA1	0.0277245607287178	0.786533917583977	125	3108	2337	345	3108	1930	55	6256	2165	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	ETOH24H	GEO	GSE58428_foxa1_vcap-etoh24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	39756
1	115	AR	0.0274508087334015	0.73510844908483	70	3110	2515	666	3110	2100	33	6311	2187	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  transfected twice with with 5nM of siLINC00844 every 24 hours, 100nM of DHT for 2 hrs Genotype: transfected with siLINC00844	GTRD	EXP052984_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	26952
1	3354	RELA	0.027393015631698	0.676476449541934	39	3111	2816	1206	3111	2380	20	6342	2200	RELA MCF7 (Invasive ductal breast carcinoma) RELA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RELA	IL1b for 45m	GTRD	EXP036986_MCF7--Invasive-ductal-breast-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	18846
1	3566	SMAD3	0.0271015473872114	0.60758652185544	21	3112	3025	1852	3112	2660	12	6360	2208	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	Treatment: TGF-beta CellType: Immortalized human mammary epithelial cells	GTRD	EXP047891_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	7624
1	2221	JUN	0.0269870028390339	0.706792110017661	53	3113	2585	905	3113	2200	26	6328	2194	JUN HeLa S3 (cervical adenocarcinoma) JUN	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	JUN		ENCODE	ENCSR000EDG_HeLa-S3_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	19799
1	1131	ERG	0.0267394189623506	0.653181627181262	32	3114	2866	1410	3114	2460	17	6349	2203	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG		GTRD	EXP038637_VCaP--prostate-carcinoma-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	24449
1	1785	FOXA1	0.0261048400235321	0.800010870800128	155	3115	2302	267	3115	1890	67	6226	2153	FOXA1 MCF7 (Invasive ductal breast carcinoma) FOXA1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOXA1	E2	GEO	GSE59530_foxa1_mcf7-e2_MACS_FOXA1_MA0148.4.damo.pwm.bed	29698
1	539	CTCF	0.0260843875888202	0.614177303044081	23	3116	2982	1739	3116	2610	13	6358	2207	CTCF CTCF	NA	NA	CTCF	NA	NA	ENCSR000DWQ_foreskin_fibroblast_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	42052
1	2545	JUNB	0.0260843875888202	0.614177303044081	23	3116	2982	1739	3116	2610	13	6358	2207	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	13157
1	3296	PPARG	0.0260843875888202	0.614177303044081	23	3116	2982	1739	3116	2610	13	6358	2207	PPARG HepG2 (hepatoblastoma) PPARG	HepG2 (hepatoblastoma)	BTO:0000599	PPARG		GTRD	EXP039615_HepG2--hepatoblastoma-_PPARG_MACS_PPARG_MA0066.1.damo.pwm.bed	33202
1	2431	JUN	0.0259481921898681	0.677208023830886	41	3119	2814	1155	3119	2360	21	6340	2199	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	33132
1	2518	JUNB	0.0259481921898681	0.677208023830886	41	3119	2814	1155	3119	2360	21	6340	2199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	20808
1	1781	FOXA1	0.0259045675413179	0.832667811039251	246	3121	2187	133	3121	1810	102	6135	2118	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	ETOH24H	GEO	GSE58428_foxa1_lncap-etoh24h_MACS_FOXA1_MA0148.4.damo.pwm.bed	65389
1	3192	ONECUT2	0.0259015653429126	0.789892255732485	137	3122	2330	320	3122	1920	60	6244	2160	ONECUT2 LNCaP (prostate carcinoma) ONECUT2	LNCaP (prostate carcinoma)	BTO:0001321	ONECUT2	Treatment: hypoxia(0.2% O2);	GTRD	EXP057824_LNCaP--prostate-carcinoma-_ONECUT2_MACS_ONECUT2_MA0756.1.damo.pwm.bed	103981
1	305	CDX2	0.025483170463506	0.72557955556717	67	3123	2545	710	3123	2130	32	6314	2188	CDX2 LS180 (colon cancer) CDX2	LS180 (colon cancer)	NULL	CDX2		GEO	GSE31939_cdx2_ls180_MACS_CDX2_MA0465.2.damo.pwm.bed	27299
1	364	CEBPB	0.0254696987830573	0.803440784774825	165	3124	2292	244	3124	1890	71	6216	2149	CEBPB SUM159PT (Triple negative breast cancer) CEBPB	SUM159PT (Triple negative breast cancer)	NULL	CEBPB	DMSO	GTRD	EXP037879_SUM159PT--pleiomorphic-breast-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	71597
1	2374	JUN	0.0254608355678393	0.75698866305469	94	3125	2453	482	3125	2020	43	6287	2177	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	18791
1	2136	HNF4A	0.0254173909844263	0.65535823344232	34	3126	2863	1349	3126	2450	18	6347	2202	HNF4A liver HNF4A	liver	BTO:0000759	HNF4A		GTRD	EXP039987_liver_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	36215
1	2819	MYC	0.0254173909844263	0.65535823344232	34	3126	2863	1349	3126	2450	18	6347	2202	MYC HeLa (cervical adenocarcinoma) MYC	HeLa (cervical adenocarcinoma)	BTO:0000567	MYC		GTRD	EXP031873_HeLa--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	30768
1	1985	GATA3	0.0250429553560073	0.619812748540575	25	3128	2967	1657	3128	2580	14	6356	2206	GATA3 T47D (invasive ductal carcinoma) GATA3	T47D (invasive ductal carcinoma)	BTO:0001248	GATA3	Passsage: <10 Genotype: wt/R330fs mutant with CRISPR	GTRD	EXP049907_T47D--invasive-ductal-carcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	6385
1	2357	JUN	0.0250429553560073	0.619812748540575	25	3128	2967	1657	3128	2580	14	6356	2206	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	5792
1	2361	JUN	0.0250429553560073	0.619812748540575	25	3128	2967	1657	3128	2580	14	6356	2206	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	5627
1	3082	NR2F6	0.0250429553560073	0.619812748540575	25	3128	2967	1657	3128	2580	14	6356	2206	NR2F6 HepG2 (hepatoblastoma) NR2F6	HepG2 (hepatoblastoma)	BTO:0000599	NR2F6	NA	GTRD	EXP039812_HepG2--hepatoblastoma-_NR2F6_MACS_NR2F6_MA0728.1.damo.pwm.bed	41750
1	1634	FOXA1	0.0249365538993468	0.8120457701966	188	3132	2247	204	3132	1860	80	6193	2140	FOXA1 A549 (lung carcinoma) FOXA1	A549 (lung carcinoma)	BTO:0000018	FOXA1	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BPX_A549_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	52980
1	167	AR	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT24H_SHFOXA1	GEO	GSE58428_AR_lncap-dht24h-shfoxa1_MACS_AR_MA0007.3.damo.pwm.bed	726
1	280	BATF	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	BATF OCI-LY3 (diffuse large B-cell lymphoma) BATF	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	BATF	NA	GEO	GSE56857_batf_ocily3_MACS_BATF_MA0462.2.damo.pwm.bed	2476
1	349	CEBPA	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	CEBPA Kasumi-1 (acute myeloblastic leukemia) CEBPA	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	CEBPA	SIRUNX1ETO	GEO	GSE60130_cebpa_kasumi1-sirunx1eto_MACS_CEBPA_MA0102.4.damo.pwm.bed	8240
1	662	CTCF	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	CTCF U2OS (osteosarcoma) CTCF	U2OS (osteosarcoma)	BTO:0001938	CTCF		GTRD	EXP037952_U2OS--osteosarcoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	5642
1	977	CTCF	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	CTCF THP-1 (acute monocytic leukemia) CTCF	THP-1 (acute monocytic leukemia)	BTO:0001370	CTCF		GEO	GSE69962_ctcf_thp1_MACS_CTCF_MA0139.1.damo.pwm.bed	4977
1	1087	ELF1	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	ELF1 GM12878 (female B-cells lymphoblastoid cell line) ELF1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ELF1		GTRD	EXP039944_GM12878--female-B-cells-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	13845
1	1091	ELF1	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	ELF1 SK-N-MC (Askin tumor) ELF1	SK-N-MC (Askin tumor)	BTO:0002914	ELF1	SHGFP_96H	GEO	GSE61944_elf1_skmnc-shgfp-96h_MACS_ELF1_MA0473.3.damo.pwm.bed	5912
1	2003	GATA3	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	GATA3 Jurkat (T-cells) GATA3	Jurkat (T-cells)	BTO:0000661	GATA3		GEO	GSE68976_gata3_jurkat_MACS_GATA3_MA0037.3.damo.pwm.bed	6813
1	2014	GATA4	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037712_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	7746
1	2047	GFI1B	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	GFI1B HEK293 (embryonic kidney) GFI1B	HEK293 (embryonic kidney)	NULL	GFI1B		GTRD	EXP039926_HEK293--embryonic-kidney-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1736
1	2202	IRF1	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	IRF1 CD14 IRF1	CD14	NA	IRF1	LPS	GEO	GSE43036_irf1_cd14-lps_MACS_IRF1_MA0050.2.damo.pwm.bed	8620
1	2621	JUND	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	JUND JUND	NA	NA	JUND	NA	GEO	GSE59021_jund_du145_MACS_JUND_MA0491.2.damo.pwm.bed	1848
1	2657	LEF1	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	LEF1 K562 (myelogenous leukemia) LEF1	K562 (myelogenous leukemia)	NULL	LEF1		GTRD	EXP039909_K562--myelogenous-leukemia-_LEF1_MACS_LEF1_MA0768.1.damo.pwm.bed	6980
1	2844	MYC	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036776_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	8593
1	2845	MYC	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036776_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	9277
1	2847	MYC	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036777_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	7009
1	2907	MYC	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	MYC BL41(Burkitt lymphoma) MYC	BL41(Burkitt lymphoma)	NULL	MYC		GEO	GSE30726_myc_bl41_MACS_MYC_MA0147.3.damo.pwm.bed	13952
1	3161	NR3C1	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	NR3C1 T47D (invasive ductal carcinoma) NR3C1	T47D (invasive ductal carcinoma)	BTO:0001248	NR3C1	DEX	GEO	GSE72249_nr3c1_t47d-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	265
1	3217	PAX5	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	PAX5 Namalwa (Burkitt lymphoma) PAX5	Namalwa (Burkitt lymphoma)	BTO:0003289	PAX5	none	GTRD	EXP031939_Namalwa--Burkitt-lymphoma-_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	8179
1	3378	RELA	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	RELA AC16 (normal cardiomyocytes) RELA	AC16 (normal cardiomyocytes)	NULL	RELA	TNFA	GEO	GSE51169_rela_ac16-tnfa_MACS_RELA_MA0107.1.damo.pwm.bed	3000
1	3393	REST	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	REST SK-N-SH (neuroblastoma) REST	SK-N-SH (neuroblastoma)	BTO:0001620	REST		ENCODE	ENCSR000BJJ_SK-N-SH_REST_MACS_REST_MA0138.2.damo.pwm.bed	5092
1	3409	REST	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	REST U87 (glioblastoma) REST	U87 (glioblastoma)	NULL	REST	None	GTRD	EXP010296_U87--glioblastoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	3445
1	3410	REST	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	REST U87 (glioblastoma) REST	U87 (glioblastoma)	NULL	REST	None	GTRD	EXP010585_U87--glioblastoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	4481
1	3510	RXRA	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	RXRA GM12878 (female B-cells lymphoblastoid cell line) RXRA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	RXRA		ENCODE	ENCSR000BJD_GM12878_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	7983
1	3576	SMAD3	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	SMAD3 MDA-MB-231 (breast adenocarcinoma) SMAD3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	SMAD3	Treatment: 2 ng/mLTGF beta, 1 hr	GTRD	EXP049373_MDA-MB-231--breast-adenocarcinoma-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	4440
1	3627	SP1	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	SP1 HEK293T (embryonic kidney) SP1	HEK293T (embryonic kidney)	BTO:0002181	SP1		Array Express	ERP007114_sp1_hek293t_MACS_SP1_MA0079.4.damo.pwm.bed	11369
1	3705	SRF	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	SRF WA01 (H1, human embryonic stem cells) SRF	WA01 (H1, human embryonic stem cells)	NULL	SRF		ENCODE	ENCSR000BIV_H1-hESC_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	3162
1	3713	SRF	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: No treatment, no TPA  Source: HEL-iMKL1 cells	GTRD	EXP053072_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	3350
1	3719	SRF	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: Treated with 10ng/ml Dox & 15nM TPA for 24 horus Genotype: mkl overexpressed	GTRD	EXP053078_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	5675
1	3760	STAT6	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	STAT6 monocyte-derived macrophages STAT6	monocyte-derived macrophages	NULL	STAT6	IL-4	GTRD	EXP036840_monocyte-derived-macrophages_STAT6_MACS_STAT6_MA0520.1.damo.pwm.bed	3624
1	3797	TCF4	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	TCF4 SH-SY5Y (neuroblastoma) TCF4	SH-SY5Y (neuroblastoma)	BTO:0000793	TCF4	Treatment: none	GTRD	EXP049704_SH-SY5Y--neuroblastoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	8086
1	3971	TP53	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	DMSO	GTRD	EXP037748_MCF7--Invasive-ductal-breast-carcinoma-_TP53_MACS_TP53_MA0106.3.damo.pwm.bed	417
1	4135	YY1	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1		GTRD	EXP038605_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	4795
1	4155	YY2	0.0247632855067383	0.347754494116962	2	3133	3603	3390	3603	3380	2	6379	2218	YY2 HeLa (cervical adenocarcinoma) YY2	HeLa (cervical adenocarcinoma)	BTO:0000567	YY2	NA	GTRD	EXP048879_HeLa--cervical-adenocarcinoma-_YY2_MACS_YY2_MA0748.2.damo.pwm.bed	5606
1	72	AR	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	AR HEE (human epididymis epithelial cells) AR	HEE (human epididymis epithelial cells)	NULL	AR	Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr	GTRD	EXP048160_HEE--human-epididymis-epithelial-cells-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3598
1	729	CTCF	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	CTCF gastrocnemius medialis CTCF	gastrocnemius medialis	NULL	CTCF		GTRD	EXP039704_gastrocnemius-medialis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	20250
1	1079	ELF1	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	ELF1 A549 (lung carcinoma) ELF1	A549 (lung carcinoma)	BTO:0000018	ELF1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPT_A549_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	12470
1	1876	GABPA	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	GABPA K562 (myelogenous leukemia) GABPA	K562 (myelogenous leukemia)	NULL	GABPA		ENCODE	ENCSR290MUH_K562_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	15212
1	2031	GATA6	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	GATA6 HUES64 (embryonic stem cells) GATA6	HUES64 (embryonic stem cells)	NULL	GATA6		GTRD	EXP036794_HUES64--embryonic-stem-cells-_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	14580
1	2388	JUN	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	10958
1	2389	JUN	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	10920
1	2391	JUN	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	10337
1	2393	JUN	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	10358
1	2394	JUN	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	10750
1	2395	JUN	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048210_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	10838
1	2826	MYC	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector	GTRD	EXP036031_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	11766
1	2876	MYC	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	MYC HEK293T (embryonic kidney) MYC	HEK293T (embryonic kidney)	BTO:0002181	MYC	Treatment: withKL-1 or KL-2 inhibitors was administrated only once; Genotype: cells lentiviral infected shRNA targeting MYC;	GTRD	EXP047292_HEK293T--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	17186
1	2946	MYCN	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	MYCN MYCN3 (neuroblastoma cell line with inducible MYCN expression) MYCN	MYCN3 (neuroblastoma cell line with inducible MYCN expression)	NULL	MYCN	Treatment: mycn-high lvl induced by 16 hr doxycycline	GTRD	EXP048927_MYCN3--neuroblastoma-cell-line-with-inducible-MYCN-expression-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	11698
1	3076	NR2F2	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	NR2F2 liver NR2F2	liver	BTO:0000759	NR2F2		GTRD	EXP040003_liver_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	16133
1	3427	REST	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	REST CRC107 (colorectal cancer metastatic stem cells) REST	CRC107 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid dissociation;	GTRD	EXP058085_CRC107--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	6528
1	3707	SRF	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	SRF HepG2 (hepatoblastoma) SRF	HepG2 (hepatoblastoma)	BTO:0000599	SRF		ENCODE	ENCSR000BLV_HepG2_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	8159
1	3774	TBX5	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5		GTRD	EXP037717_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	9843
1	3778	TBX5	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	TBX5 iPSC-derived cardiomyocytes TBX5	iPSC-derived cardiomyocytes	NULL	TBX5	day 30	GTRD	EXP053380_iPSC-derived-cardiomyocytes_TBX5_MACS_TBX5_MA0807.1.damo.pwm.bed	13824
1	3897	TFAP2C	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047540_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	11244
1	4120	YY1	0.0247624024852352	0.434486484118191	5	3167	3464	2973	3464	3200	4	6376	2216	YY1 GM12892 (female B-cells lymphoblastoid cell line) YY1	GM12892 (female B-cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000BLT_GM12892_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	13411
1	1545	FOS	0.0245918451590198	0.828519577213788	240	3188	2197	142	3188	1840	100	6141	2120	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	42986
1	66	AR	0.0245835784012584	0.677864250789288	43	3189	2813	1101	3189	2370	22	6338	2198	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR		GTRD	EXP038636_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	25963
1	3011	NFIC	0.0241542718488162	0.657295514752659	36	3190	2851	1288	3190	2440	19	6345	2201	NFIC SK-N-SH (neuroblastoma) NFIC	SK-N-SH (neuroblastoma)	BTO:0001620	NFIC	NA	ENCODE	ENCSR000BSV_SK-N-SH_NFIC_MACS_NFIC_MA0161.2.damo.pwm.bed	38430
1	2372	JUN	0.0239996471685955	0.750265289605137	91	3191	2470	506	3191	2060	42	6290	2178	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17766
1	2360	JUN	0.0239973588740369	0.624683914682121	27	3192	2963	1564	3192	2570	15	6354	2205	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	6787
1	3882	TFAP2C	0.0239973588740369	0.624683914682121	27	3192	2963	1564	3192	2570	15	6354	2205	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047535_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	30779
1	1818	FOXA2	0.0236435265861246	0.834843988034124	271	3194	2162	107	3194	1820	112	6110	2108	FOXA2 pancreatic islets FOXA2	pancreatic islets	NULL	FOXA2		Array Express	ERP004003_foxa2_islet_MACS_FOXA2_MA0047.3.damo.pwm.bed	146564
1	141	AR	0.0232294408184604	0.731300121888273	76	3195	2522	619	3195	2110	36	6305	2184	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	DHT	GEO	GSE43720_AR_lncap-dht_MACS_AR_MA0007.3.damo.pwm.bed	27366
1	1136	ERG	0.0232294408184604	0.731300121888273	76	3195	2522	619	3195	2110	36	6305	2184	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG	Infection: retrovirus expressing FLAG-ERG Treatment: nearly confluent 150 mm dishes were treated with 1% formaldehyde, and harvested in Farnham lysis buffer and a crude nuclear pellet collected after centrifugation	GTRD	EXP048484_RWPE1--prostate-epithelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	23936
1	1223	ESR1	0.0229495847735888	0.659029360789929	38	3197	2848	1238	3197	2430	20	6343	2200	ESR1 endometrioid adenocarcinoma ESR1	endometrioid adenocarcinoma	NULL	ESR1	tumor E	GTRD	EXP036413_endometrioid-adenocarcinoma_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	32917
1	1544	FOS	0.0229033913504079	0.824935007491944	239	3198	2216	143	3198	1850	100	6142	2120	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	42967
1	2318	JUN	0.0220972226765606	0.54024557307335	14	3199	3234	2252	3234	2900	9	6367	2211	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	10060
1	3631	SP1	0.0220972226765606	0.54024557307335	14	3199	3234	2252	3234	2900	9	6367	2211	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036143_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	28664
1	3876	TFAP2C	0.0220972226765606	0.54024557307335	14	3199	3234	2252	3234	2900	9	6367	2211	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040713_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	20734
1	3878	TFAP2C	0.0220972226765606	0.54024557307335	14	3199	3234	2252	3234	2900	9	6367	2211	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040713_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	21103
1	4064	TWIST1	0.0220972226765606	0.54024557307335	14	3199	3234	2252	3234	2900	9	6367	2211	TWIST1 BE2C TWIST1	BE2C	NULL	TWIST1		GEO	GSE80151_twist1_be2c_MACS_TWIST1_MA1123.2.damo.pwm.bed	33187
1	3737	STAT3	0.0220770958468617	0.678988305714741	47	3204	2812	1002	3204	2340	24	6334	2196	STAT3 MDA-MB-468 (breast adenocarcinoma) STAT3	MDA-MB-468 (breast adenocarcinoma)	BTO:0001570	STAT3	ethanol	GTRD	EXP037704_MDA-MB-468--breast-adenocarcinoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	14315
1	585	CTCF	0.0219744375087275	0.555593155236697	16	3205	3200	2127	3205	2840	10	6365	2210	CTCF CD36+ erythroid cells CTCF	CD36+ erythroid cells	NULL	CTCF	BRG1 RNAi KD	GTRD	EXP000910_CD36--erythroid-cells_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	31602
1	727	CTCF	0.0219744375087275	0.555593155236697	16	3205	3200	2127	3205	2840	10	6365	2210	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039699_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	30696
1	896	CTCF	0.0219744375087275	0.555593155236697	16	3205	3200	2127	3205	2840	10	6365	2210	CTCF NHLF (lung fibroblasts) CTCF	NHLF (lung fibroblasts)	NULL	CTCF	Treatment: None;	GTRD	EXP054033_NHLF--lung-fibroblasts-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	35434
1	2036	GATA6	0.0219744375087275	0.555593155236697	16	3205	3200	2127	3205	2840	10	6365	2210	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: JNKi;	GTRD	EXP057922_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	55840
1	2220	JUN	0.0219697406296047	0.693251717631985	54	3209	2800	886	3209	2300	27	6327	2193	JUN HeLa S3 (cervical adenocarcinoma) JUN	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	JUN		ENCODE	ENCSR000EDG_HeLa-S3_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	22278
1	261	ATF4	0.0219450382032369	0.632672860550889	31	3210	2928	1439	3210	2530	17	6350	2203	ATF4 K562 (myelogenous leukemia) ATF4	K562 (myelogenous leukemia)	NULL	ATF4		GTRD	EXP040245_K562--myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	35842
1	1142	ERG	0.0219450382032369	0.632672860550889	31	3210	2928	1439	3210	2530	17	6350	2203	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG		GEO	GSE28950_erg_vcap_MACS_ERG_MA0474.2.damo.pwm.bed	16434
1	2878	MYC	0.0219450382032369	0.632672860550889	31	3210	2928	1439	3210	2530	17	6350	2203	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047484_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	19170
1	415	CREB1	0.0219074704530092	0.521036103556034	12	3213	3318	2359	3318	2960	8	6369	2212	CREB1 A549 (lung carcinoma) CREB1	A549 (lung carcinoma)	BTO:0000018	CREB1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRC_A549_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	15904
1	3083	NR2F6	0.0219074704530092	0.521036103556034	12	3213	3318	2359	3318	2960	8	6369	2212	NR2F6 K562 (myelogenous leukemia) NR2F6	K562 (myelogenous leukemia)	NULL	NR2F6	NA	GTRD	EXP040021_K562--myelogenous-leukemia-_NR2F6_MACS_NR2F6_MA0677.1.damo.pwm.bed	27787
1	3690	SPI1	0.0219074704530092	0.521036103556034	12	3213	3318	2359	3318	2960	8	6369	2212	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1	NABUT	GEO	GSE74999_spi1_k562-nabut_MACS_SPI1_MA0080.5.damo.pwm.bed	35099
1	2172	HOXB13	0.021877172643772	0.789441130290288	153	3216	2333	272	3216	1940	67	6228	2153	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13		GEO	GSE56288_hoxb13_lncap_MACS_HOXB13_MA0901.2.damo.pwm.bed	49240
1	2324	JUN	0.0216374023970626	0.568132396481327	18	3217	3159	1996	3217	2790	11	6363	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	14720
1	255	ATF3	0.021606390320005	0.704619751377385	61	3218	2587	785	3218	2200	30	6320	2190	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		GTRD	EXP040300_K562--myelogenous-leukemia-_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	40651
1	3799	TCF4	0.0215676708869023	0.775237077117715	130	3219	2390	333	3219	1980	58	6251	2162	TCF4 SU-DHL-2 (anaplastic large cell lymphoma) TCF4	SU-DHL-2 (anaplastic large cell lymphoma)	NULL	TCF4	Treatment: 60 ng/ml Tetracyclin for 24 hrs; Genotype: inducible TCF4 expression;	GTRD	EXP058276_SU-DHL-2--anaplastic-large-cell-lymphoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	216932
1	2422	JUN	0.0214570229719959	0.845271134942495	341	3220	2128	73	3220	1810	139	6040	2081	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	58612
1	546	CTCF	0.0212602725494932	0.496247785207271	10	3221	3359	2487	3359	3020	7	6371	2213	CTCF WI-38 (lung fibroblasts) CTCF	WI-38 (lung fibroblasts)	BTO:0000458	CTCF		ENCODE	ENCSR000DYB_WI38_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	26092
1	693	CTCF	0.0212602725494932	0.496247785207271	10	3221	3359	2487	3359	3020	7	6371	2213	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039472_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27619
1	2618	JUND	0.0212602725494932	0.496247785207271	10	3221	3359	2487	3359	3020	7	6371	2213	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	10132
1	1815	FOXA2	0.0212171497521068	0.795284781665556	168	3224	2313	236	3224	1920	73	6213	2147	FOXA2 HepG2 (hepatoblastoma) FOXA2	HepG2 (hepatoblastoma)	BTO:0000599	FOXA2		ENCODE	ENCSR000BNI_HepG2_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	87150
1	203	AR	0.0211541221042672	0.578567123260503	20	3225	3145	1901	3225	2760	12	6361	2208	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881	GEO	GSE79128_AR_vcap-r1881_MACS_AR_MA0007.3.damo.pwm.bed	9419
1	859	CTCF	0.0211541221042672	0.578567123260503	20	3225	3145	1901	3225	2760	12	6361	2208	CTCF LUHMES (lund human mesencephalic cells) CTCF	LUHMES (lund human mesencephalic cells)	NULL	CTCF	Sex: female Passages: 3-10 Stage: dopaminergic neurons, differentiated Treatment: For induction of differentiation, culture medium was changed to freshly prepare DMEM:F12 with 2 mM L-glutamine, 1X N-2, 1 mM cAMP (Carbosynth, Cat # ND07996), 1 mg/mL tetracycline (Sigma, Cat # T7660), and 2 ng/mL glial cell line-derived neurotrophic factor (GDNF) (Sigma, Cat # G1777)	GTRD	EXP048230_LUHMES--lund-human-mesencephalic-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	39746
1	111	AR	0.020954441260213	0.635985441776908	33	3227	2924	1379	3227	2510	18	6348	2202	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection)	GTRD	EXP052954_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	7983
1	3581	SNAI2	0.0205724513982804	0.587385567173319	22	3228	3088	1797	3228	2700	13	6359	2207	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	LacZ_DIFF	GEO	GSE55421_snai2_keratinocytes-lacz-diff_MACS_SNAI2_MA0745.2.damo.pwm.bed	4114
1	3134	NR3C1	0.0204541428620304	0.704148453959447	63	3229	2588	753	3229	2190	31	6318	2189	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 60 min;	GTRD	EXP047632_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17423
1	2352	JUN	0.0199940658795614	0.638939120282017	35	3230	2904	1318	3230	2480	19	6346	2201	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	23699
1	3738	STAT3	0.0199491554157697	0.71316427992738	70	3231	2573	666	3231	2160	34	6311	2186	STAT3 MCF10A-ER-Src STAT3	MCF10A-ER-Src	NULL	STAT3	Genotype: non-transformed	GTRD	EXP048575_MCF10A-ER-Src_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	17279
1	157	AR	0.0199373144336273	0.463242187032534	8	3232	3428	2675	3428	3110	6	6373	2214	AR PC3(bone mets prostate adenocarcinoma) AR	PC3(bone mets prostate adenocarcinoma)	NULL	AR		GEO	GSE54110_AR_pc3_MACS_AR_MA0007.3.damo.pwm.bed	1553
1	1881	GABPA	0.0199373144336273	0.463242187032534	8	3232	3428	2675	3428	3110	6	6373	2214	GABPA HepG2 (hepatoblastoma) GABPA	HepG2 (hepatoblastoma)	BTO:0000599	GABPA		GTRD	EXP040044_HepG2--hepatoblastoma-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	12456
1	2866	MYC	0.0199373144336273	0.463242187032534	8	3232	3428	2675	3428	3110	6	6373	2214	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	none (Myc transgene expressed)	GTRD	EXP038948_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	24929
1	2867	MYC	0.0199373144336273	0.463242187032534	8	3232	3428	2675	3428	3110	6	6373	2214	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	none (Myc transgene expressed)	GTRD	EXP038948_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	25581
1	2948	MYCN	0.0199373144336273	0.463242187032534	8	3232	3428	2675	3428	3110	6	6373	2214	MYCN Kelly (neuroblastoma) MYCN	Kelly (neuroblastoma)	NULL	MYCN	Treatment: untreated	GTRD	EXP049488_Kelly--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	26612
1	3073	NR2F2	0.0199373144336273	0.463242187032534	8	3232	3428	2675	3428	3110	6	6373	2214	NR2F2 HepG2 (hepatoblastoma) NR2F2	HepG2 (hepatoblastoma)	BTO:0000599	NR2F2		ENCODE	ENCSR000BVM_HepG2_NR2F2_MACS_NR2F2_MA1111.1.damo.pwm.bed	14856
1	3270	POU5F1	0.0199373144336273	0.463242187032534	8	3232	3428	2675	3428	3110	6	6373	2214	POU5F1 MRC-5 (fetal lung fibroblasts) POU5F1	MRC-5 (fetal lung fibroblasts)	BTO:0001590	POU5F1	Treatment: Oct4, Sox2, Klf4 and Myc addition for 5 days Passage: 8	GTRD	EXP048951_MRC-5--fetal-lung-fibroblasts-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	10333
1	2558	JUNB	0.0199265316399232	0.594930063627777	24	3239	3069	1691	3239	2670	14	6357	2206	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	14999
1	1184	ESR1	0.0198397482151978	0.679909422137045	51	3240	2809	932	3240	2330	26	6330	2194	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP000882_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15997
1	2109	HLF	0.0198397482151978	0.679909422137045	51	3240	2809	932	3240	2330	26	6330	2194	HLF HepG2 (hepatoblastoma) HLF	HepG2 (hepatoblastoma)	BTO:0000599	HLF	NA	GTRD	EXP039776_HepG2--hepatoblastoma-_HLF_MACS_HLF_MA0043.3.damo.pwm.bed	35579
1	1778	FOXA1	0.0197950831762442	0.842805241651204	345	3242	2146	70	3242	1820	141	6036	2079	FOXA1 VCaP (prostate carcinoma) FOXA1	VCaP (prostate carcinoma)	BTO:0003215	FOXA1	SHPIAS1_R1881	GEO	GSE56086_foxa1_vcap-shpias1-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	150822
1	3547	RXRA	0.0196724047768957	0.663275558387475	44	3243	2840	1072	3243	2380	23	6337	2197	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	47674
1	1543	FOS	0.0194879568056277	0.818542319931458	242	3244	2234	138	3244	1870	102	6139	2118	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	43869
1	353	CEBPB	0.0192923713638802	0.800184964395521	190	3245	2300	203	3245	1920	82	6191	2138	CEBPB MCF7 (Invasive ductal breast carcinoma) CEBPB	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	CEBPB		ENCODE	ENCSR000BSR_MCF-7_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	57975
1	1666	FOXA1	0.0192409813423216	0.601456013989662	26	3246	3041	1602	3246	2630	15	6355	2205	FOXA1 HUES64 (embryonic stem cells) FOXA1	HUES64 (embryonic stem cells)	NULL	FOXA1		GTRD	EXP036704_HUES64--embryonic-stem-cells-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	28531
1	2038	GATA6	0.0192409813423216	0.601456013989662	26	3246	3041	1602	3246	2630	15	6355	2205	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout;	GTRD	EXP057932_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	73409
1	2328	JUN	0.0192409813423216	0.601456013989662	26	3246	3041	1602	3246	2630	15	6355	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040248_A549--lung-carcinoma-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	17962
1	3661	SPI1	0.0192409813423216	0.601456013989662	26	3246	3041	1602	3246	2630	15	6355	2205	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: untreated, IAV NS1(EP mRNA)	GTRD	EXP047819_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	51023
1	3814	TCF7L2	0.0192409813423216	0.601456013989662	26	3246	3041	1602	3246	2630	15	6355	2205	TCF7L2 PANC1 (pancreatic ductal adenocarcinoma) TCF7L2	PANC1 (pancreatic ductal adenocarcinoma)	NULL	TCF7L2		ENCODE	ENCSR000EXL_Panc1_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	18010
1	2376	JUN	0.0191759800935225	0.739446859235722	94	3251	2501	482	3251	2080	44	6287	2176	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	19436
1	65	AR	0.0188123498837496	0.680307954250718	53	3252	2808	905	3252	2320	27	6328	2193	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR		GTRD	EXP038432_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	11892
1	229	ASCL1	0.0186860778145384	0.664438828424308	46	3253	2837	1028	3253	2370	24	6335	2196	ASCL1 fibroblasts ASCL1	fibroblasts	NULL	ASCL1		GTRD	EXP030567_fibroblasts_ASCL1_MACS_ASCL1_MA1100.2.damo.pwm.bed	40741
1	1478	ETV1	0.0186860778145384	0.664438828424308	46	3253	2837	1028	3253	2370	24	6335	2196	ETV1 LNCaP (prostate carcinoma) ETV1	LNCaP (prostate carcinoma)	BTO:0001321	ETV1		GEO	GSE47120_etv1_lncap_MACS_ETV1_MA0761.2.damo.pwm.bed	20714
1	3309	RARA	0.0186860778145384	0.664438828424308	46	3253	2837	1028	3253	2370	24	6335	2196	RARA HepG2 (hepatoblastoma) RARA	HepG2 (hepatoblastoma)	BTO:0000599	RARA		GTRD	EXP039479_HepG2--hepatoblastoma-_RARA_MACS_RARA_MA0729.1.damo.pwm.bed	50529
1	137	AR	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXA1_R1881_HD	GEO	GSE37345_AR_lncap-shfoxa1-r1881-hd_MACS_AR_MA0007.3.damo.pwm.bed	603
1	248	ATF3	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	ATF3 HCT-116 (colon carcinoma) ATF3	HCT-116 (colon carcinoma)	BTO:0001109	ATF3		ENCODE	ENCSR000BUG_HCT116_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	2398
1	702	CTCF	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	CTCF neutrophils CTCF	neutrophils	NULL	CTCF		GTRD	EXP039544_neutrophils_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21336
1	1096	ELF4	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	ELF4 K562 (myelogenous leukemia) ELF4	K562 (myelogenous leukemia)	NULL	ELF4	NA	GTRD	EXP040067_K562--myelogenous-leukemia-_ELF4_MACS_ELF4_MA0641.1.damo.pwm.bed	9858
1	1114	EOMES	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	EOMES HUES64 (embryonic stem cells) EOMES	HUES64 (embryonic stem cells)	NULL	EOMES	NA	GTRD	EXP036786_HUES64--embryonic-stem-cells-_EOMES_MACS_EOMES_MA0800.1.damo.pwm.bed	12216
1	1181	ESR1	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP000232_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	1167
1	1893	GATA1	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1		ENCODE	ENCSR000EWM_K562_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	7904
1	2133	HNF4A	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036796_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA1494.1.damo.pwm.bed	18146
1	2629	KLF12	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	KLF12 HEK293 (embryonic kidney) KLF12	HEK293 (embryonic kidney)	NULL	KLF12	NA	GTRD	EXP035943_HEK293--embryonic-kidney-_KLF12_MACS_KLF12_MA0742.1.damo.pwm.bed	8890
1	2664	MAF	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047553_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	3330
1	2670	MAF	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	MAF Th17-cells MAF	Th17-cells	BTO:0005655	MAF	CellType:pool of expanded Th17 clones; Tissue: primary Th17-IL-10+ lymphocytes; ActivationState: recently activeted;Day:5;	GTRD	EXP047561_Th17-cells_MAF_MACS_MAF_MA1520.1.damo.pwm.bed	6360
1	2714	MAX	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	MAX COLO-829 (melanoma) MAX	COLO-829 (melanoma)	NULL	MAX	Treatment: none	GTRD	EXP053272_COLO-829--melanoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	7194
1	2792	MYC	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	MYC WA01 (H1, human embryonic stem cells) MYC	WA01 (H1, human embryonic stem cells)	NULL	MYC		ENCODE	ENCSR000EBY_H1-hESC_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	6029
1	2825	MYC	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	HA-OmoMYCwt, Doxycycline	GTRD	EXP036030_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	15401
1	2942	MYCN	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	MYCN NB-1643 (neuroblastoma) MYCN	NB-1643 (neuroblastoma)	BTO:0002833	MYCN		GTRD	EXP038399_NB-1643--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	10728
1	3127	NR3C1	0.0186259712552888	0.347652222020422	3	3256	3637	3252	3637	3380	3	6378	2217	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: untreated;	GTRD	EXP047625_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	539
1	1633	FOXA1	0.0185567803760046	0.76772949385504	131	3272	2409	328	3272	2000	59	6250	2161	FOXA1 HepG2 (hepatoblastoma) FOXA1	HepG2 (hepatoblastoma)	BTO:0000599	FOXA1		ENCODE	ENCSR000BMO_HepG2_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	73152
1	1932	GATA2	0.0185336882974595	0.607154125020403	28	3273	3026	1531	3273	2610	16	6353	2204	GATA2 SH-SY5Y (neuroblastoma) GATA2	SH-SY5Y (neuroblastoma)	BTO:0000793	GATA2		ENCODE	ENCSR000EYB_SH-SY5Y_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	44579
1	2110	HMBOX1	0.0185336882974595	0.607154125020403	28	3273	3026	1531	3273	2610	16	6353	2204	HMBOX1 K562 (myelogenous leukemia) HMBOX1	K562 (myelogenous leukemia)	NULL	HMBOX1	NA	ENCODE	ENCSR757IIU_K562_HMBOX1_MACS_HMBOX1_MA0895.1.damo.pwm.bed	35650
1	2363	JUN	0.0185336882974595	0.607154125020403	28	3273	3026	1531	3273	2610	16	6353	2204	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: ethanol 1hr;	GTRD	EXP047659_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	7029
1	2877	MYC	0.0185336882974595	0.607154125020403	28	3273	3026	1531	3273	2610	16	6353	2204	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shSCR;	GTRD	EXP047484_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	18052
1	4	AR	0.0183457335616798	0.703273695937035	67	3277	2589	710	3277	2190	33	6314	2187	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR		Array Express	ERP003503_AR_lncap_MACS_AR_MA0007.3.damo.pwm.bed	27405
1	86	AR	0.0181748288461958	0.738293677135494	96	3278	2509	475	3278	2090	45	6285	2175	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: 10 nM DHT for 4 hrs	GTRD	EXP049276_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	32515
1	2432	JUN	0.0181738385958555	0.643974822405843	39	3279	2892	1206	3279	2460	21	6342	2199	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	22637
1	2433	JUN	0.0181738385958555	0.643974822405843	39	3279	2892	1206	3279	2460	21	6342	2199	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	22379
1	14	AR	0.0178177095378364	0.612170476520768	30	3281	2986	1473	3281	2580	17	6351	2203	AR VCaP (prostate carcinoma) AR	VCaP (prostate carcinoma)	BTO:0003215	AR	R1881	GTRD	EXP000733_VCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12309
1	2171	HOXB13	0.0176890341009993	0.726095112879098	86	3282	2544	534	3282	2120	41	6295	2179	HOXB13 LNCaP95 HOXB13	LNCaP95	NULL	HOXB13	Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection	GTRD	EXP052945_LNCaP95_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	60434
1	708	CTCF	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	CTCF ascending aorta CTCF	ascending aorta	NULL	CTCF		GTRD	EXP039576_ascending-aorta_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	17823
1	771	CTCF	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	CTCF ovary CTCF	ovary	BTO:0000975	CTCF		GTRD	EXP040068_ovary_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	16715
1	1898	GATA1	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	NULL	GTRD	EXP000523_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	13610
1	2980	NEUROG2	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037153_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA0669.1.damo.pwm.bed	22655
1	2981	NEUROG2	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	NEUROG2 MRC-5 (fetal lung fibroblasts) NEUROG2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	NEUROG2	0.5 DPT	GTRD	EXP037153_MRC-5--fetal-lung-fibroblasts-_NEUROG2_MACS_NEUROG2_MA1642.1.damo.pwm.bed	21685
1	3229	PDX1	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	PDX1 CyT49-derived endodermal cells PDX1	CyT49-derived endodermal cells	NULL	PDX1	none	GTRD	EXP033205_CyT49-derived-endodermal-cells_PDX1_MACS_PDX1_MA0132.2.damo.pwm.bed	9155
1	3445	RFX5	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	RFX5 HepG2 (hepatoblastoma) RFX5	HepG2 (hepatoblastoma)	BTO:0000599	RFX5	NA	ENCODE	ENCSR000EEA_HepG2_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	9504
1	3807	TCF7L1	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	TCF7L1 HCT-116 (colon carcinoma) TCF7L1	HCT-116 (colon carcinoma)	BTO:0001109	TCF7L1	NA	GTRD	EXP036153_HCT-116--colon-carcinoma-_TCF7L1_MACS_TCF7L1_MA1421.1.damo.pwm.bed	3794
1	3832	TEAD4	0.0176035942821288	0.416988685410714	6	3283	3506	2870	3506	3220	5	6375	2215	TEAD4 HepG2 (hepatoblastoma) TEAD4	HepG2 (hepatoblastoma)	BTO:0000599	TEAD4		ENCODE	ENCSR000BRP_HepG2_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	8413
1	1736	FOXA1	0.0175084701461717	0.772277357302522	143	3292	2400	304	3292	2000	64	6238	2156	FOXA1 LNCaP95 FOXA1	LNCaP95	NULL	FOXA1	Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection	GTRD	EXP052942_LNCaP95_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	26148
1	2378	JUN	0.0173559278040328	0.719040783599129	81	3293	2560	579	3293	2140	39	6300	2181	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16135
1	2517	JUNB	0.0173163574252019	0.646136071018496	41	3294	2883	1155	3294	2440	22	6340	2198	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	21050
1	2519	JUNB	0.0173163574252019	0.646136071018496	41	3294	2883	1155	3294	2440	22	6340	2198	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	21060
1	3160	NR3C1	0.0173163574252019	0.646136071018496	41	3294	2883	1155	3294	2440	22	6340	2198	NR3C1 MCF7 (Invasive ductal breast carcinoma) NR3C1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR3C1	DEX	GEO	GSE72249_nr3c1_mcf7-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	7546
1	2709	MAX	0.0168597489251006	0.666474407835544	50	3297	2832	945	3297	2360	26	6331	2194	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048813_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	57096
1	2710	MAX	0.0168597489251006	0.666474407835544	50	3297	2832	945	3297	2360	26	6331	2194	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048813_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	53512
1	360	CEBPB	0.016494380697903	0.648100919376869	43	3299	2875	1101	3299	2420	23	6338	2197	CEBPB HepG2 (hepatoblastoma) CEBPB	HepG2 (hepatoblastoma)	BTO:0000599	CEBPB	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEX_HepG2_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	29037
1	3548	RXRA	0.016494380697903	0.648100919376869	43	3299	2875	1101	3299	2420	23	6338	2197	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	48270
1	1613	FOSL2	0.0163354660670953	0.536507477093662	17	3301	3241	2066	3301	2870	11	6364	2209	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039862_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	15665
1	2327	JUN	0.0163354660670953	0.536507477093662	17	3301	3241	2066	3301	2870	11	6364	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	14051
1	2510	JUNB	0.0163354660670953	0.536507477093662	17	3301	3241	2066	3301	2870	11	6364	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	12655
1	2512	JUNB	0.0163354660670953	0.536507477093662	17	3301	3241	2066	3301	2870	11	6364	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	12656
1	1149	ERG	0.0162893691322486	0.520810539744792	15	3305	3321	2200	3321	2940	10	6366	2210	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	DHT	GEO	GSE79128_erg_vcap-dht_MACS_ERG_MA0474.2.damo.pwm.bed	15614
1	2325	JUN	0.0162893691322486	0.520810539744792	15	3305	3321	2200	3321	2940	10	6366	2210	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039981_A549--lung-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	14062
1	1594	FOSL2	0.0162098689509513	0.549571639019093	19	3307	3216	1956	3307	2830	12	6362	2208	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	13418
1	1595	FOSL2	0.0162098689509513	0.549571639019093	19	3307	3216	1956	3307	2830	12	6362	2208	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	13481
1	2313	JUN	0.0162098689509513	0.549571639019093	19	3307	3216	1956	3307	2830	12	6362	2208	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039496_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	13233
1	2509	JUNB	0.0162098689509513	0.549571639019093	19	3307	3216	1956	3307	2830	12	6362	2208	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	12847
1	2169	HOXB13	0.0160540385310465	0.681304992959413	59	3311	2806	805	3311	2310	30	6322	2190	HOXB13 LNCaP95 HOXB13	LNCaP95	NULL	HOXB13	Treatment: 10 nM ETOH for 4 hrs Genotype: shGFP transfection	GTRD	EXP052943_LNCaP95_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	16713
1	3121	NR3C1	0.0160540385310465	0.681304992959413	59	3311	2806	805	3311	2310	30	6322	2190	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040273_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	28099
1	926	CTCF	0.0160064634988447	0.501541776033011	13	3313	3349	2306	3349	2990	9	6368	2211	CTCF SK-N-SH (neuroblastoma) CTCF	SK-N-SH (neuroblastoma)	BTO:0001620	CTCF		GTRD	EXP058186_SK-N-SH--neuroblastoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	34746
1	2616	JUND	0.0160064634988447	0.501541776033011	13	3313	3349	2306	3349	2990	9	6368	2211	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP040078_liver_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	11969
1	2828	MYC	0.0160064634988447	0.501541776033011	13	3313	3349	2306	3349	2990	9	6368	2211	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	empty vector, Doxycycline	GTRD	EXP036032_U2OS--osteosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	17641
1	3151	NR3C1	0.0160064634988447	0.501541776033011	13	3313	3349	2306	3349	2990	9	6368	2211	NR3C1 HeLa-B2 NR3C1	HeLa-B2	NA	NR3C1	TA	GEO	GSE24518_nr3c1_helab2-ta_MACS_NR3C1_MA0113.3.damo.pwm.bed	7135
1	3877	TFAP2C	0.0160064634988447	0.501541776033011	13	3313	3349	2306	3349	2990	9	6368	2211	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040713_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	20838
1	2345	JUN	0.0159601410418844	0.560610776414766	21	3318	3182	1852	3318	2780	13	6360	2207	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040320_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	20429
1	1542	FOS	0.0157927697076048	0.807030038238758	234	3319	2285	150	3319	1920	100	6147	2120	FOS MCF7 (Invasive ductal breast carcinoma) FOS	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	FOS		GTRD	EXP040137_MCF7--Invasive-ductal-breast-carcinoma-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	42631
1	2430	JUN	0.0157076287134373	0.649893909927065	45	3320	2874	1054	3320	2420	24	6336	2196	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	33939
1	2353	JUN	0.015700843050559	0.624151528928122	36	3321	2965	1288	3321	2520	20	6345	2200	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040322_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	23068
1	2544	JUNB	0.0156213695307532	0.570058931541808	23	3322	3155	1739	3322	2740	14	6358	2206	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	13125
1	2547	JUNB	0.0156213695307532	0.570058931541808	23	3322	3155	1739	3322	2740	14	6358	2206	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	13173
1	3662	SPI1	0.0156213695307532	0.570058931541808	23	3322	3155	1739	3322	2740	14	6358	2206	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: Pam3csk4 treated 4hr, IAV NS1(EP mRNA)	GTRD	EXP047820_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	49055
1	356	CEBPB	0.0154743725190308	0.779389098643036	167	3325	2385	238	3325	1980	74	6214	2146	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB		ENCODE	ENCSR000DYI_A549_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	90011
1	70	AR	0.0153967543237685	0.477505990473676	11	3326	3389	2426	3389	3050	8	6370	2212	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation, ethanol, shTRIM24 Genotype: wildtype Source: prostate cancer cells	GTRD	EXP048075_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2798
1	114	AR	0.0153967543237685	0.477505990473676	11	3326	3389	2426	3389	3050	8	6370	2212	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  transfected twice with with 5nM of siControl every 24 hours, 100nM of ETOH for 2 hrs, 100nM of ETOH for 2 hrs	GTRD	EXP052983_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	2651
1	661	CTCF	0.0153967543237685	0.477505990473676	11	3326	3389	2426	3389	3050	8	6370	2212	CTCF retinoblastoma xenograft CTCF	retinoblastoma xenograft	NULL	CTCF		GTRD	EXP037803_retinoblastoma-xenograft_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27428
1	1148	ERG	0.0153967543237685	0.477505990473676	11	3326	3389	2426	3389	3050	8	6370	2212	ERG TSU-1621-MT (adult acute myeloid leukemia) ERG	TSU-1621-MT (adult acute myeloid leukemia)	NULL	ERG		GEO	GSE60477_erg_tsu1621mt_MACS_ERG_MA0474.2.damo.pwm.bed	31788
1	1874	GABPA	0.0153967543237685	0.477505990473676	11	3326	3389	2426	3389	3050	8	6370	2212	GABPA MCF7 (Invasive ductal breast carcinoma) GABPA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GABPA		ENCODE	ENCSR000BUK_MCF-7_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	13111
1	3350	RELA	0.0153967543237685	0.477505990473676	11	3326	3389	2426	3389	3050	8	6370	2212	RELA BEAS-2B (bronchial epithelium) RELA	BEAS-2B (bronchial epithelium)	NULL	RELA	dexamethasone + TNF	GTRD	EXP036259_BEAS-2B--bronchial-epithelium-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	5097
1	2153	HNF4G	0.0152322866667748	0.681581808488038	61	3332	2805	785	3332	2310	31	6320	2189	HNF4G 22RV1 (prostate carcinoma) HNF4G	22RV1 (prostate carcinoma)	BTO:0002999	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048996_22RV1--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	15937
1	2375	JUN	0.015227534752703	0.710052237737797	80	3333	2580	585	3333	2170	39	6301	2181	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	15997
1	2557	JUNB	0.0152196721928697	0.578235580154515	25	3334	3147	1657	3334	2710	15	6356	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	15433
1	2559	JUNB	0.0152196721928697	0.578235580154515	25	3334	3147	1657	3334	2710	15	6356	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	15648
1	2561	JUNB	0.0152196721928697	0.578235580154515	25	3334	3147	1657	3334	2710	15	6356	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	15645
1	3167	NR5A2	0.0152196721928697	0.578235580154515	25	3334	3147	1657	3334	2710	15	6356	2205	NR5A2 MCF7 (Invasive ductal breast carcinoma) NR5A2	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NR5A2	NA	GTRD	EXP032283_MCF7--Invasive-ductal-breast-carcinoma-_NR5A2_MACS_NR5A2_MA0505.1.damo.pwm.bed	13855
1	2379	JUN	0.0150635690514719	0.723485910809716	92	3338	2550	498	3338	2130	44	6289	2176	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN	Source: cJun - Tet cells; CellType: ERalpha-positive breast cancer cells; Treatment: tamoxifen 1μM for 1hr;	GTRD	EXP047661_MCF7--Invasive-ductal-breast-carcinoma-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	18364
1	3681	SPI1	0.01503936819364	0.74807439666676	119	3339	2477	373	3339	2060	55	6262	2165	SPI1 macrophages SPI1	macrophages	NULL	SPI1	IL4	GEO	GSE66594_spi1_macrophages-il4_MACS_SPI1_MA0080.5.damo.pwm.bed	169689
1	1080	ELF1	0.0150228647450743	0.6273660104453	38	3340	2943	1238	3340	2510	21	6343	2199	ELF1 MCF7 (Invasive ductal breast carcinoma) ELF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELF1		ENCODE	ENCSR000BSS_MCF-7_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	23176
1	3549	RXRA	0.0150228647450743	0.6273660104453	38	3340	2943	1238	3340	2510	21	6343	2199	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA1148.1.damo.pwm.bed	44058
1	1200	ESR1	0.0147746395022712	0.585381227320967	27	3342	3090	1564	3342	2670	16	6354	2204	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	cells transfected with siNCAPG, and 1hr with 100nM E2, double crosslinked	GTRD	EXP034120_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	11536
1	2485	JUNB	0.0147746395022712	0.585381227320967	27	3342	3090	1564	3342	2670	16	6354	2204	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	30781
1	2516	JUNB	0.0143638757757945	0.630279423038941	40	3344	2941	1189	3344	2490	22	6341	2198	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	20398
1	624	CTCF	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	CTCF BEAS-2B (bronchial epithelium) CTCF	BEAS-2B (bronchial epithelium)	NULL	CTCF	NiCl2	GTRD	EXP033454_BEAS-2B--bronchial-epithelium-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	24175
1	701	CTCF	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	CTCF testis CTCF	testis	BTO:0001363	CTCF		GTRD	EXP039536_testis_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	28264
1	737	CTCF	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039772_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27869
1	1914	GATA1	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	adult bone marrow	GTRD	EXP031448_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	19672
1	1915	GATA1	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	GATA1 CD34+ hematopoietic stem cells-derived proerythroblasts GATA1	CD34+ hematopoietic stem cells-derived proerythroblasts	NULL	GATA1	adult bone marrow	GTRD	EXP031448_CD34--hematopoietic-stem-cells-derived-proerythroblasts_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	19906
1	2011	GATA4	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036790_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	32341
1	3240	PLAG1	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	PLAG1 K562 (myelogenous leukemia) PLAG1	K562 (myelogenous leukemia)	NULL	PLAG1	Treatment: no	GTRD	EXP048311_K562--myelogenous-leukemia-_PLAG1_MACS_PLAG1_MA0163.1.damo.pwm.bed	26684
1	4086	USF2	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	USF2 R3/R4 erythroid cells USF2	R3/R4 erythroid cells	NULL	USF2		GTRD	EXP035048_R3-R4-erythroid-cells_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	27017
1	4119	YY1	0.0143351050211103	0.446571850503512	9	3345	3448	2585	3448	3130	7	6372	2213	YY1 K562 (myelogenous leukemia) YY1	K562 (myelogenous leukemia)	NULL	YY1		ENCODE	ENCSR000BKU_K562_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	24540
1	2426	JUN	0.0140861830964519	0.835309781257739	374	3354	2161	55	3354	1860	154	6007	2066	JUN MCF10A-ER-Src JUN	MCF10A-ER-Src	NULL	JUN	Genotype: transformed	GTRD	EXP048572_MCF10A-ER-Src_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	65195
1	2025	GATA4	0.0140346954392112	0.701398977749861	77	3355	2590	609	3355	2180	38	6304	2182	GATA4 AGS (gastric adenocarcinoma) GATA4	AGS (gastric adenocarcinoma)	BTO:0001007	GATA4		GEO	GSE51705_gata4_ags_MACS_GATA4_MA0482.2.damo.pwm.bed	59640
1	179	AR	0.0138101250695118	0.597257958683711	31	3356	3053	1439	3356	2620	18	6350	2202	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881_HOTAIR	GEO	GSE61268_AR_lncap-r1881-hotair_MACS_AR_MA0007.3.damo.pwm.bed	9734
1	854	CTCF	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	CTCF HeLa S3 (cervical adenocarcinoma) CTCF	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	CTCF	treatment: no block with TSA CellPopulation:synchronized	GTRD	EXP048089_HeLa-S3--cervical-adenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	14324
1	1086	ELF1	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	ELF1 COLO-320 (colon adenocarcinoma) ELF1	COLO-320 (colon adenocarcinoma)	BTO:0002047	ELF1		GTRD	EXP037555_COLO-320--colon-adenocarcinoma-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	15775
1	1507	FLI1	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	FLI1 UAE FLI1	UAE	NA	FLI1	ZINC	GEO	GSE23730_fli1_uae-zinc_MACS_FLI1_MA0475.2.damo.pwm.bed	18411
1	2721	MAX	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	MAX P493-6 (B-cell lymphoma) MAX	P493-6 (B-cell lymphoma)	BTO:0003291	MAX		GEO	GSE42262_max_p4936_MACS_MAX_MA0058.3.damo.pwm.bed	17698
1	2796	MYC	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	MYC K562 (myelogenous leukemia) MYC	K562 (myelogenous leukemia)	NULL	MYC		ENCODE	ENCSR000FAG_K562_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	13576
1	2809	MYC	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	MYC HepG2 (hepatoblastoma) MYC	HepG2 (hepatoblastoma)	BTO:0000599	MYC	NULL	GTRD	EXP000993_HepG2--hepatoblastoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10732
1	2810	MYC	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	MYC HepG2 (hepatoblastoma) MYC	HepG2 (hepatoblastoma)	BTO:0000599	MYC	NULL	GTRD	EXP000993_HepG2--hepatoblastoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11330
1	3300	PRDM1	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	PRDM1 HEK293 (embryonic kidney) PRDM1	HEK293 (embryonic kidney)	NULL	PRDM1		GTRD	EXP035871_HEK293--embryonic-kidney-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	14703
1	3308	RARA	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	RARA UPR9 (hematopoietic stem cells) RARA	UPR9 (hematopoietic stem cells)	NULL	RARA	5 hours zinc	GTRD	EXP000748_UPR9--hematopoietic-stem-cells-_RARA_MACS_RARA_MA0159.1.damo.pwm.bed	17224
1	3460	RUNX1	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	RUNX1 CD34+ hematopoietic stem cells RUNX1	CD34+ hematopoietic stem cells	NULL	RUNX1		GTRD	EXP031976_CD34--hematopoietic-stem-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	25141
1	3898	TFAP2C	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047540_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	12691
1	3899	TFAP2C	0.0137480847757785	0.347549917835678	4	3357	3653	3105	3653	3370	4	6377	2216	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047540_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	13121
1	307	CEBPA	0.0137314874423977	0.669653115000272	58	3369	2827	824	3369	2340	30	6323	2190	CEBPA liver CEBPA	liver	BTO:0000759	CEBPA		Array Express	ERP002306_cebpa_liver_MACS_CEBPA_MA0102.4.damo.pwm.bed	29334
1	3831	TEAD3	0.0137255825263842	0.632931028794916	42	3370	2927	1124	3370	2470	23	6339	2197	TEAD3 HepG2 (hepatoblastoma) TEAD3	HepG2 (hepatoblastoma)	BTO:0000599	TEAD3	NA	GTRD	EXP040048_HepG2--hepatoblastoma-_TEAD3_MACS_TEAD3_MA0808.1.damo.pwm.bed	59658
1	372	CEBPB	0.0133103630065047	0.602243499548255	33	3371	3037	1379	3371	2600	19	6348	2201	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039499_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	18104
1	1092	ELF3	0.0133103630065047	0.602243499548255	33	3371	3037	1379	3371	2600	19	6348	2201	ELF3 HepG2 (hepatoblastoma) ELF3	HepG2 (hepatoblastoma)	BTO:0000599	ELF3		GTRD	EXP040160_HepG2--hepatoblastoma-_ELF3_MACS_ELF3_MA0640.2.damo.pwm.bed	37428
1	3098	NR3C1	0.0133103630065047	0.602243499548255	33	3371	3037	1379	3371	2600	19	6348	2201	NR3C1 embryonic kidney NR3C1	embryonic kidney	NULL	NR3C1	dexamethasone, stably expressing SUMOylation-defective GR	GTRD	EXP032211_embryonic-kidney_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	31363
1	3545	RXRA	0.0133103630065047	0.602243499548255	33	3371	3037	1379	3371	2600	19	6348	2201	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	40103
1	189	AR	0.0131090705316797	0.635353546069505	44	3375	2925	1072	3375	2460	24	6337	2196	AR prostate AR	prostate	NULL	AR		GEO	GSE65478_AR_prostate_MACS_AR_MA0007.3.damo.pwm.bed	12596
1	2623	JUND	0.0131090705316797	0.635353546069505	44	3375	2925	1072	3375	2460	24	6337	2196	JUND HT29 (colon adenocarcinoma) JUND	HT29 (colon adenocarcinoma)	BTO:0000182	JUND	DSMO	GEO	GSE77039_jund_ht29-dsmo_MACS_JUND_MA0491.2.damo.pwm.bed	11616
1	2168	HOXB13	0.0130562520872757	0.726937386775231	103	3377	2539	434	3377	2120	49	6278	2171	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  R1881 for 4 hours	GTRD	EXP049581_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	38138
1	230	ASCL1	0.0128979880020953	0.65571543001474	53	3378	2862	905	3378	2380	28	6328	2192	ASCL1 fibroblasts ASCL1	fibroblasts	NULL	ASCL1		GTRD	EXP030567_fibroblasts_ASCL1_MACS_ASCL1_MA1631.1.damo.pwm.bed	40642
1	355	CEBPB	0.0128704487620464	0.692278962563853	74	3379	2801	640	3379	2270	37	6307	2183	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB		ENCODE	ENCSR000BUB_A549_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	41194
1	4075	USF1	0.0126485894239276	0.405288817948973	7	3380	3527	2768	3527	3220	6	6374	2214	USF1 A549 (lung carcinoma) USF1	A549 (lung carcinoma)	BTO:0000018	USF1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPV_A549_USF1_MACS_USF1_MA0093.3.damo.pwm.bed	13288
1	117	AR	0.0125516496112827	0.731355971489349	110	3381	2521	404	3381	2100	52	6271	2168	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment:  2 mM DSG for 25 mins	GTRD	EXP053225_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	37153
1	1165	ESR1	0.0121704356484046	0.520523727581012	18	3382	3323	1996	3382	2900	12	6363	2208	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TAM	Array Express	ERP000380_esr1_mcf7-tam_MACS_ESR1_MA0112.3.damo.pwm.bed	5899
1	2338	JUN	0.0121704356484046	0.520523727581012	18	3382	3323	1996	3382	2900	12	6363	2208	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	13271
1	2508	JUNB	0.0121704356484046	0.520523727581012	18	3382	3323	1996	3382	2900	12	6363	2208	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12976
1	2546	JUNB	0.01216037472014	0.5338498872146	20	3385	3246	1901	3385	2840	13	6361	2207	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	12561
1	3131	NR3C1	0.01216037472014	0.5338498872146	20	3385	3246	1901	3385	2840	13	6361	2207	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 60 min;	GTRD	EXP047629_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4478
1	2310	JUN	0.0120497464844561	0.545205775221355	22	3387	3226	1797	3387	2800	14	6359	2206	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	17069
1	2555	JUNB	0.0120497464844561	0.545205775221355	22	3387	3226	1797	3387	2800	14	6359	2206	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	11986
1	2556	JUNB	0.0120497464844561	0.545205775221355	22	3387	3226	1797	3387	2800	14	6359	2206	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	14860
1	2560	JUNB	0.0120497464844561	0.545205775221355	22	3387	3226	1797	3387	2800	14	6359	2206	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040135_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	14979
1	3153	NR3C1	0.0120497464844561	0.545205775221355	22	3387	3226	1797	3387	2800	14	6359	2206	NR3C1 LNCaP (prostate carcinoma) NR3C1	LNCaP (prostate carcinoma)	BTO:0001321	NR3C1	1F5	GEO	GSE30623_nr3c1_lncap-1f5_MACS_NR3C1_MA0113.3.damo.pwm.bed	8269
1	1563	FOSL1	0.0120473579734074	0.504828423038065	16	3392	3345	2127	3392	2950	11	6365	2209	FOSL1 K562 (myelogenous leukemia) FOSL1	K562 (myelogenous leukemia)	NULL	FOSL1	NA	ENCODE	ENCSR000BMV_K562_FOSL1_MACS_FOSL1_MA0477.2.damo.pwm.bed	14564
1	2513	JUNB	0.0120473579734074	0.504828423038065	16	3392	3345	2127	3392	2950	11	6365	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	12390
1	2309	JUN	0.0118635980699799	0.55503439564855	24	3394	3204	1691	3394	2760	15	6357	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	18784
1	2337	JUN	0.0118635980699799	0.55503439564855	24	3394	3204	1691	3394	2760	15	6357	2205	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	16827
1	3149	NR3C1	0.0118635980699799	0.55503439564855	24	3394	3204	1691	3394	2760	15	6357	2205	NR3C1 HeLa-B2 NR3C1	HeLa-B2	NA	NR3C1	P65KD_TA_TNFA	GEO	GSE24518_nr3c1_helab2-p65kd-ta-tnfa_MACS_NR3C1_MA0113.3.damo.pwm.bed	14867
1	3658	SPI1	0.0118153677648101	0.614427729956528	39	3397	2981	1206	3397	2530	22	6342	2198	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: IFNb treated 6hr	GTRD	EXP047759_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	67635
1	2341	JUN	0.0117486452677336	0.48597350501543	14	3398	3379	2252	3398	3010	10	6367	2210	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	17089
1	1766	FOXA1	0.0116811985276193	0.65800490081443	57	3399	2849	839	3399	2360	30	6324	2190	FOXA1 LNCaP C4-2B (prostate carcinoma) FOXA1	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	FOXA1		GEO	GSE40050_foxa1_c42b_MACS_FOXA1_MA0148.4.damo.pwm.bed	10874
1	2304	JUN	0.0116811985276193	0.65800490081443	57	3399	2849	839	3399	2360	30	6324	2190	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	control, 4h	GTRD	EXP038046_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	58529
1	2625	KLF1	0.0116212748577828	0.563622187350043	26	3401	3173	1602	3401	2730	16	6355	2204	KLF1 HEK293 (embryonic kidney) KLF1	HEK293 (embryonic kidney)	NULL	KLF1	NA	GTRD	EXP035894_HEK293--embryonic-kidney-_KLF1_MACS_KLF1_MA0493.1.damo.pwm.bed	21494
1	3115	NR3C1	0.0116212748577828	0.563622187350043	26	3401	3173	1602	3401	2730	16	6355	2204	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039790_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	11362
1	3310	RARA	0.0116212748577828	0.563622187350043	26	3401	3173	1602	3401	2730	16	6355	2204	RARA HepG2 (hepatoblastoma) RARA	HepG2 (hepatoblastoma)	BTO:0000599	RARA		GTRD	EXP039479_HepG2--hepatoblastoma-_RARA_MACS_RARA_MA0730.1.damo.pwm.bed	33293
1	3524	RXRA	0.0116212748577828	0.563622187350043	26	3401	3173	1602	3401	2730	16	6355	2204	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP040231_liver_RXRA_MACS_RXRA_MA0494.1.damo.pwm.bed	39747
1	3659	SPI1	0.0116212748577828	0.563622187350043	26	3401	3173	1602	3401	2730	16	6355	2204	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: untreated, eGFP(EP mRNA)	GTRD	EXP047817_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	55900
1	2481	JUNB	0.0113377843604461	0.571188166862838	28	3406	3154	1531	3406	2700	17	6353	2203	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	31510
1	1838	FOXA2	0.0113311040978959	0.617765882278304	41	3407	2971	1155	3407	2510	23	6340	2197	FOXA2 BJ (fibroblasts) FOXA2	BJ (fibroblasts)	NULL	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL Genotype: FOXA2 unind	GTRD	EXP049302_BJ--fibroblasts-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	18617
1	2434	JUN	0.0113311040978959	0.617765882278304	41	3407	2971	1155	3407	2510	23	6340	2197	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	34315
1	2514	JUNB	0.0113311040978959	0.617765882278304	41	3407	2971	1155	3407	2510	23	6340	2197	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	21064
1	3650	SPI1	0.0112188433164662	0.462905202821727	12	3410	3435	2359	3435	3070	9	6369	2211	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	untreated	GTRD	EXP036835_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	46419
1	1140	ERG	0.011115761265224	0.65902936581716	59	3411	2847	805	3411	2350	31	6322	2189	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	DHAT_18H	GEO	GSE28950_erg_vcap-dhat-18h_MACS_ERG_MA0474.2.damo.pwm.bed	30241
1	2043	GATA6	0.0110248145804921	0.577903515004777	30	3412	3151	1473	3412	2680	18	6351	2202	GATA6 YCC3 (gastric adenocarcinoma) GATA6	YCC3 (gastric adenocarcinoma)	NULL	GATA6		GEO	GSE51705_gata6_ycc3_MACS_GATA6_MA1104.2.damo.pwm.bed	25884
1	2165	HOXB13	0.0105847794100427	0.68296662898295	75	3413	2804	632	3413	2280	38	6306	2182	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13	Treatment: treated with 10nM  vehicle for 4 hours	GTRD	EXP049559_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	24586
1	2515	JUNB	0.0103973602842163	0.623617630634029	45	3414	2966	1054	3414	2480	25	6336	2195	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	23241
1	188	AR	0.0103861541442969	0.434042747284741	10	3415	3485	2487	3485	3130	8	6371	2212	AR prostate AR	prostate	NULL	AR		GEO	GSE65478_AR_prostate-res_MACS_AR_MA0007.3.damo.pwm.bed	2708
1	1602	FOSL2	0.0103861541442969	0.434042747284741	10	3415	3485	2487	3485	3130	8	6371	2212	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	9041
1	1603	FOSL2	0.0103861541442969	0.434042747284741	10	3415	3485	2487	3485	3130	8	6371	2212	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	9039
1	1630	FOXA1	0.0103861541442969	0.434042747284741	10	3415	3485	2487	3485	3130	8	6371	2212	FOXA1 Ishikawa (endometrial adenocarcinoma) FOXA1	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	FOXA1	1 h with 0.02% Dimethyl sufloxide (DMSO) (Myers)	ENCODE	ENCSR000BKW_Ishikawa_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	4846
1	3129	NR3C1	0.0103861541442969	0.434042747284741	10	3415	3485	2487	3485	3130	8	6371	2212	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: dexamethasone (DEX) 20 min;	GTRD	EXP047627_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	2268
1	3632	SP1	0.0103861541442969	0.434042747284741	10	3415	3485	2487	3485	3130	8	6371	2212	SP1 HCT-116 (colon carcinoma) SP1	HCT-116 (colon carcinoma)	BTO:0001109	SP1		GTRD	EXP036144_HCT-116--colon-carcinoma-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	34539
1	192	AR	0.0101094886691512	0.347447581547759	5	3421	3665	2973	3665	3350	5	6376	2215	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHFOXA1_RPMIFBS	GEO	GSE69043_AR_lncap-shfoxa1-rpmifbs_MACS_AR_MA0007.3.damo.pwm.bed	2514
1	1461	ETS1	0.0101094886691512	0.347447581547759	5	3421	3665	2973	3665	3350	5	6376	2215	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF stimulation for 4hours	GTRD	EXP038276_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	25252
1	1852	FOXK2	0.0101094886691512	0.347447581547759	5	3421	3665	2973	3665	3350	5	6376	2215	FOXK2 K562 (myelogenous leukemia) FOXK2	K562 (myelogenous leukemia)	NULL	FOXK2	NA	ENCODE	ENCSR302AWT_K562_FOXK2_MACS_FOXK2_MA1103.2.damo.pwm.bed	17495
1	1899	GATA1	0.0101094886691512	0.347447581547759	5	3421	3665	2973	3665	3350	5	6376	2215	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	NULL	GTRD	EXP000523_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	14159
1	3293	PPARG	0.0101094886691512	0.347447581547759	5	3421	3665	2973	3665	3350	5	6376	2215	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034435_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	14391
1	3439	RFX1	0.0101094886691512	0.347447581547759	5	3421	3665	2973	3665	3350	5	6376	2215	RFX1 MCF7 (Invasive ductal breast carcinoma) RFX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RFX1	NA	GTRD	EXP039775_MCF7--Invasive-ductal-breast-carcinoma-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	10102
1	300	CDX2	0.00999086721050294	0.594163938286704	36	3427	3070	1288	3427	2600	21	6345	2199	CDX2 Wnt+Fgf-specified intestinal culture cells CDX2	Wnt+Fgf-specified intestinal culture cells	NULL	CDX2	Genotype: wildtype;	GTRD	EXP058137_Wnt-Fgf-specified-intestinal-culture-cells_CDX2_MACS_CDX2_MA0465.2.damo.pwm.bed	118721
1	2506	JUNB	0.00999086721050294	0.594163938286704	36	3427	3070	1288	3427	2600	21	6345	2199	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039540_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	18139
1	2592	JUND	0.00999086721050294	0.594163938286704	36	3427	3070	1288	3427	2600	21	6345	2199	JUND T47D (invasive ductal carcinoma) JUND	T47D (invasive ductal carcinoma)	BTO:0001248	JUND		ENCODE	ENCSR000BVO_T47D_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	6114
1	32	AR	0.00998676011497993	0.706231140773016	96	3430	2586	475	3430	2160	47	6285	2173	AR HEK293 (embryonic kidney) AR	HEK293 (embryonic kidney)	NULL	AR	10 nM R1881	GTRD	EXP032871_HEK293--embryonic-kidney-_AR_MACS_AR_MA0007.3.damo.pwm.bed	85213
1	3657	SPI1	0.00963354767290291	0.598580987276293	38	3431	3052	1238	3431	2570	22	6343	2198	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: H5N1-dNS1 IAV infected 6hr	GTRD	EXP047758_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	73591
1	1644	FOXA1	0.00961080233438188	0.673357751240906	72	3432	2822	651	3432	2300	37	6309	2183	FOXA1 liver FOXA1	liver	BTO:0000759	FOXA1		Array Express	ERP002306_foxa1_liver_MACS_FOXA1_MA0148.4.damo.pwm.bed	37943
1	1395	ESR1	0.00958912052131308	0.758178223882872	167	3433	2450	238	3433	2040	76	6214	2144	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1		GEO	GSE48930_esr1_mcf7_MACS_ESR1_MA0112.3.damo.pwm.bed	61547
1	1571	FOSL2	0.00951781291499868	0.628573520445923	49	3434	2942	967	3434	2450	27	6332	2193	FOSL2 HepG2 (hepatoblastoma) FOSL2	HepG2 (hepatoblastoma)	BTO:0000599	FOSL2		ENCODE	ENCSR000BHP_HepG2_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	19649
1	1816	FOXA2	0.00951329670360364	0.765522466807647	182	3435	2413	215	3435	2020	82	6199	2138	FOXA2 A549 (lung carcinoma) FOXA2	A549 (lung carcinoma)	BTO:0000018	FOXA2	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BRE_A549_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	69545
1	2428	JUN	0.00927645377585847	0.602605475658024	40	3436	3035	1189	3436	2550	23	6341	2197	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	26333
1	3656	SPI1	0.00927645377585847	0.602605475658024	40	3436	3035	1189	3436	2550	23	6341	2197	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: H5N1 IAV infected 6hr	GTRD	EXP047757_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	79054
1	759	CTCF	0.00916021416534285	0.396902267432381	8	3438	3528	2675	3528	3210	7	6373	2213	CTCF tibial nerve CTCF	tibial nerve	NULL	CTCF		GTRD	EXP039994_tibial-nerve_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	27462
1	2550	JUNB	0.00910191175785532	0.531840522556533	23	3439	3251	1739	3439	2810	15	6358	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12431
1	3008	NFIA	0.00910191175785532	0.531840522556533	23	3439	3251	1739	3439	2810	15	6358	2205	NFIA K562 (myelogenous leukemia) NFIA	K562 (myelogenous leukemia)	NULL	NFIA	NA	GTRD	EXP038549_K562--myelogenous-leukemia-_NFIA_MACS_NFIA_MA0670.1.damo.pwm.bed	25291
1	1241	ESR1	0.00909997239980169	0.630775492766435	51	3441	2940	932	3441	2440	28	6330	2192	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	White Medium + E2	GTRD	EXP037779_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	23102
1	2542	JUNB	0.00908342177156502	0.50703411968839	19	3442	3343	1956	3442	2910	13	6362	2207	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12494
1	2543	JUNB	0.00908342177156502	0.50703411968839	19	3442	3343	1956	3442	2910	13	6362	2207	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12505
1	1800	FOXA1	0.00906443033452546	0.721807014016545	117	3444	2551	378	3444	2120	56	6264	2164	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHGATA2_R1881	GEO	GSE69043_foxa1_lncap-shgata2-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	36554
1	1593	FOSL2	0.00893349015095973	0.491542946662365	17	3445	3366	2066	3445	2960	12	6364	2208	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039658_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	12858
1	2652	KLF9	0.00893349015095973	0.491542946662365	17	3445	3366	2066	3445	2960	12	6364	2208	KLF9 MCF7 (Invasive ductal breast carcinoma) KLF9	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	KLF9	NA	ENCODE	ENCSR125ZYC_MCF-7_KLF9_MACS_KLF9_MA1107.2.damo.pwm.bed	10799
1	3133	NR3C1	0.00893349015095973	0.491542946662365	17	3445	3366	2066	3445	2960	12	6364	2208	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 20 min;	GTRD	EXP047631_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3299
1	251	ATF3	0.0089222593311798	0.606286466279041	42	3448	3030	1124	3448	2530	24	6339	2196	ATF3 liver ATF3	liver	BTO:0000759	ATF3		ENCODE	ENCSR480LIS_liver_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	24651
1	357	CEBPB	0.00887046472051398	0.550716637693028	27	3449	3211	1564	3449	2740	17	6354	2203	CEBPB WA01 (H1, human embryonic stem cells) CEBPB	WA01 (H1, human embryonic stem cells)	NULL	CEBPB		ENCODE	ENCSR000EBV_H1-hESC_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	27375
1	1828	FOXA2	0.00887046472051398	0.550716637693028	27	3449	3211	1564	3449	2740	17	6354	2203	FOXA2 HUES64 (embryonic stem cells) FOXA2	HUES64 (embryonic stem cells)	NULL	FOXA2		GTRD	EXP036788_HUES64--embryonic-stem-cells-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	27540
1	2438	JUN	0.00887046472051398	0.550716637693028	27	3449	3211	1564	3449	2740	17	6354	2203	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	27567
1	2479	JUNB	0.00887046472051398	0.550716637693028	27	3449	3211	1564	3449	2740	17	6354	2203	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	31160
1	2483	JUNB	0.00887046472051398	0.550716637693028	27	3449	3211	1564	3449	2740	17	6354	2203	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	30987
1	260	ATF4	0.00869455633397512	0.558565288681257	29	3454	3187	1504	3454	2720	18	6352	2202	ATF4 HAP1 (chronic myelogenous leukemia) ATF4	HAP1 (chronic myelogenous leukemia)	NULL	ATF4	2 mM histidinol, 24 hours	GTRD	EXP035036_HAP1--chronic-myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	25714
1	3144	NR3C1	0.00869455633397512	0.558565288681257	29	3454	3187	1504	3454	2720	18	6352	2202	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-KLF15 transduction	GTRD	EXP049659_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	38863
1	3552	RXRB	0.00869455633397512	0.558565288681257	29	3454	3187	1504	3454	2720	18	6352	2202	RXRB HepG2 (hepatoblastoma) RXRB	HepG2 (hepatoblastoma)	BTO:0000599	RXRB	NA	GTRD	EXP039365_HepG2--hepatoblastoma-_RXRB_MACS_RXRB_MA0855.1.damo.pwm.bed	42074
1	2507	JUNB	0.00865501913625854	0.47321638599206	15	3457	3398	2200	3457	3020	11	6366	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12233
1	408	CEBPG	0.00849122599103272	0.565577462461006	31	3458	3164	1439	3458	2690	19	6350	2201	CEBPG K562 (myelogenous leukemia) CEBPG	K562 (myelogenous leukemia)	NULL	CEBPG	NA	ENCODE	ENCSR620VIC_K562_CEBPG_MACS_CEBPG_MA0838.1.damo.pwm.bed	27165
1	3311	RARA	0.00826766481775868	0.571878652849996	33	3459	3153	1379	3459	2660	20	6348	2200	RARA HepG2 (hepatoblastoma) RARA	HepG2 (hepatoblastoma)	BTO:0000599	RARA		GTRD	EXP039479_HepG2--hepatoblastoma-_RARA_MACS_RARA_MA1149.1.damo.pwm.bed	41628
1	1145	ERG	0.00821406889028501	0.451203398606473	13	3460	3446	2306	3460	3070	10	6368	2210	ERG ME-1 (acute myeloid leukemia ) ERG	ME-1 (acute myeloid leukemia )	NULL	ERG		GEO	GSE46044_erg_me1_MACS_ERG_MA0474.2.damo.pwm.bed	34772
1	3649	SPI1	0.0081895817157872	0.68354193127362	85	3461	2803	545	3461	2270	43	6296	2177	SPI1 LCL (lymphoblastoid cell line) SPI1	LCL (lymphoblastoid cell line)	NULL	SPI1		Array Express	ERP004110_spi1_lcl_MACS_SPI1_MA0080.5.damo.pwm.bed	151294
1	3583	SNAI2	0.00802964594915386	0.577570926577374	35	3462	3152	1318	3462	2640	21	6346	2199	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SHCTR	GEO	GSE55421_snai2_keratinocytes-shctr_MACS_SNAI2_MA0745.2.damo.pwm.bed	6578
1	3191	ONECUT2	0.00783095712797798	0.74588799139681	160	3463	2482	254	3463	2070	74	6221	2146	ONECUT2 LNCaP (prostate carcinoma) ONECUT2	LNCaP (prostate carcinoma)	BTO:0001321	ONECUT2	Treatment: normoxia;	GTRD	EXP057823_LNCaP--prostate-carcinoma-_ONECUT2_MACS_ONECUT2_MA0756.1.damo.pwm.bed	240258
1	2159	HOXB13	0.00778180694857471	0.582739479071189	37	3464	3093	1264	3464	2610	22	6344	2198	HOXB13 22RV1 (prostate carcinoma) HOXB13	22RV1 (prostate carcinoma)	BTO:0002999	HOXB13		GTRD	EXP038433_22RV1--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	9153
1	77	AR	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	Treatment: targeting AR exon 7 siARFL+ ethanol	GTRD	EXP048922_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	1070
1	756	CTCF	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	CTCF sigmoid colon CTCF	sigmoid colon	BTO:0000645	CTCF		GTRD	EXP039971_sigmoid-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	10219
1	1454	ETS1	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	ETS1 CD4+ CD25+ CD45RA+ T-cells ETS1	CD4+ CD25+ CD45RA+ T-cells	NULL	ETS1		GTRD	EXP032566_CD4--CD25--CD45RA--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	3129
1	1465	ETS1	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048197_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	12978
1	2132	HNF4A	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	HNF4A HUES64 (embryonic stem cells) HNF4A	HUES64 (embryonic stem cells)	NULL	HNF4A		GTRD	EXP036796_HUES64--embryonic-stem-cells-_HNF4A_MACS_HNF4A_MA0114.4.damo.pwm.bed	15473
1	2768	MXI1	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	MXI1 WA01 (H1, human embryonic stem cells) MXI1	WA01 (H1, human embryonic stem cells)	NULL	MXI1	NA	ENCODE	ENCSR000EBR_H1-hESC_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	8966
1	2858	MYC	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	MYC HT1080 (fibrosarcoma) MYC	HT1080 (fibrosarcoma)	NULL	MYC		GTRD	EXP037759_HT1080--fibrosarcoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10458
1	2859	MYC	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	MYC HT1080 (fibrosarcoma) MYC	HT1080 (fibrosarcoma)	NULL	MYC		GTRD	EXP037759_HT1080--fibrosarcoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11008
1	3214	PAX5	0.00770281689403246	0.231753176164175	2	3465	3729	3390	3729	3530	3	6379	2217	PAX5 GM12891 (male B- cells lymphoblastoid cell line) PAX5	GM12891 (male B- cells lymphoblastoid cell line)	NULL	PAX5		ENCODE	ENCSR000BJH_GM12891_PAX5_MACS_PAX5_MA0014.3.damo.pwm.bed	12929
1	3507	RUNX2	0.00757826147310135	0.638145891600436	59	3474	2905	805	3474	2390	32	6322	2188	RUNX2 LNCaP C4-2B (prostate carcinoma) RUNX2	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	RUNX2		GEO	GSE33889_runx2_c42b_MACS_RUNX2_MA0511.2.damo.pwm.bed	36921
1	156	AR	0.00757404372714513	0.728144896508537	135	3475	2535	321	3475	2110	64	6246	2156	AR PC3(bone mets prostate adenocarcinoma) AR	PC3(bone mets prostate adenocarcinoma)	NULL	AR	R1881	GEO	GSE54110_AR_pc3-r1881_MACS_AR_MA0007.3.damo.pwm.bed	60594
1	178	AR	0.00756952331677774	0.424274699000337	11	3476	3499	2426	3499	3130	9	6370	2211	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	HOTAIR	GEO	GSE61268_AR_lncap-hotair_MACS_AR_MA0007.3.damo.pwm.bed	3497
1	1601	FOSL2	0.00756952331677774	0.424274699000337	11	3476	3499	2426	3499	3130	9	6370	2211	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039732_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	9095
1	102	AR	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	AR R1-AD1 (prostate cancer) AR	R1-AD1 (prostate cancer)	NULL	AR	Treatment: 50 uM VPC14449 + 1 nM ethanol for 4 hrs	GTRD	EXP049664_R1-AD1--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	254
1	292	BHLHE40	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	BHLHE40 A549 (lung carcinoma) BHLHE40	A549 (lung carcinoma)	BTO:0000018	BHLHE40	NA	ENCODE	ENCSR000DYJ_A549_BHLHE40_MACS_BHLHE40_MA0464.2.damo.pwm.bed	2498
1	704	CTCF	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	CTCF transverse colon CTCF	transverse colon	NULL	CTCF		GTRD	EXP039548_transverse-colon_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	5586
1	719	CTCF	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	CTCF suprapubic skin CTCF	suprapubic skin	NULL	CTCF		GTRD	EXP039663_suprapubic-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	6317
1	777	CTCF	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	CTCF omental fat pad CTCF	omental fat pad	NULL	CTCF		GTRD	EXP040089_omental-fat-pad_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	4809
1	1127	ERG	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG		GTRD	EXP037057_RWPE1--prostate-epithelial-cells-_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	300
1	1143	ERG	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	ERG RWPE1 (prostate epithelial cells) ERG	RWPE1 (prostate epithelial cells)	BTO:0003709	ERG	FLAG	GEO	GSE29808_erg_rwpe1-flag_MACS_ERG_MA0474.2.damo.pwm.bed	464
1	1880	GABPA	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	GABPA liver GABPA	liver	BTO:0000759	GABPA		GTRD	EXP039904_liver_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	5654
1	1946	GATA2	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	GATA2 HUVEC-C (HUVEC, umbilical vein endothelial cells) GATA2	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	GATA2	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048219_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	7114
1	2001	GATA3	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	GATA3 NGP (neuroblastoma) GATA3	NGP (neuroblastoma)	NULL	GATA3		GEO	GSE65664_gata3_ngp_MACS_GATA3_MA0037.3.damo.pwm.bed	5086
1	2002	GATA3	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	GATA3 SH-SY5Y (neuroblastoma) GATA3	SH-SY5Y (neuroblastoma)	BTO:0000793	GATA3		GEO	GSE65664_gata3_shsy5y_MACS_GATA3_MA0037.3.damo.pwm.bed	7709
1	2079	HIF1A	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	HIF1A renal tubular cells HIF1A	renal tubular cells	NULL	HIF1A	1 mM dimethyloxalylglycine	GTRD	EXP036851_renal-tubular-cells_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	4043
1	2080	HIF1A	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	HIF1A renal tubular cells HIF1A	renal tubular cells	NULL	HIF1A	1 mM dimethyloxalylglycine	GTRD	EXP036851_renal-tubular-cells_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	3311
1	2117	HNF1B	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	HNF1B H9 HNF1B	H9	NULL	HNF1B	NA	Array Express	ERP004206_hnf1b_esc-h9_MACS_HNF1B_MA0153.2.damo.pwm.bed	2448
1	2765	MNT	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	MNT HepG2 (hepatoblastoma) MNT	HepG2 (hepatoblastoma)	BTO:0000599	MNT	NA	GTRD	EXP039947_HepG2--hepatoblastoma-_MNT_MACS_MNT_MA0825.1.damo.pwm.bed	7914
1	2846	MYC	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036777_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	7128
1	3357	RELA	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	RELA HuH7 (hepatocellular carcinoma) RELA	HuH7 (hepatocellular carcinoma)	BTO:0001950	RELA	10ng/ml IL-1alpha for 1 h	GTRD	EXP037989_HuH7--hepatocellular-carcinoma-_RELA_MACS_RELA_MA0107.1.damo.pwm.bed	2103
1	3416	REST	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	REST A549 (lung carcinoma) REST	A549 (lung carcinoma)	BTO:0000018	REST		GTRD	EXP036865_A549--lung-carcinoma-_REST_MACS_REST_MA0138.2.damo.pwm.bed	5807
1	3749	STAT5A	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	STAT5A T-cells STAT5A	T-cells	NULL	STAT5A	IL-2	GTRD	EXP000397_T-cells_STAT5A_MACS_STAT5A_MA0519.1.damo.pwm.bed	5920
1	3750	STAT5A	0.0075251982891757	0.17386698379949	1	3478	3750	3585	3750	3600	2	6380	2218	STAT5A T-cells STAT5A	T-cells	NULL	STAT5A	IL-2	GTRD	EXP000397_T-cells_STAT5A_MACS_STAT5A_MA1624.1.damo.pwm.bed	5122
1	2013	GATA4	0.00743699714251354	0.347345213141684	6	3498	3671	2870	3671	3350	6	6375	2214	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4	shGATA4	GTRD	EXP036792_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	24476
1	2870	MYC	0.00743699714251354	0.347345213141684	6	3498	3671	2870	3671	3350	6	6375	2214	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC	0.2 µg/mL Tetracycline (Myc transgene repressed) for 72h and then released in fresh medium without Tetracycline for 24h	GTRD	EXP038952_P493-6--B-cell-lymphoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	21637
1	3709	SRF	0.00743699714251354	0.347345213141684	6	3498	3671	2870	3671	3350	6	6375	2214	SRF HCT-116 (colon carcinoma) SRF	HCT-116 (colon carcinoma)	BTO:0001109	SRF		ENCODE	ENCSR000BSC_HCT116_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	4979
1	2427	JUN	0.007270832014928	0.591760087464898	41	3501	3078	1155	3501	2580	24	6340	2196	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057912_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	31142
1	3543	RXRA	0.007270832014928	0.591760087464898	41	3501	3078	1155	3501	2580	24	6340	2196	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0074.1.damo.pwm.bed	48022
1	376	CEBPB	0.00701307793497228	0.595717078422088	43	3503	3057	1101	3503	2550	25	6338	2195	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039834_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	23959
1	1164	ESR1	0.00701307793497228	0.595717078422088	43	3503	3057	1101	3503	2550	25	6338	2195	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	SHFOXA1_E2	Array Express	ERP000380_esr1_mcf7-shfoxa1-e2_MACS_ESR1_MA0112.3.damo.pwm.bed	14212
1	2229	JUN	0.0068776187597538	0.520071532760859	24	3505	3326	1691	3505	2840	16	6357	2204	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN		ENCODE	ENCSR000FAH_K562_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	22725
1	2230	JUN	0.0068776187597538	0.520071532760859	24	3505	3326	1691	3505	2840	16	6357	2204	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN		ENCODE	ENCSR000FAH_K562_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	18577
1	2549	JUNB	0.00686393215443576	0.508591170718599	22	3507	3339	1797	3507	2880	15	6359	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12270
1	2551	JUNB	0.00686393215443576	0.508591170718599	22	3507	3339	1797	3507	2880	15	6359	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	11882
1	2552	JUNB	0.00686393215443576	0.508591170718599	22	3507	3339	1797	3507	2880	15	6359	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	12529
1	2554	JUNB	0.00686393215443576	0.508591170718599	22	3507	3339	1797	3507	2880	15	6359	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	12490
1	2336	JUN	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	19632
1	2480	JUNB	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	31087
1	2482	JUNB	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	31549
1	2484	JUNB	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	JUNB HAEC (human aortic endothelial cells) JUNB	HAEC (human aortic endothelial cells)	NULL	JUNB	control, 4h	GTRD	EXP038040_HAEC--human-aortic-endothelial-cells-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	31460
1	3663	SPI1	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: DMSO for 24 hr in RPMI with 10% fetal bovine serum	GTRD	EXP048337_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	85137
1	3834	TEAD4	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	TEAD4 Ishikawa (endometrial adenocarcinoma) TEAD4	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	TEAD4		ENCODE	ENCSR000BSW_Ishikawa_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	27888
1	3883	TFAP2C	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047535_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	28718
1	3884	TFAP2C	0.00684233865291196	0.530250525542249	26	3511	3254	1602	3511	2790	17	6355	2203	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions;	GTRD	EXP047535_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	30636
1	1139	ERG	0.00678916661472588	0.495456321147576	20	3519	3362	1901	3519	2930	14	6361	2206	ERG SKNO-1 (acute myeloid leukemia) ERG	SKNO-1 (acute myeloid leukemia)	NULL	ERG		GEO	GSE23730_erg_skno1_MACS_ERG_MA0474.2.damo.pwm.bed	53323
1	3544	RXRA	0.00675651999158001	0.599362490098413	45	3520	3051	1054	3520	2540	26	6336	2194	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0115.1.damo.pwm.bed	48566
1	2708	MAX	0.00667404853246734	0.390586613723372	9	3521	3532	2585	3532	3210	8	6372	2212	MAX liver MAX	liver	BTO:0000759	MAX		GTRD	EXP039825_liver_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	12946
1	3085	NR2F6	0.00667404853246734	0.390586613723372	9	3521	3532	2585	3532	3210	8	6372	2212	NR2F6 K562 (myelogenous leukemia) NR2F6	K562 (myelogenous leukemia)	NULL	NR2F6	NA	GTRD	EXP040021_K562--myelogenous-leukemia-_NR2F6_MACS_NR2F6_MA1539.1.damo.pwm.bed	22272
1	3682	SPI1	0.00658956186342482	0.642509176124558	65	3523	2896	738	3523	2390	35	6316	2185	SPI1 macrophages SPI1	macrophages	NULL	SPI1	TPP	GEO	GSE66594_spi1_macrophages-tpp_MACS_SPI1_MA0080.5.damo.pwm.bed	116426
1	256	ATF3	0.00656824497825951	0.730003267104313	146	3524	2528	295	3524	2120	69	6235	2151	ATF3 HCT-116 (colon carcinoma) ATF3	HCT-116 (colon carcinoma)	BTO:0001109	ATF3	CAMP	GEO	GSE74355_atf3_htc116-camp_MACS_ATF3_MA0605.2.damo.pwm.bed	51889
1	116	AR	0.00650267411952294	0.602730629503517	47	3525	3034	1002	3525	2520	27	6334	2193	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	Treatment: FA (control)	GTRD	EXP053224_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	15895
1	1620	FOSL2	0.00648276628048073	0.260635921678438	3	3526	3724	3252	3724	3500	4	6378	2216	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	3585
1	2055	GLIS2	0.00648276628048073	0.260635921678438	3	3526	3724	3252	3724	3500	4	6378	2216	GLIS2 HEK293 (embryonic kidney) GLIS2	HEK293 (embryonic kidney)	NULL	GLIS2	NA	GTRD	EXP040045_HEK293--embryonic-kidney-_GLIS2_MACS_GLIS2_MA0736.1.damo.pwm.bed	14280
1	2770	MXI1	0.00648276628048073	0.260635921678438	3	3526	3724	3252	3724	3500	4	6378	2216	MXI1 HepG2 (hepatoblastoma) MXI1	HepG2 (hepatoblastoma)	BTO:0000599	MXI1	NA	ENCODE	ENCSR000EDU_HepG2_MXI1_MACS_MXI1_MA1108.2.damo.pwm.bed	12228
1	1521	FOS	0.00639495773888109	0.462567793941765	16	3529	3436	2127	3529	3030	12	6365	2208	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0099.3.damo.pwm.bed	18319
1	2511	JUNB	0.00639495773888109	0.462567793941765	16	3529	3436	2127	3529	3030	12	6365	2208	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039614_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	12398
1	2774	MYB	0.00639495773888109	0.462567793941765	16	3529	3436	2127	3529	3030	12	6365	2208	MYB PF-382 (childhood T acute lymphoblastic leukemia) MYB	PF-382 (childhood T acute lymphoblastic leukemia)	NULL	MYB		GTRD	EXP038331_PF-382--childhood-T-acute-lymphoblastic-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	40659
1	164	AR	0.00638680487819722	0.808824335205991	370	3532	2284	56	3532	1960	157	6011	2063	AR PLHSAR AR	PLHSAR	NA	AR	FOXA1_HOXB13	GEO	GSE56288_AR_plhsar-foxa1-hoxb13_MACS_AR_MA0007.3.damo.pwm.bed	165694
1	1073	EHF	0.00638622821468568	0.560992051704771	34	3533	3179	1349	3533	2690	21	6347	2199	EHF bronchial epithelial cells EHF	bronchial epithelial cells	BTO:0002922	EHF		GTRD	EXP037682_bronchial-epithelial-cells_EHF_MACS_EHF_MA0598.3.damo.pwm.bed	12160
1	3625	SP1	0.00638622821468568	0.560992051704771	34	3533	3179	1349	3533	2690	21	6347	2199	SP1 A549 (lung carcinoma) SP1	A549 (lung carcinoma)	BTO:0000018	SP1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPE_A549_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	27083
1	1093	ELF3	0.00628735867604407	0.643791056175182	67	3535	2894	710	3535	2380	36	6314	2184	ELF3 PDAC ELF3	PDAC	NA	ELF3	KOKLF5	GEO	GSE64557_elf3_pdac-koklf5_MACS_ELF3_MA0640.2.damo.pwm.bed	45750
1	3143	NR3C1	0.00622457451425478	0.566908446694264	36	3536	3161	1288	3536	2660	22	6345	2198	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-KLF15 transduction	GTRD	EXP049658_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	47058
1	3653	SPI1	0.00622457451425478	0.566908446694264	36	3536	3161	1288	3536	2660	22	6345	2198	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	none	GTRD	EXP038591_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	84203
1	1954	GATA2	0.00610110411261969	0.707999053886904	121	3538	2584	362	3538	2160	59	6260	2161	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2	CSFCS	GEO	GSE69043_gata2_lncap-csfcs_MACS_GATA2_MA0036.3.damo.pwm.bed	58313
1	2563	JUNB	0.00603736739934356	0.441610111854467	14	3539	3459	2252	3539	3080	11	6367	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	9598
1	2567	JUNB	0.00603736739934356	0.441610111854467	14	3539	3459	2252	3539	3080	11	6367	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	9751
1	2568	JUNB	0.00603736739934356	0.441610111854467	14	3539	3459	2252	3539	3080	11	6367	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	9632
1	375	CEBPB	0.0057215450634754	0.646136831344744	71	3542	2881	659	3542	2360	38	6310	2182	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP039591_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	36641
1	1989	GATA3	0.0057215450634754	0.646136831344744	71	3542	2881	659	3542	2360	38	6310	2182	GATA3 MCF7 (Invasive ductal breast carcinoma) GATA3	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GATA3	E2	GEO	GSE29073_gata3_mcf7-e2_MACS_GATA3_MA0037.3.damo.pwm.bed	17757
1	2288	JUN	0.00568961611630579	0.581773628267881	42	3544	3095	1124	3544	2590	25	6339	2195	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	40931
1	101	AR	0.00554250770521591	0.416439503963469	12	3545	3515	2359	3545	3140	10	6369	2210	AR R1-AD1 (prostate cancer) AR	R1-AD1 (prostate cancer)	NULL	AR	Treatment: 0.1% DMSO + 1 nM ethanol for 4 hrs	GTRD	EXP049662_R1-AD1--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	3709
1	3019	NFIL3	0.00554250770521591	0.416439503963469	12	3545	3515	2359	3545	3140	10	6369	2210	NFIL3 HepG2 (hepatoblastoma) NFIL3	HepG2 (hepatoblastoma)	BTO:0000599	NFIL3	NA	GTRD	EXP038522_HepG2--hepatoblastoma-_NFIL3_MACS_NFIL3_MA0025.2.damo.pwm.bed	7900
1	3110	NR3C1	0.00554250770521591	0.416439503963469	12	3545	3515	2359	3545	3140	10	6369	2210	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039608_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3230
1	350	CEBPB	0.00550306565091351	0.585953020172136	44	3548	3089	1072	3548	2570	26	6337	2194	CEBPB HepG2 (hepatoblastoma) CEBPB	HepG2 (hepatoblastoma)	BTO:0000599	CEBPB		ENCODE	ENCSR000BQI_HepG2_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	29379
1	1608	FOSL2	0.0054801740582352	0.347242812602465	7	3549	3674	2768	3674	3330	7	6374	2213	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	7389
1	1609	FOSL2	0.0054801740582352	0.347242812602465	7	3549	3674	2768	3674	3330	7	6374	2213	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	7385
1	1610	FOSL2	0.0054801740582352	0.347242812602465	7	3549	3674	2768	3674	3330	7	6374	2213	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	7303
1	1611	FOSL2	0.0054801740582352	0.347242812602465	7	3549	3674	2768	3674	3330	7	6374	2213	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039800_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	7471
1	3146	NR3C1	0.0054801740582352	0.347242812602465	7	3549	3674	2768	3674	3330	7	6374	2213	NR3C1 SUP-B15 (Childhood B acute lymphoblastic leukemia) NR3C1	SUP-B15 (Childhood B acute lymphoblastic leukemia)	NULL	NR3C1	Treatment: 1uM dexamethasone in 0.02% ethanol Genotype: traslocation t(9;22)(q34;11) ? BCR-ABL1 e1-a2 fusion	GTRD	EXP052965_SUP-B15--Childhood-B-acute-lymphoblastic-leukemia-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	13374
1	3319	RARG	0.0054801740582352	0.347242812602465	7	3549	3674	2768	3674	3330	7	6374	2213	RARG RWPE1 (prostate epithelial cells) RARG	RWPE1 (prostate epithelial cells)	BTO:0003709	RARG	Treatment: 10 uM DMSO for 2 hr Gender: male Source: non-malignant prostate cell line infected with BAC-RARG-EGFP	GTRD	EXP048635_RWPE1--prostate-epithelial-cells-_RARG_MACS_RARG_MA0859.1.damo.pwm.bed	1626
1	3840	TEAD4	0.0054801740582352	0.347242812602465	7	3549	3674	2768	3674	3330	7	6374	2213	TEAD4 MKN28 (gastric tubular adenocarcinoma) TEAD4	MKN28 (gastric tubular adenocarcinoma)	BTO:0002381	TEAD4		GEO	GSE44416_tead4_mkn28_MACS_TEAD4_MA0809.2.damo.pwm.bed	4867
1	3938	TFAP4	0.00519557038578974	0.519845114338708	27	3556	3328	1564	3556	2820	18	6354	2202	TFAP4 LNCaP (prostate carcinoma) TFAP4	LNCaP (prostate carcinoma)	BTO:0001321	TFAP4	NA	GEO	GSE28857_tfap4_lncap_MACS_TFAP4_MA0691.1.damo.pwm.bed	12499
1	2548	JUNB	0.00516250435430796	0.498334602109505	23	3557	3357	1739	3557	2880	16	6358	2204	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039942_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	13324
1	2610	JUND	0.00516250435430796	0.498334602109505	23	3557	3357	1739	3557	2880	16	6358	2204	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	17620
1	3808	TCF7L2	0.00516177907309253	0.528947398279069	29	3559	3262	1504	3559	2780	19	6352	2201	TCF7L2 HCT-116 (colon carcinoma) TCF7L2	HCT-116 (colon carcinoma)	BTO:0001109	TCF7L2		ENCODE	ENCSR000EUV_HCT116_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	30724
1	417	CREB1	0.00513343508231703	0.277925217751872	4	3560	3717	3105	3717	3460	5	6377	2215	CREB1 K562 (myelogenous leukemia) CREB1	K562 (myelogenous leukemia)	NULL	CREB1		ENCODE	ENCSR000BSO_K562_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	15694
1	1467	ETS1	0.00513343508231703	0.277925217751872	4	3560	3717	3105	3717	3460	5	6377	2215	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048199_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	24155
1	2015	GATA4	0.00513343508231703	0.277925217751872	4	3560	3717	3105	3717	3460	5	6377	2215	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037714_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	12073
1	2402	JUN	0.00513343508231703	0.277925217751872	4	3560	3717	3105	3717	3460	5	6377	2215	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	7746
1	2695	MAX	0.00513343508231703	0.277925217751872	4	3560	3717	3105	3717	3460	5	6377	2215	MAX A549 (lung carcinoma) MAX	A549 (lung carcinoma)	BTO:0000018	MAX		ENCODE	ENCSR000DYG_A549_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	11896
1	3944	TFEB	0.00513343508231703	0.277925217751872	4	3560	3717	3105	3717	3460	5	6377	2215	TFEB HUVEC-C (HUVEC, umbilical vein endothelial cells) TFEB	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	TFEB	Strain: endothelial cells from umbilical cords newborn healthy humans	GTRD	EXP053387_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_TFEB_MACS_TFEB_MA0692.1.damo.pwm.bed	7688
1	181	AR	0.00512830950570821	0.59339490941263	48	3566	3074	982	3566	2540	28	6333	2192	AR prostate AR	prostate	NULL	AR	DHT	GEO	GSE61838_AR_prostate-dht_MACS_AR_MA0007.3.damo.pwm.bed	15464
1	2285	JUN	0.00512830950570821	0.59339490941263	48	3566	3074	982	3566	2540	28	6333	2192	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	48638
1	2292	JUN	0.00512830950570821	0.59339490941263	48	3566	3074	982	3566	2540	28	6333	2192	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	47424
1	2520	JUNB	0.00512830950570821	0.59339490941263	48	3566	3074	982	3566	2540	28	6333	2192	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039744_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	23476
1	2553	JUNB	0.00508037909896789	0.485408048037925	21	3570	3380	1852	3570	2930	15	6360	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	1 h with 100 nM Dexamethasone (Myers)	GTRD	EXP040036_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	11993
1	3097	NR3C1	0.00508037909896789	0.485408048037925	21	3570	3380	1852	3570	2930	15	6360	2205	NR3C1 embryonic kidney NR3C1	embryonic kidney	NULL	NR3C1	dexamethasone, stably expressing wt GR	GTRD	EXP032210_embryonic-kidney_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	20349
1	3613	SOX2	0.00508037909896789	0.485408048037925	21	3570	3380	1852	3570	2930	15	6360	2205	SOX2 TT (hereditary thyroid gland medullary carcinoma) SOX2	TT (hereditary thyroid gland medullary carcinoma)	BTO:0003074	SOX2		GEO	GSE46837_sox2_tt_MACS_SOX2_MA0143.4.damo.pwm.bed	7333
1	1487	FLI1	0.0050232558413988	0.544418349868851	33	3573	3231	1379	3573	2730	21	6348	2199	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	NULL	GTRD	EXP000132_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	63010
1	3041	NR1H2	0.00494256340391657	0.596720935875236	50	3574	3054	945	3574	2520	29	6331	2191	NR1H2 HT29 (colon adenocarcinoma) NR1H2	HT29 (colon adenocarcinoma)	BTO:0000182	NR1H2	GW3965_48H	GEO	GSE77039_nr1h2_ht29-gw3965-48h_MACS_NR1H2_MA0115.1.damo.pwm.bed	17654
1	3119	NR3C1	0.00494256340391657	0.596720935875236	50	3574	3054	945	3574	2520	29	6331	2191	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 10 minute	GTRD	EXP040223_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	24200
1	1581	FOSL2	0.00494212305664838	0.470620176615244	19	3576	3399	1956	3576	2980	14	6362	2206	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	14283
1	3140	NR3C1	0.00492766019774164	0.551085534681237	35	3577	3209	1318	3577	2700	22	6346	2198	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr	GTRD	EXP049655_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	44714
1	1151	ERG	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	ERG VCaP (prostate carcinoma) ERG	VCaP (prostate carcinoma)	BTO:0003215	ERG	SH2_DHT	GEO	GSE79128_erg_vcap-sh2-dht_MACS_ERG_MA0474.2.damo.pwm.bed	9521
1	1479	ETV4	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	ETV4 HepG2 (hepatoblastoma) ETV4	HepG2 (hepatoblastoma)	BTO:0000599	ETV4	NA	ENCODE	ENCSR714YZG_HepG2_ETV4_MACS_ETV4_MA0764.2.damo.pwm.bed	20960
1	2528	JUNB	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	9282
1	2529	JUNB	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	9893
1	2531	JUNB	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	9638
1	2533	JUNB	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	9448
1	2534	JUNB	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	8947
1	3114	NR3C1	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039724_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	2729
1	3376	RELA	0.00488579224274433	0.385651584246714	10	3578	3534	2487	3578	3200	9	6371	2211	RELA IMR90 (lung fibroblasts) RELA	IMR90 (lung fibroblasts)	NULL	RELA	TNF	GEO	GSE43070_rela_imr90-tnf_MACS_RELA_MA0107.1.damo.pwm.bed	9008
1	1522	FOS	0.00473664085926151	0.453541256368094	17	3587	3443	2066	3587	3030	13	6364	2207	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	22309
1	1580	FOSL2	0.00473664085926151	0.453541256368094	17	3587	3443	2066	3587	3030	13	6364	2207	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	13534
1	1586	FOSL2	0.00473664085926151	0.453541256368094	17	3587	3443	2066	3587	3030	13	6364	2207	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	13614
1	1848	FOXA3	0.00473205884065849	0.650101640507583	79	3590	2873	599	3590	2350	42	6302	2178	FOXA3 HepG2 (hepatoblastoma) FOXA3	HepG2 (hepatoblastoma)	BTO:0000599	FOXA3	NA	GTRD	EXP039891_HepG2--hepatoblastoma-_FOXA3_MACS_FOXA3_MA1683.1.damo.pwm.bed	45846
1	3655	SPI1	0.00470135887358331	0.562728542716912	39	3591	3178	1206	3591	2660	24	6342	2196	SPI1 MDM(monocyte derived macrophages) SPI1	MDM(monocyte derived macrophages)	NULL	SPI1	Treatment: mock infected 6hr	GTRD	EXP047756_MDM-monocyte-derived-macrophages-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	66089
1	3087	NR3C1	0.00457601206798929	0.567839696800187	41	3592	3160	1155	3592	2640	25	6340	2195	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	1 h with 5 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHG_A549_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	25540
1	1965	GATA3	0.00446176234883198	0.684126756355443	109	3593	2802	409	3593	2270	55	6272	2165	GATA3 MDA-MB-231 (breast adenocarcinoma) GATA3	MDA-MB-231 (breast adenocarcinoma)	BTO:0000815	GATA3		GTRD	EXP035435_MDA-MB-231--breast-adenocarcinoma-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	103007
1	2775	MYB	0.00445152226567403	0.433598311720739	15	3594	3491	2200	3594	3100	12	6366	2208	MYB AML (monocytes and acute myeloid leukemia) MYB	AML (monocytes and acute myeloid leukemia)	NULL	MYB	Treatment: DMSo vehicle	GTRD	EXP049356_AML--monocytes-and-acute-myeloid-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	35638
1	406	CEBPB	0.00440204975303587	0.605414966303124	56	3595	3032	859	3595	2500	32	6325	2188	CEBPB hFOB 1.19 (fetal osteoblast) CEBPB	hFOB 1.19 (fetal osteoblast)	BTO:0005224	CEBPB	DIFF	GEO	GSE82295_cebpb_hfob-diff_MACS_CEBPB_MA0466.2.damo.pwm.bed	63028
1	371	CEBPB	0.00422934029865914	0.607949792856848	58	3596	3024	824	3596	2480	33	6323	2187	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039491_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	28660
1	33	AR	0.00422346632981216	0.640658721709983	76	3597	2903	619	3597	2370	41	6305	2179	AR HEK293 (embryonic kidney) AR	HEK293 (embryonic kidney)	NULL	AR	10 nM R1881	GTRD	EXP032872_HEK293--embryonic-kidney-_AR_MACS_AR_MA0007.3.damo.pwm.bed	76249
1	2287	JUN	0.00417477641379306	0.580942798007545	47	3598	3096	1002	3598	2570	28	6334	2192	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	47423
1	3652	SPI1	0.00417477641379306	0.580942798007545	47	3598	3096	1002	3598	2570	28	6334	2192	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	IFN-gamma	GTRD	EXP038590_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	102674
1	2323	JUN	0.00407359484682961	0.410010078709736	13	3600	3524	2306	3600	3140	11	6368	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039869_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	12958
1	3654	SPI1	0.00407359484682961	0.410010078709736	13	3600	3524	2306	3600	3140	11	6368	2209	SPI1 monocyte-derived macrophages SPI1	monocyte-derived macrophages	NULL	SPI1	LPS	GTRD	EXP040651_monocyte-derived-macrophages_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	29563
1	2009	GATA4	0.00404625999017967	0.347140379915101	8	3602	3681	2675	3681	3320	8	6373	2212	GATA4 HUES64 (embryonic stem cells) GATA4	HUES64 (embryonic stem cells)	NULL	GATA4		GTRD	EXP036708_HUES64--embryonic-stem-cells-_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	30923
1	2894	MYC	0.00404625999017967	0.347140379915101	8	3602	3681	2675	3681	3320	8	6373	2212	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047492_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	11596
1	2911	MYC	0.00404625999017967	0.347140379915101	8	3602	3681	2675	3681	3320	8	6373	2212	MYC MM1.S (plasma cell myeloma) MYC	MM1.S (plasma cell myeloma)	BTO:0003933	MYC	DMSO	GEO	GSE36354_myc_mm1s-dmso_MACS_MYC_MA0147.3.damo.pwm.bed	18528
1	1955	GATA2	0.00403181960099544	0.64177181839312	78	3605	2897	604	3605	2370	42	6303	2178	GATA2 LNCaP (prostate carcinoma) GATA2	LNCaP (prostate carcinoma)	BTO:0001321	GATA2	FBS	GEO	GSE69043_gata2_lncap-fbs_MACS_GATA2_MA0036.3.damo.pwm.bed	27170
1	1066	EGR1	0.003961693703602	0.289417592019882	5	3606	3709	2973	3709	3430	6	6376	2214	EGR1 liver EGR1	liver	BTO:0000759	EGR1		GTRD	EXP045317_liver_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	6083
1	2396	JUN	0.003961693703602	0.289417592019882	5	3606	3709	2973	3709	3430	6	6376	2214	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	8636
1	2397	JUN	0.003961693703602	0.289417592019882	5	3606	3709	2973	3709	3430	6	6376	2214	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	8235
1	2399	JUN	0.003961693703602	0.289417592019882	5	3606	3709	2973	3709	3430	6	6376	2214	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	8547
1	2403	JUN	0.003961693703602	0.289417592019882	5	3606	3709	2973	3709	3430	6	6376	2214	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	8558
1	2711	MAX	0.00394451871168672	0.510578421757487	28	3611	3338	1531	3611	2830	19	6353	2201	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048815_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	47125
1	76	AR	0.00392944345277074	0.500522763264788	26	3612	3355	1602	3612	2860	18	6355	2202	AR 22RV1 (prostate carcinoma) AR	22RV1 (prostate carcinoma)	BTO:0002999	AR	treatment: targeting ARV1/3/4/7 siARVs+R1881	GTRD	EXP048921_22RV1--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	13558
1	3683	SPI1	0.00392944345277074	0.500522763264788	26	3612	3355	1602	3612	2860	18	6355	2202	SPI1 DOHH2 (diffuse large B-cell lymphoma) SPI1	DOHH2 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE69558_spi1_dohh2_MACS_SPI1_MA0080.5.damo.pwm.bed	73276
1	2960	MYOD1	0.00390517002261329	0.527849117520862	32	3614	3263	1410	3614	2760	21	6349	2199	MYOD1 myoblasts MYOD1	myoblasts	NULL	MYOD1	NA	GEO	GSE50413_myod1_myoblast_MACS_MYOD1_MA0499.2.damo.pwm.bed	44346
1	2442	JUN	0.003884934982702	0.489272199434595	24	3615	3369	1691	3615	2890	17	6357	2203	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	22477
1	3142	NR3C1	0.00385857020576475	0.535266999319228	34	3616	3245	1349	3616	2740	22	6347	2198	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-GFP transduction	GTRD	EXP049657_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	43217
1	3086	NR3C1	0.00384837250191026	0.642828527882764	80	3617	2895	585	3617	2370	43	6301	2177	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	1 h with 50 nM Dexamethasone (Myers)	ENCODE	ENCSR000BHF_A549_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	51277
1	2226	JUN	0.00380542035970073	0.476602578937276	22	3618	3395	1797	3618	2940	16	6359	2204	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN		ENCODE	ENCSR000EFS_K562_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	28874
1	3010	NFIB	0.00380542035970073	0.476602578937276	22	3618	3395	1797	3618	2940	16	6359	2204	NFIB MCF7 (Invasive ductal breast carcinoma) NFIB	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	NFIB	NA	GTRD	EXP039996_MCF7--Invasive-ductal-breast-carcinoma-_NFIB_MACS_NFIB_MA1643.1.damo.pwm.bed	14598
1	2233	JUN	0.00379832181941356	0.54203124258357	36	3620	3232	1288	3620	2710	23	6345	2197	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	29110
1	2240	JUN	0.00379832181941356	0.54203124258357	36	3620	3232	1288	3620	2710	23	6345	2197	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1132.1.damo.pwm.bed	28343
1	1077	ELF1	0.00368460462047096	0.462229959589112	20	3622	3439	1901	3622	2990	15	6361	2205	ELF1 K562 (myelogenous leukemia) ELF1	K562 (myelogenous leukemia)	NULL	ELF1		ENCODE	ENCSR000BMD_K562_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	44694
1	2033	GATA6	0.00359037472906176	0.381682999891317	11	3623	3544	2426	3623	3200	10	6370	2210	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057913_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	39891
1	2321	JUN	0.00359037472906176	0.381682999891317	11	3623	3544	2426	3623	3200	10	6370	2210	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039507_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	9347
1	2671	MAF	0.00359037472906176	0.381682999891317	11	3623	3544	2426	3623	3200	10	6370	2210	MAF keratinocytes MAF	keratinocytes	NULL	MAF	epidermal_PROLIF	GEO	GSE52953_maf_epidermal-keratinocytes-prolif_MACS_MAF_MA0501.1.damo.pwm.bed	2965
1	259	ATF4	0.00356019943065036	0.559156516408817	42	3626	3183	1124	3626	2640	26	6339	2194	ATF4 HAP1 (chronic myelogenous leukemia) ATF4	HAP1 (chronic myelogenous leukemia)	NULL	ATF4	2 mM histidinol, 24 hours	GTRD	EXP035035_HAP1--chronic-myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	36758
1	1856	FOXO1	0.00356019943065036	0.559156516408817	42	3626	3183	1124	3626	2640	26	6339	2194	FOXO1 hESC-1 (Embryonic stem cells) FOXO1	hESC-1 (Embryonic stem cells)	NULL	FOXO1		GEO	GSE69542_foxo1_hesc_MACS_FOXO1_MA0480.1.damo.pwm.bed	58898
1	2290	JUN	0.00356019943065036	0.559156516408817	42	3626	3183	1124	3626	2640	26	6339	2194	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	41082
1	430	CREM	0.0035155380647703	0.445789263959521	18	3629	3457	1996	3629	3030	14	6363	2206	CREM K562 (myelogenous leukemia) CREM	K562 (myelogenous leukemia)	NULL	CREM	NA	ENCODE	ENCSR077DKV_K562_CREM_MACS_CREM_MA0609.2.damo.pwm.bed	38894
1	3542	RXRA	0.00346811920638414	0.564004679343095	44	3630	3171	1072	3630	2620	27	6337	2193	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0065.2.damo.pwm.bed	52471
1	3665	SPI1	0.00346811920638414	0.564004679343095	44	3630	3171	1072	3630	2620	27	6337	2193	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: 100nM VDR ligand 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) for 24 hrs Cell type: human monocytic cell line	GTRD	EXP049120_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	96744
1	3680	SPI1	0.00338525479562903	0.655326383044331	93	3632	2865	489	3632	2330	49	6288	2171	SPI1 macrophages SPI1	macrophages	NULL	SPI1	IFNG	GEO	GSE66594_spi1_macrophages-ifng_MACS_SPI1_MA0080.5.damo.pwm.bed	147525
1	2585	JUND	0.0033721877193649	0.568499529611379	46	3633	3158	1028	3633	2610	28	6335	2192	JUND HepG2 (hepatoblastoma) JUND	HepG2 (hepatoblastoma)	BTO:0000599	JUND		ENCODE	ENCSR000BGK_HepG2_JUND_MACS_JUND_MA0491.2.damo.pwm.bed	30124
1	1523	FOS	0.00329084337364956	0.426803098677728	16	3634	3495	2127	3634	3090	13	6365	2207	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1134.1.damo.pwm.bed	21500
1	1524	FOS	0.00329084337364956	0.426803098677728	16	3634	3495	2127	3634	3090	13	6365	2207	FOS K562 (myelogenous leukemia) FOS	K562 (myelogenous leukemia)	NULL	FOS	NULL	GTRD	EXP000310_K562--myelogenous-leukemia-_FOS_MACS_FOS_MA1141.1.damo.pwm.bed	21100
1	1584	FOSL2	0.00329084337364956	0.426803098677728	16	3634	3495	2127	3634	3090	13	6365	2207	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA0478.1.damo.pwm.bed	13136
1	1587	FOSL2	0.00329084337364956	0.426803098677728	16	3634	3495	2127	3634	3090	13	6365	2207	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	13473
1	674	CTCF	0.0030191604148293	0.297597295328018	6	3638	3707	2870	3707	3400	7	6375	2213	CTCF lower leg skin CTCF	lower leg skin	NULL	CTCF		GTRD	EXP039328_lower-leg-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	15213
1	3835	TEAD4	0.0030191604148293	0.297597295328018	6	3638	3707	2870	3707	3400	7	6375	2213	TEAD4 A549 (lung carcinoma) TEAD4	A549 (lung carcinoma)	BTO:0000018	TEAD4		ENCODE	ENCSR000BUD_A549_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	7802
1	3646	SPI1	0.00299854495742002	0.511223140666753	31	3640	3337	1439	3640	2810	21	6350	2199	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1		ENCODE	ENCSR000BGW_K562_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	56378
1	3040	NR1H2	0.00299417666234477	0.502227783573613	29	3641	3348	1504	3641	2830	20	6352	2200	NR1H2 HT29 (colon adenocarcinoma) NR1H2	HT29 (colon adenocarcinoma)	BTO:0000182	NR1H2	GW3965_2H	GEO	GSE77039_nr1h2_ht29-gw3965-2h_MACS_NR1H2_MA0115.1.damo.pwm.bed	9299
1	2000	GATA3	0.00299340320215977	0.347037915064583	9	3642	3684	2585	3684	3300	9	6372	2211	GATA3 Kelly (neuroblastoma) GATA3	Kelly (neuroblastoma)	NULL	GATA3		GEO	GSE65664_gata3_kelly_MACS_GATA3_MA0037.3.damo.pwm.bed	23550
1	2077	HAND2	0.00299340320215977	0.347037915064583	9	3642	3684	2585	3684	3300	9	6372	2211	HAND2 Kelly (neuroblastoma) HAND2	Kelly (neuroblastoma)	NULL	HAND2	Treatment: untreated	GTRD	EXP049486_Kelly--neuroblastoma-_HAND2_MACS_HAND2_MA1638.1.damo.pwm.bed	28262
1	2530	JUNB	0.00299340320215977	0.347037915064583	9	3642	3684	2585	3684	3300	9	6372	2211	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	9136
1	3117	NR3C1	0.00299340320215977	0.347037915064583	9	3642	3684	2585	3684	3300	9	6372	2211	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 8 hour	GTRD	EXP040168_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3810
1	3628	SP1	0.00299340320215977	0.347037915064583	9	3642	3684	2585	3684	3300	9	6372	2211	SP1 HEK293 (embryonic kidney) SP1	HEK293 (embryonic kidney)	NULL	SP1		GTRD	EXP035873_HEK293--embryonic-kidney-_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	19122
1	2818	MYC	0.00298678418296356	0.51939163394218	33	3647	3329	1379	3647	2780	22	6348	2198	MYC HeLa (cervical adenocarcinoma) MYC	HeLa (cervical adenocarcinoma)	BTO:0000567	MYC		GTRD	EXP031873_HeLa--cervical-adenocarcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	31631
1	2158	HOXB13	0.00298380934082265	0.637011673013014	83	3648	2919	565	3648	2380	45	6298	2175	HOXB13 LNCaP (prostate carcinoma) HOXB13	LNCaP (prostate carcinoma)	BTO:0001321	HOXB13		GTRD	EXP038431_LNCaP--prostate-carcinoma-_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	24401
1	2439	JUN	0.00297071772708777	0.49227494719341	27	3649	3363	1564	3649	2860	19	6354	2201	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	30792
1	2712	MAX	0.00297071772708777	0.49227494719341	27	3649	3363	1564	3649	2860	19	6354	2201	MAX MKL-1 (Merkel cell carcinoma) MAX	MKL-1 (Merkel cell carcinoma)	NULL	MAX	Treatment: no treatment Markel Cell: positive	GTRD	EXP048815_MKL-1--Merkel-cell-carcinoma-_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	45558
1	2234	JUN	0.00296149617938891	0.526902189408763	35	3651	3264	1318	3651	2740	23	6346	2197	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	26068
1	2170	HOXB13	0.00292495224811069	0.533722638245655	37	3652	3248	1264	3652	2720	24	6344	2196	HOXB13 LNCaP95 HOXB13	LNCaP95	NULL	HOXB13	Treatment: 10 nM ETOH for 4 hrs Genotype: shARv7 transfection	GTRD	EXP052944_LNCaP95_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	12629
1	258	ATF4	0.00292482709008781	0.481204978319753	25	3653	3386	1657	3653	2900	18	6356	2202	ATF4 HAP1 (chronic myelogenous leukemia) ATF4	HAP1 (chronic myelogenous leukemia)	NULL	ATF4	2 mM histidinol, 24 hours	GTRD	EXP035034_HAP1--chronic-myelogenous-leukemia-_ATF4_MACS_ATF4_MA0833.2.damo.pwm.bed	22710
1	2612	JUND	0.00292482709008781	0.481204978319753	25	3653	3386	1657	3653	2900	18	6356	2202	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA1141.1.damo.pwm.bed	18585
1	3666	SPI1	0.00287912583505884	0.539989526635647	39	3655	3239	1206	3655	2700	25	6342	2195	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: EtOH (vehicle) for 24hrs Cell type: human monocytic cell line	GTRD	EXP049121_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	88128
1	3940	TFAP4	0.00287912583505884	0.539989526635647	39	3655	3239	1206	3655	2700	25	6342	2195	TFAP4 DLD-1 (colon adenocarcinoma) TFAP4	DLD-1 (colon adenocarcinoma)	BTO:0000391	TFAP4	NA	GEO	GSE46935_tfap4_dld1_MACS_TFAP4_MA0691.1.damo.pwm.bed	22843
1	2440	JUN	0.00285278420831082	0.468820646157714	23	3657	3400	1739	3657	2930	17	6358	2203	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	20286
1	2441	JUN	0.00285278420831082	0.468820646157714	23	3657	3400	1739	3657	2930	17	6358	2203	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	17628
1	3091	NR3C1	0.00276928398168255	0.589801949823852	58	3659	3087	824	3659	2520	34	6323	2186	NR3C1 U2OS (osteosarcoma) NR3C1	U2OS (osteosarcoma)	BTO:0001938	NR3C1	GLUCC	Array Express	ERP007081_nr3c1_u2os-glucc_MACS_NR3C1_MA0113.3.damo.pwm.bed	44490
1	1085	ELF1	0.00275052660274477	0.454875403175651	21	3660	3441	1852	3660	2980	16	6360	2204	ELF1 SNU175 (adenocarcinoma) ELF1	SNU175 (adenocarcinoma)	NULL	ELF1		GTRD	EXP037554_SNU175--adenocarcinoma-_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	22756
1	2614	JUND	0.00275052660274477	0.454875403175651	21	3660	3441	1852	3660	2980	16	6360	2204	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA1144.1.damo.pwm.bed	15576
1	163	AR	0.00268336520056839	0.772635688924333	320	3662	2397	83	3662	2050	142	6061	2078	AR LHSAR (prostate epithelial cells) AR	LHSAR (prostate epithelial cells)	NULL	AR	LACZ	GEO	GSE56288_AR_lhsar-lacz_MACS_AR_MA0007.3.damo.pwm.bed	118921
1	1078	ELF1	0.00264669892132548	0.378417285234268	12	3663	3549	2359	3663	3190	11	6369	2209	ELF1 HepG2 (hepatoblastoma) ELF1	HepG2 (hepatoblastoma)	BTO:0000599	ELF1		ENCODE	ENCSR000BMZ_HepG2_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	29760
1	2565	JUNB	0.00264669892132548	0.378417285234268	12	3663	3549	2359	3663	3190	11	6369	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	9375
1	3109	NR3C1	0.00264669892132548	0.378417285234268	12	3663	3549	2359	3663	3190	11	6369	2209	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039313_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4718
1	410	CEBPG	0.00263382747505834	0.560667017179125	47	3666	3181	1002	3666	2620	29	6334	2191	CEBPG HepG2 (hepatoblastoma) CEBPG	HepG2 (hepatoblastoma)	BTO:0000599	CEBPG	NA	GTRD	EXP039427_HepG2--hepatoblastoma-_CEBPG_MACS_CEBPG_MA1636.1.damo.pwm.bed	35091
1	2490	JUNB	0.00261375527726072	0.439056956622515	19	3667	3462	1956	3667	3030	15	6362	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	12835
1	2613	JUND	0.0024381596960958	0.420963810915087	17	3668	3504	2066	3668	3080	14	6364	2206	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA1142.1.damo.pwm.bed	12884
1	290	BHLHE22	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	BHLHE22 CAL-1 (plasmacytoid dendritic neoplasm) BHLHE22	CAL-1 (plasmacytoid dendritic neoplasm)	NULL	BHLHE22	NA	GEO	GSE43876_bhlhe22_cal1_MACS_BHLHE22_MA0818.1.damo.pwm.bed	16094
1	1472	ETS1	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GEO	GSE41166_ets1_huvec_MACS_ETS1_MA0098.3.damo.pwm.bed	18043
1	1508	FLI1	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	FLI1 UAE FLI1	UAE	NA	FLI1		GEO	GSE23730_fli1_uae_MACS_FLI1_MA0475.2.damo.pwm.bed	20528
1	2018	GATA4	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4	G296S mutant	GTRD	EXP037720_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	10774
1	2020	GATA4	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4	G296S mutant	GTRD	EXP037724_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	11181
1	2903	MYC	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057894_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	9215
1	2904	MYC	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: EGFP transfection;	GTRD	EXP057894_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	8713
1	2924	MYC	0.00234256667086996	0.173737467324312	2	3669	3770	3390	3770	3610	4	6379	2216	MYC LS174T (colon adenocarcinoma) MYC	LS174T (colon adenocarcinoma)	BTO:0001553	MYC	BI8622	GEO	GSE59223_myc_ls174t-bi8622_MACS_MYC_MA0147.3.damo.pwm.bed	2913
1	1765	FOXA1	0.00231309685983443	0.631670068737064	86	3677	2931	534	3677	2380	47	6295	2173	FOXA1 LNCaP C4-2B (prostate carcinoma) FOXA1	LNCaP C4-2B (prostate carcinoma)	BTO:0004959	FOXA1	DHT	GEO	GSE40050_foxa1_c42b-dht_MACS_FOXA1_MA0148.4.damo.pwm.bed	17925
1	1891	GABPA	0.00228552189324438	0.303687150635724	7	3678	3705	2768	3705	3380	8	6374	2212	GABPA HepG2 (hepatoblastoma) GABPA	HepG2 (hepatoblastoma)	BTO:0000599	GABPA		GEO	GSE72082_GABPA_hepg2_MACS_GABPA_MA0062.3.damo.pwm.bed	13578
1	2893	MYC	0.00228552189324438	0.303687150635724	7	3678	3705	2768	3705	3380	8	6374	2212	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 4;	GTRD	EXP047492_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	10984
1	2238	JUN	0.00228298143418604	0.511716087254854	34	3680	3335	1349	3680	2790	23	6347	2197	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	25910
1	2239	JUN	0.00228298143418604	0.511716087254854	34	3680	3335	1349	3680	2790	23	6347	2197	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	26050
1	2235	JUN	0.00227120961099187	0.519164571354866	36	3682	3330	1288	3682	2770	24	6345	2196	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	32648
1	3664	SPI1	0.00224606574721263	0.484841341672074	28	3683	3383	1531	3683	2870	20	6353	2200	SPI1 THP-1 (acute monocytic leukemia) SPI1	THP-1 (acute monocytic leukemia)	BTO:0001370	SPI1	Treatment: 250nM OG86 for 24 hr in RPMI with 10% fetal bovine serum	GTRD	EXP048338_THP-1--acute-monocytic-leukemia-_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	70105
1	2286	JUN	0.00222176118572713	0.532380713876164	40	3684	3249	1189	3684	2710	26	6341	2194	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	38984
1	2291	JUN	0.00222176118572713	0.532380713876164	40	3684	3249	1189	3684	2710	26	6341	2194	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	39052
1	1773	FOXA1	0.00221854353534331	0.34693541803589	10	3686	3689	2487	3689	3290	10	6371	2210	FOXA1 DU145 (prostate carcinoma) FOXA1	DU145 (prostate carcinoma)	BTO:0001332	FOXA1		GEO	GSE47987_foxa1_du145_MACS_FOXA1_MA0148.4.damo.pwm.bed	3432
1	2532	JUNB	0.00221854353534331	0.34693541803589	10	3686	3689	2487	3689	3290	10	6371	2210	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 7 hour	GTRD	EXP039831_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1137.1.damo.pwm.bed	9407
1	2437	JUN	0.00220280868718542	0.473975840269853	26	3688	3397	1602	3688	2900	19	6355	2201	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	28594
1	1621	FOSL2	0.00218120852103108	0.208430355477393	3	3689	3741	3252	3741	3560	5	6378	2215	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	3665
1	1622	FOSL2	0.00218120852103108	0.208430355477393	3	3689	3741	3252	3741	3560	5	6378	2215	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	3683
1	1623	FOSL2	0.00218120852103108	0.208430355477393	3	3689	3741	3252	3741	3560	5	6378	2215	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 2 hour	GTRD	EXP040181_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	3627
1	2231	JUN	0.00218120852103108	0.208430355477393	3	3689	3741	3252	3741	3560	5	6378	2215	JUN MCF7 (Invasive ductal breast carcinoma) JUN	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	JUN		ENCODE	ENCSR176EXN_MCF-7_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	2304
1	2398	JUN	0.00218120852103108	0.208430355477393	3	3689	3741	3252	3741	3560	5	6378	2215	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	8158
1	2435	JUN	0.00214013864653828	0.461891698958293	24	3694	3440	1691	3694	2940	18	6357	2202	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0099.3.damo.pwm.bed	22464
1	3104	NR3C1	0.00210215044972226	0.548659924394688	46	3695	3220	1028	3695	2650	29	6335	2191	NR3C1 BEAS-2B (bronchial epithelium) NR3C1	BEAS-2B (bronchial epithelium)	NULL	NR3C1	dexamethasone + TNF	GTRD	EXP036258_BEAS-2B--bronchial-epithelium-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	26852
1	3154	NR3C1	0.00205425006486953	0.55334963053953	48	3696	3208	982	3696	2630	30	6333	2190	NR3C1 U2OS (osteosarcoma) NR3C1	U2OS (osteosarcoma)	BTO:0001938	NR3C1	SHHIC5	GEO	GSE65847_nr3c1_u2os-shhic5_MACS_NR3C1_MA0113.3.damo.pwm.bed	50363
1	3135	NR3C1	0.00194617121356117	0.433153175780147	20	3697	3492	1901	3697	3030	16	6361	2204	NR3C1 MCF10A (breast epithelial cells) NR3C1	MCF10A (breast epithelial cells)	BTO:0001939	NR3C1	Treatment: EGF + DEX 60 min;	GTRD	EXP047633_MCF10A--breast-epithelial-cells-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4295
1	1459	ETS1	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GTRD	EXP038274_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	12009
1	1460	ETS1	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	VEGF stimulation for 1hour	GTRD	EXP038275_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	14192
1	1466	ETS1	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1	Treatment: agent VEGF, timepoint 1 Passage: P3-6	GTRD	EXP048198_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	14280
1	1489	FLI1	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	FLI1 CD34+ hematopoietic stem cells FLI1	CD34+ hematopoietic stem cells	NULL	FLI1		GTRD	EXP031972_CD34--hematopoietic-stem-cells_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	20204
1	1849	FOXJ2	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	FOXJ2 K562 (myelogenous leukemia) FOXJ2	K562 (myelogenous leukemia)	NULL	FOXJ2	NA	ENCODE	ENCSR847LBF_K562_FOXJ2_MACS_FOXJ2_MA0614.1.damo.pwm.bed	1009
1	2042	GATA6	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	GATA6 KATOIII (signet ring cell gastric adenocarcinoma) GATA6	KATOIII (signet ring cell gastric adenocarcinoma)	NULL	GATA6		GEO	GSE51705_gata6_katoiii_MACS_GATA6_MA1104.2.damo.pwm.bed	1990
1	2113	HNF1A	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	HNF1A HepG2 (hepatoblastoma) HNF1A	HepG2 (hepatoblastoma)	BTO:0000599	HNF1A		GTRD	EXP039789_HepG2--hepatoblastoma-_HNF1A_MACS_HNF1A_MA0046.2.damo.pwm.bed	8142
1	3287	PPARG	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034422_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0066.1.damo.pwm.bed	8823
1	3565	SMAD3	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	SMAD3 HMLE-Twist-ER (breast cancer) SMAD3	HMLE-Twist-ER (breast cancer)	NULL	SMAD3	Treatment: no CellType: Immortalized human mammary epithelial cells	GTRD	EXP047889_HMLE-Twist-ER--breast-cancer-_SMAD3_MACS_SMAD3_MA1622.1.damo.pwm.bed	2374
1	4129	YY1	0.00192793614571338	0.115876583860776	1	3698	3784	3585	3784	3690	3	6380	2217	YY1 K562 (myelogenous leukemia) YY1	K562 (myelogenous leukemia)	NULL	YY1		ENCODE	ENCSR000EWF_K562_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	6122
1	382	CEBPB	0.00189831348936379	0.593459118937602	67	3708	3073	710	3708	2500	39	6314	2181	CEBPB A549 (lung carcinoma) CEBPB	A549 (lung carcinoma)	BTO:0000018	CEBPB	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP040190_A549--lung-carcinoma-_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	36053
1	3158	NR3C1	0.0018474611378915	0.231512397124899	4	3709	3738	3105	3738	3520	6	6377	2214	NR3C1 hMSC NR3C1	hMSC	NA	NR3C1	DMI	GEO	GSE68864_nr3c1_hmsc-dmi_MACS_NR3C1_MA0113.3.damo.pwm.bed	4529
1	409	CEBPG	0.00182827460059592	0.595810130343381	69	3710	3056	687	3710	2480	40	6312	2180	CEBPG HepG2 (hepatoblastoma) CEBPG	HepG2 (hepatoblastoma)	BTO:0000599	CEBPG	NA	GTRD	EXP039427_HepG2--hepatoblastoma-_CEBPG_MACS_CEBPG_MA0838.1.damo.pwm.bed	52750
1	1582	FOSL2	0.00180979878379059	0.415889284602538	18	3711	3518	1996	3711	3080	15	6363	2205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1138.1.damo.pwm.bed	14829
1	1583	FOSL2	0.00180979878379059	0.415889284602538	18	3711	3518	1996	3711	3080	15	6363	2205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039502_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1144.1.damo.pwm.bed	14608
1	1585	FOSL2	0.00180979878379059	0.415889284602538	18	3711	3518	1996	3711	3080	15	6363	2205	FOSL2 A549 (lung carcinoma) FOSL2	A549 (lung carcinoma)	BTO:0000018	FOSL2	100nM dexamethasone (CHEBI:41879) for 5 hour	GTRD	EXP039554_A549--lung-carcinoma-_FOSL2_MACS_FOSL2_MA1130.1.damo.pwm.bed	13660
1	2487	JUNB	0.00180979878379059	0.415889284602538	18	3711	3518	1996	3711	3080	15	6363	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	12608
1	3810	TCF7L2	0.00180979878379059	0.415889284602538	18	3711	3518	1996	3711	3080	15	6363	2205	TCF7L2 HeLa S3 (cervical adenocarcinoma) TCF7L2	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	TCF7L2		ENCODE	ENCSR000EVE_HeLa-S3_TCF7L2_MACS_TCF7L2_MA0523.1.damo.pwm.bed	11884
1	316	CEBPA	0.00179552133017036	0.613698021046485	80	3716	2985	585	3716	2430	45	6301	2175	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA	none	GTRD	EXP030935_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	53520
1	2237	JUN	0.00174400857188399	0.504671341419055	35	3717	3347	1318	3717	2790	24	6346	2196	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	32543
1	2037	GATA6	0.00174053435019795	0.512093635501688	37	3718	3333	1264	3718	2770	25	6344	2195	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout;	GTRD	EXP057930_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	98417
1	3120	NR3C1	0.00174053435019795	0.512093635501688	37	3718	3333	1264	3718	2770	25	6344	2195	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 25 minute	GTRD	EXP040271_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	22096
1	2236	JUN	0.00172977085091821	0.518937293431945	39	3720	3331	1206	3720	2750	26	6342	2194	JUN K562 (myelogenous leukemia) JUN	K562 (myelogenous leukemia)	NULL	JUN	NULL	GTRD	EXP000309_K562--myelogenous-leukemia-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	39729
1	2035	GATA6	0.00172372174723277	0.308462403188957	8	3721	3702	2675	3721	3370	9	6373	2211	GATA6 definitive endoderm from HUES8 GATA6	definitive endoderm from HUES8	NULL	GATA6	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057920_definitive-endoderm-from-HUES8_GATA6_MACS_GATA6_MA1104.2.damo.pwm.bed	38824
1	3113	NR3C1	0.00172372174723277	0.308462403188957	8	3721	3702	2675	3721	3370	9	6373	2211	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 4 hour	GTRD	EXP039722_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3113
1	3118	NR3C1	0.00171278276284704	0.525327664592676	41	3723	3265	1155	3723	2710	27	6340	2193	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 20 minute	GTRD	EXP040221_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	21901
1	352	CEBPB	0.00169825149194431	0.4781056562141	29	3724	3388	1504	3724	2870	21	6352	2199	CEBPB HCT-116 (colon carcinoma) CEBPB	HCT-116 (colon carcinoma)	BTO:0001109	CEBPB		ENCODE	ENCSR000BSD_HCT116_CEBPB_MACS_CEBPB_MA0466.2.damo.pwm.bed	15464
1	3546	RXRA	0.00169052134057889	0.531197801244632	43	3725	3253	1101	3725	2690	28	6338	2192	RXRA liver RXRA	liver	BTO:0000759	RXRA		GTRD	EXP045021_liver_RXRA_MACS_RXRA_MA0512.2.damo.pwm.bed	50608
1	2611	JUND	0.00165954044852596	0.46745910099847	27	3726	3402	1564	3726	2900	20	6354	2200	JUND liver JUND	liver	BTO:0000759	JUND		GTRD	EXP039345_liver_JUND_MACS_JUND_MA0492.1.damo.pwm.bed	19074
1	2076	HAND2	0.00164697724651522	0.346832888813993	11	3727	3691	2426	3727	3280	11	6370	2209	HAND2 BE2C HAND2	BE2C	NULL	HAND2	Treatment: untreated	GTRD	EXP049480_BE2C_HAND2_MACS_HAND2_MA1638.1.damo.pwm.bed	39403
1	2564	JUNB	0.00164697724651522	0.346832888813993	11	3727	3691	2426	3727	3280	11	6370	2209	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1132.1.damo.pwm.bed	9304
1	2690	MAX	0.00164697724651522	0.346832888813993	11	3727	3691	2426	3727	3280	11	6370	2209	MAX A549 (lung carcinoma) MAX	A549 (lung carcinoma)	BTO:0000018	MAX		ENCODE	ENCSR000BTJ_A549_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	23200
1	12	AR	0.00156435810663987	0.604100458040314	77	3730	3033	609	3730	2460	44	6304	2176	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	R1881	GTRD	EXP000731_LNCaP--prostate-carcinoma-_AR_MACS_AR_MA0007.3.damo.pwm.bed	37939
1	3088	NR3C1	0.00156424818431893	0.550947547371076	51	3731	3210	932	3731	2620	32	6330	2188	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	1 h with 100 nM Dexamethasone (Myers)	ENCODE	ENCSR000BJR_A549_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	44340
1	1864	FOXP1	0.00156351319781292	0.584510491649487	66	3732	3092	727	3732	2520	39	6315	2181	FOXP1 HepG2 (hepatoblastoma) FOXP1	HepG2 (hepatoblastoma)	BTO:0000599	FOXP1	NA	GTRD	EXP045046_HepG2--hepatoblastoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	37646
1	2436	JUN	0.00153748461841953	0.442582966598623	23	3733	3458	1739	3733	2980	18	6358	2202	JUN definitive endoderm from HUES8 JUN	definitive endoderm from HUES8	NULL	JUN	Genotype: SOX17-GFP knockout; Treatment: DMSO;	GTRD	EXP057919_definitive-endoderm-from-HUES8_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	21661
1	315	CEBPA	0.00150278760188509	0.605931713767499	79	3734	3031	599	3734	2450	45	6302	2175	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA	none	GTRD	EXP030935_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	55309
1	4123	YY1	0.0014962510969799	0.247970188505778	5	3735	3728	2973	3735	3480	7	6376	2213	YY1 HepG2 (hepatoblastoma) YY1	HepG2 (hepatoblastoma)	BTO:0000599	YY1		ENCODE	ENCSR000BNT_HepG2_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	22789
1	2492	JUNB	0.00145095023545423	0.427931732186393	21	3736	3494	1852	3736	3030	17	6360	2203	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	13231
1	2343	JUN	0.00144895216059035	0.373345649920851	14	3737	3552	2252	3737	3180	13	6367	2207	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	19783
1	2566	JUNB	0.00144895216059035	0.373345649920851	14	3737	3552	2252	3737	3180	13	6367	2207	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	9982
1	306	CEBPA	0.00140579822301425	0.566220532244121	59	3739	3163	805	3739	2570	36	6322	2184	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA		Array Express	ERP000209_cebpa_hepg2_MACS_CEBPA_MA0102.4.damo.pwm.bed	37742
1	2486	JUNB	0.0013455416450658	0.411436139444226	19	3740	3523	1956	3740	3070	16	6362	2204	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA0490.2.damo.pwm.bed	12820
1	3648	SPI1	0.00131916637232596	0.518709799865519	42	3741	3332	1124	3741	2730	28	6339	2192	SPI1 HL-60 (acute myeloid leukemia) SPI1	HL-60 (acute myeloid leukemia)	BTO:0000738	SPI1		ENCODE	ENCSR000BUW_HL-60_SPI1_MACS_SPI1_MA0080.5.damo.pwm.bed	86544
1	1798	FOXA1	0.00130957739198907	0.679169267655512	152	3742	2811	277	3742	2280	77	6229	2143	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	R1881	GEO	GSE69043_foxa1_lncap-r1881_MACS_FOXA1_MA0148.4.damo.pwm.bed	50537
1	2320	JUN	0.00129727473787755	0.312215526475275	9	3743	3701	2585	3743	3340	10	6372	2210	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039507_A549--lung-carcinoma-_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	11925
1	3710	SRF	0.00122447578422549	0.346730327383852	12	3744	3694	2359	3744	3270	12	6369	2208	SRF Ishikawa (endometrial adenocarcinoma) SRF	Ishikawa (endometrial adenocarcinoma)	BTO:0003041	SRF		ENCODE	ENCSR000BTD_Ishikawa_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	13088
1	2488	JUNB	0.00122035318810442	0.392727337125552	17	3745	3529	2066	3745	3110	15	6364	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1134.1.damo.pwm.bed	12666
1	2489	JUNB	0.00122035318810442	0.392727337125552	17	3745	3529	2066	3745	3110	15	6364	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1135.1.damo.pwm.bed	12489
1	2491	JUNB	0.00122035318810442	0.392727337125552	17	3745	3529	2066	3745	3110	15	6364	2205	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039331_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1138.1.damo.pwm.bed	12490
1	3189	ONECUT1	0.00120655254662665	0.45008107414267	26	3748	3447	1602	3748	2930	20	6355	2200	ONECUT1 liver ONECUT1	liver	BTO:0000759	ONECUT1	NA	Array Express	ERP002306_onecut1_liver_MACS_ONECUT1_MA0679.2.damo.pwm.bed	30084
1	4125	YY1	0.00118250911832999	0.260288093903761	6	3749	3727	2870	3749	3450	8	6375	2212	YY1 A549 (lung carcinoma) YY1	A549 (lung carcinoma)	BTO:0000018	YY1	1 h with 0.02% Ethanol (Myers)	ENCODE	ENCSR000BPM_A549_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	19542
1	1121	ERG	0.00108294849607392	0.423278916836706	22	3750	3501	1797	3750	3020	18	6359	2202	ERG prostate cancer ERG	prostate cancer	NULL	ERG	NULL	GTRD	EXP000736_prostate-cancer_ERG_MACS_ERG_MA0474.2.damo.pwm.bed	10208
1	2041	GATA6	0.00108294849607392	0.423278916836706	22	3750	3501	1797	3750	3020	18	6359	2202	GATA6 AGS (gastric adenocarcinoma) GATA6	AGS (gastric adenocarcinoma)	BTO:0001007	GATA6		GEO	GSE51705_gata6_ags_MACS_GATA6_MA1104.2.damo.pwm.bed	24307
1	2335	JUN	0.00108294849607392	0.423278916836706	22	3750	3501	1797	3750	3020	18	6359	2202	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 15 minute	GTRD	EXP040263_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	18203
1	3103	NR3C1	0.00101610427130633	0.492183159354356	37	3753	3365	1264	3753	2790	26	6344	2194	NR3C1 BEAS-2B (bronchial epithelium) NR3C1	BEAS-2B (bronchial epithelium)	NULL	NR3C1	dexamethasone	GTRD	EXP036257_BEAS-2B--bronchial-epithelium-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	27789
1	3139	NR3C1	0.00100700063755818	0.484273381762257	35	3754	3384	1318	3754	2820	25	6346	2195	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr	GTRD	EXP049654_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	39106
1	3102	NR3C1	0.00100177410122352	0.407494726922501	20	3755	3526	1901	3755	3060	17	6361	2203	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	etoh	GTRD	EXP036230_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	11080
1	1840	FOXA2	0.000990259038875329	0.674800751968372	157	3756	2818	262	3756	2280	80	6224	2140	FOXA2 A549 (lung carcinoma) FOXA2	A549 (lung carcinoma)	BTO:0000018	FOXA2	Treatment: to induce FOXA2, doxycycline was added at 5ug/mL	GTRD	EXP049305_A549--lung-carcinoma-_FOXA2_MACS_FOXA2_MA0047.3.damo.pwm.bed	61874
1	2319	JUN	0.000975173432681064	0.315269126613432	10	3757	3700	2487	3757	3310	11	6371	2209	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 30 minute	GTRD	EXP039507_A549--lung-carcinoma-_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	11764
1	3020	NFIL3	0.000867076437786479	0.554279317807824	61	3758	3207	785	3758	2580	38	6320	2182	NFIL3 HepG2 (hepatoblastoma) NFIL3	HepG2 (hepatoblastoma)	BTO:0000599	NFIL3	NA	GTRD	EXP040167_HepG2--hepatoblastoma-_NFIL3_MACS_NFIL3_MA0025.2.damo.pwm.bed	41501
1	2311	JUN	0.000862250496822218	0.432707337812028	25	3759	3493	1657	3759	2970	20	6356	2200	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN	100nM dexamethasone (CHEBI:41879) for 12 hour	GTRD	EXP039416_A549--lung-carcinoma-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	19658
1	322	CEBPA	0.000857180743853896	0.582647780931454	76	3760	3094	619	3760	2490	45	6305	2175	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA		GTRD	EXP040183_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0102.4.damo.pwm.bed	47349
1	3685	SPI1	0.000809073191761991	0.419104955140631	23	3761	3505	1739	3761	3000	19	6358	2201	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1		GEO	GSE70482_spi1_k562_MACS_SPI1_MA0080.5.damo.pwm.bed	57064
1	2289	JUN	0.00078190426884333	0.500604059309837	42	3762	3354	1124	3762	2750	29	6339	2191	JUN HAEC (human aortic endothelial cells) JUN	HAEC (human aortic endothelial cells)	NULL	JUN	IL1b, 4h	GTRD	EXP038043_HAEC--human-aortic-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	44588
1	3122	NR3C1	0.000775012050402482	0.486621128577952	38	3763	3370	1238	3763	2790	27	6343	2193	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 5 minute	GTRD	EXP040277_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	17961
1	3112	NR3C1	0.000710642453071604	0.277472071593352	8	3764	3723	2675	3764	3390	10	6373	2210	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 6 hour	GTRD	EXP039702_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	3294
1	2400	JUN	0.00069747535111026	0.138901736307159	2	3765	3780	3390	3780	3640	5	6379	2215	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1127.1.damo.pwm.bed	8273
1	2401	JUN	0.00069747535111026	0.138901736307159	2	3765	3780	3390	3780	3640	5	6379	2215	JUN HUVEC-C (HUVEC, umbilical vein endothelial cells) JUN	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	JUN	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048211_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_JUN_MACS_JUN_MA1128.1.damo.pwm.bed	7635
1	3116	NR3C1	0.00069747535111026	0.138901736307159	2	3765	3780	3390	3780	3640	5	6379	2215	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 10 hour	GTRD	EXP039836_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	845
1	3440	RFX1	0.00069747535111026	0.138901736307159	2	3765	3780	3390	3780	3640	5	6379	2215	RFX1 K562 (myelogenous leukemia) RFX1	K562 (myelogenous leukemia)	NULL	RFX1	NA	GTRD	EXP039804_K562--myelogenous-leukemia-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	11385
1	2569	JUNB	0.000679420013289465	0.346525107838628	14	3769	3695	2252	3769	3240	14	6367	2206	JUNB A549 (lung carcinoma) JUNB	A549 (lung carcinoma)	BTO:0000018	JUNB	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP040136_A549--lung-carcinoma-_JUNB_MACS_JUNB_MA1140.2.damo.pwm.bed	10013
1	3762	T	0.000643933358248072	0.198346528187071	4	3770	3747	3105	3770	3540	7	6377	2213	T H9 T	H9	NULL	T	MESODERM	GEO	GSE60606_t_hes-mesoderm_MACS_T_MA0009.2.damo.pwm.bed	18454
1	1480	ETV5	0.000590852805945862	0.48144885858948	39	3771	3385	1206	3771	2790	28	6342	2192	ETV5 HepG2 (hepatoblastoma) ETV5	HepG2 (hepatoblastoma)	BTO:0000599	ETV5	NA	GTRD	EXP044865_HepG2--hepatoblastoma-_ETV5_MACS_ETV5_MA0765.2.damo.pwm.bed	47542
1	2344	JUN	0.000550178860457745	0.319922256354953	12	3772	3699	2359	3772	3280	13	6369	2207	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA1130.1.damo.pwm.bed	16087
1	2732	MEF2B	0.000544960255902013	0.283692946064823	9	3773	3716	2585	3773	3360	11	6372	2209	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: wildtype MEF2B-V5;	GTRD	EXP055128_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	16216
1	1105	ELK1	0.000496135047911158	0.086864556738224	1	3774	3795	3585	3795	3720	4	6380	2216	ELK1 HeLa S3 (cervical adenocarcinoma) ELK1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK1	NULL	GTRD	EXP000576_HeLa-S3--cervical-adenocarcinoma-_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	4076
1	3686	SPI1	0.000488612258863887	0.578984265894388	84	3775	3138	557	3775	2490	50	6297	2170	SPI1 CD34+ cells SPI1	CD34+ cells	NULL	SPI1	ADULT	GEO	GSE70660_spi1_cd34-adult_MACS_SPI1_MA0080.5.damo.pwm.bed	154599
1	420	CREB1	0.000416129667267235	0.288859950467639	10	3776	3714	2487	3776	3330	12	6371	2208	CREB1 HepG2 (hepatoblastoma) CREB1	HepG2 (hepatoblastoma)	BTO:0000599	CREB1		ENCODE	ENCSR000BVL_HepG2_CREB1_MACS_CREB1_MA0018.4.damo.pwm.bed	18377
1	2340	JUN	0.000416129667267235	0.288859950467639	10	3776	3714	2487	3776	3330	12	6371	2208	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		GTRD	EXP040265_A549--lung-carcinoma-_JUN_MACS_JUN_MA0462.2.damo.pwm.bed	16698
1	3092	NR3C1	0.000375452771406112	0.382547838509162	21	3778	3543	1852	3778	3060	19	6360	2201	NR3C1 IMR90 (lung fibroblasts) NR3C1	IMR90 (lung fibroblasts)	NULL	NR3C1		Array Express	ERP007093_nr3c1_imr90_MACS_NR3C1_MA0113.3.damo.pwm.bed	28830
1	3090	NR3C1	0.000280386063290765	0.380613385490949	22	3779	3547	1797	3779	3040	20	6359	2200	NR3C1 IMR90 (lung fibroblasts) NR3C1	IMR90 (lung fibroblasts)	NULL	NR3C1	GLUCC	Array Express	ERP007081_nr3c1_imr90-glucc_MACS_NR3C1_MA0113.3.damo.pwm.bed	28403
1	3687	SPI1	0.000280386063290765	0.380613385490949	22	3779	3547	1797	3779	3040	20	6359	2200	SPI1 CD34+ cells SPI1	CD34+ cells	NULL	SPI1	FETAL	GEO	GSE70660_spi1_cd34-fetal_MACS_SPI1_MA0080.5.damo.pwm.bed	60680
1	3141	NR3C1	0.000229903434591325	0.435141114625596	34	3781	3463	1349	3781	2860	27	6347	2193	NR3C1 HASM2 (Human airway smooth muscle 2) NR3C1	HASM2 (Human airway smooth muscle 2)	NULL	NR3C1	Treatment: dexamethasone for 4 hr Genotype: Ad-GFP transduction	GTRD	EXP049656_HASM2--Human-airway-smooth-muscle-2-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	42684
1	2706	MAX	0.000227118713794064	0.14872636471166	3	3782	3779	3252	3782	3600	7	6378	2213	MAX liver MAX	liver	BTO:0000759	MAX		GTRD	EXP039669_liver_MAX_MACS_MAX_MA0058.3.damo.pwm.bed	16160
1	3761	T	0.000204021951219545	0.115738120209371	2	3783	3794	3390	3794	3660	6	6379	2214	T H9 T	H9	NULL	T	ENDODERM	GEO	GSE60606_t_hes-endoderm_MACS_T_MA0009.2.damo.pwm.bed	14361
1	1110	ELK4	0.000194554542042521	0.192693722468743	5	3784	3748	2973	3784	3500	9	6376	2211	ELK4 HeLa S3 (cervical adenocarcinoma) ELK4	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK4	NULL	GTRD	EXP000581_HeLa-S3--cervical-adenocarcinoma-_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	8307
1	2707	MAX	0.000194554542042521	0.192693722468743	5	3784	3748	2973	3784	3500	9	6376	2211	MAX liver MAX	liver	BTO:0000759	MAX		GTRD	EXP039669_liver_MAX_MACS_MAX_MA0059.1.damo.pwm.bed	16902
1	3841	TEAD4	0.000175066825982535	0.325803477087593	16	3786	3698	2127	3786	3200	17	6365	2203	TEAD4 SNU216 (gastric tubular adenocarcinoma) TEAD4	SNU216 (gastric tubular adenocarcinoma)	NULL	TEAD4		GEO	GSE44416_tead4_snu216_MACS_TEAD4_MA0809.2.damo.pwm.bed	21813
1	321	CEBPA	0.000148741799786627	0.559116956155222	91	3787	3186	506	3787	2490	56	6290	2164	CEBPA HepG2 (hepatoblastoma) CEBPA	HepG2 (hepatoblastoma)	BTO:0000599	CEBPA		GTRD	EXP040183_HepG2--hepatoblastoma-_CEBPA_MACS_CEBPA_MA0019.1.damo.pwm.bed	59957
1	3111	NR3C1	0.000136909051768468	0.220597919235935	7	3788	3740	2768	3788	3430	11	6374	2209	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1	100nM dexamethasone (CHEBI:41879) for 3 hour	GTRD	EXP039685_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	4624
1	1108	ELK4	0.000127788884826707	0.0694761844343234	1	3789	3796	3585	3796	3720	5	6380	2215	ELK4 HeLa S3 (cervical adenocarcinoma) ELK4	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK4		ENCODE	ENCSR000EVI_HeLa-S3_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	6307
1	3441	RFX1	0.000127788884826707	0.0694761844343234	1	3789	3796	3585	3796	3720	5	6380	2215	RFX1 K562 (myelogenous leukemia) RFX1	K562 (myelogenous leukemia)	NULL	RFX1	NA	GTRD	EXP039819_K562--myelogenous-leukemia-_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	10739
1	3007	NFIA	0.000110943157210695	0.231030397154132	8	3791	3739	2675	3791	3400	12	6373	2208	NFIA HepG2 (hepatoblastoma) NFIA	HepG2 (hepatoblastoma)	BTO:0000599	NFIA	NA	GTRD	EXP038543_HepG2--hepatoblastoma-_NFIA_MACS_NFIA_MA0670.1.damo.pwm.bed	9551
1	3155	NR3C1	9.88598712803312e-05	0.32772367076184	18	3792	3697	1996	3792	3160	19	6363	2201	NR3C1 U2OS (osteosarcoma) NR3C1	U2OS (osteosarcoma)	BTO:0001938	NR3C1	SHNS	GEO	GSE65847_nr3c1_u2os-shns_MACS_NR3C1_MA0113.3.damo.pwm.bed	15065
1	3496	RUNX1	7.23756177944785e-05	0.154135815645398	4	3793	3778	3105	3793	3560	9	6377	2211	RUNX1 CD34+ cells RUNX1	CD34+ cells	NULL	RUNX1		GEO	GSE64862_runx1_cd34_MACS_RUNX1_MA0002.2.damo.pwm.bed	27202
1	2761	MLX	5.08386836469496e-05	0.202115779435711	7	3794	3746	2768	3794	3440	12	6374	2208	MLX HepG2 (hepatoblastoma) MLX	HepG2 (hepatoblastoma)	BTO:0000599	MLX	NA	GTRD	EXP039860_HepG2--hepatoblastoma-_MLX_MACS_MLX_MA0663.1.damo.pwm.bed	19689
1	2626	KLF1	4.35201010969393e-05	0.359264190776269	26	3795	3554	1602	3795	2980	25	6355	2195	KLF1 HEK293 (embryonic kidney) KLF1	HEK293 (embryonic kidney)	NULL	KLF1	NA	GTRD	EXP039484_HEK293--embryonic-kidney-_KLF1_MACS_KLF1_MA0493.1.damo.pwm.bed	18389
1	2731	MEF2B	3.29137510258365e-05	0.0578392559260637	1	3796	3798	3585	3798	3730	6	6380	2214	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: wildtype MEF2B-V5;	GTRD	EXP055127_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	6120
1	146	AR	2.37834745574644e-05	0.331052551473555	23	3797	3696	1739	3797	3080	24	6358	2196	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	ARQ6540X	GEO	GSE47987_AR_du145-arq6540x_MACS_AR_MA0007.3.damo.pwm.bed	17439
1	149	AR	2.93064506195078e-06	0.307946175267612	25	3798	3704	1657	3798	3050	28	6356	2192	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR		GEO	GSE47987_AR_du145_MACS_AR_MA0007.3.damo.pwm.bed	11076
1	55	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR	radiation	GTRD	EXP036886_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	28
1	103	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR R1-D567 (prostate cancer) AR	R1-D567 (prostate cancer)	NULL	AR	Treatment: 0.1% DMSO for 4 hrs	GTRD	EXP049665_R1-D567--prostate-cancer-_AR_MACS_AR_MA0007.3.damo.pwm.bed	12
1	105	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR LNCaP95 AR	LNCaP95	NULL	AR	Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection	GTRD	EXP052946_LNCaP95_AR_MACS_AR_MA0007.3.damo.pwm.bed	48
1	118	AR	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	AR primary prostate cancer AR	primary prostate cancer	NULL	AR	Treatment: FA (control)	GTRD	EXP053232_primary-prostate-cancer_AR_MACS_AR_MA0007.3.damo.pwm.bed	21
1	129	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	KDP53	GEO	GSE31294_AR_lncap-kdp53_MACS_AR_MA0007.3.damo.pwm.bed	34
1	136	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR LNCaP (prostate carcinoma) AR	LNCaP (prostate carcinoma)	BTO:0001321	AR	SHCTR_R1881_HD	GEO	GSE37345_AR_lncap-shctr-r1881-hd_MACS_AR_MA0007.3.damo.pwm.bed	7
1	145	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR DU145 (prostate carcinoma) AR	DU145 (prostate carcinoma)	BTO:0001332	AR	ARG56W	GEO	GSE47987_AR_du145-arg56w_MACS_AR_MA0007.3.damo.pwm.bed	31
1	151	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncap-dht1nm_MACS_AR_MA0007.3.damo.pwm.bed	8
1	152	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncaparmo-ar-dht100nm_MACS_AR_MA0007.3.damo.pwm.bed	31
1	153	AR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	AR AR	NA	NA	AR	NA	GEO	GSE48308_AR_lncaparmo-ar-dht1nm_MACS_AR_MA0007.3.damo.pwm.bed	61
1	214	ARNT	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ARNT renal tubular cells ARNT	renal tubular cells	NULL	ARNT	1 mM dimethyloxalylglycine	GTRD	EXP036852_renal-tubular-cells_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	1903
1	215	ARNT	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ARNT renal tubular cells ARNT	renal tubular cells	NULL	ARNT	1 mM dimethyloxalylglycine	GTRD	EXP036852_renal-tubular-cells_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	1976
1	216	ARNT	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ARNT renal tubular cells ARNT	renal tubular cells	NULL	ARNT	1 mM dimethyloxalylglycine	GTRD	EXP036852_renal-tubular-cells_ARNT_MACS_ARNT_MA0259.1.damo.pwm.bed	1573
1	217	ARNT	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ARNT HEK293T (embryonic kidney) ARNT	HEK293T (embryonic kidney)	BTO:0002181	ARNT		GTRD	EXP039727_HEK293T--embryonic-kidney-_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	909
1	218	ARNT	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ARNT HEK293T (embryonic kidney) ARNT	HEK293T (embryonic kidney)	BTO:0002181	ARNT		GTRD	EXP039727_HEK293T--embryonic-kidney-_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	1238
1	219	ARNT	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ARNT HEK293T (embryonic kidney) ARNT	HEK293T (embryonic kidney)	BTO:0002181	ARNT		GTRD	EXP039727_HEK293T--embryonic-kidney-_ARNT_MACS_ARNT_MA0259.1.damo.pwm.bed	959
1	223	ARNT	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ARNT HUVEC-C (HUVEC, umbilical vein endothelial cells) ARNT	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ARNT	Passage: 4-6	GTRD	EXP049262_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ARNT_MACS_ARNT_MA0004.1.damo.pwm.bed	700
1	224	ARNT	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ARNT HUVEC-C (HUVEC, umbilical vein endothelial cells) ARNT	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ARNT	Passage: 4-6	GTRD	EXP049262_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ARNT_MACS_ARNT_MA0006.1.damo.pwm.bed	712
1	227	ARNTL	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ARNTL U2OS (osteosarcoma) ARNTL	U2OS (osteosarcoma)	BTO:0001938	ARNTL	NA	GTRD	EXP035003_U2OS--osteosarcoma-_ARNTL_MACS_ARNTL_MA0603.1.damo.pwm.bed	531
1	228	ARNTL	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ARNTL ARNTL	NA	NA	ARNTL	NA	GEO	GSE74439_arntl_u2os-dmso_MACS_ARNTL_MA0603.1.damo.pwm.bed	12
1	231	ASCL1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ASCL1 G523NS (glioblastoma) ASCL1	G523NS (glioblastoma)	NULL	ASCL1		GTRD	EXP037901_G523NS--glioblastoma-_ASCL1_MACS_ASCL1_MA1100.2.damo.pwm.bed	1692
1	232	ASCL1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ASCL1 G523NS (glioblastoma) ASCL1	G523NS (glioblastoma)	NULL	ASCL1		GTRD	EXP037901_G523NS--glioblastoma-_ASCL1_MACS_ASCL1_MA1631.1.damo.pwm.bed	1409
1	243	ATF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ATF3 GM12878 (female B-cells lymphoblastoid cell line) ATF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ATF3		ENCODE	ENCSR000BJY_GM12878_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	2516
1	244	ATF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ATF3 WA01 (H1, human embryonic stem cells) ATF3	WA01 (H1, human embryonic stem cells)	NULL	ATF3		ENCODE	ENCSR000BKC_H1-hESC_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	4098
1	249	ATF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ATF3 K562 (myelogenous leukemia) ATF3	K562 (myelogenous leukemia)	NULL	ATF3		ENCODE	ENCSR000DOG_K562_ATF3_MACS_ATF3_MA0605.2.damo.pwm.bed	548
1	257	ATF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ATF3 HCT-116 (colon carcinoma) ATF3	HCT-116 (colon carcinoma)	BTO:0001109	ATF3	DMSO_KOATF3	GEO	GSE74355_atf3_htc116-dmso-koatf3_MACS_ATF3_MA0605.2.damo.pwm.bed	643
1	262	ATF4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ATF4 hMSC ATF4	hMSC	NA	ATF4		GEO	GSE68864_atf4_hmsc_MACS_ATF4_MA0833.2.damo.pwm.bed	539
1	269	BACH1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	BACH1 BACH1	NA	NA	BACH1	NA	NA	ENCSR585CVE_GM12878_BACH1_MACS_BACH1_MA0591.1.damo.pwm.bed	1701
1	284	BCL6	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	BCL6 OCI-LY1 (diffuse large B-cell lymphoma) BCL6	OCI-LY1 (diffuse large B-cell lymphoma)	NULL	BCL6		GTRD	EXP040595_OCI-LY1--diffuse-large-B-cell-lymphoma-_BCL6_MACS_BCL6_MA0463.2.damo.pwm.bed	618
1	402	CEBPB	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CEBPB CEBPB	NA	NA	CEBPB	NA	GEO	GSE66192_cebpb_cd14-oxldl_MACS_CEBPB_MA0466.2.damo.pwm.bed	3427
1	413	CLOCK	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CLOCK CLOCK	NA	NA	CLOCK	NA	GEO	GSE74439_clock_u2os-6an_MACS_CLOCK_MA0819.1.damo.pwm.bed	166
1	428	CREB1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CREB1 KG1 (acute myeloid leukemia) CREB1	KG1 (acute myeloid leukemia)	BTO:0000670	CREB1	DMSO	GEO	GSE74928_CREB1_kg1-dmso_MACS_CREB1_MA0018.4.damo.pwm.bed	282
1	627	CTCF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CTCF SK-OV-3 (ovarian serous cystadenocarcinoma) CTCF	SK-OV-3 (ovarian serous cystadenocarcinoma)	NULL	CTCF		GTRD	EXP036562_SK-OV-3--ovarian-serous-cystadenocarcinoma-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	136
1	649	CTCF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CTCF 226LDM (normal breast luminal cells) CTCF	226LDM (normal breast luminal cells)	NULL	CTCF	hydroxyurea and nocodazole	GTRD	EXP036891_226LDM--normal-breast-luminal-cells-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	68
1	688	CTCF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CTCF subcutaneous adipose tissue CTCF	subcutaneous adipose tissue	BTO:0004042	CTCF		GTRD	EXP039456_subcutaneous-adipose-tissue_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	118
1	700	CTCF	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	CTCF stomach CTCF	stomach	BTO:0001307	CTCF		GTRD	EXP039534_stomach_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	1594
1	707	CTCF	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	CTCF lower leg skin CTCF	lower leg skin	NULL	CTCF		GTRD	EXP039574_lower-leg-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	877
1	725	CTCF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CTCF omental fat pad CTCF	omental fat pad	NULL	CTCF		GTRD	EXP039695_omental-fat-pad_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	21
1	731	CTCF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CTCF lower leg skin CTCF	lower leg skin	NULL	CTCF		GTRD	EXP039707_lower-leg-skin_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	8
1	892	CTCF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CTCF EndoC-BH1 (human pancreatic beta cell line) CTCF	EndoC-BH1 (human pancreatic beta cell line)	NULL	CTCF	Source: Pancreas	GTRD	EXP053296_EndoC-BH1--human-pancreatic-beta-cell-line-_CTCF_MACS_CTCF_MA0139.1.damo.pwm.bed	3
1	992	CTCFL	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CTCFL NHDF CTCFL	NHDF	NA	CTCFL	NA	GEO	GSE70764_ctcfl_nhdf_MACS_CTCFL_MA1102.2.damo.pwm.bed	2
1	994	CUX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CUX1 GM12878 (female B-cells lymphoblastoid cell line) CUX1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	CUX1	NA	ENCODE	ENCSR000DYR_GM12878_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	184
1	998	CUX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	GTRD	EXP038271_K562--myelogenous-leukemia-_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	1318
1	1000	CUX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	CUX1 K562 (myelogenous leukemia) CUX1	K562 (myelogenous leukemia)	NULL	CUX1	NA	GTRD	EXP038273_K562--myelogenous-leukemia-_CUX1_MACS_CUX1_MA0754.1.damo.pwm.bed	1663
1	1005	E2F1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	E2F1 HeLa S3 (cervical adenocarcinoma) E2F1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	E2F1		ENCODE	ENCSR000EVJ_HeLa-S3_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	3015
1	1027	E2F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F1 hTERT-RPE1 E2F1	hTERT-RPE1	BTO:0004790	E2F1		GTRD	EXP055165_hTERT-RPE1_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	798
1	1028	E2F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F1 U2OS (osteosarcoma) E2F1	U2OS (osteosarcoma)	BTO:0001938	E2F1		GTRD	EXP055169_U2OS--osteosarcoma-_E2F1_MACS_E2F1_MA0024.3.damo.pwm.bed	343
1	1033	E2F4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F4 GM12878 (female B-cells lymphoblastoid cell line) E2F4	GM12878 (female B-cells lymphoblastoid cell line)	NULL	E2F4		ENCODE	ENCSR000DYY_GM12878_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	713
1	1035	E2F4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4		ENCODE	ENCSR505NMN_MCF-7_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	204
1	1038	E2F4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	Treatment: treated with 100nm ICI 182780 for 48hrs;	GTRD	EXP054361_MCF7--Invasive-ductal-breast-carcinoma-_E2F4_MACS_E2F4_MA0470.2.damo.pwm.bed	853
1	1039	E2F4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F4 lymphoblastoid cells E2F4	lymphoblastoid cells	NULL	E2F4		GEO	GSE21488_e2f4_lymphoblastoid_MACS_E2F4_MA0470.2.damo.pwm.bed	244
1	1040	E2F4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F4 MCF7 (Invasive ductal breast carcinoma) E2F4	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F4	ICI	GEO	GSE41561_e2f4_mcf7-ici_MACS_E2F4_MA0470.2.damo.pwm.bed	644
1	1042	E2F4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F4 retina E2F4	retina	BTO:0001175	E2F4	pigment	GEO	GSE60024_e2f4_retinal-pigment_MACS_E2F4_MA0470.2.damo.pwm.bed	523
1	1049	E2F8	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	E2F8 MCF7 (Invasive ductal breast carcinoma) E2F8	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	E2F8	NA	GTRD	EXP040284_MCF7--Invasive-ductal-breast-carcinoma-_E2F8_MACS_E2F8_MA0865.1.damo.pwm.bed	386
1	1059	EGR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	EGR1 GM12878 (female B-cells lymphoblastoid cell line) EGR1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	EGR1		ENCODE	ENCSR000BRG_GM12878_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	1686
1	1067	EGR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	EGR1 HL-60 (acute myeloid leukemia) EGR1	HL-60 (acute myeloid leukemia)	BTO:0000738	EGR1	Treatment: untreated	GTRD	EXP047937_HL-60--acute-myeloid-leukemia-_EGR1_MACS_EGR1_MA0162.4.damo.pwm.bed	3238
1	1075	EHF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	EHF Calu-3 (lung adenocarcinoma) EHF	Calu-3 (lung adenocarcinoma)	BTO:0002750	EHF		GEO	GSE63398_ehf_calu3_MACS_EHF_MA0598.3.damo.pwm.bed	78
1	1083	ELF1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ELF1 MCF7 (Invasive ductal breast carcinoma) ELF1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELF1		ENCODE	ENCSR475SOC_MCF-7_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	1331
1	1084	ELF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELF1 K562 (myelogenous leukemia) ELF1	K562 (myelogenous leukemia)	NULL	ELF1		ENCODE	ENCSR975SSR_K562_ELF1_MACS_ELF1_MA0473.3.damo.pwm.bed	4493
1	1089	ELF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELF1 ELF1	NA	NA	ELF1	NA	GEO	GSE59021_elf1_du145_MACS_ELF1_MA0473.3.damo.pwm.bed	126
1	1095	ELF4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELF4 HEK293T (embryonic kidney) ELF4	HEK293T (embryonic kidney)	BTO:0002181	ELF4	NA	GTRD	EXP039387_HEK293T--embryonic-kidney-_ELF4_MACS_ELF4_MA0641.1.damo.pwm.bed	1386
1	1097	ELF4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELF4 ELF4	NA	NA	ELF4	NA	GEO	GSE53357_elf4_t3m1_MACS_ELF4_MA0641.1.damo.pwm.bed	187
1	1098	ELF5	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELF5 T47D (invasive ductal carcinoma) ELF5	T47D (invasive ductal carcinoma)	BTO:0001248	ELF5	ELF5_48H	GEO	GSE31216_elf5_t47d-elf5-48h_MACS_ELF5_MA0136.2.damo.pwm.bed	181
1	1099	ELK1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK1 HeLa S3 (cervical adenocarcinoma) ELK1	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	ELK1		ENCODE	ENCSR000ECI_HeLa-S3_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3506
1	1100	ELK1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK1 K562 (myelogenous leukemia) ELK1	K562 (myelogenous leukemia)	NULL	ELK1		ENCODE	ENCSR000EFU_K562_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3082
1	1101	ELK1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK1 K562 (myelogenous leukemia) ELK1	K562 (myelogenous leukemia)	NULL	ELK1		ENCODE	ENCSR338QAC_K562_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3535
1	1102	ELK1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ELK1 MCF7 (Invasive ductal breast carcinoma) ELK1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ELK1		ENCODE	ENCSR382WLL_MCF-7_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	3996
1	1103	ELK1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK1 A549 (lung carcinoma) ELK1	A549 (lung carcinoma)	BTO:0000018	ELK1		ENCODE	ENCSR623KNM_A549_ELK1_MACS_ELK1_MA0028.2.damo.pwm.bed	351
1	1104	ELK1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK1 WA01 (H1, human embryonic stem cells) ELK1	WA01 (H1, human embryonic stem cells)	NULL	ELK1		Array Express	ERP002417_elk1_esc-h1_MACS_ELK1_MA0028.2.damo.pwm.bed	677
1	1107	ELK4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK4 HEK293 (embryonic kidney) ELK4	HEK293 (embryonic kidney)	NULL	ELK4		ENCODE	ENCSR000EVB_HEK293_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	134
1	1109	ELK4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK4 HEK293 (embryonic kidney) ELK4	HEK293 (embryonic kidney)	NULL	ELK4	NULL	GTRD	EXP000103_HEK293--embryonic-kidney-_ELK4_MACS_ELK4_MA0076.2.damo.pwm.bed	1186
1	1111	ELK4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ELK4 ELK4	NA	NA	ELK4	NA	GEO	GSE59021_elk4_du145_MACS_ELK4_MA0076.2.damo.pwm.bed	63
1	1174	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 breast ESR1	breast	NA	ESR1	glyc	Array Express	ERP002305_esr1_breast-glyc_MACS_ESR1_MA0112.3.damo.pwm.bed	45
1	1179	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	hormone starved for 3 days, treated with 1% ethanol for 45 minutes	GTRD	EXP000177_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	437
1	1219	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	DMSO	GTRD	EXP036389_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	15
1	1220	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	E2	GTRD	EXP036390_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	247
1	1301	ESR1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040950_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	376
1	1304	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	control	GTRD	EXP040953_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	186
1	1368	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 primary endometrium cancer ESR1	primary endometrium cancer	NULL	ESR1	Treatment: FA (control)	GTRD	EXP053240_primary-endometrium-cancer_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	171
1	1371	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	Treatment: vehicle (0.01% EtOH) for 30 mins Genotype: pS118-ER	GTRD	EXP053337_MCF7--Invasive-ductal-breast-carcinoma-_ESR1_MACS_ESR1_MA0112.3.damo.pwm.bed	34
1	1386	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 H3396 (breast carcinoma) ESR1	H3396 (breast carcinoma)	NULL	ESR1	ETOH	GEO	GSE32349_esr1_h3396-etoh_MACS_ESR1_MA0112.3.damo.pwm.bed	883
1	1398	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	LETR_ANDRO	GEO	GSE54592_esr1_letr-andro_MACS_ESR1_MA0112.3.damo.pwm.bed	28
1	1411	ESR1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESR1 MCF7 (Invasive ductal breast carcinoma) ESR1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	ESR1	TNF	GEO	GSE59530_esr1_mcf7-tnf_MACS_ESR1_MA0112.3.damo.pwm.bed	441
1	1443	ESRRA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ESRRA GM12878 (female B-cells lymphoblastoid cell line) ESRRA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	ESRRA		ENCODE	ENCSR000DYQ_GM12878_ESRRA_MACS_ESRRA_MA0592.3.damo.pwm.bed	788
1	1456	ETS1	0	0	0	3799	3799	3799	3799	3800	2	6381	2218	ETS1 CD4+ CD25- T-cells ETS1	CD4+ CD25- T-cells	NULL	ETS1		GTRD	EXP032568_CD4--CD25--T-cells_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	8216
1	1463	ETS1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ETS1 HUVEC-C (HUVEC, umbilical vein endothelial cells) ETS1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	ETS1		GTRD	EXP038278_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_ETS1_MACS_ETS1_MA0098.3.damo.pwm.bed	2734
1	1486	ETV6	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ETV6 Reh (ATCC CRL-8286) ETV6	Reh (ATCC CRL-8286)	BTO:0001163	ETV6	Positive IP/test condition	GTRD	EXP040493_Reh--ATCC-CRL-8286-_ETV6_MACS_ETV6_MA0645.1.damo.pwm.bed	737
1	1496	FLI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 0 Passage: P3-6	GTRD	EXP048205_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	2489
1	1498	FLI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FLI1 HUVEC-C (HUVEC, umbilical vein endothelial cells) FLI1	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	FLI1	Treatment: agent VEGF, timepoint 4 Passage: P3-6	GTRD	EXP048207_HUVEC-C--HUVEC--umbilical-vein-endothelial-cells-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	6327
1	1501	FLI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FLI1 A-673 clone Asp114 (Ewing sarcoma) FLI1	A-673 clone Asp114 (Ewing sarcoma)	NULL	FLI1	Passage: 15-19	GTRD	EXP049960_A-673-clone-Asp114--Ewing-sarcoma-_FLI1_MACS_FLI1_MA0475.2.damo.pwm.bed	12288
1	1509	FLI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHFLI_48H	GEO	GSE61944_fli1_skmnc-shfli-48h_MACS_FLI1_MA0475.2.damo.pwm.bed	523
1	1510	FLI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FLI1 SK-N-MC (Askin tumor) FLI1	SK-N-MC (Askin tumor)	BTO:0002914	FLI1	SHFLI_96H	GEO	GSE61944_fli1_skmnc-shfli-96h_MACS_FLI1_MA0475.2.damo.pwm.bed	126
1	1525	FOS	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOS GM12878 (female B-cells lymphoblastoid cell line) FOS	GM12878 (female B-cells lymphoblastoid cell line)	NULL	FOS	NULL	GTRD	EXP000437_GM12878--female-B-cells-_FOS_MACS_FOS_MA0476.1.damo.pwm.bed	2335
1	1629	FOSL2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOSL2 hFOB 1.19 (fetal osteoblast) FOSL2	hFOB 1.19 (fetal osteoblast)	BTO:0005224	FOSL2	DIFF	GEO	GSE82295_fosl2_hfob-diff_MACS_FOSL2_MA0478.1.damo.pwm.bed	1464
1	1688	FOXA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOXA1 K562 (myelogenous leukemia) FOXA1	K562 (myelogenous leukemia)	NULL	FOXA1		GTRD	EXP039676_K562--myelogenous-leukemia-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	123
1	1692	FOXA1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	FOXA1 HEK293T (embryonic kidney) FOXA1	HEK293T (embryonic kidney)	BTO:0002181	FOXA1		GTRD	EXP039910_HEK293T--embryonic-kidney-_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	278
1	1716	FOXA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOXA1 prostate tumor FOXA1	prostate tumor	NULL	FOXA1	Patient: #1	GTRD	EXP048494_prostate-tumor_FOXA1_MACS_FOXA1_MA0148.4.damo.pwm.bed	273
1	1763	FOXA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOXA1 HuH7 (hepatocellular carcinoma) FOXA1	HuH7 (hepatocellular carcinoma)	BTO:0001950	FOXA1	MITO	GEO	GSE39241_foxa1_huh7-mito_MACS_FOXA1_MA0148.4.damo.pwm.bed	13
1	1799	FOXA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOXA1 LNCaP (prostate carcinoma) FOXA1	LNCaP (prostate carcinoma)	BTO:0001321	FOXA1	SHGATA2_ETOH	GEO	GSE69043_foxa1_lncap-shgata2-etoh_MACS_FOXA1_MA0148.4.damo.pwm.bed	41
1	1857	FOXP1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOXP1 SU-DHL-4 (diffuse large B-cell lymphoma) FOXP1	SU-DHL-4 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	Array Express	ERP010999_foxp1_sudhl4_MACS_FOXP1_MA0481.3.damo.pwm.bed	225
1	1861	FOXP1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOXP1 HT (diffuse large B-cell lymphoma) FOXP1	HT (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	GTRD	EXP034308_HT--diffuse-large-B-cell-lymphoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	2544
1	1862	FOXP1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	FOXP1 OCI-LY19 (diffuse large B-cell lymphoma) FOXP1	OCI-LY19 (diffuse large B-cell lymphoma)	NULL	FOXP1	NA	GTRD	EXP034311_OCI-LY19--diffuse-large-B-cell-lymphoma-_FOXP1_MACS_FOXP1_MA0481.3.damo.pwm.bed	889
1	1866	FOXP1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	FOXP1 neural-progenitor FOXP1	neural-progenitor	NA	FOXP1	NA	GEO	GSE62718_foxp1_neural-progenitor_MACS_FOXP1_MA0481.3.damo.pwm.bed	1155
1	1875	GABPA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GABPA MCF7 (Invasive ductal breast carcinoma) GABPA	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	GABPA		ENCODE	ENCSR038RXU_MCF-7_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	1288
1	1878	GABPA	0	0	0	3799	3799	3799	3799	3800	2	6381	2218	GABPA CD34+CD133+ hematopoietic progenitors GABPA	CD34+CD133+ hematopoietic progenitors	NULL	GABPA	NULL	GTRD	EXP000224_CD34-CD133--hematopoietic-progenitors_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	9848
1	1882	GABPA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GABPA THP-1 (acute monocytic leukemia) GABPA	THP-1 (acute monocytic leukemia)	BTO:0001370	GABPA	Treatment: 100 nM ethanol for 24 hrs	GTRD	EXP049795_THP-1--acute-monocytic-leukemia-_GABPA_MACS_GABPA_MA0062.3.damo.pwm.bed	1795
1	1885	GABPA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GABPA HeLa (cervical adenocarcinoma) GABPA	HeLa (cervical adenocarcinoma)	BTO:0000567	GABPA		GEO	GSE31417_gabpa_hela_MACS_GABPA_MA0062.3.damo.pwm.bed	2460
1	1890	GABPA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GABPA DU145 (prostate carcinoma) GABPA	DU145 (prostate carcinoma)	BTO:0001332	GABPA		GEO	GSE59021_gabpa_du145_MACS_GABPA_MA0062.3.damo.pwm.bed	2381
1	1895	GATA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA1 erythroblasts GATA1	erythroblasts	NULL	GATA1		ENCODE	ENCSR000EXR_erythroblast_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	633
1	1900	GATA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	24 hours following induction with TPA	GTRD	EXP000588_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	3085
1	1901	GATA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	24 hours following induction with TPA	GTRD	EXP000588_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	3006
1	1922	GATA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Hub KO	GTRD	EXP040811_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0035.4.damo.pwm.bed	4753
1	1923	GATA1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA1 K562 (myelogenous leukemia) GATA1	K562 (myelogenous leukemia)	NULL	GATA1	MYO1D Hub KO	GTRD	EXP040811_K562--myelogenous-leukemia-_GATA1_MACS_GATA1_MA0140.2.damo.pwm.bed	5256
1	1939	GATA2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA2 Kasumi-3 (adult acute myeloid leukemia with minimal differentiation) GATA2	Kasumi-3 (adult acute myeloid leukemia with minimal differentiation)	NULL	GATA2		GTRD	EXP036547_Kasumi-3--adult-acute-myeloid-leukemia-with-minimal-differentiation-_GATA2_MACS_GATA2_MA0036.3.damo.pwm.bed	14
1	1973	GATA3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA3 WA09 (embryonic stem cells) GATA3	WA09 (embryonic stem cells)	NULL	GATA3	BMP4 for 3 day	GTRD	EXP040703_WA09--embryonic-stem-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	2418
1	1974	GATA3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA3 WA09 (embryonic stem cells) GATA3	WA09 (embryonic stem cells)	NULL	GATA3	BMP4 for 3 day	GTRD	EXP040704_WA09--embryonic-stem-cells-_GATA3_MACS_GATA3_MA0037.3.damo.pwm.bed	488
1	1991	GATA3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA3 CCRF-CEM (T acute lymphoblastic leukemia) GATA3	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	GATA3		GEO	GSE33850_gata3_ccrfcem_MACS_GATA3_MA0037.3.damo.pwm.bed	497
1	1992	GATA3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA3 RPMI-8402 (T acute lymphoblastic leukemia) GATA3	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	GATA3		GEO	GSE39179_gata3_rpmi8402_MACS_GATA3_MA0037.3.damo.pwm.bed	233
1	2005	GATA3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA3 CD4 GATA3	CD4	NA	GATA3	TH1	GEO	GSE72266_gata3_cd4-th1_MACS_GATA3_MA0037.3.damo.pwm.bed	80
1	2016	GATA4	0	0	0	3799	3799	3799	3799	3800	3	6381	2217	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4		GTRD	EXP037716_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	10796
1	2019	GATA4	0	0	0	3799	3799	3799	3799	3800	4	6381	2216	GATA4 iPSC-derived cardiomyocytes GATA4	iPSC-derived cardiomyocytes	NULL	GATA4	G296S mutant	GTRD	EXP037722_iPSC-derived-cardiomyocytes_GATA4_MACS_GATA4_MA0482.2.damo.pwm.bed	6893
1	2028	GATA6	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	GATA6 H9 GATA6	H9	NULL	GATA6		Array Express	ERP004206_gata6_esc-h9_MACS_GATA6_MA1104.2.damo.pwm.bed	1609
1	2039	GATA6	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GATA6 Caco-2 (colon adenocarcinoma) GATA6	Caco-2 (colon adenocarcinoma)	BTO:0000195	GATA6	DIFF	GEO	GSE23436_gata6_caco2-diff_MACS_GATA6_MA1104.2.damo.pwm.bed	309
1	2048	GFI1B	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: DMSO; Genotype: wildtype;	GTRD	EXP058347_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	3543
1	2050	GFI1B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: DMSO; Genotype: drug-resistant SET-2 LSD1 (Leu659_Asn660insArg);	GTRD	EXP058351_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1253
1	2051	GFI1B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	GFI1B SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens) GFI1B	SET2 (Adult acute megakaryoblastic leukemia, Homo Sapiens)	NULL	GFI1B	Treatment: GSK-LSD1 for 48 hrs; Genotype: drug-resistant SET-2 LSD1 (Leu659_Asn660insArg);	GTRD	EXP058353_SET2--Adult-acute-megakaryoblastic-leukemia--Homo-Sapiens-_GFI1B_MACS_GFI1B_MA0483.1.damo.pwm.bed	1493
1	2052	GFI1B	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	GFI1B CD34+ cells GFI1B	CD34+ cells	NULL	GFI1B		GEO	GSE52924_gfi1b_cd34_MACS_GFI1B_MA0483.1.damo.pwm.bed	2688
1	2081	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048717_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	949
1	2082	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048717_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	849
1	2083	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048721_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	739
1	2084	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours, HIF2a knockout	GTRD	EXP048721_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	553
1	2085	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048722_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	3020
1	2086	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048722_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	2809
1	2087	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048723_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	592
1	2088	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A RCC4 (kidney cancer cell line) HIF1A	RCC4 (kidney cancer cell line)	BTO:0005691	HIF1A	Treatment: degree of hypoxia - normoxia	GTRD	EXP048723_RCC4--kidney-cancer-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	745
1	2089	HIF1A	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048736_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	678
1	2090	HIF1A	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048736_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	597
1	2091	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048737_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	3131
1	2092	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HepG2 (hepatoblastoma) HIF1A	HepG2 (hepatoblastoma)	BTO:0000599	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048737_HepG2--hepatoblastoma-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	3126
1	2093	HIF1A	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 6 hours	GTRD	EXP048740_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	41
1	2094	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 6 hours	GTRD	EXP048740_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	57
1	2095	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 48 hours	GTRD	EXP048746_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	126
1	2096	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 48 hours	GTRD	EXP048746_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	158
1	2097	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048753_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA0259.1.damo.pwm.bed	1377
1	2098	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A HKC8 (kidney proximal tubule cell line) HIF1A	HKC8 (kidney proximal tubule cell line)	NULL	HIF1A	Treatment: degree of hypoxia 0.5%, duration of hypoxia 16 hours	GTRD	EXP048753_HKC8--kidney-proximal-tubule-cell-line-_HIF1A_MACS_HIF1A_MA1106.1.damo.pwm.bed	1289
1	2104	HIF1A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	HIF1A RCC 7860 (Renal cell carcinoma) HIF1A	RCC 7860 (Renal cell carcinoma)	BTO:0003781	HIF1A		GEO	GSE34871_hif1a_786o_MACS_HIF1A_MA1106.1.damo.pwm.bed	1945
1	2106	HIF1A	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HIF1A macrophages HIF1A	macrophages	NULL	HIF1A	HYPO_IL	GEO	GSE43109_hif1a_macrophage-hypo-il_MACS_HIF1A_MA1106.1.damo.pwm.bed	1143
1	2107	HINFP	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HINFP hTERT-RPE1 HINFP	hTERT-RPE1	BTO:0004790	HINFP	NA	GTRD	EXP055168_hTERT-RPE1_HINFP_MACS_HINFP_MA0131.2.damo.pwm.bed	27
1	2108	HINFP	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HINFP U2OS (osteosarcoma) HINFP	U2OS (osteosarcoma)	BTO:0001938	HINFP	NA	GTRD	EXP055172_U2OS--osteosarcoma-_HINFP_MACS_HINFP_MA0131.2.damo.pwm.bed	71
1	2118	HNF1B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HNF1B HUES64 (embryonic stem cells) HNF1B	HUES64 (embryonic stem cells)	NULL	HNF1B	NA	GTRD	EXP036713_HUES64--embryonic-stem-cells-_HNF1B_MACS_HNF1B_MA0153.2.damo.pwm.bed	659
1	2151	HNF4G	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HNF4G LNCaP (prostate carcinoma) HNF4G	LNCaP (prostate carcinoma)	BTO:0001321	HNF4G	Treatment: Cells were harvested in log phase growth Genotype: wildtype	GTRD	EXP048990_LNCaP--prostate-carcinoma-_HNF4G_MACS_HNF4G_MA0484.2.damo.pwm.bed	8
1	2162	HOXB13	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HOXB13 prostate tumor HOXB13	prostate tumor	NULL	HOXB13	Patient: #1	GTRD	EXP048490_prostate-tumor_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	509
1	2163	HOXB13	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HOXB13 prostate tumor HOXB13	prostate tumor	NULL	HOXB13	Patient: #2	GTRD	EXP048491_prostate-tumor_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	722
1	2164	HOXB13	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HOXB13 prostate tumor HOXB13	prostate tumor	NULL	HOXB13	Patient: #3	GTRD	EXP048492_prostate-tumor_HOXB13_MACS_HOXB13_MA0901.2.damo.pwm.bed	223
1	2173	HSF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HSF1 HepG2 (hepatoblastoma) HSF1	HepG2 (hepatoblastoma)	BTO:0000599	HSF1	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EET_HepG2_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	1185
1	2176	HSF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HSF1 K562 (myelogenous leukemia) HSF1	K562 (myelogenous leukemia)	NULL	HSF1	30 min at 42C	GTRD	EXP030798_K562--myelogenous-leukemia-_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	700
1	2177	HSF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HSF1 WA09 (embryonic stem cells) HSF1	WA09 (embryonic stem cells)	NULL	HSF1	Treatment: under normal conditions	GTRD	EXP047922_WA09--embryonic-stem-cells-_HSF1_MACS_HSF1_MA0486.2.damo.pwm.bed	16
1	2184	HSF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HSF1 HCT-15 (colon carcinoma) HSF1	HCT-15 (colon carcinoma)	BTO:0002201	HSF1		GEO	GSE38901_hsf1_hct15_MACS_HSF1_MA0486.2.damo.pwm.bed	380
1	2190	HSF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HSF1 ZR-75-1 (invasive ductal carcinoma) HSF1	ZR-75-1 (invasive ductal carcinoma)	BTO:0003136	HSF1		GEO	GSE38901_hsf1_zr751_MACS_HSF1_MA0486.2.damo.pwm.bed	795
1	2193	HSF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HSF1 HCT-116 (colon carcinoma) HSF1	HCT-116 (colon carcinoma)	BTO:0001109	HSF1	KOFBXW7	GEO	GSE57398_hsf1_hct166-kofbxw7-heat_MACS_HSF1_MA0486.2.damo.pwm.bed	164
1	2196	HSF2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	HSF2 K562 (myelogenous leukemia) HSF2	K562 (myelogenous leukemia)	NULL	HSF2	30 min at 42C	GTRD	EXP030799_K562--myelogenous-leukemia-_HSF2_MACS_HSF2_MA0770.1.damo.pwm.bed	211
1	2205	IRF2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	IRF2 CD34+ cells IRF2	CD34+ cells	NULL	IRF2	ADULT	GEO	GSE70660_irf2_cd34-adult_MACS_IRF2_MA0051.1.damo.pwm.bed	2818
1	2206	IRF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	IRF3 HeLa S3 (cervical adenocarcinoma) IRF3	HeLa S3 (cervical adenocarcinoma)	BTO:0000568	IRF3	NA	ENCODE	ENCSR000EDF_HeLa-S3_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	1187
1	2207	IRF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	IRF3 HepG2 (hepatoblastoma) IRF3	HepG2 (hepatoblastoma)	BTO:0000599	IRF3	NA	ENCODE	ENCSR000EEJ_HepG2_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	419
1	2208	IRF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	IRF3 GM12878 (female B-cells lymphoblastoid cell line) IRF3	GM12878 (female B-cells lymphoblastoid cell line)	NULL	IRF3	NA	ENCODE	ENCSR408JQO_GM12878_IRF3_MACS_IRF3_MA1418.1.damo.pwm.bed	1957
1	2214	IRF4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	IRF4 OCI-LY3 (diffuse large B-cell lymphoma) IRF4	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	IRF4	SHSPIB	GEO	GSE56857_irf4_ocily3-shspib_MACS_IRF4_MA1419.1.damo.pwm.bed	487
1	2218	JUN	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	JUN WA01 (H1, human embryonic stem cells) JUN	WA01 (H1, human embryonic stem cells)	NULL	JUN		ENCODE	ENCSR000ECA_H1-hESC_JUN_MACS_JUN_MA0488.1.damo.pwm.bed	1510
1	2219	JUN	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	JUN WA01 (H1, human embryonic stem cells) JUN	WA01 (H1, human embryonic stem cells)	NULL	JUN		ENCODE	ENCSR000ECA_H1-hESC_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	1427
1	2232	JUN	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	JUN A549 (lung carcinoma) JUN	A549 (lung carcinoma)	BTO:0000018	JUN		ENCODE	ENCSR996DUT_A549_JUN_MACS_JUN_MA0489.1.damo.pwm.bed	2282
1	2584	JUNB	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	JUNB keratinocytes JUNB	keratinocytes	NULL	JUNB	neonatal	GEO	GSE63080_junb_neonatal-keratincoytes_MACS_JUNB_MA0490.2.damo.pwm.bed	74
1	2624	JUND	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	JUND hFOB 1.19 (fetal osteoblast) JUND	hFOB 1.19 (fetal osteoblast)	BTO:0005224	JUND	DIFF	GEO	GSE82295_jund_hfob-diff_MACS_JUND_MA0492.1.damo.pwm.bed	711
1	2655	KLF9	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	KLF9 GBM1A KLF9	GBM1A	NA	KLF9	NA	GEO	GSE62211_klf9_gbm1b_MACS_KLF9_MA1107.2.damo.pwm.bed	876
1	2656	LEF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	LEF1 HUES64 (embryonic stem cells) LEF1	HUES64 (embryonic stem cells)	NULL	LEF1		GTRD	EXP036720_HUES64--embryonic-stem-cells-_LEF1_MACS_LEF1_MA0768.1.damo.pwm.bed	1224
1	2658	LEF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	LEF1 K562 (myelogenous leukemia) LEF1	K562 (myelogenous leukemia)	NULL	LEF1		GTRD	EXP039982_K562--myelogenous-leukemia-_LEF1_MACS_LEF1_MA0768.1.damo.pwm.bed	393
1	2659	LEF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	LEF1 hESC-1 (Embryonic stem cells) LEF1	hESC-1 (Embryonic stem cells)	NULL	LEF1	WNT3A	GEO	GSE64758_lef1_esc-wnt3a_MACS_LEF1_MA0768.1.damo.pwm.bed	691
1	2660	LEF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	LEF1 hESC-1 (Embryonic stem cells) LEF1	hESC-1 (Embryonic stem cells)	NULL	LEF1		GEO	GSE64758_lef1_esc_MACS_LEF1_MA0768.1.damo.pwm.bed	82
1	2730	MEF2B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2B SU-DHL-10 (diffuse large B-cell lymphoma) MEF2B	SU-DHL-10 (diffuse large B-cell lymphoma)	NULL	MEF2B	Genotype: MEF2B- D83V mutant with flag and HA	GTRD	EXP048302_SU-DHL-10--diffuse-large-B-cell-lymphoma-_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	1153
1	2733	MEF2B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: K4E-MEF2B-V5;	GTRD	EXP055129_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	69
1	2734	MEF2B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2B HEK293-A MEF2B	HEK293-A	NULL	MEF2B	Genotype: K4E-MEF2B-V5;	GTRD	EXP055130_HEK293-A_MEF2B_MACS_MEF2B_MA0660.1.damo.pwm.bed	17
1	2737	MEF2B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2B MEF2B	NA	NA	MEF2B	NA	GEO	GSE69558_mef2b_db_MACS_MEF2B_MA0660.1.damo.pwm.bed	1595
1	2739	MEF2B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2B KARPAS-422 (diffuse large B-cell lymphoma) MEF2B	KARPAS-422 (diffuse large B-cell lymphoma)	BTO:0004981	MEF2B		GEO	GSE69558_mef2b_karpas422_MACS_MEF2B_MA0660.1.damo.pwm.bed	2156
1	2740	MEF2B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2B OCI-LY7 (diffuse large B-cell lymphoma) MEF2B	OCI-LY7 (diffuse large B-cell lymphoma)	NULL	MEF2B		GEO	GSE69558_mef2b_ocily7_MACS_MEF2B_MA0660.1.damo.pwm.bed	349
1	2741	MEF2B	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2B MEF2B	NA	NA	MEF2B	NA	GEO	GSE69558_mef2b_sudhl4_MACS_MEF2B_MA0660.1.damo.pwm.bed	2798
1	2743	MEF2C	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2C HUVEC-C (HUVEC, umbilical vein endothelial cells) MEF2C	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MEF2C	STATIN	GEO	GSE32644_mef2c_huvec-statin_MACS_MEF2C_MA0497.1.damo.pwm.bed	55
1	2744	MEF2C	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEF2C HUVEC-C (HUVEC, umbilical vein endothelial cells) MEF2C	HUVEC-C (HUVEC, umbilical vein endothelial cells)	BTO:0001949	MEF2C		GEO	GSE32644_mef2c_huvec_MACS_MEF2C_MA0497.1.damo.pwm.bed	66
1	2748	MEIS1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MEIS1 HSPC MEIS1	HSPC	NA	MEIS1	NA	GEO	GSE26014_meis1_hspc_MACS_MEIS1_MA0498.2.damo.pwm.bed	132
1	2753	MITF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MITF melanocytes MITF	melanocytes	NULL	MITF	none	GTRD	EXP033916_melanocytes_MITF_MACS_MITF_MA0620.3.damo.pwm.bed	395
1	2760	MITF	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MITF 501Mel (melanoma) MITF	501Mel (melanoma)	BTO:0002956	MITF		GEO	GSE64137_mitf_501mel_MACS_MITF_MA0620.3.damo.pwm.bed	5
1	2777	MYB	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYB MV-4-11 (Childhood acute monocytic leukemia) MYB	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	MYB	Treatment: none	GTRD	EXP049401_MV4-11--childhood-acute-monocytic-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	214
1	2778	MYB	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYB MV-4-11 (Childhood acute monocytic leukemia) MYB	MV-4-11 (Childhood acute monocytic leukemia)	BTO:0004479	MYB	Treatment: TG3 control peptide	GTRD	EXP049402_MV4-11--childhood-acute-monocytic-leukemia-_MYB_MACS_MYB_MA0100.3.damo.pwm.bed	268
1	2834	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036146_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	704
1	2835	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HCT-116 (colon carcinoma) MYC	HCT-116 (colon carcinoma)	BTO:0001109	MYC		GTRD	EXP036146_HCT-116--colon-carcinoma-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	681
1	2838	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WT-MYC expression	GTRD	EXP036690_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	219
1	2839	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WT-MYC expression	GTRD	EXP036690_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	182
1	2840	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WBM-MYC expressing	GTRD	EXP036691_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	71
1	2841	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HEK293 (embryonic kidney) MYC	HEK293 (embryonic kidney)	NULL	MYC	WBM-MYC expressing	GTRD	EXP036691_HEK293--embryonic-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	97
1	2842	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036775_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	3210
1	2843	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC HUES64 (embryonic stem cells) MYC	HUES64 (embryonic stem cells)	NULL	MYC		GTRD	EXP036775_HUES64--embryonic-stem-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	2931
1	2883	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047487_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	805
1	2884	MYC	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	MYC MCF10A (breast epithelial cells) MYC	MCF10A (breast epithelial cells)	BTO:0001939	MYC	Characteristic: pBABE-hygro-MYC, pMN-IRES-GFP-PI3KH1047R, pLKO-tetON-puro-shG9a 1;	GTRD	EXP047487_MCF10A--breast-epithelial-cells-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	888
1	2905	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: SNF5 transfection;	GTRD	EXP057897_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0059.1.damo.pwm.bed	1617
1	2906	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC G401 (rhabdoid tumor of the kidney) MYC	G401 (rhabdoid tumor of the kidney)	BTO:0002586	MYC	Passage: ten-thirty; Genotype: SNF5 transfection;	GTRD	EXP057897_G401--rhabdoid-tumor-of-the-kidney-_MYC_MACS_MYC_MA0147.3.damo.pwm.bed	1490
1	2909	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC CA-46 (Burkitt lymphoma) MYC	CA-46 (Burkitt lymphoma)	BTO:0000789	MYC		GEO	GSE30726_myc_ca46_MACS_MYC_MA0147.3.damo.pwm.bed	643
1	2915	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC P493-6 (B-cell lymphoma) MYC	P493-6 (B-cell lymphoma)	BTO:0003291	MYC		GEO	GSE36354_myc_p493_MACS_MYC_MA0147.3.damo.pwm.bed	3212
1	2923	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC		GEO	GSE44672_myc_u2os_MACS_MYC_MA0147.3.damo.pwm.bed	3774
1	2925	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC LS174T (colon adenocarcinoma) MYC	LS174T (colon adenocarcinoma)	BTO:0001553	MYC	DMSO	GEO	GSE59223_myc_ls174t-dmso_MACS_MYC_MA0147.3.damo.pwm.bed	387
1	2934	MYC	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC	SHMYC	GEO	GSE77356_myc_u2os-shmyc_MACS_MYC_MA0147.3.damo.pwm.bed	3935
1	2936	MYC	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYC U2OS (osteosarcoma) MYC	U2OS (osteosarcoma)	BTO:0001938	MYC		GEO	GSE77356_myc_u2os_MACS_MYC_MA0147.3.damo.pwm.bed	3790
1	2939	MYCN	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	MYCN Tet21N (neuroblastoma) MYCN	Tet21N (neuroblastoma)	BTO:0004654	MYCN	0.2 ug/mL DOX for 2HR	GTRD	EXP036327_Tet21N--neuroblastoma-_MYCN_MACS_MYCN_MA0104.4.damo.pwm.bed	2594
1	2950	MYCN	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	MYCN BE2C MYCN	BE2C	NULL	MYCN		GEO	GSE72640_mycn_be2c_MACS_MYCN_MA0104.4.damo.pwm.bed	144
1	2965	NEUROD1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	NEUROD1 NCI-H524 (small cell lung carcinoma) NEUROD1	NCI-H524 (small cell lung carcinoma)	BTO:0004825	NEUROD1		GEO	GSE69394_neurod1_h524_MACS_NEUROD1_MA1109.1.damo.pwm.bed	2260
1	2998	NFE2L2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NFE2L2 lymphoblastoid cells NFE2L2	lymphoblastoid cells	NULL	NFE2L2	10 uM D,L-sulforaphane for 5 hours	GTRD	EXP031474_lymphoblastoid-cells_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	196
1	3003	NFE2L2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NFE2L2 BEAS-2B (bronchial epithelium) NFE2L2	BEAS-2B (bronchial epithelium)	NULL	NFE2L2	Treatment: D,L-sulforaphane (SFN) for 5 hr	GTRD	EXP048850_BEAS-2B--bronchial-epithelium-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	195
1	3004	NFE2L2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NFE2L2 BEAS-2B (bronchial epithelium) NFE2L2	BEAS-2B (bronchial epithelium)	NULL	NFE2L2	Treatment: 0.1% (v/v) DMSO as vehicle for 5 hr	GTRD	EXP048851_BEAS-2B--bronchial-epithelium-_NFE2L2_MACS_NFE2L2_MA0150.2.damo.pwm.bed	310
1	3027	NFYA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NFYA GM12878 (female B-cells lymphoblastoid cell line) NFYA	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NFYA	NA	ENCODE	ENCSR000DNN_GM12878_NFYA_MACS_NFYA_MA0060.3.damo.pwm.bed	753
1	3043	NR1H4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR1H4 NR1H4	NA	NA	NR1H4	NA	GEO	GSE57227_nr1h4_primaryhepatocyte-dmso_MACS_NR1H4_MA1110.1.damo.pwm.bed	764
1	3048	NR2C2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR2C2 GM12878 (female B-cells lymphoblastoid cell line) NR2C2	GM12878 (female B-cells lymphoblastoid cell line)	NULL	NR2C2		ENCODE	ENCSR000EUL_GM12878_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	153
1	3051	NR2C2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR2C2 K562 (myelogenous leukemia) NR2C2	K562 (myelogenous leukemia)	NULL	NR2C2		ENCODE	ENCSR000EWH_K562_NR2C2_MACS_NR2C2_MA0504.1.damo.pwm.bed	309
1	3055	NR2C2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR2C2 HeLa (cervical adenocarcinoma) NR2C2	HeLa (cervical adenocarcinoma)	BTO:0000567	NR2C2		GEO	GSE46237_nr2c2_hela_MACS_NR2C2_MA0504.1.damo.pwm.bed	558
1	3057	NR2C2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR2C2 erythroid cells NR2C2	erythroid cells	NULL	NR2C2	D8	GEO	GSE54759_NR2C2_erythroid-d8_MACS_NR2C2_MA0504.1.damo.pwm.bed	117
1	3059	NR2F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR2F1 H9-derived neural crest cells NR2F1	H9-derived neural crest cells	NULL	NR2F1	NA	GTRD	EXP030994_H9-derived-neural-crest-cells_NR2F1_MACS_NR2F1_MA0017.2.damo.pwm.bed	3183
1	3089	NR3C1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR3C1 HepG2 (hepatoblastoma) NR3C1	HepG2 (hepatoblastoma)	BTO:0000599	NR3C1	low-glucose DMEM with 0.5% BSA supplemented with 1uM forskolin and 1mM pyruvate for 6h. (Snyder)	ENCODE	ENCSR000EEV_HepG2_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	154
1	3101	NR3C1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR3C1 monocyte-derived macrophages NR3C1	monocyte-derived macrophages	NULL	NR3C1		GTRD	EXP034069_monocyte-derived-macrophages_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	188
1	3108	NR3C1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR3C1 HepG2 (hepatoblastoma) NR3C1	HepG2 (hepatoblastoma)	BTO:0000599	NR3C1		GTRD	EXP037679_HepG2--hepatoblastoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	523
1	3123	NR3C1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR3C1 A549 (lung carcinoma) NR3C1	A549 (lung carcinoma)	BTO:0000018	NR3C1		GTRD	EXP040297_A549--lung-carcinoma-_NR3C1_MACS_NR3C1_MA0113.3.damo.pwm.bed	16
1	3159	NR3C1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR3C1 RS4-11 (adult B acute lymphoblastic leukemia) NR3C1	RS4-11 (adult B acute lymphoblastic leukemia)	BTO:0004505	NR3C1	DEX	GEO	GSE71616_nr3c1_rsa411-dex_MACS_NR3C1_MA0113.3.damo.pwm.bed	879
1	3164	NR5A1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR5A1 H295R (adrenal cortex carcinoma) NR5A1	H295R (adrenal cortex carcinoma)	BTO:0002588	NR5A1		GTRD	EXP031924_H295R--adrenal-cortex-carcinoma-_NR5A1_MACS_NR5A1_MA1540.1.damo.pwm.bed	30
1	3165	NR5A1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR5A1 H295R (adrenal cortex carcinoma) NR5A1	H295R (adrenal cortex carcinoma)	BTO:0002588	NR5A1	overexpressed SF-1	GTRD	EXP031925_H295R--adrenal-cortex-carcinoma-_NR5A1_MACS_NR5A1_MA1540.1.damo.pwm.bed	170
1	3166	NR5A1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NR5A1 H295R (adrenal cortex carcinoma) NR5A1	H295R (adrenal cortex carcinoma)	BTO:0002588	NR5A1		GTRD	EXP031926_H295R--adrenal-cortex-carcinoma-_NR5A1_MACS_NR5A1_MA1540.1.damo.pwm.bed	47
1	3168	NRF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	NRF1 WA01 (H1, human embryonic stem cells) NRF1	WA01 (H1, human embryonic stem cells)	NULL	NRF1		ENCODE	ENCSR000ECC_H1-hESC_NRF1_MACS_NRF1_MA0506.1.damo.pwm.bed	4041
1	3187	OCT4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	OCT4 OCT4	NA	NA	OCT4	NA	GEO	GSE17917_oct4_esc_MACS_OCT4_MA0142.1.damo.pwm.bed	10
1	3188	OCT4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	OCT4 OCT4	NA	NA	OCT4	NA	GEO	GSE20650_oct4_esc_MACS_OCT4_MA0142.1.damo.pwm.bed	125
1	3219	PAX5	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	PAX5 DOHH2 (diffuse large B-cell lymphoma) PAX5	DOHH2 (diffuse large B-cell lymphoma)	NULL	PAX5		GEO	GSE69558_pax5_dohh2_MACS_PAX5_MA0014.3.damo.pwm.bed	787
1	3241	POU2F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU2F1 LNCaP (prostate carcinoma) POU2F1	LNCaP (prostate carcinoma)	BTO:0001321	POU2F1	none	GTRD	EXP036097_LNCaP--prostate-carcinoma-_POU2F1_MACS_POU2F1_MA0785.1.damo.pwm.bed	946
1	3242	POU2F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU2F1 HCT-116 (colon carcinoma) POU2F1	HCT-116 (colon carcinoma)	BTO:0001109	POU2F1		GTRD	EXP058390_HCT-116--colon-carcinoma-_POU2F1_MACS_POU2F1_MA0785.1.damo.pwm.bed	20
1	3244	POU2F2	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	POU2F2 BJAB (Burkitt lymphoma) POU2F2	BJAB (Burkitt lymphoma)	BTO:0001931	POU2F2	BIRA_T223A	GEO	GSE79480_pou2f2_bjab-birA-t223a_MACS_POU2F2_MA0507.1.damo.pwm.bed	577
1	3245	POU2F2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU2F2 BJAB (Burkitt lymphoma) POU2F2	BJAB (Burkitt lymphoma)	BTO:0001931	POU2F2	BIRA	GEO	GSE79480_pou2f2_bjab-birA_MACS_POU2F2_MA0507.1.damo.pwm.bed	462
1	3246	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 WA01 (H1, human embryonic stem cells) POU5F1	WA01 (H1, human embryonic stem cells)	NULL	POU5F1		ENCODE	ENCSR000BMU_H1-hESC_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	2676
1	3247	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 POU5F1	NA	NA	POU5F1	NA	NA	ENCSR264RJX_induced_pluripotent_stem_cell_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	7664
1	3248	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	NULL	GTRD	EXP000209_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	2929
1	3249	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1	NULL	GTRD	EXP000209_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	3311
1	3253	POU5F1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036730_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	6069
1	3254	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 HUES64 (embryonic stem cells) POU5F1	HUES64 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP036732_HUES64--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	7209
1	3256	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038693_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	1057
1	3257	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038693_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	956
1	3258	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038694_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA0142.1.damo.pwm.bed	3271
1	3259	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 WA09 (embryonic stem cells) POU5F1	WA09 (embryonic stem cells)	NULL	POU5F1		GTRD	EXP038694_WA09--embryonic-stem-cells-_POU5F1_MACS_POU5F1_MA1115.1.damo.pwm.bed	3363
1	3278	POU5F1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	POU5F1 NCCIT (testicular embryonic carcinoma) POU5F1	NCCIT (testicular embryonic carcinoma)	BTO:0004180	POU5F1		GEO	GSE36134_pou5f1_nccit_MACS_POU5F1_MA1115.1.damo.pwm.bed	3849
1	3288	PPARG	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	PPARG subcutaneous white adipose tissue PPARG	subcutaneous white adipose tissue	NULL	PPARG		GTRD	EXP034423_subcutaneous-white-adipose-tissue_PPARG_MACS_PPARG_MA0065.2.damo.pwm.bed	3917
1	3301	PRDM1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1		GTRD	EXP036693_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	3638
1	3302	PRDM1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1		GTRD	EXP036694_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	2576
1	3303	PRDM1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	PRDM1 HUES64 (embryonic stem cells) PRDM1	HUES64 (embryonic stem cells)	NULL	PRDM1		GTRD	EXP036695_HUES64--embryonic-stem-cells-_PRDM1_MACS_PRDM1_MA0508.3.damo.pwm.bed	1935
1	3323	RBPJ	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RBPJ REC-1 (Mantle cell lymphoma) RBPJ	REC-1 (Mantle cell lymphoma)	BTO:0003558	RBPJ	Treatment: untreated	GTRD	EXP049777_REC-1--Mantle-cell-lymphoma-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	1135
1	3324	RBPJ	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RBPJ SP-49 (Mantle cell lymphoma) RBPJ	SP-49 (Mantle cell lymphoma)	NULL	RBPJ	Treatment: untreated	GTRD	EXP049779_SP-49--Mantle-cell-lymphoma-_RBPJ_MACS_RBPJ_MA1116.1.damo.pwm.bed	377
1	3327	RBPJ	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	RBPJ CUTLL1 (T-cell lymphoblastic lymphoma 1) RBPJ	CUTLL1 (T-cell lymphoblastic lymphoma 1)	NULL	RBPJ		GEO	GSE29600_rbpj_cutll_MACS_RBPJ_MA1116.1.damo.pwm.bed	5497
1	3377	RELA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RELA IMR90 (lung fibroblasts) RELA	IMR90 (lung fibroblasts)	NULL	RELA		GEO	GSE43070_rela_imr90_MACS_RELA_MA0107.1.damo.pwm.bed	497
1	3407	REST	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	REST HCT-116 (colon carcinoma) REST	HCT-116 (colon carcinoma)	BTO:0001109	REST		ENCODE	ENCSR000BVI_HCT116_REST_MACS_REST_MA0138.2.damo.pwm.bed	3918
1	3408	REST	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	REST hepatocytes REST	hepatocytes	NULL	REST		Array Express	ERP000395_rest_hepatocytes_MACS_REST_MA0138.2.damo.pwm.bed	860
1	3414	REST	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		GTRD	EXP036861_WA01--H1--human-embryonic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	3650
1	3419	REST	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	REST WA01 (H1, human embryonic stem cells) REST	WA01 (H1, human embryonic stem cells)	NULL	REST		GTRD	EXP039423_WA01--H1--human-embryonic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	2516
1	3429	REST	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	REST CRC121 (colorectal cancer metastatic stem cells) REST	CRC121 (colorectal cancer metastatic stem cells)	NULL	REST	Source: organoid dissociation;	GTRD	EXP058087_CRC121--colorectal-cancer-metastatic-stem-cells-_REST_MACS_REST_MA0138.2.damo.pwm.bed	1784
1	3431	REST	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	REST H295R (adrenal cortex carcinoma) REST	H295R (adrenal cortex carcinoma)	BTO:0002588	REST	SF1	GEO	GSE49014_rest_ncih295r-sf1_MACS_REST_MA0138.2.damo.pwm.bed	1687
1	3432	REST	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	REST H295R (adrenal cortex carcinoma) REST	H295R (adrenal cortex carcinoma)	BTO:0002588	REST		GEO	GSE49014_rest_ncih295r_MACS_REST_MA0138.2.damo.pwm.bed	1637
1	3434	REST	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	REST GP5d (colon adenocarcinoma) REST	GP5d (colon adenocarcinoma)	NULL	REST	SIRAD21	GEO	GSE51234_rest_gp5d-sirad21_MACS_REST_MA0138.2.damo.pwm.bed	1827
1	3435	REST	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	REST GP5d (colon adenocarcinoma) REST	GP5d (colon adenocarcinoma)	NULL	REST		GEO	GSE51234_rest_gp5d_MACS_REST_MA0138.2.damo.pwm.bed	1725
1	3437	RFX1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	RFX1 HepG2 (hepatoblastoma) RFX1	HepG2 (hepatoblastoma)	BTO:0000599	RFX1	NA	ENCODE	ENCSR928API_HepG2_RFX1_MACS_RFX1_MA0509.2.damo.pwm.bed	3047
1	3442	RFX2	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	RFX2 GP5d (colon adenocarcinoma) RFX2	GP5d (colon adenocarcinoma)	NULL	RFX2	NA	GEO	GSE51234_rfx2_gp5d_MACS_RFX2_MA0600.2.damo.pwm.bed	246
1	3444	RFX5	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RFX5 WA01 (H1, human embryonic stem cells) RFX5	WA01 (H1, human embryonic stem cells)	NULL	RFX5	NA	ENCODE	ENCSR000ECF_H1-hESC_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	1046
1	3447	RFX5	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RFX5 K562 (myelogenous leukemia) RFX5	K562 (myelogenous leukemia)	NULL	RFX5	NA	ENCODE	ENCSR000EGO_K562_RFX5_MACS_RFX5_MA0510.2.damo.pwm.bed	1256
1	3452	RUNX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RUNX1 Jurkat E6.1 (T-cells) RUNX1	Jurkat E6.1 (T-cells)	BTO:0001948	RUNX1	NULL	GTRD	EXP000300_Jurkat-E6.1--T-cells-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	1539
1	3457	RUNX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP030418_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	687
1	3464	RUNX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RUNX1 Kasumi-1 (acute myeloblastic leukemia) RUNX1	Kasumi-1 (acute myeloblastic leukemia)	BTO:0004136	RUNX1		GTRD	EXP036423_Kasumi-1--acute-myeloblastic-leukemia-_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	3576
1	3469	RUNX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RUNX1 peripheral blood mononuclear cells RUNX1	peripheral blood mononuclear cells	BTO:0001025	RUNX1		GTRD	EXP037690_peripheral-blood-mononuclear-cells_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	307
1	3474	RUNX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RUNX1 ME-1 (acute myeloid leukemia ) RUNX1	ME-1 (acute myeloid leukemia )	NULL	RUNX1	Treatment: DMSO for 6 hr; CellType: human inv(16) leukemia cell line;	GTRD	EXP047572_ME-1--acute-myeloid-leukemia--_RUNX1_MACS_RUNX1_MA0002.2.damo.pwm.bed	2443
1	3487	RUNX1	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE29180_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	6978
1	3488	RUNX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RUNX1 CCRF-CEM (T acute lymphoblastic leukemia) RUNX1	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	RUNX1		GEO	GSE33850_runx1_ccrfcem_MACS_RUNX1_MA0002.2.damo.pwm.bed	280
1	3490	RUNX1	0	0	0	3799	3799	3799	3799	3800	3	6381	2217	RUNX1 Jurkat (T-cells) RUNX1	Jurkat (T-cells)	BTO:0000661	RUNX1		GEO	GSE42575_runx1_jurkat_MACS_RUNX1_MA0002.2.damo.pwm.bed	3694
1	3497	RUNX1	0	0	0	3799	3799	3799	3799	3800	2	6381	2218	RUNX1 RUNX1	NA	NA	RUNX1	NA	GEO	GSE65313_runx1_mcf7_MACS_RUNX1_MA0002.2.damo.pwm.bed	894
1	3503	RUNX1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RUNX1 MCF7 (Invasive ductal breast carcinoma) RUNX1	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	RUNX1		GEO	GSE75070_runx1_mcf7_MACS_RUNX1_MA0002.2.damo.pwm.bed	21
1	3513	RXRA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA0074.1.damo.pwm.bed	108
1	3514	RXRA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA0159.1.damo.pwm.bed	122
1	3515	RXRA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA0494.1.damo.pwm.bed	153
1	3516	RXRA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA1146.1.damo.pwm.bed	88
1	3517	RXRA	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	RXRA NB4 (acute promyelocytic leukemia ) RXRA	NB4 (acute promyelocytic leukemia )	NULL	RXRA		GTRD	EXP000741_NB4--acute-promyelocytic-leukemia--_RXRA_MACS_RXRA_MA1147.1.damo.pwm.bed	142
1	3562	SMAD2	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	SMAD2 endoderm SMAD2	endoderm	NA	SMAD2	NA	GEO	GSE29422_smad2_endoderm_MACS_SMAD2_MA0513.1.damo.pwm.bed	5064
1	3563	SMAD2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SMAD2 hESC-1 (Embryonic stem cells) SMAD2	hESC-1 (Embryonic stem cells)	NULL	SMAD2	NA	GEO	GSE29422_smad2_esc_MACS_SMAD2_MA0513.1.damo.pwm.bed	1571
1	3579	SMAD4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SMAD4 hESC-1 (Embryonic stem cells) SMAD4	hESC-1 (Embryonic stem cells)	NULL	SMAD4	NA	GEO	GSE29422_smad4_esc_MACS_SMAD4_MA1153.1.damo.pwm.bed	1528
1	3580	SNAI2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SNAI2 HUES64 (embryonic stem cells) SNAI2	HUES64 (embryonic stem cells)	NULL	SNAI2		GTRD	EXP036746_HUES64--embryonic-stem-cells-_SNAI2_MACS_SNAI2_MA0745.2.damo.pwm.bed	5748
1	3584	SNAI2	0	0	0	3799	3799	3799	3799	3800	2	6381	2218	SNAI2 keratinocytes SNAI2	keratinocytes	NULL	SNAI2	SHSNAI2	GEO	GSE55421_snai2_keratinocytes-shsnai2_MACS_SNAI2_MA0745.2.damo.pwm.bed	441
1	3594	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP032066_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	4329
1	3595	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036751_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	6027
1	3596	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036751_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	5728
1	3597	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 HUES64 (embryonic stem cells) SOX2	HUES64 (embryonic stem cells)	NULL	SOX2		GTRD	EXP036753_HUES64--embryonic-stem-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	5679
1	3602	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 MRC-5 (fetal lung fibroblasts) SOX2	MRC-5 (fetal lung fibroblasts)	BTO:0001590	SOX2	Treatment: Oct4, Sox2-VP16 (strong activator) and Klf4 addition for 5 days Passage: 8	GTRD	EXP048947_MRC-5--fetal-lung-fibroblasts-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	1263
1	3607	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 iPS (derived pancreatic precursor cells) SOX2	iPS (derived pancreatic precursor cells)	NULL	SOX2	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048957_iPS--derived-pancreatic-precursor-cells-_SOX2_MACS_SOX2_MA0142.1.damo.pwm.bed	2441
1	3608	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 iPS (derived pancreatic precursor cells) SOX2	iPS (derived pancreatic precursor cells)	NULL	SOX2	Treatment: iPS protocol 3s2 Passage: 20	GTRD	EXP048957_iPS--derived-pancreatic-precursor-cells-_SOX2_MACS_SOX2_MA0143.4.damo.pwm.bed	2088
1	3619	SOX2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX2 hESC-1 (Embryonic stem cells) SOX2	hESC-1 (Embryonic stem cells)	NULL	SOX2		GEO	GSE69479_sox2_esc_MACS_SOX2_MA0143.4.damo.pwm.bed	1707
1	3623	SOX9	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SOX9 hES-PRE SOX9	hES-PRE	NULL	SOX9	CellType: ES-derived RPE cells	GTRD	EXP048488_hES-PRE_SOX9_MACS_SOX9_MA0077.1.damo.pwm.bed	19
1	3624	SP1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SP1 K562 (myelogenous leukemia) SP1	K562 (myelogenous leukemia)	NULL	SP1		ENCODE	ENCSR000BKO_K562_SP1_MACS_SP1_MA0079.4.damo.pwm.bed	1982
1	3637	SP2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SP2 K562 (myelogenous leukemia) SP2	K562 (myelogenous leukemia)	NULL	SP2	NA	ENCODE	ENCSR000BNL_K562_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	3420
1	3638	SP2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SP2 WA01 (H1, human embryonic stem cells) SP2	WA01 (H1, human embryonic stem cells)	NULL	SP2	NA	ENCODE	ENCSR000BQG_H1-hESC_SP2_MACS_SP2_MA0516.2.damo.pwm.bed	1623
1	3671	SPI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SPI1 macrophages SPI1	macrophages	NULL	SPI1	IL4	GEO	GSE47188_spi1_macrophage-il4_MACS_SPI1_MA0080.5.damo.pwm.bed	3318
1	3675	SPI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SPI1 OCI-LY3 (diffuse large B-cell lymphoma) SPI1	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPI1	SHSPIB	GEO	GSE56857_spi1_ocily3-shspib_MACS_SPI1_MA0080.5.damo.pwm.bed	436
1	3676	SPI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SPI1 OCI-LY3 (diffuse large B-cell lymphoma) SPI1	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPI1		GEO	GSE56857_spi1_ocily3_MACS_SPI1_MA0080.5.damo.pwm.bed	2560
1	3689	SPI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SPI1 RS4-11 (adult B acute lymphoblastic leukemia) SPI1	RS4-11 (adult B acute lymphoblastic leukemia)	BTO:0004505	SPI1		GEO	GSE71616_spi1_rsa411_MACS_SPI1_MA0080.5.damo.pwm.bed	8068
1	3692	SPI1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SPI1 K562 (myelogenous leukemia) SPI1	K562 (myelogenous leukemia)	NULL	SPI1		GEO	GSE74999_spi1_k562_MACS_SPI1_MA0080.5.damo.pwm.bed	1808
1	3695	SPIB	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SPIB OCI-LY3 (diffuse large B-cell lymphoma) SPIB	OCI-LY3 (diffuse large B-cell lymphoma)	NULL	SPIB	SHSPIB	GEO	GSE56857_spib_ocily3-shspib_MACS_SPIB_MA0081.2.damo.pwm.bed	1930
1	3697	SREBF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SREBF1 HepG2 (hepatoblastoma) SREBF1	HepG2 (hepatoblastoma)	BTO:0000599	SREBF1	DMEM with 0.5% BSA supplemented with 100 nM insulin and 10 uM 22-hydroxycholesterol for 6 h. (Snyder)	ENCODE	ENCSR000EEO_HepG2_SREBF1_MACS_SREBF1_MA0595.1.damo.pwm.bed	885
1	3698	SREBF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SREBF1 HepG2 (hepatoblastoma) SREBF1	HepG2 (hepatoblastoma)	BTO:0000599	SREBF1	DMEM with 0.5% BSA supplemented with 100 nM insulin and 10 uM 22-hydroxycholesterol for 6 h. (Snyder)	ENCODE	ENCSR000EEO_HepG2_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	718
1	3699	SREBF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SREBF1 HepG2 (hepatoblastoma) SREBF1	HepG2 (hepatoblastoma)	BTO:0000599	SREBF1	For sterol deprivation, cells were cultured with pravastatin (2 uM, Sigma) in DMEM with 0.5% BSA for 16 h. (Snyder)	ENCODE	ENCSR000EZP_HepG2_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	79
1	3702	SREBF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SREBF1 A549 (lung carcinoma) SREBF1	A549 (lung carcinoma)	BTO:0000018	SREBF1		ENCODE	ENCSR897MYK_A549_SREBF1_MACS_SREBF1_MA0595.1.damo.pwm.bed	1620
1	3703	SREBF1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	SREBF1 A549 (lung carcinoma) SREBF1	A549 (lung carcinoma)	BTO:0000018	SREBF1		ENCODE	ENCSR897MYK_A549_SREBF1_MACS_SREBF1_MA0829.2.damo.pwm.bed	1677
1	3712	SRF	0	0	0	3799	3799	3799	3799	3800	2	6381	2218	SRF HEL (Erythro Leukemia) SRF	HEL (Erythro Leukemia)	NULL	SRF	Treatment: No treatment, no TPA  Source: HEL-iMKL1 cells	GTRD	EXP053071_HEL--Erythro-Leukemia-_SRF_MACS_SRF_MA0083.3.damo.pwm.bed	3239
1	3721	STAT1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	Interferon gamma treatment - 30 minutes (Snyder)	ENCODE	ENCSR000EHK_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	1039
1	3722	STAT1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	Interferon alpha treatment - 6 hours (Snyder)	ENCODE	ENCSR000FAU_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	484
1	3723	STAT1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT1 K562 (myelogenous leukemia) STAT1	K562 (myelogenous leukemia)	NULL	STAT1	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000FAV_K562_STAT1_MACS_STAT1_MA0137.3.damo.pwm.bed	273
1	3727	STAT1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT1 AGS (gastric adenocarcinoma) STAT1	AGS (gastric adenocarcinoma)	BTO:0001007	STAT1		GTRD	EXP048898_AGS--gastric-adenocarcinoma-_STAT1_MACS_STAT1_MA0517.1.damo.pwm.bed	1527
1	3728	STAT2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT2 K562 (myelogenous leukemia) STAT2	K562 (myelogenous leukemia)	NULL	STAT2	30 m of Interferon alpha (Snyder)	ENCODE	ENCSR000FAT_K562_STAT2_MACS_STAT2_MA0517.1.damo.pwm.bed	1182
1	3729	STAT2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT2 K562 (myelogenous leukemia) STAT2	K562 (myelogenous leukemia)	NULL	STAT2	Interferon alpha treatment - 6 hours (Snyder)	ENCODE	ENCSR000FBC_K562_STAT2_MACS_STAT2_MA0517.1.damo.pwm.bed	1214
1	3733	STAT3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT3 Th17-cells STAT3	Th17-cells	BTO:0005655	STAT3		GTRD	EXP036973_Th17-cells_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	831
1	3743	STAT3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT3 JB6 (Human anaplastic large cell lymphoma) STAT3	JB6 (Human anaplastic large cell lymphoma)	BTO:0004831	STAT3	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053278_JB6--Human-anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	601
1	3745	STAT3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT3 SU-DHL-1 (Anaplastic large cell lymphoma) STAT3	SU-DHL-1 (Anaplastic large cell lymphoma)	BTO:0005058	STAT3	Treatment: 300 nM Crizotinib for 3 hrs	GTRD	EXP053282_SU-DHL-1--Anaplastic-large-cell-lymphoma-_STAT3_MACS_STAT3_MA0144.2.damo.pwm.bed	535
1	3747	STAT3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	STAT3 U2932 (diffuse large B-cell lymphoma) STAT3	U2932 (diffuse large B-cell lymphoma)	NULL	STAT3		GEO	GSE50723_stat3_u2932_MACS_STAT3_MA0144.2.damo.pwm.bed	397
1	3751	STAT5A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032561_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA0519.1.damo.pwm.bed	1015
1	3752	STAT5A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032561_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA1624.1.damo.pwm.bed	977
1	3753	STAT5A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032562_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA0519.1.damo.pwm.bed	1864
1	3754	STAT5A	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	STAT5A CD4+ CD25+ CD45RA+ T-cells STAT5A	CD4+ CD25+ CD45RA+ T-cells	NULL	STAT5A		GTRD	EXP032562_CD4--CD25--CD45RA--T-cells_STAT5A_MACS_STAT5A_MA1624.1.damo.pwm.bed	1707
1	3767	TAL1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TAL1 CCRF-CEM (T acute lymphoblastic leukemia) TAL1	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	TAL1	NA	GEO	GSE33850_tal1_ccrfcem_MACS_TAL1_MA0091.1.damo.pwm.bed	2262
1	3784	TCF12	0	0	0	3799	3799	3799	3799	3800	2	6381	2218	TCF12 Jurkat (T-cells) TCF12	Jurkat (T-cells)	BTO:0000661	TCF12	NA	GEO	GSE29180_tcf12_jurkat_MACS_TCF12_MA0521.1.damo.pwm.bed	1286
1	3785	TCF12	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TCF12 CCRF-CEM (T acute lymphoblastic leukemia) TCF12	CCRF-CEM (T acute lymphoblastic leukemia)	BTO:0000736	TCF12	NA	GEO	GSE33850_tcf12_ccrfcem_MACS_TCF12_MA0521.1.damo.pwm.bed	389
1	3790	TCF3	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TCF3 RPMI-8402 (T acute lymphoblastic leukemia) TCF3	RPMI-8402 (T acute lymphoblastic leukemia)	BTO:0001880	TCF3		GEO	GSE39179_tcf3_rpmi8402_MACS_TCF3_MA0522.3.damo.pwm.bed	799
1	3796	TCF4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TCF4 SH-SY5Y (neuroblastoma) TCF4	SH-SY5Y (neuroblastoma)	BTO:0000793	TCF4	Treatment: none	GTRD	EXP049703_SH-SY5Y--neuroblastoma-_TCF4_MACS_TCF4_MA0830.2.damo.pwm.bed	2464
1	3805	TCF7	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TCF7 DLD-1 (colon adenocarcinoma) TCF7	DLD-1 (colon adenocarcinoma)	BTO:0000391	TCF7	1 ug/mL Doxycycline	GTRD	EXP033183_DLD-1--colon-adenocarcinoma-_TCF7_MACS_TCF7_MA0769.2.damo.pwm.bed	15
1	3821	TCF7L2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TCF7L2 MDA-MB-453 (breast adenocarcinoma) TCF7L2	MDA-MB-453 (breast adenocarcinoma)	BTO:0001908	TCF7L2	DHT	GEO	GSE45201_tcf7l2_mdamb453-dht_MACS_TCF7L2_MA0523.1.damo.pwm.bed	81
1	3830	TEAD1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TEAD1 hFOB 1.19 (fetal osteoblast) TEAD1	hFOB 1.19 (fetal osteoblast)	BTO:0005224	TEAD1	DIFF	GEO	GSE82295_tead1_hfob-diff_MACS_TEAD1_MA0090.3.damo.pwm.bed	439
1	3839	TEAD4	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TEAD4 WA01 (H1, human embryonic stem cells) TEAD4	WA01 (H1, human embryonic stem cells)	NULL	TEAD4	Treatment: None Genotype: wildtype hESC	GTRD	EXP049867_WA01--H1--human-embryonic-stem-cells-_TEAD4_MACS_TEAD4_MA0809.2.damo.pwm.bed	4856
1	3862	TFAP2A	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040710_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0810.1.damo.pwm.bed	48
1	3863	TFAP2A	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TFAP2A WA09 (embryonic stem cells) TFAP2A	WA09 (embryonic stem cells)	NULL	TFAP2A	BMP4 for 3 day	GTRD	EXP040710_WA09--embryonic-stem-cells-_TFAP2A_MACS_TFAP2A_MA0872.1.damo.pwm.bed	124
1	3875	TFAP2C	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TFAP2C WA09 (embryonic stem cells) TFAP2C	WA09 (embryonic stem cells)	NULL	TFAP2C	BMP4 for 3 day	GTRD	EXP040711_WA09--embryonic-stem-cells-_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	6
1	3891	TFAP2C	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047538_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0524.2.damo.pwm.bed	84
1	3892	TFAP2C	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047538_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0814.2.damo.pwm.bed	139
1	3893	TFAP2C	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TFAP2C UCLA1 hESCs TFAP2C	UCLA1 hESCs	NULL	TFAP2C	PasNumber: p28; CellType: Prime UCLA1 hESSCs;	GTRD	EXP047538_UCLA1-hESCs_TFAP2C_MACS_TFAP2C_MA0815.1.damo.pwm.bed	205
1	4007	TP53	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TP53 U2OS (osteosarcoma) TP53	U2OS (osteosarcoma)	BTO:0001938	TP53	ETO	GEO	GSE21939_tp53_u2os-eto-ps46_MACS_TP53_MA0106.3.damo.pwm.bed	57
1	4014	TP53	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TP53 MCF7 (Invasive ductal breast carcinoma) TP53	MCF7 (Invasive ductal breast carcinoma)	BTO:0000093	TP53	NUT	GEO	GSE47041_tp53_mcf7-nut_MACS_TP53_MA0106.3.damo.pwm.bed	23
1	4022	TP53	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TP53 HCT-116 (colon carcinoma) TP53	HCT-116 (colon carcinoma)	BTO:0001109	TP53		GEO	GSE58714_tp53_hct166_MACS_TP53_MA0106.3.damo.pwm.bed	30
1	4023	TP53	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	TP53 IMR90 (lung fibroblasts) TP53	IMR90 (lung fibroblasts)	NULL	TP53	DMSO	GEO	GSE58740_tp53_imr90-dmso_MACS_TP53_MA0106.3.damo.pwm.bed	115
1	4089	USF2	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	USF2 SK-N-SH (neuroblastoma) USF2	SK-N-SH (neuroblastoma)	BTO:0001620	USF2		GTRD	EXP039372_SK-N-SH--neuroblastoma-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	6564
1	4092	USF2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	USF2 K562 (myelogenous leukemia) USF2	K562 (myelogenous leukemia)	NULL	USF2	Treatment: no	GTRD	EXP048313_K562--myelogenous-leukemia-_USF2_MACS_USF2_MA0526.3.damo.pwm.bed	3168
1	4093	VDR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	1α,25(OH)2D3	GTRD	EXP000242_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	1652
1	4096	VDR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	EtOH for 2h	GTRD	EXP037992_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	2091
1	4097	VDR	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 2h	GTRD	EXP037993_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	3641
1	4098	VDR	0	0	0	3799	3799	3799	3799	3800	1	6381	2219	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	100 nM 1,25(OH)2D3 for 2h	GTRD	EXP037993_THP-1--acute-monocytic-leukemia-_VDR_MACS_VDR_MA0693.2.damo.pwm.bed	3066
1	4103	VDR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	VDR RWPE1 (prostate epithelial cells) VDR	RWPE1 (prostate epithelial cells)	BTO:0003709	VDR	Treatment: vehicle;	GTRD	EXP058194_RWPE1--prostate-epithelial-cells-_VDR_MACS_VDR_MA0074.1.damo.pwm.bed	6
1	4110	VDR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	1H_125D	GEO	GSE51181_VDR_thp1-1h-125d_MACS_VDR_MA0693.2.damo.pwm.bed	35
1	4111	VDR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	2H_125D	GEO	GSE51181_VDR_thp1-2h-125d_MACS_VDR_MA0693.2.damo.pwm.bed	88
1	4112	VDR	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	VDR THP-1 (acute monocytic leukemia) VDR	THP-1 (acute monocytic leukemia)	BTO:0001370	VDR	CAL	GEO	GSE53041_vdr_thp1-cal_MACS_VDR_MA0693.2.damo.pwm.bed	590
1	4116	XBP1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	XBP1 T47D (invasive ductal carcinoma) XBP1	T47D (invasive ductal carcinoma)	BTO:0001248	XBP1	HYPO_GLUDEP	GEO	GSE49952_xbp1_t47d-hypo-gludep_MACS_XBP1_MA0844.1.damo.pwm.bed	22
1	4128	YY1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	YY1 GM12878 (female B-cells lymphoblastoid cell line) YY1	GM12878 (female B-cells lymphoblastoid cell line)	NULL	YY1		ENCODE	ENCSR000EUM_GM12878_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	650
1	4130	YY1	0	0	0	3799	3799	3799	3799	3800	2	6381	2218	YY1 NT2-D1 (embryonic carcinoma) YY1	NT2-D1 (embryonic carcinoma)	BTO:0000946	YY1		ENCODE	ENCSR000EXG_NT2_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	8132
1	4138	YY1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Lys179*)	GTRD	EXP038608_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1045
1	4148	YY1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1 hemizygous deletion	GTRD	EXP038618_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	752
1	4149	YY1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	YY1 lymphoblastoid cells YY1	lymphoblastoid cells	NULL	YY1	YY1-mutated (p.Leu366Pro)	GTRD	EXP038619_lymphoblastoid-cells_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	1004
1	4150	YY1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	YY1 HEK293 (embryonic kidney) YY1	HEK293 (embryonic kidney)	NULL	YY1		GTRD	EXP040324_HEK293--embryonic-kidney-_YY1_MACS_YY1_MA0095.2.damo.pwm.bed	969
1	4152	YY1	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	YY1 HeLa (cervical adenocarcinoma) YY1	HeLa (cervical adenocarcinoma)	BTO:0000567	YY1		GEO	GSE31417_yy1_hela_MACS_YY1_MA0095.2.damo.pwm.bed	772
1	4154	YY2	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	YY2 HEK293 (embryonic kidney) YY2	HEK293 (embryonic kidney)	NULL	YY2	NA	GTRD	EXP039558_HEK293--embryonic-kidney-_YY2_MACS_YY2_MA0748.2.damo.pwm.bed	1384
1	4156	ZFX	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ZFX NOMO-1 (acute monocytic leukemia) ZFX	NOMO-1 (acute monocytic leukemia)	NULL	ZFX	NA	GEO	GSE43147_zfx_nomo1_MACS_ZFX_MA0146.2.damo.pwm.bed	6072
1	4160	ZNF143	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ZNF143 HeLa (cervical adenocarcinoma) ZNF143	HeLa (cervical adenocarcinoma)	BTO:0000567	ZNF143		GEO	GSE31417_znf143_hela_MACS_ZNF143_MA0088.2.damo.pwm.bed	1274
1	4162	ZNF143	0	0	0	3799	3799	3799	3799	3800	0	6381	2220	ZNF143 HPB-ALL (T acute lymphoblastic leukemia) ZNF143	HPB-ALL (T acute lymphoblastic leukemia)	BTO:0001952	ZNF143		GEO	GSE39263_znf143_hpball_MACS_ZNF143_MA0088.2.damo.pwm.bed	1435
